"";"terms"
"1";"-------------------------------Week 54-----------------------------------"
"2";"------------------------------Week 30------------------------------"
"3";"-------------Week 30------------------------------ --------------------"
"4";"------------Week 54-----------------"
"5";"- <—■ bb—-►"
"6";"- HDL Cholesterol"
"7";"- LDL Cholesterol"
"8";"- Median fasting serum glucose (mg/dL) (IQR)"
"9";"- Median pulse pressure (mm Hg) (IQR)"
"10";"- Median TG (IQR)"
"11";"- Median urine ACR (mg/g) (IQR)"
"12";"- recurrent VTE during overall study period"
"13";"- thienopyridine"
"14";"- Triglycerides"
"15";"-[The null hypothesis is that there are no differences among subgroups; for age and time since randomization, the inter-"
"16";"-°-287; wom-"
"17";"-0-0331 (-0-2776too 2115)"
"18";"-0-29 (95% Cl -0-52 to -0-06)"
"19";"-0-50 (95% Cl -0-81 to -0-27)"
"20";"-0.54 (95%CI: -0.74, -0.34, n=185)"
"21";"-0.93 (95%CI: -1.12, -0.73, n=178) A -0.39%, *p=0.007"
"22";"-1 Placebo"
"23";"-2 < FLEX FN F- score"
"24";"-2.0 < LS T-score"
"25";"-2.2 (-3.5, -C).9r"
"26";"-2.5 < FLEX FN F-score < -2"
"27";"-2.5 < LS T-score < —2.0"
"28";"-23.7 (0.9)*ll"
"29";"-44.2 (95%CI: -53.8, -34.6, n=60)"
"30";"-45.4 ± lNO^"
"31";"-45.8 ± 1.44§tI"
"32";"-48.1 (95%CI: -56.7, -39.5, n=68) *p=0.523"
"33";"-5.65 to -3 cm"
"34";"-7-2 (95% Cl -10-8 to -3-5)"
"35";"-7-6 (95% Cl-11-2 to 4-0)"
"36";"-B-i-"
"37";"-B-i—"
"38";"-bI-"
"39";"-F2.88 (-I-0.16)"
"40";"-ICS/+ LABA n Z 597"
"41";"-major bleed"
"42";"-O-OO95 (-0-0348 to 0-0159)"
"43";"-O.OS"
"44";"-O8O (-1-lOto -0-50)"
"45";"-Oil"
"46";"— no. (%)"
"47";"—2.0 < FN T-score"
"48";"—2.5 < FN T-score < —2.0"
"49";"—b-H—"
"50";"! Amlodipine"
"51";"# of prior bDMARDs"
"52";"# of prior non-TNFi bDMARDs*"
"53";"# of prior TNFi among non-TNFi naive"
"54";"# PTS"
"55";"#1 year"
"56";"#100 kg"
"57";"$ 10 years (N = 586)"
"58";"$ 2 exacerbations"
"59";"$ 65 years (n = 454)"
"60";"$ Race was determined by the investigator during the patient's interview."
"61";"$10 years"
"62";"$3and,10 years"
"63";"%-Point difference (95% CI)c"
"64";"% (95% CI)"
"65";"% (SE)"
"66";"% \mean ± SD"
"67";"% anti-CCP+ (>60 units)"
"68";"% Asthma control days{,#"
"69";"% bronchial reversibility (SD)"
"70";"% change"
"71";"% change (mean ± SE)"
"72";"% change (mean±SE)"
"73";"% change (meanlSE)"
"74";"% change (meantSE)"
"75";"% change (median; Q1, Q3)"
"76";"% change from baseline"
"77";"% change from baseline LS means (SE)"
"78";"% change from baseline to Week 24"
"79";"% change from baseline, mean (s.e.)"
"80";"% change median Baseline CRP >2mg/L"
"81";"% change, 95% CI)"
"82";"% difference, 95% CI)"
"83";"% FHG"
"84";"% HbA1c (mmol/mol)"
"85";"% improvement in dactylitis score at week 24, N"
"86";"% improvement in enthesitis score at week 24, N"
"87";"% of patients 22.2    22.5"
"88";"% of predicted"
"89";"% of predicted normal value*"
"90";"% Patients"
"91";"% patients with no progression"
"92";"% PHG"
"93";"% pred"
"94";"% predicted"
"95";"% Predicted"
"96";"% predicted FEV,"
"97";"% predicted FEV^"
"98";"% predicted FEV1"
"99";"% Predicted FEV1"
"100";"% predicted post-bronchodilator FEV, (SD) ml"
"101";"% Predicted post-bronchodilator FEV1, mean (SD), L"
"102";"% predicted pre-BD"
"103";"% predicted pre-bronchodilator FEV1, %*"
"104";"% Predicted prebronchodilator FEV1, mean (SD), L"
"105";"% predicted value (SD)"
"106";"% predicted” FEV, at baseline, %*"
"107";"% Reduction"
"108";"% Reversibility"
"109";"% Reversibility in FEV^ at"
"110";"% RF+"
"111";"% Risk Reduction (95% Cl)"
"112";"% risk reduction (95%CI)"
"113";"% Stenosis (core lab)"
"114";"% Stenosis (investigator)"
"115";"% Stenosis, as assessed by core laboratory"
"116";"% Stenosis, as assessed by investigator"
"117";"% to goal"
"118";"% With HAQ-DI decrease >0.22"
"119";"%/year"
"120";"%/yr"
"121";"& Median"
"122";"($100 mg/dL [5.6 mmol/L])"
"123";"($110 mg/dL [6.1 mmol/L])"
"124";"($90 ml/min per 1.73 m2)"
"125";"(% of group)"
"126";"(% of Target)∗"
"127";"(%) Control (45002)"
"128";"(%) Control (45054)"
"129";"(%),28 mean (SD)"
"130";"(%, 95% Cl)"
"131";"(,60 ml/min per 1.73 m2)"
"132";"(:> blockers"
"133";"(_> 1.7 mmol/L) HDL-C women:< 50 mg/dL (< 1.3 mmol/L) men: < 40 mg/dL"
"134";"(< 1.0 mmol/L)"
"135";"(<5 mg/L)"
"136";"(<60 ml/minute)*"
"137";"(≥5 mg/L)"
"138";"(0-10-cm VAS)"
"139";"(156 patients)"
"140";"(158 patients)"
"141";"(21 patients)"
"142";"(217 subjects)"
"143";"(219 subjects)"
"144";"(22 patients)"
"145";"(3-Blocker"
"146";"(3-blockers"
"147";"(3-sitosterol (p.mol/L)"
"148";"(3 blocker"
"149";"(60-89 ml/min per 1.73 m2)"
"150";"(88.5%); values were not collected for 113 patients (11.5%) who were enrolled"
"151";"(95% CI)"
"152";"(95% CI)    P Value"
"153";"(95% CI);"
"154";"(95% CI)a"
"155";"(95% CI)b"
"156";"(95% CI)c"
"157";"(95% CI] 1"
"158";"(95% Cl)"
"159";"(95% Cl) Interaction"
"160";"(95% ell'll"
"161";"(95% ell'll,* Non-HDL-C"
"162";"(95%CI]h"
"163";"(96% Cl)"
"164";"(a blocker"
"165";"(a) AZA treatment (ref)"
"166";"(a) BMI subgroups"
"167";"(a) Demographics"
"168";"(b) Age subgroups"
"169";"(b) AZA treatment (ref)"
"170";"(b) Concomitant respiratory medications [N (%)]"
"171";"(baseline)"
"172";"(c) ' ' KZA treatment (ref)"
"173";"(cells per pL)t"
"174";"(CI)b"
"175";"(cm)"
"176";"(composite endpoint)"
"177";"(d) AZA treatment (ref)"
"178";"(e-blocker"
"179";"(e) AZA treatment (ref)"
"180";"(Fxs)"
"181";"(GM)"
"182";"(HAQ-DI, 0-3)"
"183";"(i-Blocker"
"184";"(ID"
"185";"(incl. uncertain)"
"186";"(including hypertension)"
"187";"(Interquartile range) (mm)"
"188";"(IQR)"
"189";"(IQR) — days"
"190";"(L)t"
"191";"(mean % change, 95% CI)"
"192";"(mean % difference, 95% CI)"
"193";"(mean +. SD)"
"194";"(mean ± SD)"
"195";"(mean change, 95% CI)"
"196";"(mean difference, 95% CI)"
"197";"(median, h)"
"198";"(mg/dL ± SD)"
"199";"(mg/dl)"
"200";"(mg/dL)"
"201";"(min)*"
"202";"(minimum-maximum) focal seizure fre- quency/28 days at baseline"
"203";"(mmol/L)"
"204";"(mmol/L]"
"205";"(mU/L$mmol/L)b"
"206";"(n = 325)    (n = 649)"
"207";"(n = 335)    (n = 666)"
"208";"(n = 335)    (n = 667)"
"209";"(N = 58)""'    (N = 46)"
"210";"(n = MS)"
"211";"(n=152) (n=151)"
"212";"(n=171) (n=156)"
"213";"(n=1l2)"
"214";"(n=205) (n=213)"
"215";"(n=211) (n=203)"
"216";"(n=241) (n=242)"
"217";"(n=28) (n=32)"
"218";"(n=285)    (n=561)"
"219";"(n=30) (n=39)"
"220";"(n=36) (n=29)"
"221";"(n=38) (n=29)"
"222";"(n=42) (n=50)"
"223";"(n=68) (n=73)"
"224";"(n=69) (n=84)"
"225";"(n=79) (n=79)"
"226";"(n=82) (n=84)"
"227";"(n=l44)"
"228";"(NE, NE)"
"229";"(ngml '') Total mean IPSS score"
"230";"(NYHA grade III or IV)"
"231";"(Ofl)"
"232";"(pg/mg)"
"233";"(Phase 2 dose-finding trial)"
"234";"(points)"
"235";"(range)"
"236";"(Ref)"
"237";"(ri = 149)"
"238";"(ri = 622)"
"239";"(SCALE Diabetes)"
"240";"(SCALE Obesity and Prediabetes)"
"241";"(SD)"
"242";"(SD) l/min ACQ-5 score, mean (SD)"
"243";"(SD),mg/dL"
"244";"(SE)"
"245";"(SE)t*"
"246";"(SE]+"
"247";"(SE]t"
"248";"(SE]t*"
"249";"(SE]tf"
"250";"(SE]tf HDL-C"
"251";"(SE]tf Total-C"
"252";"(SEM)"
"253";"(subgroup)"
"254";"(tiotropium n = 105, placebo n"
"255";"(tiotropium n = 86; placebo n ="
"256";"(Tiotropium n=82 Non-tiotropium n=322)"
"257";"(Tiotropium n=83 Non-tiotropium n=322)"
"258";"(Tiotropium n=86 Non-tiotropium n=327)"
"259";"(Tiotropium n=90 Non-tiotropium n=333)"
"260";"(Tiotropium n=93 Non-tiotropium n=3 16"
"261";"(Tiotropium n=95 Non-tiotropium n=326)"
"262";"(total SES-CD score at"
"263";"(Week)"
"264";"(women only)"
"265";"(years)"
"266";"(yes/no)"
"267";"* data are expr"
"268";"* Eligibility risk factors, n (%)*"
"269";"* Hypercholesterolemia was defined as a low-density lipoprotein cholesterol level at enrollment of more than 130 mg per deciliter (3.4 mmol per liter) after an overnight fast. † Nonsustained ventricular tachycardia was defined as 3 or more consecutive ventricular beats at a heart rate of more than 100 beats per minute. ‡ To convert weight to kilograms, divide by 2.2. § To convert values for creatinine to micromoles per liter, multiply by 88.4. ¶Data for follow-up medication were available for 2500 patients (amiodarone, 840; placebo, 838; and ICD, 822). ACE de-notes angiotensin-converting enzyme, and ARB angiotensin II–receptor blocker. ¿ P<0.001 for the comparison among the groups"
"270";"* Non-Black*"
"271";"* Nonfatal Ml"
"272";"* P value"
"273";"* Patient characterization data are reproduced from Morrow et al. (16)."
"274";"* Plus-minus values are means 士SD. Race or ethnic group was self-determined. The body-mass index is the weight in kilograms divided by"
"275";"* Plus-minus values are means ±SD. There were no significant differences (at"
"276";"* Plus–minus values are means ±SD. Percentages may not total 100 because of rounding. The body-mass index is the weight in kilograms divided by the square of the height in meters. To convert the values for creatinine to micromoles per liter, multiply by 88.4. ACE denotes angiotensin-converting enzyme, CABG coronary-artery bypass grafting, NT-proBNP N-terminal pro-B–type natriuretic peptide, NYHA New York Heart Association, and PCI percutaneous coro-nary intervention. † Race was reported by the investigators. ‡ One patient in NYHA class I was mistakenly included in the placebo group. § This category includes any angina-like symptoms at any time in the past, with no confirmation of diagnosis of coro-nary heart disease required. ¶ Possible scores range from 0 to 105, with lower scores indicating a better quality of life. ∥ Anemia was defined by World Health Organization criteria as a hemoglobin level of less than 13 g per deciliter in men and less than 12 g per deciliter in women. ** NT-proBNP levels are influenced by a variety of factors, including age, sex, body-mass index, and renal function. No clinically useful normal range has been established. †† Some patients were taking both loop and thiazide diuretics."
"277";"* The P‐value is from the test statistic for testing the interaction between the treatment group and Diabetes group."
"278";"** Positive stress test"
"279";"*** Unstable angina"
"280";"*Atherosclerotic coronary heart disease, ischaemic stroke or peripheral arterial disease. †n/N = number of people in phase 3 studies only. ‡High‐intensity statins were defined as atorvastatin 40 to 80 mg, rosuvastatin 20 to 40 mg or simvastatin 80 mg daily."
"281";"*CI denotes confidence interval."
"282";"*Data are expressed as median ± SD, except"
"283";"*Data are given as percentage of subjects unless otherwise specified. PTCA indicates percutaneous transluminal coronary angioplasty; CABG, coronary artery bypass graft; ACE, angiotensin-converting enzyme; BMI, body mass index (calculated as weight in kilograms divided by square of height in meters); HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; FPG, fasting plasma glucose; and FPI, fasting plasma insulin. tTo convert cholesterol values to micromoles per liter, multiply by 0.0259. To convert triglycerides to micromoles per liter, multiply by 0.0113. To convert FPG to micromoles per liter, multiply by 0.0555. To convert FPI to picomoles per liter, multiply by 6.945."
"284";"*Data reported as n (%) or median (quartiles 1, 3)."
"285";"*Determined by investigator to be possibly, probably or definitely related to study drug tMyopathy defined as CPK > 10 x ULN with associated muscle symptoms with no other plausible etiology ^Consecutive defined as two or more measurements at least one week apart or one measurement < 2 days after the last dose of study drug (presumed consecutive) §Two patients had incomplete data to assess CHD status SIMVA = simvastatin; EZE = ezetimibe; AE = adverse event; ALT = alanine aminotransferase; AST = aspartate aminotransferase; CPK = creatine phosphokinase; ULN = upper limit of normal"
"286";"*Interquartile range"
"287";"*Other - Europe (n=12), Australia (n=7) and India (n=134) - the data from these regions were collapsed due to the small numbers"
"288";"*p < 0.0001 for EZE/SIMVA (pooled across doses) vs. SIMVA (pooled across doses) for the entire cohort Data are presented as least squares mean ± standard error (†median ± SE for TG) for the entire cohort and also for each selected subgroup SIMVA = simvastatin; EZE = ezetimibe; TC = total cholesterol; TG = triglycerides; HDL-C = high-density lipoprotein-cholesterol; Non-HDL-C = non-high-density lipoprotein cholesterol; Apo = apolipoprotein"
"289";"*p < 0.05 for between-treatment difference with same dose of simvastatin for entire cohort Data are expressed as least squares mean ± standard error SIMVA = simvastatin; EZE = ezetimibe; CHD = coronary heart disease"
"290";"*P for heterogeneity of treatment effect between tertiles >0.8."
"291";"*Per 1000 participant years. Composite of first occurrence death (all cause), nonfatal Ml, or nonfatal stroke. Cardiovascular death excluding those classified as “unable to determine.”"
"292";"*Rate is number of events per 100 patient-years of follow-up. fThe p value for number of patients from log-rank, for total number of hospitalizations from permutation test. ^By treatment comparing the"
"293";"*Reported by physicians. †Data are median (IQR). All data are mean (SD) or number (%) unless otherwise indicated."
"294";"*Risk reduction, 95 percent confidence interval (CI), and P value are derived from Cox models.
For risk reductions, negative numbers indicate an increase in risk. †Diabetes and hypertension were defined by clinical history. ‡A family history was defined as having one or more first-degree relatives with either myocardial infarction or sudden death before the age of 55. §HDL cholesterol levels are shown according to the median value (31.5 mg per deciliter [0.8 mmol per liter]). ¶Triglyceride levels are shown according to the median value (151 mg per deciliter [1.7 mmol per liter]).
¿LDL cholesterol levels are shown according to the median value (112 mg per deciliter [2.9 mmol per liter]) and according to the values that divide the subjects into three equal groups (<104, 104 to 121, and >121 mg per deciliter [<2.7, 2.7 to 3.1, and >3.1 mmol per liter])."
"295";"*Subgroups were defined on the basis of variables assessed before randomization. The lipid levels represent the averages of the values measured four weeks before randomization and those measured at randomization. To convert values for cholesterol to millimoles per liter, multiply by 0.02586; to convert values for triglycerides to millimoles per liter, multiply by 0.01129. CI denotes confidence interval, LDL low-density lipoprotein, and HDL high-density lipoprotein. Tests for heterogeneity of treatment effect were undertaken across each of the subgroups. In addition, we performed tests for interaction between treatment and the following continuous base-line variables: age; total, LDL, and HDL cholesterol; and triglyceride levels. There was no evidence of significant heterogeneity of treat-ment effect in any prespecified subgroup (P»0.08). †Data were missing for three patients, two in the placebo group and one in the pravastatin group."
"296";"*The 2 substrata with baseline (BL) LDL cholesterol  100 to  130 mg/dl and  130 to  160 mg/dl were combined to make 1 group with BL LDL cholesterol  100 to  160 mg/dl because of small numbers of patients included in the substrata with  130 to  160 mg/dl. †BL HDL cholesterol cutoffs were  40 or  40 mg/dl for men and  50 or  50 mg/dl for women. Bars indicate SE. BMI   body mass index; E   ezetimibe 10 mg; HDL-C   HDL cholesterol; LDL-C   LDL cholesterol; TG   triglycerides"
"297";", 10 years (N = 1480)"
"298";", 65 years (n = 1613)"
"299";", n/N (%)"
"300";",0-blocker"
"301";",0-Blockers"
"302";",1/week"
"303";",2 step"
"304";",3 years"
"305";",3.4 mg/mmol"
"306";". 1.0 mL/s/m2(60 mL/min/ 1.73 m2), n (%)"
"307";".100 kg"
"308";".100 kg MTX use"
"309";".3 step or incident vitrectomy or photocoagulation"
"310";".33.9 mg/mmol"
"311";"/\ge category"
"312";"/’-value"""
"313";"/’-value1’"
"314";"/’interaction"
"315";"/3-Blocker"
"316";"/3-blockers"
"317";"/J-valuc!l"
"318";"/pl 655 631"
"319";": MI, Previous PCI and Chronic Obstructive Pulmonary Disease."
"320";"? f? n"
"321";"[}ifrerence vs. placebo, % (95% Cl)"
"322";"[2.6 mmol/L])"
"323";"[95% CI]*"
"324";"[95% Cl]"
"325";"[cm(female)/cm(male)]"
"326";"[cm{female)/cm{male)]"
"327";"[kg/m^]"
"328";"[Min, Max]"
"329";"[no/yes] (%)"
"330";"[SD]"
"331";"[zi = 2334] 9334 (50.7)"
"332";"[zi = 2782] 2188 (78.6)"
"333";"[zi = 52] 44 (84.6)"
"334";"[zi = 70] 281 (56.8)"
"335";"\BL-SC n/N"
"336";"^-blocker"
"337";"^-Blocker"
"338";"^-blockers"
"339";"^≥2% incidence in any treatment group in the overall safety population."
"340";"^10 days"
"341";"^12 months"
"342";"^135 mm Hg"
"343";"^30 mg/g, n (%)"
"344";"^6 hrs"
"345";"^60 mL/min"
"346";"^75 y, n (%)"
"347";"^8-cell function — %§"
"348";"^median"
"349";"^median >median"
"350";"^Numbers do not always sum to group totals due to missing information for some variables. fBody mass index was calculated as weight in kilograms divided by the square of height in meters. ^Hypertension was defined as a self-reported systolic blood pressure >140 mm Hg, a diastolic blood pressure >90 mm Hg, or physician-diagnosed hypertension. §Hyperlipidemia was defined as a self-reported total cholesterol >240 mg/dL (6.2 mmol/L) or physician-diagnosed high cholesterol. ||Diabetes was defined by self-report."
"351";"|    Interactior 1    P"
"352";"|:S blocker"
"353";"|?)-Blocker, %"
"354";"|?>-Blocker (n, %)"
"355";"■335 years"
"356";"“Off”"
"357";"“On” with troublesome dyskinesia"
"358";"“On” without troublesome dyskinesia"
"359";"“Relative risk of outcome in ACEI group iw control group. bBaseline variables for models included: logarithm of age, reciprocal of serum creatinine, SBP, UP excretion, treatment assignment and terms for studies 2, 5 10 and 11 (see footnotes of Table 1). Other baseline variables considered for analysis (P < 0.2 in univariate analysis) included DP mean arterial pressure, type of antihypertensive regimen in the control group, planned duration of follow-up, whether or not the investigators were blinded, whether or not dietary advice was given and the year of publication."
"360";"£ 47 min"
"361";"£ 62.5 yrs"
"362";"£ 74.5 min"
"363";"£ Median"
"364";"£ median (2.8)"
"365";"£ median (64)"
"366";"£1.58 mmol/L"
"367";"£100 mg/dl"
"368";"£150 mg/dl"
"369";"£3% BSA psoriasis, no. (%)"
"370";"£30 kg/m2"
"371";"£34 kg/m2"
"372";"£40 (men)/ £50 (women)"
"373";"£60 mL/min"
"374";"£65 to <75 years"
"375";"£65 years"
"376";"£65 yo (N=2739)"
"377";"£75 years"
"378";"£75 yr"
"379";"£80 m b'm in"
"380";"£90 kg"
"381";"£90 ml/minute"
"382";"£l 00 kg"
"383";"+ thienopyridine"
"384";"+ICS/+ LABA n Z 945"
"385";"+ICS/+ LABA nZ 945"
"386";"<-2.5 - VFx"
"387";"<-2.5 + VFx"
"388";"<-5.65 cm"
"389";"< 0.04 ng/ml"
"390";"< 0.6 tng>clL"
"391";"< 1 year"
"392";"< 1 years"
"393";"< 10 years"
"394";"< 100 mg"
"395";"< 150 cells/pl"
"396";"< 150 cells/ul    623    654"
"397";"< 160 mg/dL"
"398";"< 160 mg/dL EZE/SIMVA"
"399";"< 160 mg/dL EZE/SIMVA (n = 337)"
"400";"< 160 mg/dL EZE/SIMVA (n = 337}"
"401";"< 160 mg/dL SIMVA"
"402";"< 160 mg/dL SIMVA (n = 320)"
"403";"< 160 mg/dL SIMVA (n = 320]"
"404";"< 180 min"
"405";"< 1st quartile"
"406";"< 2 years"
"407";"< 20 mgday P.Eq."
"408";"< 21 mm"
"409";"< 24 hr"
"410";"< 25 kg/m2"
"411";"< 3.4 mg/mmol"
"412";"< 30 kg/m2"
"413";"< 30 ml/min"
"414";"< 30 mL/min"
"415";"< 30 mm"
"416";"< 30 years"
"417";"< 47 min"
"418";"< 5 years"
"419";"< 5 yr since menopause"
"420";"< 6 month n = 426"
"421";"< 6 month n=417"
"422";"< 60 Kg"
"423";"< 60 L/min"
"424";"< 60 yr"
"425";"< 62.5 yrs"
"426";"< 65 years"
"427";"< 65 years (%)"
"428";"< 65 Years EZE/SIMVA"
"429";"< 65 Years EZE/SIMVA (n = 917)"
"430";"< 65 Years EZE/SIMVA (n = 917}"
"431";"< 65 Years SIMVA"
"432";"< 65 Years SIMVA (n = 948)"
"433";"< 65 Years SIMVA (n = 948}"
"434";"< 65 years, n (%)"
"435";"< 65 yr"
"436";"< 65 yrs"
"437";"< 74.5 min"
"438";"< 75 mg"
"439";"< 75 years"
"440";"< 75 Years"
"441";"< 75 yr"
"442";"< 80 mg/dl"
"443";"< median"
"444";"< Median"
"445";"< median (4.5)"
"446";"< Median (81 kg)"
"447";"< median 151.13"
"448";"<= 75 yr"
"449";"<=€0 kg"
"450";"<=1 year, n (%)"
"451";"<=100 kg"
"452";"<=60 kg"
"453";"<0% predicted ARR (n = 18,524)"
"454";"<0.00 ld"
"455";"<0.03 l-g/L"
"456";"<0.04 ng/ml"
"457";"<0.94 mmol/L"
"458";"<1-35 mmol/L"
"459";"<1-42 mmol/L"
"460";"<1 mg/L (n = 1278)"
"461";"<1 week"
"462";"<1 year"
"463";"<1 years"
"464";"<1 yr"
"465";"<1.05 mmol/liter"
"466";"<1.05 mmol/liter Triglyceride level"
"467";"<1.0mg/l"
"468";"<1.30 mmol/l"
"469";"<1.5 mg/dl"
"470";"<1.5 ng/ml (n = 304)"
"471";"<1.6 mg/dl"
"472";"<1.9 ng/L (n=131) n (%)"
"473";"<1.9 ng/L (n=251)"
"474";"<10 days"
"475";"<10 days (%)"
"476";"<10 mm Hg"
"477";"<10 years"
"478";"<10 yr"
"479";"<100 kg"
"480";"<100 mg"
"481";"<100 mg/dl"
"482";"<100 mg/dL"
"483";"<100 mg/dl*"
"484";"<100 mm Hg"
"485";"<104 mg/dl"
"486";"<112 mg/dl"
"487";"<12 months"
"488";"<120 mm Hg"
"489";"<120/<75 mm Hg"
"490";"<122.5 mm Hg"
"491";"<122.5 mm Hg Diastolic blood pressure"
"492";"<125 mm Hg"
"493";"<126 mg/dL"
"494";"<129 min"
"495";"<13.1 years"
"496";"<130 mg/dL"
"497";"<130 mm Hg"
"498";"<130 mm Hg— no. (%)"
"499";"<130/80 mm Hg+"
"500";"<130/80 mmHg, LDL-C <100 mg/dL"
"501";"<133 mg/dl"
"502";"<133.83 mm Hg"
"503";"<135 mg/dl"
"504";"<135 mm Hg"
"505";"<136 mm Hg"
"506";"<140 mg/dl"
"507";"<140 ml"
"508";"<140 mm Hg"
"509";"<140 mmHg"
"510";"<140/90 mm Hg"
"511";"<15 enroll"
"512";"<15 ml/s"
"513";"<150 cells/mm^"
"514";"<150 mg/dl"
"515";"<150 mg/dL"
"516";"<150 regardless of historical count"
"517";"<150 with historical count >300"
"518";"<150 with no historical count >300"
"519";"<1500 mg"
"520";"<151 mg/dl"
"521";"<160 mm Hg"
"522";"<18 kg/m2"
"523";"<18 mg/dL"
"524";"<18 mon (N=4097)"
"525";"<180 mm Hg"
"526";"<1year"
"527";"<2 and no moderate or severe deformity (N = 6803)"
"528";"<2 days"
"529";"<2 mg/liter"
"530";"<2 mo"
"531";"<2 months"
"532";"<2 years"
"533";"<2% Blood Eosinophils at Baseline"
"534";"<2.12 mmol/liter"
"535";"<2.12 mmol/liter Estimated GFR"
"536";"<2.59 mmol/l"
"537";"<2.59 mmol/L"
"538";"<20 mg"
"539";"<20 mg/d PEq"
"540";"<20 mg/day"
"541";"<20 mm Hg"
"542";"<200 lb"
"543";"<200 mg/dl"
"544";"<21 kg/m2"
"545";"<213 mg/dl"
"546";"<24 h, n (%)"
"547";"<24 kg/m2"
"548";"<24, kg/m2"
"549";"<242 ng/mL"
"550";"<25 — no. {%)"
"551";"<25 kg/m2"
"552";"<25 kg/m2 ( n = 93)"
"553";"<25 ppb"
"554";"<25.0 kg/m2"
"555";"<250 microg/l"
"556";"<25kg/m2"
"557";"<26 mm Hg"
"558";"<27.2 kg/m2"
"559";"<277.6 pmol/liter"
"560";"<28 kg/m2"
"561";"<2xULN"
"562";"<3 — no. (%)"
"563";"<3 days"
"564";"<3 hr"
"565";"<3 mm"
"566";"<3 mo"
"567";"<3 months"
"568";"<3 Months"
"569";"<3 Months In - 1 Kill"
"570";"<3 months, n (%)"
"571";"<3 no. (%)"
"572";"<3.0 mmol/liter"
"573";"<3.12 mmol/liter"
"574";"<3.12 mmol/liter ApoB:ApoA-l ratio"
"575";"<3.36 mmol/l"
"576";"<3.4   mmol/l"
"577";"<3.4 mmol/L"
"578";"<30    kg/m2"
"579";"<30 CrCl"
"580";"<30 days (n = 7181)"
"581";"<30 kg, mJ (reference)"
"582";"<30 kg/m 2"
"583";"<30 kg/m^"
"584";"<30 kg/m2"
"585";"<30 kg/m2 (n — 274)"
"586";"<30 kg/mA2"
"587";"<30 ky/nr"
"588";"<30 mg dL (reference)"
"589";"<30 mg/dL"
"590";"<30 mg/g"
"591";"<30 mg/g, n (%)"
"592";"<30 ml/min"
"593";"<30 mL/min"
"594";"<30 mL/min per 1-73 m2"
"595";"<30 mL/min/1.73 m2"
"596";"<30 mL/min/1.73ni-"
"597";"<30 ml/minute"
"598";"<30% predicted"
"599";"<300 cells/pL"
"600";"<30mLmin) 1"
"601";"<31.5 mg/dl"
"602";"<325 meters"
"603";"<35 mg/dl"
"604";"<35 years"
"605";"<39 mg/dl"
"606";"<3mo,n (%)"
"607";"<4-01 mmol/L"
"608";"<4-1 mmol/L"
"609";"<4 hr"
"610";"<4 mmol/L"
"611";"<4 months, mean (SD)"
"612";"<4 months, median (min, max)"
"613";"<4.0 mU/L-mmol/L"
"614";"<4.0 mU/L$mmol/L"
"615";"<40 (men) / <50 (women)"
"616";"<40 mg/dl"
"617";"<40 mg/dL (<1.04 mmol/L)"
"618";"<40 mm"
"619";"<45 mL/min/1,73m2"
"620";"<45 ml/min/1.73 m2"
"621";"<5 years"
"622";"<5 yr"
"623";"<5 yr of education — no. (%)"
"624";"<5 yrs"
"625";"<5.0 mg/liter"
"626";"<5.18 mmol/l"
"627";"<5.5 mmol/liter"
"628";"<5.8 mg/liter"
"629";"<50 CrCl, n (%)"
"630";"<50 kg"
"631";"<50 ml/min"
"632";"<50 ml/min — %"
"633";"<50 mL/min (n=3374)"
"634";"<50 years"
"635";"<50 yr"
"636";"<50 yrs"
"637";"<508 ng/mL"
"638";"<50nWrrtn"
"639";"<51 ml/min/1.73 m2"
"640";"<51 ml/min/1.73 m2 NT-pro-BNP"
"641";"<54 mg/dl"
"642";"<55 vr — no. (%)"
"643";"<55 y, n (%)"
"644";"<55 years (n=824)"
"645";"<55 yr"
"646";"<6-21 mmol/L"
"647";"<6 hr"
"648";"<6 hrs"
"649";"<6 mg/L"
"650";"<6 mo"
"651";"<6 months—number/N (%)"
"652";"<6 weeks"
"653";"<60 kg"
"654";"<60 Kg"
"655";"<60 kg'i'"
"656";"<60 mi/min"
"657";"<60 mL min’1 1.73 m""2"
"658";"<60 ml/min"
"659";"<60 mL/min"
"660";"<60 ml/min per 1.73 m2, n (%)"
"661";"<60 ml/min/1,73 m^"
"662";"<60 ml/min/1.73 m^"
"663";"<60 ml/min/1.73 m^ — no. {%)"
"664";"<60 ml/min/1.73 m2"
"665";"<60 mL/min/1.73 m2"
"666";"<60 ml/min/1.73 m2— no. (%)"
"667";"<60 ml/min/1.73 m2 — no. (%)"
"668";"<60 mL/min/1.73 m2, n (%)"
"669";"<60 ml/min/1.73m2"
"670";"<60 mL/min/1.73m2"
"671";"<60 mLYmin"
"672";"<60 years"
"673";"<60 yr"
"674";"<60 yr— no. {%)"
"675";"<60kg"
"676";"<65 y (n=422)"
"677";"<65 y (n=433)"
"678";"<65 y (N=5497, 26.0%)"
"679";"<65 y ears"
"680";"<65 y, n (%)"
"681";"<65 years"
"682";"<65 Years"
"683";"<65 years (n=1757)"
"684";"<65 years (n=4031)"
"685";"<65 years (placebo n =3,941; saxagliptin n =3,990)"
"686";"<65 years n Z 1761"
"687";"<65 years of age"
"688";"<65 Years of Age"
"689";"<65 years, n (%)"
"690";"<65 yo (N=2306)"
"691";"<65 yr"
"692";"<65 yr — no. (%)"
"693";"<65 yr(n = 367)"
"694";"<65 yrs"
"695";"<65 yrs of age (n = 3,239)"
"696";"<66 yr"
"697";"<67 mg/dl"
"698";"<69 yr"
"699";"<7 years"
"700";"<7.9 mmol/liter"
"701";"<70 kg"
"702";"<70 yr"
"703";"<70 yrs"
"704";"<73 mm Hg"
"705";"<73 mm Hg Heart rate"
"706";"<75 Baseline Killip class"
"707";"<75 beats/min"
"708";"<75 mm Hg"
"709";"<75 y (n=8932)"
"710";"<75 yea's"
"711";"<75 years"
"712";"<75 Years"
"713";"<75 years (placebo n =7,051; saxagliptin n =7,111)"
"714";"<75 yr"
"715";"<75 Yr"
"716";"<75 yr — no. (%)"
"717";"<75 yr (N = 5337)"
"718";"<75.5 bpm"
"719";"<77 bpm (n=3144)"
"720";"<77 yr"
"721";"<8 days"
"722";"<8 years"
"723";"<8% (<64 mmol/mol)"
"724";"<8% (64 mmol/mol)"
"725";"<8.0% (64 mmol/mol)"
"726";"<8.5 mg/dL"
"727";"<80 kg"
"728";"<80 kg, n (%)"
"729";"<80kg"
"730";"<82.0 kg"
"731";"<85 mg/dl"
"732";"<850 beds"
"733";"<9 months"
"734";"<9 yr"
"735";"<9 yr— no. {%)"
"736";"<9.0% ( <75 mmol/mol)"
"737";"<90 kg"
"738";"<90 ml/minute)"
"739";"<90 mmHg"
"740";"<950 ft"
"741";"<97 mg/dL"
"742";"<99 cm"
"743";"<l0 years"
"744";"<Mean"
"745";"<median"
"746";"<Median (0.37 years)—number/N (%)"
"747";"<Median (0.5)—number/N (%)"
"748";"<Median (1.375)—number/N (%)"
"749";"<Median (4.5)—number/N (%)"
"750";"<Median (5.4)—number/N (%)"
"751";"<median (54 Year-old)"
"752";"<Median (62)—number/N (%)"
"753";"<Median (7 days)"
"754";"<Median {7 days)"
"755";"<Median prednisone dose,n (%)"
"756";"<Q1 (0)—number/N (%)"
"757";"<Q1 (1.5)—number/N (%)"
"758";"<Q1 (2)—number/N (%)"
"759";"★Reported by physicians. tData are median (IQR). All data are mean (SD) or number (%) unless otherwise indicated."
"760";"卞at discharge."
"761";"赛 65 years"
"762";"≤  Median"
"763";"≥ 2 years"
"764";"= calcium channel blocker;BMI = body"
"765";"= cerebrospinal fluid."
"766";"= ezetimibe; TC = triglycerides; HDL-C = lg/dL L> 7.0 mmol/L]). To qualify as having"
"767";"= International Prostate Symptom Score;"
"768";"≤ median"
"769";"= placebo; EZE :tes (FC J>126 rr 1 definition)."
"770";"= placebo; EZE = ezetimibe; erol; Apo = apolipoprotein; metabolic syndrome, patients were eans and percentage changes are"
"771";"≤ 58 mmol/mol (7.5%), N (%)"
"772";"≥ 64 mmol/mol (8.0%), N (%)"
"773";"≥1 AE"
"774";"≥1 SAE"
"775";"≥1 TEAE"
"776";"≤1 U/kg/day"
"777";"≤1 year"
"778";"≥10 years"
"779";"≥10.0% (≥86 mmol/mol)"
"780";"≥100 to <130 mg/dL"
"781";"≥126 to <150 mg/dL"
"782";"≥13.1 to <19.3 years"
"783";"≥130 to <160 mg/dL"
"784";"≥133 to <165 mg/dL"
"785";"≥150 mg/dL"
"786";"≥150 to <200 mg/dL"
"787";"≥150 to <220 mg/dL"
"788";"≥160 mg/dL"
"789";"≥160 to <190 mg/dL"
"790";"≥165 to <226 mg/dL"
"791";"≥18 to <25 mg/dL"
"792";"≥19.3 years"
"793";"≥190 mg/dL"
"794";"≥200 mg/dL"
"795";"≥220 to <300 mg/dL"
"796";"≥226 mg/dL"
"797";"≥24, kg/m2"
"798";"≥242 ng/mL"
"799";"≥25 to <32 mg/dL"
"800";"≥28 kg/m2"
"801";"≥30 kg/m2"
"802";"≥30 mg/dL"
"803";"≥30 to <300 mg/g"
"804";"≥30 to <45 mL/min/1.73 m2"
"805";"≥30 to <50 mg/dL"
"806";"≥300 mg/g"
"807";"≥32 to <43 mg/dL"
"808";"≥35 kg/m2"
"809";"≤40 years"
"810";"≥43 mg/dL"
"811";"≥45 to <60 mL/min/1.73 m2"
"812";"≥5 years"
"813";"≤5 years"
"814";"≥50 mg/dL"
"815";"≤500 ug/g"
"816";"≥508 ng/mL"
"817";"≤6 mg/L"
"818";"≥60 mL/min/1.73 m2"
"819";"≥60 to <90 mL/min/1.73 m2"
"820";"≥60 years"
"821";"≥65 to <75 years"
"822";"≥65 years"
"823";"≥65 Years"
"824";"≥7.5% and <9.0%"
"825";"≥75 yearsa"
"826";"≥75a(N=38)"
"827";"≥75a(N=41)"
"828";"≥75a(N=47)"
"829";"≥77 bpm (n=3357)"
"830";"≥80 mL/min"
"831";"≥9.0% and ≤10.5%"
"832";"≥90 mL/min/1.73 m2"
"833";"≥97 to <133 mg/dL"
"834";"=sia"
"835";">-2.5 - VFx"
"836";">-2.5 + VFx"
"837";">-2.5 and <-1.0"
"838";">-3 cm"
"839";">  Median"
"840";"> < 0.05,    < 0.01, r< MMSE = Mini-Mental ;"
"841";"> 1 Concomitant medication"
"842";"> 1 med at baseline Cardiac disorder*"
"843";"> 10 years"
"844";"> 10 years vs. ≤ 2 years"
"845";"> 100 mg"
"846";"> 130 mmHg"
"847";"> 15 yrs"
"848";"> 160 mg/dL EZE/SIMVA"
"849";"> 160 mg/dL EZE/SIMVA („ = 899)"
"850";"> 160 mg/dL EZE/SIMVA 0 = 899}"
"851";"> 160 mg/dL SIMVA"
"852";"> 160 mg/dL SIMVA („ = 914)"
"853";"> 160 mg/dL SIMVA 0 = 914]"
"854";"> 160mg/dL CHD status"
"855";"> 1st and < 2nd quartile"
"856";"> 2 to ≤ 5 years vs. ≤ 2 years"
"857";"> 2 years"
"858";"> 24 hr"
"859";"> 2nd and < 3rd quartile"
"860";"> 3 days"
"861";"> 3.5 vs. 2.1 to ≤ 3.5"
"862";"> 30 kg/m2"
"863";"> 30 kg/m2 Smokers"
"864";"> 300 cells/pl"
"865";"> 300 cells/ul"
"866";"> 33.9 mg/mmol"
"867";"> 3rd quartile"
"868";"> 40 and ≤ 60 vs. ≤ 40"
"869";"> 40 to ≤ 60 vs. ≤ 40"
"870";"> 40 years vs. ≤ 40 years"
"871";"> 47 min"
"872";"> 5 and < 10 years"
"873";"> 5 to S 15 yrs"
"874";"> 5 to ≤ 10 years vs. ≤ 2 years"
"875";"> 5 years"
"876";"> 5 years vs. ≤ 5 years"
"877";"> 5 yr since menopause"
"878";"> 50 years"
"879";"> 55 years"
"880";"> 6 month n = 367"
"881";"> 60 and ≤ 80 vs. ≤ 40"
"882";"> 60 and ≤ 80 vs ≤ 40"
"883";"> 60 mL/min"
"884";"> 60 to ≤ 80 vs. ≤ 40"
"885";"> 60 years"
"886";"> 60 years 47 / 1425 (7.4)"
"887";"> 62.5 yrs"
"888";"> 65 years"
"889";"> 65 years (%)"
"890";"> 65 years Baseline LDL-C"
"891";"> 65 Years EZE/SIMVA („ = 319}"
"892";"> 65 Years EZE/SIMVA (n = 319)"
"893";"> 65 Years EZE/SIMVA Baseline LDL-C"
"894";"> 65 years old"
"895";"> 65 Years SIMVA"
"896";"> 65 Years SIMVA („ = 286}"
"897";"> 65 Years SIMVA (n = 286)"
"898";"> 65 years, n (%)"
"899";"> 65 yr"
"900";"> 7 years"
"901";"> 720 min"
"902";"> 74.5 min"
"903";"> 75 mg"
"904";"> 75 years"
"905";"> 75 years BMI"
"906";"> 75 years, n (%)"
"907";"> 75 yr"
"908";"> 8 % and <9 %"
"909";"> 8.0% and ≤ 9.0%"
"910";"> 80 mL min)1"
"911";"> 80 vs. ≤ 40"
"912";"> 9 % and <10 %"
"913";"> 9.0% and ≤ 10.0%"
"914";"> 90 mL/min/1.73 m2"
"915";"> IS years"
"916";"> l0 years"
"917";"> median"
"918";"> Median"
"919";"> median (2.8)"
"920";"> Median (21 mm)"
"921";"> Median (30 mm)"
"922";"> median (4.5)"
"923";"> Median (60%)"
"924";"> median (64)"
"925";"> Median (81 kg)"
"926";"> median 151.13"
"927";"> 58–< 64 mmol/mol (7.5–8.0%), N (%)"
"928";">= 35 kg/m2"
"929";">= 60 L/min"
"930";">= 60 l_/min"
"931";">= 60 yr"
"932";">= 75 years"
"933";">= 75 Years"
"934";">= 75 yr"
"935";">= 80 mL/mln"
"936";">= Median"
"937";">=1.9 to <10 ng/L (n=2033) n (%)"
"938";">=10 day s Initial Heparin Treatment Duration"
"939";">=10 days"
"940";">=10 to <26 ng/L (n=656) n (%)"
"941";">=10 years"
"942";">=100 kg"
"943";">=100 mmHg"
"944";">=140 mmHg"
"945";">=140 mmHq"
"946";">=26 ng/L (n=375) n (%)"
"947";">=26 ng/L (n=617)"
"948";">=30 kg/mA2"
"949";">=300 mg/g"
"950";">=325 meters"
"951";">=5 years and < 10 years"
"952";">=60 Kg"
"953";">=60^ Initial Heparin Treatment Duration"
"954";">=60kg"
"955";">=65 yea's"
"956";">=65 years"
"957";">=65 years (n=2474)"
"958";">=65 years (placebo n =4,271; saxagliptin n =4,290)"
"959";">=75 years"
"960";">=75 Years"
"961";">=75 years (placebo n = 1,161; saxagliptin n =1,169)"
"962";">=8% and <9% (>=64and <75 mmol/mol)"
"963";">=9% (75 mmol/mol)"
"964";">=9.0% ( >=75 mmol/mol)"
"965";">=90-<100 mmHg"
"966";">=90 ml/min/1.73m2"
"967";">=medan (54 Year-old)"
"968";">=Median (7 days)"
"969";">=Medion (7 days)"
"970";">0 to <12-5 mg/week"
"971";">0% and <1% predicted ARR (n = 8,943)"
"972";">0.03 -g/L"
"973";">0.04 ng/ml"
"974";">0.76 HDL cholesterol level"
"975";">0.94 mmol/L"
"976";">1-42 mmol/L"
"977";">1-5 years"
"978";">1 AEs"
"979";">1 AEs leading to discontinuation"
"980";">1 Antihypertensive medication, No. (%)"
"981";">1 Corticosteroids or immunosuppressants"
"982";">1 DES type"
"983";">1 drug-related"
"984";">1 drug-related AEs*"
"985";">1 erosion, n (%)"
"986";">1 exacerbation in prev 12 m (n=294)"
"987";">1 exacerbation in prev 12 m (n=316)"
"988";">1 exacerbation in prev 12 m (n=333)"
"989";">1 exacerbation in prev 12 m (n=443)"
"990";">1 failure"
"991";">1 Failure"
"992";">1 Glucose-lowering medication. No. (%)"
"993";">1 oral antidiabetic medication"
"994";">1 Prior myocardial infarction — no. (%)"
"995";">1 serious AEs"
"996";">1 to <=5 years, n (%)"
"997";">1 to <2 h, n (%)"
"998";">1 to 5 years"
"999";">1 to 5 years"
"1000";">1 type"
"1001";">1 U/kg/day"
"1002";">1 year"
"1003";">1 yr"
"1004";">1 yr, n (%)"
"1005";">1% predicted ARR (n = 472)"
"1006";">1.05 mmol/liter"
"1007";">1.30 mmol/l"
"1008";">1.5 mg/dl"
"1009";">1.5 ng/ml (n = 257)"
"1010";">1.58 mmol/L"
"1011";">1.6 mg/dl"
"1012";">1/3 lung fields"
"1013";">1/day"
"1014";">1:11 hrs:min (n=739)"
"1015";">1+35 mmol/L"
"1016";">10-14 (moderate risk)"
"1017";">10 DA of capillary nonperfusion in the eyec"
"1018";">10 days"
"1019";">10 years"
"1020";">10 years to <20 years"
"1021";">10 yr"
"1022";">10 years"
"1023";">100 & <130 mg/dl"
"1024";">100 and <130 mg/dl"
"1025";">100 but <130 mg/dl"
"1026";">100 kg"
"1027";">100 mg"
"1028";">100 mg/dl"
"1029";">100 ng/L"
"1030";">1000b (109b to 121a)"
"1031";">1000b (124b to 156a)"
"1032";">1000b (259b to 382a)"
"1033";">101 mg/dl"
"1034";">110 cm"
"1035";">12-5 mg/week"
"1036";">12 months"
"1037";">12 Months"
"1038";">12 Months (n = 1,746)"
"1039";">12 years"
"1040";">12 years education"
"1041";">121 mg/dl"
"1042";">122.5 mm Hg"
"1043";">1275 ft"
"1044";">129 min"
"1045";">12months"
"1046";">12months, n (%)"
"1047";">13.5 mm"
"1048";">130 & <160 mg/dl"
"1049";">130 ^mol/liter — no. (%)"
"1050";">130 and <160 mg/dl"
"1051";">130 mg/dl"
"1052";"〉130 ml/min per 1.73 m2, n (%)"
"1053";">130 to <140 mm Hg"
"1054";">130/tmol/liter— no. (%)"
"1055";">135 to <150 mm Hg"
"1056";">136 mm Hg"
"1057";">14 (high risk)"
"1058";">140-<160 mmHg"
"1059";">140 (ml) Additional angiography"
"1060";">140 mg/dl"
"1061";">140 ml"
"1062";">140 mm Hg"
"1063";">140 mm Hg — no. (%)"
"1064";">140 mmHg"
"1065";">140/>90 mm Hg"
"1066";">15 drinks"
"1067";">15 drinks/wk"
"1068";">15 enroll"
"1069";">15 min"
"1070";">15 ml/s"
"1071";">15 years"
"1072";">15 yr"
"1073";">150 at screening"
"1074";">150 mg/dl"
"1075";">150 mg/dL"
"1076";">150 mg/dl — %"
"1077";">150 mm Hg"
"1078";">150 per pL at screening"
"1079";">150 to <300 cells/mm^"
"1080";">150 to <300 cells/mm’"
"1081";">1500 and <2000"
"1082";">1500 mg"
"1083";">160 mm Hg"
"1084";">164.34 mm Hg"
"1085";">18 mon (N=948)"
"1086";">180 mm Hg"
"1087";">2 and/or >1 moderate or severe deformity, or both (N = 759)"
"1088";">2 Antihypertensive Medications"
"1089";">2 CHD risk factors"
"1090";">2 CV risk factors^ or established atherosclerotic CV disease"
"1091";">2 CV risk factors咐 or established atherosclerotic CV disease"
"1092";">2 days"
"1093";">2 drinks/week"
"1094";">2 episodes of atrial fibrillation in previous 6 mo"
"1095";">2 exacerbations"
"1096";">2 Exacerbations"
"1097";">2 h, n (%)"
"1098";">2 hr"
"1099";">2 lesions per vessel"
"1100";">2 mg/liter"
"1101";">2 mo"
"1102";">2 months"
"1103";">2 OADs"
"1104";">2 Previous venous thromboembolisms (%)"
"1105";">2 servings/wk (n=127)"
"1106";">2 symptom days per week"
"1107";">2 vessels treated"
"1108";">2 vessels with >50% stenosis"
"1109";"〉2 years"
"1110";">2 years"
"1111";">2 yr"
"1112";">2% Blood Eosinophils at Baseline"
"1113";">2(1) drinks/day if male(female)"
"1114";">2(n=15l6)"
"1115";">2.12 mmol/liter"
"1116";">2.59 mmol/L"
"1117";">2/3 lung fields"
"1118";">20 mg"
"1119";">20 mg/d PEq"
"1120";">20 mg/day"
"1121";">20 mm Hg"
"1122";">20 ng/L"
"1123";">20 years"
"1124";">20 yrs"
"1125";">200 lb"
"1126";">200 mg/dl"
"1127";">200 mg/dl — %"
"1128";">2000 and <3000"
"1129";">21 kg/m2"
"1130";">23-^25 kg/m’"
"1131";">23-s25 kg/m’"
"1132";">24 kg/m2"
"1133";">25-<30kg/m2 (n = 327)"
"1134";">25-<s27 kg/m’"
"1135";">25-s27 kg/m’"
"1136";">25 kg/m2"
"1137";">25 to <50 ppb"
"1138";">25 years"
"1139";">250 microg/l"
"1140";">25kg/m2"
"1141";">27-^30 kg/m’"
"1142";">27-s30 kg/m’"
"1143";">27.2 kg/m2 Hypertension:"
"1144";">277.6 pmol/liter"
"1145";">277.6 pmol/liter hsCRP level"
"1146";">2to<59 ULN"
"1147";">3 additional CV risk factors11"
"1148";">3 diseased vessels"
"1149";">3 drinks/dav"
"1150";">3 hr"
"1151";">3 mg/L (n = 2139)"
"1152";">3 mm"
"1153";">3 oral agents"
"1154";">3.0 mg/l"
"1155";">3.0 mmol/liter"
"1156";">3.12 mmol/liter"
"1157";">3.4 mmol/l"
"1158";">3.4 mmol/L"
"1159";">3.5 vs. > 2.1 and ≤ 3.5"
"1160";">30 — no. {%)"
"1161";">30 —no. {%)"
"1162";">30 (moderate or high bleeding risk), No./total (%)"
"1163";">30 days"
"1164";">30 days to 1 year (n = 6501)"
"1165";">30 kg nr"
"1166";">30 kg/m^"
"1167";">30 kg/m^ (obesity)"
"1168";">30 kg/m’"
"1169";">30 kg/m2"
"1170";">30 kg/m2 (n — 221)"
"1171";">30 kg/m2 (n = 155)"
"1172";">30 ky/nr"
"1173";">30 mg/g"
"1174";">30 min"
"1175";">30 to <45 mL/min/L73nr"
"1176";">30 to <50 ml/min"
"1177";">30 to <60 eGFR, mL/min/1.73 m2 a"
"1178";">30 to <60 mg dL"
"1179";">30 to <60ml/min/1.73m2"
"1180";">30 to <700 IU/L"
"1181";">30 to 300 mg/g"
"1182";">30% and <50%"
"1183";">30% predicted to <50% predicted"
"1184";">30, No. (%)"
"1185";">30.0 kg/m2"
"1186";">300 cells/mm^"
"1187";">300 in previous"
"1188";">300 mg/g"
"1189";">300 per pL in 12 months before screening"
"1190";">33 mm Hg"
"1191";">35 kg/nr"
"1192";">4'01 mmol/L"
"1193";">4-1 mmol/L"
"1194";">4 hr"
"1195";">4 mmol/L"
"1196";">4 months, mean (SD)"
"1197";">4 months, median (min, max)"
"1198";">4 y Pathogenesis, n (%)"
"1199";">4.0 to <5.5 mU/L-mmol/L"
"1200";">4.0 to <5.5 mU/L$mmol/L"
"1201";">4.13 mmol/l"
"1202";">4.18mmol/L (n=730)"
"1203";">4/week"
"1204";">40 and <50%"
"1205";">40 mg/dl"
"1206";">40 mm"
"1207";">40 mm Hg"
"1208";">40 years"
"1209";">40, obesity class 3"
"1210";">40: obese class III"
"1211";">42 mm (n=555)"
"1212";">43 mg/dl"
"1213";">45 ml/min/1.73 m2"
"1214";">45 to <60 mL/min/L73nr"
"1215";">5-<15 years"
"1216";">5-10 years"
"1217";">5 - <15 years"
"1218";">5 to <10 years"
"1219";">5 to <15 yr"
"1220";">5 to 10 years"
"1221";">5 to 10 years"
"1222";">5 years"
"1223";">5 years, n (%)"
"1224";">5 yr"
"1225";">5.0 mg/liter"
"1226";">5.5 mmol/liter"
"1227";">5.5 to <8.5 mU/L-mmol/L"
"1228";">5.5 to <8.5 mU/L$mmol/L"
"1229";">5.8 mg/liter"
"1230";">5.8 mg/liter Antiplatelet agents"
"1231";">50-100 kg"
"1232";">50-60 yr"
"1233";">50 ml/min"
"1234";">50 mL/min"
"1235";">50 ml/min/1.73 m2"
"1236";">50 ng/L"
"1237";">50 ppb"
"1238";">50 to <80 ml/min"
"1239";">50 yr"
"1240";">50% coronary stenosis"
"1241";">50% predicted"
"1242";">50% responder rate, n (%)"
"1243";">50% stenosis of coronary, carotid, or lower extremity arteries"
"1244";">50% stenosis of major artery, n (%)"
"1245";">503 ug/g"
"1246";">51 ml/min/1.73 m2"
"1247";">55 y, n (%)"
"1248";">55 years to <65 years (n=2819)"
"1249";">59ULN"
"1250";">5yearstos IS years"
"1251";">6-21 mmol/L"
"1252";">6 hr"
"1253";">6 hrs"
"1254";">6 mg/L"
"1255";">6 mo"
"1256";">6 month n = 368"
"1257";">6 months"
"1258";">6 months—number/N (%)"
"1259";">6 weeks"
"1260";">6.21 mmol/l"
"1261";">60-67 years"
"1262";">60 CrCl"
"1263";">60 eGFR, mL/min/1.73 m2"
"1264";">60 kg"
"1265";">60 kg Body Weight at Randomization"
"1266";">60 mg/dL (>1.55 mmol/L)++"
"1267";">60 mi/min"
"1268";">60 ml/min"
"1269";">60 mL/min"
"1270";">60 ml/min/1.73 m2"
"1271";">60 ml/min/1.73 m2— no. (%)"
"1272";">60 mL/niin/L73ni-"
"1273";">60 mLYmin"
"1274";">60 to <90 eGFR, mL/min/1.73 m2 a"
"1275";">60 to <90 mg dL"
"1276";">60 to <90 ml/min/1.73 m^"
"1277";">60 to <90iiil/iiim/1.73 m2"
"1278";">60 years"
"1279";">60 years 47/1425(7.4)"
"1280";">60 yr"
"1281";">60.0 ml/min/1.73 m2"
"1282";">64 yr"
"1283";">65 mm Hg"
"1284";">65 to <75 years"
"1285";">65 to <75 yr"
"1286";">65 y (n=125)"
"1287";">65 y (n=127)"
"1288";">65 y, n (%)"
"1289";">65 y, No. (%)"
"1290";">65 years"
"1291";">65 years (n=1263)"
"1292";">65 years n Z 1330"
"1293";">65 years of age"
"1294";">65 Years of Age"
"1295";">65 years of age, n (%)"
"1296";">65 years to <75 years (n=3523)"
"1297";">65 years, n (%)"
"1298";">65 yr"
"1299";">65 yr — no. (%)"
"1300";">65 yr (%)"
"1301";">65 yr (n = 212)"
"1302";">65 yr From the United States"
"1303";">65 yrs"
"1304";">65 yrs of age (n = 3,116)"
"1305";">65 yrs Sex:"
"1306";">65, n (%) Gender, n (%)"
"1307";">65y,No. (%)"
"1308";">66 mg/dl"
"1309";">67 to <84 mg/dl"
"1310";">67 years"
"1311";">69 yr"
"1312";">7 years"
"1313";">7.5 mg/day, %"
"1314";">7.9 mmol/liter"
"1315";">70-90 kg"
"1316";">70-96 kg"
"1317";">70 & <100 mg/dl"
"1318";">70 and < 100 mg/dl"
"1319";">70 but <100 mg/dl"
"1320";">70 y, n (%)"
"1321";">70 years"
"1322";">70 years (n=556)"
"1323";">70 years, n (%)"
"1324";">70 yr"
"1325";">70 yr— no. {%)"
"1326";">70 yr — no. (%)"
"1327";">70 yrs"
"1328";">700 IU/L"
"1329";">73 mm Hg"
"1330";">75 (n, %) Weight, kg"
"1331";">75 beats/min"
"1332";">75 y (n=18)"
"1333";">75 y (n=19)"
"1334";">75 y (n=2010)"
"1335";">75 y (N=8474, 40.2%)"
"1336";">75 y. n (%)"
"1337";">75 years"
"1338";">75 years (n=1066)"
"1339";">75 years or <50 CrCl, n (%)"
"1340";">75 years, n (%)"
"1341";">75 yr"
"1342";">75 yr— no. (%)"
"1343";">75 yr— no. {%)"
"1344";">75 yr — no. (%)"
"1345";">75 yr —%"
"1346";">75 yr (N = 2471)"
"1347";">75 yrs"
"1348";">75.5 bpm"
"1349";">75.5 bpm Current smoker"
"1350";">77 bpm (n=3357)"
"1351";">77 yr"
"1352";">77 yr Sex"
"1353";">8% to <9% (>64 to <75 mmol/mol)"
"1354";">8% to <9% (>64 to 5 mmol/mol)"
"1355";">8%, n (% of patients)"
"1356";">8.5 mg/dL"
"1357";">8.5 mU/L- mmol/L"
"1358";">8.5 mU/L$ mmol/L"
"1359";">80 (n, %) CHADS2 score"
"1360";">80 kg"
"1361";">80 kg— no. (%)"
"1362";">80 ml/min"
"1363";">80 mL/min"
"1364";">80 mL/min (n=3880)"
"1365";">80, < 100 mg/dl"
"1366";">80, <100 mg/dl"
"1367";">80kg"
"1368";">82.0-97.3 kg"
"1369";">84 mg/dl Baseline high-sensitivity CRP"
"1370";">85 mm Hg"
"1371";">85 years"
"1372";">850 beds"
"1373";">87 bpm (n=13l8)"
"1374";">9 months"
"1375";">9 yr"
"1376";">9 yr— no. {%)"
"1377";">9% (>75 mmol/mol)"
"1378";">90 days (%)"
"1379";">90 eGFR, mL/min/1.73 m2 a"
"1380";">90 kg"
"1381";">90 mg dL"
"1382";">90 mL min-1 1.73 m'2"
"1383";">90 mL/min per 1-73 m2"
"1384";">90 mL/min per 1.73 m^"
"1385";">90 ml/min/1.73"
"1386";">90 ml/min/1.73 m^"
"1387";">90 ml/min/1.73 m2"
"1388";">90 mL/min/1.73m2"
"1389";">90ml/min/1.73"
"1390";">96 kg"
"1391";">97.3 kg"
"1392";">99-110 cm"
"1393";">II"
"1394";">l:36hrs:min (n=742)"
"1395";">lto £2 symptom days per week"
"1396";">lto<2 (n=951)"
"1397";">lto<2 (n=963)"
"1398";">Mean"
"1399";">median"
"1400";">Median"
"1401";">Median (0.37 years)—number/N (%)"
"1402";">Median (0.5)—number/N (%)"
"1403";">Median (1.375)—number/N (%)"
"1404";">Median (4.5)—number/N (%)"
"1405";">Median (5.4)—number/N (%)"
"1406";">Median (62)—number/N (%)"
"1407";">o-9-i-i"
"1408";">o-9-ii"
"1409";">Q1 (0)-Q2 (0.5)—number/N (%)"
"1410";">Q1 (1.5)-Q2 (4.5)—number/N (%)"
"1411";">Q1 (2)-Q2 (4.5)—number/N (%)"
"1412";">Q2 (0.5)-Q3 (5)—number/N (%)"
"1413";">Q2 (4.5)-Q3 (8.5)—number/N (%)"
"1414";">Q3 (5)—number/N (%)"
"1415";">Q3 (8.5)—number/N (%)"
"1416";">ULNand<20 ng/L"
"1417";">Year 1"
"1418";"± SD."
"1419";"±standard deviation. Triglyceride"
"1420";"«60 kg"
"1421";"»65 yr"
"1422";"»75 years"
"1423";"§ Classes on the Canadian Cardiovascular Society (CCS) scale range from I to IV,"
"1424";"†Includes patients originally randomized to placebo who were switched to secukinumab per the study designs. ‡AEs that occurred in at least 2.0% of the patients in the Any secukinumab group during the 16‐week placebo‐controlled period and events with an EAIR of at least 5.0 cases per 100 patient‐years in the Any secukinumab group during the entire treatment period. Events listed according to preferred term in the Medical Dictionary for Regulatory Activities (MedDRA version 17.0), sorted in descending order of EAIR in the Any secukinumab group for the entire treatment period. The entire treatment period for safety data was from baseline to Week 52 visit of the last patient enrolled in these studies. AE, adverse event; AS, ankylosing spondylitis; EAIR, Exposure adjusted incidence rates; N, number of randomized patients; SAE, serious adverse event; URTI, upper respiratory tract infection."
"1425";"• 1: Death from any cause, major coronary event, or nonfatal stroke"
"1426";"• Any MI"
"1427";"• Any stroke"
"1428";"• Death from any cause"
"1429";"• Death from coronary heart disease"
"1430";"• Death from CV causes, major coronary event, or nonfatal stroke"
"1431";"• Hemorrhagic stroke"
"1432";"• Hospitalization for unstable angina"
"1433";"• II: Death from coronary heart disease, nonfatal MI, coronary revascularization > 30 days"
"1434";"• III: Death from CV causes, nonfatal MI, hospitalization for UA, all revascularization > 30 days, nonfatal stroke"
"1435";"• Ischemic stroke"
"1436";"• Ml with ST-segment elevation"
"1437";"• Ml without ST-segment elevation"
"1438";"• Unstable angina"
"1439";"• Urgent coronaiy revascularization > 30 days"
"1440";"•?SD ml/min"
"1441";"•j. The body-mass index is the weight in kilograms divided by the square of the"
"1442";"0-10 (low risk)"
"1443";"0-10 (mild)"
"1444";"0-12 hours"
"1445";"0-15 min"
"1446";"0-30 min"
"1447";"0-32 (O18-O-55)"
"1448";"0-33 (95% Cl 0-23 to 0-49)"
"1449";"0-45 (O-35-O-58)"
"1450";"0-46 (O-37-O-58)"
"1451";"0-5 days"
"1452";"0-5 mm"
"1453";"0-52 (O-3O-O-91)"
"1454";"0-55 (95% Cl 0-38 to 0-81)"
"1455";"0-56 (O-23-I-41)"
"1456";"0-59 (O-32-I-O6)"
"1457";"0-59 fO-42 0-82^"
"1458";"0-60 (O-4O-O-91)"
"1459";"0-65 (O-4S-O-87)"
"1460";"0-67 (O-51-O-87)"
"1461";"0-68 (O-52-O-89)"
"1462";"0-69 (O-5O-O-94)"
"1463";"0-72 (O-66-O-8O)"
"1464";"0-72 (O-6I-O-85)"
"1465";"0-73 (O-53-1-OO)"
"1466";"0-74 (O-61-O-91)"
"1467";"0-74 (O-63-O-86)"
"1468";"0-76 (O-7O-O-83)"
"1469";"0-77 (O-65-O-91)"
"1470";"0-80 (O-67-O-95)"
"1471";"0-81 (O-51-I-28)"
"1472";"0-83 fO-74-O-Q^I"
"1473";"0-87 {O-75-1-O1)"
"1474";"0-92 (O7O-I-I9)"
"1475";"0-95 (s1-14)t"
"1476";"0-96 (s1-16)t"
"1477";"0-97 (O-7S-I-21)"
"1478";"0-Blocker"
"1479";"0—5 days"
"1480";"0 (or 1, if female only)"
"1481";"0 63 fO 39-1 01)"
"1482";"0 86 (O-69-I-O8)"
"1483";"0 drinks"
"1484";"0 drinks/wk"
"1485";"0 exacerbations"
"1486";"0 or 1"
"1487";"0 or 1 — no./total no. (%)"
"1488";"0 or 1, n (%)"
"1489";"0 or 1, No./total No. (%)"
"1490";"0 to <1 h, n (%)"
"1491";"0 to <2 hr"
"1492";"0 to 1 symptom days per week"
"1493";"0 vessel"
"1494";"0.098 (0.004-0.i9i)"
"1495";"0.125 mg"
"1496";"0.15 (0.02, 1.28) PTY=111"
"1497";"0.250 mg"
"1498";"0.375 mg"
"1499";"0.4 VS 0.6"
"1500";"0.47 95%CI: 0.23-0.98 P =0.043"
"1501";"0.5 mg"
"1502";"0.5 mg (N = 824)"
"1503";"0.5 mg (N = 826)"
"1504";"0.500 mg"
"1505";"0.62 (0.43, 0.89) PTY=2364"
"1506";"0.64 (0.45, 0.92) PTY = 2439"
"1507";"0.67 {0.49, 0.91) PTY = 2680"
"1508";"0.68 (0.49, 0.95) PTY=2036"
"1509";"0.69 (0.50, 0.94) PTY= 2788"
"1510";"0.7(0.4-l.l)"
"1511";"0.73 (0.55, 0.97) PTY = 3225"
"1512";"0.75 (95% CI 0.61 to 0.93) P =0.008"
"1513";"0.76 {0.46, 1.26} PTY=1301"
"1514";"0.77 {0.41,1.44) PTY = 548"
"1515";"0.79 (95% CI 0.53 to 1.18)"
"1516";"0.8 vs 1.3"
"1517";"0.81 (0.52, 1.26) PTY = 898"
"1518";"0.87 (0.55, 1.36) PTY = 972"
"1519";"0.89 (0.46, 1.74) PTY = 657"
"1520";"0.90 (95% CI 0.60 to 1.33)"
"1521";"0.95 (95% Cl 0.80 to 1.11) P =0.50"
"1522";"0.97 (0.88-1.OS)"
"1523";"0.97to.86. I.IOt"
"1524";"0.i23 (0.04i-0.205)"
"1525";"0=no symptoms"
"1526";"0119 (O-O65-O-173)"
"1527";"0134 (O-O88-O-179)"
"1528";"0134 (OO86-O.181)"
"1529";"048 (O-28-O-81)"
"1530";"08 IX"
"1531";"0tob 12 months"
"1532";"0tob 12 months, n (%)"
"1533";"0tol(n=1082)"
"1534";"0tol(n=1102)"
"1535";"1-14 drinks"
"1536";"1-14 drinks/wk"
"1537";"1-2 years"
"1538";"1-2 yr"
"1539";"1-2 yrs"
"1540";"1-3 drinks/dav"
"1541";"1-3/month"
"1542";"1-3/week"
"1543";"1-4/week (n = 3603)"
"1544";"1-5 years"
"1545";"1-5 yr"
"1546";"1-5/day"
"1547";"1-6 months"
"1548";"1-6/week"
"1549";"1——BH—I"
"1550";"1—e-H"
"1551";"1—eM"
"1552";"1    Placebo n=238"
"1553";"1 ($90 ml/min)"
"1554";"1 (4 SI"
"1555";"1 (except for female alone)"
"1556";"1 (FEVi ^80% pred)"
"1557";"1 (ref)"
"1558";"1 Abciximab (n = 1012)"
"1559";"1 Amlodipine- Chlorthalidone"
"1560";"1 Antihypertensive Medication"
"1561";"1 Aspirin (n = 19 934)"
"1562";"1 Baricitinib 2 mg ■ Baricitinib 4 mg"
"1563";"1 Chlorthalidone"
"1564";"1 Chlorthalidone (n = 15255)"
"1565";"1 Chlorthalidone Amlodipine"
"1566";"1 Cl)"
"1567";"1 day L"
"1568";"1 Degree of ICA stenosis丰"
"1569";"1 e5 years"
"1570";"1 Early Intervention (n = 203)"
"1571";"1 event, 0.1 per 100 py (0.0-0.4)"
"1572";"1 exacerbation"
"1573";"1 Exacerbation"
"1574";"1 exacerbation in prev 12 m (n=1238)"
"1575";"1 exacerbation in prev 12 m (n=1279)"
"1576";"1 exacerbation in prev 12 m (n=1299)"
"1577";"1 exacerbation in prev 12 m (n=1708)"
"1578";"1 exacerbations"
"1579";"1 IS ( 3.2)"
"1580";"1 Lisinopril"
"1581";"1 Lisinopril- Chlorthalidone"
"1582";"1 Low (n = 1024)"
"1583";"1 med at baseline"
"1584";"1 mg (288, 24.5%)"
"1585";"1 mg a"
"1586";"1 mg/day"
"1587";"1 mg/day - placebo"
"1588";"1 mg/day delayed-start"
"1589";"1 mg/day early-start"
"1590";"1 mg/day early-start - delayed-start"
"1591";"1 month L"
"1592";"1 n qi"
"1593";"1 n/N"
"1594";"1 No. of Events"
"1595";"1 OAD"
"1596";"1 OAM"
"1597";"1 or 2"
"1598";"1 or more"
"1599";"1 oral antidiabetic medication"
"1600";"1 P Value"
"1601";"1 Parameter"
"1602";"1 Placebo"
"1603";"1 Placebo (n = 19 942)"
"1604";"1 prior TNF antagonist failure, n (%)b"
"1605";"1 Prolonged Antithrombotic Pretreatment (n = 207)"
"1606";"1 st < 2.7"
"1607";"1 Standard (n = 1002)"
"1608";"1 t    i"
"1609";"1 to 2 years"
"1610";"1 to 3 mg/L (n = 1963)"
"1611";"1 vessel"
"1612";"1 Vitamin E"
"1613";"1 Vitamin E (n = 19 937)"
"1614";"1 week to 1 month"
"1615";"1 year mean change from baseline"
"1616";"1 year or more"
"1617";"1.0-2.9 mg/l"
"1618";"1.0 (Reference)"
"1619";"1.0 (referent)"
"1620";"1.0 mg"
"1621";"1.0 mg (N = 822)"
"1622";"1.0 mg (N = 825)"
"1623";"1.00 (ref.)"
"1624";"1.00 (reference)"
"1625";"1.00 (Reference)"
"1626";"1.14 (95% CI 0.77 to 1.68)"
"1627";"1.14f0.87, 1.5H"
"1628";"1.2 (fi.6)"
"1629";"1.3 vs 1.3"
"1630";"1.4 vs 1.0"
"1631";"1.5 VS 2.3"
"1632";"1.6 vs 1.9"
"1633";"1.7% vs. 3.8%"
"1634";"1.9-<10 ng/L (n=1917)"
"1635";"1=minor symptoms; no limitations"
"1636";"10-<15 yrs"
"1637";"10-<26 ng/L (n=1023)"
"1638";"10-Year Framingham CHD risk"
"1639";"10-Year Framingham CHD risk (%)28 mean /SD)"
"1640";"10-year Framingham CHD risk, %"
"1641";"10-year risk for CHD"
"1642";"10-Year risk of CHD, %#"
"1643";"10-Year risk of CHD, %# <5.0"
"1644";"10-Yr Rate/100 Participants"
"1645";"10-yr risk of coronary heart disease (%)^|"
"1646";"10 μg (n=207)"
"1647";"10 μg (n=217)"
"1648";"10 mg"
"1649";"10 mg (N = 1127)"
"1650";"10 mg (n = 120)"
"1651";"10 mg (n = 74)"
"1652";"10 mg (n 5 74)"
"1653";"10 mg (n=80)"
"1654";"10 mg empagliflozin"
"1655";"10 mg/d (n = 333)"
"1656";"10 mg/kg"
"1657";"10 ml/min"
"1658";"10 to <19 mm Hg"
"1659";"10 to <20 mm Hg"
"1660";"10 years or more"
"1661";"10 yrs"
"1662";"10% (-Ito 20)"
"1663";"10% (Oto 19)"
"1664";"10% participants"
"1665";"10.0 per 100 py"
"1666";"10.8 per 100 py"
"1667";"10/10 mg"
"1668";"10/20 mg"
"1669";"10/40 mg"
"1670";"10/80 mg"
"1671";"100-125 mg/dl*"
"1672";"100 mg"
"1673";"100 mg (n = 74)"
"1674";"100 mg + MTX"
"1675";"100 mg sirukumab every 2 weeks (n=292)"
"1676";"100 mg/50 mgb"
"1677";"100 ml (70 to 140) (n=301/253)"
"1678";"100 to <140 mm Hg"
"1679";"100/50 mga(n = 72)"
"1680";"1000 mg/day"
"1681";"100to<140mmHg"
"1682";"104-121 mg/dl"
"1683";"106-115 mg/dl"
"1684";"108 (mono)"
"1685";"10mg"
"1686";"11-20 (moderate)"
"1687";"11-20/day"
"1688";"11-30 days (%)"
"1689";"11 Cl)"
"1690";"11% (-Ito 22)"
"1691";"11% (Ito 20)"
"1692";"11% (Oto 21)"
"1693";"11.4 per 100 py"
"1694";"11.9 per 100 py"
"1695";"110 mg dabigatran"
"1696";"110 mg dabigatran (n=6014)"
"1697";"110 ml (80 to 140) (n=283/267)"
"1698";"115 (95% Cl 23 to 207)"
"1699";"116-125 mg/dl"
"1700";"118 < SBP < 128mmHg n = 373"
"1701";"118b (58b to >1000a)"
"1702";"12-17 years"
"1703";"12-17 yr"
"1704";"12-24 Hours"
"1705";"12-lead ECG heart rate, beats/min"
"1706";"12-wk Kaplan-Meier Rate, %"
"1707";"12 Carotid artery sites"
"1708";"12 Cl)"
"1709";"12 LOCF)"
"1710";"12 mo"
"1711";"12 mo, mean (SD)x"
"1712";"12 months"
"1713";"12 montlts"
"1714";"12% (Ito 22)"
"1715";"12.5 per 100 py"
"1716";"120-129/75-84 mm Hg"
"1717";"120 ml (90 to 150) (n=300/324)"
"1718";"120 ml (90 to 160) (n-242/236)"
"1719";"120 ml (90 to 160) (n=233/237)§"
"1720";"1200 mg (n = 201)"
"1721";"1200mg vs Placebo"
"1722";"121 to 139 mm Hg"
"1723";"125 to <140 mm Hg"
"1724";"128< SBP< 138 mmHg n = 403"
"1725";"128< SBP< 138 mmHg n=403"
"1726";"130-139/85-89 mm Hg"
"1727";"130 mg (N = 209)"
"1728";"130 mg (N = 245)"
"1729";"130 ml (100 to 160) (n=263/268)"
"1730";"130 ml (100 to 160) (n=272/267)"
"1731";"130 ml (90 to 160) (n=247/237)"
"1732";"130 ml (90 to 170) (n=205/180)"
"1733";"130 to <140 mm Hg — no. {%)"
"1734";"133-230 mg/dl"
"1735";"133 events,"
"1736";"133.83 to <149.34 mmHg"
"1737";"135-173 mg/dl"
"1738";"13O-I49 mm Hg"
"1739";"14.1 per 100 py"
"1740";"14.1 per 100 pyr"
"1741";"14.4 per 100 py"
"1742";"14.7% vs. 18.2%"
"1743";"140 events,"
"1744";"140 ml (100 to 170) (n=229/251)"
"1745";"140 ml (110 to 170) (n=331/285)"
"1746";"140 to <160 mm Hg"
"1747";"140 to<160mmHg"
"1748";"143 [106-198JS"
"1749";"143 f6q%)"
"1750";"148.0 (95%CI: 140.5, 155.6, n=60)"
"1751";"149.34 to <164.34 mm Hg"
"1752";"15-<20 yrs"
"1753";"15-year predicted risk (%) of"
"1754";"15 mg"
"1755";"15 mg (n=95)"
"1756";"15 min/time)"
"1757";"15 to <25 years"
"1758";"15+ drinks/wk"
"1759";"150 mg"
"1760";"150 mg (n=1094)"
"1761";"150 mg (N=110)"
"1762";"150 mg (N=125)"
"1763";"150 mg (N=72)"
"1764";"150 mg (N=87)"
"1765";"150 mg (n=92)"
"1766";"150 mg dabigatran"
"1767";"150 mg dabigatran (n=6076)"
"1768";"150 to < 300 cel"
"1769";"150 to < 300 cells"
"1770";"150 mg"
"1771";"150mg"
"1772";"150mg (n=80)"
"1773";"151.7 (95%CI: 143.5, 159.9, n=68)"
"1774";"154.4i11.9 (n=323)"
"1775";"159 (23.8%), 144 (20.8%), 9.3 per 100 7.9 per pyr 100 pyr"
"1776";"15mg"
"1777";"16.2 per 100 13.6 per 100 pyr pyr"
"1778";"16.8 per 100 py"
"1779";"160 mg"
"1780";"160 to <180 mm Hg"
"1781";"164 (95% Cl 71 to 257)"
"1782";"165.9i10.3 (n=573)"
"1783";"166 (24.9%), 147 (21.2%), 8.1 per 100 6.8 per pyr 100 pyr"
"1784";"1689 (10.9) (Continued )"
"1785";"1697 (only 1 distal)"
"1786";"16O/17O8 (9-4%)"
"1787";"17.5 per 100 py"
"1788";"17.6% vs. 25.6%"
"1789";"1700 mg/day"
"1790";"173 f3l%1"
"1791";"174 (1S.S)"
"1792";"175<8S)n 88(9.8)"
"1793";"179 events,"
"1794";"18-39 yr"
"1795";"18-40 years"
"1796";"18-64 yr"
"1797";"18 - <40 years"
"1798";"18 -24.9 kg/m2"
"1799";"18 (9.5%), 3.2 per 100 pyr"
"1800";"18 9.51 (0.43) [80 (4.7)] -0.64 (-0.99 to -0.29) [-7.0 (-10.8 to -3.2)] -0.82 (0.18) [-9.0 (2.0)]"
"1801";"18 to <40 years"
"1802";"18 to <65 years"
"1803";"180-360 min"
"1804";"189b (71b to 291a)"
"1805";"19 to <33 mm Hg"
"1806";"19.4 per 100 pyr"
"1807";"1st Tertile (<=87 mg/dL [<= 2.3 mmol/L])b"
"1808";"1st: 0-96.55 pmol/L"
"1809";"1Yr"
"1810";"2-10 years"
"1811";"2-3 days"
"1812";"2-5 years"
"1813";"2-5 yrs"
"1814";"2-gi"
"1815";"2-h PG (mmol/L)"
"1816";"2-h plasma glucose during OGTT (mmol/L)"
"1817";"2-h PMG (mg/dL)"
"1818";"2-h PMG (mmol/L)"
"1819";"2-h PMG, mmol/L (mean ± SD)"
"1820";"2-h postprandial C-peptide (ng/mL)"
"1821";"2-h postprandial insulin (mIU/mL)"
"1822";"2-h postprandial proinsulin (pmol/L)"
"1823";"2-h PPG (mmol/L)"
"1824";"2-h PPG (mmol/l)*"
"1825";"2-hour postload glucose,"
"1826";"2-hour PPG, mmol/L"
"1827";"2-Hr plasma glucose — mg/dl"
"1828";"2-y Kaplan-Meier rate (95% CI)"
"1829";"2 — no./total no. (%)"
"1830";"2 (60 to < 90 ml/min)"
"1831";"2 (FEVi 50-<80% pred)"
"1832";"2 5 to <30 kg/m2"
"1833";"2 BMI, kg/m"
"1834";"2 exacerbations"
"1835";"2 hr after glucose challenge"
"1836";"2 mg"
"1837";"2 mg (293, 25.0%)"
"1838";"2 mg/day"
"1839";"2 mg/day - placebo"
"1840";"2 mg/day delayed-start"
"1841";"2 mg/day early-start"
"1842";"2 mg/day early-start - delayed-start"
"1843";"2 mg/day early-start - delayed start"
"1844";"2 non-MTX"
"1845";"2 OADs"
"1846";"2 or 3"
"1847";"2 or 3 d/mo"
"1848";"2 or 3 d/wk"
"1849";"2 or 3 days"
"1850";"2 or 3 high-risk categories"
"1851";"2 or 3 high cardiovascular risk categories"
"1852";"2 or 3 step"
"1853";"2 or more"
"1854";"2 prior TNF antagonist failures, n (%)b"
"1855";"2 vessels"
"1856";"2 yr KM % (n)"
"1857";"2 yr. KM Rate"
"1858";"2, No./total No. (%)"
"1859";"2.0 (NE, NE)"
"1860";"2.0 vs 1.5"
"1861";"2.1 range 0-5"
"1862";"2.2, range 0-5"
"1863";"2.3 vs 2.7"
"1864";"2.5 mg (n = 113)"
"1865";"2.5 mg (n=82)"
"1866";"2.5 mg BID"
"1867";"2.59-3.35 mmol/l"
"1868";"2.5mg"
"1869";"2.6 per 100 py"
"1870";"2.6 vs 2.0"
"1871";"2.6 vs 3.1"
"1872";"2.7% VI. 2.9%"
"1873";"2.7% vs. 2.9%"
"1874";"2.8% vs. 5.2%"
"1875";"2.9 VS 1.9"
"1876";"2=some restrictions; no help needed"
"1877";"20 9.64 (0.52) [82 (5.7)] 0.18 (-0.19 to 0.54) [2.0 (-2.1 to 5.9)]"
"1878";"20 I-26-81AI"
"1879";"20 mg"
"1880";"20 mg (N = 1107)"
"1881";"20 mg (n = 115)"
"1882";"20 mg (n = 75)"
"1883";"20 mg (n 5 75)"
"1884";"20 mg (n=82)"
"1885";"20 mg twice daily n=169"
"1886";"20 mg, rosuvastatin 5 mg."
"1887";"20 to <40 mm Hg"
"1888";"20.6 (ll.35)"
"1889";"200/100 mg (n = 331)"
"1890";"206 mgrdL"
"1891";"20mg"
"1892";"21-30 (severe)"
"1893";"21-35 mmol/L"
"1894";"21-42 mmol/L"
"1895";"210 (31.5%), 194 (28.0%), 12.3 per    10.6 per 100 pyr    100 pyr"
"1896";"213-250 mg/dl"
"1897";"2140 mm Hg"
"1898";"2160 mmHg"
"1899";"22 vessel PCI"
"1900";"224 kg/m2"
"1901";"225 years"
"1902";"23.0 per 100 py"
"1903";"23.7% VI, 26.3%"
"1904";"23.7% vs. 26.3%"
"1905";"2300 mg/g, n (%)"
"1906";"238b (78b to 223a)"
"1907";"24-01 mmol/L"
"1908";"24-Hour maDBP, mm Hg"
"1909";"24-Hour maSBP, mm Hg"
"1910";"24 months"
"1911";"24.5% vs. 33.7%"
"1912";"2400 mg (n = 196)"
"1913";"2400mg vs Placebo"
"1914";"25-29.9 kg/m2"
"1915";"25 - <30 kg/m2"
"1916";"25 - 29.9 kg/m2"
"1917";"25 (OH) vitamin D (ng/mL)"
"1918";"25 μg BID (N=185)"
"1919";"25 μg BID (N=200)"
"1920";"25 μg BID (N=231)"
"1921";"25 μg BID (N=245)"
"1922";"25 μg BID (N=47)"
"1923";"25 mg"
"1924";"25 mg empagliflozin"
"1925";"25 to <30 — no. {%)"
"1926";"25 to <30 kg/m2"
"1927";"25 yrs"
"1928";"25.0-29.9 kg/m2"
"1929";"25<BMI<30"
"1930";"250 mg"
"1931";"250 years"
"1932";"251 events,"
"1933";"2553 (io-6%)"
"1934";"25mg"
"1935";"25th-75th Percentiles"
"1936";"25th—75th Percentiles"
"1937";"26-21 mmol/L"
"1938";"26 to <43 mm Hg"
"1939";"260 years"
"1940";"265 years"
"1941";"2690 C.T"
"1942";"27-29-9, overweight"
"1943";"27-29.9: overweight"
"1944";"271b (81b to 199a)"
"1945";"275 Yr"
"1946";"280rrMnl)"
"1947";"29-33 kg/m2"
"1948";"29 (16.7%), 4.8 per 100 pyr"
"1949";"29.1 per 100 py"
"1950";"290 kg"
"1951";"2922 A.G"
"1952";"2baseline mean"
"1953";"2hr prandial glucose'*’"
"1954";"2i9 (2i.2)"
"1955";"2l.8 (l2.5l)"
"1956";"2l60mmHg"
"1957";"2nd >2.7/<7.5"
"1958";"2nd Tertile (>87 to <=120 mg/dL [>2.3 to <=3.1 mmol/L])c"
"1959";"2nd: 96.56-125.77 pmol/L"
"1960";"2or3"
"1961";"2S.4±S.9"
"1962";"2S.6±S.9"
"1963";"3-<6 months, n (%)"
"1964";"3-<6mo,n (%)"
"1965";"3-6 — no./total no. (%)"
"1966";"3-6 hr"
"1967";"3-6 mo"
"1968";"3-6 months"
"1969";"3-6 Months fn = 1.009)"
"1970";"3-6, No./totalNo. (%)"
"1971";"3-Blocker"
"1972";"3-Month Follow-Up Median (IQ Range)"
"1973";"3-point MACE"
"1974";"3-polnt MACE"
"1975";"3-yr KM Mortality Rate"
"1976";"3-yr%"
"1977";"3–6 months"
"1978";"3–6 Months"
"1979";"3 (30 to < 60 ml/min)"
"1980";"3 (FEVi 30-<50% pred)"
"1981";"3 (moderate disease)"
"1982";"3 (Moderate disease)"
"1983";"3 blocker"
"1984";"3 blocker before admission"
"1985";"3 blockers"
"1986";"3 coenzyme Q10 subgroups for time to first hospitalization (number of patients variable)."
"1987";"3 mo-2 y"
"1988";"3 months"
"1989";"3 mortis"
"1990";"3 or more"
"1991";"3 prior TNF antagonist failures, n (%)b"
"1992";"3 vessels or left main"
"1993";"3 year mean change from baseline"
"1994";"3.0 VS 3.2"
"1995";"3.2 VS 2.7"
"1996";"3.2 vs 3.2"
"1997";"3.3 vs 2.6"
"1998";"3.3 vs 3.1"
"1999";"3.36-4.12 mmol/l"
"2000";"3.4 - < 33.9 mg/mmol"
"2001";"3.4 to #33.9 mg/mmol"
"2002";"3.5 per 100 py"
"2003";"3.6 per 100 py"
"2004";"3.6 vs 2.9"
"2005";"3.6 vs 3.9"
"2006";"3.6 vs 4.3"
"2007";"3.8 per 100 py"
"2008";"3.8 vs 3.5"
"2009";"3.9 (LO-7.5)"
"2010";"3.9 (LO-7.7)"
"2011";"3.9 per 100 py"
"2012";"3=help needed; still independent"
"2013";"30−300 mg/g"
"2014";"30-300 mg/g"
"2015";"30-34-9, obesity class 1"
"2016";"30-34.9: obese class I"
"2017";"30-44 yr"
"2018";"30-49 ml/min"
"2019";"30-49 ml/min/1.73 m2"
"2020";"30-50 mL min)1"
"2021";"30-50 mL/min"
"2022";"30-50 mL/rain"
"2023";"30-60 CrCl"
"2024";"30–≤50 mL/min"
"2025";"30 - <35 kg/m2"
"2026";"30 - <50 mL/min"
"2027";"30 - <60 mL/min"
"2028";"30 (15.8%), 5.0 per 100 pyr"
"2029";"30 days composite of death/new MI/urgent revascularization and definite ST"
"2030";"30 days definite ST"
"2031";"30 days new MI"
"2032";"30 days new MI or definite acute ST"
"2033";"30 days stroke (ischemic)"
"2034";"30 days until end of study (Landmark analysis)"
"2035";"30 days urgent revascularization"
"2036";"30 kg/m2 or more"
"2037";"30 mg"
"2038";"30 mg (n = 74)"
"2039";"30 mg (n 5 74)"
"2040";"30 mg QD (n = 140)"
"2041";"30 mg twice daily n=167"
"2042";"30 mg/g"
"2043";"30 months"
"2044";"30 to <35 kg/m2"
"2045";"30 to <40 years"
"2046";"30 to <50 ml/min"
"2047";"30 to <50 mL/min"
"2048";"30 to <50 mUmin"
"2049";"30 to <60 mL per 1-73 m2"
"2050";"30 to <60 ml/min"
"2051";"30 to <60 mL/min per 1.73 m^"
"2052";"30 to <60 ml/min/1.73 m2"
"2053";"30 to <60 ml/minute"
"2054";"30 to 300 mg/g"
"2055";"30 to less than 60"
"2056";"30 to o 60 mL/min/1.73 m2"
"2057";"30 wk"
"2058";"30.0-44.9 ml/min/1.73 m2"
"2059";"300 mg"
"2060";"300 mg (n = 72)"
"2061";"300 mg (n=1132)"
"2062";"300 mg clopidogrel load"
"2063";"300 mg LD"
"2064";"300 mg Q4W"
"2065";"300 mg"
"2066";"300mg (n=81)"
"2067";"300Q4W (n = 146)"
"2068";"30e< 50%, n (%)"
"2069";"31-40 (very severe)"
"2070";"31-90 days (%)"
"2071";"31.6 vs 46.7"
"2072";"312b (94b to 237a)"
"2073";"316 events,"
"2074";"325 mg"
"2075";"33 events[1.1]"
"2076";"33.1 per 100 py"
"2077";"33.8i6.4 (n=564)"
"2078";"33.9i6.4 (n=572)"
"2079";"33.l (7.l)"
"2080";"33S f21)"
"2081";"35-39-9, obesity class 2"
"2082";"35-39.9: obese class II"
"2083";"35 to <43 mg/dl"
"2084";"35 to <50 years"
"2085";"35% Cl"
"2086";"35.1 per 100 py"
"2087";"35.8 per 100 py"
"2088";"361-720 min"
"2089";"361 events[13.7]"
"2090";"365b (87b to 167a)"
"2091";"37 events[1.2]"
"2092";"37.3 per 100 py"
"2093";"382 events,"
"2094";"39.5 per 100 py"
"2095";"3MS score†"
"2096";"3rd >7.5"
"2097";"3rd Tertile (>120 mg/dL [>3.1 mmol/L])d"
"2098";"3rd: 125.89-154.80 pmol/L"
"2099";"4-5(<30 ml/min)"
"2100";"4-6 — no. (%)"
"2101";"4-8 days"
"2102";"4-point MACE"
"2103";"4-point MACE (3-point MACE plus hospitalization for unstable angina)"
"2104";"4‐point reduction in SELENA–SLEDAI score, %"
"2105";"4-year cumulative incidence, % (CI)"
"2106";"4-year rates in placebo groups"
"2107";"4 (FEV1 <30% pred)"
"2108";"4 (severe disease)"
"2109";"4 (Severe disease)"
"2110";"4 mg"
"2111";"4 mg a"
"2112";"4 or more"
"2113";"4 TCZ+MTX"
"2114";"4 TCZ+MTX MTX"
"2115";"4 week"
"2116";"4 yrs L"
"2117";"4.0 per 100 py"
"2118";"4.1 vs 4.1"
"2119";"4.1 vs 5.9"
"2120";"4.1% vs. 5.1%"
"2121";"4.3 vs 4.2"
"2122";"4.4 vs 3.7"
"2123";"4.4±20.lf"
"2124";"4.5 per 100 py"
"2125";"4.5 vs 4.1"
"2126";"4.5 vs 4.6"
"2127";"4.7 vs 4.7"
"2128";"4.8 per 100 py"
"2129";"4.9 vs 2.8"
"2130";"40-59 yr"
"2131";"40-60 with CV Disease (n=1761)"
"2132";"40-60, CV disease (n=1,761)"
"2133";"40 - <50 years"
"2134";"40 (21.1%), 8.0 per 100 pyr"
"2135";"40 mg"
"2136";"40 mg (n=79)"
"2137";"40 mg eow N = 161"
"2138";"40 mg eow n =99"
"2139";"40 mg ew n = 150"
"2140";"40 mg ew n =107"
"2141";"40 to <50 years"
"2142";"40 to <65 years"
"2143";"400/200 mg (n = 331)"
"2144";"41-64 years"
"2145";"41 (19.3%), 6.4 per 100 pyr"
"2146";"41 8.35 (0.30) [68 (3.3)] -0.68 (-0.85 to -0.51) [-7.4 (-9.3 to -5.6)] -0.64 (0.12) [-7.0 (1.3)]"
"2147";"410/week (n=371)"
"2148";"42 7.44 (0.34) [58 (3.7)] -0.42 (-0.63 to -0.21) [-4.6 (-6.9 to -2.3)]"
"2149";"42 years"
"2150";"420/day"
"2151";"43 to <65 mm Hg"
"2152";"430 min twice/week"
"2153";"438 events[17.0]"
"2154";"44.6±ii.5"
"2155";"44.8 vs 39.4"
"2156";"45-54 years"
"2157";"45-54 yr"
"2158";"45-54 yr(%)"
"2159";"45-64 yr"
"2160";"45-73 (men)"
"2161";"45 mg"
"2162";"45 to <60 mL/min/1,73m2"
"2163";"45.0-59.9 ml/min/1.73 m2"
"2164";"45.0±ii.6"
"2165";"45.i±ii.6"
"2166";"46 8.37 (0.27) [68 (3.0)] -0.04 (-0.20 to 0.13) [-0.4 (-2.2 to 1.4)]"
"2167";"47 (49 Cl)"
"2168";"47 min"
"2169";"48 (25.3%), 9.6 per 100 pyr"
"2170";"48.5 vs 41.4"
"2171";"48.6 vs 46.2"
"2172";"489 events,"
"2173";"49 7.32 (0.54) [56 (5.9)] -0.79 (-1.00 to -0.57) [-8.6 (-10.9 to -6.2)] -0.36 (0.11) [-3.9 (1.2)]"
"2174";"49.1 (io.i)"
"2175";"4S=Scandinavian Simvastatin Survival Study.13 WOSCOPS=West of Scotland Coronary Prevention Study.14 CARE=Cholesterol And Recurrent Events.15 Post-CABG=Post-Coronary Artery Bypass Graft.16 AFCAPS/TexCAPS=Air Force/Texas Coronary Atherosclerosis Prevention Study.17 LIPID=Long-term Intervention with Pravastatin in Ischaemic Disease.18 GISSI Prevention=Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico.19 LIPS=Lescol Intervention Prevention Study.20 HPS=Heart Protection Study.21 PROSPER=PROspective Study of Pravastatin in the Elderly at Risk.22 ALLHAT-LLT=Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.23 ASCOT-LLA=Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm.24 ALERT=Assessment of Lescol in Renal Transplantation.25 CARDS=Collaborative Atorvastatin Diabetes Study.26 S=simvastatin.
L=lovastatin. P=pravastatin. F=ﬂuvastatin. A=atorvastatin. *Mean duration of follow-up based on survival times within each trial. Overall mean is weighted by trial-speciﬁc variances of logrank (o–e) for major vascular events. †All trials included dietary intervention: WOSCOPS, GISSI Prevention, LIPID, 4S, LIPS, and HPS provided dietary advice; AFCAPS/TexCAPS, Post-CABG, CARE, ALLHAT, ALERT, CARDS, and PROSPER used American Heart Association (AHA) Step 1 diet and CARE intensiﬁed to Step 2 diet if LDL cholesterol  4·5 mmol/L (175 mg/dL). ‡Other CHD includes patients with a history of other symptomatic CHD but excludes those with a history of MI (as already counted in MI column). §Other vascular includes history of intracerebral bleed, transient ischaemic attack, ischaemic stroke, unknown stroke, and peripheral artery disease. ¶None includes individuals without a history of MI, symptomatic CHD, intracerebral bleed, transient ischaemic attack, ischaemic stroke, unknown stroke, or peripheral artery disease"
"2176";"4th: 154.81 -400 pmol/L"
"2177";"5-<10 yrs"
"2178";"5-7/week (n = 684)    8-10/week (n = 314)"
"2179";"5-Aminosalicylates{"
"2180";"5-aminosalicylates|| ||"
"2181";"5-Aminosalicylates’i""i‘"
"2182";"5-Aminosalicylic compounds — no. (%)"
"2183";"5-ASA compounds, n (%)"
"2184";"5 μg (n=208)"
"2185";"5 μg (n=209)"
"2186";"5 231 mg/dl"
"2187";"5 75 years, n (%)"
"2188";"5 mentis"
"2189";"5 mg"
"2190";"5 mg ( n = 117)"
"2191";"5 mg BID"
"2192";"5 mg/kg"
"2193";"5 to <15 years"
"2194";"5 years"
"2195";"5.0 (3.O-7.O)"
"2196";"5.0±l.l"
"2197";"5.1 per 100 py"
"2198";"5.18-6.20 mmol/l"
"2199";"5.3 per 100 py"
"2200";"5.4 per 100 py"
"2201";"5.4 vs 3.4"
"2202";"5.4% vs. 7.8%"
"2203";"5.5-8.5 mm"
"2204";"5.5 or more"
"2205";"5.5 VS 5.2"
"2206";"5=70 yr — no. (%)"
"2207";"50-<80 ml/min"
"2208";"50-<80 mVmin"
"2209";"50-59 yr"
"2210";"50-64 years"
"2211";"50-67 years"
"2212";"50-79 ml/min"
"2213";"50-80 mL min""1"
"2214";"50-99 kg"
"2215";"50–<80 mL/min"
"2216";"50—80 nlMW"
"2217";"50 - <100 kg"
"2218";"50 - <65 years"
"2219";"50 - <80mL/min"
"2220";"50 μg BID (N=178)"
"2221";"50 μg BID (N=193)"
"2222";"50 μg BID (N=239)"
"2223";"50 μg BID (N=254)"
"2224";"50 μg BID (N=38)"
"2225";"50 mg"
"2226";"50 mg (n=1089)"
"2227";"50 mg (n=92)"
"2228";"50 mg + MTX"
"2229";"50 mg sirukumab every 4 weeks (n=292)"
"2230";"50 to <100 kg"
"2231";"50 to <60 m Um in"
"2232";"50 to <65 years"
"2233";"50 to <80 ml/min"
"2234";"50 to <80 mL/min"
"2235";"50 to <80 mL/min (n=10 697)"
"2236";"50 to 69 y, n (%)"
"2237";"50 mg"
"2238";"50% decrease in WOMAC pain score"
"2239";"50.3 vs 40.6"
"2240";"50.8 ±b.b"
"2241";"50mg"
"2242";"50mg/100 mgc"
"2243";"5112 mg/dl"
"2244";"5151 mg/dl LDL cholesterol ||"
"2245";"5174 mg/dl"
"2246";"523 kg/m’"
"2247";"5251 mg/dl"
"2248";"531.5 mg/dl Triglycerides^"
"2249";"539 mg/dl"
"2250";"54 to <66 mg/dl"
"2251";"55-64 years"
"2252";"55-64 yr"
"2253";"55-64 yr — no. (%)"
"2254";"55-64 yr(%)"
"2255";"55-73 (women)"
"2256";"56 wk"
"2257";"56.0 (I0.S)"
"2258";"56.0 vs 48.5"
"2259";"565 years"
"2260";"566 yr"
"2261";"57 (26.9%), 11.2 per 100 pyr"
"2262";"570 kg"
"2263";"570 yr"
"2264";"58%, n (% of patients)"
"2265";"58.2 (1 l.l)"
"2266";"581(14.1 )/532Z(1Ze)"
"2267";"595 tQ-fi'i"
"2268";"5fe Black*"
"2269";"5ii (49.2)"
"2270";"5l (l5)"
"2271";"5l.5 (l0.5)"
"2272";"5mg"
"2273";"5mg (n=93)"
"2274";"6-10/day"
"2275";"6-12 months"
"2276";"6-12 Months (n = 886)"
"2277";"6-12 months, n (%)"
"2278";"6-mercaptopurine"
"2279";"6-Mercaptopurine"
"2280";"6-mercaptopurine/azathioprine"
"2281";"6-min walk distance (m)"
"2282";"6-min walk distance m"
"2283";"6-min walk distance, ft"
"2284";"6-Minute walk distance — m"
"2285";"6-UP and/or AZA at baseline"
"2286";"6-y Incidence Rate (SE) per 100 Participants"
"2287";"6-y Rate per 100 Persons (SE), n"
"2288";"6-Year KM %"
"2289";"6–12 months"
"2290";"6–12 Months"
"2291";"6 days"
"2292";"6 mg/kgf (N = 209)"
"2293";"6 mg/kgf (N = 249)"
"2294";"6 mo"
"2295";"6 mo to 2 yr"
"2296";"6 months"
"2297";"6 mq/kq*"
"2298";"6.0 per 100 py"
"2299";"6.0% vs. 7.6%"
"2300";"6.2 per 100 py"
"2301";"6.2% vs. 11.0%"
"2302";"6.3 per 100 py"
"2303";"6.3 vs 6.3"
"2304";"6.4 vs 7.6"
"2305";"6.5 (G.l)"
"2306";"6.8 VS 7.4"
"2307";"6.9 per 100 py"
"2308";"60-80 with CV Disease (n=4096)"
"2309";"60-80 with CV Risk but not Disease (n=2285)"
"2310";"60-80, CV disease (n=4,096)"
"2311";"60-80, risk, not disease (n=2,285)"
"2312";"60-90 ml/min/1.73m2"
"2313";"60 mg"
"2314";"60 mg cohort"
"2315";"60 mg QD (n = 158)"
"2316";"60 ml (20 to 90) (n=213/242)"
"2317";"60 ml (30 to 90) (n=304/306)"
"2318";"60 ml (30 to 90) (n=321/290)"
"2319";"60 to <100 kg"
"2320";"60 to <70 yr"
"2321";"60 to <70 yr — no. {%)"
"2322";"60 to <90 kg"
"2323";"60 to <90 mL min’1 1.73 m'2"
"2324";"60 to <90 mL per 1-73 m2"
"2325";"60 to <90 mL/min per 1.73 m^"
"2326";"60 to <90 ml/min/1-73"
"2327";"60 to <90 mL/min/1,73m2"
"2328";"60 to <90 ml/min/1.73 m^"
"2329";"60 to <90 ml/min/1.73 m2"
"2330";"60 to <90 mL/min/1.73m2"
"2331";"60 to <90 ml/minute"
"2332";"60 to <90kg"
"2333";"60 to 130 ml/min per 1.73 m2, n (%)"
"2334";"60 to less than 90"
"2335";"60 to o90 mL/min/1.73 m2"
"2336";"60.4 vs 41.4"
"2337";"600 mg"
"2338";"600 mg clopidogrel load"
"2339";"61-65 yr"
"2340";"61.4 vs 48.4"
"2341";"61.9 (lO.I)"
"2342";"62.5 yrs"
"2343";"629 (6i.i)"
"2344";"63.3 vs 48.8"
"2345";"63.3 vs 49.6"
"2346";"64.0 vs 54.3"
"2347";"65-<75 years"
"2348";"65-69 vr — no. (%)"
"2349";"65-69 yr"
"2350";"65-74 years"
"2351";"65-74 yr"
"2352";"65-75 years"
"2353";"65-89 yr"
"2354";"65—<75 years"
"2355";"65—75 years"
"2356";"65 - <75 years"
"2357";"65 to <75 years"
"2358";"65 to <75 yr"
"2359";"65 to <75 yr — no. (%)"
"2360";"65 to 74 y (N=7134, 33.8%)"
"2361";"65 to 75 yr"
"2362";"65 years or older"
"2363";"65 years, n (%)"
"2364";"65 yrs or more"
"2365";"65.2 vs 49.3"
"2366";"65+, No. (%)"
"2367";"68.8 vs 53.0"
"2368";"6mo"
"2369";"6moto<1 yr, n (%)"
"2370";"6MW Distance, m"
"2371";"6MWD decrease >50 m"
"2372";"6MWD, m"
"2373";"6MWT (m)"
"2374";"7 (7 SI"
"2375";"7 days"
"2376";"7 events, 0.1 per 100 py (0.0-0.2)"
"2377";"7.0% vs. 6.3%"
"2378";"7.1 per 100 py"
"2379";"7.2 (95%CI: 7.1,7.4, n=178)"
"2380";"7.3 (95%CI: 7.2, 7.4, n=185)"
"2381";"7.4 per 100 py"
"2382";"7.5% or more"
"2383";"7.6 VS 5.7"
"2384";"7.7 per 100 py"
"2385";"7.7% vs. 8.2%"
"2386";"7.8% vs. 8.2%"
"2387";"70-74 yr"
"2388";"70 (33.0%), 13.8 per 100 pyr"
"2389";"70 ml (30 to 110) (n=271/260)"
"2390";"70 ml (30 to 110) (n=302/289)"
"2391";"70 ml (40 to 110) (n=335/350)"
"2392";"70 to <72 bpm (n=987)"
"2393";"70 to <90 kg"
"2394";"70.9 vs 55.3"
"2395";"72 to <75 bpm (n=1364)"
"2396";"72/134 (53.7) (continued)"
"2397";"74.5 min"
"2398";"75-81 years"
"2399";"75-84 y, n (%)"
"2400";"75—<85 years"
"2401";"75 mg"
"2402";"75 to <80 bpm (n=1545)"
"2403";"75 to <85 mm Hg"
"2404";"75 Years (n=2010)"
"2405";"75 years or older"
"2406";"759(12J)Z728(11.e"
"2407";"75mg (n = 77)"
"2408";"75Q2W (n = 37)"
"2409";"8-30 days"
"2410";"8-9 days"
"2411";"8—9 days"
"2412";"8 TCZ+MTX"
"2413";"8 week"
"2414";"8% < HbA1c <= 9%"
"2415";"8% < HbA1c <= 9% (n 5 158)"
"2416";"8% < HbA1c <= 9% (n 5 161)"
"2417";"8.0 to <9.0% (64 to <75 mmol/mol)"
"2418";"8.1 per 100 py"
"2419";"8.2 per 100 py"
"2420";"8.3 ± O.lt"
"2421";"8.6 per 100 py"
"2422";"8.8 vs 8.5"
"2423";"80 mg"
"2424";"80 ml (40 to 130) (n=226/199)"
"2425";"80 ml (50 to 120) (n=290/289)"
"2426";"80 ml (60 to 110) (n=352/322)"
"2427";"80 to <87 bpm (n=1287)"
"2428";"80±ll"
"2429";"83.4 ± l.Ot"
"2430";"84 events,"
"2431";"85 to <101 mg/dl"
"2432";"87 nil"
"2433";"87.l (2l.3)"
"2434";"8TCZ"
"2435";"9-12 years"
"2436";"9-13.5 mm"
"2437";"9 to <12 mo"
"2438";"9% (Oto 17)"
"2439";"9% (Oto 18)"
"2440";"9.'^/5t7C}    u"
"2441";"9.0 to <10.0% (75 to <86 mmol/mol)"
"2442";"9.0% vs. 9.1%"
"2443";"9.1 per 100 py"
"2444";"9.3 vs 9.0"
"2445";"9.6 ± O.lt"
"2446";"9.6 per 100 py"
"2447";"9.7 per 100 py"
"2448";"9.9% vs. 16.5%"
"2449";"90-Day CCE"
"2450";"90-Day Mortality"
"2451";"90 mg"
"2452";"90 mg cohort"
"2453";"90 mg/12 wk (N = 132)"
"2454";"90 mg/8 wk (N = 132)"
"2455";"90 ml (50 to 120) (n=199/219)"
"2456";"90 ml (50 to 130) (n=259/260)"
"2457";"90 ml (60 to 120) (n=244/274)"
"2458";"90 ml (60 to 120) (n=261/258)"
"2459";"90 or greater"
"2460";"91.9i7.1 (n=342)"
"2461";"924b (87b to 107a)"
"2462";"95-105 mg/dl"
"2463";"95% C.I."
"2464";"95% CI"
"2465";"95% CI 0.59-1.02"
"2466";"95% CI for difference"
"2467";"95% CI2"
"2468";"95% CIt"
"2469";"95% Cl"
"2470";"95% Clf"
"2471";"95% confidence interval"
"2472";"95%CI"
"2473";"950-1275 ft"
"2474";"97.9i8.3 (n=565)"
"2475";"98 (14.7%), 78 (11.2%), 4.9 per 100 3.8 per pyr 100 pyr"
"2476";"98.8i7.1 (n=573)a"
"2477";"A"
"2478";"a-blocker"
"2479";"a-Blocker"
"2480";"a-Blockers"
"2481";"α-glucosidase inhibitor"
"2482";"a-Glucosidase inhibitor"
"2483";"a-Glucosidase inhibitors"
"2484";"a-Glucosidase inhibitors'1"
"2485";"a 75 years"
"2486";"A A (340 (%)"
"2487";"A Cardiovascular Death or Hospitalization for Heart Failure"
"2488";"A Compared w"
"2489";"A Compared wi"
"2490";"A decrease of >100 points in the CDAI score"
"2491";"a Excludes two randomized patients with unknown diabetes status at baseline."
"2492";"A from baseline"
"2493";"A from baselineb"
"2494";"a Median"
"2495";"A Mini-Mental State Examination, insulin glargine vs standard care"
"2496";"A Mini-Mental State Examination, omega-3 fatty acids vs placebo"
"2497";"a New Vertebral Fractures (mFAS)"
"2498";"A ngina >7 day s previously *"
"2499";"A Prebronchodilator FEVl (% predicted)"
"2500";"A Reslizumab 0.3 mg/kg n/N"
"2501";"A Severe Hypoglycemia"
"2502";"A Stroke"
"2503";"A vs. C"
"2504";"a) Those receiving no inhaled pre-treatment maintenance medication"
"2505";"a, no VhD (n=14 162)"
"2506";"A. ACR 20"
"2507";"A. Beuralizuinab 30 ing Q4W"
"2508";"A. Overall and subgroups bv statin potency    --"
"2509";"A. Primary Composite Outcome"
"2510";"A/AML (n = 119)"
"2511";"A/AML (n = 142)"
"2512";"A/AML (n = 76)"
"2513";"A/AML (n = 96)"
"2514";"A/C"
"2515";"A/Ga"
"2516";"A/V (n=200)"
"2517";"A/V (n=574)    V (n=565)"
"2518";"A/V(n=17)    V (n=14)"
"2519";"A/V(n=63)    V (n=51)"
"2520";"A: Worldwide Black and Non-Black Patients"
"2521";"A10 + E10 (n = 526)"
"2522";"A10 vs placebo"
"2523";"A10=6.4% (Median)"
"2524";"A1C"
"2525";"A1C (%)"
"2526";"A1C (mmol/mol)"
"2527";"A1C [n (%)]"
"2528";"A1c < Median"
"2529";"A1C <6.5%"
"2530";"A1C <7.0%"
"2531";"A1C >= Median"
"2532";"A1C at baseline <9.0%"
"2533";"A1C at baseline ≥9.0%"
"2534";"A1C distribution (%)"
"2535";"A1C, %"
"2536";"A1C, % (mmol/mol)"
"2537";"A1C<6.4% (Median)"
"2538";"A20/40 (n = 527)"
"2539";"A24S-hydroxy-"
"2540";"a30 kg/m2"
"2541";"A40 + EZ n = 136    A80 n = 140"
"2542";"A40 + EZ n = 225"
"2543";"A40 + EZ n = 89"
"2544";"A40 + EZ10"
"2545";"A40 + EZ10    A80 (n = 61)    (n = 66)"
"2546";"A40 + EZ10    A80 (n = 67)    (n = 68)"
"2547";"A40 + EZIO    A80 (n = 149)    (n = 145)"
"2548";"A7C >8.5-9.0%"
"2549";"A7C >9.0%"
"2550";"A7C >S.0-S.5%"
"2551";"A80 n = 222"
"2552";"A80 n = 82"
"2553";"A9.2±1A.6"
"2554";"AA"
"2555";"AA, mol%"
"2556";"Aa/G"
"2557";"AAb42 (%)"
"2558";"AaPo2 at rest, mm Hg"
"2559";"AB 400 pg(N=720)"
"2560";"AB/FF 400/12 pg (N = 720)"
"2561";"Abaloparatide-SC, n (%)"
"2562";"Abatacept"
"2563";"Abatacept (n=213*)"
"2564";"Abatacept ~10 mg/kg (n = 128)"
"2565";"Abatacept ~10 mg/kg (n = 139)"
"2566";"Abatacept 10/10 (n = 99)"
"2567";"Abatacept 3 mg/kg (n = 130)"
"2568";"Abatacept 3 mg/kg (n = 70)"
"2569";"Abatacept 30/—10 mg/kg (n = 141)"
"2570";"Abatacept 30/—10 mg/kg (n = 65)"
"2571";"Abatacept 30/10 (n = 99)"
"2572";"Abatacept monotherapy (n=116)"
"2573";"Abatacept plus MTX (n=119)"
"2574";"Abatacept/open-label abatacept"
"2575";"Abatacept‡"
"2576";"Abbreviations: ACE, angiotensin-converting enzyme; BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); DM, diabetes mellitus; HbA1c, hemoglobin A1c; HMG-CoA, 3-hydroxy-3-methylglutaryl coenzyme A. aSome subjects took more than 1 oral anti-DM drug in addition to metformin, and thus the total number of concomitant oral anti-DM drugs in the columns exceed the “n” values in the colesevelam hydrochloride and placebo group headings. bSulfonylureas include chlorpropamide, glibenclamide, glimepiride, glipizide, and tolazamide. cThiazolidinediones include pioglitazone, pioglitazone hydrochloride, rosiglitazone, and rosiglitazone maleate. d -Glucosidase inhibitors include acarbose or miglitol."
"2577";"Abbreviations: ACE, angiotensin-converting enzyme; IQR, interquartile range; Ml, myocardial infarction. SI conversion: To convert creatinine clearance to mL/s, multiply by 0.0167. *Data are expressed as No./total (%) unless otherwise specified. fEstimated using Cockroft-Gault equation. tThe TIMI risk score was used to categorize patients at low (0-2), intermediate (3-4), and high (5-7) risk.4"
"2578";"Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; bpm, beats per minute; CCB, calcium channel blocker; MSDBP, mean sitting diastolic blood pressure; MSSBP, mean sitting systolic blood pressure. Values are No. (%) unless otherwise indicated. aMean ± SD. bMore severe, >160 and <180 mm Hg/>100 and <110 mm Hg; less severe, >140 and <160 mm Hg/>90 and <100 mm Hg. Blood pressure at baseline is with monotherapy (ie, before switch to amlodipine/valsar-tan therapy)."
"2579";"Abbreviations: BMI, body mass index; CABG, coronary artery bypass graft; NSAIDs, nonsteroidal anti-inflammatory drugs; PCI, percutaneous coronary interventions. *Values expressed as number (percentage) unless otherwise indicated. Percentages may not equal 100 due to rounding. fHistory of or currently taking antidiabetic or lipid-lowering medications. ^History of or currently have elevated serum creatinine level but less than 4 mg/dl_ (<354 pmol/L). §Patients with a history of skin, prostate, and other cancers with long survival expectancy were not excluded. ||lnsulin and/or oral hypoglycemics. IlData for women only (n = 5850 for calcium antagonist strategy and n = 5920 for non-calcium antagonist strategy)."
"2580";"Abbreviations: CHD, coronary heart disease; Cl, confidence interval; Ml, myocardial infarction; RR, relative risk. ^Defined as a composite end point comprising the first of any of these events: nonfatal Ml, nonfatal stroke, or cardiovascular death. tP value for interaction <.05 for major cardiovascular event. No other interactions are significant. ^Calculated as weight in kilograms divided by the square of height in meters. §Hypertension was defined as a self-reported systolic blood pressure >140 mm Hg, a diastolic blood pressure >90 mm Hg, or physician-diagnosed hypertension. ||Hyperlipidemia was defined as a self-reported total cholesterol >240 mg/dl_ (6.2 mmol/L) or physician-diagnosed high cholesterol. ^Diabetes defined by self-report. #Calculated using the Framingham risk score among 28 345 women who provided a blood sample at baseline."
"2581";"Abbreviations: DA, disc area; E-ETDRS, electronic Early Treatment Diabetic Retinopathy Study; IOP, intraocular pressure; OCT, optical coherence tomography."
"2582";"Abbreviations: eGFR = estimated glomerular filtration rate; IMT = intimal medial thickness; LV = left ventricular.
*
Two-sample comparison t-tests were calculated based on log-transformed variables.
**
Geometric mean with 95% confidence interval in parenthesis."
"2583";"Abbreviations: TEAE, treatment-emergent adverse event; GLY, glycopyrrolate inhalation solution; BID, twice daily."
"2584";"Abciximab"
"2585";"ABCIXIMAB"
"2586";"Abciximab-Facilitated PCI"
"2587";"Abciximab-Facilitated PCI (n = 818)"
"2588";"Abciximab-Facilitated PCI (N = 818)"
"2589";"Abciximab (n = 401)"
"2590";"Abciximab (N=1079)"
"2591";"ABCIXIMAB (N=149)"
"2592";"ABCIXIMAB (N=2411)"
"2593";"Abciximab (n=377)"
"2594";"Abciximab (n=401)"
"2595";"Abciximab (n=630)"
"2596";"Abciximab (n=635)"
"2597";"Abciximab No./total (%)"
"2598";"Abciximab vs. Primary"
"2599";"Abdominal aortic — no. (%)"
"2600";"Abdominal Obesity"
"2601";"Abdominal obesity*"
"2602";"Abdominal or perianal fistula at baseline, n (%)"
"2603";"ABI"
"2604";"ABI #0.90"
"2605";"ABI <0.85"
"2606";"ABI <0.9"
"2607";"ABI >1.3"
"2608";"ABI >1.4"
"2609";"ABL-SC mean"
"2610";"ABL-SC n/N"
"2611";"Abnormal"
"2612";"Abnormal angiogram"
"2613";"Aborted cardiac arrest"
"2614";"About 100 mg/L or more"
"2615";"About 20 mg/L"
"2616";"About 50 mg/L"
"2617";"Abrupt vessel closure"
"2618";"Absence"
"2619";"Absent"
"2620";"Absent (<100 mg/dL)"
"2621";"Absent (<110 mg/dL)"
"2622";"Absolute  Change"
"2623";"Absolute (L)"
"2624";"Absolute decline in FVC >10% predicted"
"2625";"Absolute decline in FVC >10% predicted or death, n (%)"
"2626";"Absolute decline in FVC >5% predicted"
"2627";"Absolute decline in FVC >5% predicted or death, n (%)"
"2628";"Absolute decrease >10%"
"2629";"Absolute decrease >5%"
"2630";"Absolute difference estimate vs placebo (95% CI)"
"2631";"Absolute FVC decrease >10%"
"2632";"Absolute reversibility in FEV1, mL*"
"2633";"Absolute risk difference (95% Cl)"
"2634";"Absolute Risk Difference (CI), %*"
"2635";"Absolute Risk Reduction (95% CI), %/y"
"2636";"Absolute Risk Reduction (95% Cl)*"
"2637";"Absolute risk reductions"
"2638";"Absolute time spent “on” with troublesome dyskinesia, h/day"
"2639";"Absolute time spent “on” without troublesome dyskinesia, h/day"
"2640";"Absolute time spent “on”, h/day"
"2641";"Absolute, litres"
"2642";"Absolutedifferenceestimate vs placebo(95% CI)"
"2643";"Abx-Facil. PCI"
"2644";"Ac tve cancer"
"2645";"Acarbose 一 no. (%)"
"2646";"ACC/AHA lesion class B2 or C, n (%)"
"2647";"Access site"
"2648";"ACCORD ACR <3-4"
"2649";"ACCORD ACR >3-4"
"2650";"ACCORD primary, n (%)"
"2651";"ACCP bleeding risk at inclusion, No. (%)f"
"2652";"ACCP score"
"2653";"ACD"
"2654";"ACE"
"2655";"ACE-I (n, %)"
"2656";"ACE-I or angiotensin receptor blocker"
"2657";"ACE-I or ARB"
"2658";"ACE‐I or ARB"
"2659";"ACE-I or ARB Use"
"2660";"ACE-I or ARB use at baseline"
"2661";"ACE-I or ARB, % (n)"
"2662";"ACE-I/ARB"
"2663";"ACE-I/ARB, (%)"
"2664";"ACE-Inhibitor or ARB (%)"
"2665";"ACE-inhibitor use"
"2666";"ACE-inhibitors"
"2667";"ACE-inhibitors, n (%)"
"2668";"ACE-inhibitors/ARBs, n (%)"
"2669";"ACE-l/ARBs"
"2670";"ACE-lorARB"
"2671";"ACE = angiotensin-converting enzyme; CABG = coronary artery bypass graft; CCSC = Canadian Cardiovascular Society classification; MI = myocardial infarction; PCI = percutaneous coronary"
"2672";"AcE inhibitor"
"2673";"ACE inhibitor"
"2674";"ACE inhibitor— no. (%)"
"2675";"ACE inhibitor /ARB"
"2676";"ACE inhibitor and/or ARB"
"2677";"ACE inhibitor at enrollment"
"2678";"ACE inhibitor at last follow-up"
"2679";"ACE inhibitor monotherapy"
"2680";"ACE inhibitor or angiotensin-receptor blocker — no./total no. (%)"
"2681";"ACE inhibitor or angiotensin II receptor"
"2682";"ACE inhibitor or angiotensin II receptor blocker"
"2683";"ACE inhibitor or angiotensin receptor blocker"
"2684";"ACE inhibitor or ARB"
"2685";"ACE inhibitor or ARB at enrollment"
"2686";"ACE inhibitor or ARB at last follow-up"
"2687";"ACE Inhibitor or ARB Use"
"2688";"ACE inhibitor treatment"
"2689";"Ace inhibitor use (%)"
"2690";"ACE inhibitor Yes"
"2691";"ACE inhibitor, %"
"2692";"AcE inhibitor, ARB, or both"
"2693";"ACE inhibitor, n (%)"
"2694";"ACE inhibitor/ARB"
"2695";"ACE inhibitor/ARB therapy"
"2696";"ACE inhibitor/ARB, %"
"2697";"ACE inhibitors"
"2698";"ACE Inhibitors"
"2699";"ACE inhibitors and ARB"
"2700";"ACE inhibitors or angiotensin-receptor blockers"
"2701";"ACE inhibitors or angiotensin-receptor blockers^"
"2702";"ACE inhibitors or angiotensin II"
"2703";"ACE inhibitors or angiotensin II blockers"
"2704";"ACE inhibitors or Angiotensin Receptor Blockers"
"2705";"ACE inhibitors or ARB"
"2706";"ACE inhibitors or ARBs"
"2707";"ACE inhibitors through hospital discharge or day 7 — %"
"2708";"ACE inhibitors/ARB"
"2709";"ACE inhibitors/ARBs"
"2710";"ACE inhibitors/ARBs, n (%)"
"2711";"ACE inhibitors/sartans"
"2712";"ACE or ARB"
"2713";"ACE/ARB"
"2714";"ACE/ARB medication (%)"
"2715";"ACE/ARB use"
"2716";"ACE/ARB users"
"2717";"ACE=angiotensin-converting enzyme. ARB=angiotensin receptor blockers."
"2718";"Acecoumarol, No. (%)"
"2719";"ACEI"
"2720";"ACEI and/or ARB"
"2721";"ACEi or ARB"
"2722";"ACEI or ARB"
"2723";"ACEi vs. non-ACEi"
"2724";"ACEi, n (%)"
"2725";"ACEi/ARB"
"2726";"ACEI/ARB"
"2727";"ACEi/ARB therapy, n (%)"
"2728";"ACEIs"
"2729";"ACEIs, angiotensin-converting enzyme inhibitors; C, candesartan; DES, drug-eluting stent; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; LDL, low-density lipoprotein; NC, non-candesartan."
"2730";"ACEIs, n (%)"
"2731";"ACEIs/ARBs"
"2732";"Acenocoumaroi"
"2733";"Acetaminophen"
"2734";"Acetyl-salicylic acid"
"2735";"Acetylsalicylic acid"
"2736";"ACholesterol (%)"
"2737";"Acid"
"2738";"Acitretin"
"2739";"Aclidinium 400 pg"
"2740";"Aclidinium 400 pg vs placebo"
"2741";"Aclidinium 400 μg (n = 269)a"
"2742";"Aclidinium 400 μg (n = 337)a"
"2743";"Aclidinium 400 μg (n = 583)b"
"2744";"Aclidinium 400 μg (n = 720)"
"2745";"Aclidinium 400 μg BID (n = 22)"
"2746";"Aclidinium 400 μg BID (n = 223)"
"2747";"Aclidinium 400 μg BID (n = 296)"
"2748";"Aclidinium 400 μg BID (n = 42)"
"2749";"Aclidinium 400 μg BID (n = 583)"
"2750";"Aclidinium/formoterol 400/12 pg twice daily"
"2751";"ACM"
"2752";"ACPA positive"
"2753";"ACPA positive (>7 IU/mL), n (%)"
"2754";"ACPA positive, %"
"2755";"ACPA positive, n (%)"
"2756";"ACPA positive, no. (%)"
"2757";"ACQ-5 score"
"2758";"ACQ-5 score'!'"
"2759";"ACQ-6 score"
"2760";"ACQ-6 score*"
"2761";"ACQ-6 score, mean (SD)e"
"2762";"ACQ-6 score本"
"2763";"ACQ-6 scoret"
"2764";"ACQ-7 total score∗"
"2765";"ACQ score, mean"
"2766";"ACQ5 score"
"2767";"ACQ6 score, mean (SD)"
"2768";"ACR"
"2769";"ACR (mg/g), mean (SD)"
"2770";"ACR > 30 mg/g"
"2771";"ACR Deciles"
"2772";"ACR functional class, n (%)"
"2773";"ACR response by baseline MTX use, no./total no. (%) ACR20"
"2774";"ACR response by baseline weight,"
"2775";"ACR response, %"
"2776";"ACR response, % ACR20"
"2777";"ACR, mg/mmol"
"2778";"ACR20"
"2779";"ACR20 response"
"2780";"ACR20 response at week 16, n (%)"
"2781";"ACR20 response, n/N (%)"
"2782";"ACR20 Week 12 Responders, (n = 72)"
"2783";"ACR50"
"2784";"ACR50 response"
"2785";"ACR50 response, n/N (%)"
"2786";"ACR70"
"2787";"ACR70 response"
"2788";"ACR70 response, n/N (%)"
"2789";"ACR90"
"2790";"ACS"
"2791";"ACS (n - 4,584)"
"2792";"ACS (n = 4,584)"
"2793";"ACS Event"
"2794";"ACS management, no. (%)"
"2795";"ACS presentation"
"2796";"ACS treatment"
"2797";"ACS type"
"2798";"ACT-2"
"2799";"ACT total score ≥ 20"
"2800";"ACT total score ≥ 20 and/or improvement from baseline ≥ 3"
"2801";"ACT.1"
"2802";"action tested is between the continuous variable and treatment."
"2803";"Active"
"2804";"Active-Control Study"
"2805";"Active (n=5569)"
"2806";"ACTIVE A"
"2807";"Active Canakinumab (n = 1,249)"
"2808";"Active Canakinumab (n = 5,467)"
"2809";"Active cancer"
"2810";"Active Cancer"
"2811";"Active cancer — no. (%)"
"2812";"Active cancer at any timeb"
"2813";"Active cancer at baseline"
"2814";"Active Cancer at Randomisation"
"2815";"Active Cancer at Randomization"
"2816";"Active cancer at randomization, n (%)"
"2817";"Active comparatorb"
"2818";"Active inflammatory bowel disease"
"2819";"Active or previous cancer"
"2820";"Active PSO wi111 BSA > 3%, n (.%y"
"2821";"Active smoker"
"2822";"Active smokers"
"2823";"Active smoking"
"2824";"Active treatment"
"2825";"Active vs placebo"
"2826";"Active versus placebo"
"2827";"Activities of Daily Living UPDRS subscore (baseline), mean (SD)"
"2828";"Activity"
"2829";"Activity (0-100 VAS)"
"2830";"activity (range 0-100), mean ± SD"
"2831";"Activity limitation"
"2832";"Actual (L)"
"2833";"Actual or estimated weight, kg"
"2834";"Actual treatment strategy"
"2835";"ACUITY-bleeding major/minor"
"2836";"ACUITY-defined bleeding"
"2837";"ACUITY major"
"2838";"ACUITY Major"
"2839";"ACUITY major or"
"2840";"ACUITY minor"
"2841";"Acute (<24 hr)"
"2842";"Acute and delayed reaction"
"2843";"Acute coronary event"
"2844";"Acute coronary syndrome"
"2845";"Acute coronary syndrome 3025"
"2846";"Acute DVT Study"
"2847";"Acute Increase in Serum Creatinine"
"2848";"Acute infection without septic shock"
"2849";"Acute medication intake (days/month)"
"2850";"Acute reaction"
"2851";"Acute Reperfusion"
"2852";"Acute respiratory insufficiency"
"2853";"Acute rheumatic disorders"
"2854";"Acute stent thrombosis"
"2855";"Acute Stent Thrombosis (definite or probable)"
"2856";"Acute stroke of other determined cause"
"2857";"ADA 160/80 (N[130)"
"2858";"ADA 160/80 N[130"
"2859";"ADA 80/40 (N[130)"
"2860";"ADA 80/40 N[130"
"2861";"ADA IFG"
"2862";"ADA Impaired Fasting Glucose"
"2863";"ADA, no"
"2864";"ADA, yes"
"2865";"Adalimumab"
"2866";"Adalimumab (n = 480)"
"2867";"Adalimumab (n = 70)"
"2868";"Adalimumab (n = 966)"
"2869";"Adalimumab (n=330)"
"2870";"Adalimumab Croup, n/n (%)"
"2871";"Adalimumab Group (n = 159)t"
"2872";"Adamantane derivatives"
"2873";"ADAS-cog score*"
"2874";"ADAS—cog score"
"2875";"ADCS-ADL score*"
"2876";"Add-on to MET"
"2877";"Add-on to MET + SU19"
"2878";"Add-on to MET+SU"
"2879";"Add-on to MET18"
"2880";"Additional angiography"
"2881";"Additional antihypertensive subgroup"
"2882";"Additional endpoints"
"2883";"Additional heparin"
"2884";"Additional investigations"
"2885";"Additional radiographic findings at week 24"
"2886";"Additional subgroup analyses"
"2887";"ADHERE"
"2888";"Adherence >80%"
"2889";"Adherence to study regimen — no. (%)"
"2890";"Adherence to study regimen — no. (%)ff"
"2891";"Adiusted Hazard Ratio*"
"2892";"Adj. HR (95% Cl)a"
"2893";"Adjudicated MACE5"
"2894";"Adjusted"
"2895";"Adjusted    1 OR (95% Cl)"
"2896";"Adjusted change from baseline"
"2897";"Adjusted change from baseline Mean (s.e.)"
"2898";"Adjusted exacerbation rate (per patient peryear)"
"2899";"Adjusted exacerbation rate {per patient peryear)"
"2900";"Adjusted for all baseline variables and interaction between ACEI and baseline UPb"
"2901";"Adjusted for all baseline variables, interaction between ACEI and baseline UP, and declines in SBP and UP"
"2902";"Adjusted for all baseline variables6"
"2903";"Adjusted hazard ratio (95% CI)†"
"2904";"Adjusted Hazard Ratio (95% Cl)*"
"2905";"Adjusted hazard ratio ≠ (95% CI)"
"2906";"Adjusted Hazard Ratio*"
"2907";"Adjusted Hazard Ratio§(95% CI)"
"2908";"Adjusted Hazard Ratio‡(95% CI)"
"2909";"Adjusted HR (95% CI)"
"2910";"Adjusted HR (95% CI)* Compared With No Diabetes at BL or at Year 2"
"2911";"Adjusted HR (95% CI)* Comparing IDM With BL"
"2912";"Adjusted HR (95% Cl)"
"2913";"Adjusted HR (ENL vs LCZ) (95% Cl)"
"2914";"Adjusted HR Losartan vs Atenolol*"
"2915";"Adjusted HR* (95% CI)"
"2916";"Adjusted HR* (95% CL) pValue"
"2917";"Adjusted HR; 95% CI"
"2918";"Adjusted mean (SE)"
"2919";"Adjusted mean (SE) FEVi AUCo_3, mL"
"2920";"Adjusted mean (SE) trough FEVi, mL"
"2921";"Adjusted mean _ SE change from baseline"
"2922";"Adjusted mean ± SE change from baseline"
"2923";"Adjusted mean change"
"2924";"adjusted mean change (kg)"
"2925";"Adjusted mean change from baseline"
"2926";"Adjusted mean change from baseline (95% CI), % [mmol/mol]"
"2927";"Adjusted mean change from baseline (SE)"
"2928";"Adjusted mean difference (95% CI)"
"2929";"Adjusted mean±SE (95% CI)"
"2930";"Adjusted modelc HR, 95% CI, P value"
"2931";"Adjusted OR (95% CI)b"
"2932";"Adjusted OR (95% CI)c"
"2933";"Adjusted OR (95% Cl)"
"2934";"Adjusted P-value for Interaction"
"2935";"Adjusted Rate of FEV1 Decline (SE), ml/yr"
"2936";"Adjusted rate of hospitalized pneumonia events (per patient-year), mean (95% CI)"
"2937";"Adjusted rate of pneumonia events (per patient-year), mean (95% CI)"
"2938";"Adjusted* OR (95% CI) P Value"
"2939";"Adjusted* HR"
"2940";"Adjusted∗ mean (SE) (mL)"
"2941";"Adjusted∗ mean of difference (SE) (mL)"
"2942";"Adjusted⁎Hazard Ratio (95% CI)"
"2943";"Adjusted3 Risk Reduction Losartan vs Placebo (95% Cl)"
"2944";"AdjustedaHR"
"2945";"AdjustedaOR"
"2946";"Adjustedb,c Beta (SE)"
"2947";"ADL"
"2948";"ADL subscale (range, 0-52)*"
"2949";"Administration of study-drug bolus — no./total no. (%)"
"2950";"Administration of study drug (%)"
"2951";"Admission for HF in previous year"
"2952";"Admission for HF in previous year, n (%)"
"2953";"Admission GRACE score"
"2954";"Adolescents (aged 12-17 y), No. (%)"
"2955";"ADP Antagonist"
"2956";"Adults (aged ≥ 18 y), No. (%)"
"2957";"Advanced, n (%)"
"2958";"Adverse event"
"2959";"Adverse events (any grade)"
"2960";"Adverse events leading to premature treatment discontinuation"
"2961";"Adverse eventy"
"2962";"Adverse outcome"
"2963";"Ae' (per cm/s)"
"2964";"AE/A ratio (per 0.1 unit)"
"2965";"AE/e' ratio (per 1 unit)"
"2966";"AED inducer status"
"2967";"Aerobic Activity"
"2968";"Aerobic exercise"
"2969";"AEs in ≥2 Japanese patients in a study arm, n (%)§"
"2970";"AEs leading to"
"2971";"AEs leading to discontinuation of study drugb"
"2972";"AEs leading to dose reduction of study drugb"
"2973";"AEs related to"
"2974";"AEs*"
"2975";"Aetiology of PAH"
"2976";"AF"
"2977";"AF alone"
"2978";"AF alone refers to atrial fi-brillation without coexisting cardiovascular conditions but with left atrial dilatation. ACE denotes angiotensin-con-verting enzyme, HF heart failure, and LVD left ventricular dysfunction."
"2979";"AF duration, n (%)"
"2980";"AF first diagnosis >2 years, n (%)"
"2981";"AF on baseline ECG, n (%)"
"2982";"AF or atrial flutter!"
"2983";"AF or atrial flutter卞"
"2984";"AF pattern"
"2985";"AF Pattern"
"2986";"AF type"
"2987";"AF Type"
"2988";"AF type — no. (%)"
"2989";"AFCAPS/"
"2990";"Affected body-surface area >3% — no. {%)"
"2991";"Africa"
"2992";"Africa ! Near East"
"2993";"Africa or Near East"
"2994";"Africa*"
"2995";"Africa, Asia, or the Middle East"
"2996";"African"
"2997";"African-American"
"2998";"African-American / African Heritage (n=129)"
"2999";"African-American/African heritage (n=129)"
"3000";"African-Latin American"
"3001";"African America"
"3002";"African American"
"3003";"African American N = 228"
"3004";"African American, n (%)"
"3005";"African American/black"
"3006";"African Americans"
"3007";"African descent"
"3008";"after 48 h"
"3009";"After amendment"
"3010";"After Amendment (%)"
"3011";"After bronchodilation"
"3012";"After bronchodilator use"
"3013";"After PCI"
"3014";"AG"
"3015";"AG+GG"
"3016";"Aga Group"
"3017";"Age"
"3018";"AGE"
"3019";"age-interaction"
"3020";"Age— yr"
"3021";"Age—mean (SD) (years)"
"3022";"Age—year (median)"
"3023";"Age ' 70 y (n 1220)"
"3024";"Age '^75 yrs"
"3025";"Age - mean (sd) years"
"3026";"Age - years"
"3027";"Age - years, Median (IQR)"
"3028";"Age — y, meantSD"
"3029";"Age — y£"
"3030";"Age — yr"
"3031";"Age — yr Age group — no. (%)"
"3032";"Age — yr Race — no. (%)f"
"3033";"Age — yrf"
"3034";"Age —yr"
"3035";"Age #75 yrs"
"3036";"Age $65 years§*"
"3037";"Age $65 yrs"
"3038";"Age $75 yrs"
"3039";"Age &65"
"3040";"Age ( years)"
"3041";"Age (median [IQR]), y"
"3042";"Age (median, IQR), y"
"3043";"Age (median, years)"
"3044";"Age (p=O-53)"
"3045";"Age (per 5 years)"
"3046";"Age (range) (years)"
"3047";"Age (SD), y"
"3048";"Age (y)"
"3049";"Age (y) [mean - SD]"
"3050";"Age (y)∗"
"3051";"Age (y), mean (range)"
"3052";"Age (y), mean (SD)"
"3053";"Age (y), median (25th to 75th percentiles)"
"3054";"Age (y), median (IQR)"
"3055";"Age (y), median (min, max)"
"3056";"Age (y), median (min, max}"
"3057";"Age (year)"
"3058";"Age (year), mean±SD"
"3059";"Age (years (s.d.))"
"3060";"Age (years)"
"3061";"Age (Years)"
"3062";"Age (years) - < Median (n=195, 206)"
"3063";"Age (years) - >= Median (n=228, 217)"
"3064";"Age (years) - mean ± SD"
"3065";"Age (years) (mean ± SD)"
"3066";"Age (years) (mean, SD)"
"3067";"Age (years) [median (25th to 75th percentile)]"
"3068";"Age (years) Mean (SD)"
"3069";"Age (years) mean ± SD"
"3070";"Age (years)*"
"3071";"Age (years), mean (s.d.)"
"3072";"age (years), mean (sD)"
"3073";"Age (years), mean (SD)"
"3074";"Age (years), mean _ SD"
"3075";"Age (years), mean ± s.d."
"3076";"Age (years), mean ± SD"
"3077";"Age (years), mean±SD"
"3078";"Age (years), Mean±SD"
"3079";"Age (years), median (range)"
"3080";"Age (years):"
"3081";"Age (years): <65"
"3082";"Age (years): >75"
"3083";"Age (years): 65-<75"
"3084";"Age (years): mean ± SD"
"3085";"Age (years)+"
"3086";"Age (years)a"
"3087";"Age (years; SD)"
"3088";"Age (yij"
"3089";"Age (yr)"
"3090";"Age (yr)*"
"3091";"age (yr), mean (SD)"
"3092";"Age (yr), mean (SD) BMD T-score, mean (SD)"
"3093";"Age (yrs)"
"3094";"Age (yrs) <51"
"3095";"Age (yrs) 18-40"
"3096";"Age (yrs), mean *"
"3097";"Age (yrs), mean ± SD"
"3098";"Age ,65 years"
"3099";"Age [year], mean ± SDa"
"3100";"Age [years]"
"3101";"Age [years] (Interaction: p=0.55)"
"3102";"Age [years], median (range)"
"3103";"Age ^65"
"3104";"Age ^75 yrs, n (%)"
"3105";"Age £75"
"3106";"Age £75 years (ITT) (n=154)"
"3107";"Age £75 years (ITT) (n=171)"
"3108";"Age < 65"
"3109";"age < 65 years"
"3110";"Age < 65 Years"
"3111";"age < 65 years old"
"3112";"Age < 65 yrs"
"3113";"Age < 75"
"3114";"Age < 75 years"
"3115";"Age < 85"
"3116";"Age < Median"
"3117";"Age <51 Gd Lesion >1 N=72"
"3118";"Age <51 Gd Lesion=0 N=143"
"3119";"Age <60 years"
"3120";"Age <60 years and BMI <24 kg/m2"
"3121";"Age <60 years and BMI ≥24 kg/m2"
"3122";"Age <60 yr"
"3123";"Age <65"
"3124";"Age <65 vears n = 1401"
"3125";"Age <65 vears n=1159"
"3126";"Age <65 y"
"3127";"Age <65 years"
"3128";"Age <65 years — no. (%)"
"3129";"Age <65 years (ITT) (n=1178)"
"3130";"Age <65 years (ITT) (n=895)"
"3131";"Age <65 years (n=1192)"
"3132";"Age <65 years (n=124, 66)"
"3133";"Age <65 years (n=132, 67)"
"3134";"Age <65 years (n=4031)"
"3135";"Age <65 years (n=899)"
"3136";"Age <65 years (n=905)"
"3137";"Age <65 years, n (%)"
"3138";"Age <65 yr"
"3139";"Age <65 yr or >65 yr"
"3140";"Age <65 yrs"
"3141";"Age <65: QVAI49-SFC"
"3142";"Age <65years"
"3143";"Age <65yrs"
"3144";"Age <68 years3"
"3145";"Age <69 years (median)"
"3146";"Age <70 years (median)"
"3147";"Age <75"
"3148";"Age <75 y"
"3149";"Age <75 y (n=8932)"
"3150";"Age <75 Years (n="
"3151";"Age <75 Years (n=8932)"
"3152";"Age <75 yr or >75 yr"
"3153";"Age <75 yrs"
"3154";"Age <Median"
"3155";"Age ≥60 years and BMI <24 kg/m2"
"3156";"Age ≥60 years and BMI ≥24 kg/m2"
"3157";"Age ≥65 years"
"3158";"Age ≥65 years, n (%)"
"3159";"Age ≥75 years"
"3160";"Age ≥75 yearsa"
"3161";"Age >"
"3162";"Age >- Median"
"3163";"Age > 65"
"3164";"Age > 65 years"
"3165";"Age > 65 Years"
"3166";"Age > 70"
"3167";"Age > 75"
"3168";"Age > 75 years"
"3169";"Age > 75 years, n(%)"
"3170";"Age > 75 yr"
"3171";"Age > 75 yr 十"
"3172";"Age > 85"
"3173";"age >= 65 years"
"3174";"Age >= 65 yrs"
"3175";"Age >=75"
"3176";"Age >51 Gd Lesion >1 N=37"
"3177";"Age >51 Gd Lesion=0 N=187"
"3178";"Age >60 years"
"3179";"Age >60 yr (%)"
"3180";"Age >60 yr and elevated biomarkers"
"3181";"Age >60 yr and ST-segment changes"
"3182";"Age >60 yr, elevated biomarkers, and ST-segment changes"
"3183";"Age >65 (years)t"
"3184";"Age >65 vears n = 318"
"3185";"Age >65 vears n=258"
"3186";"Age >65 y"
"3187";"Age >65 y (%)"
"3188";"Age >65 y*"
"3189";"Age >65 y, %"
"3190";"Age >65 y, n (%)"
"3191";"Age >65 years"
"3192";"Age >65 years, %"
"3193";"Age >65 years, n (%)"
"3194";"Age >65 yr"
"3195";"Age >65 yr — no. (%)"
"3196";"Age >65 yr, no. (%)"
"3197";"Age >65 yrs"
"3198";"Age >65 yrs, %"
"3199";"Age >65, %"
"3200";"Age >65: QVAI49-SFC"
"3201";"Age >68 years3"
"3202";"Age >69 years (median)"
"3203";"Age >70 y"
"3204";"Age >70 y (n=802)"
"3205";"Age >70 y(n=802)"
"3206";"Age >70 years"
"3207";"Age >70 years (median)"
"3208";"Age >70 years, n (%)"
"3209";"Age >70 yr"
"3210";"Age >70 yrs"
"3211";"Age >75"
"3212";"Age >75 y"
"3213";"Age >75 y (n = 2194)"
"3214";"Age >75 y (n = 2206)"
"3215";"Age >75 y (n=2010)"
"3216";"Age >75 y**"
"3217";"Age >75 y, %"
"3218";"Age >75 y, n (%)"
"3219";"Age >75 y, n/N (%)"
"3220";"Age >75 years"
"3221";"Age >75 years (ITT) (n=217)"
"3222";"Age >75 years (n=174)"
"3223";"Age >75 Years (n=2010)"
"3224";"Age >75 years (n=222)"
"3225";"Age >75 years, n (%)"
"3226";"Age >75 yr"
"3227";"Age >75 yr — no. (%)"
"3228";"Age >75 yrs"
"3229";"Age >75 yrs*"
"3230";"Age >75 yrs, n (%)"
"3231";"Age >75, y"
"3232";"Age ± SD (yrs)"
"3233";"Age 2 65 y"
"3234";"Age 265"
"3235";"Age 265years"
"3236";"Age 275 y"
"3237";"Age 275 years (n=156)"
"3238";"Age 3*60 yr"
"3239";"Age 50-59 yr, elevated biomarkers, and previous vascular"
"3240";"Age 55-54 y (n = 4943)"
"3241";"Age 55-64 y (n = 4968)"
"3242";"Age 55 64 y"
"3243";"AGE 65-74"
"3244";"Age 65-74 y (n = 3968)"
"3245";"Age 65-74 y (n = 3979)"
"3246";"Age 65-74 years (ITT) (n=538)"
"3247";"Age 65-74 years (ITT) (n=542)"
"3248";"Age 65-74 years (ITT) (n=728)"
"3249";"Age 65-74 years (n=542)"
"3250";"Age 65-74 years (n=551)"
"3251";"Age 65-74 years (n=737)"
"3252";"Age 65-75"
"3253";"Age 65+"
"3254";"Age 65+ y"
"3255";"Age 65+ years"
"3256";"Age 65+yrs"
"3257";"Age 75 years or more"
"3258";"Age a 65"
"3259";"Age at asthma diagnosis years"
"3260";"Age at baseline (years)"
"3261";"Age at baseline in years, mean (SD)"
"3262";"Age at completion of highest level of"
"3263";"Age at diagnosis <18 years"
"3264";"Age at diagnosis of LN, years"
"3265";"Age at diagnosis of SLE, years"
"3266";"Age at diagnosis s18 years"
"3267";"Age at diagnosis, y"
"3268";"Age at disease onset, n (%)*"
"3269";"Age at disease onset, years*"
"3270";"Age at enrollment (years)"
"3271";"Age at enrollment (years), mean (SD)"
"3272";"Age at enrolment, years"
"3273";"Age at entry (years)"
"3274";"Age at first seizure, years, mean (SD)"
"3275";"Age at lipid randomization (y)"
"3276";"Age at menopause (yr)"
"3277";"Age at onset, y"
"3278";"Age at randomisation"
"3279";"Age at Randomization"
"3280";"Age at randomization (years)"
"3281";"Age at screening"
"3282";"Age at time of first seizure,"
"3283";"Age b55 y (n = 1782)"
"3284";"Age b55 y (n = 1791)"
"3285";"Age categories"
"3286";"Age categories (y), n (%)"
"3287";"Age categories, n (%)"
"3288";"Age category"
"3289";"Age category (%)"
"3290";"Age category (years), n (%)"
"3291";"Age category >"
"3292";"Age category, n (%)"
"3293";"Age category, n (%) < 65 years"
"3294";"Age category, n (%):"
"3295";"Age cohort, no. (%)"
"3296";"Age distribution"
"3297";"Age distribution, n (%)"
"3298";"Age distribution, years, n (%)"
"3299";"Age Groiro: <18 years"
"3300";"Age group"
"3301";"Age Group"
"3302";"Age group — no. (%)"
"3303";"Age group (≥75 years)—No. (%)"
"3304";"Age group (≥75)—No. (%)"
"3305";"Age group (y)"
"3306";"Age group (years)"
"3307";"Age group 一％"
"3308";"Age group 1"
"3309";"Age group 2"
"3310";"Age group, n (%)"
"3311";"Age group, no. (%)"
"3312";"Age group, no. (%), y"
"3313";"Age Groups"
"3314";"Age groups, n (%)"
"3315";"Age in 2 classes"
"3316";"Age in 3 classes"
"3317";"Age in years"
"3318";"Age in years, mean"
"3319";"Age in years, mean (SD)"
"3320";"Age in years, median (IQR)"
"3321";"Age is >60 vrs, positive biomarkers, and no si.gni.fi.canr ECG changes"
"3322";"Age is >60 vrs, significant ECG changes, and no positive bi.omark.ers"
"3323";"Age is >60 vrs, significant ECG changes, and positive biomarkers"
"3324";"Age mean (yrs ± SD)"
"3325";"Age Mean age, years Sex"
"3326";"Age of asthma onset, years"
"3327";"Age of completion of highest education, years (SD)"
"3328";"Age of onset"
"3329";"Age of onset <40 years (n = 658)"
"3330";"Age of onset 40 years (n = 273)"
"3331";"Age range"
"3332";"Age range (years)"
"3333";"Age range, y"
"3334";"Age range, years"
"3335";"Age s*60 yr"
"3336";"Age s65 years (n=41, 21)"
"3337";"Age S65 years (n=41,19)"
"3338";"Age s75"
"3339";"Age subgroup, y"
"3340";"Age subgroups"
"3341";"Age when diabetes first diagnosed — yr"
"3342";"Age when diabetes first diagnosed (years), mean (SD)"
"3343";"Age y, median (range)"
"3344";"Age years"
"3345";"Age years Geographic region"
"3346";"Age yr, range"
"3347";"Age yrs"
"3348";"Age*"
"3349";"Age, (years)"
"3350";"Age, mean"
"3351";"Age, mean (min-max) (yrs)"
"3352";"Age, mean (range) years"
"3353";"Age, mean (s.e.)"
"3354";"Age, mean (SD)"
"3355";"Age, mean (SD) (years)"
"3356";"Age, mean (SD) [range], y"
"3357";"Age, mean (SD) years"
"3358";"Age, mean (sd) years, n (%)"
"3359";"Age, mean (SD), y"
"3360";"Age, mean (SD), y Ethnicity, No. (%)"
"3361";"Age, mean (SD), years"
"3362";"Age, mean (SD), yearsa"
"3363";"Age, mean (SD), yr"
"3364";"Age, mean (SD), yrs"
"3365";"Age, mean = SD, years"
"3366";"Age, mean ± SD (year)"
"3367";"Age, mean ± SD years"
"3368";"Age, mean ± SD, y"
"3369";"Age, mean ± SD, years"
"3370";"Age, mean 6 SD years"
"3371";"Age, mean years (SD)"
"3372";"Age, mean years (SD)’ Gender, n (%)"
"3373";"Age, mean years, [SD]"
"3374";"Age, mean yr"
"3375";"Age, mean yr (SD)"
"3376";"Age, mean, years (± SD)"
"3377";"Age, mean, yrs (SD)"
"3378";"Age, mean±SD"
"3379";"Age, mean±SD, y"
"3380";"Age, median (25th-75th percentiles), y"
"3381";"Age, median (25th—75th percentiles), y"
"3382";"Age, median (25th, 75th), y"
"3383";"Age, median (interquartile range), y"
"3384";"Age, median (IQR)"
"3385";"Age, median (IQR), y"
"3386";"Age, median (IQR), years"
"3387";"Age, median (range) (years)"
"3388";"Age, median years"
"3389";"Age, n (%)"
"3390";"Age, X"
"3391";"Age, y"
"3392";"Age, y (25th, 75th percentiles)"
"3393";"Age, y (mean ± s.d.)"
"3394";"Age, y (mean ± SD)"
"3395";"Age, y (mean±SD)"
"3396";"Age, y (SD)"
"3397";"Age, y <65"
"3398";"Age, y Gender, n (%)"
"3399";"Age, y Mean (SD)"
"3400";"Age, y Sex, No. (%)"
"3401";"Age, y, mean (SD)"
"3402";"Age, y, mean ± SD"
"3403";"Age, y, mean±SD"
"3404";"Age, y.o."
"3405";"Age, y; median (Q1–Q3)"
"3406";"Age, ya"
"3407";"Age, year"
"3408";"Age, year (median)"
"3409";"Age, years"
"3410";"Age, years (mean _+ SD) Sex, n (%):"
"3411";"Age, years (mean = SD)"
"3412";"Age, years (mean ± SD)"
"3413";"Age, years (mean 6 SD)"
"3414";"Age, years (SD)"
"3415";"Age, years mean (s.d.)"
"3416";"Age, years Mean (SD)"
"3417";"Age, years Mean±SD"
"3418";"Age, years*"
"3419";"Age, years, mean (range)"
"3420";"Age, years, mean (sd)"
"3421";"Age, years, mean (SD)"
"3422";"Age, years, mean + SD"
"3423";"Age, years, mean ± SD"
"3424";"Age, years: median (range)"
"3425";"Age, years; mean (SD)"
"3426";"Age, years^"
"3427";"Age, years“"
"3428";"Age, years1'"
"3429";"Age, yf 45-54"
"3430";"Age, yr"
"3431";"Age, yr Mean (SD)"
"3432";"Age, yr, mean (SD)"
"3433";"Age, yr, n (%)"
"3434";"Age, yrs"
"3435";"Age, yrs (mean ± SD)"
"3436";"Age, yrs*"
"3437";"Age, yrs, mean (SD)"
"3438";"Age, yrs, median (25th, 75th)"
"3439";"Age, yrs, median (IQR)"
"3440";"Age, yt"
"3441";"Age,years Geographical distribution of patients"
"3442";"Age. y"
"3443";"Age. years"
"3444";"Age........ y (n = 1791)"
"3445";"Age/GD lesion"
"3446";"Age:"
"3447";"Age: <65 years"
"3448";"Age: <70 years (n=960)"
"3449";"Age: >65 years"
"3450";"Age\\yr"
"3451";"Age<65"
"3452";"AGE<65"
"3453";"Age<65 years old"
"3454";"Age<75"
"3455";"Age ≥65 y, n (%)"
"3456";"Age>:65"
"3457";"Age>= 65 years old"
"3458";"Age>=65"
"3459";"AGE>=75"
"3460";"Age>75"
"3461";"Agea"
"3462";"AgeadJ"
"3463";"Aged ^65 years"
"3464";"Aged <65 years"
"3465";"Aged ≥65 years"
"3466";"Aged 65 y or older, n (%)"
"3467";"Aged a 65 years"
"3468";"AgeT, y"
"3469";"Aggressive (2)"
"3470";"Aggressive (7)"
"3471";"Aggressive (N = 252)"
"3472";"AGI"
"3473";"AHA status at screeningb, n (%)"
"3474";"ai10"
"3475";"AICD, (%)"
"3476";"Aii participants (n = 8162)"
"3477";"Aii Patients (n = 6886)"
"3478";"Aiirocumab"
"3479";"Aiirocumab (n = 209)"
"3480";"Ain, No. (%)**"
"3481";"Ain, No. (%)“*"
"3482";"Aiorvasiaiin"
"3483";"AIR (n = 221)"
"3484";"AIR + IG (n = 115)"
"3485";"Airflow reversibility — no. (%)|"
"3486";"Airway compromise"
"3487";"Airway reversibility, %"
"3488";"Airway reversibility, mean, %"
"3489";"Ala carriers"
"3490";"Alanine aminotransferase increased"
"3491";"Alanine aminotransferase or aspartate aminotransferase >3x upper limit of normal (N=432)"
"3492";"Alanine aminotransferase, U/L"
"3493";"Alaska Native"
"3494";"ALathosterol (%)"
"3495";"ALAV (per ml)"
"3496";"Albiglutide (n=4731)"
"3497";"Albiglutide Events/patients (%"
"3498";"Albumin-to-creatinine ratio'i""/"
"3499";"Albumin-to-creatinine ratio (ACR)"
"3500";"Albumin-to-creatinine ratio,"
"3501";"Albumin (mg/dL)"
"3502";"Albumin creatinine ratio"
"3503";"Albumin measurements^^"
"3504";"Albumin, g/dl"
"3505";"Albumin/creatinine ratio - mg/mmol, Median (IQR)"
"3506";"Albumin/creatinine ratio, n(%)"
"3507";"Albuminuria"
"3508";"albuminuria (ACR >30 m.g/g) at baseline to normoalbuminuria"
"3509";"Albuminuria (g/g)"
"3510";"Albuminuria < 1 gram/gram Cr"
"3511";"Albuminuria and previous maerovaseular disease plus established renal disease (eGFR 45-75 mL/min/L73 in- with an UACR >200 mg/g or eGFR 15 -<45 mL/inin/L73 in- with any UACR mg/g)"
"3512";"Albuminuria and previous maerovaseular disease without established renal disease"
"3513";"Albuminuria progression"
"3514";"Albuminuria_P_interaction"
"3515";"Albuterol reversibility, %"
"3516";"Albuterol Use"
"3517";"Albuterol use (SD), puffs/day"
"3518";"AlC (%)"
"3519";"AlC (mmol/mol)"
"3520";"AlC <7.0% at baseline, n (%)"
"3521";"AlC <7.5%"
"3522";"AlC >7.5-8.0%"
"3523";"AlC at week 26 (%)"
"3524";"AlC at weekO (%)"
"3525";"AlC group (%)"
"3526";"Alc<6.4%"
"3527";"Alc>=6.4%"
"3528";"Alcohol"
"3529";"Alcohol <= 2/wk"
"3530";"Alcohol > 2/wk"
"3531";"Alcohol >2 drinks per week"
"3532";"Alcohol abuse"
"3533";"Alcohol consumption"
"3534";"Alcohol consumption (%)"
"3535";"Alcohol consumption (%) <1 drink/dav"
"3536";"Alcohol consumption (yes) (n)"
"3537";"Alcohol consumption > once weekly"
"3538";"Alcohol consumption at baseline"
"3539";"Alcohol consumption!"
"3540";"Alcohol consumption*"
"3541";"Alcohol consumption, n (%)"
"3542";"Alcohol consumption, no. (%)"
"3543";"Alcohol drinker"
"3544";"Alcohol drinker, n (%)"
"3545";"Alcohol intake"
"3546";"Alcohol intake (+) (%)"
"3547";"Alcohol intake (A)"
"3548";"Alcohol intake Never/rarely"
"3549";"Alcohol use"
"3550";"Alcohol Use"
"3551";"Alcohol use (%)"
"3552";"Alcohol use (%,>1/day)"
"3553";"Alcohol use (> 1 drink/wk)"
"3554";"Alcohol use, drinks/wk"
"3555";"Alcohol use, drinks/wk*"
"3556";"Alcohol use, n (%)"
"3557";"Alcohol Use, n (%)"
"3558";"Alcohol useb"
"3559";"Alcohol usef, n (%)"
"3560";"Alcohol users, n (%)"
"3561";"Alcohol, % with >1 drink/d"
"3562";"Alcohol^"
"3563";"ALDL cholesterol"
"3564";"Aldosterone antagonist"
"3565";"Aldosterone antagonists"
"3566";"Aldosterone antagonists (e.g. spironolactone)"
"3567";"Aldosterone blocker"
"3568";"Aldosterone blocker, %"
"3569";"Aldosterone blockers"
"3570";"Aldosterone inhibitor"
"3571";"Aldosterone receptor antagonists"
"3572";"Aldosterone Use"
"3573";"Ale"
"3574";"Ale <7"
"3575";"Alendronate"
"3576";"Alendronate (n = 1841)"
"3577";"Alendronate (n = 2567)"
"3578";"Alendronate (n=1022)"
"3579";"ALERT"
"3580";"Algorithm 1"
"3581";"Algorithm 2"
"3582";"ALI"
"3583";"Alirocumab"
"3584";"Alirocumab (n = 167)"
"3585";"Alirocumab (n = 287)"
"3586";"Alirocumab (n = 294)"
"3587";"Alirocumab (n = 323)"
"3588";"Alirocumab (n = 49)"
"3589";"Alirocumab (n = 51)"
"3590";"Alirocumab (N=9462)"
"3591";"Alirocumab 150 mg Q2W"
"3592";"Alirocumab 75/150 mg"
"3593";"Alirocumab n = 2344"
"3594";"Alirocumab n = 996"
"3595";"Aliskiren"
"3596";"Aliskiren (DM-vs. DM+)"
"3597";"Aliskiren (n = 170)"
"3598";"Aliskiren (n = 1713)"
"3599";"Aliskiren (n = 55)"
"3600";"Aliskiren (n = 627)"
"3601";"Aliskiren (n=4274)"
"3602";"Aliskiren (n=567)"
"3603";"Aliskiren DM = 627 Non-DM = 1713"
"3604";"Aliskiren/Valsartan (n=574)"
"3605";"Alive (n=1649)"
"3606";"All"
"3607";"ALL"
"3608";"All-baricitinib rA (n=3492)*"
"3609";"All-causa mortality"
"3610";"All-cause"
"3611";"All-cause death"
"3612";"All-cause death    n"
"3613";"All-cause death/stroke/SEE"
"3614";"All-cause hospitalization"
"3615";"All-cause mortalitv"
"3616";"All-cause mortality"
"3617";"All-Cause Mortality"
"3618";"All-cause mortality (n=240)"
"3619";"All-cause mortality (no. of events)"
"3620";"All-cause mortality (per 100 person-years)"
"3621";"All-cause mortality at 1 year"
"3622";"All-cause mortality or HF hospitalization"
"3623";"All-cause mortality or HF hospitalization^"
"3624";"All (n = 2,530)"
"3625";"All (n = 332)"
"3626";"All (N = 4628) 71.6±9.0"
"3627";"All (n = 734)"
"3628";"All (n=1556*)"
"3629";"All (n=3405f)"
"3630";"All Bleed"
"3631";"All Bleeding"
"3632";"All CANA"
"3633";"All Canakinumab"
"3634";"All cancer"
"3635";"All cardiovascular"
"3636";"All cause mortality"
"3637";"All cause mortality or hosp. for worsening HF hs-CRP <2.0 mg/L"
"3638";"All completers"
"3639";"All completers (n 5 327)"
"3640";"All completers (n 5 333)"
"3641";"All countries"
"3642";"All death"
"3643";"All Diabetesd"
"3644";"All Doses"
"3645";"All doses (n=3315)"
"3646";"All dulaglutide 1.5 mg + insulin lispro / insulin glargine (N = 445)"
"3647";"All EZ/simva"
"3648";"All grafts"
"3649";"All Ischemic Stroke"
"3650";"All ITT Sutajects"
"3651";"All major cardiovascular events"
"3652";"All men"
"3653";"All Men"
"3654";"All Mis"
"3655";"All Mis*"
"3656";"All MN-naïve patients"
"3657";"All N=12 410"
"3658";"All N=14,671"
"3659";"All N=4487"
"3660";"All non-MN"
"3661";"All noncompleters"
"3662";"All of the above"
"3663";"All of the colon"
"3664";"All other"
"3665";"All Other"
"3666";"All others"
"3667";"All Others"
"3668";"All Others ETeed for 30 mg Edoxaban Dose at"
"3669";"All others, n (%)"
"3670";"All participants"
"3671";"All Participants"
"3672";"All Participants (N = 402)"
"3673";"All participants History of CABG"
"3674";"All participants* (N=120/115)"
"3675";"All participants* (N=381/380)"
"3676";"All participants, mm Hg: SBP, mean (SD)"
"3677";"All participants^^ (N=341/341)"
"3678";"All participantsa"
"3679";"All participantst (N=341/341)"
"3680";"all patients"
"3681";"All patients"
"3682";"All Patients"
"3683";"All patients (« = 22 192)"
"3684";"All Patients (N = 1156)"
"3685";"All Patients (N = 30,449)"
"3686";"All Patients (N = 310)"
"3687";"All Patients (N = 318)"
"3688";"All Patients (N = 323)"
"3689";"All Patients (N = 3362)"
"3690";"All patients (N = 508)"
"3691";"All Patients (N = 508)"
"3692";"All Patients (N = 5518)"
"3693";"All patients (n = 854)"
"3694";"All patients (N 5 3444)"
"3695";"All patients (n = 1161)b"
"3696";"All patients (n=1204)"
"3697";"All patients (n=1306)"
"3698";"All patients (P<0.0001)"
"3699";"All patients (P=0.08)"
"3700";"All patients (P=0.22)"
"3701";"All patients (P=0.42)"
"3702";"All patients (P=0.98)"
"3703";"All patients N =10 372"
"3704";"All patients n=868"
"3705";"All patients on maximally tolerated statin ± other LLT"
"3706";"All patients with fistulas (n = 117)"
"3707";"All Patients With OPG n-1447"
"3708";"All patients, N ="
"3709";"All patientsb"
"3710";"All randomized"
"3711";"All Randomized"
"3712";"All randomized All-cause mortality"
"3713";"All randomized All-cause mortality or hospitalization for worsening HF^"
"3714";"All randomized Coronary end point"
"3715";"All randomized patients"
"3716";"All randomized patients (range)"
"3717";"All randomized women"
"3718";"All randomly assigned"
"3719";"All recurrent strokes"
"3720";"All Responders, (n = 240)"
"3721";"All Responders, (n = 244)"
"3722";"All rosuva"
"3723";"All stroke"
"3724";"All Stroke"
"3725";"All strokes"
"3726";"All strokes*"
"3727";"All Strokes, n (%)"
"3728";"All subjects"
"3729";"All Subjects"
"3730";"All subjects - N"
"3731";"All TEAEs"
"3732";"All TEAEs*"
"3733";"All treatments"
"3734";"All trials"
"3735";"All With Coenzyme Q10 (n = 1,191)"
"3736";"All with diabetes (n=1195)"
"3737";"All without diabetes (n=7998)"
"3738";"All women"
"3739";"All Women"
"3740";"All~cause mort/HF hosp."
"3741";"Alleles"
"3742";"Allergic disease by historyb, n (%)"
"3743";"Allergic rhinitis"
"3744";"Allergic rhinitis — no. (%)"
"3745";"Allergic rhinitis duration, mean ± SD, y*"
"3746";"ALLHAT-LLT"
"3747";"Allogliptin"
"3748";"Allopurinol"
"3749";"Allopurinol 200/300 mg daily N = 756"
"3750";"Allopurinol 200/300 mg N = 131"
"3751";"Allopurinol 300 mg (n = 268)+"
"3752";"Allopurinol 300/200 mg daily N = 755"
"3753";"Allopurinolt"
"3754";"Alogliptin"
"3755";"Alogliptin (N = 2701)"
"3756";"Alogliptin (n=1930)"
"3757";"Alogliptin (n=2701)"
"3758";"Alogliptin (n=771)"
"3759";"Alogliptin 12.5 mg + pioglitazone (n=197)"
"3760";"Alogliptin 25 mg + pioglitazone ( n = 199)"
"3761";"Alogliptin, N(%)"
"3762";"Alone"
"3763";"Alpha-blocker"
"3764";"Alpha-blocker/other vasodilator"
"3765";"Alpha-blockers"
"3766";"Alpha-glucosidase inhibitors"
"3767";"Alpha 1 blockers"
"3768";"Alpha blockers"
"3769";"Alpha glucosidase inhibitors"
"3770";"Alpha receptor antagonist"
"3771";"Alpha reductase inhibitors"
"3772";"Alprostadil (n = 414)"
"3773";"Alprostadil n/N"
"3774";"Alprostadil n/N    %"
"3775";"ALT (units/L)"
"3776";"ALT >3x ULN on two consecutive visits"
"3777";"ALT and/or AST > 3 times ULN consecutive#"
"3778";"ALT increased"
"3779";"ALT or AST > 3 x ULN1"
"3780";"ALT or AST > 5 x ULN1"
"3781";"ALT, AST, or both >3x ULN"
"3782";"ALT, U/L"
"3783";"Alteplase"
"3784";"Alteplase (n=418)"
"3785";"Alteplase group (n=81)"
"3786";"Alternative Disability"
"3787";"ALVEDV (per ml)"
"3788";"ALVEF (per 1%)"
"3789";"ALVESV (per ml)"
"3790";"ALVMi (per g/m2)"
"3791";"AM PEF (SD), L/min"
"3792";"AM_%delta"
"3793";"AM_delta"
"3794";"AM△士 s.e."
"3795";"AMA 士 s.e."
"3796";"aMann Whitney U test/Wilcoxon Sum Rank test."
"3797";"AMBITION"
"3798";"Ambulance"
"3799";"Ambulance (%)"
"3800";"Ambulance, n (%)"
"3801";"ambulatory SBP, Difference vs placebo (95% Cl)"
"3802";"ambulatory SBP, N"
"3803";"Amended dabigatran protocol"
"3804";"America"
"3805";"American"
"3806";"American‐Indian/Alaska native"
"3807";"American Hispanic (n = 193)"
"3808";"American indian"
"3809";"American Indian"
"3810";"American Indian or"
"3811";"American Indian or Alaska"
"3812";"American Indian or Alaska native"
"3813";"American Indian or Alaska Native"
"3814";"American Indian or Alaska native"":"
"3815";"American indian or alaskan"
"3816";"American Indian or Alaskan native"
"3817";"American Indian or Alaskan Native"
"3818";"American Indian or Native Alaskan"
"3819";"American Indian, Alaskan Native, or Aboriginal Canadian"
"3820";"American Indian/"
"3821";"American Indian/Alaska native"
"3822";"American Indian/Alaska Native"
"3823";"American Indian/Alaskan Native"
"3824";"American Indian/Alaskan native, n (%)"
"3825";"American Indian/Native Alaskan"
"3826";"Americas"
"3827";"Americas (n=1767)"
"3828";"Americas**"
"3829";"Americas, excluding US"
"3830";"Ami 5 mg"
"3831";"Ami 5 mg n=349"
"3832";"Aminosalicylate"
"3833";"Aminosalicylates"
"3834";"Aminosalicylates**"
"3835";"Aminosalicylates, N"
"3836";"Amiodarone"
"3837";"AMIODARONE"
"3838";"Amiodarone (n = 299)"
"3839";"Amiodarone (N =845)"
"3840";"Amiodarone (n, %)"
"3841";"Amiodarone Ote at Baseline"
"3842";"Amiodarone Use at Baseline"
"3843";"Amiodarone use at baseline Yes    1,933"
"3844";"Amiodarone vs. Placebo"
"3845";"Amiodarone vs. Placebo No. Hazard ratio (97.5% Cl)"
"3846";"Amiodarone, n (%)"
"3847";"Aml"
"3848";"AML"
"3849";"AML (n = 101)"
"3850";"AML (n = 119)"
"3851";"AML (n = 150)"
"3852";"AML (n = 73)"
"3853";"AML 10 mg + HCTZ 25 mg"
"3854";"AML 10 mg + HCTZ 25 mg (n = 600)"
"3855";"AML 10 mg/HCTZ 25 mg"
"3856";"AML 10/"
"3857";"AML vs. CHL"
"3858";"AML vs. LIS"
"3859";"Aml/HCTZ (n=46)"
"3860";"Aml/HCTZ (n=63)"
"3861";"Aml/HCTZ (n=87)"
"3862";"Aml/Val 5/80 mg"
"3863";"Aml/Val, 5/80 mg rr=347*"
"3864";"Amlodipine"
"3865";"Amlodipine (N = 103)"
"3866";"Amlodipine (n = 286)"
"3867";"Amlodipine (n = 9048)"
"3868";"Amlodipine 10mg /V=471"
"3869";"Amlodipine 5to10mg (n = 324)"
"3870";"Amlodipine and valsartan"
"3871";"Amlodipine vs Chlorthalidone Normal"
"3872";"Amlodipine vs Chlorthalidone Obese"
"3873";"Amlodipine vs Chlorthalidone Overweight"
"3874";"Amlodipine/ vaisartan (n = 286)"
"3875";"Amlodipine/Chlorthalidone"
"3876";"Amlodipine/Lisinopril 12006"
"3877";"Amlodipine/Lisinopril/Chlorthalidone Comparison"
"3878";"Amlodipine/Valsartan 10/160 MG (n=45i)"
"3879";"Amlodipine/Valsartan 10/160 mg /V=473"
"3880";"Amlodipine/Valsartan 5 to 10/160 mg (n = 322)"
"3881";"Amlodipine/Valsartan 5/160 mg"
"3882";"Amlodipine/Valsartan 5/160 mg (n=443)"
"3883";"Amlodipine/Valsartan 5/160 vs 10/160 mg"
"3884";"Amlodipine/Wlsartan i0/160 MG"
"3885";"AMPD3"
"3886";"amputation"
"3887";"Amputation"
"3888";"Amputation — no. (%)"
"3889";"Amputation due to diabetes — no. (%)"
"3890";"Amputations, n (%)"
"3891";"Amputationsa"
"3892";"Anacetrapib (N = 15,225)"
"3893";"Anacetrapib (N=15225)"
"3894";"Anacetrapib 100 mg"
"3895";"Anacetrapib 100 mg (n - 153)"
"3896";"Anacetrapib 100 mg (N = 811)"
"3897";"Anacetrapib 100 mg (n=204)"
"3898";"Anacetrapib 100mg(n=204)"
"3899";"Anacetrapib 25 mg (n - 152)"
"3900";"Anaesthesia/analgesia"
"3901";"Anakinra"
"3902";"Analgesic medication, n (%)"
"3903";"Analysis"
"3904";"analysis compared with the pretreatment condition (baseline), n; LDL = low-density lipoprotein; CSF = cerebrospinal fluid."
"3905";"Anatomic complexity characteristics"
"3906";"Anatomic extent of qualifying event, n (%.)x"
"3907";"Anatomical extent of qualifying event — no. (%):t"
"3908";"anatomy"
"3909";"Ancestry (%)f"
"3910";"ANCOVA result"
"3911";"and after PCI, median (IQR), d"
"3912";"and either an ACE inhibitor or angiotension receptor blocker"
"3913";"and infusion"
"3914";"AND INFUSION"
"3915";"and microalbuminuria or macroalbuminuria"
"3916";"and Physical Examination"
"3917";"and VFx status"
"3918";"and/or AZA at baseline"
"3919";"and/or discharge"
"3920";"Anemia"
"3921";"Anemia — no. (%) ||"
"3922";"Anemia (%)"
"3923";"Anemia, %"
"3924";"Anemia, No./total (%)”"
"3925";"Anesthesiad, n (%)"
"3926";"Angina"
"3927";"Angina (past 6 weeks)"
"3928";"Angina class at baseline"
"3929";"Angina class III or IV — no. (%)"
"3930";"Angina class III or IV prior"
"3931";"Angina class III or IV prior myocardial infarction"
"3932";"angina or acute MI"
"3933";"Angina or positive stress test"
"3934";"angina pectoris"
"3935";"Angina pectoris"
"3936";"Angina pectoris — no. (%)"
"3937";"Angina pectoris*"
"3938";"Angina pectoris, (%)"
"3939";"Angina pectoris本"
"3940";"Angina pectorisf"
"3941";"Angina status — no. (%)"
"3942";"Angina symptoms^"
"3943";"Angina with documented ischemia"
"3944";"Angina, n (%)"
"3945";"angina."
"3946";"Angioedema (adjudicated), n (%)"
"3947";"Angioedema present, n (%){"
"3948";"Angioedema present, n (%)6"
"3949";"Angiogenesis"
"3950";"Angiogenin (ng/ml)"
"3951";"Angiographic characteristics, No. (%)"
"3952";"Angiographic complications, site-reported — no./total no. (%)"
"3953";"Angiographic data"
"3954";"Angiographic data and treatment:"
"3955";"Angiographic extent of disease"
"3956";"Angiographic features"
"3957";"Angiographic findings ||"
"3958";"angiography"
"3959";"Angiography"
"3960";"Angiography — no. (%)"
"3961";"Angiography and revascularization"
"3962";"Angiography during index hospitalization"
"3963";"Angioplasty"
"3964";"Angiotensin-"
"3965";"Angiotensin-converting-enzyme inhibitor"
"3966";"Angiotensin-converting-enzyme inhibitor or angiotensin-"
"3967";"Angiotensin-converting-enzyme inhibitor or angiotensin- receptor blocker§"
"3968";"Angiotensin-converting enzyme inhibitor"
"3969";"Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker"
"3970";"Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use (mITT population)"
"3971";"Angiotensin-converting enzyme inhibitor/angiotensin receptor blocker"
"3972";"Angiotensin-converting enzyme inhibitors"
"3973";"Angiotensin-converting enzyme inhibitors/ angiotensin receptor blockers"
"3974";"Angiotensin-converting enzyme inhibitors/angiotensin receptor blockers"
"3975";"Angiotensin-converting enzyme inhibitors^"
"3976";"Angiotensin-converting enzyme or angiotensin receptor blocker"
"3977";"Angiotensin-eonverting enzyme inhibitors"
"3978";"Angiotensin-eonverting enzyme inhibitors/ angiotensin reeeptor bloekers"
"3979";"Angiotensin-receptor"
"3980";"Angiotensin-receptor blocker"
"3981";"Angiotensin II antagonists"
"3982";"Angiotensin II receptor blocker"
"3983";"Angiotensin II receptor blockers"
"3984";"Angiotensin Il-receptor blocker"
"3985";"Angiotensin ll-receptor antagonist — no. (%)"
"3986";"Angiotensin ll-receptor blocker"
"3987";"Angiotensin receptive blocker"
"3988";"Angiotensin receptor"
"3989";"Angiotensin receptor blocker"
"3990";"Angiotensin Receptor Blocker"
"3991";"Angiotensin receptor blocker and/or ACE"
"3992";"Angiotensin receptor blocker Yes"
"3993";"Angiotensin receptor blockers"
"3994";"Angiotensin Receptor Blockers"
"3995";"Angiotension converting enzyme-inhibitor"
"3996";"aniagonisi"
"3997";"Ankle-brachial index £0.9"
"3998";"Ankle-brachial index <0.9"
"3999";"Ankle-brachial index <0.9— no. (%)"
"4000";"Ankle edema"
"4001";"Ankle fracture"
"4002";"Ankle/brachial index"
"4003";"Annanginal drugs (0/l/s»2)^"
"4004";"aNNT or bNNH (95%CI)"
"4005";"Annual asthma exacerbation rates"
"4006";"Annual exacerbation rate"
"4007";"Annualized rate IND/GLY SFC"
"4008";"Anorexigen use"
"4009";"Antagonist"
"4010";"anterior"
"4011";"Anterior"
"4012";"Anterior (n, %)"
"4013";"Anterior {%)"
"4014";"Anterior circulation"
"4015";"Anterior infarct location"
"4016";"Anterior MI"
"4017";"Anterior myocardial infarction — no. (%)"
"4018";"Anterior myocardial infarction — no./total no. (%)"
"4019";"Anterior or Non- Anterior Ml"
"4020";"Anthropometric characteristics"
"4021";"Anthropometrics, mean (SD)"
"4022";"Anthropometry: mean (SD)"
"4023";"Anti-anaemics"
"4024";"Anti-arthritic medications"
"4025";"Anti-CCP antibodies*"
"4026";"Anti-CCP antibody-positive, n (%)"
"4027";"Anti-CCP antibody (U/"
"4028";"Anti-CCP antibody positive"
"4029";"Anti-CCP antibody positive, n (%)"
"4030";"Anti-CCP Positive"
"4031";"Anti-CCP positive (>10 U/mL), n (%)"
"4032";"Anti-cholinergics (long-acting)"
"4033";"Anti-cholinergics (short-acting)a"
"4034";"Anti-coagulants"
"4035";"Anti-coagulants - no. (%)"
"4036";"Anti-dsDNA (>30 IU/ml), %"
"4037";"Anti-dsDNA positive"
"4038";"Anti-GAD negative"
"4039";"Anti-GAD negative (n = 7895)"
"4040";"Anti-GAD positive"
"4041";"Anti-GAD positive (n = 267)"
"4042";"Anti-histamines"
"4043";"Anti‐hyperglycaemic agent, n (%)"
"4044";"Anti-hypertensive"
"4045";"Anti-hypertensive therapy"
"4046";"Anti-hypertensive therapy - no. (%)"
"4047";"Anti-hypertensive treatment history, n (%)"
"4048";"Anti-hypertensives"
"4049";"Anti-inflammatory drugs"
"4050";"Anti-ischaemia agents*"
"4051";"Anti-p40"
"4052";"Anti‐platelet agents, n (%)"
"4053";"Anti-platelet therapy"
"4054";"Anti-thrombotics"
"4055";"Anti-TNF"
"4056";"Anti-TNF-experienced patients"
"4057";"Anti-TNF-IR patients"
"4058";"Anti-TNF-naive patients"
"4059";"Anti-TNF-naive patients3"
"4060";"Anti-TNF-naive, n (%)"
"4061";"Anti‐TNF‐naïve, n (%)"
"4062";"Anti-TNF agent(s)"
"4063";"Anti-TNF IR"
"4064";"Anti arrhythmic"
"4065";"Anti platelet therapy"
"4066";"Antialdosterone agents"
"4067";"Antianginal medications"
"4068";"Antiarrhythmic"
"4069";"Antiarrhythmic agent"
"4070";"Antiarrhythmic drug"
"4071";"Antiarrhythmic drugs, n (%)"
"4072";"Antiarrhythmic therapy"
"4073";"Antiarrhythmics"
"4074";"Antibiotics**"
"4075";"Antibodies to infliximab, n (%)**"
"4076";"antibody binding level at baseline"
"4077";"Anticholinergic"
"4078";"Anticholinergic drug"
"4079";"Anticholinergic use, n (%)"
"4080";"Anticholinergics"
"4081";"Anticoagulant"
"4082";"Anticoagulant— no. (%)"
"4083";"Anticoagulant Group (N = 187)"
"4084";"Anticoagulant therapy"
"4085";"Anticoagulants"
"4086";"Anticyclic citrullinated peptide positive^, n (%)"
"4087";"Antidepressant"
"4088";"Antidiabetes drug usage [% (n)]"
"4089";"Antidiabetic"
"4090";"Antidiabetic agent"
"4091";"Antidiabetic agents"
"4092";"Antidiabetic drug"
"4093";"Antidiabetic drug‘i“j‘"
"4094";"Antidiabetic medication"
"4095";"Antidiabetic medication||"
"4096";"Antidiabetic medications"
"4097";"Antihyperglycaemic medication at baseline"
"4098";"AntihyperglycemiC"
"4099";"Antihyperglycemic Medication Usage"
"4100";"Antihyperglycemic medications"
"4101";"Antihyperglycemic oral agent therapy"
"4102";"Antihyperglycemictherapies,%"
"4103";"Antihypertensive"
"4104";"Antihypertensive agent use"
"4105";"Antihypertensive agents"
"4106";"Antihypertensive agents (n per patient)"
"4107";"Antihypertensive agents*"
"4108";"Antihypertensive agents, n (%)"
"4109";"Antihypertensive drug, %"
"4110";"Antihypertensive drugs"
"4111";"Antihypertensive medication"
"4112";"Antihypertensive medication or"
"4113";"Antihypertensive medication use, n (%)"
"4114";"antihypertensive medication)"
"4115";"Antihypertensive medication, open-label, no. (%)"
"4116";"Antihypertensive medication1'"
"4117";"Antihypertensive randomization, No. (%)a"
"4118";"Antihypertensive therapy"
"4119";"Antihypertensive therapy — no. (%)"
"4120";"Antihypertensive therapy, n (%)"
"4121";"Antihypertensive treatment"
"4122";"Antihypertensive treatment, n (%)"
"4123";"Antihypertensive treatments"
"4124";"Antihypertensive use"
"4125";"Antihypertensive, antianginal, and other cardiovascular medications"
"4126";"Antihypertensives"
"4127";"Antihypertensives'*"
"4128";"Antihypertensives, n (%)"
"4129";"Antimalarial"
"4130";"Antimalarials only"
"4131";"Antiplatelet"
"4132";"Antiplatelet-Onl Group (N = 174)"
"4133";"Antiplatelet-Only Group (N = 235)"
"4134";"Antiplatelet— no. (%)"
"4135";"Antiplatelet — no./total no. (%)"
"4136";"Antiplatelet agent"
"4137";"Antiplatelet agent N(%)"
"4138";"Antiplatelet agent or anticoagulant"
"4139";"Antiplatelet agents"
"4140";"Antiplatelet agents (%)"
"4141";"Antiplatelet at randomization"
"4142";"Antiplatelet drug"
"4143";"Antiplatelet drugs"
"4144";"Antiplatelet or anti-inflammatory drugs"
"4145";"Antiplatelet or anticoagulant"
"4146";"Antiplatelet or anticoagulant therapy"
"4147";"Antiplatelet therapy"
"4148";"Antiplatelet therapy Dual"
"4149";"Antiplatelet therapy§"
"4150";"Antiplatelet use"
"4151";"Antiplatelet within 3 mo before randomization"
"4152";"Antiplatelets"
"4153";"Antiplatelets agents"
"4154";"Antiplatelets or anticoagulants"
"4155";"Antiplatelets, any"
"4156";"Antiplateletsa"
"4157";"Antithrombin"
"4158";"Antithrombotic"
"4159";"Antithrombotic agents"
"4160";"Antithrombotic agents, n (%)"
"4161";"Antithrombotic and anticoagulant medications"
"4162";"Antithrombotic drug use at time of event"
"4163";"Antithrombotic medications, n (%)"
"4164";"Antithrombotic therapy"
"4165";"Antithrombotic use"
"4166";"Antithrombotic use before enrollment, No. (%)"
"4167";"Antithrombotic! I"
"4168";"Antithrombotic/coagulant"
"4169";"Any"
"4170";"Any (including corticosteroid)"
"4171";"Any ACUITY bleeding"
"4172";"Any adverse event (AE)"
"4173";"Any adverse event leading to study drug discontinuation, n (%)"
"4174";"Any AE"
"4175";"Any AE leading to discontinuation, n (%)"
"4176";"Any AE, n (%)‡"
"4177";"Any AEs"
"4178";"Any AEs, n (%)"
"4179";"Any albuminuria"
"4180";"Any albuminuria — no. (%)"
"4181";"Any anti-hypertensive agent"
"4182";"Any antianginal drug!"
"4183";"Any anticoagulant"
"4184";"Any antihypertensive agent"
"4185";"Any antihypertensive drug"
"4186";"Any bleeding"
"4187";"Any blood"
"4188";"Any blood-pressure-lowering drug 一 no. (%)"
"4189";"Any blood pressure medications (%)"
"4190";"Any Blood Product Transfusion"
"4191";"Any blood transfusion"
"4192";"Any BP-lowering agents^"
"4193";"Any cardiovascular disease"
"4194";"Any cardiovascular disease history, n (%)"
"4195";"Any cardiovascular diseased"
"4196";"any cause"
"4197";"Any cause"
"4198";"Any clinical AE"
"4199";"Any Clinical or Lesion RF for ST"
"4200";"Any condition"
"4201";"Any COPD medication"
"4202";"Any coronary artery disease"
"4203";"Any coronary revascularization"
"4204";"Any cough"
"4205";"Any CV history/risk factors, n (%)"
"4206";"Any CVD history (%)"
"4207";"Any death"
"4208";"Any disease"
"4209";"Any Dose Reduction"
"4210";"Any drug-related AE, n (%)"
"4211";"Any dynamic ST-segment shift"
"4212";"Any early adverse event"
"4213";"Any electrocardiographic abnormality — no. (%)"
"4214";"Any established coronary artery disease"
"4215";"Any established peripheral arterial disease"
"4216";"Any glucocorticoid*"
"4217";"Any glycoprotein IIb/IIIa inhibitor use"
"4218";"Any GUSTO bleeding"
"4219";"Any HbA1c"
"4220";"Any history of congestive heart failure"
"4221";"Any immunosuppressive agent"
"4222";"Any infarct"
"4223";"Any lipid-lowering agent"
"4224";"Any lipid-lowering agent use"
"4225";"Any LLT other than nutraceuticals, n (%)"
"4226";"Any LLT other than statins, n (%)b"
"4227";"Any medication"
"4228";"Any MI"
"4229";"Any MI (n - 5,340)"
"4230";"Any New Anti-Hyperglycemic Rx"
"4231";"Any of the above"
"4232";"Any oral hypoglycemic drug 一 no. (%)"
"4233";"Any other antihyperglycaemic drugs"
"4234";"Any other lipid‐lowering therapy, n (%)"
"4235";"Any other LLTs (other than statin)"
"4236";"Any overt bleed"
"4237";"Any peripheral arterial disease"
"4238";"Any peripheral revascularization"
"4239";"Any placebo"
"4240";"Any prerandomization failure of an antiarrhythmic drug — no. (%)"
"4241";"Any prior anti-TNF treatment failure"
"4242";"Any pulmonary medication"
"4243";"Any pulmonary medication, n (%)"
"4244";"Any recurrent stroke"
"4245";"Any relevant infarct"
"4246";"Any revascularization"
"4247";"Any risk factor for stent thrombosis"
"4248";"Any SAE"
"4249";"Any secukinumab (N = 49)"
"4250";"Any serious AE, n (%)"
"4251";"Any serious TEAEs"
"4252";"Any severity"
"4253";"Any site"
"4254";"Any statin"
"4255";"Any statin (with/without LLT)"
"4256";"Any statin + other LLT"
"4257";"Any statin versus no statin at randomization"
"4258";"Any stroke"
"4259";"Any Stroke (N=641)"
"4260";"Any sulfonylurea"
"4261";"Any TEAE"
"4262";"Any TEAEs"
"4263";"Any therapy — no. (%)"
"4264";"Any thiazide diuretic"
"4265";"Any thiazolidinedione"
"4266";"Any TIMI bleeding"
"4267";"Any treatment-emergent AE"
"4268";"Any type, according to daily dose**"
"4269";"Any ulcerative colitis medication"
"4270";"Any use"
"4271";"Any vascular diasease"
"4272";"Any vascular disease"
"4273";"Any vascular* efficacy"
"4274";"Any VTE-related death"
"4275";"Any VTE or VTE-related death — no. (%)"
"4276";"Anyantianginal agent"
"4277";"Aortic"
"4278";"Aortic-valve replacement"
"4279";"Aortic stenosis"
"4280";"Aortic stenosis, n (%)"
"4281";"Aortic valve disease (n=21 014)"
"4282";"aP-value from an ANCOVA with corresponding baseline lipid value as the covariate and with a effect for treatment group."
"4283";"aP = 0.536; bP   0.001; cP = 0.016. *The study-speciﬁc BP targets were SBP   140 mm Hg and DBP   90 mm Hg (or SBP   130 mm Hg and DBP   80 mm Hg in those with DM). The LDL-C target was   100 mg/dL or   130 mg/dL, depending on risk factor status at baseline in accordance with NCEP ATP III guidelines. Odds ratio and P value calculated based on generalized linear mixed model with generalized estimating equations method that includes compound symmetry covariance matrix for subjects from the same site.  An interaction between treatment effect and DM status was observed for BP goal attainment (P = 0.051) and dual BP/LDL-C goal attainment (P = 0.024) among patients with or without DM calculated based on a mixed-effects linear model (not adjusted for differences in baseline values).
Abbreviations: BP, blood pressure; DBP, diastolic blood pressure; DM, diabetes mellitus; LDL-C, low-density lipoprotein cholesterol; NCEP ATP III; National Cholesterol Education Program–Adult Treatment Panel III; OR, odds ratio; SBP, systolic blood pressure"
"4284";"APASP (per mmHg)"
"4285";"Aphasia"
"4286";"Apixaban"
"4287";"Apixaban (N = 3705)"
"4288";"Apixaban 2.5 mg BID"
"4289";"Apixaban 5 mg BID"
"4290";"Apixaban dose (or matching placebo)"
"4291";"Apixaban vs. Placebo"
"4292";"Apixaban, 2.5 mg"
"4293";"Apixaban, 2.5 mg (N = 840)"
"4294";"Apixaban, 5 mg"
"4295";"Apixaban, 5 mg (N = 813)"
"4296";"Aplxaban 2.5 mg BID"
"4297";"Apo-B"
"4298";"apo A-1, mean (SD), mg/dL"
"4299";"Apo A-I"
"4300";"Apo A-I (mg/dL)*"
"4301";"Apo A-I, mg/dl"
"4302";"Apo A-l (g/L)"
"4303";"Apo A-l (mg/dL) - mean ± SD"
"4304";"apo A1 (g/L)"
"4305";"Apo A1 (mg/dl)"
"4306";"Apo A1, mean (SD)"
"4307";"Apo A1, mg/dL, mean (SD)"
"4308";"Apo B"
"4309";"apo B (g/L)"
"4310";"Apo B (g/L)"
"4311";"Apo B (mg/dl)"
"4312";"Apo B (mg/dL)"
"4313";"Apo B (mg/dL) - mean ± SD"
"4314";"Apo B (mg/dl) **"
"4315";"Apo B*"
"4316";"Apo B, mean (SD)"
"4317";"apo B, mean (SD), mg/dL"
"4318";"Apo B, mg/dl"
"4319";"Apo B, mg/dL, mean (SD)"
"4320";"Apo B/Apo A-L"
"4321";"Apo B/Apo A-l ratio (mean)"
"4322";"Apo B:Apo A-I ratio"
"4323";"Apo Bt"
"4324";"apo, apolipoprotein; DM, diabetes mellitus; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TC, total cholesterol;"
"4325";"Apo, apolipoprotein; DM, diabetes mellitus; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TC, total cholesterol; TG, triglycerides. *Includes agents acting on the renin-angiotensin system, beta blocking agents, calcium channel blockers, and diuretics. †Median values [standard deviation for medians calculated by (Q3   Q1)/1.075]. §Includes cardiac glycosides, antiarrhythmics class I and III, vasodilators used in cardiac diseases and other cardiac preparations. ‡Expressed as g/l."
"4326";"ApoA-1, g/l"
"4327";"ApoA-I"
"4328";"ApoA1, mg/dL"
"4329";"ApoAl"
"4330";"ApoAl (mg/dl) *"
"4331";"ApoAl, mg/dL"
"4332";"ApoB"
"4333";"ApoB (mg/dl)"
"4334";"ApoB (week 24)"
"4335";"ApoB, g/l"
"4336";"ApoB, g/l, mean (SD)"
"4337";"ApoB, mg/dL"
"4338";"ApoB: ApoAl"
"4339";"ApoB:ApoA-1 ratio"
"4340";"ApoB:ApoA-I"
"4341";"ApoB:ApoA-I ratio"
"4342";"ApoB:ApoA-l ratio"
"4343";"ApoB:ApoA1"
"4344";"ApoB:ApoA1 ratio"
"4345";"ApoB:ApoAl ratio"
"4346";"ApoB48"
"4347";"ApoBe"
"4348";"APOE e4 carriers, No. (%)"
"4349";"APOE ε4 carrier"
"4350";"Apolipoproiein A1 (tng/1)"
"4351";"Apolipoproiein B (mij/1)"
"4352";"Apolipoprotein"
"4353";"Apolipoprotein A-I*"
"4354";"Apolipoprotein A1 (g/L)"
"4355";"Apolipoprotein A1 (mg/dL)"
"4356";"Apolipoprotein B (g/L)"
"4357";"Apolipoprotein B (mg/dl)"
"4358";"Apolipoprotein B (mg/dL)"
"4359";"Apolipoprotein B 100, mg/dL"
"4360";"Apolipoprotein B Tx difference vs Pbo, LS mean % change from baseline (SE)"
"4361";"Apolipoprotein B, mean (SD), g/L"
"4362";"Apolipoprotein B, mg/dL"
"4363";"Apolipoprotein B^"
"4364";"Apremilast"
"4365";"Apremilast 20 mg BID n=169"
"4366";"Apremilast 30 mg BID n=167"
"4367";"Aqc<75"
"4368";"Aqe ^65"
"4369";"Aqe <65"
"4370";"Aqe i65"
"4371";"AQLQ Score"
"4372";"AQLQ score, mean"
"4373";"AQLQ score, mean (SD)"
"4374";"AQLQ(S) score"
"4375";"AQLQ(S)+12 score, mean (SD)c,f"
"4376";"AQLQ(S)+12 score:§"
"4377";"AQLQ(S)+12 scored"
"4378";"AQLQ(S)+12 scoretS"
"4379";"AQLQ(SI+12 score’"
"4380";"ARA Functional Class"
"4381";"ARA functional class — no. (%)"
"4382";"ARB"
"4383";"ARB (n, %)"
"4384";"ARB + CCB (n = 586)"
"4385";"ARB = angiotensin II receptor blocker;CCB"
"4386";"ARB at enrollment"
"4387";"ARB at last follow-up"
"4388";"ARB monotherapy"
"4389";"ARB or ACE inhibitor"
"4390";"ARB or ACE inhibitor, n (%)"
"4391";"ARB, %"
"4392";"ARB, n (%)"
"4393";"ARB/ACE"
"4394";"ARBs"
"4395";"ARBs or ACE inhibitors"
"4396";"ARD (95% Cl) per 1000 patient-years"
"4397";"ARD per 10 000 Patient-Years (95% CI)"
"4398";"area"
"4399";"Area of fluorescein leakage within the grid, mean (SD), DAb"
"4400";"Area of retinal hemorrhage within the grid, mean (SD), DAb"
"4401";"Area of retinal thickening within the grid, mean (SD), DAb"
"4402";"areas"
"4403";"Argentina"
"4404";"Arial flutter or fibrillation"
"4405";"arm"
"4406";"ARR"
"4407";"ARR (%)"
"4408";"ARR (95% CI)"
"4409";"ARR (95% Cl)"
"4410";"Arrhythmia"
"4411";"Arrhythmia!"
"4412";"Arrhythmias"
"4413";"Arteriai access"
"4414";"Arterial access"
"4415";"Arterial area (mm2)"
"4416";"Arterial blood pressure, mm Hg"
"4417";"Arterial graft"
"4418";"Arterial hypertension"
"4419";"Arterial hypertension — no. (%)"
"4420";"Arterial hypertension*"
"4421";"Arterial hypertension, n (%)"
"4422";"Arterial hypertension, no. (%)"
"4423";"Arterial revascularization"
"4424";"Arteriosclerosis"
"4425";"Arthralgia"
"4426";"Arthritis characteristics"
"4427";"Arthritis mutilans"
"4428";"Arthritis type*"
"4429";"ARVFAC (per 1%)"
"4430";"as"
"4431";"AS"
"4432";"As-needed inhalations/day"
"4433";"AS duration, y, mean (SD)"
"4434";"as major component — no. (%)"
"4435";"ASA"
"4436";"ASA < 150 mg"
"4437";"ASA > 150 mg"
"4438";"ASA or antiplatelet agent"
"4439";"ASA use at baseline"
"4440";"ASA use at baseline, n (%)"
"4441";"ASA, n (%)"
"4442";"ASAS 5/6, %"
"4443";"ASAS 5/6, n (%)"
"4444";"ASAS partial remission, %"
"4445";"ASAS partial remission, n (%)"
"4446";"ASAS20"
"4447";"ASAS20, %"
"4448";"ASAS20, %"
"4449";"ASAS40, %"
"4450";"ASAS40, %"
"4451";"ASAS50"
"4452";"ASAstoppedat randomization,n"
"4453";"ASCOT-LLA"
"4454";"ASCVD"
"4455";"ASCVD as per protocol"
"4456";"ASCVD including TIA"
"4457";"ASCVD no prior Ml"
"4458";"ascvd"""
"4459";"ASCVD*. n (%)"
"4460";"ASCVD, n (%)"
"4461";"ASCVD,b No. (%)"
"4462";"ASCVDor >2 CV risk factors"
"4463";"ASDAS-CRP Δ ≥ 1.1"
"4464";"ASDAS-CRP*"
"4465";"ASDAS-CRP < 1.3"
"4466";"ASDAS inactive disease, %"
"4467";"Asia"
"4468";"Asia-Pacific"
"4469";"Asia-pacific and South Africa"
"4470";"Asia-Pacific and South Africa"
"4471";"Asia-Pacific HR (95% Cl)"
"4472";"Asia-Pacific region and South Africa"
"4473";"Asia (excluding Japan)"
"4474";"Asia (n=1,337)"
"4475";"Asia (n=1337)"
"4476";"Asia and Pacific Islands"
"4477";"Asia Pacific"
"4478";"Asia Pacific (n= 758)"
"4479";"Asia Pacific and Africa"
"4480";"Asia Pacific and other"
"4481";"Asia Pacific and Other"
"4482";"Asia Pacific and South Africa"
"4483";"Asia Pacific or other"
"4484";"Asia#"
"4485";"Asia, Pacific and other"
"4486";"Asia/Australia/New Zealand"
"4487";"Asia/Pacific"
"4488";"Asia/Pacific (%)"
"4489";"Asia/Pacific/other"
"4490";"Asia/Pacific/Other"
"4491";"Asian"
"4492";"Asian (3.2%)"
"4493";"Asian (n — 57)"
"4494";"Asian (n = 392)"
"4495";"Asian (N = 392)"
"4496";"Asian (n = 769)"
"4497";"Asian (n=1,360)"
"4498";"Asian (n=1360)"
"4499";"Asian (n=2782)"
"4500";"Asian ITT population by treatment group"
"4501";"Asian ITT population Total (n = 325)"
"4502";"Asian or Oriental"
"4503";"Asian or Pacific Islander"
"4504";"Asian*"
"4505";"Asian, n (%)"
"4506";"Asian, n(%)"
"4507";"Asian/black/white/hispanic/other (%) Clinical parameters"
"4508";"Asian/Oriental"
"4509";"Asian/Pacific Islander, n (%)"
"4510";"Asians (n = 157)"
"4511";"Asians (n = 163)"
"4512";"Aslan"
"4513";"Asp"
"4514";"Aspartate aminotransferase increased"
"4515";"Aspartate aminotransferase, U/L"
"4516";"Aspirin"
"4517";"Aspirin-ERDP    Clopidogrel no. of patients/total no."
"4518";"Aspirin-ERDP (N = 10,181)"
"4519";"Aspirin — no. (%)"
"4520";"Aspirin (%)"
"4521";"Aspirin (any dose)"
"4522";"Aspirin (ASA) (» = 19 934)"
"4523";"Aspirin (n = 19 934)"
"4524";"Aspirin (N = 19,934)"
"4525";"Aspirin (N =3782)"
"4526";"Aspirin (n, %)"
"4527";"Aspirin (n=175)"
"4528";"Aspirin (N=18 652)"
"4529";"Aspirin (n=21 101)"
"4530";"Aspirin (N=7740) no. of participants with events (%)"
"4531";"Aspirin <24 hours"
"4532";"Aspirin <7 day"
"4533";"Aspirin 一 no. (%)"
"4534";"Aspirin 100 mg"
"4535";"Aspirin 100 mg (N = 1131)"
"4536";"Aspirin 1029"
"4537";"Aspirin 1040"
"4538";"Aspirin 1559"
"4539";"Aspirin 16,241"
"4540";"Aspirin 4 Clopidogrel"
"4541";"Aspirin alone"
"4542";"Aspirin Alone"
"4543";"Aspirin Alone (N = 9126)"
"4544";"Aspirin Alone (N = 9126) 68.2±8.0"
"4545";"Aspirin alone (n/N)"
"4546";"Aspirin alone (n= 8261)"
"4547";"Aspirin alone (n=1376)"
"4548";"Aspirin alone (n=2504)"
"4549";"Aspirin Alone (n=2514)"
"4550";"Aspirin Alone (N=2514) 2.4"
"4551";"Aspirin alone group No of events/total N (%)"
"4552";"Aspirin and other antiplatelet"
"4553";"Aspirin and PPI"
"4554";"Aspirin and thienopyridine therapy"
"4555";"Aspirin at any dose"
"4556";"Aspirin at baseline"
"4557";"Aspirin at enrollment"
"4558";"Aspirin at Enrollment"
"4559";"Aspirin at last follow-up"
"4560";"Aspirin before admission"
"4561";"Aspirin but no PPI"
"4562";"Aspirin dose"
"4563";"Aspirin Dose"
"4564";"Aspirin dose at baseline ,mg"
"4565";"Aspirin dose at Randomization"
"4566";"Aspirin Dose at Randomization"
"4567";"Aspirin dose, mg/d"
"4568";"Aspirin group"
"4569";"Aspirin group (N = 18 652) (181 467 person years)"
"4570";"Aspirin Group (N=7740)"
"4571";"Aspirin i Clopidogrel (N = 5,814)"
"4572";"Aspirin Only"
"4573";"Aspirin Only (N = 1,202)"
"4574";"Aspirin or other antiplatelet agent"
"4575";"Aspirin or other antiplatelet agents"
"4576";"Aspirin or other antiplatelet drug"
"4577";"Aspirin or other antiplatelet or anticoagulant agent"
"4578";"Aspirin or thienopyridines (%)"
"4579";"Aspirin orother antiplatelet drug"
"4580";"Aspirin plus Clopidogrel (N = 1517)"
"4581";"Aspirin plus Placebo (N = 1503)"
"4582";"Aspirin use"
"4583";"Aspirin use (%)"
"4584";"Aspirin use (> 80 mg)"
"4585";"Aspirin use (p=0-19十)"
"4586";"Aspirin use (p=0-19t)"
"4587";"Aspirin use (p=0-26t)"
"4588";"Aspirin use (p=0-92t)"
"4589";"Aspirin use (p=0.89t)"
"4590";"Aspirin use at baseline"
"4591";"Aspirin Use at Baseline"
"4592";"Aspirin use at randomization"
"4593";"Aspirin use at randomization - n (%)"
"4594";"Aspirin use before screening— no. {%)"
"4595";"Aspirin use n (%)"
"4596";"Aspirin, n (%)"
"4597";"Aspirin, No. (%)"
"4598";"Aspirin/antiplatelet"
"4599";"Aspirin/antiplatelet medication"
"4600";"Aspirin/other antiplatelet agents, n (%)"
"4601";"Aspirin+ Clopidogrel (N=2531) 2.6"
"4602";"Aspirin+dipyridamole"
"4603";"Aspirin+dipyridamole (n=1363)"
"4604";"Aspirin+thienopyridine"
"4605";"ASQoL, LS mean change ± SE"
"4606";"ASQoL, LS mean change from baseline ± SE"
"4607";"Assessment of physical function (0-3, HAQ-DI)"
"4608";"Assigned to placebo"
"4609";"Assigned to topiramate"
"4610";"Assigned treatment by sex interaction"
"4611";"Assoc, with connective tissue disease"
"4612";"Assoc, with corrected congenital shunts"
"4613";"Associated with an atrial septal defect"
"4614";"Associated with connective tissue disease"
"4615";"Associated with corrected"
"4616";"Associated with corrected-congenital shunts"
"4617";"Associated with CTD"
"4618";"Associated with drug or toxin exposure"
"4619";"Associated with drug/toxin"
"4620";"Associated with HIV infection"
"4621";"Associated with transient or reversible risk factor"
"4622";"Associatedproximaldeep-veinthrombosisatdiagnosis, No. (%)"
"4623";"AST >3x ULN on two consecutive visits"
"4624";"AST increased"
"4625";"AST, U/L"
"4626";"ASTERIA I/II"
"4627";"Asthma"
"4628";"Asthma-control status at randomization — no. (%)"
"4629";"Asthma-related health-"
"4630";"Asthma control test score at baseline"
"4631";"Asthma duration (SD), years"
"4632";"Asthma exacerbations"
"4633";"Asthma symptoms in the past 2 weeks"
"4634";"aSubset of the ≥65 years subgroup."
"4635";"ASUI score, mean"
"4636";"ASUI score, mean (SD)"
"4637";"Asymmetric peripheral arthritis"
"4638";"At"
"4639";"At 4 years"
"4640";"At any time"
"4641";"At baseline"
"4642";"At baseline — no. (%)"
"4643";"At C change (%)*"
"4644";"At C data"
"4645";"At clinic diastolic pressure <85 mm Hg"
"4646";"At clinic diastolic pressure >85 mm Hg"
"4647";"At clinic systolic pressure <135 mm Hg"
"4648";"At clinic systolic pressure >135 mm Hg"
"4649";"At end of follow-up"
"4650";"At end of follow-up — no. (%)"
"4651";"At end of follow-up — no./total no. (%)"
"4652";"At entry"
"4653";"at femoral neck, mean (SD)"
"4654";"At goal"
"4655";"At home diastolic pressure < 82 mm Hg"
"4656";"At home diastolic pressure >82 mm Hg"
"4657";"At home systolic pressure <132 mm Hg"
"4658";"At home systolic pressure >132 mm Hg"
"4659";"At Increased Fall Risk (n - 900)"
"4660";"At index ACS event"
"4661";"At index event"
"4662";"At index event: no. (%)"
"4663";"At LDL-C (BQ) goal* at baseline- no. (%)"
"4664";"At least 1 /mo"
"4665";"At least 1 flare"
"4666";"At least 1 severe flare"
"4667";"At least 1/mo"
"4668";"At least two cardiovascular risk factors"
"4669";"At or above median"
"4670";"At or above the median"
"4671";"At qualifying event"
"4672";"At randomization"
"4673";"At screening"
"4674";"At six weeks"
"4675";"At week 12"
"4676";"At week 6"
"4677";"At weeks 6 and 26"
"4678";"Atenoioi (N=2112)"
"4679";"Atenoioi (N=2476)"
"4680";"Atenolol"
"4681";"Atenolol (« = 11 098)"
"4682";"Atenolol (n = 259)"
"4683";"Atenolol (n = 263)"
"4684";"Atenolol (n = 3,622)"
"4685";"Atenolol (n = 4,325)"
"4686";"Atenolol (n = 579)"
"4687";"Atenolol (n = 666)"
"4688";"Atenolol (n = 966)"
"4689";"Atenolol (n=2184)"
"4690";"Atenolol (n=2404)"
"4691";"Atenolol (n=609)"
"4692";"Atenolol (No.=3231)"
"4693";"Atenolol n=3231"
"4694";"Atenolol strategy"
"4695";"Atenolol strategy (n = 2,973)"
"4696";"Atenolol use at 1 month"
"4697";"Atenolol*"
"4698";"Atherectomy"
"4699";"Atherosclerosis"
"4700";"atherosclerosis^, n (%)"
"4701";"Atherosclerotic cardiovascular disease"
"4702";"Atherosclerotic cardiovascular disease*"
"4703";"Atherosclerotic CVD"
"4704";"Atherosclerotic CVD§"
"4705";"Atherosclerotic CVDJ"
"4706";"Atherosclerotic disease (%)"
"4707";"Atherosclerotic disease*"
"4708";"Atherosclerotic vascular disease — no."
"4709";"Atherosclerotic vascular disease history, n (%)t"
"4710";"Atherosclerotic vascular disease history, No. (%)‡"
"4711";"Atherosclerotic vascular disease history†"
"4712";"Atherosclerotic vascular disease, n (%)§"
"4713";"Atherothrombotic infarction, n (%)"
"4714";"Atherothrombotic stroke, n (%)"
"4715";"atients with Event"
"4716";"ATio - Pla"
"4717";"ATM-Locm"
"4718";"ATM-Locus"
"4719";"ATO 10 mg and SIM 20-40 mg (n = 9221)"
"4720";"ATO 10 mg and SIM 20^10 mg (n = 234)"
"4721";"ATO 80 mg (n = 261)"
"4722";"ATO 80 mg (n = 9173)"
"4723";"Atonic"
"4724";"Atopic"
"4725";"Atopic (based on Phadiatop test)"
"4726";"Atopic at baseline: Yes"
"4727";"Atopy (n = 1,375)"
"4728";"Atopy (specific IgE)c, n (%)"
"4729";"Atopy by Phadiatop test, n (%)"
"4730";"Atorvastatin"
"4731";"Atorvastatin    LS means difference 10 mg    (95% CI)a (n = 1407)"
"4732";"Atorvastatin (n=84, 44)"
"4733";"Atorvastatin {n=81,42)"
"4734";"Atorvastatin 10 mg"
"4735";"Atorvastatin 10 mg (n = 1407)"
"4736";"Atorvastatin 10 mg (n = 21)"
"4737";"Atorvastatin 10 mg (n = 4,951)"
"4738";"Atorvastatin 10 mg (n = 55)"
"4739";"Atorvastatin 10 mg and simvastatin 20-40 mg (zi = 9455)"
"4740";"Atorvastatin 20 mg"
"4741";"Atorvastatin 30 mg"
"4742";"Atorvastatin 40 mg"
"4743";"Atorvastatin 40 mg (n = 263)"
"4744";"Atorvastatin 40 mg + Ezetimibe 10 mg (n = 288)"
"4745";"Atorvastatin 60 mg"
"4746";"Atorvastatin 80 mg"
"4747";"Atorvastatin 80 mg (n = 156)"
"4748";"Atorvastatin 80 mg (n = 291)"
"4749";"Atorvastatin 80 mg (n = 9,278)"
"4750";"Atorvastatin 80 mg (zi = 9434)"
"4751";"Atorvastatin dose"
"4752";"Atorvastatin Factorial Study"
"4753";"Atorvastatin Monotherapy (n = 917*)"
"4754";"Atorvastatin, n (%)"
"4755";"Atorvastatinb"
"4756";"Atrial fibrillation"
"4757";"Atrial Fibrillation"
"4758";"Atrial fibrillation — no. (%)"
"4759";"Atrial fibrillation — no./total no. (%)"
"4760";"Atrial fibrillation (%)"
"4761";"Atrial fibrillation alone);"
"4762";"Atrial fibrillation LDL cholesterol level"
"4763";"Atrial fibrillation on baseline EcG, n (%)"
"4764";"Atrial fibrillation onset"
"4765";"Atrial fibrillation or flutter"
"4766";"Atrial fibrillation or flutter— no. (%)"
"4767";"Atrial fibrillation or flutter — no. (%)"
"4768";"Atrial fibrillation or flutter (ECG)§"
"4769";"Atrial fibrillation pattern"
"4770";"Atrial fibrillation type, n (%)"
"4771";"Atrial fibrillation!"
"4772";"Atrial fibrillation, %"
"4773";"Atrial fibrillation, duration — no. (%)"
"4774";"Atrial fibrillation, n (%)"
"4775";"Atrial fibrillation, n (%)"
"4776";"Atrial fibrillation. No. (%)"
"4777";"Atrial fibrillation/atrial flutter, %"
"4778";"Atrial fibrillation/flutter"
"4779";"Atrial fibrillation/flutter, n (%)"
"4780";"Atrial Fibrillation/Flutter, n (%)"
"4781";"Atrial flutter"
"4782";"Atrial flutter/fibrillation"
"4783";"attack (%)"
"4784";"ATTAIN"
"4785";"ATV 10 mg"
"4786";"ATV 20 mg Study Protocol"
"4787";"Atv n(%)"
"4788";"ATV, atorvastatin; LDL-C, low-density lipoprotein cholesterol. *p-values pertain to treatment-by-stratum interaction test for stratum or treatment-by-subgroup interaction test for subgroups. 'Multiplicity adjustments were not applied to this predefined subgroup analysis of LDL-C goal attainment, ""[expressed as number of patients reaching LDL-C goal at week 6/number of patients above goal at baseline, ^treatment stratum was defined by intake of ATV 10 or 20 mg."
"4789";"ATV20 mg (n = 214)"
"4790";"aTwo‐Sample T‐test."
"4791";"Atypical absence"
"4792";"AUGMENT COPD"
"4793";"aUnivariate Logistic regression."
"4794";"Austrafca and New Zealand"
"4795";"Austral ia/New Zealand"
"4796";"Australasia"
"4797";"Australia"
"4798";"Australia and New Zealand"
"4799";"Australia/New Zealand"
"4800";"Australia/New Zealand/South Africa"
"4801";"Australia/NZ"
"4802";"Austria"
"4803";"Autonomic neuropathy"
"4804";"Available baseline blood specimen n"
"4805";"available data"
"4806";"Average age (year)"
"4807";"Average Daily Dose"
"4808";"Average Daily Dose (% of Target)*"
"4809";"average dose (mg/week)"
"4810";"Average maximum CIMT (mm)"
"4811";"Average maximum common and bifurcation CIMT (mm)"
"4812";"Average of maximum common carotid CIMT (mm)"
"4813";"Average of maximum far wall CIMT (mm)"
"4814";"Average weekly MTX dose (mg/week)"
"4815";"Average weekly MTX dose (mg/week)t"
"4816";"AVM % △  (SE)"
"4817";"AVM % △ (SE)"
"4818";"AVM % △(SE)"
"4819";"AVM (N = 344)"
"4820";"AVP pg/mL"
"4821";"AVR"
"4822";"AZA (N = 170)"
"4823";"Azathioprine"
"4824";"Azathioprine (N = 170)"
"4825";"Azathioprine monotherapy"
"4826";"Azathioprine/6-mercaptopurine"
"4827";"AZL-M"
"4828";"AZL-M + HCTZ (N = 306)"
"4829";"AZL-M 40 mg (n = 132)"
"4830";"AZL-M 40 mg + CLD 25 mg"
"4831";"AZL-M 40 mg 4-CLD 25 mg (n=l85)"
"4832";"AZL-M 80 mg (n = 130)"
"4833";"AZL-M 80 mg + CLD 25 mg"
"4834";"AZL-M 80 mg 4-CLD 25 mg (n=l82)"
"4835";"AZL-M/CLD (N = 303)"
"4836";"AZL-M+CLDb"
"4837";"AZL-Ma"
"4838";"b"
"4839";"B"
"4840";"b-agonists (long-acting)a"
"4841";"b-agonists (short-acting)a"
"4842";"b-blocker"
"4843";"b-Blocker"
"4844";"b-Blockers"
"4845";"b-Blockers at baseline"
"4846";"b-Blockers, n (%)"
"4847";"B-Natriuretic Peptide. pg/mL"
"4848";"B Digit Symbol Substitution, insulin glargine vs standard care"
"4849";"B Digit Symbol Substitution, omega-3 fatty acids vs placebo"
"4850";"b Includes both ex-smokers and nonsmokers."
"4851";"B lack"
"4852";"B MACE"
"4853";"B Major Cardiovascular Events"
"4854";"B Nonsevere Hypoglycemia"
"4855";"b Pooled New and Worsened Vertebral Fractures (mFAS)"
"4856";"B Postbronchodilator FEVl (% predicted)"
"4857";"B Reslizumab 3.0 mg/kg n/N"
"4858";"b) those on inhaled corticosteroids and long-acting bronchodilators as previous treatment use."
"4859";"B, VhD (n=3950)"
"4860";"B. ACR 50"
"4861";"B. Benralizumab 30 mg Q8W"""
"4862";"b.i.d., twice daily; CAT, COPD assessment test; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; GOLD, Global Initiative for Chronic Obstructive Lung Disease; ICS, inhaled corticosteroid; MCID, minimum clinically important difference; mMRC, modified Medical Research Council; o.d., once daily; SD, standard deviation; SGRQ-C, St. George’s Respiratory Questionnaire for COPD"
"4863";"B.Myocardial Infarction"
"4864";"B: U.S. Black and Non-Black Patients"
"4865";"B+A (n=2059)"
"4866";"B+A (n=2887)"
"4867";"B+A (n=791)"
"4868";"B+H (n=2098)"
"4869";"B+H (n=2822)"
"4870";"B+H (n=825)"
"4871";"Back pain"
"4872";"Back Pain"
"4873";"Background AHA therapy at screening, n"
"4874";"Background AHA therapy at screening, n (%)"
"4875";"Background AHA therapy at screening, n (%)§"
"4876";"Background AHA therapy at screening,a"
"4877";"Background AHA therapy at screening,a n (%)"
"4878";"Background csDMARD category"
"4879";"Background LABA use"
"4880";"Background LABA use - yes, n (%)"
"4881";"Background lipid-lowering therapy"
"4882";"Background lipid therapy per ACC/AHA definition, n (%)a"
"4883";"Background therapy"
"4884";"Background treatment, N (%)"
"4885";"Bacterial pneumonia"
"4886";"Bail‐out use of glycoprotein IIb/IIIa inhibitors"
"4887";"Balloon angioplasty"
"4888";"Balloon angioplasty — no. (%)"
"4889";"Balloon angioplasty plus abciximab"
"4890";"BARC 2-5"
"4891";"BARC 3-5"
"4892";"BARC Types 2, 3, or 5"
"4893";"Bare-metal"
"4894";"Bare-metal stent"
"4895";"Bare-metal stent — no. (%)"
"4896";"Bare metal"
"4897";"Bare metal stent"
"4898";"Bare Metal Stent"
"4899";"Bare metal stent, n (%)"
"4900";"Baricitinib 2 mg"
"4901";"Baricitinib 2 mg (N=229)"
"4902";"baricitinib 2 mg (n=479)"
"4903";"Baricitinib 2 mg QD (N=229)"
"4904";"baricitinib 2/4 mg"
"4905";"Baricitinib 4 mg"
"4906";"Baricitinib 4 mg (N=227)"
"4907";"baricitinib 4 mg (n=487)"
"4908";"baricitinib 4 mg (n=997)"
"4909";"Baricitinib 4 mg QD"
"4910";"Baricitinib 4 mg QD (N=227)"
"4911";"Baricitinib, 2 mg Daily (N = 174)"
"4912";"Baricitinib, 4 mg Daily (N = 177)"
"4913";"Basal"
"4914";"Basal alone"
"4915";"Basal insulin"
"4916";"Basal insulin analogue dose*(coefficient"
"4917";"Basal insulin analogue: insulin"
"4918";"Basal insulin dose at run-in (U/day)"
"4919";"Basal insulin doset"
"4920";"Basal only"
"4921";"Basal plus bolus"
"4922";"BASDAI question 2 score (1-10), mean (SD)"
"4923";"BASDAI responses at week 24"
"4924";"BASDAI score (1-10), mean (SD)"
"4925";"BASDAI score, mean (SD)"
"4926";"BASDAI, LS mean change from baseline ± SE"
"4927";"BASDAI, mean change from baseline"
"4928";"BASDAI, total, mean ± SD"
"4929";"BASDAI⁎⁎"
"4930";"BASDAI20, n (%)"
"4931";"BASDAI50, %"
"4932";"BASDAI50, n (%)"
"4933";"BASDAI70, n (%)"
"4934";"Base"
"4935";"Baseiine ACEi/ARB"
"4936";"Baseiine Aspirin"
"4937";"Baseiine CCB"
"4938";"Baseiine Diuretic"
"4939";"Baseiine Statin"
"4940";"baseline"
"4941";"Baseline"
"4942";"Baseline-adjusted HR"
"4943";"Baseline --MDRD"
"4944";"Baseline - CKD-Epi"
"4945";"Baseline % BSA involvement"
"4946";"Baseline % predicted FEV1"
"4947";"Baseline (geometric mean, CV)"
"4948";"baseline (mean, SD)"
"4949";"Baseline (mean, SD)"
"4950";"Baseline (mmol/L)"
"4951";"Baseline (n)"
"4952";"Baseline (SD)"
"4953";"Baseline ^STE, mm"
"4954";"Baseline £STD, mm"
"4955";"Baseline 2-h PPG,"
"4956";"Baseline 24-hour mean SBP, mm Hg"
"4957";"Baseline 5-ASA"
"4958";"Baseline 6-Mlnute Walk Distance:"
"4959";"Baseline A1C (%)"
"4960";"Baseline A1C (%) [LSM (SE)]"
"4961";"Baseline ABI, affected limb"
"4962";"Baseline ACQ-7 score"
"4963";"Baseline ADAS-Cog 12"
"4964";"Baseline age"
"4965";"Baseline albumin/creatinine ratio in 3 classes"
"4966";"Baseline albumin: <30"
"4967";"Baseline albuminuria"
"4968";"Baseline AlC <8.0%"
"4969";"Baseline AlC category"
"4970";"Baseline anti-hyperglycemic medications"
"4971";"Baseline Anti-hyperglycemic Medications, n(%)"
"4972";"Baseline anti-hypertensive usea"
"4973";"Baseline antihyperglycemic medications, n (%)"
"4974";"Baseline ASDAS-CRP"
"4975";"Baseline aspirin dose <100 mg"
"4976";"Baseline aspirin use"
"4977";"Baseline aspirin use strata"
"4978";"Baseline Aspirin Use Strata"
"4979";"Baseline BASDAI"
"4980";"Baseline BASFI"
"4981";"Baseline BII, mean (SD)"
"4982";"Baseline BMI"
"4983";"Baseline BMI (kg/m^)"
"4984";"Baseline BMI (kg/m2),"
"4985";"Baseline BMI < 30 kg/m2"
"4986";"Baseline BMI > 30 kg/m2"
"4987";"baseline BMI > 35 kg/m2, n = 2,383"
"4988";"baseline BMI > 35 kg/m2, n = 2,383 change from baseline to 56 weeks"
"4989";"baseline BMI > 35 kg/m2, n = 350 change from baseline to 56 weeks"
"4990";"baseline BMI > 35 kg/m2, n=350"
"4991";"baseline BMI 27 to <35 kg/m2, n = 1,279"
"4992";"baseline BMI 27 to <35 kg/m2, n = 1,279 change from baseline to 56 weeks"
"4993";"baseline BMI 27 to <35 kg/m2, n = 273 change from baseline to 56 weeks"
"4994";"baseline BMI 27 to <35 kg/m2, n=273"
"4995";"Baseline BNp concentration (pg/mL)"
"4996";"Baseline body mass index"
"4997";"Baseline body weight quartile"
"4998";"Baseline BP, mean (SD)*"
"4999";"Baseline BSA, mean (SD)"
"5000";"Baseline Calcium Yes"
"5001";"Baseline cardiac biomarkers"
"5002";"Baseline cardiac biomarkers elevated"
"5003";"Baseline cardiovascular assessment"
"5004";"Baseline cardiovascular disease"
"5005";"Baseline cardiovascular medication"
"5006";"Baseline cardiovascular medication,c n (%)"
"5007";"Baseline Cardiovascular Medications, n(%)"
"5008";"Baseline CDAI score, mean (s.d.)"
"5009";"Baseline CDAI score, mean (SD)"
"5010";"Baseline CDAI,"
"5011";"Baseline CDAI, mean (SD)"
"5012";"Baseline CDR-sb (N = 249 + 251)"
"5013";"Baseline CHA2DS2-VAScb,c"
"5014";"Baseline CHADS2a,c"
"5015";"Baseline characteristic"
"5016";"Baseline Characteristic"
"5017";"Baseline characteristics"
"5018";"Baseline Characteristics"
"5019";"Baseline characteristics, mean (SD) a"
"5020";"Baseline CKD eGFR <60 mL/min/1.73 m2"
"5021";"Baseline CKD eGFR >60 mL/min/1.73 m2"
"5022";"Baseline composite Mayo Clinic score"
"5023";"Baseline concentration"
"5024";"Baseline concomitant cardiovascular medications"
"5025";"Baseline COPD exacerbation history,* n (%)"
"5026";"Baseline corticosteroid use (mg)"
"5027";"Baseline corticosteroids*"
"5028";"Baseline corticosteroidst (mean dose: 6.52 mg/day), n (%)"
"5029";"Baseline CrCl, ml/min"
"5030";"Baseline creatinine clearance"
"5031";"Baseline creatinine, median (range) mg/dl"
"5032";"Baseline Crohn's disease medications"
"5033";"Baseline CRP"
"5034";"Baseline CRP (mg/dL)"
"5035";"Baseline CRP <2mg/L"
"5036";"Baseline CRP category (mg/L)"
"5037";"Baseline CRP levels <10 mg/L"
"5038";"Baseline CRP levels ≥10 mg/L"
"5039";"Baseline CV medications"
"5040";"Baseline CV medications, n (%)"
"5041";"Baseline CV treatment"
"5042";"Baseline CV treatment, n (%)y"
"5043";"Baseline DAD (N = 249 + 251)"
"5044";"Baseline DAS28, mean (s.e.)"
"5045";"Baseline data"
"5046";"Baseline daytime nasal symptoms score, mean ± SD"
"5047";"Baseline DBP (mm Hg)"
"5048";"Baseline DBP,"
"5049";"Baseline DBP, mean±SD, mm Hg"
"5050";"Baseline demographics"
"5051";"Baseline Demographics"
"5052";"Baseline diabetes"
"5053";"Baseline Diabetes"
"5054";"Baseline diabetes mellitus therapy, n (%)"
"5055";"Baseline diastolic blood"
"5056";"Baseline diastolic blood pressure (mm Hg)"
"5057";"Baseline diastolic blood pressure, mean (SD), mm Hg"
"5058";"Baseline dipeptidyl peptidase 4"
"5059";"Baseline disease and quality-of-life scores"
"5060";"Baseline DLCO. mmol kPa-’-"
"5061";"Baseline DLQI, mean (SD)"
"5062";"Baseline DMARD use, n (%)"
"5063";"Baseline dyslipidemia"
"5064";"Baseline dyspnea index score"
"5065";"Baseline dyspnea index, mean total score"
"5066";"Baseline ECG with LVH, n (%)"
"5067";"Baseline eCrCl"
"5068";"Baseline eCrCl 2 80 mL/min"
"5069";"Baseline eCrCl k 30 to < 60 mL/min"
"5070";"Baseline eCrO < 30 mUmin"
"5071";"Baseline eCrQ 2 60 to < 80 mL/min"
"5072";"Baseline ED severity**:"
"5073";"Baseline eGFR (mL/min per 1«73 m’)"
"5074";"Baseline eGFR < 60 mL/min/1.73 m2"
"5075";"Baseline eGFR <15"
"5076";"Baseline eGFR <60 mL/min/1.73 m2c"
"5077";"Baseline eGFR ≥15 to <30"
"5078";"Baseline eGFR ≥30 to <45"
"5079";"Baseline eGFR ≥45 to <60"
"5080";"Baseline eGFR ≥60 to <90"
"5081";"Baseline eGFR > 60 mL/min/1.73 m2"
"5082";"Baseline eGFR, mL/min/1.73 m2"
"5083";"Baseline eGFR, mL/min/1.73 m2"
"5084";"Baseline eosinophil <300 cells/pL"
"5085";"Baseline eosinophil 2300 cells/pL"
"5086";"Baseline erosion"
"5087";"Baseline estimated GFR"
"5088";"Baseline ezetimibe usec"
"5089";"Baseline factor"
"5090";"Baseline fasting plasma glucose"
"5091";"Baseline fasting TGs, mg/dL"
"5092";"Baseline Fc-LDL-C"
"5093";"Baseline Feature"
"5094";"Baseline fecal caicrctectin"
"5095";"Baseline FEV, (L)"
"5096";"Baseline FEV1"
"5097";"Baseline FEV1#"
"5098";"Baseline FEV1% predicted"
"5099";"Baseline FEV1, L*"
"5100";"Baseline FEV1, median (range), L"
"5101";"Baseline focal seizure frequency/28 days, median (Q1-Q3)"
"5102";"Baseline focal seizure frequency/28 days, median (Q1, Q3)"
"5103";"Baseline FPG,"
"5104";"Baseline FPG, mean (s.e.)"
"5105";"Baseline FPG, mg/dL"
"5106";"Baseline free PCSK9 level"
"5107";"Baseline free PCSK9 level by median"
"5108";"Baseline FVC, L"
"5109";"Baseline geometric mean (10®/L)"
"5110";"Baseline GFR < 60 ml/min/1.73m2, n (%)"
"5111";"Baseline GFR <60 mL/min per 1.73 m2, n (%)"
"5112";"Baseline Glycated"
"5113";"Baseline glycated hemoglobin (%)"
"5114";"Baseline glycemic control"
"5115";"Baseline HAQ mean (s.e.)"
"5116";"Baseline Hb < 120 g 1 1 n=499"
"5117";"Baseline Hb 120g I 1 n=788"
"5118";"Baseline HbA^c"
"5119";"Baseline HbA1c"
"5120";"Baseline HbA1c (%)"
"5121";"Baseline HbA1c < 9.0%"
"5122";"Baseline HbA1c <8.0%"
"5123";"Baseline HbA1c <8.0% (64 mmol/mol)"
"5124";"Baseline HbA1c ≤ median 7.9% (63 mmol/mol)"
"5125";"Baseline HbA1c ≥69 mmol/mol (≥8.5%), n (%)"
"5126";"Baseline HbA1c ≥8.0% to <9.0% (64–75 mmol/mol)"
"5127";"Baseline HbA1c ≥9.0% (75 mmol/mol)"
"5128";"Baseline HbA1c > 9.0%"
"5129";"Baseline HbA1c > median 7.9% (63 mmol/mol)"
"5130";"Baseline HbA1c >8.0%"
"5131";"Baseline HbA1c concentration"
"5132";"Baseline HbA1c in 3 classes"
"5133";"Baseline HbA1c subgroup"
"5134";"Baseline HbA1c, %"
"5135";"Baseline HbA1c, mean (s.e.)"
"5136";"Baseline HbA1c, n (%)"
"5137";"Baseline HbA1c^"
"5138";"Baseline HbAlc"
"5139";"Baseline HbAlc <8%"
"5140";"Baseline HbAlc >69 mmol/mol (>8.5%)"
"5141";"Baseline HbAlc >8% to <9%"
"5142";"Baseline HbAlc >8.5% (69 mmol/mol) 49"
"5143";"Baseline HbAlc >9%"
"5144";"Baseline HbAlc^"
"5145";"Baseline HbAlc’"
"5146";"Baseline HbAlc<8.5% (69 mmol/mol) 131"
"5147";"Baseline HBI, mean (SD)"
"5148";"Baseline HDL-C"
"5149";"Baseline HDL-C in 2 classes"
"5150";"Baseline HDL-C level (n=80» 40) >51.0 mg/dL"
"5151";"Baseline HDL-C level (n=81. 41) >51.0 mg/dL"
"5152";"Baseline HDL-C level (n=89, 46) s51.0 mg/dL"
"5153";"Baseline HDL-C level (n=S5, 45) <51.0 mg/dL"
"5154";"Baseline HDL-C, mg/dL"
"5155";"Baseline HDL‐C, mg/dL"
"5156";"Baseline heart failure severity amongthose with priorheartfailure,%"
"5157";"Baseline heart failure severity NYHA class I"
"5158";"Baseline heart rate"
"5159";"Baseline heart rate (beat/min)"
"5160";"Baseline heart rate (beats/min)"
"5161";"Baseline height ( cm)"
"5162";"Baseline hematocrit, median (IQR)"
"5163";"Baseline hemoglobin Aj^ values"
"5164";"Baseline hemoglobin, median (IQR, g/dL)"
"5165";"Baseline high-density lipoprotein cholesterol (mg/dL)"
"5166";"Baseline high-sensitivity CRP"
"5167";"Baseline history of vascular disease (%)"
"5168";"Baseline hs-CRP tertiles (mg/i]"
"5169";"Baseline hsTnI"
"5170";"Baseline IBDQ total score, mean"
"5171";"Baseline ICS"
"5172";"Baseline ICS >1000 pg per day (fluticasone propionate DPI or equivalent) and LABA"
"5173";"Baseline ICS dose, n (%)"
"5174";"Baseline ICS use, n (%)"
"5175";"Baseline ICS use: no"
"5176";"Baseline ICS use: yes"
"5177";"Baseline if have 2 yr follow-up*"
"5178";"Baseline IFG (FPG 5.6-6.9 mmol/L) - N"
"5179";"Baseline In-Check*’ PIFR (L/min)"
"5180";"Baseline inflammation markers"
"5181";"Baseline insulin"
"5182";"Baseline Insulin"
"5183";"Baseline insulin daily dose/kg"
"5184";"Baseline insulin dose (U=kg) [LSM (SE)]"
"5185";"Baseline Killip class"
"5186";"Baseline laboratory values, median (IQR)d"
"5187";"Baseline LDL-C"
"5188";"Baseline LDL-C > 160 mg/dL"
"5189";"Baseline LDL-C > 2.5 to < 4.2 mmol/lc"
"5190";"Baseline LDL-C 2.0 to < 2.5 mmol/lc"
"5191";"Baseline LDL-C strata, n (°/o)"
"5192";"Baseline LDL-C, mg/dL"
"5193";"Baseline LDL‐C, mg/dL"
"5194";"Baseline LDL-C:"
"5195";"Baseline LDL (mg %)"
"5196";"Baseline LDL cholesterol"
"5197";"Baseline LDL cholesterol (derived)"
"5198";"Baseline LDLC level (n=81, 45) >125.0 mgZdL"
"5199";"Baseline LDLC level (n=84, 40) ^125.0 mg/dL"
"5200";"Baseline LDLC level (n=84. 45) >125.0 mg/dL"
"5201";"Baseline LDLC level (n=86, 42) S125.0 mg/dL"
"5202";"Baseline lipid and apolipoprotein levels"
"5203";"Baseline lipid and lipoprotein values"
"5204";"Baseline lipid parameters, mg/dL, mmol/L or g/L"
"5205";"Baseline lipid profile, mg/dL, mean (sd)"
"5206";"Baseline lipid therapy"
"5207";"Baseline lipid/lipoprotein values"
"5208";"Baseline lipid/lipoprotem values"
"5209";"Baseline lipids"
"5210";"Baseline lipids, mg/dL"
"5211";"Baseline lipids; mean ± SD (mmol/1)"
"5212";"Baseline lipids; mean ± SD (mmol/l)"
"5213";"Baseline lipoprotein (a) (nmol/L), median (IQR)"
"5214";"Baseline Los Angeles Grade of EO, n (%)"
"5215";"Baseline low-density lipoprotein cholesterol (mg/dl)"
"5216";"Baseline Lp(a) in 2 classes"
"5217";"Baseline Lp(a) in 3 classes"
"5218";"Baseline Lp(a), mg/dL"
"5219";"Baseline LUTS severity*:"
"5220";"Baseline LUTS severity, n (%):"
"5221";"Baseline LVEF"
"5222";"Baseline LVEF, %"
"5223";"BaseLine LVEF, %"
"5224";"Baseline Mayo score"
"5225";"Baseline MDRD eGFR <60 mL/min/1.73 m2"
"5226";"Baseline MDRD eGFR >60 mL/min/1.73 m2"
"5227";"baseline mean"
"5228";"Baseline mean"
"5229";"Baseline mean (mg/dL]"
"5230";"Baseline mean (SD)"
"5231";"Baseline mean (SD), % [mmol/mol]"
"5232";"Baseline mean (SE)"
"5233";"Baseline mean 士 SD"
"5234";"Baseline mean ambulatory SBP, mm Hg (SD)*"
"5235";"Baseline Mean FEV1(SD), ml"
"5236";"Baseline mean mTSS"
"5237";"Baseline mean seated SBP, mm Hg (SD)"
"5238";"Baseline mean serum uric acid, pmol/L (SD)"
"5239";"Baseline mean, mg/dL"
"5240";"Baseline measurements"
"5241";"baseline median"
"5242";"Baseline Median (IQ Range)"
"5243";"Baseline median [mg/L]"
"5244";"Baseline median, mg/dL"
"5245";"Baseline median, mg/L"
"5246";"Baseline medical therapy"
"5247";"Baseline medical therapy, n (%)"
"5248";"Baseline medication"
"5249";"Baseline medications"
"5250";"Baseline medications (%)"
"5251";"Baseline medications, n (%)"
"5252";"Baseline metformin"
"5253";"Baseline Metformin"
"5254";"Baseline Microalbumin: <30"
"5255";"Baseline monthly POS seizure rate"
"5256";"Baseline msDBP (mmHg), mean±SD"
"5257";"Baseline msSBP (mmHg), mean±SD"
"5258";"Baseline msSBP/msDBP, mm Hg"
"5259";"Baseline mTSS subgroup"
"5260";"Baseline MWD, m"
"5261";"Baseline NBP"
"5262";"Baseline NIH Stroke Scale — no. (%)^"
"5263";"Baseline NIHSS"
"5264";"Baseline NIHSS score (%)#"
"5265";"Baseline NIHSS score, median (range)"
"5266";"Baseline non-HDL-Ca"
"5267";"Baseline normoglycaemia (FPG < 5.6 mmol/L) - N"
"5268";"Baseline Normoglycemia"
"5269";"Baseline numberf of ADM classes, n (%)"
"5270";"Baseline OCS use: Yes"
"5271";"baseline of induction"
"5272";"baseline of induction), n (%)"
"5273";"Baseline outcomes"
"5274";"Baseline parameter"
"5275";"Baseline PASI score"
"5276";"Baseline PASI, mean (SD)"
"5277";"Baseline PAV - < Median (n=209, 220)"
"5278";"Baseline PAV - >= Median (n=214, 203)"
"5279";"Baseline PAVa"
"5280";"Baseline PCSI<9a"
"5281";"Baseline PFD, m"
"5282";"Baseline POS frequency per 28 days,"
"5283";"Baseline POS frequency per 28 days, median (min, max)"
"5284";"Baseline post-bronchodilator % predicted FEV, < 30%"
"5285";"Baseline post-bronchodilator % predicted FEV, > 30% and concurrent tiotropium use"
"5286";"Baseline post-bronchodilator % predicted FEV, > 30% and no concurrent tiotropium"
"5287";"Baseline post-bronchodilator % predicted FEV, > 30% and no prior ICS use"
"5288";"Baseline post-bronchodilator % predicted FEV, > 30% and prior ICS use"
"5289";"Baseline post-bronchodilator FEV1 (SD), ml"
"5290";"Baseline PPASI score, mean (SD)"
"5291";"Baseline pre- bronchodilator FEV1,L"
"5292";"Baseline PreDiabetes"
"5293";"Baseline prednisone or oral prednisone equivalent daily dose,"
"5294";"Baseline presence of nasal polyps"
"5295";"Baseline procedure, n (%)"
"5296";"Baseline PSSI score, mean (SD)"
"5297";"Baseline PtGA"
"5298";"Baseline pulmonary medication"
"5299";"Baseline pulmonary medication, n (%)"
"5300";"Baseline pulmonary medication,b n (%)"
"5301";"Baseline pulmonary medications"
"5302";"Baseline renal function (eCLcr)"
"5303";"Baseline Risk Factors"
"5304";"Baseline RST-segment"
"5305";"Baseline RST-segment elevation, mm"
"5306";"Baseline SBP"
"5307";"Baseline SBP (mm Hg)"
"5308";"Baseline SBP (mm)"
"5309";"Baseline SBP {p=O-78)"
"5310";"Baseline SBP,"
"5311";"Baseline SBP, mean±SD, mm Hg"
"5312";"Baseline scales, median (range)"
"5313";"Baseline SeDBP, mean (SD), mm Hg§"
"5314";"Baseline serum calcium level, n (%)"
"5315";"Baseline serum K+, mEq/L"
"5316";"Baseline serum Mg <0.74 mmol/L"
"5317";"Baseline serum Mg >=0.74 mmol/L"
"5318";"Baseline Serum Urate (mg/dL)a"
"5319";"Baseline SeSBP, mean (SD), mm Hg§"
"5320";"Baseline SGRQ score"
"5321";"Baseline SGRQ total score"
"5322";"Baseline SGRQ Total Score"
"5323";"Baseline short-acting anticholinergics"
"5324";"Baseline short-acting anticholinergics, n (%)"
"5325";"Baseline SHS (0-440)"
"5326";"Baseline sildenafil dose mg"
"5327";"Baseline Sitosterol"
"5328";"Baseline Sitosterol/Cholesterol"
"5329";"Baseline Sitosterol/Lathosterol"
"5330";"Baseline sitting DBP,* mm Hg"
"5331";"Baseline sitting SBP,1mm Hg"
"5332";"Baseline SJC, mean (s.e.)"
"5333";"Baseline Skin Pain VAS, mean (SD)"
"5334";"Baseline smoking status"
"5335";"Baseline sPGA, mean (SD)"
"5336";"Baseline spirometry"
"5337";"Baseline statin"
"5338";"Baseline statin intensity"
"5339";"Baseline statin use"
"5340";"Baseline statin usec"
"5341";"Baseline STE in worst lead, mm"
"5342";"Baseline steroids"
"5343";"Baseline SU Dose < 1/2 Maximal"
"5344";"Baseline SU Dose > 1/2 Maximal"
"5345";"Baseline sUA, mean ± SD mg/dl"
"5346";"Baseline subgroup"
"5347";"Baseline Subgroup"
"5348";"Baseline Sulfonylurea    Yes"
"5349";"Baseline symptom days perweek"
"5350";"Baseline systolic blood pressure"
"5351";"Baseline systolic blood pressure (mm Hg)"
"5352";"Baseline systolic blood pressure, mean (SD), mm Hg"
"5353";"Baseline systolic BP"
"5354";"Baseline T-score at femoral neck, n (%)"
"5355";"Baseline TAV - < Median (n=210, 214)"
"5356";"Baseline TAV - >= Median (n=213, 209)"
"5357";"Baseline TAVa"
"5358";"Baseline TBP"
"5359";"Baseline TC, mg/dL"
"5360";"Baseline TG"
"5361";"Baseline TG <1.8 mmol/L"
"5362";"Baseline TG > 1.8 mmol/L"
"5363";"Baseline TG level (n=83, 40) <102.0 mg/dL"
"5364";"Baseline TG level (n=85, 41) s102.0 mg/dL"
"5365";"Baseline TG level (n=85. 46) >102.0 mg/dL"
"5366";"Baseline TG level {n=82, 45) >102.0 mg/dL"
"5367";"Baseline TG, (mg/dL), median (IQR)"
"5368";"Baseline therapy"
"5369";"Baseline TJC, mean (s.e.)"
"5370";"baseline to EoM Placebo (n = 168)"
"5371";"Baseline to year 1"
"5372";"Baseline tobacco use"
"5373";"Baseline Tophusa"
"5374";"Baseline total cholesterol"
"5375";"Baseline Total IPSS"
"5376";"Baseline total IPSS, mean (SD)"
"5377";"Baseline total PCSK9 level"
"5378";"Baseline total PCSK9 level by median"
"5379";"Baseline treatments, n (%)a"
"5380";"Baseline Trig >150 millycerides g/dL"
"5381";"Baseline triglycerides"
"5382";"Baseline Triglycerides <150 mg/dL"
"5383";"Baseline triglycerides >200 mg/dl and"
"5384";"Baseline triglycerides by quintiles"
"5385";"Baseline triglycerides in 2 classes"
"5386";"Baseline triglycerides in 3 classes"
"5387";"Baseline TRL-C by quintiles"
"5388";"Baseline TRL-C in 2 classes"
"5389";"Baseline UACR <300 mg/g"
"5390";"Baseline UACR >300 mg/g"
"5391";"Baseline UAS7"
"5392";"Baseline UPGR >3 gm/gm (339 mg/mmole)"
"5393";"Baseline UPGR, mg/mmole (n = 99, 99, 99)"
"5394";"Baseline use of ADM, n (%)"
"5395";"Baseline use of hormone therapy (%)"
"5396";"Baseline value"
"5397";"Baseline variable"
"5398";"Baseline Variable"
"5399";"Baseline vertebral fracture"
"5400";"Baseline VFx"
"5401";"Baseline Vitamin-D"
"5402";"Baseline weekly ISS"
"5403";"Baseline weight, kg"
"5404";"Baseline WHO Function Class"
"5405";"Baseline,"
"5406";"Baseline, % (n)"
"5407";"Baseline, mean (SD)"
"5408";"baseline, mg/dL (mmol/L)"
"5409";"Baseline, mm Hg"
"5410";"baseline, No. (%)"
"5411";"Baseline.mean _ SD, mg/dL"
"5412";"Baseline.mean _ SD.mg/dL"
"5413";"Baseline.mean _ SD.mg/mg"
"5414";"Baseline/concomitant therapies"
"5415";"Baseline: <3.9 mEq/L EOS: >3.9 or <3.9 mEq/L"
"5416";"Baseline: >3.9 mEq/L EOS: <3.9 mEq/L"
"5417";"Baseline: >3.9 mEq/L EOS: >3.9 mEq/L"
"5418";"Baselineb"
"5419";"Baselinec"
"5420";"BASFI*"
"5421";"BASFI, mean (SD)"
"5422";"BASMI (linear), mean (SD)"
"5423";"Batellna C-reective protein"
"5424";"BB"
"5425";"BDI focal score"
"5426";"BDI Focal Score"
"5427";"BDI focal score1"
"5428";"BDI total score (baseline)"
"5429";"bDMARD-IR"
"5430";"bDMARD-naive"
"5431";"BDP/FF/G (n=764)"
"5432";"BeAM values (mg/dL), mean (SD)"
"5433";"BeAM < 50 mg/dL at week 30, n (%)"
"5434";"Because of AE"
"5435";"Because of drug‐relateda AE"
"5436";"Because of drug‐relateda SAE"
"5437";"Because of SAE"
"5438";"before a change to the enrollment form was implemented in August 2007. BNP"
"5439";"before admission), %"
"5440";"Before amendment"
"5441";"Before Amendment (%)"
"5442";"Before bronchodilation"
"5443";"Before bronchodilation — liters§"
"5444";"Before bronchodilator use"
"5445";"Before index ACS event"
"5446";"Before PCI"
"5447";"Belgium"
"5448";"Belimumab 200 mg SC (n 5556)"
"5449";"Below-knee popliteal"
"5450";"Below-knee popliteal crural"
"5451";"Below median"
"5452";"Bempedoic"
"5453";"Bempedoic Acid (N = 1488)"
"5454";"Benazepril-Amlodipine Group (N = 5744)"
"5455";"Benazepril-Hydrochlorothiazide Group (N = 5762)"
"5456";"Benign prostatic hyperplasia"
"5457";"Benralizumab"
"5458";"Benralizumab 30 mg Q4W (n=116)"
"5459";"Benralizumab 30 mg Q4W (n=124)"
"5460";"Benralizumab 30 mg Q4W (n=241)"
"5461";"Benralizumab 30 mg Q4W (n=275)"
"5462";"Benralizumab 30 mg Q4W (n=399)"
"5463";"Benralizumab 30 mg Q4W (n=425)"
"5464";"Benralizumab 30 mg Q6W"
"5465";"Benralizumab 30 mg Q8W"
"5466";"Benralizumab 30 mg Q8W (n=125)"
"5467";"Benralizumab 30 mg Q8W (n=131)"
"5468";"Benralizumab 30 mg Q8W (n=239)"
"5469";"Benralizumab 30 mg Q8W (n=267)"
"5470";"Benralizumab 30 mg Q8W (n=398)"
"5471";"Benralizumab 30 mg Q8W (n=441)"
"5472";"Benralizumab Q4W (n - 15)"
"5473";"Benralizumab Q4W (n = 241)"
"5474";"Benralizumab Q4W (n = 349)"
"5475";"Benralizumab Q4W (n = 398)"
"5476";"Benralizumab Q4W (n=349)"
"5477";"Benralizumab Q4W (n=398)"
"5478";"Benralizumab Q8W (n - 15)"
"5479";"Benralizumab Q8W (n = 239)"
"5480";"Benralizumab Q8W (n = 352)"
"5481";"Benralizumab Q8W (n = 393)"
"5482";"Benralizumab Q8W (n =352)"
"5483";"Benralizumab Q8W (n=393)"
"5484";"Benzodiazepine or BzRA‡"
"5485";"Beta-adrenergic blocker"
"5486";"Beta-blocker"
"5487";"Beta-Blocker"
"5488";"Beta-blocker— no. (%)"
"5489";"Beta-blocker — no./total no. (%)"
"5490";"Beta-blocker % target dose"
"5491";"Beta-blocker (except sotalol)"
"5492";"Beta-blocker at enrollment"
"5493";"Beta-blocker at last follow-up |"
"5494";"Beta-blocker N(%)"
"5495";"Beta-blocker use"
"5496";"Beta-blocker use at baseline"
"5497";"Beta-blocker use at randomization"
"5498";"Beta-blocker!"
"5499";"Beta-blocker, %"
"5500";"Beta-blockers"
"5501";"Beta-Blockers"
"5502";"Beta-blockers (all), n (%)"
"5503";"Beta-blockers through hospital discharge or day 7 — %"
"5504";"Beta-blockers, (%)"
"5505";"Beta-blockers, n (%)"
"5506";"Beta-carotene"
"5507";"Beta-carotene (n = 18,405)"
"5508";"Beta-carotene (N = 18,405)"
"5509";"Beta blocker"
"5510";"Beta blocker use (%)"
"5511";"Beta Blocker users"
"5512";"Beta blocker, %"
"5513";"Beta blocker, n (%)"
"5514";"Beta blockers"
"5515";"Beta bloekers"
"5516";"Beta receptor antagonist"
"5517";"Beta1 selective"
"5518";"Betablocker"
"5519";"Betablocker Use"
"5520";"Between-treatment comparison of percentage change from baseline in total hip BMD"
"5521";"Beyond popliteal pedal"
"5522";"BI (15.4)"
"5523";"Biack"
"5524";"Biack Hispanic"
"5525";"Biack non-Hispanic"
"5526";"BIAsp 30"
"5527";"BIAsp 30 BID"
"5528";"BID"
"5529";"Bifurcation"
"5530";"Bifurcation lesion"
"5531";"Bifurcation lesion with side branch $2.5 mm stented"
"5532";"Bifurcation lesion with side branch ≥2.5 mm stented"
"5533";"Bifurcation per lesion‡"
"5534";"Bifurcation, n (%)"
"5535";"Biguanide"
"5536";"Biguanide (metformin)"
"5537";"Biguanide use at baseline"
"5538";"Biguanides"
"5539";"Biguanides (metformin)"
"5540";"Biguanides¶"
"5541";"BII (mean ± SD)"
"5542";"BII score"
"5543";"BILAG A, B or C domain score, n (%)"
"5544";"Bilateral disease (%)'j''j'"
"5545";"Biochemical events"
"5546";"Biochemical measures, mean (SD)"
"5547";"Biochemical parameters at randomization, mean"
"5548";"Biolimus A9-eluting stent¶"
"5549";"Biologic"
"5550";"Biologic agents"
"5551";"Biologic naive"
"5552";"Biologic therapeutic failure"
"5553";"Biological"
"5554";"Biologics User"
"5555";"Biomarker high"
"5556";"Biomarker high (periostin > 50ng/mL or blood eosinophils > 300cells per pL), na"
"5557";"Biomarker high (periostin >50 ng/mL or blood eosinophils >300 cells per pL)t"
"5558";"Biomarker levels"
"5559";"Biomarker low"
"5560";"Biomarker low (periostin < 50 ng/mL or blood eosinophils < 300 cells per pL), na"
"5561";"Biomarker status"
"5562";"Biomarkers at baseline"
"5563";"Biometric parameters"
"5564";"Bisphosphonates"
"5565";"Bivalirudin"
"5566";"Bivalirudin (n = 1,245)"
"5567";"Bivalirudin (N = 127)"
"5568";"Bivalirudin (n = 735)"
"5569";"Bivalirudin (N= 127)"
"5570";"Bivalirudin (n=1928)"
"5571";"Bivalirudin (n=735)"
"5572";"Bivalirudin Alone (N = 4612)"
"5573";"Bivalirudin only"
"5574";"Bivalirudin Only"
"5575";"Bivalirudin plus Glycoprotein IIb/IIIa Inhibitors (N = 4604)"
"5576";"Bivalirudin used"
"5577";"Bivalirudin used during PCI"
"5578";"Bivariate frailty model (statin users vs non-users)"
"5579";"Biventricular pacemaker"
"5580";"BL"
"5581";"BL AlC <8.0%"
"5582";"BL BM1<35 kg/m^"
"5583";"BL BMIOO kg/m^"
"5584";"BL BMl <30 kg/m^"
"5585";"BL BMl <35 kg/m^"
"5586";"BL BMl >30 kg/m^"
"5587";"BL BMl >35 ke/m^"
"5588";"BL BMl >35 kg/m^"
"5589";"BL H/Y: Bilateral"
"5590";"BL H/Y: Unilateral"
"5591";"BL mean (cm)"
"5592";"BL mean (mmHg)"
"5593";"BL mean, mg/dl (mmol/1)"
"5594";"BL UPDRS: High"
"5595";"BL UPDRS: Low"
"5596";"Black"
"5597";"Black (n = 102)"
"5598";"Black (N = 102)"
"5599";"Black (n = 166)"
"5600";"Black (n = 174)"
"5601";"Black (n = 181)"
"5602";"Black (n = 183)"
"5603";"Black (n = 95)"
"5604";"Black (n=302)"
"5605";"Black (n=302); Adjusted Hazard Ratio*"
"5606";"Black (n=492)"
"5607";"Black and Other"
"5608";"Black Hispanic"
"5609";"Black Hispanic - n (%)"
"5610";"Black non-Hispanic"
"5611";"Black Non-Hispanic"
"5612";"Black non-Hispanic - n (%)"
"5613";"Black or African"
"5614";"Black or African‐American"
"5615";"Black or African-American"
"5616";"Black or African America"
"5617";"Black or African American"
"5618";"Black or African heritage"
"5619";"Black or Asian"
"5620";"Black participants"
"5621";"Black Participants"
"5622";"Black race"
"5623";"Black race — no./total no. (%)f"
"5624";"Black race (n=58 vs 33)"
"5625";"Black race and SS <9 (n=19 vs 15) ■-"
"5626";"Black race and SS >10 (n=39 vs 18)"
"5627";"Black race, n (%)"
"5628";"Black Region or country (%)"
"5629";"Black(n — 22)"
"5630";"Black*"
"5631";"black, n (%)"
"5632";"Black, n (%)"
"5633";"Black, n(%)"
"5634";"Black, No. (%)"
"5635";"Black, non-Hispanic"
"5636";"Black/"
"5637";"BLack/Af rican American"
"5638";"Black/African"
"5639";"Black/African- American"
"5640";"Black/African-American"
"5641";"Black/African-American (10.3%)"
"5642";"Black/African American"
"5643";"Black/African American*"
"5644";"Black/non-black"
"5645";"Bladder"
"5646";"Blaek"
"5647";"Blaek/Afriean-Ameriean"
"5648";"BLAIC <9.0%"
"5649";"BLAIC >8.0%"
"5650";"BLAIC >9.0%"
"5651";"bleeding"
"5652";"Bleeding"
"5653";"Bleeding end points"
"5654";"Bleeding Events During First 90 Days of Treatmen"
"5655";"Bleeding Events During the Entire Study"
"5656";"Bleeding Outcomes"
"5657";"blisibimod (n=245)"
"5658";"blocker"
"5659";"blockers"
"5660";"Blood-glucose control"
"5661";"Blood-pressure medications at randomization — no./total no. (%)"
"5662";"Blood bilirubin increased"
"5663";"Blood eosinophil"
"5664";"Blood eosinophil concentration, 109 cells per L"
"5665";"Blood eosinophil count — cells/mm’"
"5666";"Blood eosinophil count (109 cells per L)"
"5667";"Blood eosinophil count >150/mm3 at screening — no. (%)"
"5668";"Blood eosinophil count >300/mm3 in 12 months before screening — no. (%)"
"5669";"Blood Eosinophil Count cells/mm3    no."
"5670";"Blood eosinophil count, geometric mean (SD loge scale) cells/ll"
"5671";"Blood eosinophil proportion (%)"
"5672";"Blood eosinophils count"
"5673";"Blood eosinophils, cells/mL"
"5674";"Blood eosinophils, mean (range), cells/mL"
"5675";"Blood eosinophils, mean (range), cells/mLb"
"5676";"Blood glucose"
"5677";"Blood glucose-lowering drugs, excluding insulin, n (%)"
"5678";"Blood glucose-lowering treatments, n (%)"
"5679";"Blood glucose lowering treatment"
"5680";"Blood leucocyte concentration (109 cells per L)"
"5681";"Blood leukocyte count (109 cells per L)"
"5682";"Blood oxygenation, mean ± SD"
"5683";"Blood pressure"
"5684";"Blood pressure-lowering treatment"
"5685";"Blood pressure— mm Hg"
"5686";"Blood pressure — mm Hg"
"5687";"Blood pressure — mmHg"
"5688";"Blood pressure (%)"
"5689";"Blood pressure (mm Hg)"
"5690";"Blood pressure (mm Hg) Systolic"
"5691";"Blood pressure (mm Hg)*"
"5692";"Blood pressure (mmHg)"
"5693";"Blood Pressure <140/90 mmHg, n(%)"
"5694";"blood pressure <90 mm Hg"
"5695";"blood pressure >90 mm Hg"
"5696";"Blood pressure at baseline:"
"5697";"Blood pressure at entry (mm Hg)"
"5698";"Blood pressure at target level (%)§"
"5699";"Blood pressure control"
"5700";"Blood pressure control*"
"5701";"Blood pressure eontrolt"
"5702";"Blood Pressure in mm Hg, mean(SD)"
"5703";"Blood pressure lowering medication use"
"5704";"Blood pressure systolic, mm Hg"
"5705";"Blood pressure while seated — mm Hg"
"5706";"Blood pressure, mean (SD) [range], mm Hg"
"5707";"Blood pressure, mean (SD), mm Hg"
"5708";"Blood pressure, mean (SD), mm Hg Systolic"
"5709";"Blood pressure, mean (SD), mm Hgt"
"5710";"Blood pressure, mean ± SD mm Hg"
"5711";"Blood pressure, mm"
"5712";"Blood pressure, mm Hg"
"5713";"Blood pressure, mm Hg, mean (SD)"
"5714";"Blood pressure, mmHg"
"5715";"Blood pressure, mmHg Systolic"
"5716";"Blood pressure, mmHg, mean (SD)"
"5717";"Blood pressure: systolic/diastolic (mm Hg) (mean, SD)"
"5718";"blood pressure; Pbo y patients with diabe teristics (NCEP ATP I"
"5719";"Blood transfusion"
"5720";"Blood urea nitrogen (mg/dL)"
"5721";"Blood urea nitrogen, mg/dL"
"5722";"Bloodpressure,mean (SD), m m Hg"
"5723";"BM1 (kg/m2)"
"5724";"BM1, kg/m2 (mean ± s.d.)"
"5725";"BMI"
"5726";"BMI—mean (SD) (kg/m2)"
"5727";"BMI - kg/m2"
"5728";"BMI (.kg/m-)*"
"5729";"BMI (27.0; 29.9)"
"5730";"BMI (30.0; 34.9)"
"5731";"BMI (35.0; 39.9)"
"5732";"BMI (kg/ m 2 )"
"5733";"BMI (kg/(m)2)"
"5734";"BMI (kg/m)"
"5735";"BMI (kg/m^)"
"5736";"BMI (kg/m^), mean (SD)"
"5737";"BMI (kg/m^), mean ± s.d."
"5738";"BMI (kg/m’)"
"5739";"BMI (Kg/m2 )"
"5740";"BMI (kg/m2)"
"5741";"BMI (kg/m2) (mean ± SD)"
"5742";"BMI (kg/m2) (SD)"
"5743";"BMI (kg/m2) [mean-SD]"
"5744";"BMI (kg/m2) [median (25th to 75th percentile)]"
"5745";"BMI (kg/m2) <25"
"5746";"BMI (kg/m2) <30"
"5747";"BMI (kg/m2) Cardiac parameters"
"5748";"BMI (kg/m2) Cardiovascular history"
"5749";"BMI (kg/m2) Mean (SD)"
"5750";"BMI (kg/m2) mean ± SD"
"5751";"BMI (kg/m2)*"
"5752";"BMI (kg/m2), mean (SD)"
"5753";"BMI (kg/m2), mean (SD)a"
"5754";"BMI (kg/m2), mean±SD"
"5755";"BMI (kg/m2), Mean±SD"
"5756";"BMI (kg/m2), median (range)"
"5757";"BMI (kg/m2): mean ± SD"
"5758";"BMI (kg/m2)a"
"5759";"BMI (kg/rrr)"
"5760";"BMI (kg=m2)"
"5761";"BMI (median, IQR), kg/m2"
"5762";"BMI (SD), kg/m2"
"5763";"BMI [kg/m2]"
"5764";"BMI £30 kg/m* (N=64/61)"
"5765";"BMI <= 30"
"5766";"BMI <25"
"5767";"BMI <25 kg/m"" (N=144/129)"
"5768";"BMI <25 kg/m* (N=10/19)"
"5769";"BMI <25 kg/m* (N=144/129)"
"5770";"BMI <25 kg/m^ (N=10/19)"
"5771";"BMI <25 kg/m^ (N=144/129)"
"5772";"BMI <25 kg/m^ (N=32/35)"
"5773";"BMI <25 kg/m2(N=10/19)"
"5774";"BMI <30"
"5775";"BMI <30 kg/m2"
"5776";"BMI = body mass index; BNP = brain natriuretic peptide; DBP = diastolic blood pressure; GFR = glomerular filtration rate; HR = heart rate; IQR = interquartile range; KCCQ = Kansas City Cardiomyopathy Questionnaire; N = number; NT = N-terminal; NYHA = New York Heart Association; SBP = systolic blood pressure"
"5777";"BMI > 25, n (%)"
"5778";"BMI > 30"
"5779";"BMI > 30 kg/m2"
"5780";"BMI > 30kg/m2"
"5781";"BMI >= 35"
"5782";"BMI >=25 kg/m2 Population (n = 1632)"
"5783";"BMI >=25Kg/m2"
"5784";"BMI >=40"
"5785";"BMI >25 —no. {%)$"
"5786";"BMI >30"
"5787";"BMI >30 — no. (%)f"
"5788";"BMI >30 kg/m^ (N=203/199)"
"5789";"BMI >30 kg/m^ (N=69/77)"
"5790";"BMI >30 kg/m2"
"5791";"BMI >30 kg/m2 (%)"
"5792";"BMI >30 kg/m2*"
"5793";"BMI >30 kg/m2, n (%)"
"5794";"BMI >30 Obese"
"5795";"BMI >40"
"5796";"BMI ¼ body mass index; HCTZ ¼ hydrochlorothiazide; MSDBP ¼ mean sitting diastolic blood pressure; MSSBP ¼ mean sitting systolic blood pressure; SD ¼ standard deviation"
"5797";"BMI 25-<30 kg/m- (N=168/1074)"
"5798";"BMI 25-<30 kg/m"" (N=106/107)"
"5799";"BMI 25-<30 kg/m"" (N=168/1074)"
"5800";"BMI 25-<30 kg/m* (N =46/35)"
"5801";"BMI 25-<30 kg/m^ (N=106/107)"
"5802";"BMI 25-<30 kg/m^ (N=46/35)"
"5803";"BMI 25-<30 kg/ni- (N=168/1074)"
"5804";"BMI 25–30 Overweight"
"5805";"BMI 27-0-29-9"
"5806";"BMI 30 0-34 9"
"5807";"BMI 35-0-39 9"
"5808";"BMI 35 0-39 9"
"5809";"BMI 640"
"5810";"BMI a40"
"5811";"BMI at baseline (kg/m2 )"
"5812";"BMI categories, n (%)"
"5813";"BMI category"
"5814";"BMI category (%)"
"5815";"BMI category (Kg/m2)"
"5816";"BMI category, no. (%)"
"5817";"BMI distribution, n (%)"
"5818";"BMI group — no. (%)"
"5819";"BMI group (kg/m^)"
"5820";"BMI in kg/m2, mean (SD)"
"5821";"BMI indicates body mass index; SBP, systolic blood pressure; DBP, lipoprotein(a). LDL-C was calculated with the Friedewald formula. 'Hypertension and diabetes were based on physician diagnosis. !Smoker includes current and past smokers."
"5822";"BMI kg - m-2"
"5823";"BMI kg·m−2"
"5824";"BMI o30 kg/m2, n (%)"
"5825";"BMI kg·m−2"
"5826";"BMI# kg-m“2"
"5827";"BMI* (kg/m2), median (Q1, Q3)"
"5828";"BMI, body mass index; HRT, hormone replacement therapy; LVH, left ventricular hypertrophy; NSAIDs, nonsteroidal anti-inflammatory drugs; PVD, peripheral vascular disease;TIA, transient ischemic attack. aHistory of and/or currently taking lipid-lowering or antidiabetic medications. bP< 0.05 for verapamil sustained-release (SR) vs. atenolol. cHistory of or currently have elevated serum creatinine but less than 4 mg/dl. dBlood pressure control defined as <140/90 or <130/80 in patients with diabetes or a history of renal insufficiency."
"5829";"BMI, kg per m2"
"5830";"BMI, kg/m^"
"5831";"BMi, kg/m^*"
"5832";"BMI, kg/m^, mean (SD)"
"5833";"BMI, kg/m^, mean (SD)’"
"5834";"BMI, kg/m’"
"5835";"BMI, kg/m2"
"5836";"BMI, kg/m2 (mean 6 SD)"
"5837";"BMI, kg/m2 (SD)"
"5838";"BMI, kg/m2 Cholesterol, mg/dL"
"5839";"BMI, kg/m2 UAC, No. (%)"
"5840";"BMI, kg/m2, mean"
"5841";"BMI, kg/m2, mean (SD)"
"5842";"BMI, kg/m2, mean + SD"
"5843";"BMI, kg/m2, mean ± SD"
"5844";"BMI, kg/m2, median (IQR)"
"5845";"BMI, kg/m2, n"
"5846";"BMI, kg/m2, n (%)"
"5847";"BMI, kg/m2; median (IQR)"
"5848";"BMI, kg/m21"
"5849";"BMI, mean (SD)"
"5850";"BMI, mean (SD) (kg/m2)"
"5851";"BMI, mean (SD) kg/m2"
"5852";"BMI, mean (SD), kg/m^"
"5853";"BMI, mean (SD), kg/m2"
"5854";"BMI, mean (SD), kg/m2c"
"5855";"BMI, mean (SD), kg/rn2"
"5856";"BMI, mean (SD)b"
"5857";"BMI, mean ± SD"
"5858";"BMI, mean ± SD kg/m2"
"5859";"BMI, mean ± SD, kg/m2"
"5860";"BMI, mean, kg/m2"
"5861";"BMI, mean, kg/m2 (± SD)"
"5862";"BMI, mean±SD, kg/m2"
"5863";"BMI, median (IQR)"
"5864";"BMI, median (IQR), kg/m2"
"5865";"BMI, median (SD), kg/m2"
"5866";"BMI, n (%)"
"5867";"BMI, no. (%)"
"5868";"BMI, X30 kg/m2"
"5869";"BMI: <30.0 kg/m2"
"5870";"BMI: <35 kg/nr"
"5871";"BMI: >30.0 kg/m2"
"5872";"BMI: body mass index; DBP: diastolic blood pressure; GM: Geometric mean; SBP: systolic blood pressure. The analysis was based on observed data without imputation on missing values. aSubgroup of patients in whom 24 h urine was collected (see Materials and Methods section)."
"5873";"BMI^"
"5874";"BMI< 30kg/m2"
"5875";"BMI<=30"
"5876";"BMI<25"
"5877";"BMI<25Kg/m2"
"5878";"BMI<30kg/m2"
"5879";"BMI> 30kg/m2"
"5880";"BMI>25(%)"
"5881";"BMI>30"
"5882";"BMI>30kg/m* (N=64/61)"
"5883";"BMI>30kg/m2 (N =203/199)"
"5884";"BMI>30kg/m2 (N=203/199)"
"5885";"BMI>30kg/m2 (N=69/77)"
"5886";"BMIa"
"5887";"BMIJ"
"5888";"BMIT"
"5889";"BMP kg-m“2"
"5890";"BMS"
"5891";"bMultivariate Logistic regression with variables forced in the modela"
"5892";"BNP"
"5893";"BNP — pg/ml"
"5894";"BNP — pg/ml;i;"
"5895";"BNP (n=430)"
"5896";"BNP (pg/ml)"
"5897";"BNP (pg/mL)"
"5898";"BNP (pg/ml)H"
"5899";"BNP <80 pg/ml n=2537"
"5900";"BNP > 500 pg/mL or NT pro-BNP > 2000 pg/mL, n (%)"
"5901";"BNP >80 pg/ml n=1874"
"5902";"BNP >80 pg/mL, N = 9751027"
"5903";"BNP >80 pg/mL, N = 325 138"
"5904";"BNP >80 pg/mL, N = 975 1027"
"5905";"BNP indicates brain natriuretic peptide; and NYHA, New York Heart Association."
"5906";"BNP O 500 pg/mL or NT pro-BNP O 2000 pg/mL, n (%)"
"5907";"BNP(pg/mL)"
"5908";"BNP, median (IQR), pg/mL"
"5909";"BNP, pg/ml"
"5910";"BNP, pg/mL"
"5911";"BNP, pg/mLt"
"5912";"BNP,* median (IQR), pg/mL"
"5913";"BNP/NT-proBNP"
"5914";"BNP/NTBNP (n=687)"
"5915";"BOCF-iike imputation (Random.) (n=1613)"
"5916";"BOCF-iike imputation (Random.) (n=1616)"
"5917";"BOCF-iike imputation (Random.) (n=2153)"
"5918";"Bodily pain"
"5919";"Body-mass index"
"5920";"Body-mass Index"
"5921";"Body-mass index-!'"
"5922";"Body-mass index - kg/m2, Median (IQR)"
"5923";"Body-mass index — no. (%)$"
"5924";"Body-mass index — no. (%):i:"
"5925";"Body-mass index ( kg / cm2)"
"5926";"Body-mass index (kg/m')"
"5927";"Body-mass index (kg/m-)"
"5928";"Body-mass index (kg/m-)!"
"5929";"Body-mass index (kg/m 2)"
"5930";"Body-mass index (kg/m’)"
"5931";"Body-mass index (kg/m2)"
"5932";"Body-mass index (kg/m2) (mean, SD)"
"5933";"Body-mass index (kg/m2)*"
"5934";"Body-mass index (kg/m2), mean (SD)"
"5935";"Body-mass index (kg/m2)t"
"5936";"Body-mass index (kg/mJ) Previous diagnosis"
"5937";"Body-mass index (kg/mQ"
"5938";"Body-mass index \ kg/m2"
"5939";"Body-mass index > 30, n(%)"
"5940";"Body-Mass Index >30"
"5941";"Body-mass index >30 kg/nrn"
"5942";"Body-mass index categories — no. (%):c"
"5943";"Body-mass index$"
"5944";"Body-mass index)"
"5945";"Body-mass index)'"
"5946";"Body-mass index)-"
"5947";"Body-mass index)"""
"5948";"Body-mass index*"
"5949";"Body-mass index, kg/m2"
"5950";"Body-mass index, kq/nrn"
"5951";"Body-mass index, mean (SD)"
"5952";"Body-mass index:!:"
"5953";"Body-mass index:!: Blood pressure — mm Hg"
"5954";"Body-mass index;!;"
"5955";"Body-mass index;!; Waist-to-hip ratio"
"5956";"Body-mass index^"
"5957";"Body-mass index^:"
"5958";"Body-mass index^;"
"5959";"Body-mass index”"
"5960";"Body-mass index§"
"5961";"Body-mass indexf"
"5962";"Body-mass indexj"
"5963";"Body height (cm)"
"5964";"Body mass index"
"5965";"Body Mass Index"
"5966";"Body mass index - kg/m2T"
"5967";"Body mass index - mean (sd)"
"5968";"Body mass index (BMI), kg/m2"
"5969";"Body mass index (BMI; kg/m2), n (%) < 30 kg/m2"
"5970";"Body mass index (kg/m )"
"5971";"Body mass index (kg/m^)"
"5972";"Body mass index (kg/m^)^"
"5973";"Body mass index (kg/m’)^"
"5974";"Body mass index (kg/m“)^"
"5975";"Body mass index (kg/m1)"
"5976";"Body mass index (kg/m2 )"
"5977";"Body mass index (kg/m2 ),"
"5978";"body mass index (kg/m2)"
"5979";"Body mass index (kg/m2)"
"5980";"Body Mass Index (kg/m2)"
"5981";"Body mass index (kg/m2) - mean ± SD"
"5982";"Body mass index (kg/m2) Baseline systolic blood"
"5983";"Body mass index (kg/m2)∗"
"5984";"Body mass index (kg/m2)*'"
"5985";"Body mass index (kg/m2),"
"5986";"Body mass index (kg/m2), mean (SD)c"
"5987";"Body mass index (kg/ma)"
"5988";"Body mass index (kg/nr)"
"5989";"Body mass index (kgm _2)"
"5990";"Body Mass Index (median,"
"5991";"Body mass index (mg/m2)"
"5992";"Body Mass Index (range) (kg/m2)"
"5993";"Body mass index [kg/m2], mean ± SD"
"5994";"Body mass index <30 kg/m2"
"5995";"Body mass index >30 — no. (%)f"
"5996";"Body mass index >30 kg/m , n (%)"
"5997";"Body mass index >30 kg/m2*"
"5998";"Body mass index >30 kg/m2, n (%)"
"5999";"Body mass index >30, n (%)"
"6000";"Body mass index >30t"
"6001";"Body mass index Blood pressure — mmHg"
"6002";"Body mass index category, no. (%)l"
"6003";"Body mass index group (≥ 30 kg/m2)—No. (%)"
"6004";"Body mass index group (kg/m2) ≥30 kg/m2—No. (%)"
"6005";"Body mass index mean kg/m2 (SD)"
"6006";"Body mass index subgroups"
"6007";"Body mass index*"
"6008";"Body mass index,"
"6009";"Body mass index, %"
"6010";"Body mass index, kg/m^"
"6011";"Body mass index, kg/m^ (meaniSD)"
"6012";"Body mass index, kg/m^ mean (SD)"
"6013";"Body mass index, kg/m^^"
"6014";"Body mass index, kg/m’"
"6015";"Body mass index, kg/m2"
"6016";"Body Mass Index, kg/m2"
"6017";"BoDy Mass InDex, kg/m2"
"6018";"Body mass index, kg/m2 (mean ± SD)"
"6019";"Body mass index, kg/m2 (SD)"
"6020";"Body mass index, kg/m2 (SD)"
"6021";"Body mass index, kg/m2, mean (SD)"
"6022";"Body mass index, kg/m2, mean (SD)§"
"6023";"Body mass index, kg/m2, mean + SD"
"6024";"Body mass index, kg/m2, mean±SD"
"6025";"Body mass index, kg/m2, median (Q1, Q3)"
"6026";"Body mass index, kg/rn \ mean (SD)"
"6027";"Body mass index, mean (sd)"
"6028";"Body mass index, mean (SD)"
"6029";"Body mass index, mean (SD) (kg m)2)"
"6030";"Body mass index, mean (SD) [range]a"
"6031";"Body mass index, mean (sd) Kg/M2"
"6032";"Body mass index, mean (SD) kg/m2"
"6033";"Body mass index, mean (SD), kg/m2"
"6034";"Body mass index, mean (SD)d"
"6035";"Body mass index, mean (SD)t"
"6036";"Body mass index, mean kg/m^ (SD)"
"6037";"Body mass index, median (IQR)"
"6038";"Body mass index, median (IQR)b"
"6039";"Body mass index, median, (25th—75th percentiles), kg/m2"
"6040";"Body mass index,* kg/m2"
"6041";"Body mass index/ Mean (SD)"
"6042";"Body Mass Index:"
"6043";"Body mass index; mean + SD (kg/m )"
"6044";"Body mass index; mean ± SD (kg/m2)"
"6045";"Body mass index^"
"6046";"Body mass index+"
"6047";"Body mass index3"
"6048";"Body mass indexa"
"6049";"Body mass indexa <Median"
"6050";"Body mass indexb"
"6051";"Body mass indexc"
"6052";"Body mass indexf"
"6053";"Body mass indexf; <25"
"6054";"Body mass indext"
"6055";"Body mass, kg"
"6056";"Body massindex,mean (SD)a"
"6057";"Body weight"
"6058";"Body weight — kg"
"6059";"Body weight (change from baseline)"
"6060";"Body weight (kg)"
"6061";"Body weight (kg)*"
"6062";"Body weight (kg), mean (s.d.)"
"6063";"Body weight (kg), mean (SD)"
"6064";"Body weight (kg), mean±SD"
"6065";"Body weight (kg), n (%)"
"6066";"Body Weight at Randomization"
"6067";"Body Weight at Randonization {IXRS)"
"6068";"Body weight index (kg/m2)"
"6069";"Body weight reduction >5%"
"6070";"Body weight*"
"6071";"Body weight, %"
"6072";"Body weight, kg"
"6073";"Body weight, kg (mean ± SD)"
"6074";"Body weight, kg (SD)"
"6075";"Body weight, kg^"
"6076";"Body weight, mean = SD, kg"
"6077";"Body weight, mean ± SD, kg"
"6078";"Body weighta, kg"
"6079";"Body weiqht"
"6080";"Bodymass index (kg/m2)"
"6081";"Bodyweight (kg)"
"6082";"Bodyweight, kg"
"6083";"Bolus"
"6084";"Bolus administered — no. (%)"
"6085";"Bolus alone"
"6086";"Bolus and corrections"
"6087";"Bolus and infusion"
"6088";"Bolus insulin doseH"
"6089";"Bolus of heparin given"
"6090";"Bone erosion ( judged by physician), n (%)"
"6091";"Bone erosion (judged by physician), n (%)"
"6092";"Bone erosion score, mean (SD)"
"6093";"Bone fracture"
"6094";"Bone fracture due to fall"
"6095";"Bone mineral density (g/cm2), mean (SD)"
"6096";"Bonferroni- adjusted P Value, B vs a"
"6097";"Bonferroni- adjusted P Value, c vs a"
"6098";"Bonferroni- adjusted P Value, D vs a"
"6099";"BOOST INTENSIFY ALL (pan-Asian patient population)"
"6100";"BOOST INTENSIFY PREMIX I (global patient population)"
"6101";"Borg dyspnea score WHO functional class, n (%)"
"6102";"bosentan"
"6103";"Bosentan"
"6104";"Bosentan (N = 407)"
"6105";"Bosentan Use:"
"6106";"Both"
"6107";"Both (%)"
"6108";"Both ACE inhibitor and ARB"
"6109";"Both adalimumab groups (n = 26)"
"6110";"Both adalimumab groups (n = 31) No baseline CD-related antibiotic use"
"6111";"Both adalimumab groups (n = 39) Baseline immunosuppressant use"
"6112";"Both adalimumab groups (n = 44) Baseline CD-related antibiotic use"
"6113";"Both deep-vein thrombosis and pulmonary embolism"
"6114";"Both impaired glucose tolerance and impaired fasting glucose tolerance — no."
"6115";"Both IV vasodilator and inotrope"
"6116";"Both PTCA and CABG"
"6117";"Both unfractionated heparin and low-molecular-weight heparin"
"6118";"Bowel function"
"6119";"Bowel stricturing,' n (%)"
"6120";"BP-Lowering Treatment (n=1119)"
"6121";"BP-lowering treatments, n (%)"
"6122";"BP <140/90, n (%)"
"6123";"BP = blood pressure;eGFR = estimated glomerular filtration rate (men: 194 en: 194 X Cr 1.094 X age 0.287 X 0.739);HDL = high-density lipoprotein."
"6124";"BP and fasting glucose results"
"6125";"BP Component (mm Hg)"
"6126";"BP control"
"6127";"BP goal attainment"
"6128";"BP goal, no. (%)"
"6129";"BP in pre-treated patients"
"6130";"BP Variable, mm Hg"
"6131";"BP: blood pressure; CI: confidence interval; ESRD: end-stage renal disease; HR, hazard ratio.
All patients (except patients with other race) were included with missing covariates imputed.
Event: no. of patients with ESRD; rate: event rate per 1000 years of follow-up; pre-specified: a Cox model with treatment group and region as covariates and baseline proteinuria level (o or X2 g/g) as strata; adjusted: a multivariate Cox model with treatment group, time-varying systolic and diastolic BP as covariates.
Pre-specified analysis and adjusted for time-varying BP"
"6132";"bPearson's chi‐square test."
"6133";"BPH-LUTS severity"
"6134";"BPH-related health status"
"6135";"Brachial"
"6136";"Brain volume, cm'"
"6137";"Brain volume, cm3"
"6138";"bRandomization was stratified by diabetic status."
"6139";"Brazil"
"6140";"Breakfastb"
"6141";"Bronchial reversibility %"
"6142";"Bronchitis"
"6143";"BRV >50 mg/day"
"6144";"BRV 100 mg/day ( n = 14)"
"6145";"BRV 100 mg/day (n = 252)"
"6146";"BRV 100 mg/day (n = 253)"
"6147";"BRV 100 mg/day (n = 36)"
"6148";"BRV 100 mg/day (n = 61)"
"6149";"BRV 100 mg/day"
"6150";"BRV 200 mg/day ( n = 6)"
"6151";"BRV 200 mg/day (n ="
"6152";"BRV 200 mg/day (n = 16)"
"6153";"BRV 200 mg/day (n = 249)"
"6154";"BRV 200 mg/day (n = 250)"
"6155";"BRV 200 mg/day (n=41)"
"6156";"BRV 200 mg/day"
"6157";"BRV 50 mg/day (n = 32)"
"6158";"BRV 50 mg/day (n = 4)"
"6159";"BRV 50 mg/day (n = 7)"
"6160";"BRV 50 mg/day"
"6161";"BRV dosage, mg/d"
"6162";"BRV overall"
"6163";"BRV overall (n = 24)"
"6164";"BRV overalla (n = 134)"
"6165";"BRV overalla (n = 59)"
"6166";"BSA (%)"
"6167";"BSA (%), mean (SD)"
"6168";"BSA >3%, n (%)t"
"6169";"BSA affected, %"
"6170";"BSA affected, mean ± SD, %"
"6171";"BSA involved, %1"
"6172";"BSA, %*"
"6173";"Bsl Hb, gl-1"
"6174";"Bsl, baseline; Cl, confidence interval; ESRD, end-stage renal disease; Hb, hemoglobin; HR, hazard ratio; K (rate), # of events per 1000 patient-years of follow-up; Yr, year. Multivariate Cox model with hemoglobin category and baseline urinary albumimcreatinine ratio, serum albumin, serum creatinine, and hemoglobin as covariates."
"6175";"bsl, baseline; Cl, confidence interval; ESRD, end-stage renal disease; Hb, hemoglobin; K (rate), # of events per 1000 patient-years of follow-up; RRR, relative risk reduction; Yr, year. ^Treatment effect of losartan versus placebo. interaction test between treatment group and hemoglobin group (<120 or > 120g I-1). cMultivariate Cox model with baseline log urinary albumimcreatinine ratio, serum albumin, serum creatinine, and hemoglobin as covariates. dMultivariate Cox model with baseline log urinary albumimcreatinine ratio, serum albumin, serum creatinine, and hemoglobin and change in hemoglobin at year 1 as covariates."
"6176";"BUD 320 ptg n = 123"
"6177";"BUD/FM 320/9 Atg n = ^27"
"6178";"Budesonide"
"6179";"Budesonide- Formoterol (N = 5846)"
"6180";"Budesonide- Formoterol 160 ^g + 4.5 ^g (N = 4201)"
"6181";"Budesonide- Formoterol 80    + 4.5 ^g (N = 1645)"
"6182";"Budesonide — no. (%)"
"6183";"Budesonide (N = 5847)"
"6184";"Budesonide (symptom days a week)"
"6185";"Budesonide {symptom days a week)"
"6186";"Budesonide 160 ^g (N = 4201)"
"6187";"Budesonide 80 ^g (N = 1646)"
"6188";"Budesonide MMX 6 mg, (n=128)"
"6189";"Budesonide MMX 9 mg, (n=128)"
"6190";"Budesonide, n (%)"
"6191";"Budesonide/formoterol FDC"
"6192";"Bumetanide"
"6193";"BUN (mg/dl)"
"6194";"BUN, mg/dL"
"6195";"BUN, mmol/l"
"6196";"BUN, mmol/L"
"6197";"Bundle branch block"
"6198";"BW at 24 weeks, kg+"
"6199";"BW, kg"
"6200";"BW, mean (SD), kg"
"6201";"By baseline diabetic status"
"6202";"By Cause of Death"
"6203";"By genotyping"
"6204";"By GFR stratum for all participants, mL/min per 1.73 m’!"
"6205";"By GFR stratum for diabetic participants, mt/min per 1.73 m’§"
"6206";"By GFR stratum tor all participants, mL/min per 1.73 m^!"
"6207";"By GFR stratum tor diabetic participants, mL/min per 1.73 m’§"
"6208";"By Treatment Arm"
"6209";"By WHO/Simon Broome criteria"
"6210";"Bypass graft"
"6211";"Bypass graft§"
"6212";"Bypass surgery"
"6213";"c"
"6214";"C"
"6215";"C-peptide"
"6216";"C-Peptide Tx difference vs Pbo, median change from baseline (SE)1"
"6217";"C-Peptide, median (Q1, Q3), nmol/L"
"6218";"C-Peptide, median (Ql, Q3), nmol/L"
"6219";"C-reactive protein"
"6220";"C-reactive protein — mg/liter**"
"6221";"C-reactive protein — mg/literj"
"6222";"C-reactive protein (high-sensitivity assay); MITT = modified intent-to-treat; Pbo cholesterol; Cl = confidence intervals; HDL-C = high-density lipoprotein cholest = National Cholesterol Education Program Adult Treatment Panel y patients with diabetes (FC >_ 126 mg/dL [> 7.0 mmol/L]). To qualify as having acteristics described in Methods (NCEP ATP III definition); + Baseline values are rr d hs-CRR for which medians are presented; **p<0.001; §p=0.002; *p=0.027. nteractions were not statistically significant (p>0.05)."
"6223";"C-reactive protein (mg/dl)"
"6224";"C-reactive protein (mg/dl_)"
"6225";"C-reactive protein (mg/L)"
"6226";"C-reactive protein concentration (mg/L)"
"6227";"C-reactive protein, median (IQR), mg/L"
"6228";"C-reactive protein, median (Q1, Q3)"
"6229";"C-reactive protein, mg/L"
"6230";"C-Reactive Protein, mg/L"
"6231";"C-reactive protein, U/L"
"6232";"C-reactive protein,* mg/L"
"6233";"C-reactive proteinc"
"6234";"c Clinical Fractures (FAS)"
"6235";"C group ( n = 585)"
"6236";"C peptide, nmol/L*'"
"6237";"c, right-sided VhD (n=165)"
"6238";"C. DAS28-CRP <3.2"
"6239";"C100 ml decrease in trough FEV1"
"6240";"C4-unit SGRQ total score increase"
"6241";"c7E3 Fab BOLUS"
"6242";"c7E3 Fab Bolus (N = 695)"
"6243";"c7E3 Fab Bolus and Infusion (N = 708)"
"6244";"Ca-channel blockers, n (%)"
"6245";"CABG"
"6246";"CABG — no. (%)"
"6247";"CABG — no. {%)"
"6248";"CABG (%)"
"6249";"CABG >1 month ago"
"6250";"CABG during index hospitalization"
"6251";"CABG history"
"6252";"CABG only"
"6253";"CABG or angioplasty"
"6254";"CABG or PCI"
"6255";"CABG or PTCA (%)"
"6256";"CABG or PTCA/PCI"
"6257";"CABG or valve"
"6258";"CABG performed during index hospitalization"
"6259";"CABG surgery"
"6260";"CABG surgery by No. of vessels 1"
"6261";"CABG(%)"
"6262";"CABG, n (%)"
"6263";"CABG:"
"6264";"CABGorPTCA"
"6265";"CAD"
"6266";"CAD and ABI <0-90§"
"6267";"CAD and/or CRVD (%)"
"6268";"CAD Death"
"6269";"CAD history and risk factors, n (%)"
"6270";"CAD*"
"6271";"Caffeine"
"6272";"Caffeine consumption (yes) (n)"
"6273";"Caffeine consumption*"
"6274";"Caffeine user"
"6275";"Caffeine user, n (%)"
"6276";"Caffeine users, n (%)"
"6277";"Calcification, n (%)"
"6278";"Calcitonin"
"6279";"Calcium-channel antagonists"
"6280";"Calcium-channel blocker"
"6281";"Calcium-channel blocker (ratelowering)"
"6282";"Calcium-channel blocker*"
"6283";"Calcium-channel blockerf"
"6284";"Calcium-channel blockers"
"6285";"Calcium-channel blockers (%)"
"6286";"Calcium-channel blockersubgroup"
"6287";"Calcium-channel inhibitor"
"6288";"Calcium (mmol/L)"
"6289";"Calcium aniagonisi"
"6290";"Calcium antagonist"
"6291";"Calcium antagonist— no. (%)"
"6292";"Calcium Antagonist Strategy (CAS) (events/n)"
"6293";"Calcium Antagonist Strategy (n = 11 267)"
"6294";"Calcium antagonists"
"6295";"Calcium antagonists, n (%)"
"6296";"Calcium channel"
"6297";"Calcium channel antagonists, n (%)"
"6298";"Calcium channel blocker"
"6299";"Calcium channel blocker (%)"
"6300";"Calcium channel blockers"
"6301";"Calcium Channel Blockers"
"6302";"Calcium channel blockers, n (%)"
"6303";"calcium channelantagonist"
"6304";"Calcium Level"
"6305";"Calcium supplements"
"6306";"Calcium, mmol 1 1"
"6307";"Calculated annual decline, mean ± SE"
"6308";"Calculated LDL-C in 4 classes"
"6309";"Calculated LDL cholesterol (week 12)"
"6310";"Caleitonin, ng/L, females Mean±SD"
"6311";"Caleitonin, ng/L, males Mean±SD"
"6312";"Caleium ehannel bloekers (CCB)"
"6313";"CALIMA Japan (N = 83)"
"6314";"CALIMA Japandhigh-dosage ICS/LABA and baseline blood eosinophils >300 cells/mL (n = 46)y"
"6315";"CALIMA overall (N = 1306)"
"6316";"CALIMA overalldhigh-dosage ICS/LABA and baseline blood eosinophils >300 cells/mL (n = 728)"
"6317";"CANA"
"6318";"Cana 100 mg"
"6319";"CANA 100 mg"
"6320";"CANA 100 mg ( n 5 665)"
"6321";"CANA 100 mg (n- 157)"
"6322";"CANA 100 mg (n-195)"
"6323";"CANA 100 mg (n-368)"
"6324";"CANA 100 mg (n = 1441)"
"6325";"CANA 100 mg (n = 1445)"
"6326";"CANA 100 mg (n = 1557)"
"6327";"CANA 100 mg (n = 159)"
"6328";"CANA 100 mg (n = 159)*"
"6329";"CANA 100 mg (n = 217)"
"6330";"CANA 100 mg (n = 315)"
"6331";"CANA 100 mg (n = 338)"
"6332";"CANA 100 mg (n = 339)"
"6333";"CANA 100 mg (n = 368)"
"6334";"CANA 100 mg (n = 408)"
"6335";"CANA 100 mg (n = 425)"
"6336";"CANA 100 mg (n = 493)"
"6337";"CANA 100 mg (n = 494)"
"6338";"CANA 100 mg (n = 518)"
"6339";"CANA 100 mg (n = 59)"
"6340";"CANA 100 mg (n = 616)"
"6341";"CANA 100 mg (n = 674)"
"6342";"CANA 100 mg (n = 774)"
"6343";"CANA 100 mg (n = 833)"
"6344";"CANA 100 mg (n = 867)"
"6345";"CANA 100 mg (n 5 168)"
"6346";"CANA 100 mg (n= 197)"
"6347";"CANA 100 mg (n=222)"
"6348";"CANA 100 mg (n=611)"
"6349";"CANA 100 mg (n=833)"
"6350";"CANA 100mg (n=833)"
"6351";"Cana 300 mg"
"6352";"CANA 300 mg"
"6353";"CANA 300 mg (n-156)"
"6354";"CANA 300 mg (n-197)"
"6355";"CANA 300 mg (n-367)"
"6356";"CANA 300 mg (n = 1074)"
"6357";"CANA 300 mg (n = 1441)"
"6358";"CANA 300 mg (n = 149)"
"6359";"CANA 300 mg (n = 191)"
"6360";"CANA 300 mg (n = 1932)"
"6361";"CANA 300 mg (n = 260)"
"6362";"CANA 300 mg (n = 328)"
"6363";"CANA 300 mg (n = 340)"
"6364";"CANA 300 mg (n = 377)"
"6365";"CANA 300 mg (n = 404)"
"6366";"CANA 300 mg (n = 430)"
"6367";"CANA 300 mg (n = 494)"
"6368";"CANA 300 mg (n = 506)"
"6369";"CANA 300 mg (n = 56)"
"6370";"CANA 300 mg (n = 598)"
"6371";"CANA 300 mg (n = 643)"
"6372";"CANA 300 mg (n = 645)"
"6373";"CANA 300 mg (n = 685)"
"6374";"CANA 300 mg (n = 744)"
"6375";"CANA 300 mg (n = 778)"
"6376";"CANA 300 mg (n = 834)"
"6377";"CANA 300 mg (n 5 141)"
"6378";"CANA 300 mg (n 5 693)"
"6379";"CANA 300 mg (n=226)"
"6380";"CANA 300 mg (n=608)"
"6381";"CANA 300 mg (n=834)"
"6382";"CANA 300mg (n=1461)"
"6383";"CANA 300mg (n=834)"
"6384";"CANA100 (n =237)"
"6385";"CANA100/MET (n = 237)"
"6386";"CANA300/MET (n =237)"
"6387";"Canada"
"6388";"Canada or United States"
"6389";"Canagiiflozin"
"6390";"Canagliflozin"
"6391";"Canagliflozin (N = 5795)"
"6392";"Canagliflozin (n=1110)"
"6393";"Canagliflozin (n=4684)"
"6394";"Canagliflozin (n=4992)"
"6395";"Canagliflozin (n=803)"
"6396";"Canagliflozin 100 mg vs Sitagliptin 100 mg"
"6397";"Canagliflozin 300 mg vs Sitagliptin 100 mg"
"6398";"Canagliflozin Dose"
"6399";"Canakinumab"
"6400";"Canakinumab 150 mg"
"6401";"Canakinumab 300 mg"
"6402";"Canakinumab 50 mg"
"6403";"Canakinumab Dose"
"6404";"Canakinumab Dose (per mo)"
"6405";"Canakinumab Dose (per month)"
"6406";"Canakinumab, 3-month on-treatment IL-6 below the median value (<1.65 ng/L) (n = 1617)"
"6407";"Canakinumab, 3 month on-treatment Il-6 above the median value (≥1.65 ng/L) (n = 1619)"
"6408";"Canakinumab, hsCRP <2-0 mg/L at 3 months (n=3484)"
"6409";"Canakinumab, hsCRP >2-0 mg/L at 3 months (n=2868)"
"6410";"Canakinumab, IL-6 lowest tertile"
"6411";"Canakinumab, IL-6 middle tertile"
"6412";"Canakinumab, IL-6 top tertilec"
"6413";"Cancer"
"6414";"Cancer — no. (%)"
"6415";"Cancer (N=1480)"
"6416";"Cancer Medications"
"6417";"Cancer n (%)"
"6418";"Cancer surgery"
"6419";"Cancer*"
"6420";"Cancer**"
"6421";"Cancer, fatal and nonfatal"
"6422";"Cancer§"
"6423";"Cancert"
"6424";"Candesartan"
"6425";"Candesartan 14/63"
"6426";"Candesartan 37/62"
"6427";"Candesartan group (n = 203)"
"6428";"Candesartan Group (N = 391)"
"6429";"Cangrelor"
"6430";"Cangrelor    Clopidogrel no. of events/total no. (%)"
"6431";"Cangrelor (N = 3946)"
"6432";"Cangrelor (N = 4433)"
"6433";"Cangrelor (N = 487)"
"6434";"Cangrelor (N = 5472)"
"6435";"Cangrelor (n = 6639)"
"6436";"Cangrelor (N=1558)"
"6437";"Cangrelor (N=1558) n/N (%)"
"6438";"Cangrelor (N=1583) n/N (%)"
"6439";"Cangrelor (N=3914)"
"6440";"Cangrelor (N=3914) n/N (%)"
"6441";"Cangrelor (N=3946) n/N (%)"
"6442";"Cangrelor (N=5404)"
"6443";"Cangrelor (N=68)"
"6444";"Cangrelor Dyspnoea vs No dyspnoea*"
"6445";"Cangrelor n/N (%)"
"6446";"Cangrelor, %"
"6447";"Canrenone (n Z 146)"
"6448";"Canrenone (n Z 73)"
"6449";"CANVAS"
"6450";"CANVAS-R"
"6451";"CANVAS (N = 4327): Placebo (n = 1441); CANA 100 mg (n = 1445); CANA 300 mg (n = 1441)"
"6452";"Carbamazepine"
"6453";"Cardiac"
"6454";"Cardiac-biomarker status — no./total no. (%)$"
"6455";"Cardiac-biomarker status 一no./total no. (%)$"
"6456";"Cardiac and echocardiography parameters"
"6457";"Cardiac arrhythmia"
"6458";"Cardiac arrhythmia, n (%)"
"6459";"Cardiac biomarker elevation"
"6460";"Cardiac biomarker status!"
"6461";"Cardiac biomarker, n (%)"
"6462";"Cardiac catheterisation or PCI for index event"
"6463";"Cardiac death"
"6464";"Cardiac disease"
"6465";"Cardiac diseasec"
"6466";"Cardiac disorder"
"6467";"Cardiac disorder, n (%)§"
"6468";"Cardiac disorders (SOC)"
"6469";"Cardiac enzyates raised"
"6470";"Cardiac failure"
"6471";"Cardiac failure—"
"6472";"Cardiac failure*"
"6473";"Cardiac failure, n (%)"
"6474";"Cardiac failure§"
"6475";"Cardiac failurec"
"6476";"Cardiac glycosides"
"6477";"Cardiac history"
"6478";"Cardiac history, %"
"6479";"Cardiac index, L • mn ' • m 2"
"6480";"Cardiac mediations"
"6481";"Cardiac medications at discharge, %"
"6482";"Cardiac medications during index hospital stay and/or discharge"
"6483";"Cardiac medications during index hospitalization"
"6484";"Cardiac medications during index hospitalization — no. (%)"
"6485";"Cardiac medications during index hospitalization, %"
"6486";"Cardiac medications during indexhospitalization and/or discharge"
"6487";"Cardiac pacemaker — no. (%)"
"6488";"Cardiac parameters"
"6489";"Cardiac Procedure:"
"6490";"Cardiac resynchronization therapy"
"6491";"Cardiac resynchronization therapy N(%)"
"6492";"Cardiac rhythm"
"6493";"Cardiac rhythm disorder at baseline NO"
"6494";"Cardiac rhythm disorder at baseline YES"
"6495";"Cardiac rhythm disorders"
"6496";"Cardiac risk"
"6497";"Cardiac stretch"
"6498";"Cardiac therapy"
"6499";"Cardiac therapy, n (%)d"
"6500";"Cardiac therapy§"
"6501";"Cardiac troponin T level >0.03 pg/L"
"6502";"Cardiac troponin T level, median (IQR), pg/L"
"6503";"Cardiac valve surgery: No (n=707)"
"6504";"Cardiac valvular disease"
"6505";"Cardio-renal risk"
"6506";"Cardioembolic"
"6507";"Cardioembolic infarction, n (%)"
"6508";"Cardioembolism"
"6509";"Cardiogenic shock during first 24 hr after randomization"
"6510";"Cardiometabolic syndrome, ^n (%)"
"6511";"Cardiomyopathy"
"6512";"Cardiothoracic ratio >0.55"
"6513";"Cardiovascu lar subg roup"
"6514";"Cardiovascuiar mortaiity"
"6515";"Cardiovascular"
"6516";"Cardiovascular and oral hypoglycemic drugs - no.(%)"
"6517";"Cardiovascular and respiratory"
"6518";"Cardiovascular death"
"6519";"Cardiovascular Death"
"6520";"Cardiovascular death (n=104)"
"6521";"Cardiovascular death and hospital admission for heart failure"
"6522";"Cardiovascular Death or Heart Failure Hospitalization"
"6523";"Cardiovascular death or hospitalization for heart failure"
"6524";"Cardiovascular death or hospitalized HF"
"6525";"Cardiovascular death or nonfatal myocardial infarction"
"6526";"Cardiovascular death!"
"6527";"Cardiovascular death*"
"6528";"Cardiovascular death, MI, or stroke"
"6529";"Cardiovascular death, myocardial infarction, or stroke"
"6530";"Cardiovascular death, nonfatal myocardial infarction, nonfatal stroke"
"6531";"Cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke"
"6532";"Cardiovascular death/ Hospitalization for heart failure"
"6533";"Cardiovascular death/myocardial infarction/stroke"
"6534";"Cardiovascular death®"
"6535";"cardiovascular disease"
"6536";"Cardiovascular disease"
"6537";"Cardiovascular Disease"
"6538";"Cardiovascular disease (n=1083)"
"6539";"Cardiovascular disease (n=1101)"
"6540";"Cardiovascular disease (n=1480)"
"6541";"Cardiovascular disease history"
"6542";"Cardiovascular disease history, n (%)*"
"6543";"Cardiovascular disease history‡"
"6544";"Cardiovascular disease n (%)"
"6545";"Cardiovascular disease risk category"
"6546";"Cardiovascular disease*"
"6547";"Cardiovascular disorder"
"6548";"Cardiovascular disorder, n (%)"
"6549";"Cardiovascular events"
"6550";"Cardiovascular history"
"6551";"Cardiovascular history — no. (%)"
"6552";"Cardiovascular history — no./total no. (%)"
"6553";"Cardiovascular history 一no. (%)"
"6554";"Cardiovascular hospitalisation§"
"6555";"Cardiovascular hospitalization"
"6556";"Cardiovascular inclusion criteriat"
"6557";"Cardiovascular Medication Usage"
"6558";"Cardiovascular medications"
"6559";"Cardiovascular medications, %"
"6560";"Cardiovascular metabolic syndrome risk lactors"
"6561";"Cardiovascular mortality"
"6562";"Cardiovascular Mortality"
"6563";"Cardiovascular mortality (per 100 person-years)"
"6564";"Cardiovascular mortality or MI"
"6565";"Cardiovascular mortality, MI, or revascularization"
"6566";"Cardiovascular risk"
"6567";"Cardiovascular risk factor—no. {%)"
"6568";"Cardiovascular risk factors"
"6569";"Cardiovascular risk factors — no. {%)"
"6570";"Cardiovascular risk factors — no./total no. (%)"
"6571";"Cardiovascular Risk Factors Alone (n=2565)"
"6572";"Cardiovascular risk factors and history"
"6573";"Cardiovascular risk factors and history — no. (%)"
"6574";"Cardiovascular risk factors and history (%)"
"6575";"Cardiovascular risk factors and medical history"
"6576";"Cardiovascular risk factors, n (%)"
"6577";"Cardiovascular risk factors, no. (%)"
"6578";"Cardiovascular risk, n (%)"
"6579";"Cardiovascular therapies — no. {%)"
"6580";"Cardiovasculardeath"
"6581";"Cardiovasculardeath/myocardial infarction/stroke"
"6582";"Cardioversion in previous 2 wk"
"6583";"CARDS"
"6584";"CARE"
"6585";"care use"
"6586";"Caribbean"
"6587";"Carisbamate 1,200 mg (N = 182)"
"6588";"Carisbamate 800 mg (N = 180)"
"6589";"Carotid"
"6590";"Carotid artery— no. (%)"
"6591";"Carotid artery disease"
"6592";"Carotid artery diseaset"
"6593";"Carotid artery intervention*"
"6594";"Carotid artery stenosis, n (%)"
"6595";"Carotid bulb sites"
"6596";"Carotid endarterectomy"
"6597";"Carotid IMT"
"6598";"Carotid infarct"
"6599";"Carotid revascularization"
"6600";"Carotid Stenosis"
"6601";"Carrier (N=194)"
"6602";"Carvedilol"
"6603";"Carvedilol, % (n)"
"6604";"Cases"
"6605";"Casual plasma glucose (mg/dL)"
"6606";"CAT >=  15 (n = 2,544)"
"6607";"CAT >=  20 (n = 1,617)"
"6608";"CAT >= 10"
"6609";"CAT >= 10 (n = 3,227)"
"6610";"CAT >=15"
"6611";"CAT >=20"
"6612";"CAT score"
"6613";"CAT Score"
"6614";"CAT score category"
"6615";"CAT score, mean (SD)"
"6616";"CAT scoreff"
"6617";"CAT total score"
"6618";"CAT total score1"
"6619";"Cat. 1 n/N (%)"
"6620";"Cat. 2 n/N (%)"
"6621";"CAT<10"
"6622";"CAT>0"
"6623";"Cataract"
"6624";"Cataract removal"
"6625";"Catecholamines or corticosteroids without hospitalization"
"6626";"Categorical variables,"
"6627";"Categorical variables. No. (%)*’"
"6628";"Categories of Urinary ACR, ^g/mg"
"6629";"Category"
"6630";"Category— no./total no. (%)"
"6631";"Category 1"
"6632";"Category 2"
"6633";"Category 3"
"6634";"Category 4 and 5"
"6635";"Catheter access site"
"6636";"Catheter site—femoral"
"6637";"Catheterization laboratory in"
"6638";"Catheterization laboratory in center"
"6639";"Catheterization performed for qualifying event"
"6640";"CATscorecategory,n (%)"
"6641";"Caucasian"
"6642";"Caucasian (%)"
"6643";"Caucasian 1"
"6644";"Caucasian ethnicity"
"6645";"Caucasian EZE/SIMVA"
"6646";"Caucasian EZE/SIMVA („ = 1082}"
"6647";"Caucasian EZE/SIMVA (n = 1082)"
"6648";"Caucasian N = 1,863"
"6649";"Caucasian race"
"6650";"Caucasian race (%)"
"6651";"Caucasian SIMVA"
"6652";"Caucasian SIMVA („ = 1055}"
"6653";"Caucasian SIMVA (n = 1055)"
"6654";"Caucasian, %"
"6655";"Caucasian, n (%)"
"6656";"Caucasian, n (%)*"
"6657";"Caucasiana (%)"
"6658";"Caucasians"
"6659";"Caucasians (n = 651)"
"6660";"Caucasians (n = 668)"
"6661";"Causaslan"
"6662";"Cause of death unknown"
"6663";"Cause of DVT or PE — no. (%)"
"6664";"Cause of heart failure"
"6665";"Cause of heart failure — no. (%)"
"6666";"Causes of DVT or PE — no. (%)^|"
"6667";"Causes of DVT or PE, n (%)"
"6668";"CBZ-exposed"
"6669";"CBZ-naive"
"6670";"CC"
"6671";"CCB"
"6672";"CCBs, (%)"
"6673";"CCLEAR <50"
"6674";"CCLEAR 50-79"
"6675";"CCLEAR 80+"
"6676";"CCLEAR<50"
"6677";"CCQ score§§"
"6678";"CCQ total score"
"6679";"CCS class§"
"6680";"CCSC at 1 month before enrollment"
"6681";"CCV history/condition"
"6682";"CCV history/condition at baseline"
"6683";"CD [GEMINI 2]*’"
"6684";"CD [GEMINI 3]*’"
"6685";"CD complications"
"6686";"CD duration, y"
"6687";"CDAI"
"6688";"CDAI (0-76)"
"6689";"CDAI <10t"
"6690";"CDAI <2.8*"
"6691";"CDAI >330, n [%]"
"6692";"CDAI score"
"6693";"CDAI score <250"
"6694";"CDAI score, mean (s.d.)"
"6695";"CDAI score, mean ± SDa"
"6696";"CDAI score, median (min, max)"
"6697";"CDAI score§"
"6698";"CDAI, mean (SD)"
"6699";"CDAI, mean [SD]"
"6700";"CDAI§"
"6701";"cDMARD"
"6702";"cDMARD experience, n (%)"
"6703";"Celecoxib"
"6704";"Celecoxib (N = 318)"
"6705";"center"
"6706";"Center-Level IHR Percent Time in Therapeutic Range for Warfarin Subjects"
"6707";"Center Level TTR"
"6708";"Center location"
"6709";"Central America and South America"
"6710";"Central and Eastern Europe"
"6711";"Central and South America"
"6712";"Central and South America and Mexico"
"6713";"Central eosinophil count"
"6714";"Central eosinophil count (cells per pL)"
"6715";"Central eosinophil count (cells per pL)t"
"6716";"Central Europe"
"6717";"Central nervous system"
"6718";"Central or South America"
"6719";"Central/Eastern"
"6720";"Central/Eastern Europe and Russia HR (95% Cl)"
"6721";"Central/Eastern Europe/Russia"
"6722";"Central/South"
"6723";"Central/South America"
"6724";"Central/South America and Mexico"
"6725";"Centrally acting sympathomimetics"
"6726";"centre"
"6727";"Centrilobular emphysema"
"6728";"Cerebral"
"6729";"Cerebral embolism"
"6730";"Cerebral hemorrhage"
"6731";"Cerebral infarction"
"6732";"Cerebral ischemia"
"6733";"Cerebral thrombosis"
"6734";"Cerebral vascular disease"
"6735";"Cerebrovascuiar disease"
"6736";"Cerebrovascular"
"6737";"Cerebrovascular accident"
"6738";"Cerebrovascular accident/TIA"
"6739";"Cerebrovascular disease"
"6740";"Cerebrovascular disease n (%)"
"6741";"Cerebrovascular disease, %"
"6742";"Cerebrovascular disease, n (%)"
"6743";"Cerebrovascular disorders, n (%)"
"6744";"Cerebrovascular or peripheral arterial disease"
"6745";"Cerebrovascular or peripheral arterial disease, n (%)"
"6746";"Cerebrovascular or peripheral arterial disease, n (%)"
"6747";"Certolizumab Group"
"6748";"Certolizumab Group (N = 215)"
"6749";"Certolizumab Group (N = 331)"
"6750";"Certolizumab pegol (n = 223)"
"6751";"CFB at Week 168"
"6752";"CFB at Week 216"
"6753";"CFB at Week 96"
"6754";"cFisher's exact test."
"6755";"Cg/LD"
"6756";"cGFR, ml/min/1.73m2"
"6757";"cGFRby CKD-EPI, mL/min/1.73 m2, median (IQR)"
"6758";"CGI-S, n (%)z:"
"6759";"CGM use"
"6760";"CHA0S2 Score"
"6761";"CHA2DS2-VASc"
"6762";"CHA2DS2-VASc #4"
"6763";"CHA2DS2-VASc $2"
"6764";"CHA2DS2-VASc <4"
"6765";"CHA2DS2-VASc >2"
"6766";"CHA2DS2-VASc >4"
"6767";"CHA2DS2-VASC >5"
"6768";"CHA2DS2-VASC 0-1"
"6769";"CHA2DS2-VASC 0 1"
"6770";"CHA2DS2-VASc score"
"6771";"CHA2DS2-VASc score (median, IQR)"
"6772";"CHA2DS2-VASc score,"
"6773";"CHA2DS2-VASc score, mean±SD"
"6774";"CHA2DS2-VASc score, n (%)"
"6775";"CHA2DS2-VASc, mean±SD"
"6776";"CHA2DS2VASC score"
"6777";"CHA2DS2VASC Score"
"6778";"CHA2DS2VASc score (%)"
"6779";"CHA3DS2-VASC 2-4"
"6780";"CHAD52>3"
"6781";"CHADS-2 score"
"6782";"CHADS score, n (%)"
"6783";"chads2"
"6784";"CHADS2"
"6785";"CHADS2 risk factors, n (%)"
"6786";"CHADS2 score"
"6787";"CHADS2 Score"
"6788";"CHADS2 score >3"
"6789";"CHADS2 Score 2"
"6790";"CHADS2 score 4-6, n (%)"
"6791";"CHADS2 Score per Outcome Stroke or systemic embolism"
"6792";"CHADS2 score*"
"6793";"CHADS2 score, Mean (±SD)"
"6794";"CHADS2 score, mean±SD"
"6795";"CHADS2 score, n (%)"
"6796";"CHADS2 scoreb"
"6797";"CHADS2 scoret"
"6798";"CHADS2 score, n (%)"
"6799";"CHADS2, mean±SD"
"6800";"chads2^"
"6801";"CHADS2<3"
"6802";"CHADS2components, n (%)"
"6803";"CHADS2scoref"
"6804";"CHADSa <3"
"6805";"CHADSj <3"
"6806";"CHADSj >3"
"6807";"CHAjDSa-VASc 2-4"
"6808";"CHAjDSj-VASc >5"
"6809";"CHAjDSj-VASc 2-4"
"6810";"CHAjDSrVASc 0-1"
"6811";"Change"
"6812";"Change at week 104"
"6813";"Change From"
"6814";"Change from baseline"
"6815";"Change from baseline (%)"
"6816";"Change from baseline at week 12"
"6817";"Change from baseline at week 164"
"6818";"Change from baseline at week 26"
"6819";"Change from baseline at Week 26"
"6820";"Change from baseline at week 28"
"6821";"Change from baseline in"
"6822";"Change from Baseline in % Predicted FEV1"
"6823";"Change from baseline in ACQ-5"
"6824";"Change from baseline in ACQ-5 score"
"6825";"Change from baseline in AQLQ{S) score"
"6826";"Change from baseline in DAS28-ESR, mean6 SD"
"6827";"change from baseline in FEVj (mb)"
"6828";"Change from baseline in HbA1c (%)"
"6829";"Change from baseline in mean 24-h DBP, mmHg"
"6830";"Change from baseline in mean 24-h SBP, mmHg"
"6831";"Change from baseline in morning PEF during weeks 28-32, mean l/min (SE)"
"6832";"Change from baseline in post-BD"
"6833";"Change from baseline in pre-BD"
"6834";"Change from baseline in rescue medication use (puffs per day)"
"6835";"Change from baseline in SGRQ"
"6836";"Change from baseline Stage 3 CKD"
"6837";"Change from baseline Stage 4 CKD"
"6838";"Change from baseline to EOS, mg/dL"
"6839";"Change from baseline to EOS, uU/mL"
"6840";"Change from baseline to final APBM"
"6841";"Change from baseline to week 12 in DLQI scorez"
"6842";"Change from baseline to week 12 in UAS7"
"6843";"Change from baseline to week 12 in weekly ISS"
"6844";"Change from baseline to week 12 in weekly no. of hives score"
"6845";"Change from baseline to week 12 in weekly size of largest hive score"
"6846";"Change from baseline to week 24"
"6847";"Change from baseline*"
"6848";"Change from baseline, adjusted mean (95% CI)"
"6849";"Change from baseline, adjusted mean (95% CI), %"
"6850";"Change from baseline, median (IQR)"
"6851";"Change from baseline, mg/dL, mean(sd)"
"6852";"Change from baseline, mmHg"
"6853";"Change from pre- to"
"6854";"Change in BP, mm Hg"
"6855";"Change in DAS28-ESR (mean)i Physical function outcomes week 52"
"6856";"Change in DAS28 > 1.2"
"6857";"Change in erosion score (mean)"
"6858";"Change in femoral neck BMD from FIT baseline to FLEX baseline"
"6859";"Change in FPG 0 to month 4 (mg/dl)"
"6860";"Change in HAQ-DI (mean)t"
"6861";"Change in HbA1c 0 to month 4 (%)"
"6862";"Change In HbAlc after 18 weeks ETD (95% Cl)"
"6863";"Change In HbAlc after 26 weeks ETD (95% Cl)"
"6864";"Change in HDL‐C"
"6865";"Change in LDL‐C"
"6866";"Change in Lp(a)"
"6867";"Change in mTSS (mean)"
"6868";"Change in NT-proBNP at 12 months (log-transformed)"
"6869";"Change in NT-proBNP at 4"
"6870";"Change in NT-proBNP at 8"
"6871";"Change in PAV, Mean (95% Cl), %"
"6872";"Change in PsA‐modified SHS, baseline to week 24‡"
"6873";"Change in PsA‐modified SHS, baseline to week 52"
"6874";"Change in retinal pathology"
"6875";"Change in SBP"
"6876";"Change in SBP (12 months)"
"6877";"Change in SBP (4 months)"
"6878";"Change in SBP (8 months)"
"6879";"Change in SeDBP, LS mean (SE)"
"6880";"Change in SeSBP, LS mean (SE)"
"6881";"Change in TC"
"6882";"Change in TG"
"6883";"Change to Week 12"
"6884";"Change to Week 48*"
"6885";"Change to Week 48*’’"
"6886";"Change to Week 12"
"6887";"change, mg/dL (mmol/L)"
"6888";"Change3"
"6889";"Changes (A) in metabolic syndrome parameters HDL cholesterol"
"6890";"Changes at baseline"
"6891";"Changes from baseline in msSBP and msDBP are shown as least-squares mean SEM. *P 0.05 vs  65 y."
"6892";"Changes in serum creatinine, pmol/L"
"6893";"Changes in SHS"
"6894";"characteristic"
"6895";"Characteristic"
"6896";"CHARACTERISTIC"
"6897";"Characteristic (A)"
"6898";"Characteristic Age"
"6899";"Characteristic Age — yr"
"6900";"Characteristic Age Mean ±SD — yr"
"6901";"Characteristic and Treatment"
"6902";"Characteristic at Baseline"
"6903";"Characteristic*"
"6904";"Characteristic, No. (%)"
"6905";"Characteristic/Outcome"
"6906";"Characteristic^"
"6907";"Characteristic_level"
"6908";"Characteristic_name"
"6909";"Characteristic†"
"6910";"Characteristica"
"6911";"Characteristics"
"6912";"Characteristics No. of participants"
"6913";"Characteristics of pulmonary embolism at inclusion"
"6914";"Characteristics*"
"6915";"Characteristicsa"
"6916";"Charlson"
"6917";"Charlson comobility score, n (%)"
"6918";"Charlson comorbidity index"
"6919";"Charlson Comorbidity Index"
"6920";"Charlson comorbidity index, mean (SD)"
"6921";"Charlson index (%)"
"6922";"CHARM"
"6923";"CHD"
"6924";"CHD (nonfatal MI + fatal CHD)"
"6925";"CHD (primary outcome)"
"6926";"CHD + Cl All"
"6927";"CHD at baseline"
"6928";"CHD death"
"6929";"CHD Death"
"6930";"CHD deaths"
"6931";"CHD disease death"
"6932";"CHD EZE/SIMVA"
"6933";"CHD EZE/SIMVA („ = 240)"
"6934";"CHD EZE/SIMVA (n = 240]"
"6935";"CHD history, n (%)"
"6936";"CHD Men"
"6937";"CHD plus cerebral infarction"
"6938";"CHD Risk- no. (%)"
"6939";"CHD risk equivalents, n (%)"
"6940";"CHD risk factors#"
"6941";"CHD SIMVA"
"6942";"CHD SIMVA („ = 210)"
"6943";"CHD SIMVA 0 = 210]"
"6944";"CHD status"
"6945";"CHD status §"
"6946";"CHD*, n (%)"
"6947";"CHD, coronary heart disease; EZE/SIMVA, ezetimibe/simvastatin combination tablet; FPG, fasting plasma glucose; PVD, peripheral vascular disease;"
"6948";"CHD, n (%)"
"6949";"CHD, total"
"6950";"CHD+ cerebrovascular disease Men    71 /1248 (12.9)"
"6951";"CHD+ cerebrovascular disease Men 71 / 1248 (12.9)"
"6952";"CHD+cerebral infarction"
"6953";"CHDa"
"6954";"Chest discomfort"
"6955";"Chest x-ray"
"6956";"CHF"
"6957";"CHF (%)"
"6958";"CHF on Losartan (%)"
"6959";"CHF on Placebo (%)"
"6960";"CHF score (U)"
"6961";"Chi-square p value"
"6962";"China"
"6963";"China/Japan"
"6964";"China/tJapan"
"6965";"Chinese"
"6966";"Chinese Subgroup"
"6967";"CHL"
"6968";"Chlor"
"6969";"Chloroquine"
"6970";"Chlorthalidone"
"6971";"Chlorthalidone (N = 171)"
"6972";"Chlorthalidone 10174"
"6973";"Chlorthalidone Group"
"6974";"Chlorthalidone vs Amlodipine"
"6975";"Chlorthalidone vs Doxazosin"
"6976";"Chlorthalidone vs Lisinopril"
"6977";"Cholecystectomy (N=267)"
"6978";"Cholecystitis chronic"
"6979";"Cholesterol"
"6980";"Cholesterol- mean (sd, N)"
"6981";"Cholesterol — mg/dl"
"6982";"Cholesterol — mmol/liter"
"6983";"cholesterol (%)"
"6984";"Cholesterol (mg/dl)"
"6985";"Cholesterol (mg/dL)"
"6986";"Cholesterol (mmol/L)"
"6987";"cholesterol (ng/ml)"
"6988";"Cholesterol (nmol/L)"
"6989";"Cholesterol absorption inhibitor (ezetimibe)"
"6990";"Cholesterol, (. 5.5 mmol/L), n (%)"
"6991";"Cholesterol, mg/dL"
"6992";"Cholesterol, mg/dL Total"
"6993";"Cholesterol, mg/dl, mean (SD)§"
"6994";"Cholesterol, mmol/L"
"6995";"Cholinesterase inhibitor use at baseline, No. (%)"
"6996";"Chondroitin"
"6997";"Chondroitin Sulfate"
"6998";"Chondroitin Sulfate (N = 318)"
"6999";"Chronic bronchitis"
"7000";"Chronic bronchitis (%)"
"7001";"Chronic bronchitis (ITT) (n=1075)"
"7002";"Chronic bronchitis (ITT) (n=1088)"
"7003";"Chronic bronchitis (ITT) (n=792)"
"7004";"Chronic bronchitis (ITT) (n=800)"
"7005";"Chronic bronchitis (ITT) (n=817)"
"7006";"Chronic bronchitis (ITT) (n=824)"
"7007";"Chronic bronchitis (n=855)"
"7008";"Chronic bronchitis!"
"7009";"Chronic bronchitist"
"7010";"Chronic cardiovascular disease, no. (%)"
"7011";"Chronic COX2 inhibitors"
"7012";"Chronic CVD"
"7013";"Chronic heart failure"
"7014";"Chronic inflammatory disease"
"7015";"Chronic kidney disease"
"7016";"Chronic kidney disease (%)"
"7017";"Chronic kidney disease stage: eGFR (ml/min per 1.73 m2)"
"7018";"Chronic kidney disease, n (%)"
"7019";"Chronic kidney disease, no. (%)t"
"7020";"Chronic kidney disease†"
"7021";"Chronic kidney diseased"
"7022";"Chronic non-steroidal antiinflammatory drugs"
"7023";"Chronic obstructive lung disease"
"7024";"Chronic obstructive pulmonary"
"7025";"Chronic obstructive pulmonary disease"
"7026";"Chronic obstructive pulmonary disease—No. (%)"
"7027";"Chronic obstructive pulmonary disease, n (%)"
"7028";"Chronic pulmonary disease"
"7029";"Chronic renal disease"
"7030";"Chronic renal disease—No. (%)"
"7031";"Chronic renal failure"
"7032";"Chronic renal failure, n (%)"
"7033";"Chronic renal insufficiency"
"7034";"Chronic renal insufficiency, %"
"7035";"Chronic respiratory failure"
"7036";"Chronic sinusitis + nasal polypsd, n (%)"
"7037";"Chronic stable angina"
"7038";"Chronic treatment with aspirin"
"7039";"Chylomicron cholesterol"
"7040";"Chylomicron triglycerides"
"7041";"CI-AKI risk score"
"7042";"CI = confidence interval; NA = not applicable or not analyzed."
"7043";"CI, confidence interval; ESRD, end-stage renal disease; n/N, number of patients who had an event/total number of patients. aAdjusted with terms including treatment (losartan or placebo), geographic region, genotype, and the treatment  genotype interaction. bP value for treatment  genotype interaction (i.e., comparison of the losartan treatment effect between the 3 genotype groups)."
"7044";"Ciass i"
"7045";"Ciass ll-IV"
"7046";"Cigarette-smoking status — no. (%)"
"7047";"Cigarette-smoking status (%)"
"7048";"Cigarette smoker"
"7049";"Cigarette smoker*"
"7050";"Cigarette smoker, No. (%)"
"7051";"Cigarette smoking"
"7052";"Cigarette Smoking in the past year"
"7053";"Cigarette smoking status"
"7054";"Cigarette smoking, mean pack-years (SD)"
"7055";"Cigarette smoking, n (%)"
"7056";"Cigarette users"
"7057";"Cigarettesmoking,%"
"7058";"Cilostazol"
"7059";"Circumflex"
"7060";"CK-MB, ng/ml"
"7061";"CK > 10 x ULN1"
"7062";"CK > 5 x ULN1"
"7063";"CK>10xULN"
"7064";"CK>5xULN"
"7065";"CKD"
"7066";"CKD (eGFR < 60b)"
"7067";"CKD (eGFR<60), n (%)"
"7068";"CKD N"
"7069";"CKD prognosis by KDIGO''"
"7070";"CKD Rate (#events)"
"7071";"CKD Stage 1"
"7072";"CKD Stage 1 (%)"
"7073";"CKD Stage 2"
"7074";"CKD Stage 2 (%)"
"7075";"CKD Stage 3"
"7076";"CKD Stage 3 (%)"
"7077";"CKD stages"
"7078";"CKD*"
"7079";"CKD, n (%)t"
"7080";"CKDC, n (%)"
"7081";"Cl-3]"
"7082";"Cl-7]"
"7083";"Cl-8]"
"7084";"Cl-9]"
"7085";"Cl 95%"
"7086";"Class >11"
"7087";"Class >II"
"7088";"Class 1"
"7089";"Class 1 antiarrhythmic agents"
"7090";"Class 1 or no symptoms"
"7091";"Class 111"
"7092";"Class I"
"7093";"Class I or III AAD use in 12 months before enrollment"
"7094";"Class I or no symptoms"
"7095";"Class IA"
"7096";"Class IB"
"7097";"Class IC"
"7098";"Class II"
"7099";"Class II (b-blockers)"
"7100";"Class III"
"7101";"Class III/III - V"
"7102";"Class IV"
"7103";"Class IV glomerulonephritis"
"7104";"Class IV only"
"7105";"Class IV/IV - V"
"7106";"Class l/ll heart failure"
"7107";"Class ll-IV"
"7108";"Class V only"
"7109";"Classification of AF, No. (%)"
"7110";"Classification of epilepsy type, n (%)"
"7111";"Classification of index venous thromboembolism — no. (%)"
"7112";"Claudication"
"7113";"Claudication (Fontaine class > 1)"
"7114";"Claudication (Fontaine class >1)"
"7115";"Claudication only"
"7116";"Clavicle fracture"
"7117";"CLD 25 mg"
"7118";"CLD 25 mg (n=l84)"
"7119";"Clean, n (%)a"
"7120";"Clinic research experience, n (%)"
"7121";"Clinical"
"7122";"Clinical AE, n (%}"
"7123";"Clinical and laboratory measurements"
"7124";"Clinical and patient-reported characteristics at baseline and randomization"
"7125";"Clinical and patient reported outcomes, % (observed n) unless otherwise indicated"
"7126";"Clinical atherosclerotic disease*"
"7127";"Clinical characteristics"
"7128";"Clinical characteristics (%)"
"7129";"Clinical characteristics, n (%)"
"7130";"Clinical COPD phenotype^"
"7131";"Clinical criteria3"
"7132";"Clinical Dementia Rating sum of boxes, mean (SD)f"
"7133";"Clinical details"
"7134";"Clinical disease activity index"
"7135";"Clinical Disease Activity Index score (0-76)"
"7136";"Clinical efficacy at week 100"
"7137";"Clinical Endpoint"
"7138";"Clinical features of HF"
"7139";"Clinical fracture"
"7140";"Clinical history"
"7141";"Clinical history— no. (%)"
"7142";"Clinical history — no. (%)"
"7143";"Clinical history, n (%)"
"7144";"Clinical history, no. (%)"
"7145";"Clinical indication at the index procedure, n (%)"
"7146";"Clinical or Lesion RF for ST"
"7147";"clinical outcome"
"7148";"Clinical presentation"
"7149";"Clinical presentation of VTE at initial diagnosis — no. (%)"
"7150";"Clinical remissione"
"7151";"Clinical responsed"
"7152";"Clinical variables, median (IQR)"
"7153";"Clinically relevant non"
"7154";"Clonic"
"7155";"Clopidogrel"
"7156";"Clopidogrel %"
"7157";"Clopidogrel (N = 10,151)"
"7158";"Clopidogrel (N = 2549)"
"7159";"Clopidogrel (N = 3935)"
"7160";"Clopidogrel (n = 425)"
"7161";"Clopidogrel (N = 4444)"
"7162";"Clopidogrel (N = 509)"
"7163";"Clopidogrel (N = 5470)"
"7164";"Clopidogrel (N = 570)"
"7165";"Clopidogrel (n = 6604)"
"7166";"Clopidogrel (n = 864)"
"7167";"Clopidogrel (N=1493)"
"7168";"Clopidogrel (N=1493) n/N (%)"
"7169";"Clopidogrel (N=1509) n/N (%)"
"7170";"Clopidogrel (N=17)"
"7171";"Clopidogrel (N=1752)"
"7172";"Clopidogrel (n=22 961)"
"7173";"Clopidogrel (N=3977)"
"7174";"Clopidogrel (N=3977) n/N (%)"
"7175";"Clopidogrel (N=4018) n/N (%)"
"7176";"Clopidogrel (N=5453)"
"7177";"Clopidogrel /total no. of patients%%"
"7178";"Clopidogrel dose"
"7179";"Clopidogrel dose on/ before PCI"
"7180";"Clopidogrel Dyspnoea vs No dyspnoea*"
"7181";"Clopidogrel given before procedure"
"7182";"Clopidogrel loading dose 300 mg"
"7183";"Clopidogrel loading dose 600 mg"
"7184";"Clopidogrel n/N (%)"
"7185";"Clopidogrel n/N {%)"
"7186";"Clopidogrel no. of patients%)"
"7187";"Clopidogrel or ticlopidine"
"7188";"Clopidogrel plus Aspirin"
"7189";"Clopidogrel plus Aspirin %/yr"
"7190";"Clopidogrel plus Aspirin (N = 3772)"
"7191";"Clopidogrel Plus Aspirin (n=174)"
"7192";"Clopidogrel Pretreatment Duration"
"7193";"Clopidogrel, %"
"7194";"Clopidogrel, 300-mg loading dose"
"7195";"Clopidogrel, 300 mg loading dose!"
"7196";"Clopidogrel, 300 mg loading doset"
"7197";"Clopidogrel, 300 mg*"
"7198";"Clopidogrel, 600-mg loading dose"
"7199";"Clopidogrel, 600 mg loading dose!"
"7200";"Clopidogrel, 600 mg loading doset"
"7201";"Clopidogrel, 600 mg*"
"7202";"Clopidogrel, ticlopidine, or prasugrel"
"7203";"Clopidogrel/ticlopidine"
"7204";"Clopidogrel+Aspirin (n=2531)"
"7205";"Clopiodogrel"
"7206";"Closure"
"7207";"cLow-potency stratum: simvastatin 20mg, pravastatin 40 mg, fluvastatin 80 mg,atorvastatin 10 mg; high-potency stratum: simvastatin 40 mg, atorvastatin"
"7208";"Cluster 1: diuretic (N=454)"
"7209";"Cluster 2: reversible, no diuretic (N=756)"
"7210";"Cluster 3: not reversible, no diuretic (N=333)"
"7211";"Cluster seizures"
"7212";"CM"
"7213";"cMann Whitney U test/Wilcoxon Sum Rank test."
"7214";"CMH RR (95% CI)"
"7215";"CNS systemic embolism"
"7216";"Co-morbidities"
"7217";"Co-morbidities, n (%)"
"7218";"Co-morbidities,a n (%)"
"7219";"CochraneManteleHaenszel (repeated 97.5% CI)c"
"7220";"Coefficient"
"7221";"Coenzyme Q10"
"7222";"Coenzyme Q10 p,g/ml#"
"7223";"Coenzyme Q10, ^g/ml#"
"7224";"Coexisting conditions"
"7225";"Coexisting conditions — no. (%)"
"7226";"Cognitive"
"7227";"Cognitive subscale on Alzheimer's Disease Assessment Scale, mean (SD)e"
"7228";"Cohort"
"7229";"Cohort 1 (N = 225)f"
"7230";"Cohort 1 (uACR <22.5 mg/g)"
"7231";"Cohort 2 (N = 521)"
"7232";"Cohort 2 (uACR >22.5 mg/g)"
"7233";"Coiticosieroids at baseline"
"7234";"Colchicine (n = 179)"
"7235";"Colectomy (partial or total)"
"7236";"Colesevelam (n = 77)"
"7237";"Colesevelam Hydrochloride Group (n=159)"
"7238";"College degree or higher"
"7239";"College graduate or more"
"7240";"Colombia"
"7241";"Colon"
"7242";"Colon' SES-CD score, mean (SD)"
"7243";"Colon only"
"7244";"Colon only,' n (%)"
"7245";"Colon only, n (%)"
"7246";"Colon or rectum"
"7247";"Colonic area involved"
"7248";"Colonoscopy"
"7249";"Colorectal cancer"
"7250";"Combination"
"7251";"Combination-Facilitated PCI (%)"
"7252";"Combination-Facilitated PCI (N = 828)"
"7253";"Combination (n = 107)"
"7254";"Combination Therapy (N = 169)"
"7255";"Combination therapy**"
"7256";"combination therapy, n=4121"
"7257";"Combination treatment IFX + AZA"
"7258";"Combinationf"
"7259";"Combinations of aspirin and PPI use (p=0.63t)"
"7260";"Combined"
"7261";"Combined (dutasteride/ta msu losi n)"
"7262";"Combined (N = 746)"
"7263";"Combined cardiac failure, cardiomyopathy or other cardiac disorder, n (%) LUTS severity, n (%)"
"7264";"Combined cardiac failure, cardiomyopathy or other cardiac disorders"
"7265";"Combined CHD"
"7266";"Combined CVD"
"7267";"Combined End Point"
"7268";"Combined end points"
"7269";"Combined End Poir"
"7270";"Combined estimated GFR and albuminuria status"
"7271";"Combined fatal/nonfatal outcomes"
"7272";"Combined golimumab groups"
"7273";"Combined Infliximab"
"7274";"Combined insulin/oral hypoglycaemic agent use"
"7275";"Combined ischaemic heart disease and/or cerebrovascular disorder*"
"7276";"Combined macro+micro"
"7277";"Combined major macrovascular events, neohroDathv. and all-cause mortalitv    ■"
"7278";"Combined major macrovascular events."
"7279";"Combined n=1287"
"7280";"Combined statin and other lipid-lowering agent use"
"7281";"Combined therapy (/V= 1610), 0/0"
"7282";"Combined therapy vsdutasteride"
"7283";"Combined therapy vsta msu Iosin"
"7284";"Combined Trials"
"7285";"Combo-Facilitated PCI"
"7286";"Combo vs. Primary"
"7287";"Commercially available fondaparinux"
"7288";"Common carotid artery sites"
"7289";"Common study baseline"
"7290";"Community hospital"
"7291";"Community hospital (%)"
"7292";"Community hospital, n (%)"
"7293";"Comorbid conditionsb"
"7294";"Comorbid Diseasesa Diabetesb"
"7295";"Comorbid illnesses"
"7296";"Comorbidites, n (%)"
"7297";"Comorbidities"
"7298";"Comorbidities (%)"
"7299";"Comorbidities and concomitant medications"
"7300";"Comorbidities other than diabetes"
"7301";"Comorbidities, %"
"7302";"Comorbidities, n (%)a"
"7303";"Comorbidities, no. (%)"
"7304";"Comorbidities/concomitant medications"
"7305";"Comorbidity, no. (%)"
"7306";"Companion: 5-6 hours"
"7307";"Companion: Wake-Up Stroke"
"7308";"Comparator"
"7309";"comparison"
"7310";"Comparison"
"7311";"comparison with baseline"
"7312";"Comparison with baseline"
"7313";"Comparison with baseline (mean"
"7314";"comparison with placebo"
"7315";"Comparison with placebo"
"7316";"Comparison with placebo (mean"
"7317";"Comparison: Cat. 2 vs. Cat. 1"
"7318";"Complete healinga"
"7319";"Complete Mayo Clinic Score, median (min, max}"
"7320";"Completed Previous Febuxostat Study"
"7321";"Completed Prior Febuxostat Studya"
"7322";"Completed trial"
"7323";"Complex Anatomy (n - 3,730)"
"7324";"Complex lesions^"
"7325";"Complex partial (IB)"
"7326";"component. For all instruments, higher scores indicate more severe disease. ARA denotes American Rheumatism Association (now called"
"7327";"Components"
"7328";"Components of Primary Composite End Point—Secondary End Points"
"7329";"Components of the first CID"
"7330";"Composite"
"7331";"Composite endpoint"
"7332";"Composite endpoint (A1C <7.0%, BP"
"7333";"Composite endpoint of doubling of serum creatinine, ESRD,"
"7334";"Composite events"
"7335";"Composite Index of Insulin Sensitivity (ISI)"
"7336";"Composite microvascular end point*"
"7337";"Composite ocular end point^"
"7338";"Composite of 40% reduction in eGFR, end-stage kidney disease, or death from renal causes"
"7339";"Composite of Death/MI/Stro ke/Urgent Revasc/Definit e Acute Stent Thrombosis"
"7340";"Composite of Death/MI/Urg ent Revasc"
"7341";"Composite of doubling of serum creatinine, end-stage kidney disease, or death from renal causes"
"7342";"Composite physiologic index§"
"7343";"Composite vascular endpoint"
"7344";"Compression stockings"
"7345";"Computed tomographic angiography"
"7346";"concentrations at baseline"
"7347";"Concern"
"7348";"Concomitant"
"7349";"Concomitant AEDs, n (%)"
"7350";"Concomitant AEDsa"
"7351";"Concomitant AEDsb, n (%)"
"7352";"Concomitant AEDsb, n (%)"
"7353";"Concomitant aminosalicylates, N [%] Concomitant corticosteroids, N [%] Mayo score, mean [SD]"
"7354";"Concomitant antibiotic use, n [%]"
"7355";"Concomitant anticoagulant, antithrombotic or NSAID, n (%)"
"7356";"Concomitant antihyperglycaemic drugs, n (%)"
"7357";"Concomitant Antiplatelet"
"7358";"Concomitant Aspirin Use"
"7359";"Concomitant asthma medications, n (%)"
"7360";"Concomitant atorvastatin dose, mg"
"7361";"Concomitant cardiovascular therapies — no. (%)"
"7362";"Concomitant cardiovascular therapy"
"7363";"Concomitant cardiovascular therapy — no. (%)"
"7364";"Concomitant cardiovascular therapy (taken >30 days)"
"7365";"Concomitant conventional DMARD use"
"7366";"concomitant corticosteroid use"
"7367";"Concomitant corticosteroid use, n (%)"
"7368";"Concomitant csDMARDs other than methotrexate, n (%)"
"7369";"Concomitant drug therapies, n (%)"
"7370";"Concomitant drug therapy at discharge"
"7371";"Concomitant drug treatment"
"7372";"Concomitant drugs"
"7373";"Concomitant drugs, %"
"7374";"Concomitant DVT — no. (%) Baseline NT-proBNP — no. (%)"
"7375";"Concomitant DVT, n (%)"
"7376";"Concomitant immunosuppressive and/or prior anti-TNF use"
"7377";"Concomitant lipid-lowering therapy (any)"
"7378";"Concomitant lipid-lowering therapy, n (%)"
"7379";"Concomitant lipid-modifying therapy — no. {%)"
"7380";"Concomitant medication"
"7381";"Concomitant medication — no. (%)"
"7382";"Concomitant medication — no. {%) | ACE inhibitor"
"7383";"Concomitant medication (%)"
"7384";"Concomitant medication (>10%)"
"7385";"Concomitant medication after randomisation"
"7386";"Concomitant medication use"
"7387";"Concomitant medication, n (%)"
"7388";"Concomitant medication, n (%)d"
"7389";"Concomitant medication, n [%]"
"7390";"Concomitant medication, no. (%)"
"7391";"Concomitant medication||"
"7392";"Concomitant medications"
"7393";"Concomitant medications — no. (%)"
"7394";"Concomitant medications (%)"
"7395";"Concomitant medications (yes), n (%}"
"7396";"Concomitant medications after randomization"
"7397";"Concomitant medications at baseline"
"7398";"Concomitant medications for ulcerative colitis — no. (%)"
"7399";"Concomitant medications in >10% of subjects, No. (%)"
"7400";"Concomitant medications, n (%)"
"7401";"Concomitant medications, no. (%)"
"7402";"Concomitant medications,* n (%)"
"7403";"Concomitant methotrexate use, n (%)"
"7404";"Concomitant methotrexate, n (%)"
"7405";"Concomitant MTX—"
"7406";"Concomitant MTX use, n (%)"
"7407";"Concomitant OADs, n (%)"
"7408";"Concomitant oral anti-DM drugs, No. (%)a"
"7409";"Concomitant oral corticosteroids, n (%)**"
"7410";"Concomitant oral glucose-lowering agents, zz (%)"
"7411";"Concomitant PD medications at baseline, n (%)c,d"
"7412";"Concomitant therapies at hospital discharge"
"7413";"Concomitant therapies n (%)"
"7414";"Concomitant therapy"
"7415";"Concomitant therapy, n [%]"
"7416";"Concomitant therapy, no. (%)"
"7417";"Concomitant treatment"
"7418";"Concomitant treatment 一 no. (%)"
"7419";"Concomitant treatments at randomization"
"7420";"Concomitant use of bosentan, n (%)"
"7421";"Concomitant use of conventional synthetic DMARD up to 3 mo — no. {%) Methotrexate"
"7422";"Concomitant use of corticosteroids"
"7423";"Concomitant use of MTX to Week 96"
"7424";"Concomitant Use of NSAIDs to Week 96"
"7425";"Concordant stress test abnormalities"
"7426";"Concurrent illness"
"7427";"Concurrent medications"
"7428";"Concurrent prednisolone"
"7429";"Concurrent treatment at study entry — no. (%)**"
"7430";"Concurrent treatment of Crohn's disease at study entry — no. of patients (%)ff"
"7431";"Condition 3622 (32.1)"
"7432";"Congenital heart disease"
"7433";"congenital shunts"
"7434";"Congestion*"
"7435";"Congestive Heart"
"7436";"Congestive heart failure"
"7437";"Congestive Heart Failure"
"7438";"Congestive heart failure— no. (%)"
"7439";"Congestive heart failure—No. (%)"
"7440";"Congestive heart failure — %"
"7441";"Congestive heart failure — no. (%)"
"7442";"Congestive heart failure — no. (%)|"
"7443";"Congestive heart failure — no. (%)||"
"7444";"Congestive heart failure (<6 wk)"
"7445";"Congestive heart failure (CHF) (in past 6 weeks)"
"7446";"Congestive heart failure (definite)"
"7447";"Congestive heart failure at randomisation"
"7448";"Congestive heart failure, n (%)"
"7449";"Congestive heart failure§"
"7450";"Congestive heart failure†"
"7451";"Congestive HF"
"7452";"Conieosieroids and/or 6-MP"
"7453";"Connective-tissue disease"
"7454";"Connective tissue disease"
"7455";"Conservative"
"7456";"Conservative strategy (n = 3,116)"
"7457";"Consistency of effect"
"7458";"Constipation"
"7459";"Constitutional"
"7460";"Continuation"
"7461";"Continuation (n=635)"
"7462";"Continue Thienopyridine N=2715"
"7463";"Continue Thienopyridine N=3147"
"7464";"Continued Thienopyridine %"
"7465";"Continued thienopyridine (n 5 5862)"
"7466";"Continued Thienopyridine (n=1737)"
"7467";"Continued Thienopyridine (N=5862)"
"7468";"Continued Thienopyridine N (%)"
"7469";"Continued Thienopyridine N=5020 Subjects"
"7470";"Continued Treatment Study"
"7471";"Continued use of GPA"
"7472";"Continued Use of GPA"
"7473";"Continuous"
"7474";"Continuous LVEF 3 treatment interaction"
"7475";"Continuous variables, mean (SD)"
"7476";"Continuous variables, mean (SD)^"
"7477";"Contrast angiography"
"7478";"Contrast nephropathy risk score"
"7479";"Contrast used (ml)*"
"7480";"Contrast volume"
"7481";"Contrast volume (ml)"
"7482";"Contrast volume >140 (ml)"
"7483";"Contrast volume >140 ml"
"7484";"Contrast volume, ml"
"7485";"control"
"7486";"Control"
"7487";"Control (n - 252)"
"7488";"Control (n = 150)"
"7489";"Control (n = 252)"
"7490";"Control (N = 265)"
"7491";"Control (N = 495)"
"7492";"Control (n = 569)"
"7493";"Control (n=1331)"
"7494";"Control (n=1355)"
"7495";"Control (n=271)"
"7496";"Control (n=9319)"
"7497";"Control (nZ2222)"
"7498";"Control (nZ784)"
"7499";"Control = Warfarin"
"7500";"Control 12 Months (n - 131)"
"7501";"Control Baseline (n - 150)"
"7502";"Control group"
"7503";"Control group (n = 203)"
"7504";"Control group (n=244)"
"7505";"Control group (n=442)"
"7506";"Control group (N=7988)"
"7507";"Control n = 1336"
"7508";"Control n = 558"
"7509";"Control n = 785"
"7510";"Control n =785"
"7511";"Controlld"
"7512";"Controlled"
"7513";"Controlled: ACQ-6 <1.5"
"7514";"Controlled11—no. (%)"
"7515";"Controllertreatment before entry*"
"7516";"Controls (n=1649)"
"7517";"Controls (n=9319)"
"7518";"Contusion"
"7519";"Conventional agents*"
"7520";"Conventional synthetic DMARD use at baseline"
"7521";"Conventional treatment"
"7522";"Conversion to sinus rhythm in <5 days"
"7523";"converting enzyme inhibitor"
"7524";"Convulsion"
"7525";"COPD"
"7526";"COPD-placebo (522 pt) N. (%)"
"7527";"COPD-placebo (N = 522)"
"7528";"COPD-rosuvastatin (538 pt) N. (%)"
"7529";"COPD-rosuvastatin (N = 538)"
"7530";"COPD —no. (%) Medication use"
"7531";"COPD (%)"
"7532";"COPD (N = 1060)"
"7533";"COPD assessment test (CAT) score"
"7534";"COPD disease severity"
"7535";"COPD duration, mean (SD), yr*"
"7536";"COPD exacerbation history in the previous year, n (%)"
"7537";"COPD exacerbation history, n (%)"
"7538";"COPD Exacerbation History, n (%)"
"7539";"COPD exacerbation: no"
"7540";"COPD exacerbation: yes"
"7541";"COPD exacerbations during the previous year"
"7542";"COPD history yrs"
"7543";"COPD medication at study entry"
"7544";"COPD medication taken for at least 2 months before st"
"7545";"COPD medication taken for at least 2 months before study entry"
"7546";"COPD or asthma"
"7547";"COPD or asthma, (%)"
"7548";"COPD severity"
"7549";"COPD severity (GOLD 20087)"
"7550";"COPD severity stage (GOLD)"
"7551";"COPD severity, %"
"7552";"COPD severity, n (%)"
"7553";"COPD severity, n (%)*"
"7554";"COPD severity, n (%)a"
"7555";"COPD severity: mild/moderate"
"7556";"COPD severity: severe/very severe"
"7557";"COPD severitya, n (%)"
"7558";"COPD severityy"
"7559";"COPD type"
"7560";"COPD worsening"
"7561";"COPD, n (%)"
"7562";"Coping"
"7563";"Cor Revasc"
"7564";"Core Cardiovascular Endpoint"
"7565";"Core laboratory percent stenosis"
"7566";"Core study to first infusion"
"7567";"Corneii product, mm-ms"
"7568";"Cornell index, pV"
"7569";"Cornell voltage-duration product (mmxmsec)*"
"7570";"Cornell voltage-duration product, mm × ms"
"7571";"Cornell voltage-duration product, mm x ms"
"7572";"Cornell voltage duration (mV×ms)"
"7573";"Cornell voltage x duration product, mm x ms"
"7574";"Coronaiy artery disease"
"7575";"Coronar y-artery bypass grafting"
"7576";"Coronar y artery disease"
"7577";"Coronarv arterv disease"
"7578";"Coronary"
"7579";"coronary-artery bypass grafting"
"7580";"Coronary-artery bypass grafting"
"7581";"Coronary-artery bypass grafting§"
"7582";"Coronary angiography"
"7583";"Coronary Angiography"
"7584";"Coronary angiography — no. (%)"
"7585";"Coronary angiography and intervention"
"7586";"Coronary angiography during the index hospital stay"
"7587";"Coronary angiography during the index hospitalization"
"7588";"Coronary angioplasty or stenting"
"7589";"Coronary artery"
"7590";"Coronary artery bypass"
"7591";"Coronary artery bypass graft"
"7592";"Coronary artery bypass graft—No. (%)"
"7593";"Coronary artery bypass graft, n (%)"
"7594";"Coronary artery bypass grafting"
"7595";"Coronary artery bypass grafting N (%)"
"7596";"Coronary artery bypass surgery"
"7597";"Coronary artery disease"
"7598";"Coronary Artery Disease"
"7599";"Coronary artery disease — %"
"7600";"Coronary artery disease — no. (%)"
"7601";"Coronary artery disease — no. (%):!:"
"7602";"Coronary artery disease — no. (%):c"
"7603";"Coronary artery disease — no./total no. (%)"
"7604";"Coronary artery disease (%)"
"7605";"Coronary artery disease (n=21 102)"
"7606";"Coronary Artery Disease History"
"7607";"Coronary artery disease*"
"7608";"Coronary artery disease, %"
"7609";"Coronary artery disease, n (%)"
"7610";"Coronary artery disease, n (%)"
"7611";"Coronary artery disease^"
"7612";"Coronary artery disease§"
"7613";"coronary artery Osteochondrosis"
"7614";"Coronary artery stenosis >50%"
"7615";"Coronary artery treated, no. (%)"
"7616";"Coronary bypass graft"
"7617";"Coronary bypass surgery"
"7618";"Coronary bypass, n (%)"
"7619";"Coronary disease"
"7620";"Coronary end point"
"7621";"Coronary Endpoint"
"7622";"Coronary events5"
"7623";"Coronary heart disease"
"7624";"Coronary heart disease — no. (%)"
"7625";"Coronary heart disease (%)"
"7626";"Coronary heart disease death"
"7627";"Coronary heart disease risk equivalents, n (%)c"
"7628";"coronary heart disease, n (%) Cardiovascular risk (per protocol), n (%) Very high"
"7629";"Coronary heart disease, n (%) t"
"7630";"Coronary heart disease, n (%)b"
"7631";"Coronary procedure (% of group)"
"7632";"Coronary revascularisation"
"7633";"Coronary revascularisation§"
"7634";"Coronary revascularization"
"7635";"Coronary revascularization 230 days after randomization"
"7636";"coronary revascularization procedure"
"7637";"Coronary revascularization procedure"
"7638";"Coronary risk factors — no. (%)"
"7639";"coronary syndrome. CI = confidence interval; HR = hazard ratio."
"7640";"Cortical only"
"7641";"Corticosteroid"
"7642";"Corticosteroid-free remissioni"
"7643";"Corticosteroid - azathioprine/6-mercaptopurine"
"7644";"Corticosteroid (with or without immunosuppressants)"
"7645";"Corticosteroid (without IMM)"
"7646";"Corticosteroid (without IMM), N"
"7647";"Corticosteroid + IMM"
"7648";"Corticosteroid and immunosuppressant"
"7649";"Corticosteroid dose (prednisone"
"7650";"Corticosteroid or azathioprine/6-mercaptopurine"
"7651";"Corticosteroid or immunosuppressant"
"7652";"Corticosteroid use"
"7653";"Corticosteroid Use"
"7654";"Corticosteroid use at baseline"
"7655";"Corticosteroid use at baseline-No"
"7656";"Corticosteroid use at baseline-Yes"
"7657";"Corticosteroid use at randomization"
"7658";"Corticosteroid use at randomization, n (%)"
"7659";"Corticosteroid use, %"
"7660";"Corticosteroid use, n (%)"
"7661";"Corticosteroid use,11 n (%)"
"7662";"Corticosteroids"
"7663";"Corticosteroids'1"
"7664";"Corticosteroids (excluding budesonide)"
"7665";"Corticosteroids and antimalarials only"
"7666";"Corticosteroids and immunosuppressants"
"7667";"Corticosteroids and immunosuppressants only"
"7668";"Corticosteroids only"
"7669";"Corticosteroids. immunosuppressants. and antimalarials"
"7670";"corticosteroidsa"
"7671";"Corticosteroidsa"
"7672";"CortteosteroM relrsclory status"
"7673";"Cough"
"7674";"Cough (investigator reported)"
"7675";"Cough (leading to study drug discontinuation)"
"7676";"Cough, n (%)"
"7677";"Coumadin"
"7678";"Country"
"7679";"Country, n (%)"
"7680";"Country: Argentina (n=342)"
"7681";"Covariate"
"7682";"Covariates"
"7683";"COX-2 selective inhibitor use"
"7684";"COX-2 selective NSAID"
"7685";"COX-2 selective NSAID use"
"7686";"Cox bsl onlyc"
"7687";"Cox bsl+Yr 1 Hbd"
"7688";"Cox HR (95% CI)"
"7689";"CPK > 10 times ULN"
"7690";"CR + CRPnorr"
"7691";"CR + MH"
"7692";"CR + MH + CRPnorr"
"7693";"CR imputation (Random.) (n=1613)"
"7694";"CR imputation (Random.) (n=1616)"
"7695";"CR imputation (Random.) (n=2153)"
"7696";"CrCb- (ml/min), mean (s.e.)"
"7697";"CrCI>50"
"7698";"CrCI>60-<90"
"7699";"CrCI>90"
"7700";"CrCl (ml/min)"
"7701";"CrCl (mL/min)"
"7702";"CrCl (mL/min) at randomization"
"7703";"CrCL (SD) mL/min"
"7704";"CrCl < 60"
"7705";"CrCl < 60 mL/min"
"7706";"CrCl <50 ml/min"
"7707";"CrCl <50 mL/min"
"7708";"CrCl <50ml/min"
"7709";"CrCl > 30-< 50mL/min"
"7710";"CrCl >50 ml/min"
"7711";"CrCl >50ml/min"
"7712";"CrCl 30-50"
"7713";"CrCl at baseline <60 ml/min"
"7714";"CrCl at baseline, mL/min"
"7715";"CrCl at randomization - mL/min"
"7716";"CrCl at randomization, ml/min"
"7717";"CrCl of 30-50 mL min ', n (%)"
"7718";"CrCl, mean, mL/min (± SD)"
"7719";"CrCl, median (IQR), mL/min"
"7720";"CrCl, mL/min"
"7721";"CrCL, mL/min Mean (SD)"
"7722";"Creat Clearance <30 ml/min"
"7723";"Creat Clearance >30 ml/min"
"7724";"Creatine clearance category"
"7725";"Creatine clearance category 0 to <30 mL/min    0/0"
"7726";"Creatine clearance, ml/min"
"7727";"Creatinine"
"7728";"creatinine — mg/dl"
"7729";"Creatinine — mg/dl"
"7730";"Creatinine — mg/dl Urinary albumin-to-creatinine ratio§"
"7731";"Creatinine (^mol/L) (median, IQR)"
"7732";"Creatinine (µmol/l)"
"7733";"Creatinine (mg/dL)"
"7734";"Creatinine (mg/dL), mean (SD)"
"7735";"Creatinine (p,mol/L)"
"7736";"Creatinine ≥3.0 mg/dL"
"7737";"Creatinine >1.5x baseline and above ULN"
"7738";"Creatinine >2 x baseline"
"7739";"Creatinine 1.7 mg/dl Medications"
"7740";"Creatinine ciearance"
"7741";"Creatinine clearance"
"7742";"Creatinine Clearance"
"7743";"Creatinine clearance — ml/min"
"7744";"Creatinine clearance — no. (%)"
"7745";"Creatinine clearance (ml/min)"
"7746";"Creatinine clearance (mL/min)"
"7747";"Creatinine clearance (mL/min), mean±SD"
"7748";"Creatinine clearance <30 mL/min"
"7749";"Creatinine clearance <50 ml/min"
"7750";"Creatinine clearance <50 ml/min — no. (%) Weight <60 kg — no. (%)"
"7751";"Creatinine clearance <60 ml/min"
"7752";"Creatinine clearance <60 mL/min"
"7753";"Creatinine clearance <60 mL/min (%)"
"7754";"Creatinine clearance <60 mL/min, No./total (%)"
"7755";"Creatinine clearance >30 to <50 ml/ min — no. (%)f"
"7756";"Creatinine clearance at admission (mL/min)"
"7757";"Creatinine Clearance at Randomization"
"7758";"Creatinine Clearance at Randomization (IXRS)"
"7759";"Creatinine clearance by C-G (mL/min)"
"7760";"Creatinine Clearance category [ml/min]"
"7761";"Creatinine clearance category, mL/min, No. (%)b"
"7762";"Creatinine clearance, mL/min"
"7763";"Creatinine clearance, ml/min-1*"
"7764";"Creatinine clearance, n (%)"
"7765";"Creatinine clearance, no. (%)"
"7766";"Creatinine clearance，::60 ml/min, %"
"7767";"Creatinine clearance,an (%)"
"7768";"Creatinine clearanceb, mL/min"
"7769";"Creatinine level"
"7770";"Creatinine ratio"
"7771";"creatinine ratio 30-300"
"7772";"Creatinine, mean (SD), mg/dL"
"7773";"Creatinine, mg/dL"
"7774";"Creatinine, mg/dL (SD)"
"7775";"Creatinine, mg/dL, mean"
"7776";"Creatinine, mg/dl_"
"7777";"Creatinine, mmol八"
"7778";"Creatinine, pmol/l"
"7779";"Creatinine, pmol/L"
"7780";"Criteria for subcortical VaD (by MRI), %"
"7781";"Criterion"
"7782";"Criterion reached first, n (%)"
"7783";"Critical site"
"7784";"CRj"
"7785";"Crohn's disease"
"7786";"Crohn's disease-related medication at baseline, n (%)"
"7787";"Crohn's Disease Activity Index score]"
"7788";"Crohn's disease duration"
"7789";"Crohn’s disease related surgery"
"7790";"Cromoglicate"
"7791";"Cross-clamp"
"7792";"Cross-damp time: <l:llhrs:min (n=724)"
"7793";"cRosuvastatin + fenofibric acid vs. rosuvastatin monotherapy."
"7794";"CRP"
"7795";"CRP—mg/L"
"7796";"CRP — mg/liter^"
"7797";"CRP $10 mg/l, N"
"7798";"CRP (mg/dl)"
"7799";"CRP (mg/dL)"
"7800";"CRP (mg/dl) <1.7"
"7801";"CRP (mg/dL)**"
"7802";"CRP (mg/dl; per unit)"
"7803";"CRP (mg/L)"
"7804";"CRP (mg/L) (CV)"
"7805";"CRP (mg/L) [b], median (min - max)"
"7806";"CRP (mg/L), mean (SD)"
"7807";"CRP (mg/L), median (min, max)"
"7808";"CRP (mg/L), median ± SD"
"7809";"CRP (mg/L), n"
"7810";"CRP (mg/L): <10"
"7811";"CRP (ng/ml)"
"7812";"CRP (normal <1.0 mg/dL)"
"7813";"CRP (normal range: 0-0.5), mg/dL, mean (SD)"
"7814";"CRP [mg/L], median"
"7815";"CRP <10 mg/l, N"
"7816";"CRP >0.8 mg/dL, n (%)"
"7817";"CRP >10 mg/1, n [%]"
"7818";"CRP concentration >1.0 mg/dl (10 mg/l), n (%)"
"7819";"CRP concentration >10 mg/L, n (%)\"
"7820";"CRP level, mean ± SD mg/dl"
"7821";"CRP mean (mg/dl ± SD)"
"7822";"CRp median (SE), rng/L"
"7823";"CRP, mean [SD] mg/1"
"7824";"CRP, mean mg/l (SD)"
"7825";"CRP, median (range) mg/literl"
"7826";"CRP, median, mg/dL"
"7827";"CRP, mg/dl"
"7828";"CRP, mg/dL"
"7829";"CRP, mg/dl, mean (SD)"
"7830";"CRP, mg/dl, median"
"7831";"CRP, mg/L"
"7832";"CRP, mg/L*"
"7833";"CRP, mg/l: median (range)"
"7834";"CRP, nmol/L, median (range)"
"7835";"CRP ≤ ULN"
"7836";"CRP > ULN"
"7837";"CRPnonr?"
"7838";"CRT"
"7839";"CRT-D"
"7840";"CRT-P"
"7841";"CRT-P+D, n (%)"
"7842";"Crude"
"7843";"Crude analysis, n (%)"
"7844";"Crude model HR (95% CI)"
"7845";"Crude Rate"
"7846";"CRUSADE bleeding score"
"7847";"CRUSADE bleeding score, mean (SD)^"
"7848";"CRUSADE score"
"7849";"Cryptogenic"
"7850";"Cryptogenic localization-related"
"7851";"CS"
"7852";"CS and IM"
"7853";"CS and IMM"
"7854";"CS and IS"
"7855";"CS only"
"7856";"CS use: No"
"7857";"csDMARD otherthan methotrexate"
"7858";"csDMARD use at baseline^"
"7859";"csDMARDs + MTX (n = 245)"
"7860";"CSE]+"
"7861";"CSF"
"7862";"CSF 24S-hydroxy-"
"7863";"CSF A (340 (PM)"
"7864";"CSF A (342 (PM)"
"7865";"CSF cholesterol"
"7866";"CSF lathosterol (|JLg/cll)"
"7867";"CSII"
"7868";"CT"
"7869";"CT findings"
"7870";"CT or MR scan of the brain*"
"7871";"CT ratio (%)"
"7872";"CT ratio > 0.55"
"7873";"CT, calcitonin; CV, cardiovascular; eGFR, estimated glomerular filtration rate; HbAlc, glycated hemoglobin; H2, histamine 2; IQR, interquartile range; n, number of patients; SD, standard deviation."
"7874";"CT+TT"
"7875";"CTD population subgroup"
"7876";"cTn-I, ng/ml"
"7877";"cTn-l, ng/ml"
"7878";"CU index test, n (%)3"
"7879";"Cuban"
"7880";"Culprit vessel"
"7881";"Cumulative Events"
"7882";"Cumulative incidence 2 years"
"7883";"Cumulative incidence 3years"
"7884";"Cumulative incidence lyear"
"7885";"Cumulative NSAID score, mean ± SD"
"7886";"CURE Trial"
"7887";"Current"
"7888";"Current (%)"
"7889";"Current (,15 cigs/day)"
"7890";"Current (15+ cigs/day)"
"7891";"Current (n = 2,630)"
"7892";"Current alcohol drinking, n (%)"
"7893";"Current alcohol use — no./total no. (%)"
"7894";"Current alcohol use, n (%)"
"7895";"Current alcohol, n (%)"
"7896";"Current alendronate use"
"7897";"Current angina"
"7898";"Current angina (%)"
"7899";"Current atrial fibrillation or flutter on ECG"
"7900";"Current bone disease"
"7901";"Current cigarette smoker"
"7902";"Current cigarette smoker or within past year"
"7903";"Current cigarette smoker, n (%)"
"7904";"Current cigarette smoking"
"7905";"Current cigarette smoking, No. (%)"
"7906";"Current cigarette use"
"7907";"Current cigarette use, n (%)"
"7908";"Current cigarette, n (%)"
"7909";"Current corticosteroid use, n"
"7910";"Current CVD/diabetes, n (%)"
"7911";"Current dactylitis, n"
"7912";"Current drinker"
"7913";"Current enthesitis, n (%)’"
"7914";"Current inhaled corticosteroid use"
"7915";"Current LABA use"
"7916";"Current LAMA use"
"7917";"Current LRA use"
"7918";"Current medication — no. (%)"
"7919";"Current medication use"
"7920";"Current medication, n (%)"
"7921";"Current n Z 1278"
"7922";"Current Non-Smoker"
"7923";"Current nonsmoker"
"7924";"Current nonsmokers"
"7925";"Current or former smoker"
"7926";"Current or previous atrial fibrillation"
"7927";"Current or prior smoking, %"
"7928";"Current oral corticosteroid use"
"7929";"Current other (predefined) medical conditions"
"7930";"Current smoker"
"7931";"Current Smoker"
"7932";"Current smoker— no. (%)"
"7933";"Current smoker— no. {%)"
"7934";"Current smoker—no. (%)"
"7935";"Current smoker — no. (%)"
"7936";"Current smoker — no. (%) Blood pressure — mm Hg"
"7937";"Current smoker — no. of patients (%)"
"7938";"Current smoker — no./total no. (%)"
"7939";"Current smoker    »"
"7940";"Current smoker (%)"
"7941";"Current smoker (>10 cigarettes/day) — no. (%)"
"7942";"Current smoker (n=3,804)"
"7943";"Current smoker (n=3,804) Former smoker (n=4,428)"
"7944";"Current Smoker (n=3804)"
"7945";"Current Smoker (n=95, 110)"
"7946";"Current smoker 一 no. (%)"
"7947";"Current smoker 一no. (%)"
"7948";"Current smoker at baseline, n (%)"
"7949";"Current smoker at screening, n (%)"
"7950";"Current smoker at screeninga, n (%)"
"7951";"Current smoker Yes"
"7952";"Current smoker,"
"7953";"Current smoker, %"
"7954";"Current smoker, n (% of patients)"
"7955";"Current smoker, n (%)"
"7956";"Current smoker, n (%) Post-bronchodilator screening"
"7957";"Current smoker, n (%}"
"7958";"Current smoker, n [%]"
"7959";"Current smoker, n/N (%)"
"7960";"Current smoker, no (%)"
"7961";"Current smoker, no. (%)"
"7962";"Current smoker, No. (%)"
"7963";"Current smoker:ex-smoker (%)"
"7964";"Current smokers"
"7965";"Current smokers (%)"
"7966";"Current smokers (ITT) (n=1005)"
"7967";"Current smokers (ITT) (n=1018)"
"7968";"Current smokers (ITT) (n=758)"
"7969";"Current smokers (ITT) (n=768)"
"7970";"Current smokers (ITT) (n=779)"
"7971";"Current smokers (ITT) (n=784)"
"7972";"Current smokers (n=683)"
"7973";"Current smokers*"
"7974";"Current smokers, n (%)"
"7975";"Current smokers, n (%) Medicai history, n (%)"
"7976";"Current smokers, n (%)"
"7977";"current smoking"
"7978";"Current smoking"
"7979";"Current smoking — no. (%)"
"7980";"Current smoking — no./total no. (%)"
"7981";"Current smoking (%)"
"7982";"Current smoking*"
"7983";"Current smoking, %"
"7984";"Current smoking, n (%)"
"7985";"Current tobacco abuse, n (%)"
"7986";"Current tobacco smoker"
"7987";"Current tobacco smoker (%) Qualifying event (%)"
"7988";"Current tobacco use"
"7989";"Current Tobacco Use"
"7990";"Current use of an ACE inhibitor"
"7991";"Current use of hormone therapy"
"7992";"Current weekly alcohol use (%)"
"7993";"Current xanthine derivative use"
"7994";"Current, n (%)"
"7995";"Current/past"
"7996";"Current/past smoker"
"7997";"Currentd"
"7998";"Currently"
"7999";"Currently on AHA therapy"
"8000";"Currently smoker"
"8001";"Currently smokes"
"8002";"Currentother(notpredefined) medical conditions"
"8003";"Cutoffs"
"8004";"CV"
"8005";"CV death"
"8006";"CV Death"
"8007";"CV death    n"
"8008";"CV death + HF hospitalization"
"8009";"CV death or first HHF"
"8010";"CV death or HF hosp."
"8011";"CV death or HF hospitalization    n"
"8012";"CV death or HHF"
"8013";"CV death or Ml"
"8014";"CV death, MI, ischemic stroke"
"8015";"CV death, MI, ischemic stroke, hospitalization for HF, coronary revascularization, UA"
"8016";"CV death, MI, or ischemic stroke"
"8017";"CV death, MI, or stroke"
"8018";"CV death, MI, stroke"
"8019";"CV death, MI, stroke, or urgent coronary revascularization"
"8020";"CV death, MI, stroke, recurrent ischemia"
"8021";"CV death, Ml or ischemic stroke"
"8022";"CV death, Ml, ischemic stroke"
"8023";"CV Death, Ml, Ischemic Stroke"
"8024";"CV Death, Ml, Ischemic Stroke, Hosp. for HF, Cor. Revasc., UA"
"8025";"CV DEATH, Ml, ISCHEMIC STROKE, HOSPITALIZATION FOR UNSTABLE ANGINA, REVASCULARIZATION OR HEART FAILURE"
"8026";"CV death, Ml, or stroke"
"8027";"CV Death, Myocardial infarction, Stroke"
"8028";"CV death, Non-fatal MI or Non-fatal Stroke"
"8029";"CV Death/MI/Stroke"
"8030";"CV Death/MI/Stroke/UCR"
"8031";"CV disease"
"8032";"CV disease history, No. (%)§"
"8033";"CV Endpoints n (%)"
"8034";"CV entry criteria"
"8035";"CV Entry Criteria"
"8036";"CV event, years"
"8037";"CV historya"
"8038";"CV medication"
"8039";"CV medication, % of patients"
"8040";"CV mortality"
"8041";"CV Mortality"
"8042";"CV risk factor"
"8043";"CV risk factor - no. (%)"
"8044";"CV risk factors"
"8045";"CV risk factors and history"
"8046";"CV risk factors, % of patients"
"8047";"CVD"
"8048";"CVD death"
"8049";"CVD deaths"
"8050";"CVD events"
"8051";"CVD mortality"
"8052";"CVD or MI"
"8053";"CVD risk factors (age > 60)^“^"
"8054";"CVD risk factors (age >60 )"
"8055";"CVD subjects"
"8056";"CVD Without MI or Stroke (n=3083)"
"8057";"CVD without MIAtroke"
"8058";"CVD without Ml/stroke"
"8059";"CVD without Ml^troke"
"8060";"CVD, MI, or stroke"
"8061";"CVD, MI, stroke, or recurrent ischemia- urgent revascularization, or hospitalization for unstable angina"
"8062";"CVD, MI, stroke, or recurrent ischemia-urgent revascularization"
"8063";"CVD, total"
"8064";"CVD/MI/stroke"
"8065";"CVD/MI/stroke/revascularization/urgent vascular hospitalization"
"8066";"CVD/MI/stroke/urgent coronary revascularization"
"8067";"CVD/MI/stroke/urgent vascular hospitalization"
"8068";"CVD/stroke/SEE"
"8069";"CVDEATH, Ml, OR ISCHEMIC STROKE"
"8070";"CWT, Mean (SE), mm"
"8071";"Cyclo"
"8072";"Cyclosporin"
"8073";"Cyclosporine (N = 474)"
"8074";"CYP26A1"
"8075";"CYP3A4 inhibitors"
"8076";"Cystitis"
"8077";"Cystoscopic procedure"
"8078";"Czech Republic"
"8079";"Czech RepuMc"
"8080";"CZP 200 mg"
"8081";"CZP 200 mg (n = 201)"
"8082";"CZP 200 mg (n = 326)"
"8083";"CZP 200 mg (n = lll)"
"8084";"CZP 200 mg (n 5 326)"
"8085";"CZP 200 mg (n 5111)"
"8086";"CZP 200 mg (n5201)"
"8087";"CZP 200 mg every 2 weeks (n = 138)"
"8088";"CZP 200 mg Q2W"
"8089";"CZP 400 mg"
"8090";"CZP 400 mg (n = 109)"
"8091";"CZP 400 mg (n = 221)"
"8092";"CZP 400 mg (n = 305)"
"8093";"CZP 400 mg (n 5 221)"
"8094";"CZP 400 mg (n 5305)"
"8095";"CZP 400 mg (n5109)"
"8096";"CZP 400 mg every 4 weeks (n = 135)"
"8097";"CZP 400 mg Q4W"
"8098";"CZP 400 mg, % (n/N)"
"8099";"CZP baseline"
"8100";"CZP combined arms (n = 219)"
"8101";"CZP combined arms (n = 54)"
"8102";"CZP+MTX"
"8103";"CZP+MTX n=159"
"8104";"CZP+MTX n=655"
"8105";"CZP+MTX to MTX"
"8106";"CZP+MTX^MTX"
"8107";"d"
"8108";"D"
"8109";"D-Dimer (ng/ml)"
"8110";"D-dimer level, mean (SD), ng/mLd"
"8111";"D-dimer levelsatinclusion"
"8112";"D-value"
"8113";"D (95% CI)"
"8114";"D 110 mg vs. warfarin"
"8115";"D 150 mg vs. warfarin"
"8116";"d Includes cardiac glycosides, antiarrhythmics classes I and III, vasodilators used in cardiac disease and other cardiac preparations."
"8117";"d Non-Vertebral Fragility Fractures (FAS)"
"8118";"d population"
"8119";"D, Mitral stenosis VhD (n=193)"
"8120";"D/MI/IDFVST"
"8121";"D/MI/IDR/ST"
"8122";"D110 % (n/N)"
"8123";"D110 vs Warfarin"
"8124";"D110 vs Warfarin RR (95% CI, P Value)"
"8125";"D150 % (n/N)"
"8126";"D150 vs Warfarin"
"8127";"D150 vs Warfarin RR (95% CI, P Value)"
"8128";"Dabetes"
"8129";"Dabigatran"
"8130";"Dabigatran (N = 1273)"
"8131";"Dabigatran (N = 1430)"
"8132";"Dabigatran (N = 681)"
"8133";"Dabigatran 110 mg"
"8134";"dabigatran 110 mg (n=6015)"
"8135";"Dabigatran 110 mg 150 mg % per yr"
"8136";"Dabigatran 110 mg bid"
"8137";"Dabigatran 110 mg BID"
"8138";"Dabigatran 110 mg BID (N=1487)"
"8139";"Dabigatran 110 mg BID Events/n (%/y)"
"8140";"Dabigatran 110 mg BID vs Warfarin"
"8141";"dabigatran 110 mg versus warfarin"
"8142";"Dabigatran 110 mg b.i.d."
"8143";"Dabigatran 150 mg"
"8144";"dabigatran 150 mg (n=6076)"
"8145";"Dabigatran 150 mg BID"
"8146";"Dabigatran 150 mg BID (N = 1546)"
"8147";"Dabigatran 150 mg BID Events/n (%/y)"
"8148";"Dabigatran 150 mg BID vs Warfarin"
"8149";"dabigatran 150 mg versu swarfarin"
"8150";"Dabigatran 150 vs Dabigatran 110 mg BID"
"8151";"Dabigatran 150 mg b.i.d."
"8152";"Dabigatran 150mg bid"
"8153";"Dabigatran 220 mg (n= 2,156)"
"8154";"Dabigatran group"
"8155";"Dabigatran, 110 mg"
"8156";"Dabigatran, 110 mg BID"
"8157";"Dabigatran, 110 mg Twice Daily"
"8158";"Dabigatran, 110 mg, vs. Warfarin"
"8159";"Dabigatran, 150 mg"
"8160";"Dabigatran, 150 mg BID"
"8161";"Dabigatran, 150 mg Twice Daily"
"8162";"Dabigatran, 150 mg,"
"8163";"Dabigatran, 150 mg, vs. Warfarin"
"8164";"Dabigatran110 vs. WARFARIN P(INTER)"
"8165";"Dabigatran150 vs. WARFARIN P(INTER)"
"8166";"Dactylitis"
"8167";"Dactylitis count"
"8168";"Dactylitis count (0-20), mean (SD)"
"8169";"Dactylitis in >1 digit"
"8170";"Dactylitis score"
"8171";"Dactylitis score (1-60)"
"8172";"Dactylitis score (1-60), mean (SD)"
"8173";"Dactylitis score (1–60 scale)"
"8174";"Dactylitis score at baseline, median (IQR) Week 100"
"8175";"Dactylitis Severity Score) Score >0 — no. {%)"
"8176";"Dactylitis, %#"
"8177";"Dactylitis, n (%)"
"8178";"Daily"
"8179";"Daily “off” time, mean ± SD, h/dayf"
"8180";"Daily bowel movements"
"8181";"Daily dose > 1600 mg n = 1339"
"8182";"Daily dose 400 mg n = 2380"
"8183";"Daily dose 401-1599 mg n = 4334"
"8184";"Daily dose of inhaled glucocorticoid — no. (%)§"
"8185";"Daily dose of study medication prescribed"
"8186";"Daily dose of vitamin D (IU/day)"
"8187";"Daily Exercise (%)"
"8188";"Daily iGlar dose at week 30 (U)"
"8189";"Daily insulin dose, mean (SD), IU"
"8190";"Daily total dose of insulin — lU/kg"
"8191";"Dalteparin (n=746)"
"8192";"DAPA+MET n =179"
"8193";"DAPA+MET n=179"
"8194";"Dapaglifloiin, n*"
"8195";"Dapaglifloz.in, n"
"8196";"Dapagliflozin"
"8197";"Dapagliflozin (n=225)"
"8198";"Dapagliflozin (n=57)"
"8199";"Dapagliflozin (n=60)"
"8200";"Dapagliflozin (N=8582)"
"8201";"Dapagliflozin (n=92)"
"8202";"Dapagliflozin 10 mg"
"8203";"Dapagliflozin 10 mg (N = 108)"
"8204";"Dapagliflozin 10 mg + insulin (n = 270)"
"8205";"Dapagliflozin 10 mg + Insulin (n=270)"
"8206";"Dapagliflozin 10 mg group (n = 263)"
"8207";"Dapagliflozin 10 mg group (n = 455)"
"8208";"Dapagliflozin 10 mg group (n =455)"
"8209";"Dapagliflozin 10 mg group (n=192)"
"8210";"Dapagliflozin 10 mg/day (N = 108)"
"8211";"Dapagliflozin 5 mg"
"8212";"Dapagliflozin 5 mg + insulin (n = 271)"
"8213";"Dapagliflozin 5 mg + Insulin (n=271)"
"8214";"Dapagliflozin 5mg"
"8215";"Dapagliflozin Placebo no. of events/no. of patients"
"8216";"Dapagliflozin, n*"
"8217";"Dapagliflozint"
"8218";"DAS-28 (CRP) <2.6, n (%)"
"8219";"DAS-28 (CRP), mean (SD)"
"8220";"DAS28"
"8221";"DAS28-4 (ESR) <2.6*"
"8222";"DAS28-4 (ESR) <3.2t"
"8223";"DAS28-4(ESR)"
"8224";"DAS28-4(ESR)1"
"8225";"DAS28‐CRP"
"8226";"DAS28-CRP"
"8227";"DAS28-CRP, LS mean change from baseline (SE)¥"
"8228";"DAS28-CRP, LS mean change from baseline (SE)§"
"8229";"DAS28-CRP§"
"8230";"DAS28-ESR"
"8231";"DAS28-ESR LDA"
"8232";"DAS28-ESR remission"
"8233";"DAS28-ESR remission, %"
"8234";"DAS28-ESR, mean (SD)"
"8235";"DAS28-ESR, mean ± SD DAS28-ESR remission, %"
"8236";"DAS28-hsCRP"
"8237";"DAS28-hsCRP, mean (SD)"
"8238";"DAS28 (C-reactive protein)"
"8239";"DAS28 (CRP)"
"8240";"DAS28 (CRP), mean (SD)"
"8241";"DAS28 (ESR)"
"8242";"DAS28 score"
"8243";"DAS28(CRP)"
"8244";"DAS28(ESR)"
"8245";"DAS28(ESR), mean (SD)"
"8246";"DAS28, mean (SD)"
"8247";"DAS28, mean ± SD"
"8248";"DAS28, range 0-10, mean (SD)"
"8249";"Data are expressed as n/total (%) unless otherwise speciﬁed. Systeme International unit conversion: to convert creatinine clearance to ml/s, multiply by 0.0167. *Estimated with Cockroft-Gault equation; †at discharge.
ACE   angiotensin-converting enzyme; CABG   coronary artery bypass graft; CCSC   Canadian Cardiovascular Society classiﬁcation; MI   myocardial infarction; PCI   percutaneous coronary intervention."
"8250";"Data are expressed as n/total (%) unless otherwise specified. Systeme International unit conversion: to convert creatinine clearance to ml/s, multiply by 0.0167. *Estimated with Cockroft-Gault equation;"
"8251";"Data are mean (SD) or n (%).  ACE=angiotensin-converting enzyme, ARB=angiotensin-receptor blocker. 
CHF=congestive heart failure. *Any use in 24 h before surgery except for aspirin which only required any use in the 7 days before surgery."
"8252";"Data are mean (SD) or number (%). BMI=body-mass index. SBP=systolic blood pressure. DBP=diastolic blood pressure. LVEF=left ventricular ejection fraction. 
HF=heart failure. AMI=acute myocardial infarction. CABG=coronary artery bypass graft. PCI=percutaneous coronary intervention. ICD=implantable cardioverter deﬁ brillator. COPD=chronic obstructive pulmonary disease. ACE=angiotensin-converting enzyme. ARBs=angiotensin receptor blockers. *Available for 4523 patients (2257 rosuvastatin, 2266 placebo)."
"8253";"Data are mean (SD) or number (%). PUFA=polyunsaturated fatty acids, BMI= body-mass index. SBP=systolic blood pressure. DBP=diastolic blood pressure. NYHA=NewYork Heart Association. LVEF=left ventricular ejection fraction. HF=heartfailure. AMI=acute myocardial infarction. CABG=coronary artery bypass graft. PCI=percutaneous coronary intervention. ICD=implantable cardioverter defibrillator. COPD=chronic obstructive pulmonary disease. ACE=angiotensin-converting enzyme. ARBs=angiotensin receptor blockers. *Available for 6899 patients (3455 n-3 PUFA, 3444 placebo)."
"8254";"Data are mean ± standard deviation for continuous variables and number (%) for categoric variables. P"
"8255";"Data are number of patients (%) or hazard ratio (95% Cl), p values are forthe test of heterogeneity. CAD=coronary artery disease. BMI= body-mass index, which is weight in kg divided by the square of height in metres. LDL=low-density lipoprotein. HDL=high-density lipoprotein.There is a deficit of clinical data in some patients with the events."
"8256";"Data are number of patients (%) or mean (SD), unless otherwise indicated. CABG=coronary-artery bypass grafting. PTCA=percutaneous transluminal coronary angioplasty, LDL=low-density lipoprotein. HDL=high-density lipoprotein. IQR=i nterquarti le range, HMG CoA RI=3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. BMI=body-mass index, which is weight in kg divided by the square of height in metres, *Median (IQR)."
"8257";"Data are presented as mean   SD. * n   193 for LDL cholesterol.
†
n   390 for LDL cholesterol.
‡
Signiﬁcantly different from baseline values by repeated measures (analysis of variance), p  0.0001.
§
Signiﬁcantly different from baseline values by repeated measures (analysis of variance), p   0.0002.
¶
Signiﬁcantly different from baseline values by repeated measures (analysis of variance), p   0.0004."
"8258";"Data are reported as n (%). Event rates in parentheses are Kaplan-Meier estimates (%) at 1 year. *Cardiovascular (CV) death, myocardial infarction (MI), or recurrent ischemia. †CV death, MI, or severe recurrent ischemia"
"8259";"Data are reported as percentage or mean ± standard deviation, unless otherwise indicated. NG, normoglycemia; IGM, impaired glucose metabolism; LDL, low-density lipoprotein; HDL, high-density lipoprotein; FPG, fasting plasma glucose. a Median (interquartile range). * P < 0.05 vs. NG. † P < 0.01 vs. NG."
"8260";"Data are reported as percentage or mean ± standard deviation, unless otherwise indicated. NG, normoglycemia; IGM, impaired glucose metabolism; LDL, low-density lipoprotein; HDL, high-density lipoprotein; FPG, fasting plasma glucose. a Median (interquartile range). ‡ P < 0.05 vs. non-EPA. § P < 0.01 vs. non-EPA"
"8261";"Data missing"
"8262";"Data missing or no drug given"
"8263";"Data presented as mean ± SD, unless otherwise specified; aCOPD severity is based on the GOLD 2015 criteria [27]; GOLD 2011 [28]; bOn a scale of 0–100, with higher scores indicating worse health status; the MCID is a change of 4 units; On a scale of 0–4, with higher scores indicating more severe dyspnea; On a scale of 0–40, with higher scores indicating worse health status"
"8264";"Data represent number of patients (%) or mean (standard deviation), unless otherwise indicated. a Self-reported information. bc Physician-diagnosed diabetes or fasting plasma glucose ≥126 mg/dL or hemoglobin A1C ≥6.5%. d Physician-diagnosed hypertension or systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg.
Median (interquartile range). LDL, low-density lipoprotein; HDL, high-density lipoprotein; TG, triglyceride."
"8265";"data,'' n"
"8266";"Dates of recruitment"
"8267";"Day 1 oral glucocorticoid use — no. {%)"
"8268";"Days between ACS and Rand"
"8269";"Days from ACS to randomization"
"8270";"Days of study-drug administration (%)** 1 day"
"8271";"Days with asthma symptoms/week"
"8272";"Days with heartburna (days)"
"8273";"Days without albuterol use,* %"
"8274";"Daytime mean DBP (ABPM) at week 12, mmHg"
"8275";"Daytime mean SBP (ABPM) at week 12, mmHg"
"8276";"Daytime nasal symptoms score change from baseline, mean ± SE"
"8277";"Daytime symptoms more than twice per week"
"8278";"DB baseline (Week 0)"
"8279";"DBP"
"8280";"DBP (mean over 24 h), mmHg"
"8281";"DBP (mm Hg)"
"8282";"DBP (mm Hg), median (IQR)"
"8283";"DBP (mmgHG), mean (SD)"
"8284";"DBP (mmHg)"
"8285";"DBP (mmHg), mean (SD)"
"8286";"DBP (office measurement), mmHg"
"8287";"DBP (SD)"
"8288";"DBP (SD), mm Hg"
"8289";"DBP <80 mmHg"
"8290";"DBP <90 mmHg"
"8291";"DBP ≥90 mmHg"
"8292";"DBP >90 or SBP >140 mm Hg Laboratory determinations"
"8293";"DBP 90.0 (8.9) Baseline lipid profile, mg/dL, mean (SD)"
"8294";"DBP at Visit 2"
"8295";"DBP during the follow-up period (mmHg)"
"8296";"DBP mm Hg"
"8297";"DBP(mm Hg)"
"8298";"DBP(mmHg)"
"8299";"DBP, mean (SD)"
"8300";"DBP, mean (sd) mm Hg"
"8301";"DBP, mean (SD), mm Hg"
"8302";"DBP, mean (SD), mm Hg Glycaemic parameters"
"8303";"DBP, mean (SD), mmHg"
"8304";"DBP, mean ± SD (mmHg)"
"8305";"DBP, mm Hg"
"8306";"DBP, mm Hg (mean 24 h), mean (SD)"
"8307";"DBP, mm Hg (office measurement), mean (SD)"
"8308";"DBP, mm Hg, mean ± SDC"
"8309";"DBP, mm Hg"
"8310";"DBP, mm Hg (SD)"
"8311";"DBP, mmHg"
"8312";"DBP. mean (sd) mm Hg"
"8313";"DCCT A1c"
"8314";"DD"
"8315";"DD (n = 399)"
"8316";"DE"
"8317";"DE (n=1676)"
"8318";"DE (n=209)"
"8319";"DE (n=262)"
"8320";"DE (n=433)"
"8321";"DE (n=668)"
"8322";"DE (n=735)"
"8323";"DE 110 mg BID (n - 5,424)"
"8324";"DE 150 mg BID (n - 5,472)"
"8325";"DE110 n=2322"
"8326";"DE110 n=3693"
"8327";"DE150 n=2304"
"8328";"DE150 n=3772"
"8329";"Dead (n=313)"
"8330";"death"
"8331";"Death"
"8332";"Death (all-cause)"
"8333";"Death (all cause)"
"8334";"Death due to renal failure or sustained ESRD"
"8335";"Death due to renal failure®"
"8336";"Death from"
"8337";"Death from any cause"
"8338";"Death from cardiovascular causes"
"8339";"Death or 6MWD decrease >50 m"
"8340";"Death or absolute FVC decrease >10%"
"8341";"Death or disabling stroke"
"8342";"Death or ICH"
"8343";"Death or myocardial infarction"
"8344";"Death or stent thrombosis"
"8345";"Death*"
"8346";"Death, large MI"
"8347";"Death, MI, IDR, or ST"
"8348";"Death, MI, IDR, ST or GUSTO severe bleeding"
"8349";"Death, MI, IDR, ST or GUSTO Severe Bleeding"
"8350";"Death, MI, IDR, ST, or any TIMI bleeding"
"8351";"Death, MI, IDR, ST, or any TIMI Bleeding"
"8352";"Death, MI, IDR, ST, or GUSTO Mod/Sev Bleeding"
"8353";"Death, MI, IDR, ST, or GUSTO moderate/severe bleeding"
"8354";"Death, MI, IDR, ST, or GUSTO Moderate/Severe Bleeding"
"8355";"Death, n (%)"
"8356";"Death, Q wave MI or ischemia-driven revasc"
"8357";"Death, with PE not"
"8358";"Death/MI/IDR/ST"
"8359";"Death/MI/IDR/ST/ GUSTO-defined moderate or severe bleeding"
"8360";"Death/Q- Ml/stent thrombosis"
"8361";"Death/Q-MI/IDR"
"8362";"Death/Q-wave MI/IDR"
"8363";"Death/ST"
"8364";"Death/UDMI/IDR"
"8365";"Deaths"
"8366";"Deaths, n (%)"
"8367";"Deathsb"
"8368";"Decline# mL·yr−1"
"8369";"Decreased appetite"
"8370";"Deep-vein thrombosis"
"8371";"Deep-vein thrombosis (%)"
"8372";"Deep-vein thrombosis only"
"8373";"Deep-vein thrombosis or pulmonary embolism — no. (%)"
"8374";"Deep vein thrombosis only"
"8375";"Definite"
"8376";"Definite Acute Stent Thrombosis"
"8377";"Definite stent thrombosis"
"8378";"Definite/probable stent thrombosis"
"8379";"Degree of stenosis, % of diameter"
"8380";"Delayed"
"8381";"Delayed-Eptifibatide Group (N =4684)"
"8382";"Delayed-Start Group (N = 295)"
"8383";"Delayed-Start Group (N = 300)"
"8384";"Delayed Eptifibatide"
"8385";"Delayed reaction"
"8386";"Delighted"
"8387";"Demographic"
"8388";"Demographic 66.0 (9.7)"
"8389";"Demographic and clinical"
"8390";"Demographic and clinical characteristics"
"8391";"Demographic and medical variables"
"8392";"Demographic characteristic"
"8393";"Demographic Characteristic"
"8394";"demographic characteristics"
"8395";"Demographic characteristics"
"8396";"Demographic Characteristics"
"8397";"Demographic characteristics, mean (SD), unless otherwise stated"
"8398";"Demographic characteristics, mean ± SD unless otherwise indicated"
"8399";"Demographic data"
"8400";"Demographic factors"
"8401";"Demographic feature"
"8402";"Demographic features"
"8403";"Demographic variable"
"8404";"Demographic/disease characteristics at baseline"
"8405";"Demographics"
"8406";"Demographics Age (years)"
"8407";"Demographics Age, years, mean (SD)"
"8408";"Demographics and clinical characteristics"
"8409";"Demography"
"8410";"Denosumab"
"8411";"Denosumab (n = 166)"
"8412";"Denosumab (N=3902) n (%)"
"8413";"Denosumab (N=435)"
"8414";"denotes angiotensin-converting enzyme."
"8415";"Dense calcium"
"8416";"Dense calcium, mm’"
"8417";"density lipoprotein; CSF ="
"8418";"Dental procedure"
"8419";"Depression"
"8420";"Depression^"
"8421";"Depression®"
"8422";"Dermal"
"8423";"Dermatitis atopic"
"8424";"DES"
"8425";"DES (% previous stenting)"
"8426";"DES implantation for restenosis, n (%)"
"8427";"DES type"
"8428";"DES type at index procedure"
"8429";"descent"
"8430";"Detected during tumor evaluation"
"8431";"detemir/insulin glargine, %"
"8432";"Deterioration in renal function (investigator reported)"
"8433";"deviation, mm"
"8434";"deviation; TG, triglyceride."
"8435";"Device = Watchman Filter"
"8436";"Device Group"
"8437";"Device Group (n = 463)"
"8438";"Devices"
"8439";"Devices for heart failure at screening visit"
"8440";"Dexlansoprazole MR"
"8441";"Dexlansoprazole MR (n = 4270)"
"8442";"Dexlansoprazole MR 30 mg, N =152"
"8443";"Dexlansoprazole MR 60 mg QD"
"8444";"Dexlansoprazole MR 90 mg QD"
"8445";"dFisher's exact test."
"8446";"DHA (n = 238)"
"8447";"DHA intake on food frequency questionnaire, mean (SD), mg/d"
"8448";"Diabetes"
"8449";"Diabetes-related medication use, n (%)"
"8450";"Diabetes — no. (%)"
"8451";"Diabetes (%)"
"8452";"Diabetes (n - 6,806)"
"8453";"Diabetes (n [%])*"
"8454";"Diabetes (N = 214)"
"8455";"Diabetes (n=1106)"
"8456";"Diabetes (P = .17)"
"8457";"Diabetes (P = .46)"
"8458";"Diabetes (P = .O2)"
"8459";"Diabetes (P = .OO4)"
"8460";"Diabetes (P=.004)"
"8461";"Diabetes Absent 13202 (72.6)"
"8462";"Diabetes and currently on an oral hypoglycaemic agent orinsulin"
"8463";"Diabetes at baseline"
"8464";"Diabetes at randomization"
"8465";"Diabetes BL"
"8466";"Diabetes classificationa"
"8467";"Diabetes Duration"
"8468";"Diabetes duration (known), % of patients"
"8469";"Diabetes duration (y)"
"8470";"Diabetes duration (years)"
"8471";"Diabetes duration (years)*"
"8472";"Diabetes duration at baseline"
"8473";"Diabetes duration Mean±SD"
"8474";"Diabetes duration subgroups"
"8475";"Diabetes duration, median (IQR), years"
"8476";"Diabetes duration, n (%)"
"8477";"Diabetes duration, y"
"8478";"Diabetes duration, ycars“"
"8479";"Diabetes duration, years"
"8480";"Diabetes duration, years (mean ± SD)"
"8481";"Diabetes duration, years^"
"8482";"Diabetes durationa <Median"
"8483";"Diabetes Etiology"
"8484";"Diabetes history, mean (SD), years"
"8485";"Diabetes medication"
"8486";"Diabetes melitus"
"8487";"Diabetes mellitus"
"8488";"Diabetes meLLitus"
"8489";"Diabetes Mellitus"
"8490";"Diabetes mellitus — no. (%)"
"8491";"Diabetes mellitus — no./total no. (%)"
"8492";"Diabetes mellitus (%)"
"8493";"Diabetes mellitus (type 1 or 2)"
"8494";"Diabetes mellitus (type 2), n (%)"
"8495";"Diabetes mellitus [n (% )]"
"8496";"Diabetes mellitus 一 no. (%)"
"8497";"Diabetes mellitus classification"
"8498";"Diabetes mellitus duration (SD), y"
"8499";"Diabetes mellitus duration, y"
"8500";"Diabetes mellitus duration, y (SD)"
"8501";"Diabetes mellitus n = 1,163"
"8502";"Diabetes mellitus status"
"8503";"Diabetes mellitus Yes (n, %) Hypertension"
"8504";"Diabetes mellitus!"
"8505";"Diabetes mellitus, %"
"8506";"Diabetes mellitus, (%)"
"8507";"Diabetes mellitus, n (%)"
"8508";"Diabetes mellitus, n (%) yes"
"8509";"Diabetes mellitus, n/N (%)"
"8510";"Diabetes Mellitus, n=2907"
"8511";"Diabetes mellitus, no. (%)"
"8512";"Diabetes mellitus, No./total No. (%)"
"8513";"Diabetes mellitus,§ n (%)"
"8514";"Diabetes Mellitus:"
"8515";"Diabetes mellitust"
"8516";"Diabetes n (%)"
"8517";"Diabetes N(%)"
"8518";"Diabetes Present 4933 (27.4)"
"8519";"Diabetes status"
"8520";"Diabetes Status"
"8521";"Diabetes status, n (%)"
"8522";"Diabetes status, No. (%)"
"8523";"Diabetes t"
"8524";"Diabetes Therapy"
"8525";"Diabetes therapy at baseline (alone or in combination)"
"8526";"Diabetes therapy, n (%)"
"8527";"Diabetes treatment"
"8528";"Diabetes type II, n (%)"
"8529";"Diabetes with no use of diabetes drugs"
"8530";"Diabetes with target organ disease*"
"8531";"Diabetes with use of oral diabetes drugs"
"8532";"Diabetes*"
"8533";"Diabetes, %"
"8534";"Diabetes, n (%)"
"8535";"Diabetes, no. (%)"
"8536";"Diabetes, No. (%)c"
"8537";"Diabetes,* n (%)"
"8538";"Diabetes^"
"8539";"Diabetes||"
"8540";"Diabetes|| Yes"
"8541";"Diabetes11"
"8542";"Diabetes3"
"8543";"Diabetes5 (%)"
"8544";"Diabetesc"
"8545";"Diabetesduration,mean(SD),y"
"8546";"Diabetese"
"8547";"Diabetesf"
"8548";"DiabetesH Yes"
"8549";"Diabetesz"
"8550";"Diabetic"
"8551";"Diabetic (no)"
"8552";"Diabetic (yes)"
"8553";"Diabetic eye disease"
"8554";"Diabetic history (years)x"
"8555";"Diabetic kidney disease"
"8556";"Diabetic No"
"8557";"Diabetic participants"
"8558";"Diabetic participants!"
"8559";"Diabetic patients"
"8560";"Diabetic status"
"8561";"Diabetic status, n (%)"
"8562";"Diabetic subjects, N=312"
"8563";"Diabetic therapy use, n (%)* No therapy"
"8564";"Diabetic treatments!"
"8565";"Diabetic Yes"
"8566";"diabetic, n (%)"
"8567";"Diabetic, n (%)"
"8568";"Diabetic0"
"8569";"Diabeticb"
"8570";"Diabetics"
"8571";"Diabetics - No (n=155, 80)"
"8572";"Diabetics - Yes (n=10, 5)"
"8573";"Diabetics - Yes (n=12, 5)"
"8574";"Diabetics (n= 4221)"
"8575";"Diabetics • No (n=161, 83)"
"8576";"Diagnosed Diabetes (n = 627)"
"8577";"Diagnosed, y"
"8578";"Diagnoses/risk factors, n (%)"
"8579";"Diagnoses/risk factors, n (%]"
"8580";"diagnosis — yr"
"8581";"diagnosis (y), mean (SD)"
"8582";"diagnosis (years)"
"8583";"Diagnosis at presentation"
"8584";"Diagnosis at presentation — no. (%)"
"8585";"Diagnosis at study entry — no. (%)"
"8586";"Diagnosis of allergic rhinitis"
"8587";"Diagnosis of diabetes, n (%)"
"8588";"Diagnosis of HeFH, n (%)"
"8589";"Diagnosis of heterozygous familial hypercholester"
"8590";"Diagnostic angiography"
"8591";"Diagnostic catheterization"
"8592";"Diameter stenosis, mean (SD), %"
"8593";"Diarrhea"
"8594";"Diarrhoea"
"8595";"Diary variables, mean (SD)"
"8596";"Diastoiic biood pressure, mm Hg"
"8597";"diastolic"
"8598";"Diastolic"
"8599";"Diastolic—mean (SD) (mm Hg)"
"8600";"Diastolic — mm Hg"
"8601";"Diastolic (mean, SD)"
"8602";"Diastolic (mmHg)"
"8603";"Diastolic blood pressure"
"8604";"Diastolic blood pressure - mmHg"
"8605";"Diastolic blood pressure — mm Hg"
"8606";"Diastolic blood pressure (mm Hg)"
"8607";"Diastolic blood pressure (mm Hg) Medications"
"8608";"Diastolic blood pressure (mm Hg), mean (SD)"
"8609";"Diastolic blood pressure (mm Hg):"
"8610";"Diastolic blood pressure (mmHg)"
"8611";"Diastolic blood pressure >85 mm Hg,"
"8612";"Diastolic blood pressure mmHg, mean(sd)"
"8613";"Diastolic blood pressure subgroups"
"8614";"Diastolic blood pressure,"
"8615";"Diastolic blood pressure, (mm Hg)"
"8616";"Diastolic blood pressure, mm Hg"
"8617";"Diastolic blood pressure, mm Hg (SD)"
"8618";"Diastolic blood pressure, mm Hg, mean (SD)"
"8619";"Diastolic blood pressure, mm Hg, mean±SD"
"8620";"Diastolic blood pressure, mm Hg, median (range)"
"8621";"Diastolic blood pressure, mm Hg^"
"8622";"Diastolic blood pressure, mm Hq"
"8623";"Diastolic blood pressure, mm Hg"
"8624";"Diastolic blood pressure, mmHg"
"8625";"Diastolic blood pressure, mmHg, mean (SD)"
"8626";"diastolic blood pressure; and Lp(a),"
"8627";"Diastolic blood pressurea,mmHg"
"8628";"Diastolic BP"
"8629";"Diastolic BP (mm Hg)"
"8630";"diastolic BP (mmHg)"
"8631";"Diastolic BP (mmHg)"
"8632";"Diastolic BP (mmHg)*"
"8633";"Diastolic BP, mm Hg"
"8634";"Diastolic BP, mm Hg, mean (SD)"
"8635";"Diastolic BP, mm Hg, mean (SD)"
"8636";"Diastolic BP, mmHg"
"8637";"Diastolic BP, mmHg (SD)"
"8638";"Diastolic BP, mmHg, mean ± SD"
"8639";"Diastolic fmmHff')"
"8640";"Diastolic pressure, mm Hg"
"8641";"Diastolic(mm Hg)"
"8642";"Diastolic, mean (SD), mm Hg"
"8643";"Diastolic, total"
"8644";"Diastolic, treated at baseline"
"8645";"Diclofenac"
"8646";"Diclofenac (n = 17,289)"
"8647";"Diclofenac (n=10378)"
"8648";"Diclofenac (n=11 616)"
"8649";"Diclofenac (n=17 289)"
"8650";"Diclofenac (n=5673)"
"8651";"Diclofenac (n=6911)"
"8652";"Diclofenac 150 mg (n = 2054) n (%)"
"8653";"Diclofenac 150 mg (N 5 2054), ...n..(.%..)............"
"8654";"Diclofenac 150 mg (N 5 2162), .n...(.%..)..........."
"8655";"Diclofenac 150 mg (N 5 2855), ...n..(.%..)..........."
"8656";"Diclofenac 150 mg (N 5 3518), ..n...(.%..)................."
"8657";"Diclofenac 150 mg (N 5 6700), ..n..(.%..)..........."
"8658";"Diclofenac 150 mg, N = 3518,n(%)"
"8659";"Diclofenac group (n=17 289)"
"8660";"Did not enrol into Osler"
"8661";"Did not meet atopy and IgE30-700kU/Lcriteriaa (n = 1,471)"
"8662";"diet"
"8663";"Diet"
"8664";"Diet-controlled (%)"
"8665";"Diet-i-Pravastatin (n=2638)"
"8666";"Diet    Diet + pravastatin"
"8667";"Diet    Diet + pravastatin Event / Patients (1OOO/pt-y)"
"8668";"Diet (n 二2718)"
"8669";"Diet (n=2718)"
"8670";"diet + pravastatin"
"8671";"Diet + pravastatin group"
"8672";"Diet 49 / 1248 (8.9)"
"8673";"Diet 49/1248 (8.9)"
"8674";"Diet alone"
"8675";"Diet and exercise"
"8676";"Diet controlled or no"
"8677";"Diet group"
"8678";"Diet group (n=3966)"
"8679";"Diet only"
"8680";"Diet plus pravastatin group (n=3866)"
"8681";"Diet(n 二1664)"
"8682";"diet+ pravastatin"
"8683";"Diet+pravastatin"
"8684";"Diet+Pravastatin (n=1613)"
"8685";"Diet+Pravastatin (n=2638)"
"8686";"Diet+pravastatin 31 / 1228 (5.7)"
"8687";"Dietary calcium intake, mean (SD), mg/d"
"8688";"Dietary EPA-DHA intake (mg/day)*"
"8689";"diff_measure"
"8690";"diff_measure (DM added this as table had multiple headings)"
"8691";"Difference"
"8692";"Difference (%)"
"8693";"Difference (95% CI)*"
"8694";"Difference (95% CI; p value)"
"8695";"Difference (95% Cl)"
"8696";"Difference (a) vs Placebo (95% Cl)"
"8697";"Difference (Glargine -Standard Care) LSM ± SE (mm/year)"
"8698";"Difference (N-3 FA - Placebo) LSM ± SE (mm/year)"
"8699";"Difference (SE)"
"8700";"Difference (Tiotropium - Placebo) ml (95% CI)"
"8701";"Difference 2 Years-Baseline"
"8702";"Difference 4 Years-Baseline*"
"8703";"Difference FF/VI versus UC, %"
"8704";"Difference from  placebo"
"8705";"Difference from baselinea"
"8706";"Difference from placebo"
"8707";"Difference from placebo (95% CI)"
"8708";"Difference from placebo (95% Cl)"
"8709";"Difference from placebo* (95% CI)"
"8710";"Difference from placebo¥"
"8711";"Difference from placeboa"
"8712";"Difference in Change"
"8713";"Difference in LS mean vs placebo (95% CI), %"
"8714";"Difference in LS mean vs placebo (95% CI), mmol/mol"
"8715";"Difference in LS mean8 (95% Cl)"
"8716";"Difference in LS means (95 % CI)4"
"8717";"Difference in LS means (95% Ci)"
"8718";"Difference in LS Means (95% CI)"
"8719";"Difference in LS means (95% CI) versus placebo"
"8720";"Difference in LS means (95% CI)a"
"8721";"Difference in means"
"8722";"Difference in means (95% Cl)"
"8723";"Difference in SBP between treatment"
"8724";"Difference MEPO-PBO (95% CI)"
"8725";"Difference vs FF 100 pg (95 % CI)"
"8726";"Difference vs PBO"
"8727";"Difference vs PBO (95% CI)"
"8728";"Difference vs placebo"
"8729";"Difference vs placebo'"
"8730";"Difference vs placebo (95 % CI)"
"8731";"Difference vs placebo**"
"8732";"Difference vs placebo, % [95% Cl], P"
"8733";"Difference vs. PBOf Mean (s.e.)t"
"8734";"Difference vs. placebo"
"8735";"Difference VS. placebo, % (95% Cl)"
"8736";"Difference vs. placebo, kg (95% Cl)"
"8737";"Difference, % median"
"8738";"Difference13"
"8739";"Differences between indacaterol + tiotropium versus tiotropium + placebo"
"8740";"Differencevs. PBOf"
"8741";"Diffusion capacity of the lung for carbon monoxide, % predicted!"
"8742";"Digit Symbol Substitution"
"8743";"Digital clubbing, n (%)"
"8744";"Digitalis"
"8745";"Digitalis glycoside"
"8746";"Digitalis, n (%)"
"8747";"Digoxin"
"8748";"Digoxin at enrollment"
"8749";"Digoxin at last follow-up"
"8750";"Digoxin N(%)"
"8751";"Digoxin n=6327 (30%)"
"8752";"Digoxin or digitalis glycoside"
"8753";"Digoxin or digitalis preparation"
"8754";"Digoxin or digitalis preparations"
"8755";"Digoxin SCD, No. (%/y)"
"8756";"Digoxin, %"
"8757";"Digoxin, % (n)"
"8758";"Digoxin, (%)"
"8759";"Digoxin, n (%)"
"8760";"Digoxin/digitalis glycoside"
"8761";"Dihydropyridine"
"8762";"Dihydropyridine calcium-channel blocker"
"8763";"Dihydropyridine CCBs"
"8764";"Dilatative"
"8765";"Dilatative, n (%)"
"8766";"Dilated cardiomyopathy"
"8767";"Diltiazem or verapamil"
"8768";"DIP involvement,! n (%)"
"8769";"DIP joint arthritis"
"8770";"Dipeptidyl peptidase-4 inhibitor"
"8771";"Dipeptidyl peptidase 4 inhibitor"
"8772";"Dipeptidyl peptidase 4 inhibitors"
"8773";"Dipyridamole"
"8774";"Dipyridamole alone"
"8775";"Direct stenting per lesion‡"
"8776";"Direct thrombin inhibitors"
"8777";"Direction of HR"
"8778";"Disabling or fatal"
"8779";"Disabling or fatal stroke"
"8780";"Disabling stroke"
"8781";"Discharge medication, n (%)"
"8782";"discontinu- ation"
"8783";"Discontinuation of ICS/LABA prior to baseline, n (%)"
"8784";"Discontinuation of LAMA prior to baseline, n (%)"
"8785";"Discontinuations"
"8786";"Discontinuations due to AE"
"8787";"Discontinuations TEAEs"
"8788";"Discontinued"
"8789";"disease"
"8790";"Disease"
"8791";"Disease-progression composite outcome!"
"8792";"Disease activity"
"8793";"Disease activity (n (%))"
"8794";"Disease activity outcomes (ITT population) week 52"
"8795";"disease activity]"
"8796";"Disease and quality-of-life scores"
"8797";"Disease and quality-of-life scores, mean (SD)"
"8798";"disease characteristics"
"8799";"Disease characteristics"
"8800";"Disease characteristics Duration of psoriatic arthritis — yr"
"8801";"Disease characteristics*"
"8802";"Disease characteristics,"
"8803";"Disease characteristics, n (%), unless otherwise stated"
"8804";"Disease duration"
"8805";"Disease duration (y), median (m/n, max)"
"8806";"Disease duration (years)"
"8807";"Disease duration (years), mean ± s.d."
"8808";"Disease duration (yr)"
"8809";"Disease duration [year], mean ± SDa"
"8810";"Disease duration > 5 years ( N = 536)"
"8811";"Disease duration >7 years, 77 [%] Disease activity‘s"
"8812";"Disease duration 2 to b5 years (N=148)"
"8813";"Disease duration b 2 years ( N = 93)"
"8814";"Disease duration, mean [SD] years"
"8815";"Disease duration, mean yr (SD)"
"8816";"Disease duration, median (range) years"
"8817";"Disease duration, y"
"8818";"Disease duration, y, mean ± SD"
"8819";"Disease duration, year (median)"
"8820";"Disease duration, years"
"8821";"Disease duration, years: median (range)"
"8822";"Disease duration, yrs, mean (SD)"
"8823";"Disease duration: <baseline mean"
"8824";"Disease extent, n (%)"
"8825";"Disease Hare. no. (%)i"
"8826";"Disease history"
"8827";"Disease localization'’, n (%)"
"8828";"Disease localization, n (%)"
"8829";"Disease location (%)*"
"8830";"Disease location, %"
"8831";"Disease location/type: terminal ileum"
"8832";"Disease Severity"
"8833";"Disease site — no. (%)^"
"8834";"Disease site — no. of patients (%)|"
"8835";"Disease site, n [%]"
"8836";"disorders (SOC)"
"8837";"Disposition Index"
"8838";"Dissatisfied with/stopped $ 1 prior systemic therapy because of side effects"
"8839";"Dissatisfied with/stopped $ 2 prior systemic therapies because of side effects"
"8840";"Disseminated  tuberculosis"
"8841";"Distal"
"8842";"Distal anastomosis (%)"
"8843";"Distal forearm"
"8844";"Distal Lower"
"8845";"Distal one-third of radius"
"8846";"Distance to LDL-C goal"
"8847";"Distribution— no. {%)"
"8848";"Distribution — no. (%)"
"8849";"Distribution — no. {%)"
"8850";"Distribution of metformin dose at randomization, n (%)"
"8851";"distribution time"
"8852";"Diurciic"
"8853";"Diuretic"
"8854";"Diuretic— no. (%) Surgery"
"8855";"Diuretic — no./total no. (%)"
"8856";"Diuretic (any)"
"8857";"Diuretic agent"
"8858";"Diuretic agents"
"8859";"Diuretic agents (excluding antialdosterone)"
"8860";"Diuretic drugs"
"8861";"Diuretic drugs (excluding antialdosterone)"
"8862";"Diuretic drugs, n (%)"
"8863";"Diuretic N(%)"
"8864";"Diuretic subgroup"
"8865";"Diuretic therapy"
"8866";"Diuretic Thiazide"
"8867";"Diuretic use"
"8868";"Diuretic use at baseline"
"8869";"Diureticff"
"8870";"Diuretics"
"8871";"Diuretics (%)"
"8872";"Diuretics group (n=544)"
"8873";"Diuretics**"
"8874";"Diuretics, %"
"8875";"Diuretics, n (%)"
"8876";"Diuretics^"
"8877";"Diureties"
"8878";"Dizziness"
"8879";"DLQI"
"8880";"DLQI (0-30), mean (SD)"
"8881";"DLQI (patients with £3% BSA psoriasis)"
"8882";"DLQI improvement from baseline to week 24"
"8883";"DLQI score"
"8884";"DLQI, 0-30*"
"8885";"DLQI§"
"8886";"DM"
"8887";"DM- (Aliskiren vs. Placebo)"
"8888";"DM (n = 2,153)"
"8889";"DM (n=3623)"
"8890";"DM absent"
"8891";"DM Duration"
"8892";"DM duration, years"
"8893";"DM medication, n (%)c"
"8894";"DM or CKD*"
"8895";"DM or diabetic complications"
"8896";"DM present"
"8897";"DM, n (%)"
"8898";"DM+ (Aliskiren vs. Placebo)"
"8899";"DMAb (N = 151)"
"8900";"DMAb (N = 191)"
"8901";"DMAb (N = 342)"
"8902";"DMAb (N = 628)"
"8903";"DMARD− (n = 74)"
"8904";"DMARD-biologic IR"
"8905";"DMARD-IR"
"8906";"DMARD-IR/anti-TNF-IR"
"8907";"DMARD at baseline"
"8908";"DMARD or Corticosteroid"
"8909";"DMARD User"
"8910";"DMARD||"
"8911";"DMARD+ (n = 199)"
"8912";"Documented asymptomatic cardiac ischemiac"
"8913";"Documented coronary artery disease"
"8914";"Documented hypoglycaemiac"
"8915";"Documented MI"
"8916";"Documented symptomatic CHDb"
"8917";"Door-to-balloon time — hr"
"8918";"Dopa and dopa derivativese"
"8919";"Dopamine agonist use, No. (%)"
"8920";"Dose (IU)"
"8921";"Dose (mg/day)"
"8922";"Dose (mg/week)"
"8923";"Dose (n)"
"8924";"Dose Adjusted"
"8925";"Dose adjustment n (%)"
"8926";"Dose adjustment reason < 60 kg"
"8927";"dose equivalent, mg (SD))"
"8928";"Dose of aspirin"
"8929";"Dose of atorvastatin"
"8930";"Dose of rosuvastatin"
"8931";"Dose ratio at week 18 (95% Cl)"
"8932";"Dose ratio at week 26 (95% Cl)"
"8933";"Dose reduced at randomization*"
"8934";"Dose reduction at randomization"
"8935";"Dose reduction at randomization — no. (%);i;"
"8936";"Dose reduction at randomization, %"
"8937";"Dose reduction, n (%)"
"8938";"Dose, mg"
"8939";"Dose/weight (IU/kg)"
"8940";"Dosing"
"8941";"Double-dummy phase**"
"8942";"Double-vessel disease, n (%)"
"8943";"Doubling of baseline serum creatinine or ESRD RR (CI)“"
"8944";"Doubling of creatinine"
"8945";"Doubling of creatinine level,"
"8946";"Doubling of creatinine†"
"8947";"Doubling of serum creatinine"
"8948";"Doubling statin dose"
"8949";"Doxazosin"
"8950";"Doxazosin Group"
"8951";"DPP-4"
"8952";"DPP-4 inhibitor"
"8953";"DPP-4 inhibitor therapy"
"8954";"DPP‐4 inhibitors"
"8955";"DPP-4 inhibitors"
"8956";"Draining cutaneous fistula at baseline, n (%)"
"8957";"Draining fistulae, n (%)"
"8958";"Drinker (%)"
"8959";"Drinker (%)a"
"8960";"Drinker (1-14 drinks/week)"
"8961";"Drinker (1 to 14 drinks/week)"
"8962";"Drinker, n (%)"
"8963";"Drinking"
"8964";"Drinking, n (%)"
"8965";"Drinking, n (%) Lipid values, mmol/L"
"8966";"Dronedarone"
"8967";"Dronedarone (n = 2168)"
"8968";"Dronedarone (N = 2301) 71.6±8.9"
"8969";"Dronedarone (N = 411)"
"8970";"Dronedarone (N = 417)"
"8971";"Dronedarone (N = 828)"
"8972";"Dronedarone (n = 95)"
"8973";"dRosuvastatin + fenofibric acid vs. fenofibric acid monotherapy."
"8974";"Drug- related AE*"
"8975";"Drug-eluting"
"8976";"Drug-eluting stent"
"8977";"Drug-Eluting Stent"
"8978";"Drug-eluting stent — no. (%)"
"8979";"Drug-eluting stent implanted"
"8980";"Drug-eluting stent implanted (at least one)"
"8981";"Drug-eluting stent, n (%)"
"8982";"Drug-related SAEs"
"8983";"Drug-related TEAEs"
"8984";"Drug-related TEAEs*"
"8985";"Drug-related TEAEs3"
"8986";"Drug‐relateda"
"8987";"Drug-relateda"
"8988";"drug and insulint"
"8989";"Drug Discontinuation Not Due To Death"
"8990";"Drug eluting"
"8991";"Drug eluting stent"
"8992";"Drug Naive"
"8993";"Drug therapy"
"8994";"Drug therapy at admission — no. (%) Aspirin"
"8995";"Drug therapy at admission 一no. (%) Aspirin"
"8996";"Drug therapy, n (%)"
"8997";"Drug therapy, No. (%)"
"8998";"Drugs and toxins"
"8999";"Drugs used in diabetes"
"9000";"Drugs used in diabetes, n (%)"
"9001";"Dual antiplatelet"
"9002";"Dual antiplatelet therapy"
"9003";"Dual BP/LDL-C goal attainment"
"9004";"DUAL I extension"
"9005";"DUAL II"
"9006";"DUAL IV"
"9007";"Dual therapy"
"9008";"Due to AE"
"9009";"Due to drug-relateda AE"
"9010";"Due to drug-relateda SAE"
"9011";"due to ECG changes"
"9012";"Due to SAE"
"9013";"due worsening angina"
"9014";"Dulaglutide 0.75 mg"
"9015";"Dulaglutide 0.75 mg (n = 270)"
"9016";"Dulaglutide 0.75 mgf"
"9017";"Dulaglutide 0·75 mg (n=190)"
"9018";"Dulaglutide 1.5 mg"
"9019";"Dulaglutide 1.5 mg (n = 269)"
"9020";"Dulaglutide 1.5 mg*"
"9021";"Dulaglutide 1·5 mg (n=192)"
"9022";"Dupiiumab, 200 mg (N = 631)"
"9023";"Dupiiumab, 300 mg (N = 633)"
"9024";"Dupilumab 631"
"9025";"Dupilumab 633"
"9026";"Duplex ultrasonography"
"9027";"Durable clinical remissionh"
"9028";"Durable clinical responseg"
"9029";"Duration"
"9030";"Duration — yr"
"9031";"Duration <1 year, n (%)"
"9032";"Duration >1 to <5 years, n (%)"
"9033";"Duration >5 years, n (%)"
"9034";"Duration alendronate use, years (meaniSD)"
"9035";"Duration antiplatelet use as % of study duration (SD)"
"9036";"Duration diabetes (years)"
"9037";"Duration DM in DM (years)"
"9038";"Duration from clopidogrel/placebo to PCI, min (median, IQR)"
"9039";"Duration from hospital admission to PCI, h (median, IQR)"
"9040";"Duration of"
"9041";"Duration of alendronate use, mean (SD), y"
"9042";"Duration of AS, n (%)"
"9043";"Duration of AS, years"
"9044";"Duration of assigned regimen before surgery"
"9045";"Duration of assigned regimen before surgery POST-RANDOMISATION CHARACTERISTIC*"
"9046";"Duration of assigned regimen before surgery POST-RANDOMISATION CHARACTERISTIC**"
"9047";"Duration of asthma — yr"
"9048";"Duration of asthma (years)"
"9049";"Duration of asthma >5 years"
"9050";"Duration of asthma,"
"9051";"Duration of asthma, y"
"9052";"Duration of asthma, years"
"9053";"Duration of CHF (months)"
"9054";"Duration of chronic kidney disease* (years)"
"9055";"Duration of clopidogrel pretreatment — hr Median"
"9056";"Duration of clopidogrel pretreatment 一hr Median"
"9057";"Duration of COPD — days^"
"9058";"Duration of COPD — yr"
"9059";"Duration of COPD (years)"
"9060";"Duration of COPD (years), mean (SD)"
"9061";"Duration of COPD (yr)"
"9062";"Duration of COPD (yr)f"
"9063";"Duration of COPD,"
"9064";"Duration of COPD, y"
"9065";"Duration of COPD, years"
"9066";"Duration of COPD, yr"
"9067";"Duration of coronary artery disease — yr"
"9068";"Duration of Crohn's disease (yrs)"
"9069";"Duration of Crohn’s disease (yrs)"
"9070";"Duration of current flare, median (range) months (n = 99, 99, 96)"
"9071";"Duration of dementia symptoms, months"
"9072";"Duration of diabetes"
"9073";"Duration of Diabetes"
"9074";"Duration of diabetes — yr"
"9075";"Duration of diabetes — yr^"
"9076";"Duration of Diabetes    <5 yrs"
"9077";"Duration of diabetes (months)"
"9078";"Duration of diabetes (y)"
"9079";"Duration of diabetes (years)"
"9080";"Duration of diabetes (years), mean (SD)"
"9081";"Duration of diabetes (years), mean, (SD)"
"9082";"Duration of diabetes (years)t"
"9083";"Duration of Diabetes < 10 years"
"9084";"Duration of Diabetes > 10 years"
"9085";"Duration of diabetes by tertiles"
"9086";"Duration of diabetes in years, median (IQR)"
"9087";"Duration of diabetes mellitus"
"9088";"Duration of diabetes mellitus, median (IQR), y"
"9089";"Duration of diabetes mellitus, y"
"9090";"Duration of diabetes mellitus, y, mean (SD)§"
"9091";"Duration of diabetes Microvascular disease — no. (%)"
"9092";"Duration of diabetes, mean (SD), y"
"9093";"Duration of diabetes, Median (IQR)"
"9094";"Duration of diabetes, y"
"9095";"Duration of diabetes, y, mean (SD)"
"9096";"Duration of diabetes, years"
"9097";"Duration of Diabetes, years"
"9098";"Duration of diabetes, years, mean (SD)"
"9099";"Duration of diabetes, years, median (IQR)"
"9100";"Duration of diabetes, yrs"
"9101";"Duration of disease — mo"
"9102";"Duration of disease — yr"
"9103";"Duration of disease — yr:t"
"9104";"Duration of disease — yr^ Mean"
"9105";"Duration of disease (y), median (min, max}"
"9106";"Duration of disease (years)"
"9107";"Duration of disease (yr)"
"9108";"Duration of disease before baseline"
"9109";"Duration of disease since"
"9110";"Duration of disease, median"
"9111";"Duration of disease, n (%)"
"9112";"Duration of disease, y"
"9113";"Duration of DM-years"
"9114";"Duration of epilepsy, mean (SD), years"
"9115";"duration of epilepsy, years"
"9116";"Duration of epilepsy, years, mean (SD)"
"9117";"Duration of full-dose warfarin therapy before enrollment (mo)"
"9118";"Duration of heart failure (years)"
"9119";"Duration of HF, y"
"9120";"Duration of hypercholesterolaemia; mean ± SD (year)"
"9121";"Duration of hypercholesterolemia (yr)"
"9122";"Duration of hypercholesterolemia; mean ± SD (years)"
"9123";"Duration of hypertension (months)"
"9124";"Duration of hypertension (years)"
"9125";"Duration of hypertension, n (%)"
"9126";"Duration of hypertension, y"
"9127";"Duration of infusion — hr"
"9128";"Duration of infusion after PCI — hr"
"9129";"Duration of infusion before CABG — hr"
"9130";"Duration of infusion before PCI — hr"
"9131";"Duration of infusion during medical management— hr"
"9132";"Duration of initial anticoagulation, mean (SD), mo"
"9133";"Duration of last qualifying episode of atrial fibrillation >7 days"
"9134";"Duration of macular edema, mo"
"9135";"Duration of metformin therapy (months)"
"9136";"Duration of morning"
"9137";"Duration of oral antidiabetic treatment, y, mean (SD)"
"9138";"Duration of osteoarthritis symptoms — yr"
"9139";"Duration of PAOD (years), mean ± SD"
"9140";"Duration of PCI — min"
"9141";"Duration of PCI (min), median"
"9142";"Duration of PCI (min), median N (IQR)"
"9143";"Duration of PCI, min"
"9144";"Duration of PD, y"
"9145";"Duration of pre-randomization anticoagulant therapy"
"9146";"Duration of previous use of VKA, months"
"9147";"Duration of prior alendronate use, months"
"9148";"Duration of prior statin therapy^"
"9149";"Duration of procedure"
"9150";"Duration of psoriasis (years), mean (SD)"
"9151";"Duration of psoriasis, years"
"9152";"Duration of qualifying atrial fibrillation »2 days — no. (%)"
"9153";"Duration of RA"
"9154";"Duration of RA (time from symptom onset), years"
"9155";"Duration of RA (Years)"
"9156";"Duration of RA, mean (min-max) (yrs)"
"9157";"Duration of RA, mean ± SD years"
"9158";"Duration of RAt, years"
"9159";"Duration of rheumatoid arthritis — yr"
"9160";"Duration of rheumatoid arthritis (years)"
"9161";"Duration of rheumatoid arthritis, year"
"9162";"Duration of study-drug administration — hr"
"9163";"Duration of study-drug infusion"
"9164";"Duration of sulphonylurea use (months), mean ± s.d."
"9165";"Duration of symptoms > 10 min"
"9166";"Duration of symptoms, h"
"9167";"Duration of T1D (years)"
"9168";"Duration of T2D (years)"
"9169";"Duration of T2D, y"
"9170";"Duration of T2DM"
"9171";"Duration of T2DM (%)"
"9172";"Duration of T2DM (years)"
"9173";"Duration of T2DM <10 years"
"9174";"Duration of T2DM >10 years"
"9175";"Duration of T2DM, y"
"9176";"Duration of T2DM, years"
"9177";"Duration of total exposure to study treatment, weeks"
"9178";"Duration of treatment in the healing study, n"
"9179";"Duration of type 2 diabetes"
"9180";"Duration of type 2 diabetes (years)"
"9181";"Duration of type 2 diabetes categories, n (%)"
"9182";"Duration of type 2 diabetes mellitus (years)"
"9183";"Duration of type 2 diabetes mellitus, years"
"9184";"Duration of type 2 diabetes, years"
"9185";"Duration of ulcerative colitis"
"9186";"Duration ofdiabetes — yr"
"9187";"Duration since diagnosis (years)"
"9188";"Duration, mean (SD), years"
"9189";"during overall study period"
"9190";"Dutasteride"
"9191";"Dutasteride (n = 106)"
"9192";"Dutasteride (n = 184)"
"9193";"Dutasteride (n=117)"
"9194";"Dutasteride (n=67)"
"9195";"Dutasteride (W= 1623), 0/0"
"9196";"DVT"
"9197";"DVT only"
"9198";"DVT Only"
"9199";"Dx at presentation, n (%)"
"9200";"Dynamic measure of β-cell function (ϕs) (change from baseline) – assessed for MMTT subset only"
"9201";"dysfunction; EF = erectile function; IIEF = I"
"9202";"Dysglycaemia or MetS"
"9203";"Dysglycemic categories, n (%)"
"9204";"Dyslipidaemia"
"9205";"Dyslipidaemia—No. (%)"
"9206";"Dyslipidaemia and hypertension, n (%)"
"9207";"Dyslipidaemia and hypertensiont"
"9208";"Dyslipidaemia including Hypercholesterol—No. (%)"
"9209";"Dyslipidaemia, n (%)"
"9210";"Dyslipidaemia本"
"9211";"DyslipidaemiaJ"
"9212";"Dyslipidaemiat"
"9213";"Dyslipidemia"
"9214";"Dyslipidemia — no. (%)"
"9215";"Dyslipidemia — no. (%)|"
"9216";"Dyslipidemia — no. {%)"
"9217";"Dyslipidemia, n (%)"
"9218";"Dyslipidemia, n(%)"
"9219";"Dyslipidemia3"
"9220";"Dyspepsia"
"9221";"Dyspnea"
"9222";"Dyspnea – mMRC grade, n (%)"
"9223";"Dyspnea at rest (NYHA IV), (%)"
"9224";"Dyspnea t"
"9225";"Dyspnea, % (frequent/continuous)"
"9226";"Dyspnea, frequent/continuous"
"9227";"Dyspnoea - mMRC grade, n (%)"
"9228";"Dyspnoea (N=18)"
"9229";"Dyspnoea (N=68)"
"9230";"e"
"9231";"E"
"9232";"E-RS total scoreb"
"9233";"E ( Characteristic n"
"9234";"E Europe"
"9235";"e Major Non-Vertebral Fragility Fractures (FAS)"
"9236";"E. Europe"
"9237";"E/A ratio"
"9238";"E/E' (septal)"
"9239";"E10 + A10"
"9240";"E10 + A10 -"
"9241";"E10 + A20"
"9242";"E15 (n = 248)"
"9243";"E15/S100 (n = 244)"
"9244";"E15/S100 vs E15"
"9245";"E15/S100 vs S100"
"9246";"E5 (n = 250)"
"9247";"E5/S100 (n = 243)"
"9248";"E5/S100 vs E5"
"9249";"E5/S100 vs S100"
"9250";"EACIT-E total score) |"
"9251";"Early"
"9252";"Early-Eptifibatide Group (N = 4722)"
"9253";"Early-Start Group (N = 288)"
"9254";"Early-Start Group (N = 293)"
"9255";"Early (n=107)"
"9256";"Early (n=201)"
"9257";"Early (n=207)"
"9258";"Early clopidogrel intended"
"9259";"Early Crohn's disease*"
"9260";"Early death"
"9261";"Early Eptifibatide"
"9262";"Early ichaem ic stroke"
"9263";"Early invasive strategy (n = 3,116)"
"9264";"Early Invasive*"
"9265";"Early Invasive1"""
"9266";"Early load"
"9267";"Early Load"
"9268";"Early routine"
"9269";"Early use intended"
"9270";"Early, n (%)"
"9271";"EASE-2"
"9272";"EASE-3"
"9273";"ease activity]"
"9274";"East Asia"
"9275";"East Asian"
"9276";"East Europe"
"9277";"Eastern and central Europe"
"9278";"Eastern Europe"
"9279";"Eastern Europe (%)"
"9280";"Eastern Europe (n = 1,154)"
"9281";"Eastern Europe and Africa"
"9282";"Eastern Europe, Africa"
"9283";"Eastern European"
"9284";"ebriA"
"9285";"eCFR (mL/min per 1-73 m’)"
"9286";"eCFR, mL/min per 1.73 m2"
"9287";"ECG"
"9288";"ECG-LVH (Cornell)"
"9289";"ECG-LVH (Sokolow-Lyon)"
"9290";"ECG abnormality (resting), %"
"9291";"ECG abnormality at entry"
"9292";"ECG and imaging data"
"9293";"ECG at time of qualifying symptoms"
"9294";"ECG atrial fibrillation, n (%)"
"9295";"ECG changes (%)t"
"9296";"ECG findings"
"9297";"ECG findings at baseline — no. (%)"
"9298";"ECG left ventricular"
"9299";"eCrCl <30 ml/min"
"9300";"eCrCl <60 ml/min"
"9301";"eCrCl, ml/min"
"9302";"eCrCL, ml/min"
"9303";"Eczema"
"9304";"ED >1 yr, no. (%)"
"9305";"ED characteristics"
"9306";"ED duration"
"9307";"ED duration >1 yr, n (%)"
"9308";"ED duration, visit 2**"
"9309";"ED etiology, no. (%)"
"9310";"ED history, n (% Yes)"
"9311";"ED severity **, n (%):"
"9312";"ED severity, no. (%)a"
"9313";"ED severity, visit 2**"
"9314";"ED therapy"
"9315";"ED visit related to exacerbation, n (%)"
"9316";"EDA, %"
"9317";"Edema peripheral"
"9318";"Edema, %z"
"9319";"Edema, (%)"
"9320";"Edema, n (%)"
"9321";"Edema, peripheral"
"9322";"EDGE"
"9323";"EDGE II"
"9324";"Edo"
"9325";"Edoxaban"
"9326";"EdOXaban"
"9327";"Edoxaban (N = 1650)"
"9328";"Edoxaban (N = 2468)"
"9329";"Edoxaban (N = 4118)"
"9330";"Edoxaban (n=14023)"
"9331";"edoxaban at randomization, n (%)"
"9332";"Edoxaban dose adjusted at randomisation, n (%)*"
"9333";"Edoxaban higher dose vs warfarin"
"9334";"Edoxaban lower dose vs warfarin"
"9335";"Edoxaban N = 3555"
"9336";"Edoxaban N = 3555 n/N (%)"
"9337";"Edoxaban N = 563"
"9338";"Edoxaban N = 563 n/N (%)"
"9339";"Edoxaban n/N; rate (%)"
"9340";"Edoxaban vs. Warfarin"
"9341";"Edoxaban Warfarin"
"9342";"EDSS score"
"9343";"EDSS stratification, No. (%)"
"9344";"EDSS stratification. No. (%)"
"9345";"Educ >12Y"
"9346";"Educ 9-12Y"
"9347";"Educ sSY"
"9348";"Education"
"9349";"Education — no. (%)"
"9350";"Education (%)"
"9351";"education (years)"
"9352";"Education (years)"
"9353";"Education <8 y"
"9354";"Education <8 years"
"9355";"Education >12 y"
"9356";"Education >12 years"
"9357";"Education >12 yr (%)"
"9358";"Education 8-12 years"
"9359";"Education 9 to 12 y"
"9360";"Education in years, mean"
"9361";"Education in years, mean (SD)"
"9362";"Education level"
"9363";"Education*"
"9364";"Education, mean (sd) years"
"9365";"Education, mean (SD), y"
"9366";"Education, mean (SD), ya"
"9367";"Education, y"
"9368";"Education, y, mean (SD)"
"9369";"Education, years, mean (SD)"
"9370";"Education, yrs, mean (sd)"
"9371";"Eduglinozin 15 mg vs placebo/glimepiride"
"9372";"EF (%), mean (SD)"
"9373";"EF < 50% (N 5 520)"
"9374";"EF <30%"
"9375";"EF <40% (n = 3,116)"
"9376";"EF <40% n=385"
"9377";"EF <45%"
"9378";"EF <50% (N 5 520)"
"9379";"EF > 50% HFpEF (n = 1953, 26%)"
"9380";"EF >40% (n = 3,116)"
"9381";"EF >40% n=3894"
"9382";"EF >60% (N 5 1333)"
"9383";"EF 40-49%"
"9384";"EF 40-49% HFmrEF (n = 1322, 17%)"
"9385";"EF 50-54.99% (N 5 712)"
"9386";"EF 55-59.99% (N 5 879)"
"9387";"EF b 50%"
"9388";"EF domain"
"9389";"EF, %"
"9390";"EF<40%"
"9391";"EF<40% HFrEF (n = 4323, 57%)"
"9392";"EF>50%"
"9393";"Effect estimate"
"9394";"Effect of Covariates on Slopes"
"9395";"Effect of ranolazine compared with placebo on angina and recurrent ischemia"
"9396";"Effect size!"
"9397";"Effect size^"
"9398";"Efficacy"
"9399";"Efficacy and safety: net adverse clinical events*"
"9400";"Efficacy end points"
"9401";"Efficacy Endpoint"
"9402";"Efficacy endpoints*"
"9403";"Efficacy measures"
"9404";"Efficacy parameter"
"9405";"Efficacy variable"
"9406";"Efficacy, n (%)a"
"9407";"eGFR"
"9408";"eGFR-"
"9409";"eGFR— mean (sd, N)"
"9410";"eGFR — ml/min/1.73 m**"
"9411";"eGFR — mL/min/1.73 m^"
"9412";"eGFR — ml/min/1.73 m2"
"9413";"eGFR (CKD-EPI, cystatin C), mL/min/1.73 m2"
"9414";"eGFR (MDRD), ml min−1 1.73 m−2"
"9415";"eGFR (MDRD), mL/min/1.73 m**"
"9416";"eGFR (MDRD), mL/min/1.73 m2"
"9417";"eGFR (MDRD), n (%)"
"9418";"eGFR (median, IQR), mL/min/1,73m2"
"9419";"eGFR (mL/min per 1-73 kg/m^)"
"9420";"eGFR (mL/min per 1-73 m')"
"9421";"eGFR (mL/min per 1-73 m^)"
"9422";"eGFR (mL/min per 1-73 m’)"
"9423";"eGFR (mL/min per 1-73 m2)t"
"9424";"eGFR (mL/min per 1-73 m3)"
"9425";"eGFR (ml/min per 1.73 m2),"
"9426";"eGFR (mL/min per 1^73 m')"
"9427";"eGFR (mL/min per 1+73 m”"
"9428";"eGFR (mL/min per 1·73 m2)"
"9429";"eGFR (mL/min)"
"9430";"eGFR (mL/min/1-73 mz)"
"9431";"eGFR (mL/min/1.73 m2 [MDRDequation])"
"9432";"eGFR (ml/min/1.73 m2)"
"9433";"eGFR (mL/min/1.73 m2)"
"9434";"eGFR (ml/min/1.73 m2), mean (SD)"
"9435";"eGFR (mL/min/1.73 m2), mean (SD)"
"9436";"eGFR (mL/min/1.73 m2)§"
"9437";"eGFR (ml/min/1.73m2)"
"9438";"eGFR (mL/min/1.73m2)"
"9439";"eGFR (mL/min/1.78 m2)"
"9440";"eGFR (mUmin/1.73 m2)"
"9441";"eGFR ,30 mL/min/1.73 m2 (n =206)"
"9442";"eGFR ,30 mL/min/1.73 m2 (n =336)"
"9443";"eGFR ,60 mL/min/1.73 m2, n (%)"
"9444";"eGFR .50 mL/min/1.73 m2 (n = 10,621)"
"9445";"eGFR .50 mL/min/1.73 m2 (n = 13,916)"
"9446";"eGFR £60 mL/min/1.73m2"
"9447";"eGFR < 30 mL/min/1.73 m2"
"9448";"eGFR < 60 ml/min/1.73m2"
"9449";"eGFR <30"
"9450";"eGFR <30 mL/min/1.73"
"9451";"eGFR <30 ml/min/1.73 m2"
"9452";"eGFR <45 mL/min/1.73 m2"
"9453";"eGFR <45 mL/min/1.73 m2 (N = 554)"
"9454";"eGFR <45.0 (vs eGFR >75)"
"9455";"eGFR <50 mL/min, n (%)"
"9456";"eGFR <50 mL/min/1.73 m2§"
"9457";"eGFR <60"
"9458";"eGFR <60 (mL/min/1.73 m2)"
"9459";"eGFR <60 mL/ min/1.73m2"
"9460";"eGFR <60 mL/min"
"9461";"eGFR <60 mL/min per 1^73 m'"
"9462";"eGFR <60 mL/min per 1·73 m2"
"9463";"eGFR <60 mL/min/1-73 m2"
"9464";"eGFR <60 mL/min/1.73"
"9465";"eGFR <60 mL/min/1.73 m^"
"9466";"eGFR <60 ml/min/1.73 m2"
"9467";"eGFR <60 mL/min/1.73 m2"
"9468";"eGFR <60 ml/min/1.73 m2 (MDRD)"
"9469";"eGFR <60 ml/min/1.73 m2*"
"9470";"eGFR <60 mL/min/1.73 mz"
"9471";"eGFR <60 mL/min/1.73m2"
"9472";"eGFR <60, ml/min/m2"
"9473";"eGFR <60, n (%)"
"9474";"eGFR <78"
"9475";"eGFR ≥60 mL/min per 1·73 m2"
"9476";"eGFR ≥60 mL/min/1.73 m2"
"9477";"eGFR ≥90 mL/min/1.73 m2 (N = 2476)"
"9478";"eGFR > 60, n (%)"
"9479";"eGFR >=90ml/min/1.73m2 N=3,325 (22.9%)"
"9480";"eGFR >50 mL/min"
"9481";"eGFR >50 mL/min/1.73 m2"
"9482";"eGFR >60 (mL/min/1.73 m2)"
"9483";"eGFR >60 mL/min per 1^73 m'"
"9484";"eGFR >60 mL/min/1-73 m2"
"9485";"eGFR >60 mL/min/1.73 m^"
"9486";"eGFR >60 ml/min/1.73 m2"
"9487";"eGFR >60 mL/min/1.73 mz"
"9488";"eGFR >75"
"9489";"eGFR >80 mL/min, n(%)"
"9490";"eGFR >90 ml/min/1.73m2"
"9491";"eGFR 290 mL/min/1.73"
"9492";"eGFR 30-44 ml/min/1.73m2"
"9493";"eGFR 30-44 ml/min/1.73m2 N=783 (5.4%)"
"9494";"eGFR 30-50"
"9495";"eGFR 30-50 mL/min/1.73 m2 (n = 2,240)"
"9496";"eGFR 30-50 mL/min/1.73 m2 (n =1,533)"
"9497";"eGFR 30-59 ml/min/1.73 m2"
"9498";"eGFR 30–50 mL/min/1.73 m2"
"9499";"eGFR 30 to <45 mL/min/1.73"
"9500";"eGFR 45-59 ml/min/1.73m2"
"9501";"eGFR 45-59 ml/min/1.73m2 N=2,538 (17.5%)"
"9502";"eGFR 45 to <60 mL/min/1.73 m*"
"9503";"eGFR 45 to <60 mL/min/1.73 m2 (N = 1485)"
"9504";"eGFR 45.0-59.9 (vs eGFR >75)"
"9505";"eGFR 50 to <80 mL/min, n (%)"
"9506";"eGFR 560 mL/min/1.73 m^"
"9507";"eGFR 60-89 ml/min/1.73m2"
"9508";"eGFR 60-89 ml/min/1.73m2 N=7,879 (54.2%)"
"9509";"eGFR 60 to <75 mL/min/1.73 m’"
"9510";"eGFR 60 to <90 mL/min/1.73 m2 (N = 5625)"
"9511";"eGFR 60.0-74.9 (vs eGFR >75)"
"9512";"eGFR 75 to <90 mL/min/1.73 m^"
"9513";"eGFR and albuminuria"
"9514";"eGFR at baseline , 60 mL/min (%)b"
"9515";"eGFR by creatinine (mL/min per 1·73 m2)"
"9516";"eGFR by creatinine (mL/min per 1·73 m2, geometric mean [SE])"
"9517";"eGFR by cystatin C (mL/min per 1·73m2, geometric mean [SE])"
"9518";"eGFR by cystatin C (mL/min per 1·73m2, mean [SE])"
"9519";"eGFR category"
"9520";"eGFR category (mL/min/1.73 m2), n (%)"
"9521";"eGFR category, n (%)"
"9522";"eGFR CrCl <60 ml/min/1.73 m2"
"9523";"eGFR CrCl mL·min−1·1.73 m−2"
"9524";"eGFR from the MDRD equation (SD), mL·min−1·1.73 m−2"
"9525";"eGFR in 3 classes"
"9526";"eGFR in ml/min/1.73 m^ , median (IQR)"
"9527";"eGFR s60 mL/min/1.73 m^"
"9528";"eGFR S60 mL/min/1.73 m^"
"9529";"eGFR S6O mL/min/1.73 m^"
"9530";"eGFR using CG/MDRD formulae, % of patients"
"9531";"eGFR via MDRD (mL/min/1.73m2)"
"9532";"eGFR <60 ml/min/1.73 m2"
"9533";"eGFR ≥60 ml/min/1.73 m2"
"9534";"eGFR(CKD-EPI,cystatinC),mL/min/1.73 m2,n(%)"
"9535";"eGFR(mL/min/1.73 m2)"
"9536";"eGFR, mean (SD), mL/min/1.73 m2"
"9537";"eGFR, mean = SD, mL/min/1.73 m2"
"9538";"eGFR, mean±SD"
"9539";"eGFR, median (SD), mL/min"
"9540";"eGFR, mL • mn ' • 1.73 m 2"
"9541";"eGFR, ml min 1 1.73 m 2"
"9542";"eGFR, mL/ min/1.73 m2"
"9543";"eGFR, mL/kg per 1.73 m2"
"9544";"eGFR, ml/min"
"9545";"eGFR, mL/min"
"9546";"eGFR, mL/min per 1.73 m2"
"9547";"eGFR, ml/min per 1.73 m2, mean (SD)"
"9548";"eGFR, mL/min per 1·73 m2"
"9549";"eGFR, mL/min/1.73 m^"
"9550";"eGFR, ml/min/1.73 m2"
"9551";"eGFR, mL/min/1.73 m2"
"9552";"eGFR, mL/min/1.73 m2 (MDRD)"
"9553";"eGFR, mL/min/1.73 m2 (MDRD), mean (SD)"
"9554";"eGFR, mL/min/1.73 m2 (SD)"
"9555";"eGFR, mL/min/1.73 m2, mean (SD)"
"9556";"eGFR, mL/min/1.73 m2, mean ± SD"
"9557";"eGFR, mL/min/1.73 m2"
"9558";"eGFR, ml/min/1.73m2"
"9559";"eGFR, mL/min/1.73m2,‡"
"9560";"eGFR, mL/min/BSA"
"9561";"eGFR, ml/min/m2"
"9562";"eGFR, mL/minute/1.73 m2"
"9563";"eGFR, n (%) Normal (eGFR >90 mL/min/em^)"
"9564";"eGFR,* mL/min/1.73 m2"
"9565";"eGFR_P_interaction"
"9566";"eGFR+, mL/min/1.73 m2 (mean ± SD)"
"9567";"eGFR>50"
"9568";"eGFR‡ (mL/min per 1·73 m2)"
"9569";"eGFRMDRD <60 mL - min-1-1.73 m-2, n (%)"
"9570";"eGFRMDRD, mL - min-1-1.73 m-2"
"9571";"eGFRMDRD, ml/min/1.73 m2 BSA"
"9572";"eGFRMDRD，mL - min-1- 1.73 m_2"
"9573";"Either OCS use, nasal polyps, pre-BD FVC <65% of predicted or age at diagnosis sl8 years"
"9574";"Ejection fraction"
"9575";"Ejection Fraction"
"9576";"Ejection fraction — mean ±SD"
"9577";"Ejection fraction (%)"
"9578";"Ejection fraction (mean)"
"9579";"Ejection fraction based on local reading"
"9580";"Ejection fraction group"
"9581";"Ejection fraction*"
"9582";"Ejection fraction, %"
"9583";"Ejection Fraction, %"
"9584";"Ejection fraction, % NYHA class, n (%)"
"9585";"Ejection fraction, mean (SD), %"
"9586";"Ejection fraction, percent (SD)"
"9587";"Ejection fraction: <50% (n=288)"
"9588";"EL, n (%)"
"9589";"Elderly"
"9590";"Elderly (>65 years)"
"9591";"Elderly patients (n — 2778)"
"9592";"Elective peripheral revascularization"
"9593";"Elective procedure"
"9594";"Elective surgery"
"9595";"electrocardiogram"
"9596";"Electrocardiograph results, No. (%)"
"9597";"Electrocardiographic findings — no. (%)"
"9598";"Electrocardiographic findings at randomization"
"9599";"Electrocardiography"
"9600";"Electrophysiological study— no. (%) Weight — IbJ"
"9601";"Elevated at wk 0 — no. (%)!"
"9602";"Elevated at wk 12 — no. (%)1"
"9603";"Elevated baseline CRP"
"9604";"Elevated biomarkers and ST-segment changes"
"9605";"Elevated blood pressure"
"9606";"Elevated BNP"
"9607";"Elevated BNP (80 pg/ml), %"
"9608";"Elevated BNP, >80 pg/ml (n = 1,876)"
"9609";"Elevated BUN (>14.3 mEq/L)"
"9610";"Elevated cardiac markers"
"9611";"Elevated cardiac markers — no. (%):t"
"9612";"Elevated cholesterol"
"9613";"Elevated creatine kinase-MB (>24 U/L)"
"9614";"Elevated creatine kinase MB (>24 U/L)"
"9615";"Elevated creatinine (>177 pmol/L)"
"9616";"Elevated CRP (>ULNt), n (%)"
"9617";"Elevated CRP, n (%)"
"9618";"Elevated fasting glucose"
"9619";"Elevated high-sensitivity CRP—no. {%)**"
"9620";"Elevated hsCRP"
"9621";"Elevated hsCRP >5 mg/L, n (%)"
"9622";"Elevated Natriuretic Peptide Level (n=92)"
"9623";"Elevated natriuretic peptides in previous 60 days — no. (%)$"
"9624";"Elevated natriuretic peptides in previous 60 days — no. (%):!:"
"9625";"Elevated non-HDL cholesterol"
"9626";"Elevated serum creatinine (>2.5 mg/dl_)"
"9627";"Elevated Serum Creatinine, >2.5 mg/dl"
"9628";"Elevated Serum Potassium, >6.0 mmol/l"
"9629";"Elevated Symptomatic Serum Creatinine, Hypotension    >2.5 mg/dl"
"9630";"Elevated TG"
"9631";"Elevated Troponin"
"9632";"Elevated troponin — %"
"9633";"Elevated troponin (>0.03 pg/L)"
"9634";"Elevated troponin (>0.04 mg/l), %"
"9635";"Elevated troponin T (>0.03 /xg/L)"
"9636";"elevated vs normalb"
"9637";"elevated vs. normalb"
"9638";"elevated vs. normalc"
"9639";"Elevation of cardiac biomarker levels — no./total no. (%)"
"9640";"Elevation of cardiac biomarker levels or ST-seg- ment deviation >1 mm — no./total no. (%)"
"9641";"Elevation of troponin levels — no./total no. (%)"
"9642";"Eligibility risk factors"
"9643";"Eligibility risk factors—n (%):"
"9644";"Eligibility risk factors!"
"9645";"Eligibility risk factors, %t ASCVO"
"9646";"Eligibility risk factors, No. (%)t"
"9647";"Eligibility risk factors/"
"9648";"Eligibility risk factors:"
"9649";"Eligibility risk factors’)"
"9650";"Eligibility risk factorsa"
"9651";"Eligibility strata"
"9652";"Eligibility stratum"
"9653";"ElMs, n (%)"
"9654";"embolism"
"9655";"Emergent/urgent surgery"
"9656";"Emotional function"
"9657";"Emotional status"
"9658";"EMPA"
"9659";"EmpagIiflozin 10 mg"
"9660";"EmpagIiflozin 25 mg"
"9661";"Empaglifiozin 10 mg (W = 243)"
"9662";"Empaglifiozin 10 mg (W = 244)"
"9663";"Empaglifiozin 2.5 mg (W = 237)"
"9664";"Empaglifiozin 25 mg (W = 241)"
"9665";"Empaglifiozin 25 mg (W = 242)"
"9666";"Empagliflozin"
"9667";"Empagliflozin (N = 1212) 67.1±7.6"
"9668";"Empagliflozin (N = 3473) 61.7±8.5"
"9669";"Empagliflozin (n = 1175)"
"9670";"Empagliflozin (n = 3512)"
"9671";"Empagliflozin (n=1338)"
"9672";"Empagliflozin (N=1498)"
"9673";"Empagliflozin (n=2789)"
"9674";"Empagliflozin (N=3149)"
"9675";"Empagliflozin (n=509)"
"9676";"Empagliflozin 10 mg"
"9677";"Empagliflozin 10 mg (N = 2345)"
"9678";"Empagliflozin 10 mg (n=122)"
"9679";"Empagliflozin 10 mg (n=135)"
"9680";"Empagliflozin 10 mg (N=1740)"
"9681";"Empagliflozin 10 mg (n=19)"
"9682";"Empagliflozin 10 mg (n=276)"
"9683";"Empagliflozin 10 mg (N=605)"
"9684";"Empagliflozin 10 mg/day (n = 700)"
"9685";"Empagliflozin 25 mg"
"9686";"Empagliflozin 25 mg (N = 2342)"
"9687";"Empagliflozin 25 mg (n=116)"
"9688";"Empagliflozin 25 mg (n=139)"
"9689";"Empagliflozin 25 mg (N=1733)"
"9690";"Empagliflozin 25 mg (n=21)"
"9691";"Empagliflozin 25 mg (n=276)"
"9692";"Empagliflozin 25 mg (N=607)"
"9693";"Empagliflozin 25 mg/day (n = 703)"
"9694";"Empagliflozin n with event/n"
"9695";"Empagliflozin Pooled (n=1446)"
"9696";"Empagliflozin Pooled (n=1639)"
"9697";"Empagliflozin Pooled (n=1869)"
"9698";"Empagliflozin Pooled (n=3048)"
"9699";"Empagliflozin Pooled (n=564)"
"9700";"Empagliflozin Pooled (n=805)"
"9701";"Empagllflozin"
"9702";"Empagllflozln"
"9703";"Emphysema"
"9704";"Emphysema (%)"
"9705";"Emphysema (ITT) (n=433)"
"9706";"Emphysema (ITT) (n=438)"
"9707";"Emphysema (ITT) (n=444)"
"9708";"Emphysema (ITT) (n=446)"
"9709";"Emphysema (ITT) (n=577)"
"9710";"Emphysema (ITT) (n=582)"
"9711";"Emphysema (n=462)"
"9712";"empty"
"9713";"ENACT-1 Trial"
"9714";"ENACT-2 Trial Rerandomization to Natalizumab (N=168)"
"9715";"Enalapril"
"9716";"Enalapril    LCZ696 (n = 747)    (n = 752)"
"9717";"Enalapril (n = 1684)"
"9718";"Enalapril (n = 1812)"
"9719";"Enalapril (n = 2400)"
"9720";"Enalapril (n = 490)"
"9721";"Enalapril (n = 491)"
"9722";"Enalapril (n = 642)"
"9723";"Enalapril (n = 652)"
"9724";"Enalapril (n = 665)"
"9725";"Enalapril (n=1877)"
"9726";"Enalapril (n=2335)"
"9727";"Enalapril + aliskiren (n = 1675)"
"9728";"Enalapril + aliskiren (n = 665)"
"9729";"Enalapril + aliskiren DM = 665 Non-DM = 1675"
"9730";"Enalapril DM = 652 Non-DM = 1684"
"9731";"End-point (SD)"
"9732";"End-stage renal disease"
"9733";"End of Follow-up"
"9734";"End of trial"
"9735";"End point"
"9736";"End Point"
"9737";"End points"
"9738";"End Points"
"9739";"Ended >90 days before trial entry"
"9740";"Endoscopic disease severity"
"9741";"Endoscopy subscore"
"9742";"Endoscopy subscore, n (%)"
"9743";"Endothelin-receptor antagonists"
"9744";"Endothelin-receptor antagonists plus phosphodiesterase type 5 inhibitors"
"9745";"Endothelin 1 (pg/ml)"
"9746";"Endovascular"
"9747";"Endovascular— no. (%)"
"9748";"Endpoint"
"9749";"Endpoint rate"
"9750";"Endpoint Week 161"
"9751";"Endpoint*"
"9752";"Endpoint/baseline"
"9753";"Endpoint/baselinec"
"9754";"Endpointc"
"9755";"Endpoints"
"9756";"Enox"
"9757";"Enoxaparin"
"9758";"Enoxaparin (N = 10,021)"
"9759";"Enoxaparin (N = 10,256)"
"9760";"Enoxaparin (n = 4993)"
"9761";"Enoxaparin (n = 906)"
"9762";"Enoxaparin (n= 2026)"
"9763";"Enoxaparin 40 mg (n = 2,157)"
"9764";"Enoxaparin Only"
"9765";"Enoxaparin/VKA"
"9766";"Enoxaparin/VKA n/N    (%) 51/1718    (3.0)"
"9767";"Enrolled from RE-COVER II study — no. (%)"
"9768";"Enrolled from RE-COVER study — no. (%)"
"9769";"Enrolled in Russia or Georgia"
"9770";"Enrolled in the Americas"
"9771";"Enrolled into Osler"
"9772";"Enrollment by region, no. (%)"
"9773";"Enrollment in LMWH"
"9774";"Enrollment in LMWH substudy"
"9775";"Enrollment strata: prior hospitalization"
"9776";"Enrollment to randomization"
"9777";"Enrolment through HF"
"9778";"Enrope + Sonth Afriea"
"9779";"Entacapone"
"9780";"Enthesitis"
"9781";"Enthesitis count"
"9782";"Enthesitis score (MASES, 1-15), mean (SD)"
"9783";"Enthesitis score at baseline, median (IQR) Week 100"
"9784";"Enthesitis score*"
"9785";"Enthesitis, %§"
"9786";"Enthesitis, n (%)"
"9787";"Entire cohort"
"9788";"Entire cohort Gender"
"9789";"Entire evaluable cohort"
"9790";"Entocort EC (n=126)"
"9791";"Entry category"
"9792";"Entry criteria"
"9793";"Entry criteria (%)"
"9794";"Entry hip fracture location, n (%)"
"9795";"Environmental stimuli"
"9796";"EO"
"9797";"EO severity by LA classification at baseline (baseline of the healing study), n (%)"
"9798";"EOS count (cells/pL)"
"9799";"EOS serum K+, mEq/L"
"9800";"Eosinoohil count"
"9801";"Eosinophil counf cells pL '"
"9802";"Eosinophil count"
"9803";"Eosinophil count (cells per pL)"
"9804";"Eosinophil count (cells/pL), median (range)c"
"9805";"Eosinophil high"
"9806";"Eosinophil low"
"9807";"Eosinophils"
"9808";"Eosinophils (cells/ll) inclusion criteria, n (%)"
"9809";"Eosinophils £2% (ITT) (n=936)"
"9810";"Eosinophils £2% (n=1254)"
"9811";"Eosinophils <0 2x10*9/L (n=748)"
"9812";"Eosinophils <0.2x10''9 (ITT) (n=966)"
"9813";"Eosinophils <0.2x10''9 (ITT) (n=978)"
"9814";"Eosinophils <0.2x10''9 (n=978)"
"9815";"Eosinophils <0.2x10''9 (n=986)"
"9816";"Eosinophils <0.2x10*9 (ITT) (n=1294)"
"9817";"Eosinophils <0.2x10*9 (n=1310)"
"9818";"Eosinophils <2% (ITT) (n=654)"
"9819";"Eosinophils <2% (ITT) (n=670)"
"9820";"Eosinophils <2% (ITT) (n=886)"
"9821";"Eosinophils <2% (n=512)"
"9822";"Eosinophils <2% (n=661)"
"9823";"Eosinophils <2% (n=677)"
"9824";"Eosinophils <2% (n=896)"
"9825";"Eosinophils >0 2x10*9/1 (n=782)"
"9826";"Eosinophils >0.2x10''9 (ITT) (n=625)"
"9827";"Eosinophils >0.2x10'^ (ITT) (n=829)"
"9828";"Eosinophils >0.2x10*9 (n=629)"
"9829";"Eosinophils >0.2x10*9 (n=841)"
"9830";"Eosinophils >0.2x10^^ (ITT) (n=626)"
"9831";"Eosinophils >2% (ITT) (n=934)"
"9832";"Eosinophils >2% (n=1018)"
"9833";"Eosinophils >2% (n=938)"
"9834";"Eosinophils 20.2x10''9 (n=634)"
"9835";"Eosinophils 22% (ITT) (n=1236)"
"9836";"Eosinophils 22% (n-950)"
"9837";"epa"
"9838";"EPA    HR events (%)"
"9839";"EPA (mol%)"
"9840";"EPA (n = 2303)"
"9841";"EPA (n = 7023)"
"9842";"EPA Group n=485"
"9843";"EPA Group n=8841"
"9844";"EPA Group No. of Events (%)"
"9845";"EPA treatment (n=9326)"
"9846";"EPA(mol%)"
"9847";"EPA(n = 2303)"
"9848";"EPA(n = 7023)"
"9849";"EPA(n=9326)"
"9850";"EPA, mol%"
"9851";"EPA/AA ratio"
"9852";"Epilepsy drug"
"9853";"Epilepsy with grand mal seizures on awakening"
"9854";"Epistaxis"
"9855";"Eplerenone (n = 506)"
"9856";"EQ-5D-3 L, no pain or discomfortc"
"9857";"EQ-5D-3 L, no pain or discomfortf"
"9858";"EQ-5D (visual analog score)"
"9859";"EQ-5D Mobility"
"9860";"EQ-5Dprofile-mobility, n (%)"
"9861";"EQ5Da health index status score"
"9862";"ER visit"
"9863";"ERA"
"9864";"ERA and PDE-5i"
"9865";"ERA and PDE5 inhibitors"
"9866";"ERA monotherapy"
"9867";"ERD*, n (%)"
"9868";"Erectile dysfunction"
"9869";"Erectile Function; IPSS"
"9870";"Erlugliflozin 15 mg vs placebo/glimepiride"
"9871";"Erosion"
"9872";"Erosion score"
"9873";"Erosion score (0-168)"
"9874";"Erosion score (0-280)"
"9875";"Erosion score (0–320 scale)"
"9876";"Erosion score, mean ± SD"
"9877";"Erosion score, mean 6 SD"
"9878";"Erosion score, median (min, max)"
"9879";"Erosion, mean ± SD"
"9880";"ErtugliflDzin 5 mg vs placebo/glinepiride"
"9881";"Ertugliflozin"
"9882";"Ertugliflozin 15 mg"
"9883";"Ertugliflozin 15 mg (n = 153)"
"9884";"Ertugliflozin 15 mg (n 5 155)"
"9885";"Ertugliflozin 15 mg vs placebo/giimepiride"
"9886";"Ertugliflozin 15 mg vs placebo/glimepiride"
"9887";"Ertugliflozin 15 mg vs placebo/glirneplride"
"9888";"Ertugliflozin 15 mg"
"9889";"Ertugliflozin 15 mg (n = 169)"
"9890";"Ertugliflozin 5 mg"
"9891";"Ertugliflozin 5 mg (n = 156)"
"9892";"Ertugliflozin 5 mg (n 5 158)"
"9893";"Ertugliflozin 5 mg (n = 170)"
"9894";"Ertugliflozin 5 mg vs placebo/glimepiride"
"9895";"Ertugliflozin 5 mg vs placebo/glinepiride"
"9896";"Ertugliflozin 5mg"
"9897";"Ertuglrflozin 15 mg vs placebo/glimepiride"
"9898";"Erysipelas"
"9899";"Erythrocyte sedimentation rate — mm/hr||"
"9900";"Erythrocyte sedimentation rate (mm/h)"
"9901";"Erythrocyte sedimentation rate, mm/hour"
"9902";"ESAM (ng/ml)"
"9903";"Esophageal hiatal hernia*"
"9904";"ESR"
"9905";"ESR — mm/hr"
"9906";"ESR (mm/h)"
"9907";"ESR (mm/h), mean (SD)"
"9908";"ESR (mm/h), median (min - max)"
"9909";"ESR (mm/h), median (min, max)"
"9910";"ESR (mm/hour)"
"9911";"ESR (mm/hour; per unit)"
"9912";"ESR, 0-100 mm/hour"
"9913";"ESR, mean ± SD mg/dl"
"9914";"ESR, median (range) mm/hour"
"9915";"ESR, mm/hour"
"9916";"ESRD"
"9917";"ESRD'"
"9918";"ESRD on Losartan (%)"
"9919";"ESRD on Placebo (%)"
"9920";"ESRD only RR (CI)“"
"9921";"ESRD or 25% decline in GFR"
"9922";"ESRD or 50% dedine in GFR"
"9923";"ESRD or death"
"9924";"ESRD SAXA 2.5 mg (n = 15)"
"9925";"ESRD*"
"9926";"Established"
"9927";"Established (n=172)"
"9928";"Established (n=190)"
"9929";"Established (n=79)"
"9930";"Established ASCVD"
"9931";"Established ASCVD or >2 CV risk factors"
"9932";"Established atherosclerotic"
"9933";"Established atherosclerotic cardiovascular disease"
"9934";"Established atherosclerotic cardiovascular disease — no. {%)"
"9935";"Established atherosclerotic CV disease§"
"9936";"Established atherosclerotic disease"
"9937";"Established atherosclerotic disease — no. {%)"
"9938";"Established atherosclerotic disease, n(%)"
"9939";"Established cardiovascular disease"
"9940";"Established CVD (age >50)"
"9941";"Established CVD/chronic kidney disease (age > 50)^*’"
"9942";"Established maerovaseular disease and albuminuria"
"9943";"Established renal disease (eGFR 15 - <45 mL/min/1.73 m^ with any UACR mg/g or eGFR >45-75 mL/inin/L73 m2 with an UACR >200 mg/g) without previous maerovaseular and albuminuria disease"
"9944";"Established renal disease*"
"9945";"estimate"
"9946";"Estimate (95% CI)"
"9947";"Estimate (95% Cl)"
"9948";"Estimated creatinine clearance — ml/min;i;"
"9949";"Estimated creatinine clearance — ml/min§"
"9950";"Estimated creatinine clearance (mL/min)"
"9951";"Estimated creatinine clearance <60 ml/min*"
"9952";"Estimated creatinine clearance <60 mL/mint"
"9953";"Estimated creatinine clearance <60 rmb'mint"
"9954";"Estimated creatinine clearance""!"""
"9955";"Estimated creatinine clearancet"
"9956";"Estimated CV risk at baseline"
"9957";"Estimated difference"
"9958";"Estimated Difference %"
"9959";"estimated difference (95% CI)"
"9960";"Estimated GFR"
"9961";"Estimated GFR — ml/min/1.73 m^ |"
"9962";"Estimated GFR — ml/min/1.73 m2"
"9963";"Estimated GFR — no. (%)^|"
"9964";"Estimated GFR — no. (%)51"
"9965";"Estimated GFR (mL/min per 1.73 m2), mean (SD)"
"9966";"Estimated GFR (ml/min/1.73 m2)"
"9967";"Estimated GFR (mL/min/1.73 m2) Lipid baseline lipid profile"
"9968";"Estimated GFR (ml/min/1.73 m2), mean (sd)"
"9969";"Estimated GFR (ml/min/1.73 m2)^|"
"9970";"Estimated GFR (ml/min/1.73m2)"
"9971";"Estimated GFR <60 ml/min/1.73 m^ — no. (%)"
"9972";"Estimated GFR <60 ml/min/1.73 m2"
"9973";"Estimated GFR <60 mL/min/1.73 m2, no. (%)"
"9974";"Estimated GFR >60 ml/min/1.73 m2"
"9975";"Estimated GFR at Baseline, mL • min 1"
"9976";"Estimated GFR renal function stage"
"9977";"Estimated GFR, <60 ml min-1 1.73 m-2, n (%)a"
"9978";"Estimated GFR, mean (SD), mLVmin per 1.73 m^*"
"9979";"Estimated GFR, ml min-1 1.73 m-2 (SD)a"
"9980";"Estimated GFR, mL/min"
"9981";"Estimated GFR, ml/min/1.73 m2"
"9982";"Estimated GFR, mL/min/1.73 m2 of body-surface area"
"9983";"Estimated GFR^"
"9984";"Estimated glomerular filtration"
"9985";"Estimated Glomerular Filtration"
"9986";"Estimated glomerular filtration rate"
"9987";"Estimated glomerular filtration rate - mL/min, Median (IQR) '"
"9988";"Estimated glomerular filtration rate - mL/min/1.73m2TT"
"9989";"Estimated glomerular filtration rate - no. (%)::"
"9990";"Estimated glomerular filtration rate — ml/min/1.73 m^"
"9991";"Estimated glomerular filtration rate — ml/min/1.73 m2"
"9992";"Estimated glomerular filtration rate — ml/min/1.73 m2 of body-surface area§"
"9993";"Estimated glomerular filtration rate — no. (%)"
"9994";"Estimated glomerular filtration rate (MDRD), mL/min/1.73m2"
"9995";"Estimated glomerular filtration rate (MDRD), mL·min1·1.73m2"
"9996";"Estimated glomerular filtration rate (MDRD), mL·min1·1.73m2*"
"9997";"Estimated glomerular filtration rate (ml/min/1.73m2)"
"9998";"Estimated glomerular filtration rate <60"
"9999";"Estimated glomerular filtration rate <60 mL/min per 1.73 m2"
"10000";"Estimated glomerular filtration rate <60 ml/min/ 1.73 m2— no./total no. (%)§"
"10001";"Estimated glomerular filtration rate <60 ml/min/ 1.73 m2 — no./total no. (%)§"
"10002";"Estimated glomerular filtration rate <60 ml/min/1.73 m2:i:§"
"10003";"Estimated glomerular filtration rate, mL/min per 1.73 m2"
"10004";"Estimated glomerular filtration rate, mL/min/1.73 m2"
"10005";"Estimated glomerular filtration rate, mL/min/1.73 m2, mean (SD)§"
"10006";"Estimated glomerular filtration rate, n(%)"
"10007";"Estimated glomerular filtration rate^"
"10008";"Estimated glomerular filtration rate||"
"10009";"Estimated glomerular filtration rate§"
"10010";"Estimated mean"
"10011";"Estimated mean    95% Cl"
"10012";"Estimated means and difference"
"10013";"Estimated means and treatment differences (%)"
"10014";"Estimated number of pack-years"
"10015";"Estimated odds ratio"
"10016";"Estimated proportions (%) and odds ratios"
"10017";"Estimated response rate and odds ratio"
"10018";"Estimated treatment difference (%)"
"10019";"Estimated* creatinine clearance <60 mLVmin, %"
"10020";"Estonia"
"10021";"Estradiol (E2) (pmol/L)"
"10022";"Estradiol (pmol/L)"
"10023";"Estradiol quartiles"
"10024";"Estrogen"
"10025";"Estrogen-containing hormones"
"10026";"Estrogen ('%?)"
"10027";"Estrogen supplementation"
"10028";"Estrogen supplementation-"
"10029";"Estrogen therapy"
"10030";"Estrogens"
"10031";"Etanercept"
"10032";"Etanercept (n = 266)"
"10033";"Etanercept (n=358)"
"10034";"Etanercept (n=382)"
"10035";"ETD (%) [95% CI]"
"10036";"ETD (95% CI)"
"10037";"ETD: −0.01 [−0.31; 0.29]95% CI, p  = 0.9521"
"10038";"ETD: −0.10 [−3.38; 3.18]95% CI, p  = 0.9521"
"10039";"ETD: −1.86 [−2.75; −0.97]95% CI, p  < 0.0001"
"10040";"ETD: −33.58 [−49.63; −17.53]95% CI, p  < 0.0001"
"10041";"Ethacrynic acid"
"10042";"Ethnic background"
"10043";"Ethnic group"
"10044";"Ethnic group — no. (%)'"
"10045";"Ethnic group (%)"
"10046";"Ethnic minority group — no. (%)"
"10047";"Ethnic origin"
"10048";"Ethnic Origin"
"10049";"Ethnic origin White"
"10050";"Ethnic origin*"
"10051";"Ethnic origin, n (%)"
"10052";"Ethnicity"
"10053";"Ethnicity -- Hispanic or Latino"
"10054";"Ethnicity - no. (%)"
"10055";"Ethnicity (%)"
"10056";"Ethnicity t"
"10057";"Ethnicity,"
"10058";"Ethnicity, %"
"10059";"Ethnicity, Hispanic/Latino, n (%)"
"10060";"Ethnicity, n (%)"
"10061";"Ethnicity, n (%)*"
"10062";"Ethnicity, n (%):"
"10063";"Ethnicity, n (%)b"
"10064";"Ethnicity, no. (%)"
"10065";"Ethnicity, No. (%)"
"10066";"Ethnicity, not Hispanic/Latino, n (%)"
"10067";"Ethnicity1'"
"10068";"Ethnicitya Hispanic or Latino"
"10069";"Ethnieity"
"10070";"Etiology"
"10071";"Etiology (%)"
"10072";"Etiology, n (%)"
"10073";"Etiology, n (%)"
"10074";"ETN 25 mg + MTX n = 184"
"10075";"ETN 25 mg + MTX n = 201"
"10076";"ETN 25 mg + MTX n = 202"
"10077";"ETN 50 mg + MTX n = 184"
"10078";"ETN 50 mg + MTX n = 201"
"10079";"ETN 50 mg + MTX n = 202"
"10080";"ETN 50 mg + MTX N = 709"
"10081";"ETN 50 mg + MTX N = 834"
"10082";"ETN, no"
"10083";"ETN, yes"
"10084";"ETN+MTX (n = 478)"
"10085";"Etoricoxib"
"10086";"Etoricoxib (n = 17,412)"
"10087";"Etoricoxib (n=10 461)"
"10088";"Etoricoxib (n=11 667)"
"10089";"Etoricoxib (n=17 412)"
"10090";"Etoricoxib (n=5745)"
"10091";"Etoricoxib (n=6951)"
"10092";"Etoricoxib 60 mg (N 5 6769), ..n...(.%..)............"
"10093";"Etoricoxib 60 mg N = 818 n (%)"
"10094";"Etoricoxib 90 mg (N 5 2032), ...n...(.%..)..........."
"10095";"Etoricoxib 90 mg (N 5 2171), ..n...(.%..)............."
"10096";"Etoricoxib 90 mg (N 5 2841), ...n..(.%..)............"
"10097";"Etoricoxib 90 mg (N 5 3593), ...n..(.%..)..........."
"10098";"Etoricoxib 90 mg N = 468 n (%)"
"10099";"Etoricoxib 90 mg, N = 3593,n(%)"
"10100";"Etoricoxib dose"
"10101";"Etoricoxib group (n=17 412)"
"10102";"ETR: 0.78 [0.65; 0.95]95% CI, p  = 0.0121"
"10103";"EU"
"10104";"EULAR good response"
"10105";"EUROPA (n=122l8)"
"10106";"Europe"
"10107";"Europe (EU)"
"10108";"Europe (including South Africa)"
"10109";"Europe (non-EU)"
"10110";"Europe (plus South Africa)"
"10111";"Europe (Zone 1)"
"10112";"Europe (Zone 2)"
"10113";"Europe 1"
"10114";"Europe 1 (n=2,643)"
"10115";"Europe 1 (n=2643)"
"10116";"Europe 1¶"
"10117";"Europe 2"
"10118";"Europe 2 (n=2,314)"
"10119";"Europe 2 (n=2314)"
"10120";"Europe 2+"
"10121";"Europe and Australia"
"10122";"Europe and Canada"
"10123";"Europe and Russia"
"10124";"Europe I"
"10125";"Europe II"
"10126";"Europe n Z 1831"
"10127";"Europe, Israel, or Australia"
"10128";"Europe/lsrael"
"10129";"Europe1"
"10130";"European"
"10131";"European or Arab"
"10132";"European Quality of Life-5 Dimensions-5 Level (EQ-5D)"
"10133";"European subcategories"
"10134";"European Trial"
"10135";"European Union"
"10136";"EuroSCORE additive, median (25th, 75th %) §"
"10137";"EuroSCORE logistic, median (25th, 75th %) £"
"10138";"Evaluable for ACR20 at week 16, n"
"10139";"Evening"
"10140";"Evening mealb"
"10141";"Evenls per 1,000 palienl-years"
"10142";"event"
"10143";"Event"
"10144";"event (p=0.3O+)"
"10145";"Event / Patients (1000/pt-y)"
"10146";"Event during on-"
"10147";"Event during overall"
"10148";"Event Incidence/N"
"10149";"Event Number"
"10150";"Event rate"
"10151";"Event rate ( per 100"
"10152";"Event Rate (%) of Primary Endpoints"
"10153";"Event rate (%/vr)"
"10154";"event rate (%/year)"
"10155";"Event rate (%/year)"
"10156";"Event rate (per 100 person-years)"
"10157";"Event rate (per 100 person years)"
"10158";"Event rates per 100 patient-years (95% CI)"
"10159";"Event rates, %"
"10160";"event(%)"
"10161";"Event, n (%)"
"10162";"Event/patients in group (incidence/1000 person-year)"
"10163";"Event/Total"
"10164";"event{ n (%)"
"10165";"events"
"10166";"Events"
"10167";"Events (%)"
"10168";"Events / N"
"10169";"Events consistent with genital infection"
"10170";"Events consistent with UTI"
"10171";"Events consistent with volume depletion"
"10172";"Events requiring assistance"
"10173";"Events Treatment (45002)"
"10174";"Events Treatment (45054)"
"10175";"Events(%)"
"10176";"Events, n (%)"
"10177";"Events, n (%/y)"
"10178";"Events, No."
"10179";"Events/Control Group"
"10180";"Events/patient-year (n)"
"10181";"Events/Statin Group"
"10182";"Ever"
"10183";"Ever-smoker"
"10184";"Ever been on a VKA"
"10185";"Ever Been on a VKA"
"10186";"Ever smoked (current/former)"
"10187";"Everolimus"
"10188";"Everolimus-eluting"
"10189";"Every day"
"10190";"Evidence or thombus, n (%)"
"10191";"Evolocumab"
"10192";"Evolocumab (420 mg)"
"10193";"Evolocumab (n = 164)"
"10194";"Evolocumab (n = 35)"
"10195";"Evolocumab (n = 484)"
"10196";"Evolocumab + SOC (N = 3200)"
"10197";"Evolocumab 140 mg every 2weeks(n=110)"
"10198";"Evolocumab 420 mg monthly (n=110)"
"10199";"EvoMab"
"10200";"EvoMab (N = 182)"
"10201";"EvoMab (N = 194)"
"10202";"EvoMab (N = 274)"
"10203";"EvoMab (N = 325)"
"10204";"EvoMab (N = 77)"
"10205";"EvoMab + SOC"
"10206";"Ex-/current smoker"
"10207";"Ex-drinker"
"10208";"ex-smoker"
"10209";"Ex-smoker"
"10210";"Ex-smoker/ smoker, %"
"10211";"Ex-smoker/current"
"10212";"Ex-smoker/smoker, %"
"10213";"Ex-smokers"
"10214";"Ex-smokers    128"
"10215";"Ex-smokers (ITT) (n=1118)"
"10216";"Ex-smokers (ITT) (n=1133)"
"10217";"Ex-smokers (ITT) (n=825)"
"10218";"Ex-smokers (ITT) (n=831)"
"10219";"Ex-smokers (ITT) (n=833)"
"10220";"Ex-smokers (ITT) (n=844)"
"10221";"Ex-smokers (n=849)"
"10222";"Ex-smokers: QVAI49-SFC"
"10223";"Exacerbation historyh, n (%)"
"10224";"exacerbation in previous year"
"10225";"Exacerbation rate in the previous year (range)"
"10226";"Exacerbation rate per year"
"10227";"Exacerbation within 12 mo, %"
"10228";"Exacerbation within previous 12 mo, No. (%)"
"10229";"Exacerbations"
"10230";"Exacerbations in past 12 mo — no. (%)"
"10231";"Exacerbations in previous 12 mo (n), mean (SD)"
"10232";"Exacerbations in previous year"
"10233";"Exacerbations in previous year requiring hospitalization and/or ED visit, n (%)"
"10234";"Exacerbations in previous year requiring hospitalization, n (%)"
"10235";"Exacerbations in the past 12 months n"
"10236";"Exacerbations in the prev. year: 2"
"10237";"Exacerbations in the previous year"
"10238";"Exacerbations in the year before study"
"10239";"Exacerbations requiring hospitalisation ( past year) (%)"
"10240";"Exacerbations requiring oral steroids/antibiotics ( past year) (%)"
"10241";"EXACT-PRO total score, mean (SD)"
"10242";"EXACT (B)"
"10243";"Exenatide"
"10244";"Exenatide ± OAD"
"10245";"Exenatide ER"
"10246";"Exenatide LAR"
"10247";"Exenatide N=7356"
"10248";"Exenatide no. of events/total no. (%)"
"10249";"Exercise"
"10250";"Exercise (%)"
"10251";"Exercise > once weekly"
"10252";"Exercise > once weekly?"
"10253";"Exercise at least weekly (A)"
"10254";"Exercise category (%)"
"10255";"Exercise status"
"10256";"Exercise times per week, (minimum"
"10257";"Exercise, n (%)"
"10258";"Exetimibe/simvastatin"
"10259";"Exlertl ot disease"
"10260";"Expanded CV endpoint"
"10261";"Expanded MACE"
"10262";"Experience (n, %)"
"10263";"Experienced"
"10264";"Experimental intervention group (N=7980)"
"10265";"Experimental treatment group"
"10266";"Exploratory Cardiovascular and Death Outcomes"
"10267";"Exploratory Kidney and Microvascular Outcomes"
"10268";"Exposed"
"10269";"Exposed (n = 349)"
"10270";"Exposed (n = 424)"
"10271";"Exposed (n = 428)"
"10272";"Exposed (n = 578)"
"10273";"exposure"
"10274";"Exposure to study drug — days"
"10275";"Exsmoker"
"10276";"Extended- Duration Enoxaparin (n = 2159)"
"10277";"Extended- Duration Enoxaparin (n = 2975)"
"10278";"Extended- Duration Enoxaparin (n = 816)"
"10279";"Extended-Duration Enoxaparin, n/N(%)"
"10280";"Extended-Release Niacin plus Statin (N = 1718)"
"10281";"Extended Cardiovascular Endpoint"
"10282";"Extensive"
"10283";"Extensive colitis"
"10284";"Extensive colitis or pancolitis"
"10285";"Extensive colitis, N"
"10286";"Extensive colitisy"
"10287";"Extensive disease other"
"10288";"Extensive, n (%)"
"10289";"Extensive/pancolitis"
"10290";"Extenswe"
"10291";"Extent of disease"
"10292";"Extent of disease — no./total no. (%)§^|"
"10293";"Extent of disease, %"
"10294";"Extent of disease, n (%)"
"10295";"Extent of index DVT' (n, % of DVT patients')"
"10296";"Extent of index event"
"10297";"Extent of index PE'(n,%of PE patients)"
"10298";"Extracranial"
"10299";"Extracranial carotid stenosis, n (%)"
"10300";"Extreme tortuosity"
"10301";"EZ/Simva"
"10302";"EZ/Simva <%>"
"10303";"EZ/Simva 10/20 mg"
"10304";"EZ/simva 20 mg"
"10305";"EZ/simva 40 mg"
"10306";"EZ/simva 80 mg"
"10307";"EZ/Simva N=336 n (%)"
"10308";"EZ/Simva N=8727 n (%)"
"10309";"EZE"
"10310";"EZE + statin"
"10311";"EZE + statin n=552"
"10312";"EZE + statin n=691"
"10313";"EZE + statin n=768"
"10314";"EZE = ezetimibe 10 mg; pooled SINVA = simvastatin pooled across doses; pooled EZE/SINVA = ezetimibe/simvastatin tablet pooled across doses; BNI = body mass index; LDL-C = low-density lipoprotein cholesterol; T G = triglycerides; T C = total cholesterol; HDL-C = high-density lipoprotein cholesterol; apo — apolipoprotein; C RP — C-neactive protein; RLP-C= remnant-like particle-cholesterol."
"10315";"EZE 10 mg"
"10316";"EZE 10 mg (n = 187)"
"10317";"EZE/ SIMVA  - 7yr KM rale (%)"
"10318";"EZE/ SIMVA („ = 1236}"
"10319";"EZE/Simva"
"10320";"EZE/SIMVA"
"10321";"EZE/SIMVA (n = 1236)"
"10322";"EZE/SIMVA 10/20 mg (n = 221)"
"10323";"EZE/SIMVA 10/20 mg N = 100"
"10324";"EZE/SIMVA 10/20 mg N = 213"
"10325";"EZE/SIMVA Gender"
"10326";"EZE/SIMVA, 10/20 mg + FENO, 160 mg dn = 123) '"
"10327";"EZE/SIMVA, 10/20 mg + FENO, 160 mg dn = 58)"
"10328";"EZE/SIMVA, 10/20 mg dn = 7c8)"
"10329";"EZE/SIMVA, 10/20 mg dr = 106)"
"10330";"Ezetimibe"
"10331";"Ezetimibe + Simvastatin (n = 1,007*)"
"10332";"Ezetimibe + Simvastatin (n = 915*)"
"10333";"Ezetimibe 10 mg (n — 220)"
"10334";"Ezetimibe 10 mg (n = 220)"
"10335";"Ezetimibe 10 mg (n = 246*)"
"10336";"Ezetimibe 10 mg + Statin (n = 2,315)"
"10337";"Ezetimibe use"
"10338";"Ezetimibe, n (%)"
"10339";"Ezetimibe/ Simvastatin"
"10340";"Ezetimibe/Simvastatin"
"10341";"Ezetimibe/simvastatin 10/40 mg (n = 261)"
"10342";"Ezetimibe/simvastatin group"
"10343";"F"
"10344";"F-Plasma glucose, mmol/L"
"10345";"F emale"
"10346";"F40 vs placebo"
"10347";"F80 vs placebo"
"10348";"FA 135 mg"
"10349";"FA 135 mg («= 123)"
"10350";"Facial psoriasis, n (%)"
"10351";"Facilitated PCi (n = 656)"
"10352";"FACIT-F"
"10353";"FACIT-F score"
"10354";"FACIT-Fatigue. mean 6SD (range 0-52)"
"10355";"Factor"
"10356";"Factor absent"
"10357";"Factor at baseline"
"10358";"Factor present"
"10359";"Factor V Leiden (%)"
"10360";"Factor V Leiden or prothrombin mutation"
"10361";"Factor Xa inhibitor"
"10362";"Factor*"
"10363";"Factors    Dabigatran"
"10364";"Factors    Dabigatran Event Incidence/N"
"10365";"factors that confer a"
"10366";"Failure"
"10367";"Fair control (7-9.5)"
"10368";"Fair or poor"
"10369";"Fair/poor"
"10370";"Fall in last 12 mo"
"10371";"Fall in last 12 months (%)"
"10372";"Familial"
"10373";"Familv historv of CAD"
"10374";"Family history of CAD"
"10375";"Family history of CAD (diagnosed at <55 yr of age) — no. (%) Cigarette smoker — no. (%)"
"10376";"Family history of cancera"
"10377";"Family history of cancerf"
"10378";"Family History of CHD (n=133, 149)"
"10379";"Family history of coronary artery disease"
"10380";"Family history of coronary disease"
"10381";"Family history of diabetes — no. (%)"
"10382";"Family history of diabetes (-)"
"10383";"Family history of diabetes (%)*"
"10384";"Family history of diabetes (+)"
"10385";"Family history of diabetes mellitus — no. (%)"
"10386";"Family history of diabetes mellitus — no. {%)"
"10387";"Family history of myocardial infarction prior to age 60, %"
"10388";"Family history of premature"
"10389";"Family history of premature CHD"
"10390";"Family history of premature CHD**"
"10391";"Family history of premature CHDJ"
"10392";"Family history of premature coronary heart disease"
"10393";"Family history of premature heart disease"
"10394";"Family history of venous thromboembolism (%)"
"10395";"Family history of VTE"
"10396";"Family history ol diabetes?"
"10397";"Family history ot CHD, n (%)"
"10398";"Family history, n (%)"
"10399";"Family history^"
"10400";"Famotidine 20 mg (n = 177)"
"10401";"Famotidine 40 mg (n = 174)"
"10402";"FAS"
"10403";"FAS, range 0-10, mean (SD)"
"10404";"Fascng Plasma Glucose a Medan"
"10405";"Faster aspart"
"10406";"Faster aspart (mealtime)"
"10407";"Faster aspart + basal"
"10408";"Fastest third"
"10409";"Fasting"
"10410";"Fasting blood glucose"
"10411";"Fasting blood glucose — mmol/liter"
"10412";"Fasting blood glucose (mg/dL)"
"10413";"Fasting blood glucose >100 mg/dl"
"10414";"Fasting blood glucose >110 mg/dL (>6.11 mmol/L)"
"10415";"Fasting blood glucose, mean (SD), mg/dLt"
"10416";"Fasting C-peptide (ng/mL)"
"10417";"Fasting C-peptide (nmol/L)c"
"10418";"Fasting C-peptide, ng/mL"
"10419";"Fasting cholesterol — mg/dl"
"10420";"Fasting free fatty acids (^mol/liter)"
"10421";"Fasting glucose"
"10422";"Fasting glucose — mg/dl"
"10423";"Fasting glucose (mg/dL)"
"10424";"Fasting glucose (mg/dl),"
"10425";"Fasting glucose (mmol/L)"
"10426";"Fasting glucose > 126 mg/dL, n(%)"
"10427";"Fasting glucose >100 mg/dl*"
"10428";"Fasting glucose level, mg/dL"
"10429";"Fasting Glucose mg/dL Diabetes classification"
"10430";"Fasting glucose*"
"10431";"Fasting glucose, mean (SD), mg/dL"
"10432";"Fasting glucose, mg/dL"
"10433";"Fasting glucose, mg/dL '"
"10434";"Fasting glucose, mg/dl, mean (SD)§"
"10435";"Fasting glucose, mmol/L, mean±SD"
"10436";"Fasting indices"
"10437";"Fasting insulin"
"10438";"Fasting insulin — /tIU/ml§"
"10439";"Fasting insulin — pmol/liter"
"10440";"Fasting insulin (gIU/mL)"
"10441";"Fasting insulin (mIU/mL)"
"10442";"Fasting insulin (pmol/l)"
"10443";"Fasting insulin (pmol/L)"
"10444";"Fasting insulin, iiIU/mL, mean ± SD"
"10445";"Fasting Insulin, pmol/L (mean ± SD)"
"10446";"Fasting insulin,* median (IQR), gU/mL"
"10447";"Fasting lipid levels, mmol/l"
"10448";"Fasting lipids (mmol/1)"
"10449";"Fasting plasma glucose"
"10450";"Fasting plasma glucose— mmol/liter"
"10451";"Fasting plasma glucose — mg/dl"
"10452";"Fasting plasma glucose (change from baseline)"
"10453";"Fasting plasma glucose (mg/dl)"
"10454";"Fasting plasma glucose (mg/dL)"
"10455";"Fasting plasma glucose (mg/dL)1"
"10456";"Fasting plasma glucose (mmol/L)"
"10457";"Fasting plasma glucose (mmol/L)11"
"10458";"Fasting Plasma Glucose < Median"
"10459";"Fasting Plasma Glucose 2 Medan"
"10460";"Fasting plasma glucose categories, n (%)"
"10461";"Fasting plasma glucose in mmol/L (median (Q1, Q3) [n])"
"10462";"Fasting plasma glucose*"
"10463";"Fasting plasma glucose, mg/dl"
"10464";"Fasting plasma glucose, mg/dL"
"10465";"Fasting plasma glucose, mg/dL, mean (SD)"
"10466";"Fasting plasma glucose, mg/dL, mean (SD)b"
"10467";"Fasting plasma insulin — mU/liter"
"10468";"Fasting proinsulin (pmol/L)"
"10469";"Fasting serum glucose — mg/dl**"
"10470";"Fasting serum glucose (mg/dl)"
"10471";"Fasting serum glucose (mg/dL)"
"10472";"Fasting serum glucose (mg/dl), Median (IQR)"
"10473";"Fasting serum glucose level, mean (SD), mg/dL"
"10474";"Fasting serum glucose, mean (sd) mg/dl"
"10475";"Fasting serum glucose, median (SD), mg/dL"
"10476";"Fasting serum glucose, mg/dL"
"10477";"Fasting serum glucose, mmol/l, median (Q1, Q3)"
"10478";"Fasting TGs, median (Q1:Q3)"
"10479";"Fasting TGs§"
"10480";"Fasting triglyceride level, mean (SD), mg/dL"
"10481";"Fasting triglycerides"
"10482";"Fasting triglycerides — mg/dl"
"10483";"Fasting triglycerides >150 mg/dl*"
"10484";"Fasting triglycerides, mean (sd) mg/dl"
"10485";"Fasting triglycerides, mean (SD), mg/dL"
"10486";"Fasting triglycerides, mg/dL"
"10487";"Fastng Plasma Glucose < Median"
"10488";"Fatal"
"10489";"Fatal & nonfatal CCVD"
"10490";"Fatal & nonfatal hospitalized heart failure"
"10491";"Fatal & nonfatal hospitalized stroke"
"10492";"Fatal AEs"
"10493";"Fatal and nonfatal Ml"
"10494";"Fatal and nonfatal stroke"
"10495";"Fatal bleed"
"10496";"Fatal bleeding"
"10497";"Fatal Bleeding"
"10498";"Fatal CHD + Nonfatal Ml"
"10499";"Fatal CHD and nonfatal MIa"
"10500";"Fatal myocardial infarction"
"10501";"Fatal or non-fatal myocardial infarction"
"10502";"Fatal or non-fatal stroke"
"10503";"Fatal or nonfatal myocardial infarction"
"10504";"Fatal or nonfatal stroke"
"10505";"Fatal or nonlatal myocardial Inlarctlon"
"10506";"Fatal or nonlatal stroke"
"10507";"Fatal stroke"
"10508";"Fatal Stroke"
"10509";"Fatal/nonfatal MI, n (%)"
"10510";"Fatal/nonfatal Ml"
"10511";"Fatal/nonfatal stroke"
"10512";"Fatal/nonfatal stroke, n (%)"
"10513";"Fatigue"
"10514";"Fatigue (range 0-10)"
"10515";"Fatty acid composition"
"10516";"Fatty Acid Group (N = 7740)"
"10517";"Fatty acid profile"
"10518";"Favors    Favors Amlodipine    Chlorthalidone"
"10519";"Favors    Favors Lisinopril    Chlorthalidone"
"10520";"Favors Amlodipine Favors Chlorthalidone"
"10521";"Favors comparator"
"10522";"Favors dabigatran"
"10523";"Favors FF/VI    Favors Placebo"
"10524";"Favors FFA/I    Favors Placebo"
"10525";"Favors Lisinopril    Favors Chlorthalidone"
"10526";"Favors Lisinopril Favors Chlorthalidone"
"10527";"FBG (mg/dL)"
"10528";"FBG (mmol/L)"
"10529";"FBG baseline"
"10530";"FBG, mmol/l"
"10531";"FBG, mmol/L"
"10532";"FBS <100 mg/dl"
"10533";"FBS >=100 mg/dl"
"10534";"Fc-LDL-C, FriedewaLd-caLculated"
"10535";"Fc-LDL-C, mg/dL"
"10536";"FC > 110 mg/dL (>_ 6.1 mmol/L) or history of diabetes"
"10537";"fCal, mg/g, mean ± SD"
"10538";"FDC 400/12 pg"
"10539";"FDC 400/12 pg vs aclidinium 400 pg"
"10540";"FDC 400/12 pg vs formoterol 12 pg"
"10541";"FDC 400/12 pg vs placebo"
"10542";"FDC 400/12 μg (n = 720)"
"10543";"Feature"
"10544";"Febuxostat"
"10545";"Febuxostat 120 mg"
"10546";"Febuxostat 120 mg (n = 269)"
"10547";"Febuxostat 240 mg"
"10548";"Febuxostat 240 mg (n = 134)"
"10549";"Febuxostat 40 mg"
"10550";"Febuxostat 40 mg daily N = 757"
"10551";"Febuxostat 40 mg N = 115"
"10552";"Febuxostat 80 mg"
"10553";"Febuxostat 80 mg (n = 267)"
"10554";"Febuxostat 80 mg daily N = 756 % (n/N)"
"10555";"Febuxostat 80 mg daily N = 756 n (%)"
"10556";"Febuxostat 80 mg N = 128"
"10557";"Fecal calprotectin — pg/g**"
"10558";"Feet"
"10559";"Fema le"
"10560";"Femaie"
"10561";"female"
"10562";"Female"
"10563";"FemaLe"
"10564";"FEMALE"
"10565";"Female-N (%)"
"10566";"Female - n (%)"
"10567";"Female — no. (%)"
"10568";"Female (%)"
"10569";"Female (n — 238)"
"10570";"Female (n = 2,227)"
"10571";"Female (N = 392)"
"10572";"Female (n = 896)"
"10573";"Female (N = 896)"
"10574";"Female (n = 1,481)"
"10575";"Female (n=115, 117)"
"10576";"Female (n=1535)"
"10577";"Female (N=1547)"
"10578";"Female (n=2,049)"
"10579";"Female (n=2049)"
"10580";"Female (N=308)"
"10581";"Female (n=422)"
"10582";"Female (n=68, 45)"
"10583";"Female (n=71,46)"
"10584";"Female (n=lll8)"
"10585";"Female 1"
"10586";"Female ACR definition, ^g/mg"
"10587";"Female EZE/ SIMVA (n = 645)"
"10588";"Female EZE/SIMVA"
"10589";"Female EZE/SIMVA („ = 645}"
"10590";"Female gender"
"10591";"Female gender (%)"
"10592";"Female gender n (%)"
"10593";"Female N(%)"
"10594";"female participants who are ≥3 years postmenopausal"
"10595";"Female patients, n (%)"
"10596";"Female patients^"
"10597";"Female Race White"
"10598";"Female Race/ethnicity"
"10599";"Female sex"
"10600";"Female sex— no. (%)"
"10601";"Female sex— no. {%)"
"10602";"Female sex—number (%)"
"10603";"Female sex — %"
"10604";"Female sex — no. (%)"
"10605";"Female sex — no. (%) Race — no. (%)f"
"10606";"Female sex — no. {%)"
"10607";"Female sex (%)"
"10608";"Female sex, %"
"10609";"Female sex, n (% of patients)"
"10610";"Female sex, n (%)"
"10611";"Female sex, n (%) Race, n (%)"
"10612";"Female sex, no. (%)"
"10613";"Female sex, No. (%)"
"10614";"Female sex, No./total (%)"
"10615";"Female SIMVA"
"10616";"Female SIMVA („ = 645}"
"10617";"Female SIMVA (n = 645)"
"10618";"Female subgroup"
"10619";"Female subjects (n = 226)"
"10620";"Female, %"
"10621";"Female, n (%)"
"10622";"Female, n (%) Race, n (%)"
"10623";"Female, no (%)"
"10624";"Female, no. (%)"
"10625";"Female, No. (%)"
"10626";"Female/male (%)"
"10627";"Female: ≥3 years postmenopausal"
"10628";"Female: perimenopausal or <3 years postmenopausal"
"10629";"Female: Premenopausal"
"10630";"Female5"
"10631";"Femaleb"
"10632";"Females"
"10633";"Females (ITT) (n=379)"
"10634";"Females (ITT) (n=385)"
"10635";"Females (ITT) (n=388)"
"10636";"Females (ITT) (n=484)"
"10637";"Females (ITT) (n=493)"
"10638";"Females (n=432)"
"10639";"FEMALES ONLY"
"10640";"Females, %"
"10641";"Females, <0.85"
"10642";"Females, <30"
"10643";"Females, >0.85"
"10644";"Females, >30"
"10645";"Females, n (%)"
"10646";"Femalesex"
"10647";"Femoral"
"10648";"Femoral access"
"10649";"Femoral access — no./total no. (%)"
"10650";"Femoral neck"
"10651";"Femoral Neck"
"10652";"Femoral neck (n= 1,765) BMD (g/cm2) (SD)"
"10653";"Femoral neck BMD (g/cm2)"
"10654";"Femoral neck BMD T-score"
"10655";"Femoral neck F-score at FLEX baseline"
"10656";"Femoral neck T-score"
"10657";"Femoral neck T-score (mean = SD)"
"10658";"Femoral neckc"
"10659";"Femoralneck T-scorebybaselineVFxstatus"
"10660";"Femur fracture"
"10661";"FENO"
"10662";"Feno — ppb"
"10663";"FENO + EZE"
"10664";"FENO 160 mg (n = 189)"
"10665";"FENO 160 mg/EZE 10 mg (n = 185)"
"10666";"FENO Placebo (LSM)"
"10667";"FENO, 160 dn = 109)"
"10668";"FENO, 160 mg dn = 75)"
"10669";"Fenofibrate (N = 2765)"
"10670";"Fenofibric"
"10671";"Fenofibric acid"
"10672";"Fenofibric Acid"
"10673";"Fenofibric acid-1-low-dose statin"
"10674";"Fenofibric acid-i- moderate-dose statin"
"10675";"Fenofibric acid-i-low-dose statin"
"10676";"Fenofibric acid + low-dose statin"
"10677";"Fenofibric acid + moderate-dose statin"
"10678";"Fenofibric Acid 72=254"
"10679";"Fenofibric Acid n = 254"
"10680";"FEV AUC I    12h"
"10681";"FEV,"
"10682";"FEV, % predicted"
"10683";"FEV, <50% predicted"
"10684";"FEV, >50% predicted"
"10685";"FEV, at baseline"
"10686";"FEV_(L):"
"10687";"FEV1"
"10688";"FEV1 — % of predicted value"
"10689";"FEV1 — liters"
"10690";"FEV1 % pred"
"10691";"FEV1 % pred. (post-albuterol), %"
"10692";"FEV1 % predicted"
"10693";"FEV1 % predicted (post salbutamol)"
"10694";"FEV1 % predicted at baseline"
"10695";"FEV1 % predicted normal"
"10696";"FEV1 % predicted, post-albuterol, %"
"10697";"FEV1 % reversibility"
"10698";"FEV1 (% predicted normal)"
"10699";"FEV1 (% predicted)"
"10700";"FEV1 (l)"
"10701";"FEV1 (L)"
"10702";"FEV1 (L) pre-bronchodilator"
"10703";"FEV1 (L), mean (SD)"
"10704";"FEV1 (liters)"
"10705";"FEV1 (post-albuterol), L"
"10706";"FEV1 (pre-albuterol), L"
"10707";"FEV1 at week 32, mean ml (SE) Difference MEPO-PBO (95% CI)"
"10708";"FEV1 AUC5mine8h"
"10709";"FEV1 percent predicted (SD)"
"10710";"FEV1 post-bronchodilator"
"10711";"FEV1 post-bronchodilator, % predicted normal"
"10712";"FEV1 pre-bronchodilator"
"10713";"FEV1 pre-bronchodilator (% predicted normal), mean (SD)c,d"
"10714";"FEV1 pre-bronchodilator (L), mean (SD)c"
"10715";"FEV1 prebronchodilator [% PN], mean ± SD"
"10716";"FEV1 prebronchodilator [L], mean ± SD"
"10717";"FEV1 reversibility, %*"
"10718";"FEV1 reversibility, %b"
"10719";"FEV1 reversibility, pre-/post-albuterol, %"
"10720";"FEV1 reversibilityz (pre/post ipratropium), %"
"10721";"FEV1 reversibilityz (pre/post salbutamol), %"
"10722";"FEV1 % of predicted normal post-bronchodilator"
"10723";"FEV1 at baseline (randomization)∗"
"10724";"FEV1 at screening∗"
"10725";"FEV1% predicted"
"10726";"FEV1% predicted (SD)"
"10727";"FEV1% predicted <50%"
"10728";"FEV1% predicted ≥50%"
"10729";"FEV1% predicted, mean (SD)"
"10730";"FEV1% reversibility (SD)"
"10731";"FEV1(% of predicted value)"
"10732";"FEV1,"
"10733";"FEV1, % predicted"
"10734";"FEV1, % predicted, mean (SD)"
"10735";"FEV1, % predicteda"
"10736";"FEV1, L"
"10737";"FEV1, L Prebronchodilator FEV1, % predicted"
"10738";"FEV1, L*"
"10739";"FEV1, L, mean (SD)"
"10740";"FEV1, La"
"10741";"FEV1, litres (post-salbutamol), mean (SD)"
"10742";"FEV1, litres (post ipratropium), mean (SD)"
"10743";"FEV1, litres (pre ipratropium), mean (SD)"
"10744";"FEV1, litres (pre salbutamol), mean (SD)"
"10745";"FEV1, mean (SD) Pre-BD FEV1/FVC,"
"10746";"FEV1, mean, % predicted"
"10747";"FEV1, mean, L"
"10748";"FEV1, post-albuterol, L"
"10749";"FEV1, pre-albuterol, L"
"10750";"FEV1,La"
"10751";"FEV1/FVC %"
"10752";"FEV1/FVC (post-albuterol)"
"10753";"FEV1/FVC (post salbutamol)"
"10754";"FEV1/FVC at baseline (randomization) (%)∗"
"10755";"FEV1/FVC prebronchodilator, mean ± SD"
"10756";"FEV1/FVC prebronchodilatort"
"10757";"FEV1/FVC ratio*"
"10758";"FEV1/FVC ratio, %"
"10759";"FEV1/FVC ratio, % (SD)"
"10760";"FEV1/FVC, %*"
"10761";"FEV1/FVC, %, mean (SD)1"
"10762";"FEV1/FVC, %a"
"10763";"FEV1/FVC, mean (SD)"
"10764";"FEV1/FVC, post-albuterol, %"
"10765";"FEV1:FVC ratio"
"10766";"FEV1:FVC ratio;"
"10767";"FEV5 at baseline"
"10768";"FEVi AUC0-3L"
"10769";"FEVi percent predicted (%)"
"10770";"FEVi reversibility — %"
"10771";"FEVi, % predicted*"
"10772";"FEVi, % predicted, mean (SD)1"
"10773";"FEVi, L"
"10774";"FEVi, L*"
"10775";"FEVi, L, mean (SD)1"
"10776";"FEVi/FVC (%)"
"10777";"FEVi1 L"
"10778";"FEVj % predicted!,t"
"10779";"FEVt:FVC ratio — %|"
"10780";"ff-Blocker"
"10781";"FF -46% (-211%, 32%)"
"10782";"FF –1% (95% CI –15–12%)"
"10783";"FF    3% (-23%, 23%)"
"10784";"FF 100 |ig (N=1010)"
"10785";"FF 100 µg"
"10786";"FF 100 gg (N = 1,010)"
"10787";"FF 100 pgOD"
"10788";"FF 11% (-34%, 41%)"
"10789";"FF 12 pg(N=715)"
"10790";"FF 24% (95% CI –3–44%)"
"10791";"FF 4% (95% CI –22–24%)"
"10792";"FF 5% (95% CI –7–15%)"
"10793";"FF 7% (-60%, 45%)"
"10794";"FF MDI"
"10795";"FF/VI"
"10796";"FF/VI –2% (95% CI –29–20%)"
"10797";"FF/VI (n = 1325)"
"10798";"FF/VI (n = 1512)"
"10799";"FF/VI (n = 2114)"
"10800";"FF/VI (n = 484)"
"10801";"FF/VI (n = 750)"
"10802";"FF/VI (n = 997)"
"10803";"FF/VI 0.05"
"10804";"FF/VI 0.25"
"10805";"FF/VI 1% (-126%, 57%)"
"10806";"FF/VI 100 mg/25 mg (n = 806)"
"10807";"FF/VI 100/25 |ig (N=1009)"
"10808";"FF/VI 100/25 µg"
"10809";"FF/VI 100/25 gg (N = 1,009)"
"10810";"FF/VI 100/25 pg OD"
"10811";"FF/VI 12% (-32%, 42%)"
"10812";"FF/VI 20% (95% CI 10–29%)"
"10813";"FF/VI 200 mg/25 mg (n = 811)"
"10814";"FF/VI 23% (2%, 39%)"
"10815";"FF/VI 23% (95% CI 12–34%)"
"10816";"FF/VI 35% (95% CI 11–52%)"
"10817";"FF/VI 5% (-61%, 44%)"
"10818";"FF/VI 50 mg/25 mg (n = 820)"
"10819";"FFA (mmol/l)"
"10820";"FFA/I"
"10821";"FG > 13"
"10822";"FGF-23 High/ <1 Elevated Biomarkers"
"10823";"FGF-23 High/ >2 Elevated Biomarkers"
"10824";"FGF-23 High/ eGFR <60"
"10825";"FGF-23 High/ eGFR >60"
"10826";"FGF-23 Low/ <1 Elevated Biomarkers"
"10827";"FGF-23 Low/ >2 Elevated Biomarkers"
"10828";"FGF-23 Low/ eGFR <60"
"10829";"FGF-23 Low/ eGFR >60"
"10830";"FH 1"
"10831";"FH II"
"10832";"Fibrate"
"10833";"Fibrate or other lipid-lowering agent"
"10834";"Fibrates"
"10835";"fibrillation/flutter)"
"10836";"Fibrin-specific"
"10837";"Fibrin-specilic"
"10838";"Fibrinogen"
"10839";"Fibrinogen (pmol/L)c"
"10840";"Fibrinogen, g/L"
"10841";"Fibrinolysis    Primary PCI (N=944) (N =948) no. of patients/total no. (%)"
"10842";"Fibrinolysis (N = 944)"
"10843";"Fibrinolysist"
"10844";"Fibrinolytic"
"10845";"Fibrinolytic agent — no. (%):t"
"10846";"Fibrinolytic agent before randomisation"
"10847";"Fibrinolytic agents before or after entry"
"10848";"Fibrinolytic for qualifying event"
"10849";"Fibrinolytic therapy — no. (%)"
"10850";"Fibrinolytics"
"10851";"Fibrofatty"
"10852";"Fibrofatty, mm^"
"10853";"Fibrous"
"10854";"Fibrous, mm’"
"10855";"Fibula fracture"
"10856";"Figure 4 Least squares (LS) mean differences between roﬂumilast and placebo in (A) pre- and (B) postbronchodilator FEV1 in the ITT population and subpopulations. COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; ICS, inhaled corticosteroid; ITT, intent to treat; LABA, long-acting b2-agonist."
"10857";"Filtration Rate 30-60"
"10858";"Final"
"10859";"Final (mg/dL)"
"10860";"Final A1C (%)"
"10861";"Final analysis (all patients)"
"10862";"final mean"
"10863";"Final mean, mg/dL"
"10864";"Final median, mg/L"
"10865";"Final TIMI Flow"
"10866";"Final TIMI flow grade <3"
"10867";"Final TIMI flow grade post-PPCI"
"10868";"First-generation stentt"
"10869";"First-recorded event; no. (and %) of patients"
"10870";"First (N=2701)"
"10871";"First co-primary"
"10872";"First Co-Primary Outcome"
"10873";"First CV hospitalization"
"10874";"First diagnosed"
"10875";"First disease-progression outcome to occur§"
"10876";"First Dose Admin. 0-12h/12-24h post onset of symptoms"
"10877";"First episode of atrial fibrillation (vs. recurrent episode) — no. (%)f"
"10878";"First HHF"
"10879";"First hospitalization for CHF or CV death"
"10880";"First loading dose"
"10881";"First MACE"
"10882";"First medical contact — no. (%)§"
"10883";"First medical contact in ambulance"
"10884";"First primary (change in UPDRS score/wk, wk 12-36)"
"10885";"First primary composite outcome"
"10886";"first procedure"
"10887";"First serum creatinine"
"10888";"First year*"
"10889";"Fish oil"
"10890";"Fish Oil (n = 153)"
"10891";"Fistula at baseline, n (%)"
"10892";"Fistula,' n (%)"
"10893";"Fixed triple (n=1077)"
"10894";"fl( 0.0)"
"10895";"fl( 1B)"
"10896";"Flecainide"
"10897";"FLEX Ain'’"
"10898";"FLEX Aln^"
"10899";"FLEX baseline BMD T-score at femoral neck (meaniSD)"
"10900";"FLEX baseline BMD T-score at lumbar spine (meaniSD)"
"10901";"FLEX baseline BMD T score"
"10902";"FLEX baseline BMD, g/cm^ (meaniSD)"
"10903";"FLEX baseline BMD, mean (SD), g/cm2"
"10904";"FLEX FN F-score < -2.5"
"10905";"FLEX Pbo®"
"10906";"Fluindione, No. (%)"
"10907";"Fluticasone- Salmeterol (N = 5834)"
"10908";"Fluticasone Alone (N = 5845)"
"10909";"Fluticasone furoate and vilanterol (n=2114)"
"10910";"Fluticasone furoate, n=4135"
"10911";"Fluticasone propionate/salmeterol FDC"
"10912";"Fluvastatin (N = 250)"
"10913";"Fluvastatin (N=250)"
"10914";"Fluvastatin 80 mg"
"10915";"FN T-score < —2.5"
"10916";"FN T-score <= -2.5 (%)"
"10917";"Focal"
"10918";"Follow-up"
"10919";"Follow-up in-trial at 4 yr"
"10920";"Fondaparinux"
"10921";"Fondaparinux — no. (%)"
"10922";"Fondaparinux (N = 10,057)"
"10923";"Fondaparinux (n = 636)"
"10924";"Foot fracture"
"10925";"for baseline hemoglobin    120 g 1 ’"
"10926";"for baseline hemoglobin < 120 g 1 '"
"10927";"for combined hemoglobin groups"
"10928";"For patients not using personal CGM"
"10929";"For patients using personal CGM"
"10930";"For treatment of index event"
"10931";"Forearm"
"10932";"Forearm fracture"
"10933";"FORM/BUD"
"10934";"Formal education, years"
"10935";"Former"
"10936";"Former (n = 3,482)"
"10937";"Former n Z 1813"
"10938";"Former or current smokers (%)"
"10939";"Former or never"
"10940";"Former or never Diabetes"
"10941";"Former smoker"
"10942";"Former Smoker"
"10943";"Former smoker — no. (%)"
"10944";"Former smoker — no. {%)"
"10945";"Former smoker (n=4,428)"
"10946";"Former Smoker (n=4428)"
"10947";"Former smoker, n (%)"
"10948";"Former smokers"
"10949";"Former smoking"
"10950";"Former, n (%)"
"10951";"Former/current smoker (n=21 098)"
"10952";"Former/current smoker, n (%)"
"10953";"Former/non-drinker"
"10954";"Formoterol 12 gg (n=227)"
"10955";"Formoterol 12 gg (n=233)"
"10956";"Formoterol 12 gg bid"
"10957";"Formoterol 12 pg"
"10958";"Formoterol 12 pg vs placebo"
"10959";"Formoterol 12 μg (n = 715)"
"10960";"Formoterol Tiotropium n=108 Non-tiotropium n=336"
"10961";"Formoterol Tiotropium n=111 Non-tiotropium n=344"
"10962";"FP"
"10963";"FP (n [1552)"
"10964";"FP (n = 1248)"
"10965";"FP (n = 1,356)"
"10966";"FP (n[1552)"
"10967";"FP 500 mg"
"10968";"FP versus no ICS"
"10969";"FP versus other ICS"
"10970";"FP/SAL 250/50 pg (N = 314)"
"10971";"FP/SAL 250/50 pg (N= 314)"
"10972";"fPCI vs. pPCI In men"
"10973";"fPCI vs. pPCI in women"
"10974";"FPG"
"10975";"FPG (mg/dl)"
"10976";"FPG (mg/dL)"
"10977";"FPG (mmol/1)"
"10978";"FPG (mmol/l)"
"10979";"FPG (mmol/L)"
"10980";"FPG (mmol/L), mean (SD)"
"10981";"FPG (mmol/l), mean (SD)、"
"10982";"FPG (mmol/l), mean ± s.d."
"10983";"FPG (range) (mmol/L)"
"10984";"FPG change (mg/dL)*"
"10985";"FPG data'"
"10986";"FPG Month 0 (mg/dl)"
"10987";"FPG Tx difference vs Pbo, median change from baseline (SE)1"
"10988";"FPG(mg/dl)x"
"10989";"FPG, (mg/dL)"
"10990";"FPG, (mmol/L)"
"10991";"FPG, mean (SD), mg/dL"
"10992";"FPG, mean (SD), mg/dL [mmol/L]"
"10993";"FPG, mean (SD), mg/dLf"
"10994";"FPG, mean (SD), mg/dLt"
"10995";"FPG, mean (SD), mmol/L"
"10996";"FPG, median (Q1, Q3), mmol/L"
"10997";"FPG, median (Ql, Q3), mmol/L"
"10998";"FPG, mg/dL"
"10999";"FPG, mg/dL (mmol/L)"
"11000";"FPG, mg/dL, mean ± SD"
"11001";"FPG, mmol/l"
"11002";"FPG, mmol/L"
"11003";"FPG, mmol/L (mean ± SD)"
"11004";"FPG, mmol/L (mg/dL)"
"11005";"FPG, mmol/L, mean (SD)"
"11006";"FPG, mmol/La"
"11007";"FPG, mmol/Lt"
"11008";"FPI, gU/mL (pmol/L)"
"11009";"FPI, M-U/mL (pmol/L)"
"11010";"FPI, mean (SD), pU/mLt"
"11011";"FPI, mean (SD), pU/rnFf"
"11012";"fraction (%)"
"11013";"Fracture"
"11014";"Fracture during follow-up"
"11015";"Fracture history"
"11016";"Fracture history (predefined), n (%)"
"11017";"Fracture history, n (%)"
"11018";"Fracture status Prevalent vertebral fractured"
"11019";"fractures"
"11020";"Fractures (site not specified)"
"11021";"Fragile"
"11022";"Frail"
"11023";"Frailty status"
"11024";"Framingham 10-year CV risk score"
"11025";"Framingham risk score"
"11026";"Framingham risk score (%)"
"11027";"Framingham risk score*"
"11028";"Framingham risk score, arbitrary units"
"11029";"Free fatty acids — mmol/liter"
"11030";"Free fatty acids (mmol/L)"
"11031";"Freedom from GTC seizures, n (%)"
"11032";"Freqency of Events"
"11033";"Frequency of Events"
"11034";"Frequent exacerbator"
"11035";"Frequent or Continuous"
"11036";"from baseline (95% CI)"
"11037";"FSG (mg/dL)"
"11038";"FSG, mg/dL (mean ± SD)"
"11039";"fSN score, mean ± SD"
"11040";"Full analysis set"
"11041";"Full Analysis Set"
"11042";"Full analysis set, n"
"11043";"Full cohort"
"11044";"Full population"
"11045";"Function subscale"
"11046";"Functional Assessment of Chronic Illness"
"11047";"Functional outcome (mRS 3-6)"
"11048";"Furosemide"
"11049";"Furosemide equivalent, mg/kg"
"11050";"FVC"
"11051";"FVC — liters"
"11052";"FVC % predicted!,t"
"11053";"FVC (% predicted)"
"11054";"FVC (l)"
"11055";"FVC (L)"
"11056";"FVC (L) Proportion taking pulmonary medications (%)b"
"11057";"FVC (L)*"
"11058";"FVC (L);"
"11059";"FVC (liters)"
"11060";"FVC <90% predicted"
"11061";"FVC >90% predicted"
"11062";"FVC change"
"11063";"FVC post-bronchodilator"
"11064";"FVC pre-bronchodilator"
"11065";"FVC(L)"
"11066";"FVC∗"
"11067";"FVC, % predicted"
"11068";"FVC, % predicted, mean (SD)"
"11069";"FVC, L"
"11070";"FVC, L, mean (SD)"
"11071";"FVC, mL"
"11072";"G"
"11073";"G-Blockers"
"11074";"G+C"
"11075";"GA"
"11076";"Ga/A"
"11077";"GAD positive — no. (%)^"
"11078";"Gained BMD"
"11079";"GAIT"
"11080";"Galectin-3 (ng/ml)"
"11081";"Gall bladder adverse event (N=603)"
"11082";"Gallbladder-related AEs"
"11083";"Gamma glutamyltransferase, U/L"
"11084";"Gastroduodenal"
"11085";"Gastroduodenum"
"11086";"Gastroenteritis"
"11087";"Gastroesophageal reflux disease"
"11088";"Gastrointestinal (GI) disorders"
"11089";"Gastrointestinal area involved — no./ total no. (%)"
"11090";"Gastrointestinal area involved, n/total n (%)"
"11091";"Gastrointestinal bleeding"
"11092";"Gastrointestinal disorders"
"11093";"gastrointestinal event"
"11094";"Gastrointestinal major bleed"
"11095";"Gaviscon DA (n = 536)"
"11096";"GDF-15 (ng/ml)"
"11097";"GDS score*"
"11098";"Gemfibrozil"
"11099";"Gemfibrozil (N=12641"
"11100";"Gendar"
"11101";"Gender"
"11102";"Gender - male, n (%)"
"11103";"Gender - n (%)"
"11104";"Gender (%) male/female"
"11105";"Gender (female:male, %)"
"11106";"Gender (M/F), (%)"
"11107";"Gender (male), n (%)"
"11108";"Gender (male/female) (number)"
"11109";"Gender [n (%)]"
"11110";"Gender Female"
"11111";"Gender Male"
"11112";"Gender n (%)"
"11113";"Gender, %"
"11114";"Gender, % of patients"
"11115";"Gender, female, n (%)"
"11116";"Gender, male"
"11117";"Gender, male (%)"
"11118";"Gender, male, n (%)"
"11119";"Gender, male/female"
"11120";"Gender, n (%)"
"11121";"Gender, n (%) male"
"11122";"Gender, n (%]"
"11123";"Gender, N [%] male"
"11124";"Gender, No. (%)"
"11125";"Gender, women N, %)"
"11126";"Gender, N (% men)"
"11127";"Gender, n (%)"
"11128";"Gender:"
"11129";"Gender: male, n (%)"
"11130";"Gene"
"11131";"Gene/Chr/SNP"
"11132";"General"
"11133";"General allergic events"
"11134";"General alone"
"11135";"General anaesthesia"
"11136";"General and lumbar epidural"
"11137";"General andthoracic epidural"
"11138";"General health"
"11139";"General health (self-reported)"
"11140";"General health VAS, 0-100 mm"
"11141";"General health, self-reported"
"11142";"Generalized"
"11143";"Genetic Subgroup"
"11144";"Genital mycotic infections Male3"
"11145";"Genotype"
"11146";"Genotype-by- treatment interaction P values*"
"11147";"Genotype-specific treatment effect hazard ratio (95%CI)"
"11148";"Genotyping"
"11149";"Gentype"
"11150";"Geo graphic region: Asia"
"11151";"Geographic distribution - no. (%)"
"11152";"Geographic location"
"11153";"Geographic region"
"11154";"Geographic Region"
"11155";"Geographic region-Europe"
"11156";"Geographic region-North America"
"11157";"Geographic region-Other"
"11158";"Geographic region—number (%)"
"11159";"Geographic region — no. (%)"
"11160";"Geographic region, %"
"11161";"Geographic region, n (%)"
"11162";"Geographic region?"
"11163";"Geographic region^"
"11164";"Geographic site, %"
"11165";"Geographical location, n (%)"
"11166";"Geographical region"
"11167";"Geographical region (%)"
"11168";"Geographical region, n (%)"
"11169";"Geometric anti-dsDNA antibody binding level"
"11170";"Geometric C3 concentration, mg/dl"
"11171";"Geometric C4 concentration, mg/dl"
"11172";"Geometric mean"
"11173";"Geometric mean blood eosinophil count (SD on a loge scale) — cells/mm3"
"11174";"Geometric mean blood eosinophil count on loge scale — cells/^lJJ"
"11175";"Geometric mean CRP concentration (mg/L)"
"11176";"Geometric mean IgE on loge scale — U/ml"
"11177";"Geometric mean of baseline"
"11178";"Geometric mean ofCRP— mg/liter (range)"
"11179";"Geometric mean UACR"
"11180";"Germany"
"11181";"Gertder"
"11182";"GetGoal-L-Asia"
"11183";"GetGoal-S"
"11184";"GFF MDI"
"11185";"GFR (CKD-EPI)"
"11186";"GFR (MDRD) (mL/min/1-73 m3)"
"11187";"GFR (ml/min per 1.73 nr)"
"11188";"GFR <30mL/min/1.73 m2"
"11189";"GFR <60"
"11190";"GFR >60"
"11191";"GFR 2 90"
"11192";"GFR 60 - 89"
"11193";"GFR as assessed by MDRD"
"11194";"GG"
"11195";"GGT increased"
"11196";"GI Bleed"
"11197";"GI major bleeding"
"11198";"Giargine"
"11199";"Giimepiride ± OAD"
"11200";"GISSI Prevention 1/1994-5/1996"
"11201";"GLACIAL11"
"11202";"Glargine"
"11203";"Glargine 222"
"11204";"Glargine allocation"
"11205";"Glargine N (N/lOOpy)"
"11206";"glatiramer acetate, No. (%)"
"11207";"Gliclazide (modified release) 一 no. (%)^"
"11208";"glimepiride"
"11209";"Glinide"
"11210";"Glinide 一 no. (%)"
"11211";"Glipizide"
"11212";"Glipizide (n=339)"
"11213";"Global assessment of disease status score"
"11214";"Global ischemia"
"11215";"Global ischemia (%)**"
"11216";"Global trial population"
"11217";"Glomerular"
"11218";"Glomerular Filtration Rate (ml/min/1.73ma,"
"11219";"glomerular filtration rate,3 ml/min/1.73 m2"
"11220";"Glomerular filtration rate§"
"11221";"GLP-1 analogue"
"11222";"GLP-1 receptor agonist"
"11223";"GLP-1 receptor agonist (other than study drug)"
"11224";"GLP-1 receptor agonists"
"11225";"glu298asp G. T"
"11226";"Glucagon-like peptide-1 agonist"
"11227";"Glucagon-like peptide-1 receptor agonist"
"11228";"Glucocorticoid"
"11229";"Glucocorticoid]"
"11230";"Glucocorticoids"
"11231";"Glucocorticoids and immunosuppressants"
"11232";"Glucocorticoids at baseline"
"11233";"Glucocorticoids combined with immunosuppressive agents"
"11234";"Glucocorticoids only"
"11235";"Glucocorticoids plus immunosuppressive agents"
"11236";"Glucocorticoids*"
"11237";"Glucosamine"
"11238";"Glucosamine (N = 317)"
"11239";"Glucosamine + Chondroitin Sulfate"
"11240";"Glucosamine + Chondroitin Sulfate (N = 317)"
"11241";"Glucose-lowering drug"
"11242";"Glucose-lowering medication"
"11243";"Glucose-lowering medications"
"11244";"Glucose-lowering therapies"
"11245";"Glucose-lowering therapies — no. {%)"
"11246";"Glucose-lowering therapy"
"11247";"Glucose-lowering therapy - no. (%)"
"11248";"Glucose-lowering therapy, n (%)"
"11249";"Glucose — mg/dl"
"11250";"Glucose — mmol/liter"
"11251";"Glucose (mg/dL)"
"11252";"Glucose in urine, ≥1+"
"11253";"Glucose metabolism"
"11254";"Glucose test"
"11255";"Glucose, mg/dL, mean"
"11256";"Glucose, mmol/L"
"11257";"Glucose, non-fasting or random (nmol/L)"
"11258";"Glulisine + OAD"
"11259";"Glulisine monotherapy"
"11260";"GLY"
"11261";"GLY (15.6 pg b.i.d.) N=216"
"11262";"GLY 15.6 gg b.i.d n/N (%)"
"11263";"GLY 15.6 mg b.i.d. n = 251"
"11264";"GLY 25 μg BID"
"11265";"GLY 50 μg BID"
"11266";"Glyburide"
"11267";"Glyburide (n = 1441)"
"11268";"Glyburide (N = 1441)"
"11269";"Glyburide dose duringthe study (mg)"
"11270";"Glycaemic control (HbA1c), n (%)"
"11271";"Glycaemic control group"
"11272";"Glycaemic parameters"
"11273";"Glycated haemoglobin (%)"
"11274";"Glycated haemoglobin, %"
"11275";"Glycated hemoglobin"
"11276";"Glycated Hemoglobin"
"11277";"Glycated hemoglobin - %’"
"11278";"Glycated hemoglobin — %"
"11279";"Glycated hemoglobin — %-"
"11280";"Glycated hemoglobin (%)"
"11281";"Glycated hemoglobin <Median"
"11282";"Glycated hemoglobin level"
"11283";"Glycated hemoglobin, %"
"11284";"Glycated hemoglobin, %, mean (SD)"
"11285";"Glycated hemoglobin, mean (SD), %"
"11286";"Glycated hemoglobin, Median (IQR)"
"11287";"Glycated hemoglobin, n(%)"
"11288";"Glycated hemoglobin, nonstandardized level — %"
"11289";"Glycated hemoglobin, standardized level — %"
"11290";"Glycated hemoglobin||"
"11291";"Glycatedhemoglobin category,%"
"11292";"Glycemia, mg/dl"
"11293";"Glycemic characteristics"
"11294";"Glycemic drugs"
"11295";"Glycemic indexes"
"11296";"Glycemic status"
"11297";"Glycemic status f"
"11298";"Glycemic variability, mmol/Lc"
"11299";"Glyceryl trinitrate infusion"
"11300";"Glycohemoglobin, %"
"11301";"Glycohemoglobin, %, mean (SD)"
"11302";"Glycoprotein IIb/IIIa inhibitor"
"11303";"Glycoprotein IIb/IIIa inhibitor use before angiography"
"11304";"Glycoprotein IIb/IIIa inhibitors"
"11305";"Glycoprotein IIb/IIIa inhibitort"
"11306";"Glycoprotein IIb/IIIareceptorinhibitor"
"11307";"Glycoprotein Ilb/IIIa inhibitor before PCI]"
"11308";"Glycoprotein llb/Illa inhibitor"
"11309";"Glycoprotein llb/llia Inhibitor"
"11310";"Glycoprotein llb/llla inhibitors"
"11311";"Glycoprotein llb/llla receptor inhibitor"
"11312";"Glycopyrrolate/    Glycopyrrolate/ eFlow CS 25 meg eFlow CS 50 meg (n=431)    (n=432)"
"11313";"Glycopyrrolate/ eFlow CS 50 meg (n=620)"
"11314";"Glycopyrronium 50 mg (n = 1059)"
"11315";"Glycosylated hemoglobin, %"
"11316";"Glyeated haemoglobin"
"11317";"GM"
"11318";"GM, geometric mean; GMR, geometric mean ratio over baseline; UACR, urinary albumimcreatinine ratio. % Reduction: 100 x (1 —ratio of GMR for losartan versus GMR for placebo). aMean of change, with change calculated as difference between time indicated and baseline as measured for each participant, difference of changes between treatment groups. cP-values compare differences from no change."
"11319";"GMI (men)"
"11320";"GMI (women)"
"11321";"GMR"
"11322";"Goal"
"11323";"GOLD 1"
"11324";"GOLD 2"
"11325";"GOLD 2 (« = 1140)"
"11326";"GOLD 2 (« = 1148)"
"11327";"GOLD 2014 groups"
"11328";"GOLD 2014 Groups, n (%)"
"11329";"GOLD 3"
"11330";"GOLD 3-4"
"11331";"GOLD 3-4 (« = 1597)"
"11332";"GOLD 3-4 (n = 973)"
"11333";"GOLD 4"
"11334";"GOLD A"
"11335";"GOLD B"
"11336";"GOLD C"
"11337";"GOLD classification"
"11338";"GOLD D"
"11339";"GOLD Grade 2"
"11340";"GOLD Grade 2 and ICS non-users at screening"
"11341";"GOLD Grade 2 and ICS users at screening"
"11342";"GOLD Grade 3"
"11343";"GOLD Grade 3 and ICS non-users at screening"
"11344";"GOLD Grade 3 and ICS users at screening"
"11345";"GOLD Grades 1-4 (percent-predicted FEV(), n"
"11346";"Gold group"
"11347";"GOLD Group A"
"11348";"GOLD Group B"
"11349";"GOLD Group C"
"11350";"GOLD Group D"
"11351";"GOLD group D — no. (%)||"
"11352";"GOLD group, n (%)"
"11353";"GOLD Groups a-D using mMrCb"
"11354";"GOLD II"
"11355";"GOLD III-IV"
"11356";"GOLD stage"
"11357";"GOLD Stage"
"11358";"GOLD stage — no. (%)**"
"11359";"GOLD stage #"
"11360";"GOLD stage (%):c"
"11361";"GOLD stage (%)f"
"11362";"GOLD stage [N (%)]"
"11363";"GOLD stage II"
"11364";"GOLD stage III"
"11365";"GOLD stage IV"
"11366";"GOLD stage, n (%)"
"11367";"GOLD stage, nf* (%)"
"11368";"GOLD, n (%)"
"11369";"GOLDEN-3 and -4"
"11370";"GOLDEN-5"
"11371";"Golimumab"
"11372";"Golimumab 100 mg (n = 146)"
"11373";"Golimumab 2 mg/kg+MTX"
"11374";"Golimumab 200/100 mg"
"11375";"Golimumab 400/200 mg"
"11376";"Golimumab 50 mg (n = 146)"
"11377";"Golimumab 50 mg (n = 146)†"
"11378";"Golimumab 50 mg/100 mgt"
"11379";"Golimumab combined (n = 292)"
"11380";"Goncomitant treatment with AGE inhibitors/angiotensin"
"11381";"Good"
"11382";"Good control (<7)"
"11383";"Good/moderate response"
"11384";"Gout history, mean ± SD years"
"11385";"GP IIb/IIIa inhibitor before PCI—No. (%)"
"11386";"GP IIb/IIIa inhibitor used"
"11387";"GP IIb/IIIa inhibitors"
"11388";"GP llb/llla inhibitors"
"11389";"GP MDI"
"11390";"GPI used during PCI"
"11391";"GPIfeellla inhibitor use before angography"
"11392";"GPIfo'llIa inhibitor use before angography"
"11393";"GpIIb-IIIa inhibitors"
"11394";"GPIIb/IIIa receptor inhibitor"
"11395";"Grade > 2"
"11396";"Grade > 3"
"11397";"Grade > 4"
"11398";"Grade 0"
"11399";"Grade 1"
"11400";"Grade 2"
"11401";"grade 2 (moderate COPD), n (%)"
"11402";"Grade 3"
"11403";"Grade 3 (severe COPD), n (%)"
"11404";"Grade 4"
"11405";"Grade of hypertension"
"11406";"Graft"
"11407";"Graft occlusionsa"
"11408";"Graft, n (%)"
"11409";"graft; PCI, percutaneous coronary intervention; TIA, transient"
"11410";"Granulating, n (%)a"
"11411";"Greater than or equal to 140 mm Hg"
"11412";"Greater than or equal to 50%"
"11413";"Greater than or equal to 60 ml/min/1.73m2"
"11414";"Grip strength (kg)"
"11415";"Grip Strength < Meidan"
"11416";"Grip Strength >= Median"
"11417";"Group"
"11418";"Group — no. (%)"
"11419";"Group A"
"11420";"Group A (n = 103)"
"11421";"Group B"
"11422";"Group B (low risk, more symptoms), n (%)"
"11423";"Group B (n = 100)"
"11424";"Group C"
"11425";"Group C (n = 103)"
"11426";"Group D"
"11427";"Group D (high risk, more symptoms), n (%)"
"11428";"Group Dif. (4)"
"11429";"Group Dif. (9)"
"11430";"Group difference"
"11431";"Grouped region"
"11432";"Groups"
"11433";"GRS"
"11434";"GT"
"11435";"GT+TT"
"11436";"GUSTO-bleeding severe/moderate"
"11437";"GUSTO-defined bleeding"
"11438";"GUSTO moderate"
"11439";"GUSTO Moderate"
"11440";"GUSTO moderate bleeding/ICH"
"11441";"GUSTO moderate or severe"
"11442";"GUSTO moderate or severe bleeding"
"11443";"GUSTO moderate/severe"
"11444";"GUSTO Moderate/Severe"
"11445";"GUSTO moderate/severe bleed"
"11446";"GUSTO moderate/severe bleeding"
"11447";"GUSTO severe"
"11448";"GUSTO Severe"
"11449";"GUSTO severe bleed"
"11450";"GUSTO severe or"
"11451";"GUSTO Severe/Moderate"
"11452";"H"
"11453";"H DL cholesterol <35 mg/dl"
"11454";"H pylori serology*"
"11455";"H. pylori status, n (%)"
"11456";"H2-receptor antagonist"
"11457";"H2 blocker (n, %) Long-term VKA therapy"
"11458";"H2 receptor antagonist"
"11459";"HAb1c (mean±SEM), %"
"11460";"Habitual fish intake: <2 servings/wk (n=381)"
"11461";"Haematological"
"11462";"Haemodynamics and LV function"
"11463";"Haemoglobin (g/dL)"
"11464";"Haemoglobin (g/dL), mean + SD, available for 3666 patients"
"11465";"Haemoglobin (g/L)"
"11466";"Haemoglobin (mg/dL)"
"11467";"Haemoglobin (mmol/L)"
"11468";"Haemoglobin, mg/dl"
"11469";"Haemorrhagic"
"11470";"Haemorrhagic stroke"
"11471";"Haemorrhagic stroke—No. (%)"
"11472";"Hale"
"11473";"Hand"
"11474";"Hand fracture"
"11475";"Hands"
"11476";"Haplotype"
"11477";"HAQ"
"11478";"HAQ-DI"
"11479";"HAQ-DI (0-3)"
"11480";"HAQ-DI (0-3), mean (SD)"
"11481";"HAQ-DI (range 0-3)"
"11482";"HAQ-DI improvement >0.22"
"11483";"HAQ-DI improvement >0.5"
"11484";"HAQ-DI improvement from baseline to week 24"
"11485";"HAQ-DI MCIDe"
"11486";"HAQ-DI score"
"11487";"HAQ-DI score (0-3)"
"11488";"HAQ-DI score (0-3), mean (SD)"
"11489";"HAQ-DI scored"
"11490";"HAQ-DI scoreff"
"11491";"HAQ-DI total score, mean (SD)"
"11492";"HAQ-DI*"
"11493";"HAQ-DI**"
"11494";"HAQ-DI, mean (SD)"
"11495";"HAQ-DI, mean [SD]"
"11496";"HAQ-DI, number (%)"
"11497";"HAQ-DI, range 0-3, mean (SD)"
"11498";"HAQ Alternative Disability score"
"11499";"HAQ DI"
"11500";"HAQ DI (range 0-3)"
"11501";"HAQ DI score (0-3)"
"11502";"HAQ DI score (range 0-3), mean ± SD"
"11503";"HAQ Pain Scale, mean"
"11504";"HAQ Pain score"
"11505";"HAQ score"
"11506";"HAQ score (0–3 scale)"
"11507";"Hard MACE"
"11508";"Harzar ratio(95% CI)"
"11509";"Harzard ratio(95% CI)"
"11510";"HAS-BLED >3"
"11511";"HAS-BLED 1-2"
"11512";"HAS-BLED score"
"11513";"HAS-BLED Score"
"11514";"HAS-BLED score >3"
"11515";"HAS-BLED score’"
"11516";"HAS-BLED>3"
"11517";"HAS-BLED1-2"
"11518";"HAS-BLEDO"
"11519";"Hawaiian Pacific Islander"
"11520";"Hawaiian/Pacific Islander"
"11521";"Hazard"
"11522";"Hazard    Inleraction"
"11523";"Hazard    Interaction"
"11524";"Hazard ratio"
"11525";"Hazard Ratio"
"11526";"Hazard Ratio (95% C"
"11527";"Hazard ratio (95% CI)"
"11528";"Hazard Ratio (95% CI)"
"11529";"Hazard Ratio (95% CI)-j-"
"11530";"Hazard Ratio (95% CI) for Adjudicated Type 2 Diabetes"
"11531";"Hazard ratio (95% CI) vs. Placebo"
"11532";"Hazard Ratio (95% CI)*"
"11533";"Hazard ratio (95% CI)3 with vs. without psoriasis"
"11534";"Hazard ratio (95% Cl)"
"11535";"Hazard Ratio (95% Cl)"
"11536";"Hazard Ratio (95% Cl) 0.87 (0.80, 0.94)"
"11537";"Hazard Ratio (95% Cl) 0.93 (0.75, 1.14)"
"11538";"Hazard ratio (95% Cl) Nateglinide vs. Placebo"
"11539";"Hazard ratio (95% Cl) Valsartan vs. Placebo"
"11540";"Hazard Ratio (95% Cl)"""
"11541";"Hazard Ratio (95% Cl)*"
"11542";"Hazard Ratio (95% Cl]"
"11543";"Hazard Ratio (95% Confi dence Interval)"
"11544";"Hazard Ratio (95% Confidence Interval)"
"11545";"Hazard ratio (95% Confidence interval)*"
"11546";"Hazard ratio (95%CI)"
"11547";"Hazard Ratio (95%CI)"
"11548";"Hazard Ratio [95% Cl]"
"11549";"Hazard ratio [95%CI]"
"11550";"Hazard ratio 4)"
"11551";"Hazard Ratio and 95% Confidence Interval"
"11552";"Hazard Ratio for Cardiovascular Death,"
"11553";"Hazard Ratio for Cardiovascular Death, Stroke, or Myocardial Infarction (95% CI)"
"11554";"Hazard Ratio for Event (95% CI)"
"11555";"Hazard ratio GLP-1 analogue vs placebo [95% Cl]"
"11556";"Hazard ratio or difference1* (95% Cl) P-value"
"11557";"Hazard ratio or difference3 (95% Cl) P-value"
"11558";"Hazard ratio vs. Placebo"
"11559";"Hazard Ratio with"
"11560";"Hazard Ratio with Dabigatran, 110 mg (95% Cl)"
"11561";"Hazard Ratio with Dabigatran, 150 mg (95% Cl)"
"11562";"Hazard Ratio with High (95% Cl)"
"11563";"Hazard Ratio with Low (95% Cl)"
"11564";"Hazard ratio* (95% CI)"
"11565";"Hazard ratio* (and 95% CI)"
"11566";"Hazard ratio, UMEC/VI vs. TIO (95% CI)"
"11567";"Hazard Ratio2"
"11568";"Hazard Ratiof"
"11569";"Hazard ratiof (95%CI)"
"11570";"Hazard.Ratio.(95% CI).........."
"11571";"Hb decrease ≥2 g/dL"
"11572";"Hb, g/dl"
"11573";"HbA , % 1c"
"11574";"HbA <median"
"11575";"HbA,,(%)"
"11576";"HbA,c (%)"
"11577";"HbA]c (mmol/mol)"
"11578";"HbA„(%)"
"11579";"HbA1c"
"11580";"HbA1c — % Cholesterol — mmol/L"
"11581";"HbA1c $5.7% (39 mmol/mol)"
"11582";"HbA1c % (range)"
"11583";"HbA1c (% patients <7.0%)"
"11584";"HbA1c (%)"
"11585";"HBA1c (%)"
"11586";"HbA1c (%) All countries"
"11587";"HbA1c (%)*"
"11588";"HbA1c (%), mean (SD)"
"11589";"HbA1c (change from baseline)"
"11590";"HBA1c (mmol/mol [SE])"
"11591";"HbA1c (mmol/mol)"
"11592";"HbA1c (n)"
"11593";"HbA1c (SD), %"
"11594";"HbA1c (SD), mmol/mol"
"11595";"HbA1c \N;"
"11596";"HbA1c < 6.5%"
"11597";"HbA1c < 7.0%, BP < 130/80 mm Hg, LDL-C < 100 mg /dL"
"11598";"HbA1C < 8% level"
"11599";"HbA1c < 8.0%, BP < 140/90 mm Hg, LDL-C < 100 mg /dL"
"11600";"HbA1c <= 8%"
"11601";"HbA1c <= 8% (n 5 94)"
"11602";"HbA1c <= 8% (n 5 97)"
"11603";"HbA1c <7% (n - 4119)"
"11604";"HbA1c <8%"
"11605";"HbA1c ≤6.5%"
"11606";"HbA1c ≤6.5% without GI adverse reactions"
"11607";"HbA1c > 6.5%"
"11608";"HbA1C > 8% level"
"11609";"HbA1c > 9%"
"11610";"HbA1c > 9% (n 5 69)"
"11611";"HbA1c >8·5%"
"11612";"HbA1c >9%"
"11613";"HbA1c >9% (n 5 81)"
"11614";"HbA1c 12 weeks"
"11615";"HbA1c 24 weeks"
"11616";"HbA1c 6.5 to <7.0% (48-53 mmol/mol)"
"11617";"HbA1c 7-<=8%"
"11618";"HbA1c 7%-<8% (n - 5416)"
"11619";"HbA1c 8-<=9%"
"11620";"HbA1c 8%-<9% (n - 3139)"
"11621";"HbA1c at 24 weeks*"
"11622";"HbA1c at baseline"
"11623";"HbA1c at baseline, %"
"11624";"HbA1c at Baseline:"
"11625";"HbA1c categories, n (%)"
"11626";"HbA1c category"
"11627";"HbA1c category, n (%)"
"11628";"HbA1c distribution"
"11629";"HbA1c distribution at baseline"
"11630";"HbA1c distribution at baseline, n (%)"
"11631";"HbA1c in % (median (Q1, Q3) [n])"
"11632";"HbA1c in patients with baseline HbA1c <8% (<64 mmol/L), % [mmol/mol], LA, n Baseline (SD) Adjusted mean change (95% CI) Placebo-subtracted change (SE)"
"11633";"HbA1c in patients with baseline HbA1c >8% to <9% (>64 to <75 mmol/mol), % [mmol/mol], LA, n Baseline (SD) Adjusted mean change (95% CI) Placebo subtracted change (SE)"
"11634";"HbA1c in patients with baseline HbA1c >9% (>75 mmol/mol), % [mmol/mol], LA, n Baseline (SD) Adjusted mean change (95% CI) Placebo-subtracted change (SE)"
"11635";"HbA1c levels"
"11636";"HbA1c Month 0 (%)"
"11637";"HbA1c strata"
"11638";"HbA1c subgroups"
"11639";"HbA1c Tx difference vs Pbo, median change from baseline (SE)1"
"11640";"HbA1c (%)"
"11641";"HbA1c (mmol/mol)"
"11642";"HbA1c at randomization"
"11643";"HbA1c baseline (%)"
"11644";"HbA1c(%)"
"11645";"HBA1c(%) (median (IQR)"
"11646";"HbA1c, %"
"11647";"HbA1c, % (mean ± SD) [range]"
"11648";"HbA1c, % (mean 6 SD)"
"11649";"HbA1c, % (SD)"
"11650";"HbA1c, % [mmol/mol]"
"11651";"HbA1c, %*"
"11652";"HbA1c, %, mean (SD)"
"11653";"HbA1c, %, mean (SD)b"
"11654";"HbA1c, %, mean±SD"
"11655";"HbA1c, %, median (Q1, Q3)"
"11656";"HbA1c, %, n (%)b"
"11657";"HbA1c, %§"
"11658";"HbA1c, %d"
"11659";"HbA1c, (%)"
"11660";"HbA1c, (mmol/mol)"
"11661";"HbA1c, <6.0"
"11662";"HbA1c, >6.4"
"11663";"HbA1c, 6.0–6.4"
"11664";"HbA1c, Baseline mean HbA1c, % (SD)"
"11665";"HbA1c, Difference vs placebo (95% Cl)"
"11666";"HbA1c, mean (SD)"
"11667";"HbA1c, mean (SD), %"
"11668";"HbA1c, mean (SD), % [mmol/mol]"
"11669";"HbA1c, mean = SD, %"
"11670";"HbA1c, median (Q1–Q3)"
"11671";"HbA1c, median (Q1, Q3), %"
"11672";"HbA1c, median (SD), %"
"11673";"HbA1c, mmol/mol"
"11674";"HbA1c, mmol/mol (mean)"
"11675";"HbA1c, mmol/mol, mean (SD)"
"11676";"HbA1c, mmol/mol, median (Q1, Q3)"
"11677";"HbA1c, mmol/mold"
"11678";"HbA1c, mmol/mole"
"11679";"HbA1c, N"
"11680";"hba1c,%"
"11681";"HbA1c,%"
"11682";"HbA1c<7%"
"11683";"HbA1C<8%"
"11684";"HbA1C>=8%"
"11685";"HbA1c>=9%"
"11686";"HbA1ca, % (mmol/mol)"
"11687";"HbA1ca, %, mean ± SD"
"11688";"HbAi,"
"11689";"HbAic —%"
"11690";"HbAic (%)"
"11691";"HbAic (%), mean ± s.d."
"11692";"HbAic group (%)"
"11693";"HbAie (%)"
"11694";"HbAie (%) Mean±SD"
"11695";"HbAie, %"
"11696";"HbAj(- (%; mmol/mol)"
"11697";"HbAjc (mmol/mol) Mean±SD"
"11698";"HbAK <median"
"11699";"HbAK>median"
"11700";"HbAlc"
"11701";"HbAlc (%)"
"11702";"HbAlc (%), mean (SD)^"
"11703";"HbAlc (mmol/mol)"
"11704";"HbAlc £58 mmol/mol (£7.5%) (N=38/36)"
"11705";"HbAlc £58 mmol/mol (<7.5%) (N=188/201)"
"11706";"HbAlc £64 mmol/mol (£8.0%) (N=163/148)"
"11707";"HbAlc £64 mmol/mol (£8.0%) (N=51/54)"
"11708";"HbAlc £64 mmol/mol (>8.0%) (N=110/95)"
"11709";"HbAlc < 53 mmol/mol (<7.0%) at Week 20"
"11710";"HbAlc < 6% (42 mmol/mol)"
"11711";"HbAlc < Medan"
"11712";"HbAlc < Median"
"11713";"HbAlc <58 mmol/mol (£7.5%) (N=108/120)"
"11714";"HbAlc <58 mmol/mol (<7.5%) (N=108/120)"
"11715";"HbAlc <58 mmol/mol (<7.5%) (N=188/201)"
"11716";"HbAlc <58 mmol/mol (<7.5%) (N=38/36)"
"11717";"HbAlc <7% (<53 mmol/mol), n (%)"
"11718";"HbAlc <8%"
"11719";"HbAlc <median"
"11720";"HbAlc >=9% (n - 3525)"
"11721";"HbAlc >58-<64 mmol/mol (>7.5-<8.0%) (N=31/25)"
"11722";"HbAlc >58-<64 mmol/mol (>7.5-<8.0%) (N=70/73)"
"11723";"HbAlc >58-<64 mmol/mol (>7.5-<8.0%) (N=83/84)"
"11724";"HbAlc >64 mmol/mol (>8.0%) (N=110/95)"
"11725";"HbAlc >64 mmol/mol (>8.0%) (N=163/148)"
"11726";"HbAlc >64 mmol/mol (>8.0%) (N=51/54)"
"11727";"HbAlc >8%"
"11728";"HbAlc a64 mmol/mol (>8.0%) (N=110/95)"
"11729";"HbAlc in %, median (IQR)"
"11730";"HbAlc Tx difference vs Pbo, median change from baseline (SE)1"
"11731";"HbAlc, %"
"11732";"HbAlc, %, mean (SD)"
"11733";"HbAlC, mean (s.d.)"
"11734";"HbAlc, median (Ql, Q3), %"
"11735";"HbAlc, mmol/mol"
"11736";"HbAlc<median"
"11737";"HbAlc>median"
"11738";"HbAlca Median"
"11739";"HbAu, %"""
"11740";"hC"
"11741";"HCQ+MTX (n = 81)"
"11742";"HCRU (A)"
"11743";"HCTZ"
"11744";"HCTZ - hydrochlorothiazide. *Data were missing for some patients."
"11745";"HCTZ = hydrochlorothiazide. * Based on a '/_2 test, t Data were missing for some patients."
"11746";"HCTZ = hydrochlorothiazide. * Based on Wilcoxon 2-sample rank-sum tests for age and body mass index, t tests for systolic and diastolic blood and '/2 tests for categorical variables. t Data were missing for some patients."
"11747";"HCTZ*"
"11748";"HCTZ* (n=109)"
"11749";"HCTZ* (n=59)"
"11750";"HD (n=7008)"
"11751";"HD Edoxaban vs Warfarin"
"11752";"HDER*"
"11753";"HDL"
"11754";"HDL-C"
"11755";"HDL-C (median, IQR), mg/dL"
"11756";"HDL-C (mg/dl)"
"11757";"HDL-C (mg/dL)"
"11758";"HDL-C (mg/dL) - mean ± SD"
"11759";"HDL-C (mg/dL)*"
"11760";"HDL-C (mmol/L)"
"11761";"HDL-C (mmol/L, mean)"
"11762";"HDL-c < 35 mg/dL"
"11763";"HDL-C < 35 mg/dL"
"11764";"HDL-C <35 mg/dL"
"11765";"HDL-C <35 mg/dL, No. (%)"
"11766";"HDL-C <35 mg/dl_"
"11767";"HDL-C >40 mg/dL (1.0 mmol/L)"
"11768";"HDL-c at Baseline."
"11769";"HDL-C level, < 35 mg/dLd"
"11770";"HDL-C level, mean (SD), mg/dL"
"11771";"HDL-C level, mg/dL"
"11772";"HDL-C high-density lipoprotein cholesterol; LDL-C low-density lipoprotein cholesterol; SEstandard error; TG triglycerides."
"11773";"HDL-C, mean (SD)"
"11774";"HDL-C, mean (SD), mg/dL"
"11775";"HDL-C, mg/dL"
"11776";"HDL-C, mg/dL, mean (SD)"
"11777";"HDL-C, mg/dL, mean + SD"
"11778";"HDL-C, mg/dL, mean ± SD"
"11779";"HDL-C, mmol/L"
"11780";"HDL-C, mmol/L (mg/dL)"
"11781";"HDL-C, mmol/l, mean (SD)"
"11782";"HDL-C, mmol/L, mean (SD)"
"11783";"HDL-C,35 mg/dL, n (%)"
"11784";"HDL-C<35mg/dl. n (%)"
"11785";"HDL-Cd"
"11786";"HDL-cholesterol"
"11787";"HDL-cholesterol (mg/dL)"
"11788";"HDL-cholesterol (mmol/L)"
"11789";"HDL-cholesterol, mean (sd) mg/dl"
"11790";"HDL-cholesterol, mg/dL, mean (SD)"
"11791";"HDL-cholesterol, mmol/L"
"11792";"HDL-cholesterol, mmol/le"
"11793";"HDL-Cy"
"11794";"HDL—female"
"11795";"HDL—male"
"11796";"HDL (mg/dl)"
"11797";"HDL (mmol/L)"
"11798";"HDL <35 mg/dL"
"11799";"HDL <40/50 mg/dL (1.03/1.29 mmol/L) for men/women"
"11800";"HDL choleslerol"
"11801";"HDL cholesterol"
"11802";"HDL cholesterol — mg/dl"
"11803";"HDL cholesterol — mg/dl Triglycerides — mg/dl"
"11804";"HDL cholesterol (mg/dl)"
"11805";"HDL cholesterol (mg/dL)"
"11806";"HDL cholesterol (mg/dL), mean + SD, available for 3552 patients"
"11807";"HDL cholesterol (mmol/l)"
"11808";"HDL cholesterol (mmol/L)"
"11809";"HDL cholesterol (mmol/L) (median, IQR)"
"11810";"HDL cholesterol (mmol/L), mean (SD)"
"11811";"HDL cholesterol (mmol/L):"
"11812";"HDL cholesterol (SD), mg/dL"
"11813";"HDL cholesterol (week 24)a"
"11814";"HDL cholesterol <1-17 mmol/L"
"11815";"HDL cholesterol <35 mg/dl*"
"11816";"HDL cholesterol <40 (men) or <50 mg/dl (women)"
"11817";"HDL cholesterol >1-17 mmol/L"
"11818";"HDL cholesterol level"
"11819";"HDL cholesterol Mean"
"11820";"HDL cholesterol*"
"11821";"HDL cholesterol, (mmol/L)"
"11822";"HDL cholesterol, mean (SD), mg/dL"
"11823";"HDL cholesterol, mg/dl"
"11824";"HDL cholesterol, mg/dL"
"11825";"HDL Cholesterol, mg/dL"
"11826";"HDL cholesterol, mmol/冲"
"11827";"HDL cholesterol, mmol/L"
"11828";"HDL cholesterol, mmol/L*"
"11829";"HDL cholesterol, mmol/L, men, mean±SD"
"11830";"HDL cholesterol, mmol/L, women, mean±SD"
"11831";"HDL cholesterol, mmol/lt"
"11832";"HDL cholesterol^:"
"11833";"HDL cholesterol§"
"11834";"HDL*"
"11835";"HDL, mean (SD), mg/dL"
"11836";"hdl2"
"11837";"hdl2-c"
"11838";"hdl3"
"11839";"hdl3-c"
"11840";"HDLcholesterol"
"11841";"HDM n = 130"
"11842";"HDM n = 138"
"11843";"HDM n = 139"
"11844";"HDM n = 484"
"11845";"HDM n = 77"
"11846";"Headache"
"11847";"Health-care use rate (peryear)"
"11848";"Health-related quality of life"
"11849";"Health Assessment Questionnaire-Disability Index"
"11850";"Health Assessment Questionnaire (0-3 range)"
"11851";"Health Assessment Questionnaire score"
"11852";"Health habits"
"11853";"Health Practices"
"11854";"Health State Index Score, UK algorithm"
"11855";"Healthy weight"
"11856";"Heart-rate group at baseline"
"11857";"Heart disease risk factors"
"11858";"Heart failure"
"11859";"Heart Failure"
"11860";"Heart failure — no. (%)"
"11861";"Heart failure — no./total no. (%)"
"11862";"Heart failure (Class I—III)"
"11863";"Heart failure (class l-lll)"
"11864";"Heart failure (HF), (%)"
"11865";"Heart failure (NYHA II‐III), n (%)"
"11866";"Heart failure (treated /hospitalized/fatal)"
"11867";"Heart failure (treated/hospitalized/fatal)"
"11868";"Heart failure 1 mo before admission"
"11869";"Heart failure 1 month before admission"
"11870";"Heart failure 1 yr before admission"
"11871";"Heart failure at entry, No. (%)"
"11872";"Heart failure cause"
"11873";"Heart failure criteria met"
"11874";"Heart failure history"
"11875";"Heart failure hospitalisation or CV death"
"11876";"Heart failure hospitalizations"
"11877";"Heart failure NYHA II - III"
"11878";"Heart failure or LVEF <40% associated with index ACS event"
"11879";"Heart failure*"
"11880";"Heart failure, hospitalized or fatal"
"11881";"Heart failure, LVEF <40%, or both"
"11882";"Heart failure, n (%)"
"11883";"Heart failure, No./total No. (%)"
"11884";"heart failure; CI, confidence interval."
"11885";"Heart failure‡"
"11886";"Heart failurea"
"11887";"Heart rate"
"11888";"Heart Rate"
"11889";"Heart rate — beats/min"
"11890";"Heart rate — bpm"
"11891";"Heart rate (b.p.m.)"
"11892";"Heart rate (b.p.m.), mean ± SD"
"11893";"Heart rate (beats per min)"
"11894";"Heart rate (beats per minute)"
"11895";"Heart rate (beats/min)"
"11896";"Heart Rate (beats/min)"
"11897";"Heart rate (bpm)"
"11898";"Heart rate (bpm)*"
"11899";"Heart rate (bpm0)*,**"
"11900";"Heart Rate (Median 73.0}"
"11901";"Heart rate (min−1)"
"11902";"Heart rate (SD)"
"11903";"Heart rate (SD), bpm"
"11904";"Heart rate (SD), bpm Blood pressure, mm Hg"
"11905";"Heart rate < 69 bpm"
"11906";"Heart rate 一beats/min"
"11907";"Heart rate > 69 bpm"
"11908";"Heart rate at baseline (bpm"
"11909";"Heart rate at baseline, bpm"
"11910";"Heart rate at rest — beats/min"
"11911";"Heart rate at rest in the supine position (beats/min)"
"11912";"Heart rate, /min"
"11913";"Heart rate, b.p.m. mean ± SD"
"11914";"Heart rate, beats per min"
"11915";"Heart rate, beats per minute"
"11916";"Heart rate, beats/min"
"11917";"Heart rate, beats/min, mean ± SD"
"11918";"Heart rate, bpm"
"11919";"Heart rate, bpm, mean (SD)"
"11920";"Heart rate, mean (SD)"
"11921";"Heart rate, mean (SD) [range], beats/min"
"11922";"Heart rate, mean (SD), beats/min"
"11923";"Heart rate, mean (SD), bpm (n=21 074)"
"11924";"Heart rate, mean ± SD (b.p.m.)"
"11925";"Heart rate, min_1 (mean)"
"11926";"Heart rates (beats/minutes)"
"11927";"Heartburn severity during the run-in periodT"
"11928";"Heat failure"
"11929";"Heavy calcification"
"11930";"Heavy Calcification"
"11931";"Height', cm"
"11932";"Height — cm"
"11933";"Height ( cm)"
"11934";"Height (cm)"
"11935";"Height (cm) (mean ± SD)"
"11936";"Height (cm), mean (s.e.)"
"11937";"Height (cm), mean (SD)a"
"11938";"height in meters."
"11939";"Height loss"
"11940";"Height loss (cm)"
"11941";"Height, cm"
"11942";"Height, cm (mean ± s.d.)"
"11943";"Height, cm*"
"11944";"Height, cm, mean (SD)"
"11945";"Height, mean (SD), cm"
"11946";"Helicobacter pylori-negative, n (%)"
"11947";"Helicobacter pylori infection (+) (n)"
"11948";"Hematocrit, %"
"11949";"Hematologic"
"11950";"Hemispheric stroke n = 526"
"11951";"Hemispheric TIA n = 603"
"11952";"Hemodynamic parameters at baseline in the patients enrolled in the hemodynamic substudy"
"11953";"Hemoglobin"
"11954";"Hemoglobin-A1c (%)'•■**"
"11955";"Hemoglobin — g/dl"
"11956";"Hemoglobin    level, %"
"11957";"Hemoglobin (< 13 men,，::12 women)"
"11958";"Hemoglobin (g 1 !)"
"11959";"Hemoglobin (g r1)"
"11960";"Hemoglobin (g/dL)"
"11961";"Hemoglobin (g/l)"
"11962";"Hemoglobin (g/L)"
"11963";"Hemoglobin (gl ')"
"11964";"Hemoglobin (gm/dl)"
"11965";"Hemoglobin 一g/dl"
"11966";"Hemoglobin A,,, (%)"
"11967";"Hemoglobin A^c, %"
"11968";"Hemoglobin A1C"
"11969";"Hemoglobin A1c (%)"
"11970";"Hemoglobin A1c, %"
"11971";"Hemoglobin A1C, mean (SD), %"
"11972";"Hemoglobin A1c, mean (SD), %b"
"11973";"Hemoglobin Aj^ (%)"
"11974";"Hemoglobin Ale*"
"11975";"Hemoglobin Ale, %, median (IQR)"
"11976";"Hemoglobin category"
"11977";"Hemoglobin concentration — g/liter"
"11978";"Hemoglobin, g 1 1"
"11979";"Hemoglobin, g/dl"
"11980";"Hemoglobin, g/dL"
"11981";"Hemoglobin, g/dlf"
"11982";"Hemoglobin, g/l"
"11983";"Hemoglobin, g/L"
"11984";"Hemoglobin, mg/dl"
"11985";"Hemorrhagic"
"11986";"Hemorrhagic stroke"
"11987";"Hemorrhagic Stroke"
"11988";"Hemorrhagic stroke (N=102)"
"11989";"Heparin"
"11990";"Heparin + tirofiban (n=1459)"
"11991";"Heparin ± tirofiban (n=1459)"
"11992";"Heparin Alone (n = 729)"
"11993";"Heparin at randomization"
"11994";"Heparin Dose Regimen"
"11995";"Heparin only"
"11996";"Heparin Only"
"11997";"Heparin Plus a GPI (n=1870)"
"11998";"Heparin Plus GPI (n = 1,285)"
"11999";"Heparin Plus Tirofiban (n = 730)"
"12000";"Heparin use"
"12001";"Heparin, ‘ondaparinux or brvalirudin use between rxJex event"
"12002";"Heparin, fondaparinux or brvalirudin use between -oex event"
"12003";"Heparins and fondaparinux"
"12004";"Hepatic disorders"
"12005";"Heritable"
"12006";"Heterogeneity or Trend P Vaiue"
"12007";"Heterogeneity or Trend P Value"
"12008";"Heterogeneity p value"
"12009";"Heterogeneity test"
"12010";"Heterogeneity Test"
"12011";"Heterogeneity/ trend test"
"12012";"Heterozygous familial hypercholesterolemia"
"12013";"Heterozygous familial hypercholesterolemia†"
"12014";"HF"
"12015";"HF 'Without known reduced EF"
"12016";"HF cause"
"12017";"HF duration, y, n (%)"
"12018";"HF Hosp."
"12019";"HF hospitalisation"
"12020";"HF hospitalization"
"12021";"HF hospitalization    n"
"12022";"HF hospitalization or cardiovascular death"
"12023";"HF hospitalizations, median (IQR)"
"12024";"HF or LVEF <40% associated with index event"
"12025";"HF signs and symptoms"
"12026";"HF symptoms and signs"
"12027";"HF without known reduced EF"
"12028";"HF without known reduced EF (n=1316)"
"12029";"HF, LVD, or both"
"12030";"HF, total"
"12031";"HFpEF (EF N 45), (%)"
"12032";"HFrEF"
"12033";"HFrEF (n=671)"
"12034";"Hgb, g/dl"
"12035";"Hgb, g/dl <13 men, <12 women"
"12036";"HHF (N =159)"
"12037";"HI)Ah(%)"
"12038";"Hiatal hernia (yes) (n)"
"12039";"High"
"12040";"High-density lipoprotein"
"12041";"High-density lipoprotein cholesterol — mg/dl"
"12042";"High-density lipoprotein cholesterol mean (mg/dl ± SD)"
"12043";"high-density lipoprotein cholesterol metabolic syndrome, patients were to"
"12044";"High-density lipoprotein cholesterol Tx difference vs Pbo, LS mean % change from baseline (SE)"
"12045";"High-density lipoprotein cholesterol, mean (SD), mmol/L"
"12046";"High-density lipoprotein cholesterol, median, (25th—75th percentiles), mg/dL"
"12047";"High-density Lipoprotein cholesterol, mg/dL"
"12048";"High-density lipoprotein cholesterol, mg/L"
"12049";"High-density lipoprotein]"
"12050";"High-dosage ICS plus LABA with baseline blood eosinophils <300 cells per pL (n=363)"
"12051";"High-dosage ICS plus LABA with baseline blood eosinophils <300 cells per pL (n=395)"
"12052";"High-dosage ICS plus LABA with baseline blood eosinophils >300 cells per pL (n=809)"
"12053";"High-dosage ICS plus LABA with baseline blood eosinophils a300 cells per pL (n=728)"
"12054";"High-dose ARB (n = 578)"
"12055";"High-dose aspirin"
"12056";"High-dose edoxaban"
"12057";"High-Dose Edoxaban (N = 7035)"
"12058";"High-dose edoxaban vs warfarin"
"12059";"High-dose statin"
"12060";"High-Dose Statin Pretreatment (n=1692)"
"12061";"High-dose statin use at screening*"
"12062";"High-dose statin use, n (%)e"
"12063";"High-intensity statin"
"12064";"High-intensity statin use"
"12065";"High-intensity statin vs medium- or low-intensity statin at randomization"
"12066";"High-intensity statin*"
"12067";"High‐intensity statins‡"
"12068";"High-probability ventilation/perfusion lung scanning"
"12069";"High-risk"
"12070";"High-risk clinical features"
"12071";"High-risk CVD, n (%)"
"12072";"High-school graduate"
"12073";"High-school graduate or GED"
"12074";"High-sensitivity C-reactive protein — mg/liter |"
"12075";"High-sensitivity C-reactive protein (mg/L)"
"12076";"High-sensitivity C-reactive protein stratification"
"12077";"High-sensitivity C-reactive protein, mg/L"
"12078";"High-sensitivity C-reactive protein, mg/Ltt"
"12079";"High-sensitivity CRP — mg/liter||"
"12080";"High-sensitivityC-reactive protein, mg/L"
"12081";"High (> ULN and ≤ 3xULN) (n = 299)"
"12082";"High (>10%)"
"12083";"High (>2 risk factor)"
"12084";"High (>22)"
"12085";"High (>25 kg/m^) Baseline BMI"
"12086";"High (>26)"
"12087";"High (>3) (n = 4,393; 25%)"
"12088";"High (>3), %"
"12089";"High (>34.99 U/ml)"
"12090";"High (>8%) Baseline HbAlc"
"12091";"High (>ULN)"
"12092";"High (210%)"
"12093";"High (5-7)"
"12094";"High (i25 kg/m2) baseline BMI"
"12095";"High (i8 %) baseline HbA1c"
"12096";"High (N=159)"
"12097";"High blood pressure"
"12098";"High cardiovascular risk, n (%)^"
"12099";"High CRP and ESR"
"12100";"High CRP or ESR"
"12101";"High CV risk"
"12102";"High density lipoprotein (mg/dL)"
"12103";"High density lipoprotein cholesterol - mg/dL**"
"12104";"High density lipoprotein cholesterol, mg/dL^"
"12105";"High disease activity: >5.1, n (%)"
"12106";"High Dose"
"12107";"High Dose Statin (n=255, 253)"
"12108";"High Eosinophil Subgroup (>260/ml) (n = 414)"
"12109";"High FENO Subgroup (>19.5 ppb) (n = 201 )"
"12110";"High fracture risk stratum"
"12111";"High HDL-C (for men ≥40 mg/dL / for women ≥50 mg/dL)"
"12112";"High intensity"
"12113";"High Microalbuminuria to Macroalbuminuria (n=148)"
"12114";"High NAFLD Fibrosis Score (NFS > 0.67)"
"12115";"High NFS NFS >0.67 (N = 2106)"
"12116";"High Normal (n=520)"
"12117";"High on-treatment platelet reactivity*"
"12118";"High Periostin Subgroup (>50 ng/ml) (n = 255)"
"12119";"High potencyc"
"12120";"High risk"
"12121";"High risk (-ICS)"
"12122";"High risk (?ICS)"
"12123";"High risk (>14)"
"12124";"High risk (7-14)"
"12125";"High risk (N 5 4284)"
"12126";"High risk (receiving treatment for):"
"12127";"High Risk (RI≥3)"
"12128";"High risk and fewer symptoms (Group C)"
"12129";"High risk and more symptoms (Group D)"
"12130";"High risk for diabetes*"
"12131";"High risk of diabetes"
"12132";"High risk of diabetes"""
"12133";"High risk with atherosclerotic vascular disease*"
"12134";"High risk without atherosclerotic vascular disease+"
"12135";"High risk*, %"
"12136";"High sensitivity C-reactive protein (mg/L)"
"12137";"High Subgroup"
"12138";"High titre (>3 times of ULN), n (%)"
"12139";"High TRS: 5-7 (n = 1,308)"
"12140";"High TT>10.41 (N = 647)"
"12141";"high vs. normalb"
"12142";"high vs. normalc"
"12143";"High*"
"12144";"High, %"
"12145";"Higher-dose"
"12146";"Higher-Dose Edoxaban (n=7035), n (%/y)"
"12147";"Higher-Dose Edoxaban vs Warfarin"
"12148";"Higher-target group (n=1519)"
"12149";"Higher dose"
"12150";"Higher dose edoxaban regimen"
"12151";"Higher Risk (n=4911)"
"12152";"Highest"
"12153";"Highest Killip Classiciation pre-PCI"
"12154";"Highest Tertile (Range, 2.1-3.6 mg/dl; Mean ± SD, 2.4 ± 0.3 mg/dl)"
"12155";"Highest TG tertile"
"12156";"Highjj"
"12157";"Highly sensitive"
"12158";"Highly Sensitive Responder (N=140)"
"12159";"highly sensitive responders (n=131)"
"12160";"Hip"
"12161";"Hip + 1 vertebral fractures"
"12162";"Hip + nonvertebral + vertebral"
"12163";"Hip + other nonvertebral fractures"
"12164";"Hip circumference — cm"
"12165";"Hip fracture"
"12166";"Hip Fracture"
"12167";"Hip Fracture +>1"
"12168";"Hip fracture only"
"12169";"Hip Fracture Only"
"12170";"Hip, Femur"
"12171";"Hip, wrist, or spine*"
"12172";"Hispanic"
"12173";"Hispanic — no. (%)"
"12174";"Hispanic (n = 232)"
"12175";"Hispanic (N = 232)"
"12176";"Hispanic (n=9l6)"
"12177";"Hispanic American"
"12178";"Hispanic black"
"12179";"Hispanic ethnic group—no. (%)f"
"12180";"Hispanic ethnic group—no. {%)’i'"
"12181";"Hispanic ethnic group — no. (%):t"
"12182";"Hispanic ethnic group — no./total no. (%)‘j‘"
"12183";"Hispanic ethnic group, n (%)"
"12184";"Hispanic ethnicity"
"12185";"Hispanic Ethnicity"
"12186";"Hispanic ethnicity, n (%)"
"12187";"Hispanic or Latino"
"12188";"Hispanic or Latino (n — 248)"
"12189";"Hispanic or Latino (n=588)"
"12190";"Hispanic or Latino ethnic group!"
"12191";"Hispanic or Latino ethnic group*"
"12192";"Hispanic or Latino ethnic groupb"
"12193";"Hispanic or Latino ethnic groupf"
"12194";"Hispanic or non-Hispanic ethnic group — no. (%)f"
"12195";"Hispanic, n (%)"
"12196";"Hispanic, n(%)"
"12197";"Hispanic/Latin American"
"12198";"Hispanic/Latino"
"12199";"Hispanic/Latino (n=588)"
"12200";"Hispanic/Latino ethnicity"
"12201";"Hispanic/Latino ethnicity, n (%)"
"12202";"Hispanic/non-Hispanic"
"12203";"Hispanie/Latino"
"12204";"Histamine-2-receptor antagonist"
"12205";"Histor y of congestive heart failure — no. (%)"
"12206";"Histor y of heart failure"
"12207";"Histor y of myocardial infarction"
"12208";"Histor y of stable angina"
"12209";"Histor y of unstable angina"
"12210";"History"
"12211";"History (pack-years)"
"12212";"History cHD"
"12213";"History Congestive heart failure"
"12214";"History coronary"
"12215";"History coronary revascularization"
"12216";"History MI or stroke"
"12217";"History myocardial infarction"
"12218";"History of (%)"
"12219";"History of >1 previous VTE (excluding index event)"
"12220";"History of a transient ischaemic attack"
"12221";"History of AF"
"12222";"History of alcohol use"
"12223";"History of amputation"
"12224";"History of amputation — no. (%)"
"12225";"History of amputation, n (%)"
"12226";"History of amputation, No. (%)"
"12227";"History of asthma-related intubation — no. (%)"
"12228";"History of atherosclerotic vascular disease — no. (%)§"
"12229";"History of atrial arrhythmia, n (%)"
"12230";"History of atrial fibrillation"
"12231";"History of Atrial Fibrillation"
"12232";"History of atrial fibrillation and/or flutter"
"12233";"History of atrial fibrillation or fl utter"
"12234";"History of atrial fibrillation or flutter"
"12235";"History of atrial fibrillation or flutter Treatment at randomisation"
"12236";"History of atrial fibrillation, n (%)"
"12237";"History of atrial fibrillation, type 一no. (%)"
"12238";"History of atrial fibrillation/flutter"
"12239";"History of atrial fibrillation/flutter, (%)"
"12240";"History of bone disease (predefined), n (%)"
"12241";"History of bowel resection (ref)"
"12242";"History of bowel resections, n (%)"
"12243";"History of CABG"
"12244";"History of CABG surgery"
"12245";"History of CABG surgery, n (%)"
"12246";"History of CABG, n (%)"
"12247";"History of CAD"
"12248";"History of CAD/MI"
"12249";"History of cancer"
"12250";"History of Cancer"
"12251";"History of cardiac arrhythmia"
"12252";"History of cardiovascular disease"
"12253";"History of cardiovascular disease — no. (%)"
"12254";"History of cardiovascular disease — no. (%)^|"
"12255";"History of cardiovascular disease — no. {%)"
"12256";"History of cardiovascular events"
"12257";"History of carotid artery disease"
"12258";"History of Carotid Disease - n (%)"
"12259";"History of cerebrovascular disease"
"12260";"History of Cerebrovascular disease"
"12261";"History of cerebrovascular disease — no. {%)"
"12262";"History of CHD"
"12263";"History of CHD at baseline"
"12264";"History of CHD at baseline d,g"
"12265";"History of CHD at baseline, No. (%)"
"12266";"History of CHD at baseline§"
"12267";"History of CHD, n (%)"
"12268";"History of CHF"
"12269";"History of CHF - n (%)"
"12270";"History of CHF before index event"
"12271";"History of CHF, n (%)"
"12272";"History of CHF, NYHA class II or III — no. (%)"
"12273";"History of chronic HF"
"12274";"History of claudication"
"12275";"History of clinical fracture (>45 years old)"
"12276";"History of clinical fracture (>45 years)"
"12277";"History of congestive heart failure"
"12278";"History of COPD"
"12279";"History of coronary"
"12280";"History of Coronary Arteiy disease"
"12281";"History of coronary artery disease"
"12282";"History of Coronary Artery Disease - n (%)"
"12283";"History of coronary artery disease — no. {%)"
"12284";"History of coronary heart disease at"
"12285";"History of coronary heart disease, No. (%)"
"12286";"History of coronary revascularization"
"12287";"History of coronary revascularization d"
"12288";"History of coronary revascularization, No. (%)"
"12289";"History of Crohn's disease surgery, n (%)"
"12290";"History of currently treated hypertension, n (%)"
"12291";"History of CV disease"
"12292";"History of CVD"
"12293";"History of CVD and of CV risk factors - no. (%)"
"12294";"History of CVD, n (%)"
"12295";"History of diabetes"
"12296";"History of Diabetes"
"12297";"History of Diabetes - n (%)"
"12298";"History of diabetes (%)"
"12299";"History of diabetes (A)"
"12300";"History of diabetes (n=1979)"
"12301";"History of diabetes {p=0*64)"
"12302";"History of diabetes mellitus"
"12303";"History of Diabetes Mellitus"
"12304";"History of diabetes mellitus (n = 95)"
"12305";"History of diabetes mellitus, n (%)"
"12306";"History of diabetes mellitus, no. (%)"
"12307";"History of diabetes NYHA class"
"12308";"History of diabetes requiring drugs"
"12309";"History of diabetes:"
"12310";"History of diagnosed hypertension n (%)"
"12311";"History of diagnosed hypertension prior to randomization, n (%)"
"12312";"History of disease refractory to treatment with TNF antagonist — no. (%)"
"12313";"History of dyslipidaemia"
"12314";"History of Dyslipidemia"
"12315";"History of dyspepsia"
"12316";"History of ElMs, n (%)"
"12317";"History of extra-intestinal manifestations of IBD"
"12318";"History of falls"
"12319";"History of falls in year before randomization"
"12320";"History of fistulising disease, n [%]"
"12321";"History of fistulizing disease, n (%)"
"12322";"History of fistullzing disease, n (%)"
"12323";"History of gestational diabetes mellitus — no. (% of women)"
"12324";"History of GI bleeding or ulcer — no./total no. (%)"
"12325";"History of H pylori eradication*"
"12326";"History of heart failure"
"12327";"History of heart failure — no. (%)"
"12328";"History of heart failure — no. {%)"
"12329";"History of heart failure at baseline"
"12330";"History of heart failure, n (%)"
"12331";"History of heart failure, No. (%)"
"12332";"History of HF"
"12333";"History of HF hospitalization"
"12334";"History of HF or LVEF b40% with index event, no. (%)"
"12335";"History of high cholesterol (A)3"
"12336";"History of HTN, %"
"12337";"History of hypercholesterolemia"
"12338";"History of hypercholesterolemia, n (%)"
"12339";"History of hyperlipidemia (%)"
"12340";"History of hypertension"
"12341";"History of Hypertension - n (%)"
"12342";"History of hypertension — no. (%)"
"12343";"History of hypertension (%)"
"12344";"History of hypertension (A)c"
"12345";"History of hypertension (n = 344)"
"12346";"History of hypertension (n=4314)"
"12347";"History of hypertension for 6 mo or more"
"12348";"History of hypertension*"
"12349";"History of hypertension, n (%)"
"12350";"History of hypertension, No. (%)"
"12351";"History of hypertension. No. (%)"
"12352";"History of hypertension^, %"
"12353";"History of impaired renal function"
"12354";"History of impaired renal function, no. (%)"
"12355";"History of intermittent claudication and ABI <0-90 or substantial peripheral arterial stenosis >50%"
"12356";"History of ischemic heart disease — no. (%)"
"12357";"History of ischemic stroke"
"12358";"History of LVH on Echocardiogram"
"12359";"History of LVH on Electrocardiogram"
"12360";"History of macroalbuminuriat, n (%)"
"12361";"History of macrovascular disease"
"12362";"History of macrovascular disease (%)"
"12363";"History of macrovascular disease at baseline, n (%)"
"12364";"History of major bleeding"
"12365";"History of major cardiovascular disease, n (%)"
"12366";"History of major macrovascular disease — no. (%)"
"12367";"History of major macrovascular disease, n (%)"
"12368";"History of major microvascular disease — no. (%)"
"12369";"History of major microvascular disease, n (%)"
"12370";"History of MI"
"12371";"History of MI (n= 145, 142)"
"12372";"History of MI or stroke"
"12373";"History of MI or stroke d"
"12374";"History of MI or stroke History of coronary"
"12375";"History of MI or Stroke, n (%)"
"12376";"History of MI or stroke, No. (%)"
"12377";"History of MI, n (%)"
"12378";"History of MI, N (%)"
"12379";"History of microalbuminuria — no. (%)"
"12380";"History of microvascular disease"
"12381";"History of microvascular disease — no. (%)"
"12382";"History of microvascular disease (%)"
"12383";"History of microvascular eye disease本,n (%)"
"12384";"History of Ml"
"12385";"History of Ml at baseline"
"12386";"History of Ml before index event"
"12387";"History of Ml or ischemic stroke"
"12388";"History of Ml or stroke"
"12389";"History of more than 1 prior MI (%)"
"12390";"History of myocardial infarction"
"12391";"History of myocardial infarction (%)"
"12392";"History of myocardial infarction, n (%)"
"12393";"History of nicotine use"
"12394";"History of non-hemor-rhagic stroke"
"12395";"History of omalizumab treatment"
"12396";"History of omalizumab treatment:"
"12397";"History of or current cardiac disorders, %"
"12398";"History of osteoporotic fracture, n (%)a"
"12399";"History of other medical Conditions, n (%)"
"12400";"History of oxygen use - yes, n (%)"
"12401";"History of PAD"
"12402";"History of parental myocardial"
"12403";"History of paroxysmal AF"
"12404";"History of paroxysmal atrial fibrillation, n (%)"
"12405";"History of PCI"
"12406";"History of PCI — no./total no. (%):t"
"12407";"History of PCI or CABG before index event"
"12408";"History of PCI with stenting"
"12409";"History of PCI, n (%)"
"12410";"History of PCI/PTCA"
"12411";"History of percutaneous coronary intervention"
"12412";"History of Peripheral Arterial disease"
"12413";"History of peripheral arterial disease (%)"
"12414";"History of peripheral artery disease"
"12415";"History of peripheral artery disease — no. {%)"
"12416";"History of peripheral vascular disease"
"12417";"History of postmenopausal fracture*"
"12418";"History of PVD"
"12419";"History of PVD, n (%)"
"12420";"History of PVD, no. (%)"
"12421";"History of recurrent venous thromboembolism"
"12422";"History of second prior MI"
"12423";"History of second prior MI, n (%)"
"12424";"History of smoking"
"12425";"History of stroke"
"12426";"History of Stroke"
"12427";"History of stroke (%)"
"12428";"History of stroke at baseline"
"12429";"History of stroke or TIA"
"12430";"History of Stroke or TIA - n (%)"
"12431";"History of stroke or TIA — no. (%)"
"12432";"History of stroke or transient ischemic attack"
"12433";"History of stroke*"
"12434";"History of stroke**"
"12435";"History of stroke, n (%)"
"12436";"History of stroke, N (%)"
"12437";"History of stroke/ SEE/TIA, n (%)"
"12438";"History of stroke/SEE/TIA"
"12439";"History of stroke†"
"12440";"History of stroke1"
"12441";"History of strokea"
"12442";"History of symptomatic"
"12443";"History of systemic hypertension"
"12444";"History of thyroid disease, n (%)"
"12445";"History of TIA or stroke"
"12446";"History of TIA, n (%)"
"12447";"History of TIA/stroke"
"12448";"History of TNF antagonist treatment failure — no. (%)**"
"12449";"History of upper"
"12450";"History of upper gastrointestinal event"
"12451";"History of upper GI events (perforations, ulcers  and bleeding) n (%)"
"12452";"History of upper Gl events (perforations, ulcers, bleeding), n (%)"
"12453";"History of venous"
"12454";"History of VTE"
"12455";"History of VTE**"
"12456";"History ol CHD at baselines"
"12457";"History ol coronary revascularization*"
"12458";"History ol MI or stroke"
"12459";"History ot CHD, n (%)"
"12460";"History PCI"
"12461";"History/presence of tophi"
"12462";"HIT-6 score"
"12463";"HIV"
"12464";"Hl 土 15.5"
"12465";"HLA-B27"
"12466";"HLA-B27 positive at baseline, n (%)"
"12467";"HLA-B27 positive, n (%)"
"12468";"HLA‐B27 positive, n (%)"
"12469";"HLA-B27, n (%)⁎⁎"
"12470";"HMG-CoA reductase inhibitors"
"12471";"HMGCoA Rl"
"12472";"Ho"
"12473";"Ho Active Cancer"
"12474";"Hoehn & Yahr stage"
"12475";"Hoehn & Yahr stage (“off”), n (%)"
"12476";"Hoehn & Yahr stage (“on”), n (%)"
"12477";"Hoehn and Yahr stage"
"12478";"Hoehn and Yahr stage (baseline), mean (SD)"
"12479";"Hoehn and Yahr stage (range, 1-5)"
"12480";"HOMA"
"12481";"HOMA-b"
"12482";"HOMA-IR"
"12483";"HOMA-IR (%)b"
"12484";"HOMA-IR (mU/L^mmol/L)"
"12485";"HOMA-IR index"
"12486";"HOMA-IR index — median (IQR)"
"12487";"HOMA-IR score"
"12488";"HOMA-IR, mean (SD)"
"12489";"HOMA-IR, mean (SD) (mU/L$mmol/L)b"
"12490";"HOMA-IR, median (Q1, Q3)"
"12491";"HOMA-p"
"12492";"HOMA >median"
"12493";"HOMA.%B, median (Ql, Q3), %"
"12494";"HOMA.IR, median (Ql, Q3), %/100"
"12495";"HOMA_%B Tx difference vs Pbo, median change from baseline (SE)1"
"12496";"HOMA_%B, median (Q1, Q3), %"
"12497";"HOMA_IR Tx difference vs Pbo, median change from baseline (SE)1"
"12498";"HOMA_IR, median (Q1, Q3), %/100"
"12499";"HOMA>median"
"12500";"HOMAJR Tx difference vs Pbo, median change from baseline (SE)1 Lipid parameters"
"12501";"Hong Kong"
"12502";"HOPE (n=9297)"
"12503";"HOPE patients with coronary-artery disease (n=7477)"
"12504";"Hordic"
"12505";"Hormonal status"
"12506";"Hormonal therapy — no. (%)"
"12507";"hormone-refractory prostate carcinoma"
"12508";"Hormone replacement"
"12509";"Hormone replacement therapy"
"12510";"Hormone replacement therapy use"
"12511";"Hormone replacement!!"
"12512";"Hormone therapy"
"12513";"hormone therapy use"
"12514";"Hormones"
"12515";"Hosji fcrHypoglycemia"
"12516";"Hosp. for HF"
"12517";"Hosp. worsening HF"
"12518";"Hospitaiization for angina"
"12519";"Hospitaiization for heart faiiure"
"12520";"Hospital admission for heart failure"
"12521";"Hospital factor #1"
"12522";"Hospital factor #2"
"12523";"Hospital stay (days)"
"12524";"Hospital stay, days"
"12525";"Hospitalisation"
"12526";"Hospitalisation for CHF within 3 years of randomisation"
"12527";"Hospitalisation for heart failure"
"12528";"Hospitalisation related to exacerbation, n (%)"
"12529";"Hospitalization"
"12530";"Hospitalization for"
"12531";"Hospitalization for ACS"
"12532";"Hospitalization for acute limb ischemia"
"12533";"Hospitalization for heart                                 failure N(%)"
"12534";"Hospitalization for heart failure"
"12535";"Hospitalization for heart failure or CV"
"12536";"Hospitalization for heart failure or CV death"
"12537";"Hospitalization for heart failure within 6 mo"
"12538";"Hospitalization for heart failure within previous 6 mo — no. (%)"
"12539";"Hospitalization for HF"
"12540";"Hospitalization for HF previous year,(%)"
"12541";"Hospitalization for unstable angina"
"12542";"Hospitalization for unstable AP"
"12543";"Hospitalization for/due to"
"12544";"Hospitalization in previous year with management of heart failure"
"12545";"Hospitalization in previous year with management of heart failure as major component — no. (%)"
"12546";"Hospitalization in the past 12 months prior to baseline"
"12547";"hospitalization stratum, n (%)"
"12548";"Hospitalization to enrollment"
"12549";"Hospitalization, n (%)"
"12550";"Hospitalizations"
"12551";"Hospitalizations, n"
"12552";"Hospitalized"
"12553";"Hospitalized angina"
"12554";"Hospitalized Exacerbation Rates"
"12555";"Hospitalized for an exacerbation"
"12556";"Hospitalized for asthma, n (%)*"
"12557";"Hospitalized for heart failure during that time period"
"12558";"Hospitalized heart failure"
"12559";"Hospitalized HF"
"12560";"Hospitalized HF!"
"12561";"Hospitalized pneumonia events, n"
"12562";"Hospitalized without airway compromise"
"12563";"Hospitalized!"
"12564";"Hospitalized/fatal heart failure"
"12565";"Hot climate subset"
"12566";"Hours from clopidogrel loading, mean (SD)"
"12567";"HPS"
"12568";"hr"
"12569";"HR"
"12570";"HR (95% C!)"
"12571";"hr (95% cI)"
"12572";"HR (95% Ci)"
"12573";"HR (95% CI)"
"12574";"HR (95% CI)*"
"12575";"HR (95% CI), multivariate Cox proportional-hazard regression"
"12576";"HR (95% CI), univariate Cox proportional-hazard regression"
"12577";"HR (95% Cl)"
"12578";"HR (95% Cl) = 0 64 (0.43. 0,95)"
"12579";"HR (95% Cl) = 0.9B (047, 2.04)"
"12580";"HR (95% Cl) = 1.10 (0.71, 1 70)"
"12581";"HR (95% Cl) = 1.10(0 87,1.39)"
"12582";"HR (95% CL) pValue"
"12583";"HR (95% Cl)*"
"12584";"HR (95%CI)"
"12585";"HR (95%CI)    P value for interaction*"
"12586";"HR (9s%a)"
"12587";"HR (9S%CI)"
"12588";"HR (adjusteda)"
"12589";"HR (b.p.m.)"
"12590";"HR (bpm)"
"12591";"HR (ENL vs LCZ) (95% Cl)"
"12592";"HR [95%CI)"
"12593";"HR 0-54 (95% Cl 034-0-86)"
"12594";"HR 0-57 (95% Cl 0-41-0-79)"
"12595";"HR 0-60 (95% Cl 0-39-0-93)"
"12596";"HR 0.46"
"12597";"HR 0.54"
"12598";"HR 0.55"
"12599";"HR 0.75"
"12600";"HR 0.78"
"12601";"HR 0.88 (95% Cl 0.68, 1.14) p=0.33*"
"12602";"HR 0.92 (95% Cl 0.70, 1.22) p=0.56*"
"12603";"HR 0.95 (95% Cl 0.76, 1.19) p=0.67*"
"12604";"HR 0.96 (95% Cl 0.73, 1.26) p=0.77*"
"12605";"HR 1.03"
"12606";"HR 1.05"
"12607";"HR 1.08"
"12608";"HR 1.13"
"12609";"HR 1.20"
"12610";"HR 1.24"
"12611";"HR 1.28"
"12612";"HR 1.30"
"12613";"HR 1.31"
"12614";"HR 1.33"
"12615";"HR 1.38"
"12616";"HR 1.48"
"12617";"HR 95% Cl"
"12618";"HR 95%CI"
"12619";"HR and 95% CI*"
"12620";"HR is <1 if pravastatin is better than diet alone"
"12621";"HR vs control (95% Cl)*"
"12622";"HR vs placebo (95% CI)"
"12623";"HR vs. Warfarin (95% CI)"
"12624";"HR with edoxaban (95% CI)"
"12625";"HR(95% CI)"
"12626";"HR(95% CI)P Value"
"12627";"HR(95%CI)"
"12628";"HR(95%CI)“"
"12629";"HR* or RR†"
"12630";"HR* or RR† (95% CI);"
"12631";"HR, (95% Ci)"
"12632";"HR, (95% Cl)"
"12633";"HR, 95% Cl"
"12634";"HR, bpm"
"12635";"HR, bpm (SD)"
"12636";"HR: 0.33
(95% Cl: 0.14-0.79)
P=0.0088"
"12637";"HR: 0.52
(95% Cl: 0.18-1.52)
P=0.2243"
"12638";"HR: 0.63
(95% Cl: 0.34-1.18)
P=0.1427"
"12639";"HR: 1.27
(95% Cl: 0.71-2.27) P=0.4256"
"12640";"HR‡"
"12641";"HR2 and 95% Cl"
"12642";"HRadj (95%CI)"
"12643";"HRadjusted (95% CI)b"
"12644";"HRG"
"12645";"HRQL mean (SD)"
"12646";"HRQoL"
"12647";"HRT"
"12648";"HRT use"
"12649";"Hs- CRP (mg/L)"
"12650";"hs-CRP"
"12651";"Hs-CRP"
"12652";"hs-CRP    mg/L"
"12653";"hs-CRP (median, IQR), mg/L"
"12654";"hs-CRP (mg/L)"
"12655";"hs-CRP (mg/L, median)"
"12656";"hs-CRP _=2.0 mg/L"
"12657";"hs-CRP <2.0 g/L"
"12658";"hs-CRP <2.0 mg/L"
"12659";"hs-CRP <2.0 nlg L"
"12660";"hs-CRP >2.0 mg/L"
"12661";"hs-CRP J2.0 mg/L"
"12662";"hs-CRP j2.0mg/L"
"12663";"hs-CRP, mg/l"
"12664";"hs-CRP, mg/L"
"12665";"HS Graduate/GED"
"12666";"hsCRP"
"12667";"hsCRP — mg/liter"
"12668";"hsCRP (mg/l)"
"12669";"hsCRP (mg/L)"
"12670";"hsCRP (mg/L), median (first, third quartiles)"
"12671";"hsCRP (mg/l), median (min–max)"
"12672";"hsCRP (mg/L), median (minimum‒maximum)"
"12673";"HsCRP (mg/L)c"
"12674";"hsCRP (nmol/l)"
"12675";"hsCRP (nmol/L)"
"12676";"hsCRP (post-baseline/baseline ratio), LS mean ± SE"
"12677";"hsCRP < 2.0 mg/L"
"12678";"hsCRP < 2.0 mgA.    259(13.9X281(15.6)"
"12679";"hsCRP > 2.0 mg/L"
"12680";"hsCRP > 2.0 mgA."
"12681";"hsCRP >2 to <4 mg/L"
"12682";"hsCRP >2.0 mg/L"
"12683";"hsCRP >4 mg/L"
"12684";"hsCRP §"
"12685";"hsCRP at Baseline"
"12686";"hsCRP level"
"12687";"hsCRP range, mg/L"
"12688";"hsCRP, Exp LS mean change ± SE‡"
"12689";"hsCRP, mean (SD)"
"12690";"hsCRP, median (IQR), mg/L"
"12691";"hsCRP, median (min, max), mg/L"
"12692";"hsCRP, mg/dL"
"12693";"hsCRP, mg/l"
"12694";"hsCRP, mg/L"
"12695";"hsCRP, mg/L, median (min–max)"
"12696";"HTN"
"12697";"HTN hx"
"12698";"Hub"
"12699";"Humerus fracture"
"12700";"Hungary"
"12701";"Hvookalemia"
"12702";"Hvpercholesterolemia"
"12703";"Hvpertension"
"12704";"Hx CABG"
"12705";"Hx MI or stroke"
"12706";"Hx of diabetes, n (%)"
"12707";"Hx Stroke/TIA"
"12708";"Hydochlorothiazide (n=557)"
"12709";"Hydralazine"
"12710";"Hydrochlorothiazide"
"12711";"Hydroxychloroquine"
"12712";"Hydroxychloroquine treatment§"
"12713";"Hyper- tension"
"12714";"Hypercholesterolaemia"
"12715";"Hypercholesterolaemia (%)"
"12716";"Hypercholesterolemia"
"12717";"Hypercholesterolemia — no. (%)"
"12718";"Hypercholesterolemia — no. (%)*"
"12719";"Hypercholesterolemia (%)"
"12720";"Hypercholesterolemia (>240 mg/dL)"
"12721";"Hypercholesterolemia 一no. (%)"
"12722";"Hypercholesterolemia*"
"12723";"Hypercholesterolemia, n (%)"
"12724";"Hypercholesterolemia, no. (%)"
"12725";"Hypercholesterolemiat"
"12726";"Hyperkalaemia"
"12727";"Hyperkalaemia (investigator reported)"
"12728";"Hyperkalaemia (serum potassium > 5.5 mmol/L)"
"12729";"Hyperkalemia (>5.5 mEq/L)"
"12730";"Hyperkalemia*’"
"12731";"Hyperkalemia, n (%)"
"12732";"Hyperkalemia‡ (potassium ≥5.5 mmol/L)"
"12733";"Hyperkalemiab"
"12734";"Hyperlension"
"12735";"Hyperlipidaemia"
"12736";"Hyperlipidaemia (%)"
"12737";"Hyperlipidaemia therapy use, n (%)* No lipid-lowering agent therapy"
"12738";"Hyperlipidaemia, n (%) yes"
"12739";"Hyperlipidemia"
"12740";"Hyperlipidemia — no. (%)"
"12741";"Hyperlipidemia — no./total no. (%)"
"12742";"Hyperlipidemia (%)"
"12743";"Hyperlipidemia (%)§"
"12744";"Hyperlipidemia ||"
"12745";"Hyperlipidemia || Yes"
"12746";"Hyperlipidemia, %"
"12747";"Hyperlipidemia, n (%)"
"12748";"Hyperlipidemia, n/N (%)"
"12749";"Hyperlipidemia^"
"12750";"Hyperlipidemia§"
"12751";"Hyperlipidemia§ Yes"
"12752";"Hyperlipidmemia"
"12753";"Hypersensitivity, n (%)"
"12754";"Hypertension"
"12755";"Hypertension— no. (%)"
"12756";"Hypertension—No. (%)"
"12757";"Hypertension — no. (%)"
"12758";"Hypertension — no. (%) Hypercholesterolemia — no. (%)"
"12759";"Hypertension — no. (%)|"
"12760";"Hypertension — no./total no. (%)"
"12761";"Hypertension (%)"
"12762";"Hypertension (%):t"
"12763";"Hypertension (>140/90 mm Hg or taking"
"12764";"Hypertension (BP > 130/85 mmHg or using antihypertensive medication)"
"12765";"Hypertension (n 二3277)"
"12766";"Hypertension *"
"12767";"Hypertension 一 no. (%)"
"12768";"Hypertension Absent"
"12769";"Hypertension and left ventricular hypertrophy"
"12770";"Hypertension at baseline"
"12771";"Hypertension history"
"12772";"Hypertension History"
"12773";"Hypertension N(%)"
"12774";"Hypertension requiring medical treatment"
"12775";"Hypertension requiring treatment"
"12776";"Hypertension Serum lipid values"
"12777";"Hypertension severity at baseline, n (%)"
"12778";"Hypertension!"
"12779";"Hypertension*"
"12780";"Hypertension, %"
"12781";"Hypertension, (%)"
"12782";"Hypertension, n (%)"
"12783";"Hypertension, N (%)"
"12784";"Hypertension, n (%) yes"
"12785";"Hypertension, n(%)"
"12786";"Hypertension, n/N (%)"
"12787";"Hypertension, No./total No. (%) Medications in use at baseline, No./total No. (%)"
"12788";"Hypertension, receiving treatment, n (%)"
"12789";"Hypertension, treated"
"12790";"Hypertension, n (%)"
"12791";"Hypertension,* n (%)"
"12792";"Hypertension/ Yes"
"12793";"Hypertension: No (n=368)"
"12794";"Hypertension^"
"12795";"Hypertension本"
"12796";"Hypertension§"
"12797";"Hypertension§ Yes"
"12798";"Hypertension0 (%)"
"12799";"Hypertensiont"
"12800";"Hypertensive"
"12801";"Hypertensive, n (%)"
"12802";"Hypertrophic cardiomyopathy"
"12803";"Hypertrophy per ECG (n=20 950)"
"12804";"hypertrophy, n (%)"
"12805";"Hypoglycaemiad,%"
"12806";"Hypoglycaemic agents"
"12807";"Hypoglycaemic therapy"
"12808";"Hypoglycemia"
"12809";"Hypoglycemia^"
"12810";"Hypoglycemiat"
"12811";"Hypoglycemic agent"
"12812";"Hypokalaemia"
"12813";"Hypokalemia"
"12814";"Hypokalemia‡ (potassium <3.5 mmol/L)"
"12815";"Hyponatremia"
"12816";"Hyponatremic (<135 mEq/L) at Baseline"
"12817";"Hypotension"
"12818";"Hypotension, n (%)"
"12819";"Hypovolaemia"
"12820";"Hzard ratio"
"12821";"i"
"12822";"I"
"12823";"I- 5 mg/d (n = 329)"
"12824";"i-^W«-i-1"
"12825";"i-H"
"12826";"I & II: FEV1>50% predicted"
"12827";"i (0.i)"
"12828";"i 51.3 vs 33.3"
"12829";"I Amiodarone"
"12830";"I IDL cholesterol (mg/dl)"
"12831";"i Intensive; 80 mg of Atorvastatin (n = 253)"
"12832";"I Lisinopril (n = 9054)"
"12833";"i Moderate; 40 mg of Pravastatin (n = 249)"
"12834";"I No. of Events"
"12835";"I or II"
"12836";"I Placebo"
"12837";"I Placebo (n = 282)"
"12838";"I Rosuvastatin (n = 702)"
"12839";"I U -UJ"
"12840";"I Vitamin E"
"12841";"I Vitamin E (n = 19937)"
"12842";"I With MetS (n=15750)"
"12843";"I With MetS (n=7327)"
"12844";"I Without MetS (n=5491)"
"12845";"I Without MetS (n=8723)"
"12846";"i.09 (0.92-i.29)"
"12847";"i.2i (0.99-i.47)"
"12848";"I/II"
"12849";"i03 (i0.0)"
"12850";"i08 (i0.5)"
"12851";"i09 (i0.6)"
"12852";"i25 (i2.i)"
"12853";"i28 (i2.3)"
"12854";"i28 (i2.4)"
"12855";"i2i8±489"
"12856";"i34 (i2.9)"
"12857";"i35 (i3.i)"
"12858";"i370±52i"
"12859";"i393±5ii"
"12860";"i3i (i2.7)"
"12861";"i40 (i3.6)"
"12862";"i64±i48"
"12863";"i65 years of age"
"12864";"i68±i43"
"12865";"i74±i50"
"12866";"i77±i38"
"12867";"i7i±i46"
"12868";"i8i"
"12869";"IB ( 11.9)"
"12870";"IBDQ domain scores, mean [SD]"
"12871";"IBDQ score, mean (SD)"
"12872";"IBDQ score|"
"12873";"IBDQ total score"
"12874";"IBDQ total score, mean [SD]"
"12875";"IBS (5.4)"
"12876";"Ibuprofen"
"12877";"ICA stenosis 70%-99%f"
"12878";"ICD"
"12879";"ICD or CRT-D"
"12880";"ICD Therapy (N ="
"12881";"ICD Therapy vs. Placebo No. Hazard ratio (97.5% Cl)"
"12882";"ICD vs. Placebo"
"12883";"ICD, %"
"12884";"ICD, n (%)"
"12885";"ICD/CRT-D, n (%)"
"12886";"ICH"
"12887";"Icosapent Ethyl (events/n(%))"
"12888";"ICS"
"12889";"ICS (tiotropium n = 126, placebo n = 113)"
"12890";"ICS ? LABA (free or FDC)"
"12891";"ICS + LABA"
"12892";"ICS alone"
"12893";"ICS dose of stable maintenance treatment (μg)∗,†"
"12894";"ICS no LABA"
"12895";"ICS non-users"
"12896";"ICS non-users at screening"
"12897";"ICS non-users: QVAI49-SFC"
"12898";"ICs nonusers, n (%)"
"12899";"ICS only"
"12900";"ICS plus LABA"
"12901";"ICS subset"
"12902";"ICS usage"
"12903";"ICS use"
"12904";"ICS use at baseline"
"12905";"ICS use at baseline, n (%)"
"12906";"ICS Use at Baseline, n (%)"
"12907";"ICS use at baseline: no"
"12908";"ICS use at baseline: yes"
"12909";"ICS use at enrollment, mean, mg/d"
"12910";"ICs use at screening"
"12911";"ICS use at screening, n (%)"
"12912";"ICS use at screeningg, n (%)"
"12913";"ICS use No"
"12914";"ICS use Yes"
"12915";"ICS use yes/no, %"
"12916";"ICS use, %"
"12917";"ICS use, yes/no %"
"12918";"ICS use, yes/no, %"
"12919";"ICS users"
"12920";"ICS users at baseline, %"
"12921";"ICS users at baseline, n (%)"
"12922";"ICS users at screening"
"12923";"ICs users, n (%)"
"12924";"ICS users, n (%)"
"12925";"ICS users: QVAI49-SFC"
"12926";"ICS##"
"12927";"ICS, mg/day"
"12928";"ICS, n (%)"
"12929";"ICS, no LABA, n (%)"
"12930";"ICS/LABA"
"12931";"ICS/LABA subset"
"12932";"ICS/LABA therapy, n (%)"
"12933";"ICS/LABD"
"12934";"ICS/LAMA"
"12935";"ICS: no"
"12936";"ICS: yes"
"12937";"ICS; no LABA (tiotropium n = 76, placebo n = 65)"
"12938";"ICSa plus LABA, n (%)"
"12939";"ICsf"
"12940";"ICSusers atbaseline,n (%)"
"12941";"ID"
"12942";"ID (n = 674)"
"12943";"ID Genotype"
"12944";"IDeg"
"12945";"IDegAsp–BIAsp 30"
"12946";"IDegAsp BID"
"12947";"IDegLira"
"12948";"Idiopathic"
"12949";"Idiopathic/familial"
"12950";"Idiopathica"
"12951";"IDM"
"12952";"IDR"
"12953";"IDuration of symptoms > 10 min"
"12954";"IeE at baseline: <30IU/L"
"12955";"IFG"
"12956";"IFG and IGT"
"12957";"IFG Pbo (N = 99) vs EvoMab (N = 194)"
"12958";"IFG/IGT"
"12959";"IFG/prediabetes^"
"12960";"IFX (N = 169)"
"12961";"IFX + AZA (N = 169)"
"12962";"IFX treatment"
"12963";"IG (n = 223)"
"12964";"IGA 0/1"
"12965";"IGA mod 2011 score, n (%)"
"12966";"IgE (kU/L), median (range)c"
"12967";"IgE high (>150 kU/L; n = 1,204)"
"12968";"IgEhigh(>i50kU/L;n=i,204)"
"12969";"IgElow(<150kU/L; n=1,053)"
"12970";"IgElow(<i50kU/L;n=i,053)"
"12971";"IgElow(n=1,053)"
"12972";"IgG (>16.2 g/l), %"
"12973";"IGL (N = 107)"
"12974";"IGL (N = 40)"
"12975";"IGL (N = 93)"
"12976";"iGlar"
"12977";"IGlar"
"12978";"iGlar (insulin glargine l00 U)"
"12979";"iGlar (n = 258)"
"12980";"iGlar dose at randomization (U/day)"
"12981";"iGlarLixi"
"12982";"iGlarLixi (fixed-ratio combination)"
"12983";"iGlarLixi (n = 259)"
"12984";"IGM"
"12985";"IGM(n = 4565)"
"12986";"IGT or IFG"
"12987";"IGT/IFG"
"12988";"IHD"
"12989";"ii"
"12990";"II"
"12991";"II-IV"
"12992";"II - IV (%)"
"12993";"II    1 Amlodipine-    Lisinopril- Chlorthalidone    Chlorthalidone"
"12994";"II (497)"
"12995";"II (n = 370)"
"12996";"ii = 50"
"12997";"II Chiorthaiidone Amiodipine"
"12998";"II Lisinopril"
"12999";"II Lisinopril i"
"13000";"II or III"
"13001";"II.    0 (0.7) 285"
"13002";"II.    0 (0.9)160"
"13003";"II.    1 (1.1) 116"
"13004";"II.    2 (0.8) 223"
"13005";"II.    7 (0.9)177"
"13006";"II/III"
"13007";"ii=45"
"13008";"ii=46"
"13009";"ii=47"
"13010";"ii=49"
"13011";"ii=50"
"13012";"ii=51"
"13013";"ii=53"
"13014";"ii0 (i0.8)"
"13015";"ii7 (ii.4)"
"13016";"ii80±493"
"13017";"ii9 (ii.5)"
"13018";"ii9 (ii.6)"
"13019";"IIEF-EF domain score, visit 2**"
"13020";"IIEF-EF domain score, visit 3y"
"13021";"iii"
"13022";"III"
"13023";"III-IV"
"13024";"III & IV"
"13025";"III (496)"
"13026";"III / IV"
"13027";"III and IV"
"13028";"III and IV Ejection fraction"
"13029";"III or IV"
"13030";"III: FEV1>30% - <50% predicted"
"13031";"IIIV"
"13032";"iJB^"
"13033";"IL-6"
"13034";"IL-6 (pg/ml)"
"13035";"IL-6 (pg/mL)"
"13036";"IL-6 range, ng/L"
"13037";"IL-6, ng/l"
"13038";"IL-6, ng/L"
"13039";"Ilb/IIIa inhibitors"
"13040";"Ileocolon"
"13041";"Ileocolonic (both ileum and colon)"
"13042";"Ileum"
"13043";"Ileum and colon"
"13044";"Ileum and colon,' n (%)"
"13045";"Ileum and colon, n (%)"
"13046";"Ileum only"
"13047";"Ileum only, n (%)"
"13048";"Ileum or colon"
"13049";"Ileum SES-CD score, mean (SD)"
"13050";"ill-"
"13051";"IM-UNITI"
"13052";"IM and CS use: No"
"13053";"IM on]y"
"13054";"IM or CS use: No"
"13055";"IM use: No"
"13056";"image only"
"13057";"Imaged artery"
"13058";"Imaging data, mean (SD)"
"13059";"IMM"
"13060";"IMM (without corticosteroid)"
"13061";"IMM + corticosteroid, N"
"13062";"IMM only"
"13063";"ImmobAzaton"
"13064";"Immobilization"
"13065";"Immobilization — no. (%)"
"13066";"Immobilization at randomization, n (%)"
"13067";"Immunologic"
"13068";"Immunomodulators"
"13069";"Immunomodulatory drugs"
"13070";"Immunosuppressant (with or without corticosteroid)"
"13071";"Immunosuppressant use, %"
"13072";"Immunosuppressant^"
"13073";"Immunosuppressant^^"
"13074";"Immunosuppressants"
"13075";"Immunosuppressants and antimalarials only"
"13076";"Immunosuppressants only"
"13077";"Immunosuppressants onlyff"
"13078";"Immunosuppressive agents at baseline"
"13079";"Immunosuppressive agents only"
"13080";"Immunosuppressive use, n (%)"
"13081";"IMMy (without corticosteroid), N"
"13082";"Impacts"
"13083";"Impaired cognitive"
"13084";"Impaired cognitive function (SPMSQ >2). N-350 N (%) participants with the event of interest"
"13085";"impaired Fasting Giucose Levei (n = 323)"
"13086";"Impaired fasting glucose"
"13087";"Impaired fasting glucose (>100 mg/dL) (%)"
"13088";"Impaired Fasting Glucose Level (n = 323)"
"13089";"Impaired fasting glucose§"
"13090";"Impaired fasting glucosex"
"13091";"Impaired glucose tolerance or impaired fasting glucose"
"13092";"Impaired glucose tolerance or impaired fasting glucose — no. (%)"
"13093";"Impaired renal function§"
"13094";"Impaired renal function†"
"13095";"Implantable cardioverter-defibrillator"
"13096";"Implantable cardioverter-defibrillator N(%)"
"13097";"Implanted cardioverter-defibrillator"
"13098";"Implanted cardioverter defibrillator"
"13099";"Implanted pacemaker"
"13100";"Improved"
"13101";"Improvement from baseline ≥ 3"
"13102";"Improving anemia Bsl Hb < 120g I-1; Yr 1 > 120g I-1"
"13103";"Imputed"
"13104";"IMT (1)"
"13105";"IMT (mm)"
"13106";"in"
"13107";"In-clinic UAS5"
"13108";"In-clinic UASk"
"13109";"In-h"
"13110";"In-hospital medication"
"13111";"In-Hospital Ticagrelor (N = 953)"
"13112";"In-hospital ticagrelor (n=952)"
"13113";"In-stent restenosis"
"13114";"In-stent restenosis of DES"
"13115";"In-trial 6-year rates per 100 (se) Total events/number at risk"
"13116";"In-trial and post-trial 10-year rates per 100 (se) Total events/number at risk"
"13117";"In-trial nonfatal or fatal stroke N=1,525"
"13118";"In ambulance"
"13119";"In emergency department before ambulance transfer"
"13120";"in extension study"
"13121";"In hospital ticagrelor"
"13122";"in IBDQ total score at Week 52, mean [SE]"
"13123";"in IBDQ total score at Week 8, mean [SE]"
"13124";"in patients with a history of chronic angina who have presented with an acute"
"13125";"in previous year, mean (SD)"
"13126";"In remission at maintenance study baseline"
"13127";"in the spironolactone group and 197 patients in the placebo group."
"13128";"in Therapeutic Range for Warfarin Subjects"
"13129";"in thirds"
"13130";"Inadequate response"
"13131";"Inadequate response'^"
"13132";"Inadequate response'’'"
"13133";"Inadequate response (>3 months MMF/GGs)"
"13134";"Inadequate response or intolerance to >1 anti-TNFdrug"
"13135";"Inadequate response/intolerance to prior therapy, %"
"13136";"inappropriate"
"13137";"Incidence [n/N (rate per 1000 person-years)]"
"13138";"Incidence of each outcome"
"13139";"Incidence rate"
"13140";"Incidence rate (n)"
"13141";"Incidence rate (n)a"
"13142";"incidence rate (per 100 person-yr)"
"13143";"Incidence Rate Difference, Linagliptin -Placebo (95% Cl)"
"13144";"Incidence rate No. (/1000person-years)"
"13145";"Incidence rate of CV events, n (%)"
"13146";"Incidence rate per 100 person-years"
"13147";"Incidence rate per 100 person years"
"13148";"Incidence Rate*"
"13149";"Incidence*"
"13150";"Incidence, %"
"13151";"Incidence, °/o (950/0 Cl)"
"13152";"Incidence, 100 person-year"
"13153";"incidence^"
"13154";"Incidencea"
"13155";"Incident DM or change in"
"13156";"Incident or worsening nephropathy"
"13157";"Included in analysis"
"13158";"Included in this study (n = 188)"
"13159";"Inclusion criteria"
"13160";"Inclusion criteria — no. (%)"
"13161";"Inclusion findings (%)"
"13162";"Inconsistent FAO (n [ 118)"
"13163";"Incontinence episodes/24h"
"13164";"Increase Creatinine, <0.3 mg/dL"
"13165";"Increase Creatinine, >0.3 mg/dL"
"13166";"Increase in serum creatinine"
"13167";"Increased-risk for thrombotic cardiovascular"
"13168";"Increased Risk for Falls"
"13169";"Increased risk for thrombotic cardiovascular event^, n (%)"
"13170";"Increased waist circumference"
"13171";"IND + GLY (N=226)"
"13172";"IND + PBO (N=221)"
"13173";"IND 75 gg q.d. n/N (%)"
"13174";"IND 75 mg q.d. n = 256"
"13175";"IND/GLY"
"13176";"IND/GLY (n=768)"
"13177";"IND/GLY 110/50 mg Once Daily (n = 1,043)"
"13178";"IND/GLY 110/50 mg Once Daily (n = 629)"
"13179";"IND/GLY n = 811"
"13180";"IND/GLY110/50 pg o.d. n = 298"
"13181";"IND/GLYb n = 811"
"13182";"Indacaterol- Glycopyrronium Group"
"13183";"Indacaterol- Glycopyrronium Group (N = 1680)"
"13184";"Indacaterol + tiotropium (n[570)"
"13185";"Indacaterol + tiotropium (n[572)"
"13186";"Indacaterol 150 gg qd"
"13187";"Indacaterol 150 mg"
"13188";"Indacaterol 150 mg[n Z 41]"
"13189";"Indacaterol 150 mg[n Z 73]"
"13190";"Indacaterol 150 ug (n = 187)"
"13191";"Indacaterol 150 ug versus placebo"
"13192";"Indacaterol 300 gg qd"
"13193";"Indacaterol 300 mg"
"13194";"Indacaterol 300 mg[n Z 48]"
"13195";"Indacaterol 300 mg[n Z 68]"
"13196";"Indacaterol 300 ug (n = 188)"
"13197";"Indacaterol 300 ug versus indacaterol 150 ug"
"13198";"Indacaterol 300 ug versus placebo"
"13199";"Indacaterol 600 gg qd"
"13200";"Indacaterol 75 pg"
"13201";"Indacaterol Group (n = 159)"
"13202";"Indacaterol Group (n = 163)"
"13203";"Indacaterol N = 159"
"13204";"Indacaterol N = 163"
"13205";"Indacaterol/glycopyrronium 110/50 μg o.d."
"13206";"Indeterminate NFS -1.455 < NFS <0.67 !N = 7273)"
"13207";"Indeterminate!!"
"13208";"Index ACS — no. (%)"
"13209";"Index ACS (%)"
"13210";"index AcS event"
"13211";"Index ACS event"
"13212";"Index acute coronary syndrome — no. {%)"
"13213";"Index diagnosis"
"13214";"Index Diagnosis"
"13215";"Index event"
"13216";"Index event — no. (%)"
"13217";"Index event asymptomatic or unconfirmed"
"13218";"Index event information"
"13219";"Index event not confirmed"
"13220";"Index event subtype"
"13221";"Index event to randomization, median (IQR), h"
"13222";"Index event, %"
"13223";"Index event, n (%)"
"13224";"Index event, n/N (%)"
"13225";"Index events"
"13226";"Index events: DVT n (%)"
"13227";"Index events: PE ± DVT n (%)"
"13228";"Index inclusion acute coronary syndrome"
"13229";"Index MI (n - 3,576)"
"13230";"Index PCI performed"
"13231";"Index PE: event during"
"13232";"Index percutaneous coronary intervention"
"13233";"Index stroke >10 days before randomization — no. (%)"
"13234";"India"
"13235";"Indian"
"13236";"Indian (American) or Alaska Native"
"13237";"Indian (American) or Alaskan Native"
"13238";"Indian (Indian subcontinent)"
"13239";"Indian subpopulation"
"13240";"Indication"
"13241";"Indication for index PCI"
"13242";"Indication for Index PCI"
"13243";"Indication for index procedure"
"13244";"Indication for PCI"
"13245";"Indication for stent"
"13246";"Individual Endpoints"
"13247";"Individual intended study duration — no. (%)"
"13248";"Individuals with diabetes, n = 623"
"13249";"Individuals with diabetes, n = 632"
"13250";"Individuals with normoglycaemia"
"13251";"Individuals with pre-diabetes, n (%)"
"13252";"Individuals with prediabetes"
"13253";"Individuals with T2DM (SCALE Diabetes)"
"13254";"Individuals with type 2 diabetes, n (%)"
"13255";"Individuals without diabetes, n = 3,662"
"13256";"Indomethacin"
"13257";"Inducing"
"13258";"Induction-trial group assignment — no. (%)"
"13259";"Induction study treatment"
"13260";"INDZGLY"
"13261";"Ineffective therapy"
"13262";"Infarct-related vessel (%)"
"13263";"Infarct characteristics"
"13264";"Infarct ion w ithin previous 7 day s"
"13265";"Infarct localisation"
"13266";"Infarct localization"
"13267";"Infarct localization, n (%)"
"13268";"Infarct location"
"13269";"Infarct location — no./total no. (%)"
"13270";"Infarct location (Interactsn$: p=0.29)"
"13271";"Infarct location anterior"
"13272";"Infarct on brain imaging^"
"13273";"Infarct on brain imaging丰"
"13274";"Infarct related artery location"
"13275";"Infarct size"
"13276";"Infarct territory (%)"
"13277";"infarction (yr) History of congestive heart failure (%)"
"13278";"Infarction >30 days previously"
"13279";"Infarction 8-30 days"
"13280";"infarction before age 60 (A)"
"13281";"Infarction, date not reported"
"13282";"Infected, n (%)a"
"13283";"Infections"
"13284";"Infections and infestations"
"13285";"Inferior"
"13286";"Inferior (%)"
"13287";"Inferior (n, %)"
"13288";"Inferior MI*, %"
"13289";"Inferior or posterior"
"13290";"Inferior/posterior"
"13291";"Inflammation"
"13292";"Inflammatory"
"13293";"Inflammatory bowel disease"
"13294";"Inflammatory disease"
"13295";"Infliiimab i"
"13296";"INFLIX, no"
"13297";"INFLIX, yes"
"13298";"Infliximab"
"13299";"Infliximab-experienced (n = 103)"
"13300";"Infliximab-naive (n = 322)"
"13301";"Infliximab (combined 3 mg/kg and 5 mg/kg), n (%)"
"13302";"Infliximab (N = 169)"
"13303";"Infliximab 3 mg/kg"
"13304";"Infliximab 5 mg/kg"
"13305";"Infliximab combination therapy"
"13306";"Infliximab monotherapy"
"13307";"inflotmas io mgluj versus piecew"
"13308";"Influenza"
"13309";"Infrequent exacerbator"
"13310";"Infusion administered — no./total no. (%)"
"13311";"Inguinal hernia repair"
"13312";"Inhaled anticholinergic§"
"13313";"Inhaled corticosteroid"
"13314";"Inhaled corticosteroid - yes, n (%)"
"13315";"Inhaled corticosteroids"
"13316";"Inhaled glucocorticoid use at screening"
"13317";"Inhaled j82-agonist§"
"13318";"Inhaled^"
"13319";"Inhaled§"
"13320";"Inhaledb"
"13321";"inhibitor"
"13322";"inhibitors — no. {%) SE-36 physical functioning score^^"
"13323";"inHixanab 5 mgikg versus piacoM"
"13324";"Initial aspirin — no. (%)"
"13325";"Initial diagnosis — no. (%)"
"13326";"Initial heparin — no. (%)§"
"13327";"Initial Heparin Treatment Duration"
"13328";"Initial Heparin Treatment Duration On or After Randomization"
"13329";"Initial symptomatic PE"
"13330";"Initial TIMI Flow"
"13331";"Initial TIMI flow grade 3"
"13332";"Initial treatment randomization"
"13333";"Initial Type of Heparin Treatment Received"
"13334";"Initiated use during double-blind treatment period"
"13335";"initiation of dialysis, renal transplantation, or creatinine .6.0 mg/dL (530 mmol/L)"
"13336";"Initiation of Insulin"
"13337";"Injectable anti‐hyperglycaemic, n (%)"
"13338";"Injection-site reaction, n (%)"
"13339";"Inotropic agent"
"13340";"Inspiratory capacity (L)"
"13341";"insufficient"
"13342";"Insuiin giargine ± OAD"
"13343";"Insulin"
"13344";"Insulin-dependent"
"13345";"Insulin-dependent diabetes"
"13346";"Insulin-dependent diabetes mellitus"
"13347";"Insulin-na'ive"
"13348";"Insulin-naive, n (%)"
"13349";"Insulin-requiring"
"13350";"Insulin-requiring diabetes"
"13351";"Insulin-treated"
"13352";"Insulin-treated diabetes"
"13353";"Insulin-treated diabetes, %"
"13354";"Insulin-treated DM"
"13355";"Insulin — /tU/ml"
"13356";"Insulin — IU"
"13357";"Insulin (%)"
"13358";"Insulin (mU/mL)"
"13359";"Insulin (pmol/l)"
"13360";"Insulin (pmol/l)t Vital signs"
"13361";"Insulin + metformin"
"13362";"Insulin + OAD"
"13363";"Insulin + oral antidiabetic medication(s)"
"13364";"Insulin 一 no. (%)"
"13365";"Insulin administration"
"13366";"Insulin alone"
"13367";"Insulin and oral hypoglycemic drugs"
"13368";"Insulin aspart"
"13369";"Insulin aspart (mealtime)"
"13370";"Insulin at baseline"
"13371";"Insulin based"
"13372";"Insulin dependentc"
"13373";"Insulin detemir"
"13374";"Insulin dose — lU/day"
"13375";"Insulin dose (IU/day), median"
"13376";"Insulin dose (lU/day)"
"13377";"Insulin dose (U)"
"13378";"Insulin dose, U"
"13379";"Insulin Glargin Arm"
"13380";"Insulin glargine"
"13381";"Insulin Glargine"
"13382";"Insulin glargine (n=194)"
"13383";"Insulin Glargine (n=533)"
"13384";"Insulin glargine (n=58ll)"
"13385";"Insulin Glargine + Insulin Lispro (AWARD-4; N = 296)"
"13386";"Insulin Glargine Allocation"
"13387";"Insulin glargine dose at screening visit, IU"
"13388";"Insulin Glargine N (%)    /100py"
"13389";"Insulin Glargine N(X)"
"13390";"Insulin Glargine Slope LSM ± SE (mm/year)"
"13391";"Insulin glargine vs standard care Least-squares mean (95% Cl)"
"13392";"Insulin glargine ± OAD"
"13393";"Insulin glargine ± OAD + >BD prandial"
"13394";"Insulin glargine ± OAD + BD prandial"
"13395";"Insulin glargine ± OAD + OD prandial"
"13396";"Insulin lispro mix 25"
"13397";"Insulin only"
"13398";"Insulin plus >1 oral agent"
"13399";"Insulin plus 1 oral agent"
"13400";"Insulin plus oral"
"13401";"Insulin secretagogue"
"13402";"Insulin sensitivity — %§"
"13403";"Insulin therapy"
"13404";"Insulin therapy, n (%)"
"13405";"Insulin therapy, n (%)本"
"13406";"Insulin treated"
"13407";"Insulin treatment"
"13408";"Insulin treatment, n (%)"
"13409";"Insulin Tx difference vs Pbo, median change from baseline (SE)1"
"13410";"Insulin type, n (%)"
"13411";"Insulin use"
"13412";"Insulin use at baseline"
"13413";"Insulin use, n (%)"
"13414";"Insulin Yes"
"13415";"Insulin, IU/mL, median (Q1, Q3)"
"13416";"Insulin, median (Q1, Q3), pmol/L"
"13417";"Insulin, median (Ql, Q3), pmol/L"
"13418";"Insulin, n (%)"
"13419";"Insulin, pmol/L"
"13420";"Insulin:glucose ratio"
"13421";"Insulin+metformin"
"13422";"Insulin+metformin+sulphonylureas"
"13423";"Insulin+sulphonylureas"
"13424";"Insulina"
"13425";"Insulina, n (%)"
"13426";"Insulinogenic Index (Dinsulino_3o min/Dglucoseo-3o min)"
"13427";"Insulins"
"13428";"Insulins and analogs"
"13429";"Int. P*"
"13430";"Integrated analysis set (N = 679)"
"13431";"Intended clopidogrel dose 600 mg"
"13432";"Intended durat-sm of antccagubficn"
"13433";"Intended duration of anticoagulation"
"13434";"Intense"
"13435";"Intense physical activity"
"13436";"Intensification of antianginal therapy"
"13437";"Intensified (n 二 150)"
"13438";"Intensified 12 Months (n - 137)"
"13439";"Intensified Baseline (n - 150)"
"13440";"Intensity of rest pain (mmVAS), mean ± SD"
"13441";"Intensity of statin therapy"
"13442";"Intensity of statin therapy at baseline — no. {%)"
"13443";"Intensity11"
"13444";"Intensive (n=2149)"
"13445";"Intensive (n=3348)"
"13446";"Intensive blood glucose control"
"13447";"Intensive BP Lowering, <120 mm Hg (n=2154)"
"13448";"Intensive Control"
"13449";"Intensive Control (N=5571) No.of patients (percent)"
"13450";"Intensive glycemia lowering"
"13451";"Intensive Therapy (N = 5128)"
"13452";"Intent-to-treat population"
"13453";"Intent-to-treat population, n (%)"
"13454";"Intent-to-treatb"
"13455";"Intent of conservative strategy, %"
"13456";"Intent of early invasive strategy, %"
"13457";"Intent to use direct thrombin"
"13458";"Intent to use glycoprotein IIb/IIIa inhibitor"
"13459";"Intention-to-Treat"
"13460";"Intention-to-Treat with ST-segment-Elevation Myocardial Infarction"
"13461";"Intention-to-Treat without ST-segment-Elevation Myocardial Infarction"
"13462";"Intention to treat"
"13463";"Inter P-value"
"13464";"Inter."
"13465";"Inter. P- Value"
"13466";"Interact!"
"13467";"interaction"
"13468";"Interaction"
"13469";"Interaction-P"
"13470";"Interaction between treatment and baseline BMI category"
"13471";"Interaction j7-valuet"
"13472";"Interaction p"
"13473";"Interaction P"
"13474";"Interaction P-vaiue"
"13475";"Interaction p-value"
"13476";"Interaction P-value"
"13477";"Interaction P-Value"
"13478";"Interaction p-value*"
"13479";"Interaction p-value3"
"13480";"Interaction p-value4"
"13481";"Interaction p-valuef"
"13482";"Interaction p = 0.0489"
"13483";"Interaction p = 0.1026"
"13484";"Interaction p = 0.3025"
"13485";"Interaction p = 0.4147"
"13486";"Interaction p = 0.6113"
"13487";"Interaction p = 0.6955"
"13488";"Interaction P =0.689"
"13489";"interaction P vaiue"
"13490";"interaction p value"
"13491";"Interaction p value"
"13492";"Interaction p Value"
"13493";"Interaction P value"
"13494";"Interaction P Value"
"13495";"Interaction P value 0.06"
"13496";"Interaction P value 0.09"
"13497";"Interaction P value 0.57"
"13498";"Interaction P value 0.67"
"13499";"Interaction p Value!"
"13500";"Interaction P Value!"
"13501";"Interaction p Value∗"
"13502";"Interaction P Value*"
"13503";"Interaction p Value中"
"13504";"Interaction p Value§"
"13505";"Interaction P Value§"
"13506";"Interaction P values are as follows: Amlodipine vs. chlorthalidone: age, P=0.421; gender, P=0.385; race, P=0.737; history of CHD, P=0.120; history of diabetes, P=0.093. Lisinopril vs. chlorthalidone: age, P=0.408; gender, P=0.239; race, P=0.603; history of CHD, P=0.704; history of diabetes, P=0.040. Peripheral arterial disease refers to in-trial hospitalization or lower extremity revascularization procedure."
"13507";"Interaction Pf"
"13508";"Interaction: treatment by psoriasis p value6"
"13509";"Interaction: treatment by psoriasis p valueb"
"13510";"Interaction13"
"13511";"Interactior p-value"
"13512";"intercourse satisfac-"
"13513";"Interim analysis"
"13514";"Interim analysis (all patients)"
"13515";"Interleukin-6 (ng/L)"
"13516";"Interleukin 6 (pg/ml)"
"13517";"intermediate"
"13518";"Intermediate"
"13519";"Intermediate-acting"
"13520";"Intermediate  Risk (RI=2)"
"13521";"Intermediate (2) (n = 5,292; 30%)"
"13522";"Intermediate (2), %"
"13523";"Intermediate (3-4)"
"13524";"Intermediate Risk (RI=2)"
"13525";"Intermediate/long-acting + fast-acting"
"13526";"Intermittent claudication"
"13527";"Internal carotid artery sites"
"13528";"Interquartile range"
"13529";"Interquartile range — ml/min"
"13530";"Interquartile range — yr"
"13531";"Interquartile range Height — cm"
"13532";"Interruption"
"13533";"Interruption (n=624)"
"13534";"Intertrochanteric"
"13535";"Interval after index event"
"13536";"Interval between clinical evaluation and initiation of treatment —no. (%)"
"13537";"Interval between clinical evaluation and initiation oftreatment — no. (%)"
"13538";"Interval clopidogrel to PCI"
"13539";"Interval from clopidogrel loading, h"
"13540";"Interval from onset of symptoms"
"13541";"Interval from randomization to angiography"
"13542";"Interval from symptom onset to qualifying ECG obtained in the ER — hr"
"13543";"Interval of >10 yr since diagnosis of type 2 diabetes — no. (%)"
"13544";"Interval pain onset to admission"
"13545";"Interval study drug to PCI"
"13546";"Intervention"
"13547";"Intervention group (n=463)"
"13548";"Intervention in complex lesions"
"13549";"intervention."
"13550";"Interventional or surgical procedures"
"13551";"Intestinal area involved — no. (%)"
"13552";"Intestinal area involved, n (%)$"
"13553";"Intolerance"
"13554";"Intolerance'"
"13555";"Intolerance®"
"13556";"Intra-abdominal abscess (past),"
"13557";"Intracerebral"
"13558";"Intracranial"
"13559";"Intracranial bleed"
"13560";"Intracranial bleeding"
"13561";"Intracranial disease of major artery disease t"
"13562";"Intracranial disease of major artery寸"
"13563";"Intracranial hemorrhage"
"13564";"Intracranial Hemorrhage"
"13565";"Intracranial hemorrhage, n (%)"
"13566";"Intracranial hemorrhage†"
"13567";"Intraperitoneal"
"13568";"Intrathoracic or intraperitoneal surgery"
"13569";"Intravenous (N = 191)"
"13570";"Intravenous anticoagulant during hospitalisation*"
"13571";"Intravenous anticoagulant during hospitalization"
"13572";"Intravenous anticoagulant prior to pre-PCI angiography"
"13573";"Intravenous dobutamine"
"13574";"Intravenous heparin"
"13575";"Intravenous inotropes or vasopressors (%)"
"13576";"Intravenous loop diuretics!"
"13577";"Intravenous nitrates"
"13578";"Intravenous study drug administered — no. (%)"
"13579";"Intravenous vasoactive drugs, %y"
"13580";"Intravenous vasodilators (%)"
"13581";"Invasive"
"13582";"inversion"
"13583";"Investigations"
"13584";"Investigator-defined drug-related AEs"
"13585";"Investigator-determined myocardial infarction"
"13586";"Investigator-reported AEs"
"13587";"Investigator-reported hypoglycaemia*"
"13588";"Involved gastrointestinal"
"13589";"Involved Gl areas"
"13590";"Involved intestinal area, n (%)"
"13591";"IOP-lowering medication"
"13592";"IOP, mm Hg"
"13593";"IPAH, HPAH, HIV, drug or toxin induced"
"13594";"IPAH/HPAH"
"13595";"ipeated-measures State Examinatioi"
"13596";"IPF"
"13597";"IPF-related"
"13598";"IPSS"
"13599";"IPSS-S"
"13600";"IPSS-V"
"13601";"IPSS (LS mean ± SE)"
"13602";"IPSS (mean ± SD)"
"13603";"IPSS (unit)"
"13604";"IPSS categories"
"13605";"IPSS HRQL"
"13606";"IPSS QoL"
"13607";"IPSS QoL (LS"
"13608";"IPSS storage subscore"
"13609";"IPSS total score"
"13610";"IPSS voiding subscore"
"13611";"IPSS, “/o"
"13612";"IPST"
"13613";"IPST (n = 89)"
"13614";"IQR"
"13615";"Irbesartan"
"13616";"Irbesartan (N = 2067)"
"13617";"IROFIBAN"
"13618";"IRR=0.75(0.58–0.96)0.024"
"13619";"IRR=0.83(0.42–1.62)0.58"
"13620";"Irregular or ulcerated ICA p)laque:[:"
"13621";"Irregular or ulcerated ICA plaquef"
"13622";"Irritative subscore"
"13623";"IS domain LUTS severity (%)"
"13624";"IS only"
"13625";"Ischaemic"
"13626";"Ischaemic (n=4418)"
"13627";"Ischaemic (n=44l8)"
"13628";"Ischaemic aetiology"
"13629";"Ischaemic cardiomyopathy"
"13630";"Ischaemic cause"
"13631";"Ischaemic dilated cardiomyopathy"
"13632";"Ischaemic etiology N(%)"
"13633";"Ischaemic heart disease"
"13634";"Ischaemic heart disease or cerebrovascular disorder, n (%)"
"13635";"Ischaemic heart disease, n (%)"
"13636";"Ischaemic or unknown stroke"
"13637";"Ischaemic skin lesions"
"13638";"Ischaemic stroke"
"13639";"Ischaemic stroke, n (%)"
"13640";"Ischaemic, n (%)"
"13641";"Ischemia"
"13642";"Ischemia-driven revascularization"
"13643";"Ischemia driven revascularization"
"13644";"Ischemia Driven Revascularization"
"13645";"Ischemia on cECG (%)"
"13646";"Ischemia on cECG (n = 1,271)"
"13647";"Ischemic"
"13648";"Ischemic aetiology"
"13649";"Ischemic aetiology, n (%)"
"13650";"Ischemic cardiomyopathy"
"13651";"Ischemic cause"
"13652";"Ischemic cerebrovascular disease, n (%)"
"13653";"Ischemic coronary artery disease"
"13654";"Ischemic etiology"
"13655";"Ischemic etiology (%)"
"13656";"Ischemic etiology, %"
"13657";"Ischemic heart disease"
"13658";"Ischemic heart disease (%)"
"13659";"Ischemic Heart Disease Indicator    No (n=650l)"
"13660";"Ischemic heart disease*"
"13661";"Ischemic heart disease, %"
"13662";"Ischemic heart disease, (%)"
"13663";"Ischemic heart disease, n (%)"
"13664";"Ischemic heart disease, No. (%)"
"13665";"Ischemic heart failure etiology"
"13666";"Ischemic HF etiology"
"13667";"Ischemic HF, % (n)"
"13668";"Ischemic Outcomes"
"13669";"Ischemic stroke"
"13670";"Ischemic Stroke"
"13671";"Ischemic stroke (%)"
"13672";"Ischemic stroke (incl. uncertain)"
"13673";"Ischemic stroke (vs. TIA)"
"13674";"Ischemic Stroke or SEE"
"13675";"Ischemic stroke subtype"
"13676";"Ischemic Stroke with Hemnrrhnaic Cnnversinn"
"13677";"Ischemic Stroke without Hemorrhagic Conversior"
"13678";"Ischemic TVR"
"13679";"Isehemie heart disease"
"13680";"ISH"
"13681";"ISH status, n (%)"
"13682";"Islander"
"13683";"isoiated systoiic hypertension*"
"13684";"Isolated deep-vein thrombosis"
"13685";"Isolated IGT"
"13686";"Isolated impaired glucose tolerance — no."
"13687";"Isolated pulmonary embolism"
"13688";"Isolated systolic hypertension"
"13689";"Isolated systolic hypertension, n ('%>"
"13690";"Isolated systolic hypertension, n (%)“"
"13691";"Isolated systolic hypertension^"
"13692";"Isolated systolic hypertension⁎"
"13693";"Isolated upper gastrointestinal Disease behavior, n (%)"
"13694";"Israel"
"13695";"it 0.68"
"13696";"Italy"
"13697";"Italy (n=728)"
"13698";"ITCA 650 40 mg/day (n = 153)"
"13699";"ITCA 650 60 mg/day(n = 153)"
"13700";"Itch NRS"
"13701";"Itch NRS 0 (V = 50)"
"13702";"Itch NRS 1-3 (AT = 369)"
"13703";"Itch NRS 4-6 (V = 660)"
"13704";"Itch NRS 7-8 (.\' = 930)"
"13705";"Itch NRS 9-10 (A' = 550)"
"13706";"Item"
"13707";"ith vs. without)"
"13708";"itherCHDt"
"13709";"ITT"
"13710";"ITT cohort, Overall Study Period"
"13711";"ITT patients, n (%)"
"13712";"ITT population"
"13713";"ITT Population"
"13714";"ITT population, n"
"13715";"IU"
"13716";"IUSS score, mean (SD)"
"13717";"iV"
"13718";"IV"
"13719";"IV-75 mg"
"13720";"IV -150 mg"
"13721";"IV (496)"
"13722";"IV inotropic drug"
"13723";"IV nitrates"
"13724";"IV vasodilator"
"13725";"IV: FEV1 <30% predicted"
"13726";"Ivabradine"
"13727";"Ivabradine (N = 9550)"
"13728";"Ivabradine (N =9550)"
"13729";"Ivabradine group"
"13730";"Ivabradine group (n=3241)"
"13731";"IVC (n=20)"
"13732";"IVC (n=32)"
"13733";"IVC (n=61)"
"13734";"IVC (n=72)"
"13735";"IWQOL-Lite physical score (arbitrary units)"
"13736";"IWQOL-Lite total score (arbitrary units)#"
"13737";"Ixekizumab every 2 weeks (n=351)"
"13738";"Ixekizumab every 2 weeks (n=385)"
"13739";"Ixekizumab every 4 weeks (n=347)"
"13740";"Ixekizumab every 4 weeks (n=386)"
"13741";"IXEQ2W, n=40"
"13742";"IXEQ2W, n=53"
"13743";"IXEQ2W, n=63"
"13744";"IXEQ4W, n=39"
"13745";"IXEQ4W, n=57"
"13746";"IXEQ4W, n=68"
"13747";"ization — no. (%)"
"13748";"j3-Blocker, % (n)"
"13749";"j3 -Blocker"
"13750";"j3 coefficient"
"13751";"Japan"
"13752";"Japan and South Korea"
"13753";"Japan N = 148"
"13754";"Japanese"
"13755";"Japanese subgroup (N = 83)"
"13756";"Japanese subpopulation"
"13757";"JBS-2 primary prevention only3"
"13758";"JBS-2 secondary prevention only3"
"13759";"Jejunum"
"13760";"Joint damage outcomes (mITT population)"
"13761";"Joint space narrowing score"
"13762";"Joint space narrowing score, mean (SD)"
"13763";"Joint swelling"
"13764";"Joint swelling, effusion, or both on clinical examination"
"13765";"Joint swelling, effusion, or both on clinical examination — no. (%)"
"13766";"jS2-Agonists"
"13767";"JSN score"
"13768";"JSN score (0-168)"
"13769";"JSN score (0-280)"
"13770";"JSN score (0–208 scale)"
"13771";"JSN score, mean 6 SD"
"13772";"JSN, mean ± SD"
"13773";"JSN, median (min, max)"
"13774";"Jugular venous distension, n (%)"
"13775";"Jugular venous distention >10 cm"
"13776";"Juvenile myoclonic epilepsy"
"13777";"JVD $10 cm H2O, %"
"13778";"JVP $10 cm H2O"
"13779";"JVP (〉10 cm)"
"13780";"JVP >10cm"
"13781";"JVP, (%)"
"13782";"K-M %"
"13783";"K-M % n"
"13784";"K (mmol/L)"
"13785";"K (rate)"
"13786";"K, mmol/l"
"13787";"Kaplan-Meier Rates, %"
"13788";"Kaplan-Meier Rates, % I    I"
"13789";"Karnofsky score < 80"
"13790";"Karnofsky score 竺 80"
"13791";"KCCQ (12 months)"
"13792";"KCCQ score"
"13793";"KDL cholesterol (mmol/)"
"13794";"Kellgren and Lawrence radiographic reading grade 2 — no. (%)"
"13795";"Key secondary end point: ST"
"13796";"Key secondary end points"
"13797";"Key: FC = fasting glucose; BP = *This category did not include ar have 3 of the indicated charac"
"13798";"Key: TC = triglyceride; hs-CRP = LDL-C = low-density lipoprotein FC = fasting glucose; NCEP ATP * This category did not include ar to have >_ 3 of the indicated char least-square means, except TC an Note: All treatment by subgroup"
"13799";"kg"
"13800";"kg/m2"
"13801";"kg/m2)"
"13802";"kheeatne index DVT"
"13803";"Kidney disease (USRDS)"
"13804";"Killip at baseline"
"13805";"Killip ciass"
"13806";"Killip class"
"13807";"Killip class — no. (%) I"
"13808";"Killip class — no./total no. (%) I"
"13809";"Killip class (Interaction: p=0.62)"
"13810";"Killip class >11, No. (%)"
"13811";"Killip class >I, %"
"13812";"Killip class >II (%)"
"13813";"Killip class 1"
"13814";"Killip class 2/4"
"13815";"Killip class at admission — no./total no. (%)"
"13816";"Killip class I—No. (%)"
"13817";"Killip class I — no. (%)"
"13818";"Killip class II-IV, n (%)"
"13819";"Killip class II, III, or IV — %"
"13820";"Killip class IV at randomization"
"13821";"Killip class*"
"13822";"Killip class, n (%)"
"13823";"Killip class, n (%) I"
"13824";"KIM 1 (pg/ml)"
"13825";"KL 2 (%)"
"13826";"KL 3 (%)"
"13827";"KM Event (%) at 7 y"
"13828";"KM event rate (%)"
"13829";"KM Rate (%)"
"13830";"KM rates {%) E/S"
"13831";"KM rates {%) P/S"
"13832";"Knee"
"13833";"Knees (N)"
"13834";"Known CHD"
"13835";"Known duration"
"13836";"Known duration of diabetes, yr"
"13837";"Known duration of T2DM, y"
"13838";"Known duration of type 2 diabetes (years)"
"13839";"Known duration of type 2 diabetes,"
"13840";"Known prothrombotic genotype"
"13841";"Known t 'rc-iitoji cccndilon"
"13842";"Known thrombophilia"
"13843";"Known thrombophilia — no. (%)"
"13844";"Known thrombophilic condition — no. (%)"
"13845";"Known tiromtcch*c ccndifeon"
"13846";"Korea"
"13847";"Korea, Republic of"
"13848";"Korean"
"13849";"L"
"13850";"l ( < l)"
"13851";"l (< l)"
"13852";"L Compared wi"
"13853";"L Compared wit"
"13854";"L eft anterior descending"
"13855";"L eft anterior descending coronary artery"
"13856";"L vs. C"
"13857";"l.i (0.4)"
"13858";"l.l±0.3"
"13859";"L/C"
"13860";"l/ll"
"13861";"L’-value’"
"13862";"L20-40 vs placebo"
"13863";"L40-80 vs L2-5-5"
"13864";"LA diameter"
"13865";"LA grade A, n (%)f"
"13866";"LA grade B, n (%)f"
"13867";"LAA"
"13868";"LAA Closure"
"13869";"LAA Closure (n - 732)"
"13870";"LAA Closure (n = 732)"
"13871";"LAA length"
"13872";"LAA Length"
"13873";"LAA ostium"
"13874";"LAA Ostium"
"13875";"laBa"
"13876";"LABA"
"13877";"LABA'"
"13878";"LABA-inhaled glucocorticoid use at screening"
"13879";"LABA (inhaled),d n (%)"
"13880";"LABA (only monotherapy)"
"13881";"LABA (tiotropium n = 56; placebo n = 55)"
"13882";"LABA + ICS"
"13883";"LABA + ICS (free or fixed-dose combination)"
"13884";"LABA + ICS n = 269"
"13885";"LABA alone"
"13886";"LABA non-users"
"13887";"LABA or LAMA"
"13888";"LABA or LAMA’"
"13889";"LABA or LAMA’ versus IND/GLY LSM difference (95% Cl)"
"13890";"LABA or LAMAb n = 268"
"13891";"LABA plus ICS (tiotropium n = 50, placebo n = 48)"
"13892";"LABA plus ICS, n (%)"
"13893";"LABA use at enrolment"
"13894";"LABA use at screening"
"13895";"LABA use at screening, n (%)"
"13896";"LABA use, % patients"
"13897";"LABA users"
"13898";"LABA, n (%)"
"13899";"LABA, no ICS, n (%)"
"13900";"LABA/ICS use at screening, n (%)"
"13901";"LABA/ICS#"
"13902";"LABA/LAMA"
"13903";"LABA/LAMA/ICS"
"13904";"LABA+ICS"
"13905";"LABA+ICS versus INDZGLY LSM difference (95% Cl)"
"13906";"LABA + ICS"
"13907";"LABD alone"
"13908";"Laboratory AE, n (%}"
"13909";"Laboratory data"
"13910";"Laboratory data, mean (SD)"
"13911";"Laboratory determinations"
"13912";"Laboratory evaluations"
"13913";"Laboratory examination"
"13914";"Laboratory findings"
"13915";"Laboratory investigations"
"13916";"Laboratory measurements"
"13917";"Laboratory measures"
"13918";"Laboratory parameters, median (IQR)"
"13919";"Laboratory testing"
"13920";"Laboratory tests"
"13921";"Laboratory values"
"13922";"Laboratory values at admission (median and IQR)"
"13923";"Laboratory values at randomization (median and IQR)"
"13924";"Laboratory values in patients with history of diabetes"
"13925";"Laboratory variables"
"13926";"Laboratory variables at baseline"
"13927";"Labs at randomization"
"13928";"Labs at the index ACS event"
"13929";"LACI"
"13930";"LACI (n=510)"
"13931";"Lack of effectiveness"
"13932";"Lack of efficacy"
"13933";"Lack of efficacy with >1 anti-interleukin 6"
"13934";"Lack of efficacy with >1 bDMARD"
"13935";"Lacosamide"
"13936";"Lacunar"
"13937";"Lacunar infarction, n (%)"
"13938";"LAD"
"13939";"LAD artery"
"13940";"LAMA"
"13941";"LAMA (only monotherapy)"
"13942";"LAMA (tiotropium),b n (%)"
"13943";"LAMA use at screening"
"13944";"LAMA use at screening, n (%)"
"13945";"LAMA use, n (%)"
"13946";"LAMA+"
"13947";"laMad"
"13948";"Lamotrigine"
"13949";"Lansoprazole (n = 1363)"
"13950";"Lansoprazole 30 mg QD"
"13951";"Laparoscopic cholecystectomy"
"13952";"Large-artery atherosclerosis"
"13953";"Large MI"
"13954";"Large shunt"
"13955";"Large vessel"
"13956";"Large vessel atherosclerosis"
"13957";"Large/very large"
"13958";"Laser or vitrectomy"
"13959";"last infusion in the HORIZON-PFT"
"13960";"Last study visit"
"13961";"Late load"
"13962";"Late Load"
"13963";"Lateral"
"13964";"Lathosterol (jimol/L)"
"13965";"Lathosterol/Total C (|imol/mmol)"
"13966";"Latin"
"13967";"Latin America"
"13968";"Latin America (n=694)"
"13969";"Latin America HR (95% Cl)"
"13970";"Latin America or South Africa"
"13971";"Latin American"
"13972";"Latin American subgroup"
"13973";"Latin Ameriea"
"13974";"Latin and North America"
"13975";"Latino"
"13976";"Latvia"
"13977";"LAV (ml)"
"13978";"LAVOLTA 1"
"13979";"LAVOLTA II"
"13980";"lb"
"13981";"LC, n = 372"
"13982";"LCE — L-dopa/carbidopa/entacapone; LC — L-dopa/carbidopa; PD — Parkinson disease; UPDRS — Rating Scale; ADL — activities of daily living; PDQ-39 — Parkinson Disease Questionnaire."
"13983";"LCE, n = 373"
"13984";"LCL"
"13985";"LCZ696"
"13986";"LCZ696 (n = 496)"
"13987";"LCZ696 (n = 497)"
"13988";"LCZ696 (n = 649)"
"13989";"LCZ696 (n = 683)"
"13990";"LCZ696 treatment, n (%)"
"13991";"LD"
"13992";"LD Edoxaban vs Warfarin"
"13993";"LDA, %"
"13994";"LDI-B > 0 (N=155)"
"13995";"LDI, mean (SD)a"
"13996";"LDI, mean [SD]b"
"13997";"LDI1"
"13998";"LDL"
"13999";"LDL-C"
"14000";"LDL-C (BQ) (mg/dL) - mean ± SD"
"14001";"LDL-C (calculated)*"
"14002";"LDL-C (calculated), mean (SD)"
"14003";"LDL-C (calculated), mg/dL, mean (SD)"
"14004";"LDL-C (measured)*"
"14005";"LDL-C (measured), mean (SD)"
"14006";"LDL-C (median, IQR), mg/dL"
"14007";"LDL-C (mg/dL)"
"14008";"LDL-C (mg/dl) **"
"14009";"LDL-C (mg/dl) <100"
"14010";"LDL-C (mmol/L)"
"14011";"LDL-C (mmol/L, mean)"
"14012";"LDL-C < 1.8 mmol/l"
"14013";"LDL-C < 2.0 mmol/l"
"14014";"LDL-C < 2.5 mmol/l"
"14015";"LDL-C <100 mg/dL"
"14016";"LDL-C <100 mg/dL (2.6 mmol/L)"
"14017";"LDL-C <50 mg/dL"
"14018";"LDL-C <70 mg/dL"
"14019";"LDL-C >70 mg/dL"
"14020";"LDL-C 50-70 mg/dL"
"14021";"LDL-c at Baseline:"
"14022";"LDL-C goal attainment"
"14023";"LDL-C in mmol/L (baseline: mean (SD) [n]; wk 48 and change: mean (SE) [n])"
"14024";"LDL-C in mmol/L (mean ± SD for baseline [n]; mean ± SE for week 12 [n])"
"14025";"LDL-C level, mean (SD), mg/dL"
"14026";"LDL-C level, mg/dL"
"14027";"LDL-C * (mmol/L)"
"14028";"LDL-C* (mmol/L)"
"14029";"LDL-C, mean (SD)"
"14030";"LDL-C, mean (SD), mg/dL"
"14031";"LDL-C, mg/dl"
"14032";"LDL-C, mg/dL"
"14033";"LDL-C, mg/dL*"
"14034";"LDL-C, mg/dL, mean + SD"
"14035";"LDL-C, mg/dL, mean ± SD"
"14036";"LDL-C, mmol/L"
"14037";"LDL-C, mmol/L (mg/dL)"
"14038";"LDL-C, mmol/L (SD)"
"14039";"LDL-C, mmol/l, mean (SD)"
"14040";"LDL-C, mmol/L, mean (SD)"
"14041";"LDL-C/HDL-C"
"14042";"LDL-C/HDL-C ratio"
"14043";"LDL-C/HDL-C ratio, mean (SD)"
"14044";"LDL-C/HDL-Cx"
"14045";"LDL-C:HDL-C"
"14046";"LDL-C:HDL-C ratio"
"14047";"LDL-C<130mg/dL,No. (%)"
"14048";"LDL-C>median"
"14049";"LDL-cholesterol"
"14050";"LDL-cholesterol ("
"14051";"LDL-cholesterol (mg/dL)"
"14052";"LDL-cholesterol (mmol/)"
"14053";"LDL-cholesterol (mmol/L)"
"14054";"LDL-cholesterol, mean (sd) mg/dl"
"14055";"LDL-cholesterol, mg/dL, mean (SD)"
"14056";"LDL-cholesterol, mmol/L"
"14057";"LDL-cholesterol, mmol/lf"
"14058";"LDL-CiHDL-C, mean (SD)"
"14059";"LDL-Csmedian"
"14060";"LDL-Cz"
"14061";"LDL-to-HDL cholesterol ratio, mean (SD)"
"14062";"LDL (mmol/L)"
"14063";"LDL cholesicrol (minol/l)"
"14064";"LDL choleslerol"
"14065";"LDL cholesterohHDL cholesterol ratio"
"14066";"LDL cholesterol"
"14067";"LDL cholesterol-lowering therapy"
"14068";"LDL cholesterol — mg/dl"
"14069";"LDL cholesterol — mg/dl||"
"14070";"LDL cholesterol (mg/dl)"
"14071";"LDL cholesterol (mg/dL)"
"14072";"LDL cholesterol (mg/dL), mean + SD, available for 3306 patients"
"14073";"LDL cholesterol (mmol/l)"
"14074";"LDL cholesterol (mmol/L)"
"14075";"LDL cholesterol (mmol/L) (median, IQR)"
"14076";"LDL cholesterol (mmol/L), mean (SD)"
"14077";"LDL cholesterol (mmol/L):"
"14078";"LDL cholesterol (SD), mg/dL"
"14079";"LDL cholesterol <2-07 mmol/L"
"14080";"LDL cholesterol >2-07 mmol/L"
"14081";"LDL cholesterol at baseline (mmol/L)* LDL cholesterol at screening"
"14082";"LDL cholesterol level"
"14083";"LDL cholesterol Mean"
"14084";"LDL cholesterol mean (mg/dl ± SD)"
"14085";"LDL cholesterol, mean (SD), mg/dL"
"14086";"LDL cholesterol, mg/dl"
"14087";"LDL cholesterol, mg/dL"
"14088";"LDL Cholesterol, mg/dL"
"14089";"LDL cholesterol, mmol/L"
"14090";"LDL cholesterol, mmol/L*"
"14091";"LDL cholesterol, mmol/L, mean (SD)§"
"14092";"LDL cholesterol, mmol/L, mean±SD"
"14093";"LDL cholesterol, mmol/l丰"
"14094";"LDL cholesterol, mmol/lt"
"14095";"LDL cholesterol^:"
"14096";"LDL cholesterolt"
"14097";"LDL particle numbers (week 24)"
"14098";"LDL particle size (week 24)"
"14099";"LDL*"
"14100";"LDL,-C"
"14101";"LDL/HDL cholesterol ratio, mean (SD)§"
"14102";"LDL:HDL ratio"
"14103";"ldl2-c"
"14104";"ldl3-c"
"14105";"LDLC"
"14106";"LDLC:HDLC"
"14107";"LDU-C"
"14108";"LEADER"
"14109";"Leading to death"
"14110";"Leading to discontinuation"
"14111";"Leading to study drug discontinuation"
"14112";"Leading to study withdrawal"
"14113";"Lean (<25 kg/m2)"
"14114";"Least-squares mean difference (95% CI)*"
"14115";"Least-Squares Mean Difference (95% Cl)"
"14116";"Least square mean (SE)"
"14117";"Least squares mean between-treatment difference (95% CI)"
"14118";"Lebrikizumab (n = 104)"
"14119";"Lebrikizumab 125 mg"
"14120";"Lebrikizumab 125 mg (n=357)"
"14121";"Lebrikizumab 125 mg (n=359)"
"14122";"Lebrikizumab 37-5 mg"
"14123";"Lebrikizumab 37-5 mg (n=356)"
"14124";"Lebrikizumab 37-5 mg (n=360)"
"14125";"Leeds Dactylitis Index-Basic, mean (SD)’'^"
"14126";"Leeds Enthesitis Index, mean (SD)’’*’"
"14127";"Leeds Enthesitis Index^ Score >0 — no. {%)"
"14128";"LEF+MTX (n = 69)"
"14129";"Leflunomide"
"14130";"Leflunomide (mean dose: 19.20 mg/day)"
"14131";"Left"
"14132";"Left-sided colitis"
"14133";"Left-sided colitisz"
"14134";"Left-sided disease only"
"14135";"Left anterior descending"
"14136";"Left anterior descending artery"
"14137";"Left anterior descending artery, n (%)"
"14138";"Left anterior descending coronary artery"
"14139";"Left anterior descending, n (%)"
"14140";"Left atrial anteroposterior diameter — mm"
"14141";"Left atrial diameter"
"14142";"Left atrial diameter, mm (SD)"
"14143";"Left atrial diameter: <42 mm (n=480)"
"14144";"Left atrial dimension, cm"
"14145";"Left bundle-branch block"
"14146";"Left circumflex"
"14147";"Left circumflex artery"
"14148";"Left circumflex artery, n (%)"
"14149";"Left circumflex coronary artery"
"14150";"Left circumflex, n (%)"
"14151";"Left main"
"14152";"Left main artery"
"14153";"Left main coronary artery"
"14154";"Left main coronary artery bifurcation"
"14155";"Left main coronary artery, n (%)"
"14156";"Left main disease"
"14157";"Left main disease, n (%)"
"14158";"Left main treated"
"14159";"Left shoulder"
"14160";"Left side of colon"
"14161";"Left side, n (%)"
"14162";"Left sided colitis"
"14163";"Left ventricular dysfunction"
"14164";"Left ventricular EF, mean (SD), %"
"14165";"Left ventricular ejection"
"14166";"Left ventricular ejection fraction"
"14167";"Left ventricular ejection fraction — %"
"14168";"Left ventricular ejection fraction — %§"
"14169";"Left ventricular ejection fraction — no./total no. (%)"
"14170";"Left ventricular ejection fraction (%)"
"14171";"Left ventricular ejection fraction <30%"
"14172";"Left ventricular ejection fraction within previous 12 mo — no./total no. (%)1"
"14173";"Left ventricular ejection fraction within previous 6 mo |"
"14174";"Left ventricular ejection fraction, %"
"14175";"Left ventricular ejection fraction, % AF history"
"14176";"Left ventricular ejection fraction, %*"
"14177";"Left ventricular ejection fraction, mean (SD), %"
"14178";"Left ventricular ejection fraction, median (IQR), %"
"14179";"Left ventricular hypertrophy"
"14180";"Left Ventricular Hypertrophy"
"14181";"Left ventricular hypertrophy — no. (%)"
"14182";"Left ventricular hypertrophy (%)"
"14183";"Left ventricular hypertrophy on echo"
"14184";"Left ventricular hypertrophy**"
"14185";"Left ventricular hypertrophy, n (%)"
"14186";"Left ventricular systolic dysfunction, n (%)"
"14187";"Left ventricular systolic or diastolic dysfunction"
"14188";"legend"
"14189";"Legs only"
"14190";"LEI >0 (N = 403)"
"14191";"LEI, mean (SD)"
"14192";"LEI, mean [SD]c"
"14193";"LEI1"
"14194";"Lelt ventricular hypertrophy*"
"14195";"Length of stay (randomization to discharge, h)"
"14196";"Length of stent < median"
"14197";"Length of stent > median"
"14198";"Lesion Characteristics"
"14199";"Lesion length $30 mm"
"14200";"Lesion length ≥30 mm"
"14201";"Lesion length > 30 mm"
"14202";"Lesion length, mean (SD), mm"
"14203";"Lesion location"
"14204";"Lesion(s)"
"14205";"Lesions"
"14206";"Lesions B2/C"
"14207";"Lesions treated per patient"
"14208";"Less severe"
"14209";"Less severe OA symptoms at baseline"
"14210";"Less severe0"
"14211";"Less than 1 year"
"14212";"Less than 10 y ears"
"14213";"Less than 140 mm Hg"
"14214";"Less than 30"
"14215";"Less than 30 kg/m2"
"14216";"Less than 50%"
"14217";"Less than 60 ml/min/1.73m2"
"14218";"Less than 65 y ears"
"14219";"Less than 7.5%"
"14220";"Less than high school"
"14221";"Less than median"
"14222";"Less than the median"
"14223";"Leukocytes, 103/nl"
"14224";"Leukopenia"
"14225";"Leukotriene-receptor antagonist"
"14226";"Leukotriene modifier"
"14227";"Leukotriene receptor antagonists"
"14228";"LEV-exposed"
"14229";"LEV-naive"
"14230";"LEV (n = 103)"
"14231";"LEV (n = 104)"
"14232";"LEV (n = 117)"
"14233";"LEV (n = 126)"
"14234";"LEV (n = 14)"
"14235";"LEV (n = 22)"
"14236";"LEV status"
"14237";"LEV status, n (%)"
"14238";"Level — no. (%)"
"14239";"Level 1"
"14240";"Level 1 immobility§||"
"14241";"Level 2"
"14242";"Level 2 immobility^"
"14243";"Level of renal impairment"
"14244";"Level of renal impairment'"
"14245";"Level of thyroperoxidase antibody at baseline"
"14246";"Levetiracetam"
"14247";"Levodopa dose, mean ± SD, mg/day"
"14248";"Levosimendan (n = 299)"
"14249";"Levosimendan (n = 51)"
"14250";"lGM(n = 4565)"
"14251";"li 652(2.3)"
"14252";"lieum only, n (%)"
"14253";"life-threatening"
"14254";"Life-threatening bleed"
"14255";"Life-threatening bleeding, disabling stroke, and death"
"14256";"Lifestyle"
"14257";"Lifestyle behaviors"
"14258";"Lifestyle behaviours"
"14259";"Lifestyle modifications"
"14260";"Likelihood test"
"14261";"Limb"
"14262";"limb (SD)"
"14263";"Limb amputation"
"14264";"Limited"
"14265";"Limited    I-"
"14266";"Limited to left side of colon"
"14267";"Linagliptin"
"14268";"Linagliptin (n = 182)"
"14269";"Linagliptin (n = 3319)"
"14270";"Linagliptin (n = 3494)"
"14271";"Linagliptin (n = 3494)'"
"14272";"Linagliptin (n Z 1624)"
"14273";"Linagliptin, patients with events/total patients"
"14274";"Linagliptin/metformin"
"14275";"Linear regression"
"14276";"Lioid trial participants"
"14277";"LIPC"
"14278";"LIPID"
"14279";"Lipid-lowering"
"14280";"Lipid-lowering agent"
"14281";"Lipid-lowering agent§"
"14282";"Lipid-lowering agents"
"14283";"Lipid-lowering agents (%)"
"14284";"Lipid-lowering drug"
"14285";"Lipid-lowering drug**"
"14286";"Lipid-lowering drugs"
"14287";"Lipid-lowering drugs, n (%)"
"14288";"Lipid-lowering medication"
"14289";"Lipid-lowering medication (%)"
"14290";"Lipid-lowering medications"
"14291";"Lipid-lowering medications^"
"14292";"Lipid‐lowering therapies, n (%)"
"14293";"Lipid-lowering therapy"
"14294";"Lipid-lowering therapy - no. (%)"
"14295";"Lipid-lowering therapy — no. (%)"
"14296";"Lipid-lowerinq druq"
"14297";"Lipid-modulating drug"
"14298";"Lipid and lipoprotein values (mg/dL)"
"14299";"Lipid concentrations"
"14300";"Lipid concentrations Total cholesterol (mmol/L)"
"14301";"Lipid Difference (mg/dL)"
"14302";"lipid disorder"
"14303";"Lipid levels — mg/dl"
"14304";"Lipid levels — mg/dlj Total cholesterol"
"14305";"Lipid lowering"
"14306";"Lipid lowering agent N(%)"
"14307";"Lipid lowering agents"
"14308";"Lipid lowering drugs"
"14309";"Lipid lowering medication use"
"14310";"Lipid lowering therapy"
"14311";"Lipid measure*"
"14312";"Lipid measures at baseline — mg/dl"
"14313";"Lipid medication, n (%)"
"14314";"Lipid modifiers"
"14315";"Lipid parameters"
"14316";"Lipid parameters, mg/dL, mean (SD)"
"14317";"Lipid profile"
"14318";"Lipid treatment"
"14319";"Lipid trial participants"
"14320";"Lipid trial participants - n (%)"
"14321";"Lipid trial participants#"
"14322";"Lipid trial participants, No. (%)"
"14323";"Lipid trial participantsk"
"14324";"Lipid trial participantss"
"14325";"Lipid values"
"14326";"Lipid values, mean (SD)"
"14327";"Lipid values, mmol/L"
"14328";"Lipids"
"14329";"Lipids — mg/dl"
"14330";"Lipids medications"
"14331";"Lipids, mean (SD), mg/dLf"
"14332";"Lipids, mean (SD), mg/dLt"
"14333";"Lipoprotein (a) (mmol/L)"
"14334";"Lipoprotein (a) (nmol/L)"
"14335";"Lipoprotein (a) Tx difference vs Pbo, LS mean % change from baseline (SE)"
"14336";"Lipoprotein (a), median (QI, Q3), nmol/L"
"14337";"Lipoprotein (a), median (Ql, Q3), nmol/L"
"14338";"Lipoprotein(a) (mg/dL)"
"14339";"Lipoprotein(a) (nmol/L)"
"14340";"LIPS"
"14341";"Lira"
"14342";"Liraglutide"
"14343";"Liraglutide (« = 4668)"
"14344";"Liraglutide (1.8 mg) ± OAD"
"14345";"Liraglutide (N = 2487)"
"14346";"Liraglutide (n=1265)"
"14347";"Liraglutide (n=1538)"
"14348";"Liraglutide (n=1865)"
"14349";"Liraglutide (N=4,668)"
"14350";"Liraglutide (N=4668)"
"14351";"Liraglutide 1.8 mg (n= 94)"
"14352";"Liraglutide 1.8 mg (n=131)"
"14353";"Liraglutide 1.8 mg/day (n=225)"
"14354";"Liraglutide 3-0 mg (n=1505)"
"14355";"Liraglutide 3-0 mg Mean (n)"
"14356";"liraglutide 3.0 mg"
"14357";"Liraglutide 3.0 mg LS means (N)"
"14358";"Liraglutide 3.0 mg Mean (n)"
"14359";"Liraglutide 3.0 mg n = 115"
"14360";"Liraglutide 3.0 mg n = 2845"
"14361";"Liraglutide 3.0 mg n = 348"
"14362";"Liraglutide 3.0 mg n = 76"
"14363";"liraglutide 3.0 mg,"
"14364";"liraglutide 3.0 mg, n = 1,581"
"14365";"liraglutide 3.0 mg, n = 185"
"14366";"liraglutide 3.0 mg, n = 227"
"14367";"liraglutide 3.0 mg, n = 856"
"14368";"Liraglutide N(%)"
"14369";"Lis"
"14370";"LIS"
"14371";"Lisinopril"
"14372";"Lisinopril (N = 102)"
"14373";"Lisinopril CVD Total"
"14374";"Lisinopril vs Amlodipineb"
"14375";"Lisinopril vs Chlorthalidone"
"14376";"Lisinopril vs Chlorthalidone Normal"
"14377";"Lisinopril vs Chlorthalidone Obese"
"14378";"Lisinopril vs Chlorthalidone Overweight"
"14379";"Lisinopril/Chlorthalidone"
"14380";"LISRs"
"14381";"LITHE"
"14382";"Lived alone"
"14383";"Liver disorder"
"14384";"Lixi"
"14385";"Lixisenatide"
"14386";"Lixisenatide (N = 3034)"
"14387";"Lixisenatide (n=225O)"
"14388";"Lixisenatide (n=552)"
"14389";"ll (4)"
"14390";"LL, n (%)"
"14391";"ll5 (34)"
"14392";"lleocolon"
"14393";"lll-IV"
"14394";"lll/IV"
"14395";"LLPASI 75"
"14396";"Llraglutide 3-0 mg Mean (n)"
"14397";"LLT other than statin at randomization"
"14398";"llv wlalil 1 Statin"
"14399";"LM Bifurcation Not Treated"
"14400";"LM Bifurcation Treated"
"14401";"LM25 258"
"14402";"LM25 bid (N = 114)"
"14403";"LM25 bid (N = 51)"
"14404";"LM25 bid (N = 71)"
"14405";"LMWH"
"14406";"LMWH within 7 days before randomization — no./total no. (%)"
"14407";"lntensityd"
"14408";"LO(LO-LO)"
"14409";"Loading dose of clopidogrel or ticlopidine"
"14410";"Locafon of index DVT"
"14411";"Local eosinophil count"
"14412";"Local eosinophil count (cells per pL)t"
"14413";"Local eosinophil count [cells/µL], median (range)"
"14414";"Local eosinophil count [cells/mL], median (range)"
"14415";"Locally advanced"
"14416";"Location"
"14417";"Location of Crohn's disease, %"
"14418";"Location of disease, n (%)"
"14419";"Location of infarction"
"14420";"Location of infarction — no. (%)§"
"14421";"Location of Ml"
"14422";"Location of treatment center"
"14423";"Location, n (%)"
"14424";"LOCF)"
"14425";"Log-Rank"
"14426";"Log-Rank P Value"
"14427";"Log Rank P-value"
"14428";"Logistic regression"
"14429";"Lone atrial fibrillation — no. (%)§"
"14430";"Long-acting"
"14431";"Long-acting b2-agonists"
"14432";"Long-acting bronchodilator use at screening"
"14433";"Long-acting nitrate"
"14434";"Long-acting nitrate agents"
"14435";"Long-acting nitrates"
"14436";"Long-acting or short-acting nitrates"
"14437";"Long-acting, intermediate/long-acting + fast-acting"
"14438";"Long-acting^"
"14439";"Long-standing persistent"
"14440";"Long-term antiplatelet therapy"
"14441";"Long-term aspirin"
"14442";"Long-term treatment with aspirin — no./total no. (%)"
"14443";"Long-term vitamin K antagonist"
"14444";"Long-term VKA therapy"
"14445";"Long-Term Warfarin (n - 382)"
"14446";"Long-Term Warfarin (n = 382)"
"14447";"Long (>10 years) Duration of Diabetes"
"14448";"Long (>40mm) stenting Yes (N=1193)"
"14449";"Long (i10 years) duration of diabetes"
"14450";"Long acting nitratef"
"14451";"Long term (n = 331)+"
"14452";"Long term VKA Therapy"
"14453";"Long term*"
"14454";"Loop"
"14455";"Loop at enrollment"
"14456";"Loop at last follow-up"
"14457";"Loop diuretic"
"14458";"Loop diuretic use"
"14459";"Loop diuretics"
"14460";"Loop diureties"
"14461";"Loop or thiazide diuretic"
"14462";"Loop or thiazide diuretic#"
"14463";"Loop or thiazide diuretic:!:"
"14464";"Loop or thiazide diuretic^"
"14465";"lor II"
"14466";"Losartan"
"14467";"Losartan (n = 1,004)"
"14468";"Losartan (n = 264)"
"14469";"Losartan (n = 270)"
"14470";"Losartan (n = 3,601)"
"14471";"Losartan (n = 4,355)"
"14472";"Losartan (n = 605)"
"14473";"Losartan (n = 660)"
"14474";"Losartan (n=2098)"
"14475";"Losartan (N=2118)"
"14476";"Losartan (N=2487)"
"14477";"Losartan (n=2507)"
"14478";"Losartan (n=586)"
"14479";"Losartan n=26"
"14480";"Losartan n=387"
"14481";"Losartan n=648"
"14482";"Losartan plus Lisinopril (N=724)"
"14483";"Losartan plus Placebo (N = 724)"
"14484";"Losartan, n/N (%)"
"14485";"Losartan+ Lisinopril"
"14486";"Losartan+ Placebo"
"14487";"Losmapimod"
"14488";"Losmapimod (n = 1731)"
"14489";"Loss of response"
"14490";"Loss of response:!::!:"
"14491";"Loss of response‘s"
"14492";"Loss of response®"
"14493";"Lost BMD"
"14494";"Lovastatin 80 mg"
"14495";"Low"
"14496";"low-ceiling diuretic"
"14497";"Low-density lipoprotein"
"14498";"Low-density Lipoprotein choles-"
"14499";"Low-density lipoprotein cholesterol — mg/dlf"
"14500";"Low-density lipoprotein cholesterol Tx difference vs Pbo, LS mean % change from baseline (SE)"
"14501";"Low-density lipoprotein cholesterol, %"
"14502";"Low-density lipoprotein cholesterol, mean (SD), mmol/L"
"14503";"Low-density lipoprotein cholesterol, median, (25th—75th percentiles), mg/dL"
"14504";"Low-density lipoprotein cholesterol, mg/dL"
"14505";"Low-density Lipoprotein cholesterol, mg/dL"
"14506";"Low-density lipoprotein^"
"14507";"Low-dose aspirin use"
"14508";"Low-dose aspirin use at baseline"
"14509";"Low-dose aspirin use at baseline Yes"
"14510";"Low-dose aspirin use strata* n (%)"
"14511";"Low-dose aspirin use. strata*, n (%)"
"14512";"Low-dose Corticosteroid User"
"14513";"Low-dose edoxaban"
"14514";"Low-Dose Edoxaban (N = 7034)"
"14515";"Low-dose edoxaban vs warfarin"
"14516";"Low-dose rivaroxaban + aspirin (n/N)"
"14517";"Low-dose rivaroxaban + aspirin group"
"14518";"Low-dose rivaroxaban plus aspirin (n=2492)"
"14519";"Low-dose rivaroxaban plus aspirin (n=8313)"
"14520";"Low-dose statin"
"14521";"Low-Medium Microalbuminuria (n=642)"
"14522";"Low-molecular-weight"
"14523";"Low-molecular-weight heparin"
"14524";"Low-molecular-weight heparin — no. (%)"
"14525";"Low-molecular-weight heparin only"
"14526";"Low-molecular-weight only"
"14527";"Low-molecular weight heparin or intravenous unfractionated heparin"
"14528";"Low-trauma fracture since age 45, n (%)"
"14529";"Low (<25 kg/m^) Baseline BMI"
"14530";"Low (<25 kg/m2) baseline BMI"
"14531";"Low (<5%)"
"14532";"Low (<8 %) baseline HbA1c"
"14533";"Low (<8%) Baseline HbAlc"
"14534";"Low (>2.8 and <10)"
"14535";"Low (>3.3 and <11)"
"14536";"Low (0-1) (n = 8,032; 45%)"
"14537";"Low (0-1), %"
"14538";"Low (0-2)"
"14539";"Low (N=133)"
"14540";"Low (no risk factor)"
"14541";"Low {<5%)"
"14542";"Low body weight (<60 kg)"
"14543";"Low C3 (<0.9 g/L)"
"14544";"Low C3 (<90 mg/dl), %"
"14545";"Low C3/C4 and anti-dsDNA"
"14546";"Low C4 (<0.18 g/L)"
"14547";"Low C4 (<16 mg/dl), %"
"14548";"low complement/anti-dsdNA positive (n=876)"
"14549";"Low density lipoprotein cholesterol - mg/dLTT"
"14550";"Low density lipoprotein cholesterol, mg/dL**"
"14551";"Low Dose"
"14552";"Low Dose Combination Therapy"
"14553";"Low Eosinophil Subgroup (,260/ml) (n = 383)"
"14554";"Low FENO Subgroup (,19.5 ppb) (n = 193)"
"14555";"Low HDL-C"
"14556";"Low HDL-C (for men <40 mg/dL / for women <50 mg/dL)"
"14557";"Low HDL cholesterol"
"14558";"Low HDL cholesterol* |"
"14559";"Low molecular weight (LMW) heparin before randomisation"
"14560";"Low molecular weight heparin"
"14561";"Low NAFLD Fibrosis Score (NFS < -1.455)"
"14562";"Low NFS NFS <-1.455 (N = 5440)"
"14563";"Low Normal (n=508)"
"14564";"Low or moderate"
"14565";"Low Periostin Subgroup (,50 ng/ml) (n = 279)"
"14566";"Low potencyc"
"14567";"Low renin (PRA <0.65 ng/mL/h) (n=178)"
"14568";"Low risk"
"14569";"Low risk (-ICS)"
"14570";"Low risk (?ICS)"
"14571";"Low risk (0-10)"
"14572";"Low risk (0-3)"
"14573";"Low risk (N 5 2610)"
"14574";"Low Risk (RI=0-1)"
"14575";"Low risk and fewer symptoms (Group A)"
"14576";"Low risk and more symptoms (Group B)"
"14577";"Low Subgroup"
"14578";"Low to Medium Microalbuminuria (n=642)"
"14579";"Low TRS: 0-2 (n = 1,704)"
"14580";"Low TT<10.41 (N = 311)"
"14581";"Low, %"
"14582";"Low’"
"14583";"lower"
"14584";"Lower-dose"
"14585";"Lower-limb angioplasty or bypass surgery"
"14586";"Lower-limb arterial — no. (%)"
"14587";"Lower-target group (n=1501)"
"14588";"Lower dose"
"14589";"Lower dose edoxaban regimen"
"14590";"Lower limb fracture"
"14591";"Lower limb fractures"
"14592";"Lower limbs"
"14593";"Lower risk"
"14594";"Lower Risk (n=4282)"
"14595";"Lower tertile: b 0.23"
"14596";"Lower than normal range — %^"
"14597";"lowering drugs"
"14598";"Lowest"
"14599";"Lowest activated clotting"
"14600";"Lowest Normal (n=640)"
"14601";"Lowest Tertile (Range, 0.9-1.6 mg/dl; Mean ± SD, 1.4 ± 0.1 mg/dl)"
"14602";"Lowest TG tertile"
"14603";"LowZmedium intensity"
"14604";"Lp(a) (μmol/L)"
"14605";"Lp(a) (pmol/L)"
"14606";"Lp(a) (week 24)"
"14607";"Lp(a), mean (SD)"
"14608";"Lp(a), median (Q1:Q3)"
"14609";"Lp(a), mg/dL, median (Q1:Q3)"
"14610";"Lp(a), nmol/l, mean (SD)"
"14611";"Lp(a)§"
"14612";"Lpa, mg/dL"
"14613";"LRG"
"14614";"LS-mean between-group difference (95% CI)"
"14615";"LS-mean change from baseline (95% CI)"
"14616";"LS-mean difference between treatment groups (95% CI)"
"14617";"LS-mean difference® (95% Cl)"
"14618";"LS mean"
"14619";"LS Mean"
"14620";"LS mean       (SE)"
"14621";"LS mean % change from baseline _ SE"
"14622";"LS mean (95% CI)"
"14623";"LS Mean (95% CI)"
"14624";"LS mean (95% CI), %"
"14625";"LS mean (95% CI), mmol/mol"
"14626";"LS mean (95% CI)a"
"14627";"LS mean (s.e.) primary endpoint: % change from baseline to week 24"
"14628";"LS mean (SE)"
"14629";"LS Mean (SE)"
"14630";"LS mean [95% CI] treatment difference vs placebo"
"14631";"LS mean ± SE"
"14632";"LS mean change"
"14633";"LS mean change (SE)"
"14634";"LS mean change ± SEa"
"14635";"LS mean change from baseline"
"14636";"LS mean change from baseline (SE)"
"14637";"LS mean change from baseline (SE), %"
"14638";"LS mean change from baseline, mL (SE)a"
"14639";"LS mean change from baseline1"
"14640";"LS mean change from baseline2"
"14641";"LS mean change from baseline3"
"14642";"LS mean difference (95% CI)"
"14643";"LS mean difference (95% Cl)"
"14644";"LS Mean Difference (SE)"
"14645";"LS mean difference (SE) vs placebo"
"14646";"LS mean difference ± SEb"
"14647";"LS mean difference vs placebo (95% CI)"
"14648";"LS mean difference vs placebo (95%CI)"
"14649";"LS mean treatment difference (95% CI)"
"14650";"LS means difference (95% CI)3"
"14651";"LS means difference (95% CI)a"
"14652";"LS T-score < —2.5"
"14653";"ls/ul 655    631"
"14654";"LSM (95% CI)"
"14655";"LSM (95% Cl)"
"14656";"LSM difference"
"14657";"LSM difference (95% Cl)"
"14658";"LSMs difference (95% CI)3"
"14659";"LTA (max response to 20 pM ADP) defined HPR (% patients)"
"14660";"LTBR (ng/ml)"
"14661";"LTG-exposed"
"14662";"LTG-naive"
"14663";"LTG subgroup, n = 220"
"14664";"LTT other than statin"
"14665";"lU/kg"
"14666";"lue for interaction"
"14667";"Lumbar"
"14668";"Lumbar epidural"
"14669";"Lumbar spine"
"14670";"Lumbar spine BMD T-"
"14671";"Lumbar spine BMD T-score"
"14672";"Lunchb"
"14673";"Lung"
"14674";"Lung function, mean"
"14675";"Lung infection"
"14676";"Lung neoplasm malignant"
"14677";"LUTS = lower urinary tract symptoms; IS ="
"14678";"LUTS severity"
"14679";"LUTS/BPH characteristics"
"14680";"LV diastolic dysfunction, n (%)"
"14681";"LV ejection fraction"
"14682";"LV ejection fraction (%)"
"14683";"LV ejection fraction >40% and <50%,"
"14684";"LV ejection fraction, % (n=7869)"
"14685";"LV ejection fraction, mean (SD) [range], %"
"14686";"LV ejection fractionb"
"14687";"LV Function"
"14688";"LV function >0.40 and <0.50, n (%) Medications, n (% of patients)"
"14689";"LV Heart Structure"
"14690";"LV hypertrophy per ECG"
"14691";"LV hypertrophy, n (%)"
"14692";"LV mass"
"14693";"LV mass index (g/m2-7)"
"14694";"LV mass index (mg/m2)"
"14695";"LV systolic dysfunction, n (%)"
"14696";"LVDd (mm)"
"14697";"LVEDV (ml)"
"14698";"LVEF"
"14699";"LVEF — no. (%);i;"
"14700";"LVEF (%)"
"14701";"LVEF (%), mean ± SD"
"14702";"LVEF (mean ± SD)"
"14703";"LVEF (U)"
"14704";"LVEF < 30%"
"14705";"LVEF <0.40"
"14706";"LVEF <33%"
"14707";"LVEF <40%"
"14708";"LVEF <40%, N = 917 947)“"
"14709";"LVEF ≤40%, N = 302 278a"
"14710";"LVEF ≤40%, N = 917 947)a"
"14711";"LVEF >33%"
"14712";"LVEF >40%"
"14713";"LVEF within 6 mo, %"
"14714";"LVEF within 6 months, %"
"14715";"LVEF, %"
"14716";"LVEF, %, median (IQR)"
"14717";"LVEF,%, median (IQR)"
"14718";"LVEF^0.40 and NYHA class II, III at baseline"
"14719";"LVEF<30%"
"14720";"LVEF>30%"
"14721";"LVESV (ml)"
"14722";"LVH"
"14723";"LVH - N = 2652"
"14724";"LVH -N =2666"
"14725";"LVH -N =2701"
"14726";"LVH (from echocardiogram)"
"14727";"LVH (from electrocardiogram)"
"14728";"LVH +N = 771"
"14729";"LVH +N =791"
"14730";"LVH by ECG"
"14731";"LVH by ECG (Minnesota code)"
"14732";"LVH by ECG or Echo. n (%)"
"14733";"LVH by ECG or echocardiography, No (%)"
"14734";"LVH by ECG or echocardiographyd"
"14735";"LVH by ECG/Echo"
"14736";"LVH by ECGt Blood pressure, mm HG"
"14737";"LvH by echo or EcG"
"14738";"LVH by echocardiogram"
"14739";"LVH by echocardiography"
"14740";"LVH by electrocardiogram"
"14741";"LVH by electrocardiogram, n (%)"
"14742";"LVH by Minnesota code"
"14743";"LVH by Minnesota code, No. (%)"
"14744";"LVH on ECG"
"14745";"LVMI (61"
"14746";"lyear mean change from baseline"
"14747";"Lymphadenopathy"
"14748";"Lymphocytes, 103/+il"
"14749";"M"
"14750";"M being"
"14751";"M/F"
"14752";"M1 subgroup"
"14753";"M2 subgroup"
"14754";"M3 subgroup"
"14755";"M6S"
"14756";"mab"
"14757";"MACCE"
"14758";"MACCE (%)"
"14759";"MACCE (%) Abciximab Placebo"
"14760";"MACCE (death, MI, stroke)"
"14761";"MACCE (Death, MI, Stroke)"
"14762";"MACE"
"14763";"MACE category, N (%) [IR]"
"14764";"MACE+"
"14765";"Macro-albuminuria"
"14766";"Macroalbuminuria"
"14767";"Macroalbuminuria — no. (%) Drug therapy — no. (%)"
"14768";"Macroalbuminuria — no./total no. (%)"
"14769";"Macroalbuminuria (UACR >300)"
"14770";"Macroalbuminuria at baseline (11% of patients treated)"
"14771";"Macroalbuminuria, n (%)"
"14772";"Macroalbuminuriaf"
"14773";"Macrovascular disease, n (%)"
"14774";"Mae"
"14775";"MAF"
"14776";"Mafcaiancy at randorrtzaton"
"14777";"Magnetic resonance angiography"
"14778";"Main concomitant treatments, No. (%)"
"14779";"Main effect Baseline hormone"
"14780";"Main Etiology of Heart Failure"
"14781";"Maintenance dose"
"14782";"Maintenance OCS use, n (%)"
"14783";"Maintenance use — no. (%)"
"14784";"Major"
"14785";"Major adverse cardiovascular events"
"14786";"Major amputationsb"
"14787";"Major and CRNM bleeds"
"14788";"Major bleed"
"14789";"Major Bleed"
"14790";"major bleeding"
"14791";"Major bleeding"
"14792";"Major Bleeding"
"14793";"Major Bleeding (MB)"
"14794";"Major bleeding (statin use vs non-use)"
"14795";"Major bleeding 0 to 1"
"14796";"Major bleeding events*"
"14797";"Major cardiovascular"
"14798";"Major cardiovascular event"
"14799";"Major Cardiovascular Event*"
"14800";"Major cardiovascular events"
"14801";"Major cerebrovascular"
"14802";"Major clinical response"
"14803";"Major coronary"
"14804";"Major coronary disease event (Fatal/Non-fatal MI)"
"14805";"Major coronary event"
"14806";"Major CV Event"
"14807";"Major CVD/"
"14808";"Major diabetic eye disease, n (%)"
"14809";"Major gastro-intestinal bleeding"
"14810";"Major Gl Bleeding"
"14811";"Major Hypoglycemia"
"14812";"Major macrovascular events"
"14813";"Major or clinically relevant non-major bleed"
"14814";"major or clinically relevant non-major bleeding"
"14815";"Major secondary end pointf"
"14816";"Major ST depression or"
"14817";"Major ST depression or T-wave"
"14818";"Major ST depression or T-wave inversion"
"14819";"Major surgery"
"14820";"Major/CRNM bleed"
"14821";"Malaysia"
"14822";"male"
"14823";"Male"
"14824";"MALE"
"14825";"Male - no. (%)"
"14826";"Male (%)"
"14827";"Male (n - 257)"
"14828";"Male (n = 1171)"
"14829";"Male (N = 1171)"
"14830";"Male (n = 4,128)"
"14831";"Male (N = 802)"
"14832";"Male (N =1802)"
"14833";"Male (n = 4,631)"
"14834";"Male (n=102, 42)"
"14835";"Male (N=190)"
"14836";"Male (n=308, 306)"
"14837";"Male (N=3498)"
"14838";"Male (n=4970)"
"14839";"Male (n=6,183)"
"14840";"Male (n=6183)"
"14841";"Male (n=97, 40)"
"14842";"Male ACR definition, ^.g/mg"
"14843";"Male EZE/SIMVA"
"14844";"Male EZE/SIMVA („ = 591}"
"14845";"Male EZE/SIMVA (n = 591)"
"14846";"Male gender"
"14847";"male gender (%)"
"14848";"Male gender (%)"
"14849";"Male gender, n (%)"
"14850";"Male gender, n (%)"
"14851";"Male NYHA class"
"14852";"Male patients*"
"14853";"Male patients, n (%)"
"14854";"Male sex"
"14855";"Male sex— no. (%)"
"14856";"Male sex— no. (%) Race — no. (%)):"
"14857";"Male sex— no. {%)"
"14858";"Male sex — %"
"14859";"Male sex — no. (%)"
"14860";"Male sex — no. (%) Medical history — no./total no. (%)"
"14861";"Male sex — no. (%) Risk factors"
"14862";"Male sex — no. (%) Weight — no. (%)"
"14863";"Male sex — no. (%)f"
"14864";"Male sex — no. {%)"
"14865";"Male sex — no. of patients (%)"
"14866";"Male sex — no./total no. (%)"
"14867";"Male sex (%)"
"14868";"Male sex (%) Race or ethnic group (%)f"
"14869";"Male sex \ no. (%)"
"14870";"Male sex 一no. (%)"
"14871";"Male sex, %"
"14872";"Male sex, (%)"
"14873";"Male sex, n (%)"
"14874";"Male sex, N (%)"
"14875";"Male sex, n [%]"
"14876";"Male sex, no. (%)"
"14877";"Male sex, No. (%)"
"14878";"Male sex, No./total No. (%)"
"14879";"Male sex^"
"14880";"Male SIMVA"
"14881";"Male SIMVA („ = 589}"
"14882";"Male SIMVA (n = 589)"
"14883";"Male subjects (n = 3,875)"
"14884";"Male vs. female"
"14885";"Male(%)"
"14886";"Male(n-4970)"
"14887";"Male(n=1902)"
"14888";"Male*, n (%)"
"14889";"Male, %"
"14890";"Male, % (n)"
"14891";"Male, n"
"14892";"Male, n (%)"
"14893";"Male, N (%)"
"14894";"Male, n(%)"
"14895";"Male, n/N (%)"
"14896";"Male, no (%)"
"14897";"Male, n (%)"
"14898";"Male/female"
"14899";"Male/female, %"
"14900";"Males"
"14901";"Males (%)"
"14902";"Males (ITT) (n=1212)"
"14903";"Males (ITT) (n=1219)"
"14904";"Males (ITT) (n=1227)"
"14905";"Males (ITT) (n=1639)"
"14906";"Males (ITT) (n=1658)"
"14907";"Males (n=1100)"
"14908";"Males [n (% )]"
"14909";"Males, %"
"14910";"Males, <1.00"
"14911";"Males, <30"
"14912";"Males, >1.00"
"14913";"Males, >30"
"14914";"Males, n (%)"
"14915";"Malignancy at randomization"
"14916";"Malignancy death"
"14917";"Managed medically — no./total no. (%)"
"14918";"Management distribution"
"14919";"Management distribution Medical treatment"
"14920";"Management of event — no. (%)"
"14921";"MAP (mmHg)"
"14922";"MAR (ITT) (n=1532)"
"14923";"MAR imputation (Random.) (n=1613)"
"14924";"MAR Imputation (Random.) (n=1613)"
"14925";"MAR imputation (Random.) (n=1616)"
"14926";"MAR Imputation (Random.) (n=1616)"
"14927";"MAR imputation (Random.) (n=2153)"
"14928";"MAR Imputation (Random.) (n=2153)"
"14929";"Married"
"14930";"MASES (0-13), mean (SD)"
"14931";"mass index;"
"14932";"Mate"
"14933";"MATE!"
"14934";"Maternal history, n (%)"
"14935";"Maximal diameter stenosis"
"14936";"Maximum"
"14937";"Maximum CIMT < Median"
"14938";"Maximum CIMT a Med an"
"14939";"Mayo $10, N"
"14940";"Mayo <10, N"
"14941";"Mayo Clinic score, mean ± SD"
"14942";"Mayo Clinic score§"
"14943";"Mayo Clinic scoreb"
"14944";"Mayo score (0-12)"
"14945";"Mayo score, mean (SD)"
"14946";"MBEs/CRBEsb, n/N (%)"
"14947";"MBEs/CRBEsc,"
"14948";"MBEsb, n/N (%)"
"14949";"MBEsc, n/N (%)"
"14950";"MCA"
"14951";"MCS score"
"14952";"MCS score (0–100 scale)"
"14953";"MDG (mmol/L)"
"14954";"MDI"
"14955";"MDRD-eGFR (ml/min per 1.73 m2)"
"14956";"MDRD eGFR geometric mean (CV%),a,b ml/"
"14957";"MDRD eGFR, mL/min/1.73 m2"
"14958";"Mean"
"14959";"Mean — %"
"14960";"Mean — g/dl"
"14961";"Mean — kg"
"14962";"Mean — mg/dl"
"14963";"Mean — mg/dl Level — no. (%)"
"14964";"Mean — ml/min"
"14965";"Mean — ml/min/1.73 m^"
"14966";"Mean — ml/min/1.73 m2"
"14967";"Mean — ml/min/1.73 m2 Level — no. (%)"
"14968";"Mean — ml/min/1.73 m2 of body-surface area"
"14969";"Mean — ml/min/1.73m2"
"14970";"Mean — mm Hg"
"14971";"Mean — mm Hg Level — no. (%)"
"14972";"Mean — yr"
"14973";"Mean — yr Age group — no. (%)"
"14974";"Mean % change in FN BMD"
"14975";"Mean % predicted DLco* (SD)"
"14976";"Mean % predicted FVC (SD)"
"14977";"Mean % predicted value prebronchodilation"
"14978";"Mean (= SD) days since"
"14979";"Mean (±s.d.)"
"14980";"Mean (±SD) baseline score"
"14981";"Mean (±SD) change from"
"14982";"Mean (25th to75thquartile) BNP (pg/ml)"
"14983";"Mean (95% CI) change from 0.5 to 1.0 mg, %"
"14984";"Mean (95% CI) change from 0.5 to 1.0 mg, %‐points"
"14985";"Mean (95% CI) difference vs SAXA+DAPA+MET"
"14986";"Mean (median) MTX dose, mg/week"
"14987";"mean (s.d.)"
"14988";"Mean (s.d.)"
"14989";"Mean (s.d.) age, years"
"14990";"Mean (s.d.) ApoB, mg/dL"
"14991";"Mean (s.d.) ApoC-ll 1, mg/dL"
"14992";"Mean (s.d.) baseline FPG, mmol/l"
"14993";"Mean (s.d.) baseline HbA1C, %"
"14994";"Mean (s.d.) BMI, kg/m2"
"14995";"Mean (s.d.) calculated LDL cholesterol"
"14996";"Mean (s.d.) diastolic blood pressure, mm Hg"
"14997";"Mean (s.d.) duration of T2DM, years"
"14998";"Mean (s.d.) eGFR, mL/min/1.73 m2"
"14999";"Mean (s.d.) FPG"
"15000";"Mean (s.d.) free PCSK9, ng/mL"
"15001";"Mean (s.d.) HbAlc, %"
"15002";"Mean (s.d.) HbAlc, mmol/mol"
"15003";"Mean (s.d.) HDL cholesterol"
"15004";"Mean (s.d.) LDL particle number, nmol/L"
"15005";"Mean (s.d.) LDL particle size, nm"
"15006";"Mean (s.d.) measured LDL cholesterol"
"15007";"Mean (s.d.) metformin dose†, mg/day"
"15008";"Mean (s.d.) non-HDL cholesterol"
"15009";"Mean (s.d.) systolic blood pressure, mm Hg"
"15010";"Mean (s.d.) total PCSK9, ng/mL"
"15011";"Mean (s.d.) weight, kg"
"15012";"Mean (s.e.)"
"15013";"Mean (s.e.)t"
"15014";"mean (SD on loge scale) U/ml"
"15015";"mean (SD)"
"15016";"Mean (SD)"
"15017";"Mean (SD) % of predicted normal EEVi"
"15018";"Mean (SD) % of predicted normal FEV1"
"15019";"Mean (SD) % of predicted normal FEVi"
"15020";"mean (SD) % reversibility FEV1 at"
"15021";"Mean (SD) (years)"
"15022";"Mean (SD) [range]"
"15023";"Mean (SD) [range] duration of epilepsy, years"
"15024";"Mean (SD) 56.6 (9.2)"
"15025";"Mean (SD) age (years)"
"15026";"Mean (SD) age in years"
"15027";"Mean (SD) age,"
"15028";"Mean (SD) age, y"
"15029";"Mean (SD) age, y Race, n (%)*"
"15030";"Mean (SD) age, years"
"15031";"Mean (SD) age, yr"
"15032";"Mean (SD) anthropometry"
"15033";"Mean (SD) AQLQ"
"15034";"Mean (SD) Baseline"
"15035";"Mean (SD) baseline scores"
"15036";"Mean (SD) BMD in g/cm2"
"15037";"Mean (SD) BMI"
"15038";"Mean (SD) BMI (kg/m2)"
"15039";"Mean (SD) BMI, kg/m2"
"15040";"Mean (SD) body mass index, kg/m2"
"15041";"Mean (SD) calcium intake in mg daily"
"15042";"Mean (SD) CDAI*"
"15043";"Mean (SD) change from pre- to post-bronchodilator FEV1, L"
"15044";"Mean (SD) change from pre- to post-bronchodilator FEVi, mL"
"15045";"Mean (SD) change from pre- to post-bronchodilator FEVi, niL"
"15046";"Mean (SD) CRP, mg/L*"
"15047";"Mean (SD) DAS28-4(ESR)*"
"15048";"Mean (SD) disease duration, years"
"15049";"Mean (SD) duration of COPD, years"
"15050";"Mean (SD) duration of smoking, pack-years"
"15051";"Mean (SD) duration of smoking, pack years"
"15052";"Mean (SD) duration of T2DM, y"
"15053";"Mean (SD) E-ETDRS visual acuity letter score (Snellen equivalent)"
"15054";"Mean (SD) EEVi, mL"
"15055";"Mean (SD) eGFR, mL/min/1.73 m2"
"15056";"Mean (SD) ESR, mm/h*"
"15057";"Mean (SD) extent of exposure, days"
"15058";"Mean (SD) FENO, ppb"
"15059";"Mean (SD) FEV 1 , L"
"15060";"Mean (SD) FEV 1 /FVC, %"
"15061";"Mean (SD) FEV1 (L) post-bronchodilator"
"15062";"Mean (SD) FEV1 (L) pre-bronchodilator"
"15063";"Mean (SD) FEV1 postbronchodilator, L"
"15064";"Mean (SD) FEV1, L"
"15065";"Mean (SD) FEV1/FVC, %"
"15066";"Mean (SD) FEVi, mL"
"15067";"Mean (SD) FEVi/EVC, %"
"15068";"Mean (SD) FEVi/FVC, %"
"15069";"Mean (SD) HbA1c level, %"
"15070";"Mean (SD) HbA1c, %"
"15071";"Mean (SD) improvement from baseline to week 12 in BASDAI"
"15072";"Mean (SD) improvement from baseline to week 24 in BASDAI"
"15073";"Mean (SD) improvement from baseline to week 24 in BASDAI questions*"
"15074";"Mean (SD) MTX dose, mg/week"
"15075";"Mean (SD) nonstudy eye E-ETDRS visual acuity letter score"
"15076";"Mean (SD) number of albuterol per day, puff"
"15077";"Mean (SD) number of exacerbations*"
"15078";"Mean (SD) pain VAS*"
"15079";"Mean (SD) periostin, ng/ml"
"15080";"Mean (SD) PGA VAS*"
"15081";"Mean (SD) post-bronchodilator"
"15082";"Mean (SD) post-bronchodilator FEV1 percentage predicted"
"15083";"Mean (SD) post-bronchodilator FEV1 reversibility, %"
"15084";"Mean (SD) post-bronchodilator FEV1/FVC, %"
"15085";"Mean (SD) postbronchodilator FeV1 % predicted"
"15086";"Mean (SD) postbronchodilator FeV1 reversibility, %"
"15087";"Mean (SD) postbronchodilator FeV1/FVC, %"
"15088";"Mean (SD) pre-bronchodilator"
"15089";"Mean (SD) PtGA VAS*"
"15090";"Mean (SD) SDAI*"
"15091";"Mean (SD) swollen joint count*"
"15092";"Mean (SD) tender joint count*"
"15093";"Mean (SD) total asthma symptom scores"
"15094";"Mean (SD) values are presented for all variables, except medical history, race or ethnic group, and sex (n, %) and urinary albumin/creatinine ratio (median (range)). aBody mass index is the weight in kilograms divided by the square of the height in meters. bTo convert values to micromoles per liter, multiply by 88.4. Estimated using the modified equation from the Modification of Diet in Renal Disease study. dTo convert values to millimoles per liter, multiply by 0.02586. eTo convert values to millimoles per liter, multiply by 0.01129. ^To convert values to millimoles per liter, multiply by 0.6206."
"15095";"Mean (SD) weight, kg"
"15096";"mean (SD) years Daily OCS use, n (%)"
"15097";"Mean (SD)% predicted normal FEV1"
"15098";"mean (SD), kg/m2"
"15099";"mean (SD), mg/kg2"
"15100";"mean (SD), mmHg"
"15101";"mean (SD), ng/mL£"
"15102";"Mean (SD), y"
"15103";"mean (SD)d"
"15104";"Mean (SE)"
"15105";"Mean (SE) 6-Year Rates per 100 Population"
"15106";"Mean (SE) AUC^p L"
"15107";"Mean (SE) AUC0-3, L"
"15108";"Mean (SE) trough L"
"15109";"Mean (SE) trough, L"
"15110";"mean *"
"15111";"Mean = SD"
"15112";"Mean ± s.d."
"15113";"Mean ± s.d. age, years"
"15114";"Mean ± s.d. duration of diabetes, years"
"15115";"Mean ± s.d. FPG"
"15116";"Mean ± s.d. HbA1c"
"15117";"Mean ± s.d. weight, kg"
"15118";"mean ± SD"
"15119";"Mean ± sd"
"15120";"Mean ± SD"
"15121";"Mean ± SD age (y) Mean BMI category (%)"
"15122";"mean ± SD mg (n = 98, 99, 99)"
"15123";"mean ± SD unless otherwise indicated"
"15124";"Mean ± SE"
"15125";"mean ± SE) BII (LS mean ± SE)"
"15126";"Mean ± SD"
"15127";"Mean ±SD"
"15128";"Mean ±SD (yr)"
"15129";"Mean 10-year CVD risk*"
"15130";"Mean 24-h DBP+"
"15131";"Mean 24-h SBP*"
"15132";"Mean 6 SD"
"15133";"Mean 6MWD*, m (SD)"
"15134";"Mean A ± SD (mmHg)"
"15135";"Mean A ± SD, mg/dl (mmol/1)"
"15136";"Mean A ± SDt"
"15137";"Mean A ± SEM (%)"
"15138";"Mean ACQ-6 score at randomization;!;"
"15139";"Mean ACQ-7 scores"
"15140";"Mean ACRn"
"15141";"Mean age — yr"
"15142";"Mean age — yr (range)"
"15143";"Mean age (range) — yr"
"15144";"Mean age (SD)"
"15145";"Mean age (SD), y"
"15146";"Mean age (SD), years"
"15147";"Mean age (SD), yr"
"15148";"Mean age (y)"
"15149";"Mean age (y) (SD)"
"15150";"Mean age (years)"
"15151";"Mean age (years) (s.d.)"
"15152";"Mean age (years) Race"
"15153";"Mean age (years, SD)"
"15154";"Mean age (yr)"
"15155";"Mean age (yrs)"
"15156";"Mean age 士 s.d., year"
"15157";"Mean age ± s.d., year"
"15158";"Mean age ± s.d., years"
"15159";"Mean age, y"
"15160";"Mean age, y (range)"
"15161";"Mean age, y (SD)"
"15162";"Mean age, y, mean = SD"
"15163";"Mean age, y, median (range)"
"15164";"Mean age, y: (range)"
"15165";"Mean age, years"
"15166";"Mean age, years (range)"
"15167";"Mean age, years (SD)"
"15168";"Mean age, years± SD"
"15169";"Mean age, yrs"
"15170";"Mean age±SD (years)"
"15171";"Mean AlC, %"
"15172";"Mean annualized exacerbation rate"
"15173";"Mean AQLQ total score t"
"15174";"Mean arterial pressure, baseline"
"15175";"Mean arterial pressure, difference"
"15176";"Mean arterial pressure, last"
"15177";"Mean ASUI scored"
"15178";"Mean baseline (n)"
"15179";"mean baseline bmi"
"15180";"mean baseline BMI"
"15181";"Mean baseline EI score"
"15182";"Mean baseline IBDQ score (SD)§ CRP concentration, mg/L"
"15183";"Mean Baseline LDL-C (mmol/L)"
"15184";"Mean baseline nasal congestion score"
"15185";"Mean baseline UCDAI score"
"15186";"Mean BDI focal score (SD)"
"15187";"Mean blood eosinophil count (cells per pL)"
"15188";"Mean blood pressure at screening visit (mm Hg)"
"15189";"Mean blood pressure, mm Hg"
"15190";"Mean blood pressure, mmHg (s.d.j"
"15191";"Mean BM1 ± s.d., kg/m2"
"15192";"Mean BMD (= SD), g/cm2"
"15193";"Mean BMI"
"15194";"Mean BMI (kg/m2) (SD)"
"15195";"Mean BMI (SD)"
"15196";"Mean BMI (SD),"
"15197";"Mean BMI (SD), kg/m2"
"15198";"Mean BMI ± s.d., kg/m^"
"15199";"Mean BMI ± s.d., kg/m2"
"15200";"Mean BMI, kg/m2"
"15201";"Mean BMI, kg/m2 (s.d.)"
"15202";"Mean BMI, kg/m2 (SD)"
"15203";"Mean BMI, kg/m2 ± SD"
"15204";"Mean BMI±SD (kg/m2)"
"15205";"Mean BMII 士 s.d., kg/m2"
"15206";"Mean body-mass index (= SD), kg/m2"
"15207";"Mean body-mass index (kg/mQ"
"15208";"Mean body-mass index, kg/m2"
"15209";"Mean body-mass index, kg/m2 (SD)*"
"15210";"Mean body-mass index, kg/m2 (SD)*"
"15211";"Mean body-mass indexj"
"15212";"Mean body mass index (kg/m2)"
"15213";"Mean body mass index (kg/m2)*"
"15214";"Mean body mass index (SD), kg/m2"
"15215";"Mean body mass index, kg/m2"
"15216";"Mean body weight (SD), kg"
"15217";"Mean body weight, kg (range)"
"15218";"mean BP (mmHg)"
"15219";"Mean CDAI score"
"15220";"Mean CDAI score (SD)"
"15221";"Mean change at week 30"
"15222";"Mean change from baseline in ACQ overall score (SD)*"
"15223";"Mean change from baseline in FEV1 % predicted, % (SD)*"
"15224";"Mean change from baseline in the number of"
"15225";"Mean change from baseline, %"
"15226";"Mean change from baseline, %‐points"
"15227";"Mean change in ACQ score"
"15228";"Mean change in DBP from baseline, mg/dL, mean(SD)"
"15229";"Mean change in FEV1"
"15230";"Mean change in radiographic end points"
"15231";"Mean change in radiographic end points SHS, mean ± SD"
"15232";"Mean change in SBP from baseline, mmHg, mean(SD)"
"15233";"Mean change in SGRQ"
"15234";"Mean change in total UPDRS scores adjusted according to baseline UPDRS"
"15235";"Mean change,"
"15236";"Mean change, % (SE)"
"15237";"Mean change,% (SE)"
"15238";"Mean change‘s in fasting blood glucose [mg/dL (mmol/L)]"
"15239";"Mean COPD duration, y (SD)"
"15240";"Mean CRP level, mg/L (SD)"
"15241";"Mean daily dose (range) — mg;i;"
"15242";"Mean diastolic blood pressure (SD), mm Hg"
"15243";"Mean diastolic blood pressure, mm Hg"
"15244";"Mean diastolic BP, mmHg, mean = SD"
"15245";"Mean difference (95% Cl)"
"15246";"Mean difference = SEb"
"15247";"Mean disease duration, y (SD)"
"15248";"Mean disease duration, years"
"15249";"Mean DlcO ± SD"
"15250";"Mean dose'’"
"15251";"Mean dose (SD) (mg/day)"
"15252";"Mean dose (SD) (mg/week)"
"15253";"Mean doseb"
"15254";"Mean duration of disease, years"
"15255";"Mean duration of PD, yr"
"15256";"Mean duration of surgery ± SD, min"
"15257";"Mean duration offollow-up (years)*"
"15258";"Mean eosinophil count, per ml"
"15259";"Mean fecal calprotectin level, mg/g stool (SD)"
"15260";"Mean femoral neck T score"
"15261";"Mean FEV1, L (SD)"
"15262";"Mean FPG, mmol/L"
"15263";"Mean FVC ± SD"
"15264";"Mean Glycated Hemoglobin Reduction during Characteristic Follow-up (95% CI) percent"
"15265";"Mean HbA1c ± s.d., %"
"15266";"Mean HbA1c, %"
"15267";"Mean HbA1c, mmol/mol†"
"15268";"Mean HbAic =•= s.d., %"
"15269";"Mean hsCRP, mg/L (SD)"
"15270";"Mean ICS (fluticasone propionate DPI or equivalent; pg per day)"
"15271";"Mean ICS use at enrolment (pg)*"
"15272";"Mean iGlar dose ± SD (U/day)"
"15273";"Mean IIEF EF score Mean IIEF domain score by BMI (<25/<25 to <30/<30 kg/m2)"
"15274";"Mean IPSS QoL (SD)"
"15275";"Mean IPSS, storage Sub-Score (SD)"
"15276";"Mean IPSS, voiding SubScore (SD)"
"15277";"Mean Lipid Difference (mg/dL) HDL-C"
"15278";"Mean lipid values, mg/dL"
"15279";"Mean Lixi dose ± SD (lg/day)"
"15280";"Mean lumbar spine T score"
"15281";"Mean LVEF"
"15282";"Mean Mayo score (SD)"
"15283";"Mean mMRC grade, units (SD)"
"15284";"Mean MMSE score"
"15285";"Mean No. agents (SD) Other medications"
"15286";"Mean number of antihypertensive medication at last visit ‡"
"15287";"Mean number of antihypertensive medications at 1 year *"
"15288";"Mean number of CAEs in past 12 months (number per patient)] |"
"15289";"Mean number of clinically significant asthma exacerbations†"
"15290";"Mean number of combined visits/hospitalizations†"
"15291";"Mean number of exacerbations (per patient-year [95% CI])"
"15292";"Mean number of exacerbations in previous 12 months (SD)"
"15293";"Mean number of exacerbations in previous y (SD)"
"15294";"Mean number of puffs per day"
"15295";"Mean of JSW (mm)"
"15296";"Mean of maximum CIMT, mean (SD), mm"
"15297";"Mean of mean CIMT, mean (SD), mm"
"15298";"Mean or n"
"15299";"Mean percentage change from baseline to final visit"
"15300";"Mean PGA score ±SD"
"15301";"Mean platelet volume, fL"
"15302";"Mean postbronchodilatora FEV1, % predicted (SD)"
"15303";"Mean prebronchodilation (L)"
"15304";"Mean prebronchodilator FEV1 (SD), % predicted"
"15305";"Mean preoperative ABPI of the index"
"15306";"Mean proportion (%)"
"15307";"Mean pulmonary artery pressure, mm Hg"
"15308";"Mean pulse pressure, mmHg (s.d.)“"
"15309";"Mean Qmax score by BMI (<25/ <25 to <30/ <30 kg/m2)"
"15310";"Mean reversibility (%)"
"15311";"Mean score"
"15312";"Mean score (min, max range)"
"15313";"Mean score on DAS28-3(CRP)^"
"15314";"Mean score on HAQ-DI§"
"15315";"Mean SD 24-h ASBP, mm Hg"
"15316";"Mean SD FPG, mg/dL"
"15317";"Mean SD HDL-C, mg/dL"
"15318";"Mean SD LDL-C, mg/dL"
"15319";"Mean SD MSSBP, mm Hg"
"15320";"Mean SELENA-SLEDAI score ±SD"
"15321";"Mean serum cholesterol, mg/dL"
"15322";"Mean serum creatinine, mg/dL"
"15323";"Mean serum glucose, mg/dL, mean = SD"
"15324";"Mean serum potassium, mg/dL"
"15325";"Mean SGRQ total score"
"15326";"Mean SGRQ total score (SD)"
"15327";"Mean sitting DBP (mmHg)"
"15328";"mean sitting diastolic blood pressure"
"15329";"Mean sitting SBP (mmHg)"
"15330";"mean sitting systolic blood pressure"
"15331";"Mean SLICC damage index score ±SD"
"15332";"Mean stent diameter per lesion, mm (SD)†"
"15333";"Mean stents per lesion (SD)‡"
"15334";"Mean systolic blood pressure (SD), mm Hg"
"15335";"Mean systolic blood pressure, mm Hg"
"15336";"Mean systolic blood pressure, mm Hg (SD)"
"15337";"Mean systolic BP, mmHg, mean = SD"
"15338";"Mean systolic pressure gradient"
"15339";"Mean Systolic Pressure Gradient"
"15340";"Mean time since AS diagnosis, years, mean ± SD"
"15341";"Mean time since asthma"
"15342";"Mean time since diagnosis (years)"
"15343";"Mean time since diagnosis, y"
"15344";"Mean time to first oral dose postsurgeryh, hr"
"15345";"Mean time to first subcutaneous injectiong,h in relation to surgery, hr"
"15346";"Mean total IPSS (SD)"
"15347";"Mean total IPSS Mean IPSS by BMI (<25/<25 to <30/<30 kg/m2)"
"15348";"Mean total serum IgE (SD), IU/ml"
"15349";"Mean total serum PSA"
"15350";"Mean total stent length per lesion, mm (SD)‡"
"15351";"Mean treatment exposure, wk"
"15352";"Mean UCSD-SOBQ score* (SD)"
"15353";"Mean wall thickness (cm)"
"15354";"Mean weight (SD), kg"
"15355";"Mean weight, kg (SD)"
"15356";"Mean weight, kg, mean = SD"
"15357";"Mean yearly decline"
"15358";"Mean years since menopause"
"15359";"Mean ± SD"
"15360";"Mean(SE)"
"15361";"Mean, mg/dL"
"15362";"Mean, mL (SD)"
"15363";"Mean, SD"
"15364";"mean_delta"
"15365";"Mean土SD (N)"
"15366";"Mean± SD"
"15367";"Mean±s.d. BMI,kg/m2"
"15368";"Mean±SD"
"15369";"Mean±SD (N)"
"15370";"Mean±SD 24-h ADBP, mm Hg"
"15371";"Mean±SD BMI, kg/m2"
"15372";"Mean±SD eGFR, mL/min/1.73 m2"
"15373";"Mean±SD fasting insulin, uU/mL"
"15374";"Mean±SD MSDBP, mm Hg"
"15375";"Mean±SD triglycerides, mg/dL"
"15376";"Mean±SD waist circumference, cm"
"15377";"Mean±SD, n"
"15378";"Mean±SD, n (%)"
"15379";"Measure"
"15380";"MEASURE"
"15381";"Measured at clinic visit with automated device§"
"15382";"Measured at clinic visit with usual device"
"15383";"Measured at home with automated device"
"15384";"Measurements"
"15385";"Measures"
"15386";"Measures (%)"
"15387";"Measures (mmol/l)"
"15388";"Measures of lung function"
"15389";"MEDAL"
"15390";"MedDRA SMQ"
"15391";"Medial-Distal-Diag"
"15392";"Median"
"15393";"Median — ml/min"
"15394";"Median — ml/min/1.73 m2"
"15395";"Median — vr"
"15396";"Median — yr"
"15397";"Median (25th, 75th percentile)"
"15398";"Median (95% CI) time to weekly ISS MID response up to week 12 (wk)f"
"15399";"Median (days)"
"15400";"Median (interquartile range)"
"15401";"Median (interquartile range) —yr"
"15402";"Median (IQ range)"
"15403";"Median (IQR)"
"15404";"Median (IQR) — yr"
"15405";"Median (IQR) admission data"
"15406";"Median (IQR) age, years"
"15407";"Median (IQR) Change from baseline to week 100 in PsA-modified total SHS score"
"15408";"Median (IQR) cholesterol,"
"15409";"Median (IQR) Mean6SDchange from baseline to week 100 by weight group and MTX use: Weight"
"15410";"median (IQR), h"
"15411";"median (min, max)"
"15412";"Median (min, max)"
"15413";"Median (minimum–maximum) focal seizure frequency/28 days at baseline"
"15414";"Median (Q1–Q3)"
"15415";"Median (Q1 :Q3)"
"15416";"Median (Q1, Q3)"
"15417";"Median (Q1,Q3)"
"15418";"Median (Q1:Q3) duration of diabetes, years"
"15419";"Median (Q1:Q3) duration of insulin use, years"
"15420";"Median (Q1:Q3) Lp(a), mg/dL"
"15421";"Median (Q1:Q3) TG-rich lipoprotein cholesterol"
"15422";"Median (Q1:Q3) TGs"
"15423";"Median (Q1:Q3) total daily insulin dose5"
"15424";"Median (range)"
"15425";"Median (range) duration of asthma (y)"
"15426";"Median (range) duration of asthma (years)"
"15427";"Median (range) duration of hospital stayi, d"
"15428";"Median (range) total IgE level (IUml~’)4"
"15429";"Median (range) treatment duration, d"
"15430";"median (SD), mg/mmol"
"15431";"Median age — yr"
"15432";"Median age — yr§"
"15433";"Median age (25%, 75%), y"
"15434";"Median age (IQR; years)"
"15435";"Median Age [interquartile range] — yr"
"15436";"Median age, y (range)"
"15437";"Median age, years (IQR)"
"15438";"Median albumin-to-creatinine ratio (interquartile range)"
"15439";"median albumin/creatinine ratio (g/mg)"
"15440";"Median blood eosinophil count (cells per pL)t"
"15441";"Median blood eosinophil count, cells per pLa"
"15442";"Median BNP (IQR) – pg/ml"
"15443";"Median body mass index, kg/m2 (range)"
"15444";"Median body mass index, kg/m2(IQR)"
"15445";"Median body weight — kg"
"15446";"Median body weight (kg)"
"15447";"Median C-reactive protein — mg/dl^"
"15448";"Median C-reactive protein — mg/liter"
"15449";"Median cardiac troponin T (IQR) — pg/ml"
"15450";"Median cardiac troponin T (IQR) 一pg/ml"
"15451";"Median change, %"
"15452";"Median CrCl — ml/min"
"15453";"Median Crohn's disease duration, y (range)"
"15454";"Median daily dose - IU™"
"15455";"Median delay (h)§"
"15456";"Median disease duration — yr"
"15457";"Median dose (range)'’"
"15458";"Median dose (range)b"
"15459";"Median duration of CHF — mo"
"15460";"Median duration of diabetes (yr)"
"15461";"Median duration of study-drug administration"
"15462";"Median duration of study-drug administration (IQR) — days"
"15463";"Median duration of symptoms (range), yr"
"15464";"Median duration oftype 2 diabetes (IQR) — yr"
"15465";"Median eGFR (interquartile range)"
"15466";"Median fasting insulin (IQR) —pU per milliliter"
"15467";"Median fecal calprotectin — mg/kg GI areas involved — no. (%)"
"15468";"Median FeNO (ppb)f"
"15469";"Median FeNO, ppba"
"15470";"Median infusions — no. (range)"
"15471";"median m/kg2 (IQR)"
"15472";"Median N-terminal proBNP (IQR) — pg/ml"
"15473";"Median NT-proBNP (IQR) – pg/ml"
"15474";"Median of JSW"
"15475";"Median PASI score {range)'i""i'"
"15476";"median seconds"
"15477";"Median serum periostin (ng/mL)t"
"15478";"Median serum periostin, ng/mLa"
"15479";"Median time delay (interquartile range) — min"
"15480";"Median time from index acute coronary syndrome to randomization (IQR) — mo"
"15481";"Median time in therapeutic range for warfarin recipients, %"
"15482";"Median time since diagnosis* (range), yr"
"15483";"Median time to event (weeks)"
"15484";"Median time to first exacerbation (months [95% CI])"
"15485";"Median total cholesterol, mmol/L"
"15486";"Median triglyceride (mg/dl)"
"15487";"Median weight, kg (IQR)"
"15488";"Median, IQR"
"15489";"median, IQR)"
"15490";"Median, mg/dL"
"15491";"Median, mL"
"15492";"Median, range"
"15493";"Median, y (range)"
"15494";"Median§"
"15495";"Medians (IQR)"
"15496";"Medical and lifestyle history"
"15497";"Medical conditions, No. (%)"
"15498";"Medical historv"
"15499";"Medical history"
"15500";"Medical History"
"15501";"Medical history— no. (%)"
"15502";"Medical history — %"
"15503";"Medical history — no. (%)"
"15504";"Medical history — no./total no. ( %)"
"15505";"Medical history — no./total no. (%)"
"15506";"Medical history (%)"
"15507";"Medical history and risk factors"
"15508";"Medical history and risk factors (%)"
"15509";"Medical history and risk factors, No./total (%)*"
"15510";"Medical history at randomization — no. (%)"
"15511";"Medical history before index acute coronary syndrome — no. {%)"
"15512";"Medical history Duration of heart failure (years) Primary cause of heart failure"
"15513";"Medical history of CV disease or heart failure, n (%)"
"15514";"Medical history of diabetic retinopathy§"
"15515";"Medical history of hypertension"
"15516";"Medical history, n (% of patients)"
"15517";"Medical history, n (%)"
"15518";"Medical History, n (%)"
"15519";"Medical history, no. (%)"
"15520";"Medical history, No. (%)"
"15521";"Medical history, n (%)"
"15522";"Medical history. No. (%)"
"15523";"Medical History: Cancer"
"15524";"Medical management only"
"15525";"Medical management only—no. {%)"
"15526";"Medical therapies"
"15527";"Medical therapy"
"15528";"Medical Therapy"
"15529";"Medical Therapy (n = 472)"
"15530";"Medical Therapy (n=204)"
"15531";"Medical Therapy (n=214)"
"15532";"Medical Therapy (n=54)"
"15533";"Medical Therapy Alone"
"15534";"Medical therapy before admission"
"15535";"Medical therapy before randomization — no./total no. (%)"
"15536";"Medical therapy during index hospitalization — %"
"15537";"Medical therapy only"
"15538";"Medical Therapy Only (N = 472)"
"15539";"Medical treatment"
"15540";"Medical treatment, n (%)"
"15541";"Medically important infectionsa"
"15542";"medication"
"15543";"Medication"
"15544";"Medication — no. (%)"
"15545";"Medication 6418 (57.0)"
"15546";"Medication adherence"
"15547";"Medication Adherence"
"15548";"Medication after enrolment"
"15549";"Medication at enrollment — no. (%)"
"15550";"Medication at entry (%)"
"15551";"Medication at randomization"
"15552";"Medication at randomization, %"
"15553";"Medication at randomization, n (%)"
"15554";"Medication at time of randomization"
"15555";"Medication at time of randomization — no. (%)"
"15556";"Medication continued into double-blind treatment period"
"15557";"Medication in use at the baseline"
"15558";"Medication prior to admission, (%)"
"15559";"Medication taken alone or in combination"
"15560";"Medication use"
"15561";"Medication use— no. (%)^|"
"15562";"Medication use — no. (%)"
"15563";"Medication use — no. {%)"
"15564";"Medication use (%)"
"15565";"Medication use (%) Aspirin"
"15566";"Medication use at baseline - n (%)"
"15567";"Medication use at baseline — no. (%)"
"15568";"Medication use at baseline, n (%)"
"15569";"Medication use at entry (%)"
"15570";"Medication use before enrollment, No. (%)"
"15571";"Medication use, n (%)"
"15572";"Medication use, No./total No. (%)"
"15573";"Medication useb"
"15574";"Medication within 7 days before enrolment"
"15575";"medication, n (%)"
"15576";"Medication, n (%)"
"15577";"Medications"
"15578";"Medications — no. (%)"
"15579";"Medications — no. {%)**"
"15580";"Medications (%)"
"15581";"Medications Antihypertensive drugs"
"15582";"Medications at baseline, n (%)"
"15583";"Medications at baselinet"
"15584";"Medications at coronary angiography"
"15585";"Medications at discharge"
"15586";"Medications at discharge or day 7, if earlier (%)"
"15587";"Medications at enrollment, n (%):"
"15588";"Medications at enrolment"
"15589";"Medications at randomization"
"15590";"Medications at study entry — no./total no. (%)"
"15591";"Medications at the time of randomization — no. (%)"
"15592";"Medications at time of randomization — no. (%)"
"15593";"Medications at timing of randomization, n (%)"
"15594";"Medications before admission"
"15595";"Medications during hospitalization or at discharge"
"15596";"Medications for Crohn's disease taken at baseline — no. (%)"
"15597";"Medications in the hospital after randomization — no. (%)"
"15598";"Medications in use at baseline — no. (%)"
"15599";"Medications in use at baseline — no./total no. (%)"
"15600";"Medications in use at baseline, n (%)"
"15601";"Medications on admission, %"
"15602";"Medications taken at time of randomization Statins"
"15603";"Medications through day 7"
"15604";"Medications*"
"15605";"medications, n"
"15606";"Medications, n (% of patients)"
"15607";"Medications, n (%)"
"15608";"Medications, no. (%)"
"15609";"Medications. no. (%)"
"15610";"Medium"
"15611";"Medium- or low-intensity statin"
"15612";"Medium Normal (n=519)"
"15613";"Meglitinide"
"15614";"Meglitinides (glinides)"
"15615";"Meloxicam"
"15616";"Memantine use at baseline, No. (%)"
"15617";"Men"
"15618";"Men (%)"
"15619";"Men (n [%])"
"15620";"Men (n 二4269)"
"15621";"Men (n = 362)"
"15622";"Men (n, %)"
"15623";"Men (n=13 728)"
"15624";"Men (n=1493)"
"15625";"Men (N=2112)"
"15626";"Men (N=2118)"
"15627";"Men (n=363 vs 176)"
"15628";"Men (n=4269), n/N (%)"
"15629";"Men (N=723)"
"15630";"Men (N=7891)"
"15631";"Men (N=8723)"
"15632";"Men With ED (N = 716) 62.6 ± 7.9"
"15633";"Men Without ED (N = 340) 60.9 ± 7.7"
"15634";"Men, %"
"15635";"Men, <100 cm"
"15636";"Men, >100 cm"
"15637";"Men, n (%)"
"15638";"Men, n (%)*"
"15639";"Men, No. (%)"
"15640";"Men, Total (n 二2476)"
"15641";"Men, Total (n=2476)"
"15642";"Men, n (%)"
"15643";"Men/women"
"15644";"Men: <40 mg/dL (<1.04 mmol/L)"
"15645";"Men: QVAI49-SFC"
"15646";"Men:women (%)"
"15647";"Menopausal status and hormone therapy use"
"15648";"Menopausal status and hormone therapy use Premenopausal"
"15649";"Menopausal status and use of HRT(%)y"
"15650";"Menopausal status and use of HT"
"15651";"Menopause and HRT"
"15652";"Menopause and HT"
"15653";"MENSA"
"15654";"MenT"
"15655";"Mental"
"15656";"Mental activities UPDRS subscore (baseline), mean (SD)"
"15657";"Mental component"
"15658";"Mental component score (MCS)"
"15659";"Mental health"
"15660";"Mental Status"
"15661";"Mental status (baseline SPMSQ scores), n (%)"
"15662";"MEPO (N = 23)"
"15663";"MEPO (N = 331)"
"15664";"MEPO (N = 46)"
"15665";"MEPO (N = 54)"
"15666";"Mepolizumab"
"15667";"Mepolizumab 100 mg (n=274)"
"15668";"Mepolizumab Group"
"15669";"Mepolizumab, 100 mg (N = 223)"
"15670";"Mepolizumab, 100 mg (N = 233)"
"15671";"Mepolizumab, 100 mg (N = 417)"
"15672";"Mepolizumab, 300 mg (N = 225)"
"15673";"mer’s Disease Assessment"
"15674";"Mercaptopurine"
"15675";"Merformin"
"15676";"Mesalamine use, n (%)a"
"15677";"Mesothelin (ng/ml)"
"15678";"Mestizos"
"15679";"MET %△ (SE)"
"15680";"MET (N = 334)"
"15681";"MET (n =237)"
"15682";"Met atopy and IgE 30-700 kU/L criteria"" (n= 824)"
"15683";"Met criterion at BL (n [%])"
"15684";"Met criterion at BLt (n [%])"
"15685";"Met criterion at final (n [%])"
"15686";"Met criterion at finalt"
"15687";"MET%△(SE)"
"15688";"MET/SU/TZD"
"15689";"MET/TZD"
"15690";"Metabolic syndrome"
"15691";"Metabolic Syndrome"
"15692";"Metabolic syndrome — no. (%)!"
"15693";"Metabolic syndrome — no. (%)^"
"15694";"Metabolic syndrome — no. (%)5"
"15695";"Metabolic syndrome (%)"
"15696";"Metabolic syndrome (%)b"
"15697";"Metabolic syndrome (>3 of 5 characteristics)"
"15698";"Metabolic syndrome (n = 203)"
"15699";"Metabolic Syndrome (n = 2636)"
"15700";"Metabolic syndrome characteristics, n (%)"
"15701";"Metabolic syndrome Visit 2 low-density lipoprotein cholesterol strata"
"15702";"Metabolic syndrome w/o T2DM"
"15703";"Metabolic syndrome*"
"15704";"Metabolic syndrome* n=813"
"15705";"Metabolic syndrome,"
"15706";"Metabolic syndrome, n (%)"
"15707";"Metabolic syndrome, n/N (%)*"
"15708";"Metabolic syndrome,! n (%)"
"15709";"Metabolic syndrome1*"
"15710";"Metabolic syndrome11 Baseline lipids, mg/dL"
"15711";"Metabolic syndromeb"
"15712";"Metabolism and nutrition"
"15713";"Metabolizer phenotype (%)§"
"15714";"Metastatic"
"15715";"Metastatic disease"
"15716";"Metformin"
"15717";"Metformin-dose"
"15718";"Metformin — no. (%)"
"15719";"Metformin (HDM)"
"15720";"Metformin (n = 1454)"
"15721";"Metformin (N = 1454)"
"15722";"Metformin (n =268)"
"15723";"Metformin (n 5 328)"
"15724";"Metformin ? pioglitazone"
"15725";"Metformin ? SU"
"15726";"Metformin + SU"
"15727";"Metformin +SU+TZD"
"15728";"Metformin 一 no. (%)"
"15729";"Metformin ± other oral anti-DM drugs"
"15730";"Metformin • pioglitazone"
"15731";"Metformin alone"
"15732";"Metformin dose"
"15733";"Metformin dose, mg"
"15734";"Metformin monotherapy"
"15735";"Metformin Monotherapy"
"15736";"Metformin only"
"15737";"Metformin open-label*"
"15738";"Metformin Use"
"15739";"Metformin use, n (%)"
"15740";"Metformin, n (%)"
"15741";"Metformin: no/yes, %"
"15742";"Metformin+sulphonylureas"
"15743";"Metforminmonotherapy"
"15744";"Method of assessing ejection fraction"
"15745";"Method of identification ofstenosis (%)"
"15746";"Method of insulin administration"
"15747";"Method used to diagnose the incident pulmonary embolism, No. (%)"
"15748";"Methotrexate"
"15749";"Methotrexate alone^"
"15750";"Methotrexate dose at baseline"
"15751";"Methotrexate dose on day 1 — mg per wl<55"
"15752";"Methotrexate dose||, mg"
"15753";"Methotrexate plus other csDMARDfl"
"15754";"Methotrexate treatment!"
"15755";"Methotrexate use"
"15756";"Methotrexate use at baseline"
"15757";"Methotrexate use at randomisation"
"15758";"Methotrexate use at randomization"
"15759";"Methotrexate use at randomization, n (%)"
"15760";"Methotrexate User"
"15761";"Methylxanthines"
"15762";"Metoprolol (n=22 929)"
"15763";"METREO Modified Intention-to-Treat Population§"
"15764";"METREX Modified Intention-to-Treat Population with an Eosinophilic Phenotypey"
"15765";"METREX Overall Modified Intention-to-Treat Population?:"
"15766";"MetS"
"15767";"MetS Pbo (N = 107) vs EvoMab (N = 182)"
"15768";"MetS w/o T2DM"
"15769";"MetS, n (%)"
"15770";"MetSyn"
"15771";"MetSyn with LDL >156.9 mg/dL"
"15772";"Mexican"
"15773";"Mexico"
"15774";"Mexico, Central/South America"
"15775";"MFNS (n = 104)"
"15776";"MFNS (n = 164)"
"15777";"MFNS (n = 494)"
"15778";"MFNS (n = 65)"
"15779";"mg daily)"
"15780";"mg/day"
"15781";"mg/dl"
"15782";"mg/dL"
"15783";"mg/dL FPG (mmol/L)"
"15784";"mg/dL, mean ± SD"
"15785";"mg/g"
"15786";"mg/mmol"
"15787";"MH + CRPnorr"
"15788";"MHi"
"15789";"MHIS score"
"15790";"MI"
"15791";"MI—No. (%)"
"15792";"MI (fatal/nonfatal)"
"15793";"MI <3 months*"
"15794";"MI >3 months*"
"15795";"MI or CAD"
"15796";"MI type unknown (%)"
"15797";"MI*"
"15798";"MI, n (%)"
"15799";"Miami K antagonist received"
"15800";"Micral test result"
"15801";"Micro- or macroalbuminuria, n (%)§"
"15802";"Micro- or macroalbuminuria, No. (%)"
"15803";"Micro-/macro-albuminuria, CKD and/or retinopathy"
"15804";"Micro-albuminuria"
"15805";"Micro/macroaibuminuria"
"15806";"Micro/macroalbuminuria"
"15807";"Micro/Macroalbuminuria"
"15808";"Microalbuminuria"
"15809";"Microalbuminuria — no. (%)"
"15810";"Microalbuminuria — no./total no. (%)"
"15811";"Microalbuminuria (UACR 30–300)"
"15812";"Microalbuminuria at baseline (29% of patients treated)"
"15813";"Microalbuminuria or macroalbuminuria"
"15814";"Microalbuminuria or macroalbuminuria§"
"15815";"Microalbuminuria or proteinuria"
"15816";"Microalbuminuria, mg/g Cr"
"15817";"Microalbuminuria, n (%)"
"15818";"Microvascular complications, n (%)’"
"15819";"Microvascular complicationsb"
"15820";"Microvascular disease history"
"15821";"Microvascular disease history, n (%)"
"15822";"Microvascular disease history, No. (%)"
"15823";"Microvascular disease*"
"15824";"Microvascular disease, n (%)"
"15825";"Microvascular eye diseased"
"15826";"Microvascular outcome"
"15827";"Micturitions/24h"
"15828";"MIDAS score"
"15829";"middle"
"15830";"Middle East, Africa, or Asia-Pacific"
"15831";"Middle Tertile (Range, 1.6-2.0 mg/dl; Mean ± SD, 1.8 ± 0.1 mg/dl)"
"15832";"Middle tertile: > 0.23 to b 0.37"
"15833";"Middle TG tertile"
"15834";"Middle third"
"15835";"Migraine — no. (%)$"
"15836";"Migraine duration (h)"
"15837";"Migraine occurrence (days/month)"
"15838";"Migraine severity score"
"15839";"Migraine with aura"
"15840";"Migraine With Aura"
"15841";"Migraine without aura"
"15842";"Migraine Without Aura"
"15843";"mild"
"15844";"Mild"
"15845";"Mild-to-moderate (IPSS < 20)"
"15846";"Mild (<8)"
"15847";"Mild (>50 to <80)"
"15848";"Mild (3-6)"
"15849";"Mild (60–89 mL·min−1·1.73 m−2), n (%)"
"15850";"Mild (FEV, >50% predicted)"
"15851";"Mild (GOLD 1)"
"15852";"Mild (IIEF-EF 17-25)"
"15853";"Mild (IPSS <8)"
"15854";"Mild (N=187)"
"15855";"Mild (N1 = 83)1"
"15856";"Mild decrease (60-<90 mL/min per 1.73 m2)"
"15857";"Mild Decrease In GFR (60-89 mL/mln per 1.73 m^)"
"15858";"Mild dysfunction (crcl >50-95 ml/min; n=8208 [58.3%])"
"15859";"Mild ED"
"15860";"Mild ED    Severe ED"
"15861";"Mild impairment"
"15862";"Mild impairment      (eGFR 60-89)"
"15863";"Mild impairment (£60 to"
"15864";"Mild impairment (60 to <90)"
"15865";"Mild impairment (60 to590mL/min)"
"15866";"Mild impairment (eGFR 60-89 mL/min/m^)"
"15867";"Mild impairment (eGFR 60-89)"
"15868";"Mild impairment (eGFR 60–89), N (%)"
"15869";"Mild impairment, <60 to <90"
"15870";"Mild or moderate COPD"
"15871";"Mild or no dysfunction (crcl >50 ml/ min; n=11 331; [81.5%])"
"15872";"Mild Reduction in eGFR"
"15873";"Mild TEAEs"
"15874";"Mild thrombocytopenia (<100x 109/L)"
"15875";"Mild to moderate"
"15876";"Mild to moderate renal impairment*"
"15877";"Mild/moderate (IPSS < 20)"
"15878";"Mildly impaired"
"15879";"Mildly Impaired"
"15880";"MildlyDecreased Baseline GFR (60-89 mL/min/1.73m2)"
"15881";"min-’"
"15882";"Min-Max"
"15883";"Min-Max Age"
"15884";"Min–Max"
"15885";"min per 1.73 m2"
"15886";"Min, Max"
"15887";"Mineralcorticoid receptor antagonist"
"15888";"Mineralocorticoid receptor antagonist"
"15889";"Mineralocorticoid receptor antagonist N(%)"
"15890";"Mineralocorticoid receptor antagonists"
"15891";"Mini-Mental State Examination"
"15892";"Mini-Mental State Examination, mean (SD)d"
"15893";"Minimum"
"15894";"Minimum-maximum"
"15895";"Minimum—maxim um"
"15896";"Minimum—maximum"
"15897";"Minimum stent diameter"
"15898";"Minimum, maximum"
"15899";"Minimum/maximum"
"15900";"Minimum:maximum"
"15901";"minor"
"15902";"Minor"
"15903";"Minor Bleed"
"15904";"Minor bleeding"
"15905";"Minor ischaemic stroke"
"15906";"Minor surgery"
"15907";"Minor/Major"
"15908";"Minority"
"15909";"Minutes from pre-PCI angiography to post-PCI angiography, median (IQR)"
"15910";"Minutes from prehospital ECG to PCI, median (IQR)"
"15911";"Minutes from symptom onset to prehospital ECG, median (IQR)"
"15912";"Missing"
"15913";"Missing—number/N (%)"
"15914";"Missing data"
"15915";"Missing data — no./total no. (%)"
"15916";"Missing data Initial diagnosis — no."
"15917";"Missing ED duration (y)"
"15918";"Missing Hb at Yr 1"
"15919";"Missing*"
"15920";"Missing, n (%)a"
"15921";"Mitral insufficiency"
"15922";"Mitral insufficiency, n (%)"
"15923";"Mitral regurgitation, (%)"
"15924";"Mitral regurgitation, n (%)"
"15925";"Mitral valve disease (n=20 983)"
"15926";"mITT Population"
"15927";"mITT Population (n = 1856)"
"15928";"Mixed"
"15929";"Mixed (ITT) (n=329)"
"15930";"Mixed (ITT) (n=331)"
"15931";"Mixed (ITT) (n=355)"
"15932";"Mixed (ITT) (n=363)"
"15933";"Mixed (ITT) (n=454)"
"15934";"Mixed (ITT) (n=464)"
"15935";"Mixed (n=215)"
"15936";"Mixed chronic bronchitis and emphysema"
"15937";"Mixed Hispanic"
"15938";"mL"
"15939";"Ml"
"15940";"Ml    C"
"15941";"Ml with ST-segment elevation"
"15942";"Ml without ST-segment elevation!"
"15943";"mL)"
"15944";"mm Hg"
"15945";"MMF (n = 62)"
"15946";"MMF (n=22)"
"15947";"MMF (n=26)"
"15948";"MMF (n=75)"
"15949";"mmol/l"
"15950";"mmol/L"
"15951";"mmol/L [n]"
"15952";"mmol/L)"
"15953";"mmol/mol"
"15954";"MMP-3 (ng/mL)"
"15955";"MMP-3 (ng/mL)*"
"15956";"MMP-9, median (IQR), gg/L"
"15957";"mMRC at baseline"
"15958";"mMRC dyspnea scale score:t:t"
"15959";"mMRC dyspnea scale, n (%)"
"15960";"mMRC Dyspnea Scale, n (%)"
"15961";"mMRC grade"
"15962";"mMRC grade, n (%)"
"15963";"MMRM estimates, LS mean (SE), [95% CI]"
"15964";"MMSE (points)"
"15965";"MMSE <23"
"15966";"MMSE = Mini-Mental State Examination; ADAS—cog = Alzhei-"
"15967";"MMSE >28"
"15968";"MMSE 12-20"
"15969";"MMSE 12-26"
"15970";"MMSE 21-26"
"15971";"MMSE 24-27"
"15972";"MMSE score"
"15973";"MMSE score*"
"15974";"MN-naïve population"
"15975";"MN population"
"15976";"MN population, n"
"15977";"mNAPSI"
"15978";"mNAPSI, mean (SD)"
"15979";"mNAPSI, mean [SD]d"
"15980";"Mod/Sev Exacerbation Rate"
"15981";"Mod/Sev Exacerbation Rates"
"15982";"Model , n"
"15983";"Model 1"
"15984";"Model 1+"
"15985";"Model 2"
"15986";"Model 2t"
"15987";"Model 3§"
"15988";"moderate"
"15989";"Moderate"
"15990";"Moderate- dose statin"
"15991";"Moderate-dose statin"
"15992";"Moderate-intensity statin"
"15993";"Moderate-intensity statin use"
"15994";"Moderate-to-"
"15995";"Moderate-to-severe COPD exacerbation"
"15996";"Moderate    Severe (n = 408)    (n = 168)"
"15997";"Moderate    Severe (n = 452)    (n = 160)"
"15998";"Moderate    Severe (n = 453)    (n = 160)"
"15999";"Moderate    Severe (n = 463)    (n = 136)"
"16000";"Moderate (> 10 and <22)"
"16001";"Moderate (>11 and <26)"
"16002";"Moderate (>30 to <50)"
"16003";"Moderate (>5%. <10%)"
"16004";"Moderate (1 risk factor)"
"16005";"Moderate (25%. <10%)"
"16006";"Moderate (30–59 mL·min−1·1.73 m−2), n (%)"
"16007";"Moderate (30% <FEV, <50% predicted)"
"16008";"Moderate (7-16)"
"16009";"Moderate (8-19)"
"16010";"Moderate (8 < IPSS <20)"
"16011";"Moderate (GOLD 2)"
"16012";"Moderate (IIEF-EF 11-16)"
"16013";"Moderate (IIEF-EF 11-16), n (%)"
"16014";"Moderate (IPSS <20) (n=393)"
"16015";"Moderate (N=311)"
"16016";"Moderate (N1 = 187)"
"16017";"Moderate (N1 = 36)"
"16018";"Moderate (S5%. <10%)"
"16019";"Moderate chronic kidney disease"
"16020";"Moderate CKD"
"16021";"Moderate CKD at randomization"
"16022";"Moderate COPD"
"16023";"Moderate COPDb [N Z 207]"
"16024";"Moderate CORD*: QVA149-SFC"
"16025";"Moderate decrease (30-<60 mLYmin per 1.73 m2)"
"16026";"Moderate disease"
"16027";"Moderate disease activity: >3.2 to <5.1, n (%)"
"16028";"Moderate dysfunction (crcl 30-50 ml/min; n=2740 [19.5%])"
"16029";"Moderate impairment"
"16030";"Moderate impairment (30 to <60)"
"16031";"Moderate impairment (30 to560mL/min)"
"16032";"Moderate impairment (eGFR 30-59 mL/min/m^)"
"16033";"Moderate impairment (eGFR 30-59)"
"16034";"Moderate impairment (eGFR 30–59), N (%)"
"16035";"Moderate impairment, <30 to <60"
"16036";"Moderate n Z 250"
"16037";"Moderate or less airflow limitation"
"16038";"Moderate or severe COPD exacerbations"
"16039";"Moderate or Severe Decrease in GFR (<60 mL/min/1.73 m2)"
"16040";"Moderate or Severe Decrease In GFR {<60 mL/mln per 1.73 m^)"
"16041";"Moderate or severe exacerbations in the previous year (range)"
"16042";"Moderate or severe impairment"
"16043";"Moderate or severe renal disease, n (%)"
"16044";"Moderate or severe renal disease,b n (%)"
"16045";"Moderate renal impairment"
"16046";"Moderate renal impairment, n (%)*"
"16047";"Moderate risk"
"16048";"Moderate risk (>10-14)"
"16049";"Moderate risk (4-6)"
"16050";"Moderate severity"
"16051";"Moderate TEAEs"
"16052";"Moderate thrombocytopenia (<50X109/L)"
"16053";"Moderate TRS: 3-4 (n = 3,343)"
"16054";"Moderate, GOLD 2"
"16055";"Moderate, n (%)a"
"16056";"Moderate/low"
"16057";"Moderate/severe exacerbation"
"16058";"Moderate/severe exacerbations, ITT population; n (%)"
"16059";"Moderate/severe exacerbations, patient subgroups; n (%)"
"16060";"Moderate/Severe Reduction in eGFR"
"16061";"Moderate’"
"16062";"Moderately high risk"
"16063";"Moderately high risk without atherosclerotic vascular disease*"
"16064";"Moderately impaired"
"16065";"Moderately Impaired"
"16066";"Moderatex"
"16067";"Moderatey"
"16068";"Moderatez"
"16069";"Modi fied LA Grade*"
"16070";"Modified ACC-AHA lesion class B2 or C"
"16071";"Modified ACC or AHA lesion class B2 or C"
"16072";"Modified ACC/AHA lesion class B2 or CJ"
"16073";"Modified ACC/AHA Lesion Class B2/C"
"16074";"Modified Hachinski ischemia scale, mean (SD)c"
"16075";"Modified HAS-BLED"
"16076";"Modified HAS-BLED $3"
"16077";"Modified HAS-BLED <3"
"16078";"Modified HAS-BLED >3"
"16079";"Modified HAS-BLED score, mean±SD"
"16080";"Modified Rankin scale — no. (%)|"
"16081";"Modified Rankin scale at screening, 0-2"
"16082";"Modified Rankin Scale score"
"16083";"Modified Rankin score"
"16084";"Modified Rankin Score"
"16085";"Modified SE-ADL scale"
"16086";"Modified total Sharp score"
"16087";"Modified total Sharp score**"
"16088";"ModMy al randcnxzaton"
"16089";"Monitoring group (n=435)"
"16090";"Monitoring Treatment"
"16091";"Monoamine oxidase B inhibitors"
"16092";"Monocytes, 103/nl"
"16093";"Monotherapy"
"16094";"Monotherapy10"
"16095";"Monteiukast"
"16096";"Monteiukast (n = 929)"
"16097";"Monteiukast vs placebo"
"16098";"Montelukast (n = 101)"
"16099";"Month 1"
"16100";"Month 12"
"16101";"Month 12    Subgroup X Treatment Interaction p-value"
"16102";"Month 18"
"16103";"Month 24"
"16104";"Month 24    Subgroup X Treatment Interaction p-value"
"16105";"Month 25"
"16106";"Month 3"
"16107";"Month 6"
"16108";"Month12"
"16109";"Month18"
"16110";"Monthly"
"16111";"months (log-transformed)"
"16112";"Months from MI—median (IQR)"
"16113";"Months from qualifying stroke* (%)"
"16114";"Months since first RA symptom, mean (SD)f"
"16115";"Months since RA was first diagnosed, mean (SD)"
"16116";"More severe"
"16117";"More severe^"
"16118";"More than 2 lesions per vessel"
"16119";"More than 2 vessels stented"
"16120";"Morning"
"16121";"Morning peak expiratory flow — liters/min"
"16122";"Morning stiffness duration, min"
"16123";"Morning stiffness severity, 0-10 scale"
"16124";"Morphine use for index event/PCI"
"16125";"Morphometric vertebral"
"16126";"mortality"
"16127";"Mortality"
"16128";"Mortality outcomes"
"16129";"Most common AEs in any group"
"16130";"Most common AEs‡"
"16131";"Most common concomitant AEDs,d n(%)"
"16132";"Most frequent AEsa"
"16133";"Most frequent GI disorders"
"16134";"Most frequent infections"
"16135";"Most frequent non-infectious TEAEsb"
"16136";"Most frequent serious TEAEs"
"16137";"Mostly dissatisfied"
"16138";"Mostly satisfied"
"16139";"Motor"
"16140";"Motor subscale (range, 0-108)"
"16141";"Motor UPDRS subscore (baseline), mean (SD)"
"16142";"Motor weakness"
"16143";"Mouth ulceration"
"16144";"MPO (ng/ml)"
"16145";"MRA"
"16146";"MRA (spironolactone or eplerenone)"
"16147";"MRA at baseline"
"16148";"MRA at Baseline"
"16149";"MRA Regimen (n - 802)"
"16150";"MRA Use"
"16151";"MRA, (%)"
"16152";"MRAs"
"16153";"MRF"
"16154";"MRF subjects"
"16155";"MRI Substudy (n=1014)"
"16156";"MS <6, n [%]"
"16157";"MS 6-8, n [%]"
"16158";"MS 9-12, n [%]"
"16159";"Ms&ng"
"16160";"MS, mean [SD]"
"16161";"mSASSS, mean (SD)"
"16162";"msDBP"
"16163";"MSDBP"
"16164";"MSDBP (mm Hg)"
"16165";"MSDBP ± SD, mmHg"
"16166";"msDBP, mm Hg"
"16167";"MSDBP, mm Hga"
"16168";"MSDBP, mmHg (SD)"
"16169";"MSFC timed 25-foot walk test, median seconds"
"16170";"MSFC timed 25-foot walk test."
"16171";"msSBP"
"16172";"MSSBP"
"16173";"MSSBP (mm Hg)"
"16174";"MSSBP <180 mmHg"
"16175";"MSSBP <180mmHg"
"16176";"MSSBP >180 mmHg"
"16177";"MSSBP >180mmHg"
"16178";"MSSBP ± SD, mmHg"
"16179";"msSBP, mm Hg"
"16180";"MSSBP, mm Hga"
"16181";"MSSBP, mmHg (SD)"
"16182";"MSSBP/MSDBP"
"16183";"mTSS"
"16184";"mTSS (0-448)"
"16185";"mTSS at"
"16186";"mTSS at baseline Observed case"
"16187";"mTSS CfB"
"16188";"mTSS CFB mean±SD"
"16189";"mTSS units"
"16190";"mTSS, mean (SD)"
"16191";"mTSS, median (min, max)"
"16192";"MTX"
"16193";"MTX-IR"
"16194";"MTX (mean dose: 14.75 mg/wk)"
"16195";"MTX (n)"
"16196";"MTX (n=116)"
"16197";"MTX £10 mg/week"
"16198";"MTX + non-MTX"
"16199";"MTX + other csDMARDs"
"16200";"MTX + other csOMARDs"
"16201";"MTX + otheTcsDMARDs"
"16202";"MTX <15 mg/week"
"16203";"MTX ≤10 mg/week"
"16204";"MTX ≥15 mg/week"
"16205";"MTX >10–15 mg/week"
"16206";"MTX >10 and £15 mg/week"
"16207";"MTX >10 and SI 5 mg/week"
"16208";"MTX >15 mg/week"
"16209";"MTX at baseline"
"16210";"MTX at baseline, n (%)"
"16211";"MTX average weekly dose, mg/week, mean (SD)"
"16212";"MTX dose > 15 mg/week, %"
"16213";"MTX Exposure (mg/week)"
"16214";"MTX IR"
"16215";"MTX n = 167"
"16216";"MTX n = 197"
"16217";"MTX n = 200"
"16218";"MTX naive or free"
"16219";"MTX only"
"16220";"MTX plus infliximab"
"16221";"MTX plus placebo"
"16222";"MTX SIO mg/week"
"16223";"MTX use at baseline"
"16224";"MTX use at randomization, n (%)"
"16225";"Mucocutaneous"
"16226";"Mucolytic agent"
"16227";"Mucolytics"
"16228";"Mucosal healingc n/n (%)"
"16229";"Mucosal healingf"
"16230";"Multi-racial"
"16231";"Multi-Racial"
"16232";"Multi-vessel coronary artery disease"
"16233";"Multi vessel (or left main)"
"16234";"Multiple"
"16235";"Multiple (>2) CHD risk factors that confer a 10-year risk of CHD >20%"
"16236";"Multiple (2+) CHD risk"
"16237";"Multiple diagnoses"
"16238";"Multiple Risk Factors"
"16239";"Multiple TNFi and other bDMARDs§"
"16240";"Multiple TNFi*"
"16241";"Multiracial"
"16242";"Multiracial or other"
"16243";"Multiracial, n(%)"
"16244";"Multivariable"
"16245";"Multivariable Adjusted HR (95% CI)"
"16246";"Multivariable adjusted model HR (95% CI)"
"16247";"Multivariable OR (95% CI), p Value*"
"16248";"Multivariate logistic modelb"
"16249";"Multivessel (two vessel, three vessel, or left main)"
"16250";"Multivessel CAD (%)"
"16251";"Multivessel CAD, n (%)"
"16252";"Multivessel coronary-artery bypass grafting"
"16253";"Multivessel coronary artery disease"
"16254";"Multivessel coronary artery disease — no./total no. (%)"
"16255";"Multivessel disease"
"16256";"Multivessel Disease"
"16257";"Multivessel disease — no. (%)"
"16258";"Multivessel disease 一no. (%)"
"16259";"Multivessel disease, n (%)"
"16260";"Multivessel disease, no. (%)"
"16261";"Multivessel intervention, n (%)"
"16262";"Multivessel PCI"
"16263";"Multivessel stenting"
"16264";"Multivitamin use"
"16265";"Multivitamin use (current)"
"16266";"Multivitamin use Yes"
"16267";"Multivitamins"
"16268";"Muscle spasms"
"16269";"Musculoskeletal"
"16270";"MVD (n - 12,558)"
"16271";"Myalgia"
"16272";"Mycophenolate (any derivative)"
"16273";"Mycophenolate mofetil"
"16274";"Myocardiai infarction"
"16275";"Myocardial infarction"
"16276";"Myocardial Infarction"
"16277";"Myocardial infarction — no. (%)"
"16278";"Myocardial infarction (%)"
"16279";"Myocardial Infarction at Presentation (N=3576)"
"16280";"Myocardial infarction before index ACS — no. (%)"
"16281";"Myocardial infarction N(%)"
"16282";"Myocardial infarction or angina"
"16283";"Myocardial infarction within the previous 5 yr"
"16284";"Myocardial infarction without ST-segment elevation — no. (%)"
"16285";"Myocardial infarction, (%)"
"16286";"Myocardial infarction, n (%)"
"16287";"Myocardial infarction/CABG/PCI"
"16288";"Myocardial infarction/CABG/PCI <2 years"
"16289";"Myocardial infarction:"
"16290";"Myocardial infarction§"
"16291";"Myocardial ischaemia"
"16292";"Myoclonic"
"16293";"Myopathy"
"16294";"Myopathyt"
"16295";"n"
"16296";"N"
"16297";"n-3-PUFA (N=758)"
"16298";"n-3 allocation"
"16299";"n-3 fatty acids"
"16300";"N-3 Fatty Acids - Placebo LSM (95% Cl)"
"16301";"n-3 Fatty Acids (n=539)"
"16302";"N-3 Fatty Acids Slope LSM ± SE (mm/year)"
"16303";"N-3 Fatty Acit"
"16304";"n-3 PUFA"
"16305";"n-3 PUFA (n=3494)"
"16306";"n-3 PUFA Events/patients (%)"
"16307";"N-terminal pro-BNP — pg/ml§"
"16308";"N-terminal pro-brain natriuretic peptide, pg/mL"
"16309";"N    Event (rate)"
"16310";"n (% of patients)"
"16311";"n (%) Blood pressure - mean (sd) mm Hg"
"16312";"N (%) Liraglutide 1 placebo"
"16313";"n (%) Patients with risk faetors for CV disease aged >60"
"16314";"n (%) responders"
"16315";"N (%) unless otherwise specified"
"16316";"n (3yr KM Event Rate, %)"
"16317";"n (indacaterol 150 ug/ indacaterol 300 ug/placebo)"
"16318";"N (IQR)"
"16319";"n (lesions)"
"16320";"n (stented lesions)"
"16321";"n = 218t"
"16322";"n = 244t"
"16323";"N America"
"16324";"N analysed"
"16325";"N events (%)"
"16326";"N events/ N subjects"
"16327";"N events/N at risk"
"16328";"n nt"
"16329";"N o"
"16330";"n observed"
"16331";"N participants"
"16332";"n t%)"
"16333";"n.a."
"16334";"n/a"
"16335";"N/A"
"16336";"n/N"
"16337";"n/N (%)"
"16338";"n/N 138/1711"
"16339";"n/N 139/1716"
"16340";"n/N (%)"
"16341";"n/N(%/yr)"
"16342";"n/PYR"
"16343";"N/R"
"16344";"N+V (n = 177)"
"16345";"N=6413 Lesions"
"16346";"N=6594 Lesions"
"16347";"N1/N2"
"16348";"N50 yrs"
"16349";"Na"
"16350";"NA"
"16351";"Na (mmol/L)"
"16352";"NACE (primary endpoint)"
"16353";"Nadroparin"
"16354";"Nadroparin (n = 244)"
"16355";"nadroparin vs control"
"16356";"Nail involvement, %"
"16357";"naire can range from 0 to 3 for the Alternative Disability portion and from 0 to 100 for the Pain portion. Scores for the Medical Outcomes"
"16358";"Naive"
"16359";"Naive (n = 339)"
"16360";"Naive (n = 639)"
"16361";"Naive (n = 696)"
"16362";"Naive (n = 743)"
"16363";"Naive (no treatment for current flare)"
"16364";"Naive to antihyperglycemic agent therapy"
"16365";"Naive: no"
"16366";"Naive: yes"
"16367";"NAP"
"16368";"Naproxen"
"16369";"NAPSI score (0-8) of target fingernail"
"16370";"NAPSIt"
"16371";"Nasal polyposis or chronic rhinosinusitis — no. {%)"
"16372";"Nasal polyps"
"16373";"Nasal polyps at baseline: Yes"
"16374";"Nasal polyps, n (%)"
"16375";"Nasopharyngitis"
"16376";"Natalizumab (N = 724)f"
"16377";"Nateglinide (N=4645)"
"16378";"Nateglinide and repaglinide"
"16379";"Nateglinide n/N"
"16380";"Nationality"
"16381";"native american"
"16382";"Native American"
"16383";"Native American or Alaska Native"
"16384";"Native American or Alaskan Native"
"16385";"Native American/Alaskan"
"16386";"Native coronary"
"16387";"Native Coronary"
"16388";"Native coronary-artery lesions"
"16389";"Native Hawaiian or"
"16390";"Native Hawaiian or other Pacific"
"16391";"Native Hawaiian or Other Pacific"
"16392";"Native Hawaiian or other Pacific islander"
"16393";"Native Hawaiian or other Pacific Islander"
"16394";"Native Hawaiian or Other Pacific Islander"
"16395";"Native Hawaiian/ Pacific Islander"
"16396";"Native Hawaiian/Other"
"16397";"Native Hawaiian/Pacific Islander"
"16398";"Native Latin"
"16399";"Nausea"
"16400";"Nausea and/or vomiting adverse events"
"16401";"NBP"
"16402";"nc"
"16403";"NC"
"16404";"NC group ( n = 534)"
"16405";"NCEP ATP-III metabolic syndrome features, n (%)"
"16406";"NCEP ATP III risk factors"
"16407";"NCEP risk category at study entry, n (%)"
"16408";"NCT00000476"
"16409";"NCT00000542"
"16410";"NCT00000556"
"16411";"NCT00000620"
"16412";"NCT00038961"
"16413";"NCT00043784"
"16414";"NCT00059306"
"16415";"NCT00063687"
"16416";"NCT00071331"
"16417";"NCT00077792"
"16418";"NCT00089791"
"16419";"NCT00090103"
"16420";"NCT00092625"
"16421";"NCT00093158"
"16422";"NCT00093899"
"16423";"NCT00099268"
"16424";"NCT00105027"
"16425";"NCT00120289"
"16426";"NCT00134160"
"16427";"NCT00139386"
"16428";"NCT00141960"
"16429";"NCT00143221"
"16430";"NCT00144911"
"16431";"NCT00168792"
"16432";"NCT00170950"
"16433";"NCT00174785"
"16434";"NCT00174915"
"16435";"NCT00174993"
"16436";"NCT00185159"
"16437";"NCT00216619"
"16438";"NCT00222573"
"16439";"NCT00225589"
"16440";"NCT00250445"
"16441";"NCT00255164"
"16442";"NCT00259376"
"16443";"NCT00303459"
"16444";"NCT00321737"
"16445";"NCT00338260"
"16446";"NCT00350168"
"16447";"NCT00359905"
"16448";"NCT00365170"
"16449";"NCT00368979"
"16450";"NCT00377637"
"16451";"NCT00397657"
"16452";"NCT00398931"
"16453";"NCT00403910"
"16454";"NCT00430677"
"16455";"NCT00432796"
"16456";"NCT00433966"
"16457";"NCT00440050"
"16458";"NCT00441350"
"16459";"NCT00454662"
"16460";"NCT00454896"
"16461";"NCT00464269"
"16462";"NCT00475852"
"16463";"NCT00527943"
"16464";"NCT00570739"
"16465";"NCT00596752"
"16466";"NCT00621140"
"16467";"NCT00627016"
"16468";"NCT00679380"
"16469";"NCT00734630"
"16470";"NCT00740623"
"16471";"NCT00783237"
"16472";"NCT00790907"
"16473";"NCT00818883"
"16474";"NCT00862251"
"16475";"NCT00885352"
"16476";"NCT00919711"
"16477";"NCT00986050"
"16478";"NCT00993109"
"16479";"NCT01059136"
"16480";"NCT01392573"
"16481";"NCT01444430"
"16482";"NCT01472185"
"16483";"NCT01474369"
"16484";"NCT01475721"
"16485";"NCT01508936"
"16486";"NCT01523301"
"16487";"NCT01720446"
"16488";"NCT01869491"
"16489";"NCT02738632"
"16490";"NCT03021343"
"16491";"ND"
"16492";"ND not due to swelling or ICH"
"16493";"NE"
"16494";"Nebivolol (N = 258)"
"16495";"Necessitating hospitalization in previous year — no. (%)"
"16496";"Necrosis, n (%)a"
"16497";"Necrotic core"
"16498";"Necrotic core, mm^"
"16499";"Need for 30 ng Edoxaban Dose at"
"16500";"Need for urgent coronary-artery bypass grafting"
"16501";"Negative"
"16502";"Negative (<0.5), n (%)"
"16503";"Negative cTnl (n = 1,550)"
"16504";"Negative for Helicobacter pylori — no./total no. (%)"
"16505";"Neither"
"16506";"Neither ACE-I nor ARB Use"
"16507";"Neither ACE inhibitor nor ARB"
"16508";"Neither corticosteroid nor immunosuppressant"
"16509";"Neither CS nor IMM"
"16510";"Neither deep-vein thrombosis nor pulmonary embolism^"
"16511";"Neither deep-vein thrombosis nor pulmonary embolism§"
"16512";"Neither glucocorticoids nor immunosuppressive agents"
"16513";"Neither ICS nor LABA"
"16514";"Neither n = 1,044"
"16515";"Neither Pbo + statin    EZE + statin"
"16516";"Neither PE nor DVT"
"16517";"Neither T2DM nor MetS"
"16518";"Neither UH or LMW heparin"
"16519";"Neither unfractionated heparin nor low-molecular-weight heparin"
"16520";"neohroDathv. and all-cause mortalitv"
"16521";"Neoplasia"
"16522";"Neoplasia, n (%)"
"16523";"Nephropathy"
"16524";"NERD"
"16525";"Nesiritide (N = 3496)"
"16526";"Nesiritide, %z"
"16527";"Net clinical benefit*"
"16528";"Net clinical benefit: CV death, MI, stroke, GUSTO moderate/severe bleeding"
"16529";"Net clinical benefit: on-treatment VTE or major bleeding"
"16530";"Net Composite"
"16531";"Net EP 1"
"16532";"Net EP 2"
"16533";"Net EP 3"
"16534";"Network"
"16535";"Neuraxial alonee"
"16536";"Neuraxial anaesthesia"
"16537";"Neurocognitive disorders"
"16538";"Neurologicai events"
"16539";"neuropathy"
"16540";"Neuropathy"
"16541";"Neuropathy — no. (%)"
"16542";"Neuropilin (ng/ml)"
"16543";"Neutropenia"
"16544";"Neutrophils, 103/nl"
"16545";"Never"
"16546";"Never been on a VKA"
"16547";"Never Been on a VKA"
"16548";"Never drink"
"16549";"Never NSAID"
"16550";"never or past"
"16551";"Never smoked"
"16552";"Never smoked — no. (%)"
"16553";"Never smoked, n (%)"
"16554";"Never smoker"
"16555";"Never smoking"
"16556";"Never took alendronate"
"16557";"Never used LEV"
"16558";"Never/rarely"
"16559";"New-onset atrial fibrillation"
"16560";"New-onset diabetes"
"16561";"New-onset diabetes§"
"16562";"New anemia Bsl Hb > 120g I-1; Yr 1 < 120g I-1"
"16563";"New Anti-Anginal Therapy"
"16564";"New DES (N=1727)"
"16565";"New diabetes"
"16566";"New diabetes — no. (%)"
"16567";"New DM"
"16568";"New HF medication"
"16569";"New OM"
"16570";"New or suspected thrombus"
"16571";"New or worsenina neohroDathv"
"16572";"New or worsentna neohroDathv"
"16573";"New stroke*"
"16574";"New use of GPA"
"16575";"New Use of GPA"
"16576";"New York Heart Association class"
"16577";"New York Heart Association Class"
"16578";"New York Heart Association congestive heart failure class"
"16579";"New Zealand"
"16580";"Newly diagnosed asthma (n)"
"16581";"NFS <-1.455 (low)"
"16582";"NFS > 0.67 (high)"
"16583";"NFS >0.67 (high)"
"16584";"NG"
"16585";"NG (n = 14,080)"
"16586";"NGAL (ng/ml)"
"16587";"ni"
"16588";"Niacin"
"16589";"Niacin (n=87)"
"16590";"niacin, n (%)"
"16591";"Niacin+Statin"
"16592";"Niacini"
"16593";"NICE classification of COPD severity of obstruction, n (%)[2]"
"16594";"NICE primary prevention onlyb"
"16595";"NICE secondary prevention onlyb"
"16596";"Nicotine pack-years"
"16597";"night-time awakenings in past 2 weeks (SD)*"
"16598";"Night-time awakenings in past 2 weeks prior to baseline"
"16599";"Night-time awakenings/week"
"16600";"Nighttime mean DBP (ABPM) at week 12, mmHg"
"16601";"Nighttime mean SBP (ABPM) at week 12, mmHg"
"16602";"NIH Stroke Scale"
"16603";"NIHSS at baseline"
"16604";"NIHSS at randomization"
"16605";"NIHSS at randomization, 0-4"
"16606";"NIHSS score"
"16607";"Nilvadipine"
"16608";"Nintedanib (n = 61)"
"16609";"Nintedanib (n=166)"
"16610";"Nintedanib (n=472)"
"16611";"Nitrate"
"16612";"Nitrate — no. (%)"
"16613";"Nitrate (oral or intravenous)"
"16614";"Nitrate (oral or topical)"
"16615";"Nitrates"
"16616";"Nitrates (%)"
"16617";"Nitrates (oral or topical)"
"16618";"Nitrates, (%)"
"16619";"Nitrates, n (%)"
"16620";"Nitratesf"
"16621";"NKF Stage"
"16622";"NNT"
"16623";"no"
"16624";"No"
"16625";"NO"
"16626";"No-CKD intensive (N= 3244)"
"16627";"No-CKD standard (N= 3262)"
"16628";"No-diuretics group (n=586)"
"16629";"No    9,123"
"16630";"No (%)"
"16631";"no (74.8)"
"16632";"No (n = 309)"
"16633";"No (n = 412)"
"16634";"No (N=1982)"
"16635";"No (N=3441)"
"16636";"No (N=3627)"
"16637";"No (N=3852)"
"16638";"No (N=4206)"
"16639";"No (N=4731)"
"16640";"No (reference)"
"16641";"No ACE-I/ARB"
"16642";"No ACE inhibitor/ARB"
"16643";"No ACS"
"16644";"No active cancer"
"16645";"No Active Cancer Center-Level INR Percent Time"
"16646";"No adk/e cancer"
"16647";"No alcohol consumption, on average,"
"16648";"No aminosalicylates, N"
"16649";"NO AMIODARONE"
"16650";"No anemia Bsl Hb > 120g I-1; Yr 1 > 120g I-1"
"16651";"No antidiabetic drug"
"16652";"No antihypertensive medication"
"16653";"No Antihypertensive Medication"
"16654";"No antiplatelet therapy"
"16655";"No apparent heart disease"
"16656";"NO ASA"
"16657";"No ASA use at baseline"
"16658";"No ASCVD"
"16659";"No ASCVD + additional CV risk factors, n (%)"
"16660";"No aspirin"
"16661";"No aspirin at baseline"
"16662";"No aspirin or PPI"
"16663";"No atopy (n = 883)"
"16664";"No atrial fibrillation"
"16665";"NO BASELINE CHARACTERISTICS"
"16666";"No baseline corticosteroids"
"16667";"No baseline immunosuppressant use"
"16668";"No beta-blocker"
"16669";"No Beta-blocker use"
"16670";"No Betablocker Use"
"16671";"No Body Weight at Randomization (IXRS)"
"16672";"No CAD/MI"
"16673";"No cardiac disease"
"16674";"No cardiovascular disease (n=514)"
"16675";"No cardiovascular disease (n=529)"
"16676";"No cardiovascular disease (n=671)"
"16677";"No Cardiovascular disorder1'"
"16678";"No cases"
"16679";"No change"
"16680";"No CHD"
"16681";"No CHD at baseline"
"16682";"No CHD EZE/SIMVA"
"16683";"No CHD EZE/SIMVA (n = 995)"
"16684";"No CHD EZE/SIMVA 0 = 995}"
"16685";"No CHD SIMVA"
"16686";"No CHD SIMVA („ = 1023)"
"16687";"No CHD SIMVA (n = 1023]"
"16688";"No CKD"
"16689";"No CKD (%)"
"16690";"No CKD N"
"16691";"No CKD Rate (#events)"
"16692";"No Clinical or Lesion RFs for ST"
"16693";"No colchicine (n = 181)"
"16694";"No Concomitant Antiplatelet"
"16695";"No concomitant cortcosteroid use"
"16696";"No Concomitant immunosuppressive and/or prior anti-TNF use"
"16697";"No corticosteroid"
"16698";"No corticosteroid + no IMM, N"
"16699";"No corticosteroid, no IMM"
"16700";"No corticosteroids or immunosuppressants"
"16701";"No CS and IMM"
"16702";"No CS and IS"
"16703";"No culprit vessel identified"
"16704";"No current smoking"
"16705";"No Current Tobacco Use"
"16706";"No CV event (N =4,644)"
"16707";"No CVD"
"16708";"No depression"
"16709";"No Depression"
"16710";"No DES"
"16711";"No diabetes"
"16712";"No Diabetes"
"16713";"No Diabetes (n - 14,355)"
"16714";"No diabetes (N = 1,416)"
"16715";"No Diabetes (P = .07)"
"16716";"No Diabetes (P = .09)"
"16717";"No Diabetes (P = .67)"
"16718";"No Diabetes (P = .88)"
"16719";"No Diabetes (P = .O7)"
"16720";"No Diabetes (P = .O9)"
"16721";"No diabetes mellitus"
"16722";"No Diabetes Mellitus"
"16723";"No Digoxin n=14 778 (70%)"
"16724";"No Digoxin SCD, No. (%/y)"
"16725";"No diuretic therapy"
"16726";"No DM"
"16727";"No DM (n = 4,202)"
"16728";"No DM (n=13273)"
"16729";"No draining fistulas*"
"16730";"No dysglycaemia or MetS"
"16731";"No dysglycaemia or MetS Pbo (N = 119) vs EvoMab (N = 274)"
"16732";"No Dyspnoea (N=5461)"
"16733";"No Dyspnoea (N=5509)"
"16734";"No EF data||"
"16735";"No EPA Group n=457"
"16736";"No EPA Group n=8862"
"16737";"No EPA Group No. of Events (%)"
"16738";"No estimate"
"16739";"No estrogen"
"16740";"No extensive colitis, N"
"16741";"No Family History of CHD (n=290, 274)"
"16742";"No fracture history"
"16743";"No GI Bleed"
"16744";"No glucocorticoids at baseline"
"16745";"No glucocorticoids or immunosuppressants"
"16746";"No glucose lowering drugs"
"16747";"No heart failure"
"16748";"No Heart failure"
"16749";"No hemoconcentration Hemoconcentration"
"16750";"No high-intensity statin"
"16751";"No history of AF"
"16752";"No history of bowel resections"
"16753";"No History of Cancer"
"16754";"No history of CHF"
"16755";"No history of diabetes (n=4526)"
"16756";"No history of extra-intestinal manifestations of IBD (ref)"
"16757";"No history of heart failure at baseline"
"16758";"No history of HF"
"16759";"No history of hypertension (n=2191)"
"16760";"No History of MI (n=278, 281)"
"16761";"No history of migraine"
"16762";"No History of Migraine"
"16763";"No history of paroxysmal AF"
"16764";"No history of TIA/stroke"
"16765";"No history of TNF antagonist treatment — no. (%)"
"16766";"No hospitalization in the past 12 months prior to baseline (ref)"
"16767";"No HTN"
"16768";"No hx of HF (n=15173)"
"16769";"No hypertension"
"16770";"No Hypertension (n=4555)"
"16771";"No ICS"
"16772";"No Ilb/IIIa inhibitors"
"16773";"No immoMtedion"
"16774";"No immunosuppressive agents at baseline"
"16775";"No in-trial stroke N=31,832"
"16776";"No incident DM or change in FG > 13"
"16777";"No Increased Risk for Falls"
"16778";"No inducer at core study entry"
"16779";"No infarct visible"
"16780";"No IPST"
"16781";"No IPST (n = 10,850)"
"16782";"No Ischemia (n = 5,084)"
"16783";"No known frtrontxtfufoc cond Aon"
"16784";"No LABA, no ICS, n (%)"
"16785";"No LABA; no ICS (tiotropium n = 59, placebo n = 63)"
"16786";"No longer met study criteria"
"16787";"No metabolic syndrome"
"16788";"No Metformin"
"16789";"No Metformin Use"
"16790";"No methotrexate, hydroxychloroquine, or sulfasalazine treatment"
"16791";"No MI"
"16792";"No MI (n - 6,308)"
"16793";"No moderate CKD"
"16794";"No MRA at baseline"
"16795";"No MRA at Baseline"
"16796";"No MTX at baseline"
"16797";"No MTX use at baseline"
"16798";"No Multivessel Disease"
"16799";"No MVD (n - 8,600)"
"16800";"No Myocardial Infarction at Presentation (N=8072)"
"16801";"No Nadroparin (n = 259)"
"16802";"No nasal polyps"
"16803";"No new A or and no more than 1 new BILAG B domain score, %"
"16804";"No new erosions among patients with ≥1 uninvolved joint at baseline¶"
"16805";"No new JSN among patients with ≥1 uninvolved joint at baseline¶"
"16806";"No nonsevere hypoglycemia"
"16807";"No OAM"
"16808";"No OCS"
"16809";"No OCS use, no nasal polyps, pre-BD FVC s65% of predicted and age at diagnosis <18 years"
"16810";"No of Events / Total N (%)"
"16811";"No of events women men*"
"16812";"No of events womenmen*"
"16813";"No of events/total N (%)"
"16814";"No OP, no VFx"
"16815";"No OP, VFx"
"16816";"No or unknown"
"16817";"No oral antidiabetic medication"
"16818";"No p-blocker intake at randomisation (n=685)"
"16819";"No P-blocker intake at randomisation (n=685)"
"16820";"No p Value for Ischemia Ischemia HR (95% CI) Interaction"
"16821";"No pa"
"16822";"No PAD (n - 20,017)"
"16823";"No PAD baseline"
"16824";"No PAH-specific therapy"
"16825";"No PAH therapy"
"16826";"No PCI"
"16827";"No PCI or CABG — no. (%)"
"16828";"No Peripheral Revascularization (n = 4,911)"
"16829";"No Persistent WRF (n = 1,658)"
"16830";"No PO"
"16831";"No polyvascular disease (n=16 204)"
"16832";"No polyvascular disease* (n=16 204)"
"16833";"NO PPI"
"16834";"No Pretreatment"
"16835";"No previous CD related surgery3"
"16836";"No previous COPD medication"
"16837";"No Previous CV Event"
"16838";"No Previous Diagnosis of Diabetes Mellitus"
"16839";"No previous DMARD therapy"
"16840";"No Previous Ischemic Stroke/ TIA (n=15 132; 71.7%)"
"16841";"No previous myocardial infarction"
"16842";"No previous myocardial infarction 117/2659"
"16843";"No previous myocardial infarction 87/2659"
"16844";"No previous stroke or TIA (n=4819)"
"16845";"No previous stroke or TIA (n=4827)"
"16846";"No previous stroke or TIA (n=4843)"
"16847";"No previous stroke orTIA"
"16848";"No previous stroke/TIA"
"16849";"No previous treatment with infliximab"
"16850";"No Prior ADMc"
"16851";"No prior angina (n = 3,475)"
"16852";"No prior aspirin"
"16853";"No Prior CABG"
"16854";"No Prior Cancer"
"16855";"No Prior CV Event"
"16856";"No Prior CVD"
"16857";"No Prior DM"
"16858";"No Prior Heart Failure"
"16859";"No Prior Heart Failure (n = 14,387)"
"16860";"No prior HF (n = 5,286)"
"16861";"No prior HF hospitalization"
"16862";"No Prior HF Hospitalization (n = 3,125)"
"16863";"No Prior HF Hospitalization (n = 3,125)"
"16864";"No Prior HF n=5277"
"16865";"No prior HTN (n = 4,653)"
"16866";"No prior LGI event"
"16867";"No prior LLT"
"16868";"No prior MI"
"16869";"No Prior MI"
"16870";"No prior MI (n = 13,576)"
"16871";"No prior MI (n = 4,142)"
"16872";"No Prior MI n=4136"
"16873";"No prior Ml"
"16874";"No Prior Ml"
"16875";"No prior Ml or stroke"
"16876";"No prior MS therapies"
"16877";"No prior OMA use"
"16878";"No prior OMA use (N = 591)"
"16879";"No Prior PCI"
"16880";"No prior revascularization (n = 4,661)"
"16881";"No Prior Statin (n=44, 51)"
"16882";"No prior statin use"
"16883";"No Prior STEMI"
"16884";"No prior stroke"
"16885";"No Prior Stroke"
"16886";"No prior stroke (N = 6489)"
"16887";"No Prior stroke/TIA"
"16888";"No Prior Stroke/TIA"
"16889";"No prior TNF inhibitor exposure"
"16890";"No prior UGI event"
"16891";"No Readmission (n=1442)"
"16892";"No regular aspirin use"
"16893";"No regular consumption"
"16894";"No regular PPI use"
"16895";"No renal dysfunction"
"16896";"No Renal Dysfunction"
"16897";"No reperfusion"
"16898";"No resistant HTN n = 1,361"
"16899";"No revascularisation"
"16900";"No revascularization for index ACS event"
"16901";"No revascularization for index ACS event, no. (%)"
"16902";"No Second MI"
"16903";"No severe hypoglycemia"
"16904";"No smoking"
"16905";"No Smoking"
"16906";"No ST Depression or Elevation"
"16907";"No statin"
"16908";"No Statin"
"16909";"No statin (+/-LLT)"
"16910";"No statin during admission"
"16911";"No statin group"
"16912";"No Statin Use"
"16913";"No statin vs statin alone vs any statin plus other LLT"
"16914";"No steroid use at baseline (ref)"
"16915";"No steroids (n=74 vs 39)"
"16916";"No Stroke (N=17503)"
"16917";"no stroke n=13 889"
"16918";"No Stroke/TIA"
"16919";"No STSD >1 mm on admission (n = 4,109)"
"16920";"No Ststm"
"16921";"No symptoms"
"16922";"No Thienopyridine"
"16923";"No treatment or antihistamines only"
"16924";"No Type 2 Diabetes (n=336, 335)"
"16925";"No use"
"16926";"No use of 5-ASA compounds"
"16927";"No use ofdiabetes drugs — no. (%)"
"16928";"No VHD"
"16929";"No VHD Event Rate/Year (n)"
"16930";"No VKA at randomization"
"16931";"No VKA at Randomization"
"16932";"No worsening in PGA, %"
"16933";"No(n = 16,011)"
"16934";"No*"
"16935";"no."
"16936";"No."
"16937";"no. (%)"
"16938";"No. (%)"
"16939";"No. (%)'"
"16940";"No. (%) 182 (73)"
"16941";"No. (%) of Individuals*"
"16942";"No. (%) of participants"
"16943";"No. (%) of Participants"
"16944";"No. (%) of patients with ≥3% BSA affected"
"16945";"No. (%) of Patients With Atrial Tachyarrhythmia"
"16946";"No. (%) of patients with fingernail involvement"
"16947";"No. (%) of Patients With Stroke"
"16948";"No. (%) With Event [Incidence Rate per 100 patient-y]"
"16949";"No. (%)*"
"16950";"No. *"
"16951";"No. copies Gly16-Glu27-523C"
"16952";"No. evenls"
"16953";"No. fingernails"
"16954";"No. in the 12 mo before screening"
"16955";"No. Japanese"
"16956";"No. men"
"16957";"No. Needed to Treat (95% Cl)*"
"16958";"No. of"
"16959";"No. of ' signs or symptoms of CHFf"
"16960";"No. of 500-mg acetaminophen tablets/day"
"16961";"No. of 500-mg tablets of acetaminophen"
"16962";"No. of agents"
"16963";"No. of background glucose-lowering therapies, No. (%)"
"16964";"No. of cardiovascular events (cardiovascular events/1000 person-years)"
"16965";"No. of coronary vessels with >50% diameter stenosis"
"16966";"No. of days to HOMA-IR testing — median (IQR)"
"16967";"No. of days to randomization — median (IQR)"
"16968";"No. of Deaths"
"16969";"No. of diseased vessels (% of group)"
"16970";"No. of Drugs"
"16971";"no. of events"
"16972";"No. of events"
"16973";"No. of Events"
"16974";"No. of events (rate)"
"16975";"No. of events / total"
"16976";"no. of events/no. of patients"
"16977";"No. of Events/Patients"
"16978";"No. of events/patients %/yr"
"16979";"No. of Events/Sample Size"
"16980";"No. of Events/Sample Size I    I"
"16981";"no. of events/total no. (%)"
"16982";"no. of events/total no. 1%)"
"16983";"no. of events/totol no. (%)"
"16984";"No. of exacerbations in past year"
"16985";"No. of hospitalised patients"
"16986";"No. of infusions"
"16987";"No. of moderate or severe exacerbations in previous"
"16988";"No. of Non-TNFI"
"16989";"No. of pack-yr"
"16990";"no. of panents.total no. 1%)"
"16991";"no. of participants"
"16992";"No. of participants"
"16993";"No. of Participants (%)"
"16994";"no. of participants with events (%)"
"16995";"no. of patients"
"16996";"No. of patients"
"16997";"No. of Patients"
"16998";"No. OF Patients"
"16999";"No. of patients (%)"
"17000";"No. of Patients (Indacaterol/Placebo)"
"17001";"No. of patients IND/GLY SFC"
"17002";"No. of patients with AS"
"17003";"No. of patients with events (%)"
"17004";"No. of patients with PsA"
"17005";"No. of patients with RA"
"17006";"No. of patients/no. of events"
"17007";"no. of patients/no. of events (%) 742/2067 (36)    763/2061 (37)"
"17008";"no. of patients/total no. (%)"
"17009";"No. of predictors of cardiovascular risk"
"17010";"No. of previous anti-TNF drugs — no. (%)"
"17011";"No. of previous biologic DMARDs — no. (%)"
"17012";"No. of previous CIU/CSU medications"
"17013";"No. of previous CIU/CSU medications, mean (median)"
"17014";"No. of previous csDMARDs, n (%)"
"17015";"No. of previous TNE inhibitors"
"17016";"No. of previous venous thromboembolic events"
"17017";"No. of prior AEDs, n (%)"
"17018";"No. of prior AEDs, n (%) 0-1"
"17019";"No. of prior AEDs,c n(%)"
"17020";"No. of prior AEDsd"
"17021";"No. of Prior bDMARDs"
"17022";"No. of Prior TNFi"
"17023";"No. of risk factors (%)||"
"17024";"No. of risk factors for venous thromboembolism, no. (%)"
"17025";"No. of stents"
"17026";"No. of strokes (%)"
"17027";"No. of strokes/no. of patients in category (and %)"
"17028";"No. of subjects"
"17029";"No. of target vessels"
"17030";"No. of TNFi Among Non-TNFi Naive"
"17031";"No. of treated lesions"
"17032";"No. of treated vessels"
"17033";"No. of vessels"
"17034";"No. of vessels treated"
"17035";"No. of vessels with >50% stenosis"
"17036";"No. patients (%)"
"17037";"No. patients with"
"17038";"No. previous alpha-blocker use"
"17039";"No. previous DMARD, mean (SD)"
"17040";"No. pts"
"17041";"No. randomized"
"17042";"no. with event/total no. {%)"
"17043";"No. With Visit"
"17044";"No. women"
"17045";"No.*"
"17046";"No./100 Person-Yr"
"17047";"NO./100 Person-Yr"
"17048";"no./total"
"17049";"no./total no. (%)"
"17050";"no./total no. (%)t"
"17051";"no./total	no. (%)"
"17052";"No.a"
"17053";"no.of participants per 1000 patient-yr"
"17054";"No/unknown"
"17055";"No?"
"17056";"Nob Systolic blood pressure (mm Hg)"
"17057";"NoCAD/MI"
"17058";"Nocturia episodes/24h"
"17059";"Nocturnal back pain, 0–100 mm VAS, mean ± SD"
"17060";"Nocturnal symptoms in past week"
"17061";"Noirecerving"
"17062";"Noliecervrig"
"17063";"Nominal change"
"17064";"Nominal P vs placebo"
"17065";"Non- HDL-C"
"17066";"Non- White"
"17067";"Non-/Ex-drinker"
"17068";"Non-/Ex-tobacco User"
"17069";"non-anterior"
"17070";"Non-anterior"
"17071";"Non-Anterior"
"17072";"Non-Asian"
"17073";"Non-Asian (n=15 331)"
"17074";"Non-biological systemic"
"17075";"Non-black"
"17076";"Non-Black"
"17077";"Non-Black (n = 371)"
"17078";"Non-Black (n = 397)"
"17079";"Non-Black (n = 408)"
"17080";"Non-Black (n = 422)"
"17081";"Non-black participants"
"17082";"Non-Black race (n=496 vs 246)"
"17083";"Non-Black race and SS <9 (n=183 vs 96)"
"17084";"Non-Black race and SS >10 (n=313 vs 150)"
"17085";"Non-C"
"17086";"Non-CABG related bleeding at 48 h"
"17087";"Non-Calcium Antagonist Strategy (n = 11 309)"
"17088";"Non-Calcium Antagonist Strategy (NCAS) (events/n)"
"17089";"Non-CANA (n = 1178)"
"17090";"Non-CANA (n = 2109)"
"17091";"Non-CANA (n = 309)"
"17092";"Non-CANA (n = 621)"
"17093";"Non-cardiovascular Mortality"
"17094";"Non-carrier (N=135)"
"17095";"Non-caucasian"
"17096";"Non-Caucasian"
"17097";"Non-Caucasian EZE/SIMVA"
"17098";"Non-Caucasian EZE/SIMVA („ = 154}"
"17099";"Non-Caucasian EZE/SIMVA (n = 154)"
"17100";"Non-Caucasian SIMVA"
"17101";"Non-Caucasian SIMVA („ = 179}"
"17102";"Non-Caucasian SIMVA (n = 179)"
"17103";"Non-colorectal cancer"
"17104";"Non-compliance"
"17105";"Non-cortical"
"17106";"Non-CV mortality"
"17107";"Non-CVD deaths"
"17108";"Non-CVD mortality"
"17109";"Non-detectable/unknown"
"17110";"Non-detectable/unknown, n (%)"
"17111";"Non-diabetes"
"17112";"Non-diabetic"
"17113";"Non-Diabetic"
"17114";"Non-diabetic (n=1914)"
"17115";"Non-diabetic patients"
"17116";"Non-diabetic subjects, N=1957"
"17117";"Non-diabetics"
"17118";"Non-diabetics (n = 13892)"
"17119";"Non-dihydropyridine CCBs"
"17120";"Non-DM"
"17121";"Non-drug-eluting stent"
"17122";"Non-early Crohn's disease"
"17123";"Non-East Asian§"
"17124";"Non-East Asianf"
"17125";"Non‐elderly"
"17126";"Non-elderly (<65 years)"
"17127";"Non-end-stage renal dysfunction"
"17128";"Non-Endstage Renal Dysfunction*"
"17129";"Non-EPA (n = 2262)"
"17130";"Non-EPA (n = 7057)"
"17131";"non-EPA Number of <"
"17132";"Non-EPA(n = 2262)"
"17133";"Non-EPA(n = 7057)"
"17134";"Non-European Trial"
"17135";"Non-extensive"
"17136";"Non-fatal MI"
"17137";"Non-fatal Ml"
"17138";"Non-fatal myocardial infarction"
"17139";"Non-fatal stroke"
"17140";"Non-fibrin-specific"
"17141";"Non-frail"
"17142";"Non‐haemorrhagic stroke—No. (%)"
"17143";"Non-HDL"
"17144";"non-HDL-C"
"17145";"Non-HDL-C"
"17146";"Non-HDL-C (mg/dL)"
"17147";"Non-HDL-C (mg/dL)- mean ± SD"
"17148";"Non-HDL-C (mg/dl) **"
"17149";"Non-HDL-C (mmol/L)"
"17150";"Non-HDL-C (mmol/L, mean)"
"17151";"Non-HDL-C in 4 classes"
"17152";"Non-HDL-C*"
"17153";"Non-HDL-C, mean (SD)"
"17154";"Non-HDL-C, mean (SD), rng/dL"
"17155";"Non-HDL-C, mg/dl"
"17156";"Non-HDL-C, mg/DL"
"17157";"Non-HDL-C, mg/dL, mean (SD)"
"17158";"Non-HDL-C, mmol/L"
"17159";"Non-HDL-C, mmol/l, mean (SD)"
"17160";"Non-HDL-C/HDL-C"
"17161";"Non-HDL (mg/dl) <130"
"17162";"Non-HDL choleslerol"
"17163";"Non-HDL cholesterol"
"17164";"Non‐HDL cholesterol"
"17165";"Non-HDL cholesterol (mg/dl)"
"17166";"Non-HDL cholesterol (mg/dL)"
"17167";"Non-HDL cholesterol (week 24)"
"17168";"Non-HDL cholesterol J"
"17169";"Non-HDL cholesterol(mmol/l)"
"17170";"Non-HDL cholesterol/ApoB (ratio)"
"17171";"Non-HDLC"
"17172";"Non-High Density Lipoprotein (mg/dL) - Baseline - < Median (n=204, 212)"
"17173";"Non-High Density Lipoprotein (mg/dL) - Baseline - >= Median (n=214, 199)"
"17174";"Non-HisHnic"
"17175";"Non-Hispanic"
"17176";"Non-Hispanic and Latino"
"17177";"Non-Hispanic black"
"17178";"Non-Hispanic black or African-American"
"17179";"Non-Hispanic or Latino"
"17180";"Non-Hispanic white"
"17181";"Non-Hispanic, non-Latino"
"17182";"Non-Hispanic/Latino"
"17183";"Non-Hispanicwhite"
"17184";"Non-ICS+"
"17185";"Non-inhaled steroid use, n (%)"
"17186";"Non-insulin treated DM"
"17187";"Non-ischaemic"
"17188";"Non-ischaemic (n=2087)"
"17189";"Non-ischaemic (n=2O87)"
"17190";"Non-ischaemic aetiology"
"17191";"Non-ischaemic cardiomyopathy"
"17192";"Non-ischaemic cause"
"17193";"Non-ischaemic dilated cardiomyopathy"
"17194";"Non-Ischemic"
"17195";"Non-LAD artery"
"17196";"Non-MetS"
"17197";"Non-MetSyn"
"17198";"Non-MTX"
"17199";"Non-MTX csDMARDs"
"17200";"Non-PCI intravenous unfractionated heparin"
"17201";"Non-Q-wave myocardial infarction"
"17202";"Non-reversible (%)"
"17203";"Non-rheumatic valvular heart disease"
"17204";"Non-rollover"
"17205";"Non-severe hypoglycaemia"
"17206";"Non-smoker"
"17207";"Non-smoker (n=328, 313)"
"17208";"Non-smokers (at baseline)"
"17209";"Non-smokers receiving lipid-lowering drugs, p blockers,"
"17210";"Non-smokers receiving lipid-lowering drugs, p blockers, and either an ACE inhibitor or angiotension receptor blocker"
"17211";"Non-smokers receiving lipid lowering drugs, (5 blockers, and either an ACE inhibitor or angiotension receptor blocker"
"17212";"Non-spondylitis"
"17213";"Non-ST-elevation MI"
"17214";"Non-ST-Elevation MI"
"17215";"Non-ST-elevation Ml"
"17216";"Non-ST-Elevation Ml"
"17217";"Non-ST-elevation myocardial infarction"
"17218";"Non-ST-segment elevation"
"17219";"Non-ST-segment elevation ACS"
"17220";"Non-ST-Segment Elevation ACS"
"17221";"Non-ST-segment elevation MI"
"17222";"Non-ST-segment elevation myocardial infarction"
"17223";"Non-ST—elevation MI"
"17224";"non-statin (n=1054)"
"17225";"non-statin (n=704)"
"17226";"Non-STEMI"
"17227";"Non-stenotic vessels, n (%)"
"17228";"Non-steroidal anti-inflammatory drugs"
"17229";"Non-study PPI use"
"17230";"Non-sulfonylurea secretagogues"
"17231";"non-tiotropium"
"17232";"Non-tiotropium"
"17233";"Non-TNF inhibitors"
"17234";"Non-transient risk factors for recurrent VTE, n (%)"
"17235";"Non-trial antiplatelet"
"17236";"Non-trial p blocker"
"17237";"Non-trial treatment during hospital stay"
"17238";"Non-U.S."
"17239";"Non-United States"
"17240";"Non-US"
"17241";"Non-US (N=6845)"
"17242";"Non-user 1"
"17243";"Non-white"
"17244";"Non-White"
"17245";"Non-White race"
"17246";"Non-White Raceb"
"17247";"non–small-cell lung cancer"
"17248";"Non—ST-segment—elevation myocardial infarction"
"17249";"Non CNS embolism"
"17250";"Non CV Mortality"
"17251";"Non diuretics"
"17252";"Non High Dose Statin (n=168, 170)"
"17253";"Non Stent Thrombosis-Related MI"
"17254";"Non USA"
"17255";"Non white"
"17256";"Nonanterior"
"17257";"Nonaspirin antiplatelet"
"17258";"Nonaspirin antiplatelet agent"
"17259";"Nonbiologic disease-modifying drug other than methotrexate::"
"17260";"Nonblack"
"17261";"Nonblack (n=1465)"
"17262";"Nonblack (n=1465); Adjusted Hazard Ratio*"
"17263";"Nonblack Participants"
"17264";"Nonblack race — no. (%)-j-"
"17265";"Nonblack race — no. (%)f"
"17266";"Noncardiac death"
"17267";"Noncardiovascular"
"17268";"Noncardiovascular death"
"17269";"Noncaucasian"
"17270";"Noncomplex Anatomy (n - 7,824)"
"17271";"Noncompliant"
"17272";"Noncurrent smoker"
"17273";"Nondiabetes"
"17274";"Nondiabetic"
"17275";"Nondiabetic participants!"
"17276";"Nondisabling, nonfatal stroke"
"17277";"none"
"17278";"None"
"17279";"None (cDMARD-naive or past use at baseline)"
"17280";"None (n = 4216)"
"17281";"None 一 no. (%)"
"17282";"None at baseline"
"17283";"None of the above"
"17284";"None or diet"
"17285";"None or Seldom"
"17286";"NoneH"
"17287";"Nonfatai Myocardiai infarction"
"17288";"Nonfatal"
"17289";"Nonfatal ischemic stroke"
"17290";"Nonfatal MI (N = 316)"
"17291";"Nonfatal MI+fatal CHDt"
"17292";"Nonfatal Ml"
"17293";"Nonfatal Myocardiail Infarction"
"17294";"Nonfatal myocardial infarction"
"17295";"Nonfatal myocardial infarction®"
"17296";"Nonfatal stroke"
"17297";"Nonfatal stroke (N=57)"
"17298";"Nonfatal stroke®"
"17299";"Nonglycemic cardiovascular risk factors"
"17300";"Nonglycemic cardiovascular risk factors Systolic blood pressure — mmHg"
"17301";"Noninducing"
"17302";"Noninsulin therapy"
"17303";"Nonischemic"
"17304";"Nonischemic cardiomyopathy"
"17305";"Nonischemic cardiomyopathy — no. (%)"
"17306";"Nonmetabolic Syndrome (n = 5196)"
"17307";"Nonobese (<30 kg/nr)"
"17308";"nonreversible"
"17309";"Nonsevere hypoglycemia"
"17310";"Nonsmoker"
"17311";"Nonsmoker, n (%)"
"17312";"Nonsustained ventricular tachycardia — no. (%)-j-"
"17313";"Nontatal Ml"
"17314";"Nontraumatic leg or foot amputation"
"17315";"Nontrial PPI"
"17316";"Nonuser"
"17317";"Nonvertebral"
"17318";"Nonwhite"
"17319";"Nonwhite race"
"17320";"Nonwhite race — no. (%) Ejection fraction"
"17321";"Nonwhite race!"
"17322";"NOPPI"
"17323";"Nordic"
"17324";"Nordic countries"
"17325";"Normai Fasting Giucose Levei (n = 1425)"
"17326";"Normal"
"17327";"Normal-high renin (PRA >0.65 ng/mL/h) (n=144)"
"17328";"Normal (£90 ml/minute)"
"17329";"Normal (<34.99 U/ml)"
"17330";"Normal (≤ ULN) n = 371"
"17331";"Normal (≥90 mL·min−1·1.73 m−2), n (%)"
"17332";"Normal (>80)"
"17333";"Normal (>90 mL/min)"
"17334";"Normal (>90 mLVmin per 1.73 m2)"
"17335";"Normal (>90)"
"17336";"Normal (BMI <25)"
"17337";"Normal (eGFR ≥90), N (%)"
"17338";"Normal (eGFR >90)"
"17339";"Normal >0-90"
"17340";"normal ACR (<30 mg/mg) at baseline to albuminuria (ACR >30 mg/g)"
"17341";"Normal albuminuria (UACR <30)"
"17342";"Normal baseline CRP"
"17343";"Normal BNP, ^80 pg/ml (n = 2,542)"
"17344";"Normal cognitive"
"17345";"Normal cognitive function (SPMSQ <2). N-1.616 N (%) participants with the event of interest"
"17346";"Normal coronary angiography"
"17347";"Normal CRP and"
"17348";"normal eGFR (60 < eGFR < 130 ml/min per 1.73 m2) at baseline to high eGFR (>130 ml/min per 1.73 m2)"
"17349";"Normal Fasting Glucose Level (n = 1425)"
"17350";"normal Function (crcl >95 ml/ min; n=3123 [22.2%])"
"17351";"Normal function or mild impairment"
"17352";"Normal HbA1c, n=2158"
"17353";"Normal hsCRP"
"17354";"Normal left ventricular ejection fraction — no. (%)J"
"17355";"normal or high eGFR (>60 ml/min per 1.73 m2) at baseline to low eGFR (<60 ml/min per 1.73 m2)"
"17356";"Normal or Increased Baseline GFR (>90 mL/min/1.73 m2)"
"17357";"Normal or Increased eGFR"
"17358";"Normal or Increased GFR (>90 mL/mln per 1.73 m^)"
"17359";"Normal or mild (IIEF-EF 17-30), n (%)"
"17360";"Normal renal function"
"17361";"Normal responder"
"17362";"Normal Responder (N=2982)"
"17363";"normal responders (n=2459)"
"17364";"Normal study termination"
"17365";"Normal Troponin"
"17366";"Normal weight (BMI <25)"
"17367";"Normal, <90"
"17368";"Normal/mild CKD"
"17369";"Normalfunction or mild impairment"
"17370";"Normalized"
"17371";"Normalized volume measures"
"17372";"Normalized WOMAC score"
"17373";"Normoalbuminuria"
"17374";"Normoalbuminuria — no. (%)"
"17375";"Normoalbuminuria — no./total no. (%)"
"17376";"Normoalbuminuria (UACR <30 mg/g)"
"17377";"Normoalbuminuria at baseline (59% of patients treated)"
"17378";"Normoalbuminuria or microalbuminuria"
"17379";"Normoalbuminuria, No. (%)"
"17380";"Normoalbuminuria§"
"17381";"Normoglycaemic individuals, n (%)"
"17382";"Normoglycemia"
"17383";"Normoglycemia^"
"17384";"Normoglycemic"
"17385";"Normoglycemic^"
"17386";"Normoglycemic{"
"17387";"Normoglycemic3"
"17388";"Normonatremic (>135 mEq/L) at Baseline"
"17389";"Normotensive (n=314)"
"17390";"North"
"17391";"North America"
"17392";"North America (%)"
"17393";"North America (n=162)"
"17394";"North America (n=1960)"
"17395";"North America (plus America and New Zealand)"
"17396";"North America (plus Australia and New Zealand)"
"17397";"North America HR (95% Cl)"
"17398";"North America n Z 786"
"17399";"North America plus Australia and New Zealand"
"17400";"North America*"
"17401";"North America/Oceania"
"17402";"North American"
"17403";"North Ameriea"
"17404";"NorthAmerica"
"17405";"NOS3 2690 C.T, n (%)"
"17406";"NOS3 2922 A.G, n (%)"
"17407";"NOS3 glu298asp G.T, n (%)"
"17408";"Not-Japan"
"17409";"Not-Japan N = 3,066"
"17410";"Not anterior"
"17411";"Not assessable"
"17412";"Not at goal"
"17413";"not available"
"17414";"Not available"
"17415";"Not collected^"
"17416";"Not estimable"
"17417";"Not Hispanic"
"17418";"Not Hispanic or Latino"
"17419";"Not Hispanic or Latino (n — 247)"
"17420";"Not Hispanic or Latino (n=7644)"
"17421";"Not Hispanic/Latino"
"17422";"Not Hispanic/Latino (n=7,644)"
"17423";"Not Hispanie/Latino"
"17424";"Not hospitalized for heart failure in the year prior to study enrollment"
"17425";"Not localized"
"17426";"Not on an AHA"
"17427";"Not on metformin"
"17428";"not perfused"
"17429";"Not present at screening, but within previous year"
"17430";"Not provided"
"17431";"Not Rando. in NA*"
"17432";"Not receiving"
"17433";"Not reported"
"17434";"Not reported in eCRF"
"17435";"Not reported/unknown"
"17436";"Not Severe"
"17437";"Not tested"
"17438";"Not treated"
"17439";"Notable abnormalities"
"17440";"NotatIncreased Fall Risk (n - 20,205)"
"17441";"Notes:"
"17442";"NotHFrEF"
"17443";"NP Tercile 1 (BNP <166 pg/ml, NT-proBNP <682 pg/ml) (n - 230)"
"17444";"NP Tercile 3 (BNP >322 pg/ml, NT-proBNP >1,431 pg/ml) (n - 227)"
"17445";"NPH"
"17446";"NPI-12 score*"
"17447";"NPTercile2(BNP166-322 pg/ml, NT-proBNP 684-1,431 pg/ml) (n - 230)"
"17448";"ns"
"17449";"Ns"
"17450";"NS"
"17451";"Ns cardiac cisease"
"17452";"NSAID"
"17453";"NSAID use — no./total no. (%)"
"17454";"NSAID at Least Once"
"17455";"NSCLC"
"17456";"NSTE-ACS"
"17457";"NSTE-MI"
"17458";"NSTE ACS"
"17459";"NSTEACS"
"17460";"NSTEMI"
"17461";"NSTEMI (%)"
"17462";"NSTEMI (n = 3,240)"
"17463";"NT-pro-BNP"
"17464";"NT-pro-BNP— pmol/liter-j-"
"17465";"NT-pro-BNP — pmol/literf"
"17466";"NT-pro BNP"
"17467";"NT-proBNP — pg/ml"
"17468";"NT-proBNP —pg/ml**"
"17469";"NT-proBNP ( pg/mL)"
"17470";"NT-proBNP (pg/ml)"
"17471";"NT-proBNP (pg/mL) (Q1-Q3)"
"17472";"NT-proBNP (pg/ml)H"
"17473";"NT-proBNP pg/mLa (IQR)"
"17474";"NT-proBNP pg/mLa(IQR)"
"17475";"NT-proBNP values were reported in 868 of 981 patients enrolled in this stratum"
"17476";"NT-proBNP, median (IQR), pg/mL"
"17477";"NT-proBNP, median pg/ml"
"17478";"NT-proBNP, pg/ml"
"17479";"NT-proBNP, pg/mL"
"17480";"NT-proBNP, pg/mLt"
"17481";"NT-proBNP, pmol/H"
"17482";"NT-proBNP, pmol/L"
"17483";"NT-proBNP, pmol/L^"
"17484";"NT-proBNP，pmol/H"
"17485";"NT-proBNP11 pmol-L-1"
"17486";"Nt estimated"
"17487";"NT proBNP > 500 ng/mL n (%)§"
"17488";"NTBNP (n=257)"
"17489";"nteraction p value"
"17490";"nternational Index of"
"17491";"NTpro-CNP (ng/ml)"
"17492";"NTproBNP (pg/mL)"
"17493";"numab"
"17494";"Number"
"17495";"Number (%)"
"17496";"Number (%) of patients"
"17497";"Number (%) of patients with event"
"17498";"Number (%) reporting migraine on 12-month questionnaire"
"17499";"Number and % of participants with events, and incidence rate per 100 person-year"
"17500";"Number insulin glargine"
"17501";"Number of (%) females"
"17502";"Number of (%) patients >65 years"
"17503";"Number of “off” periods"
"17504";"Number of agents"
"17505";"Number of antidiabetes drugs at screening, n (%)"
"17506";"Number of antihypertensive agent reported"
"17507";"Number of antihypertensive medications at study entry"
"17508";"Number of antihypertensive medications used, n (%) No antihypertensive therapy"
"17509";"Number of antihypertensive medications, n (%)"
"17510";"Number of arterial beds involved"
"17511";"Number of clinically significant asthma exacerbations in last year prior to baseline"
"17512";"Number of co-AEDs, n (%)"
"17513";"Number of concomitant AEDs, n (%)"
"17514";"Number of concomitant AEDsc"
"17515";"Number of concomitant csDMARDs, n (%)"
"17516";"Number of COPD exacerbations in the previous year, n (%)"
"17517";"Number of COPD exacerbations in the previous year, n (%)"
"17518";"Number of COPD exacerbations within 12 months, mean (SD)"
"17519";"Number of diseased vessels, mean (SD)"
"17520";"Number of draining fistulae per patient, n"
"17521";"Number of e"
"17522";"Number of ER visits in last year prior to baseline"
"17523";"number of events"
"17524";"Number of events (annualised rate [%])"
"17525";"Number of events, event per 1000 person-years"
"17526";"Number of events/patients"
"17527";"Number of exacerbation in the previous 12 months, n (%)"
"17528";"Number of exacerbations"
"17529";"Number of exacerbations 12 months before randomisation"
"17530";"Number of exacerbations in last 12 months,"
"17531";"Number of exacerbations in previous 12 months"
"17532";"Number of exacerbations in previous 12 months"
"17533";"Number of exacerbations in previous year, mean (SD)"
"17534";"Number of exacerbations in the 12 months before screening"
"17535";"Number of exacerbations in the last 12 months,"
"17536";"Number of exacerbations in the last 12 months, mean ± SD"
"17537";"Number of exacerbations in the past 12 months"
"17538";"Number of females n (%)"
"17539";"Number of hospitalizations in last year prior to baseline"
"17540";"Number of implanted stents, n, mean (SD)"
"17541";"Number of individuals"
"17542";"Number of lesions, n (%)a"
"17543";"Number of medications, n (%)"
"17544";"Number of pack-years"
"17545";"Number of Pack Years"
"17546";"Number of participants"
"17547";"Number of participants with an event"
"17548";"number of patients"
"17549";"Number of patients"
"17550";"Number of Patients"
"17551";"Number of patients (%) or mean 士 SD"
"17552";"Number of patients (%) or mean ±SD"
"17553";"Number of patients >65 years (%)"
"17554";"Number of patients randomized"
"17555";"Number of patients with"
"17556";"Number of patients with available data"
"17557";"Number of patients with dose available"
"17558";"Number of patients with events"
"17559";"Number of patients with exacerbations in the previous 12 months, n (%)"
"17560";"Number of patients with fractures"
"17561";"Number of people (n)"
"17562";"Number of prevalent vertebral fractures"
"17563";"Number of previous anti-TNF treatments for PsA, n (%)"
"17564";"Number of previous anti-TNF treatments for psoriatic arthritis"
"17565";"Number of previous DMARDS"
"17566";"Number of previous reported AEDs"
"17567";"Number of previous TNFa inhibitors"
"17568";"Number of prior AEDs"
"17569";"Number of prior AEDs, n (%)"
"17570";"Number of prior AEDs, n (%)"
"17571";"Number of prior csDMARDS, n (%)"
"17572";"Number of stent=1"
"17573";"Number of stent=l or 2 or 3"
"17574";"Number of stents"
"17575";"Number of stents (per patient)"
"17576";"Number of stents implanted"
"17577";"Number of subjects"
"17578";"Number of Subjects in Analysis"
"17579";"Number of swollen joints (0-66)"
"17580";"Number of swollen joints (0-66), mean (SD)"
"17581";"Number of swollen joints (66 assessed)"
"17582";"Number of target vessels,"
"17583";"Number of tender joints (0-68)"
"17584";"Number of tender joints (0-68), mean (SD)"
"17585";"Number of tender joints (68 assessed)"
"17586";"Number of treated lesions"
"17587";"Number of treated lesions (per patient)"
"17588";"Number of treated patients"
"17589";"Number of treated vessels"
"17590";"Number of treated vessels (per patient)"
"17591";"Number of vessels disease"
"17592";"Number of vessels treated, index PCI"
"17593";"Number of visits, mean ± SD"
"17594";"Number of visits, median"
"17595";"Number ol (%) patients >65 years"
"17596";"Number omega-3 Number placeb fatty acid"
"17597";"Number randomized"
"17598";"Number resulting in ED visit"
"17599";"Number resulting in emergency department visit"
"17600";"Number resulting in hospital admission"
"17601";"Number standard care"
"17602";"Number stent >2"
"17603";"Number stent >3"
"17604";"Number(s) of features present"
"17605";"Numbera"
"17606";"Numbers of events (%):"
"17607";"Nutraceuticals, n (%)"
"17608";"NVF at FLEX baseline -2 < FLEX FN T- score"
"17609";"Nx*"
"17610";"NYHA"
"17611";"NYHA cHF class"
"17612";"NYHA class"
"17613";"NYHA Class"
"17614";"NYHA class — no. (%)"
"17615";"NYHA class —no. (%)"
"17616";"NYHA class —no. (%)$"
"17617";"NYHA class (when patient was last in stable condition"
"17618";"NYHA class (when patient was last in stable condition before admission), %"
"17619";"NYHA class >II"
"17620";"NYHA class 2-4: No { n=llll)"
"17621";"NYHA class 3 or higher"
"17622";"NYHA class I"
"17623";"NYHA class II"
"17624";"NYHA class II (n=3169)"
"17625";"NYHA class II (n=3l69)"
"17626";"NYHA class III"
"17627";"NYHA class III or IV (n=3334)"
"17628";"NYHA class III or IV, n (%)"
"17629";"NYHA class III, % (n)"
"17630";"NYHA class III/IV"
"17631";"NYHA class IV"
"17632";"NYHA class not reported"
"17633";"NYHA class within past month — no./total no. (%)"
"17634";"NYHA class, (%)"
"17635";"NYHA class, n (%)"
"17636";"NYHA Class, n (%)    I"
"17637";"NYHA class, n (%) I"
"17638";"NYHA class, n (%) II"
"17639";"NYHA classes III-IV"
"17640";"NYHA functional class"
"17641";"NYHA functional class (%)"
"17642";"NYHA functional class 1"
"17643";"NYHA functional class at randomization"
"17644";"NYHA functional class at screening"
"17645";"NYHA functional class I"
"17646";"NYHA functional class III"
"17647";"NYHA functional class III (%)"
"17648";"NYHA functional class, n (%)"
"17649";"NYHA functional classification — no. (%)"
"17650";"NYHA functional classification — no. (%) I"
"17651";"NYHA II"
"17652";"NYHA II, n (%)"
"17653";"NYHA III or IV"
"17654";"NYHA III or IV§ (n=11 988)"
"17655";"NYHA III, n (%)"
"17656";"NYHA IV, %"
"17657";"NYHA IV, n (%)"
"17658";"NYHA ll/lll patients with LVEF <0.40 at baseline"
"17659";"NYHA lll-IV"
"17660";"NYHA_class"
"17661";"NYHAII"
"17662";"NYHAIIIorIV"
"17663";"o"
"17664";"O-OI65 (-0-0097 to 0-0427)"
"17665";"O-OO37 (-0-0144 to 0-0217)"
"17666";"O Total randomized"
"17667";"O12O(OO31-O-21O)"
"17668";"o80 kg, n (%)"
"17669";"OA"
"17670";"OAB-q score, mean (SD)"
"17671";"OAB therapy"
"17672";"OAC experienced,bn (%)"
"17673";"OAD"
"17674";"OAD at screening, n (%)"
"17675";"OAD history, years"
"17676";"OAD only"
"17677";"OAD plus insulin"
"17678";"OAD use, n (%)"
"17679";"OADs, n (%)"
"17680";"OAM"
"17681";"OAM use [n (%)]"
"17682";"OASCVD"
"17683";"OAT"
"17684";"OAT (n = 23)"
"17685";"Obese"
"17686";"Obese (>30 kg/m^2)"
"17687";"Obese (>30 kg/m2)"
"17688";"Obese (>30 kg/m2)b"
"17689";"Obese (BMI £30)"
"17690";"Obese (BMI >30kg/m2)"
"17691";"Obese patients,! n (%)"
"17692";"Obesity"
"17693";"Obesity (%)§"
"17694";"Obesity (BMI £30 kg/m2)"
"17695";"Obesity (BMI >25 kg/m2), %"
"17696";"Obesity (body mass index >30 kg/m2)"
"17697";"Obesity t"
"17698";"Obesity*"
"17699";"Obesity* (BM1 > 30 kg/m2)"
"17700";"Obesity, %*"
"17701";"Obesityj"
"17702";"Observation"
"17703";"Observed"
"17704";"Observed case"
"17705";"Obstructive subscore"
"17706";"ocn"
"17707";"OCS"
"17708";"OCS at baseline"
"17709";"OCS dose*, mean (SD)"
"17710";"OCS maintained/increased"
"17711";"OCS reduced/stopped"
"17712";"OCS use"
"17713";"OCS, n (%)"
"17714";"OCT center point thickness, pm"
"17715";"OCTAVE Induction 1"
"17716";"OCTAVE Induction 1 and 2"
"17717";"OCTAVE Induction 2"
"17718";"OCTAVE Sustain"
"17719";"OCTI"
"17720";"OCTI & MATE1"
"17721";"Odds‐ratio (95% CI)"
"17722";"Odds ratio"
"17723";"Odds Ratio"
"17724";"Odds ratio (95% CI)"
"17725";"Odds Ratio (95% CI)"
"17726";"Odds ratio (95% Cl)"
"17727";"Odds Ratio (95% Cl)"
"17728";"Odds ratio (95%CI)"
"17729";"Odds ratio adj (95% Cl)"
"17730";"Odds Ratio and 95% Cl"
"17731";"Odds ratio versus placebo (95% CI)"
"17732";"Odds ratios (95% CI)"
"17733";"of patients"
"17734";"of Patients"
"17735";"of patients meeting criterion/total no. of patients"
"17736";"of T2DM (years)"
"17737";"of variation), IU"
"17738";"Off-pump"
"17739";"Off OMT"
"17740";"Off OMT (N=4280)"
"17741";"Off pump"
"17742";"oHS graduate"
"17743";"Oil"
"17744";"ol/L)"
"17745";"olaemia, n (%)"
"17746";"Old stroke*"
"17747";"Older DES (N=3318)"
"17748";"Older patients (aged > 75 years)"
"17749";"Older subjects (aged >55 years'"
"17750";"Older than 75 years"
"17751";"Olmesartan (N = 2232)"
"17752";"Olmesartan (n = 578)"
"17753";"Olmesartan along with CCB (N - 1057)"
"17754";"Olmesartan along with CCB (N - 1399)"
"17755";"Olmesartan along with diuretic (N- 1379)"
"17756";"Olmesartan along with diuretic (N - 1041)"
"17757";"Olmesartan medoxomil 40 mg (n = 282)"
"17758";"Olmesartan medoxomil 40mg/HCTZ12.5mg (n = 556)"
"17759";"Olodaterol"
"17760";"Olodaterol 1 0 |ig Tiotropium n=114 Non-tiotropium n=333"
"17761";"Olodaterol 1 0 |ig Tiotropium n=115 Non-tiotropium n=341"
"17762";"Olodaterol 10 gg (n=225)"
"17763";"Olodaterol 10 gg (n=234)"
"17764";"Olodaterol 10 Jig"
"17765";"Olodaterol 5 |ig Tiotropium n=117 Non-tiotropium n=332"
"17766";"Olodaterol 5 |ig Tiotropium n=117 Non-tiotropium n=335"
"17767";"Olodaterol 5 gg (n=227)"
"17768";"Olodaterol 5 gg (n=232)"
"17769";"Olodaterol 5 Jig"
"17770";"Olodaterol 5 m g"
"17771";"Olodaterol 5 Mg"
"17772";"Olodaterol 5 mg(n = 1038)"
"17773";"Olodaterol 5pg"
"17774";"Olodaterol Sgg"
"17775";"OM 40 mg + AML 10 mg + HCTZ 25 mg"
"17776";"OM 40 mg + AML 10 mg + HCTZ 25 mg (n = 627)"
"17777";"OM 40 mg/ AML 10 mg"
"17778";"OM 40 mg/ AML 10 mg (n = 628)"
"17779";"OM 40 mg/ HCTZ 25 mg"
"17780";"OM 40 mg/ HCTZ 25 mg (n = 637)"
"17781";"OM 40 mg/AML 10 mg"
"17782";"OM 40 mg/AML 10 mg/HCTZ 25 mg"
"17783";"OM 40 mg/HCTZ 25 mg"
"17784";"OM 40/"
"17785";"OM 40/ AML 10/"
"17786";"OM 40/AML 10/HCTZ 12.5 mg"
"17787";"OM 40/AML 10/HCTZ 25 mg"
"17788";"OM 40/AML 5/HCTZ 12.5 mg"
"17789";"OM 40/AML 5/HCTZ 12.5 mg*"
"17790";"OM 40/AML 5/HCTZ 25 mg"
"17791";"OM 40mg/AML 10 mg"
"17792";"OMA/OAT"
"17793";"OMA/OAT (n = 59)"
"17794";"Omalizumab"
"17795";"Omalizumab (LSM)"
"17796";"Omalizumab 150 mg (n [ 162)"
"17797";"Omalizumab 300 mg (n [ 160)"
"17798";"Omalizumab 300 mg (n [ 252)"
"17799";"Omega-3 FA"
"17800";"Omega-3 FA (n = 7740)"
"17801";"Omega-3 FA intake 1st third"
"17802";"Omega-3 FA intake 2nd third"
"17803";"Omega-3 FA intake 3,d third"
"17804";"Omega-3 fatty acid"
"17805";"Omega-3 fatty acid (n=5855)"
"17806";"Omega-3 fatty acid vs placebo Least-squares mean (95% Cl)"
"17807";"Omega-3 fatty acids"
"17808";"Omega 3 Allocation"
"17809";"Omeprazole"
"17810";"OMERACT-OARSI response"
"17811";"On-pump"
"17812";"On-pump time: <l:36hrs:min (n=721)"
"17813";"On-Treatment"
"17814";"On 1"
"17815";"On 2"
"17816";"On antihypertensive medication at baseline, n (%)‡"
"17817";"On antihypertensive treatment, n (%)"
"17818";"On aspirin at baseline"
"17819";"On BP medication, n (%)"
"17820";"On drug treatment (%)"
"17821";"On maximum tolerated medications (%) Median (25th to 75th quartile) SUA (mg/dl)"
"17822";"On metformin IR or metformin XR 1000 mg/d"
"17823";"On non‐metformin AHA"
"17824";"On OAC at time of randomisation, n (%)"
"17825";"On OMT"
"17826";"On OMT (N=7363)"
"17827";"On or After E^andomization"
"17828";"On pump"
"17829";"On statins at baseline"
"17830";"On Step-1 Drug, %"
"17831";"On steroid at baseline"
"17832";"On sulfonylurea"
"17833";"One-third radius"
"17834";"One-vessel disease"
"17835";"One antihypertensive medication"
"17836";"One at baseline"
"17837";"One lesion"
"17838";"One of the above"
"17839";"One or more blood pressure medications, n (%)"
"17840";"One or more COPD exacerbations (n/N [%])"
"17841";"One or more exacerbations"
"17842";"One or more medications"
"17843";"One or more requiring hospitalization in 12 mo before screening — no. (%)1"
"17844";"One TNFi and"
"17845";"One TNFi*"
"17846";"One vessel"
"17847";"Ongoing atopic or allergic condition — no. {%)"
"17848";"Only cerebrovascular disease"
"17849";"Only coronary artery disease"
"17850";"Only DVT"
"17851";"Only peripheral artery disease"
"17852";"onset 1 [5]"
"17853";"onset 2 [6]"
"17854";"onset 3 [7]"
"17855";"OnsetofAF,No.(%)"
"17856";"Ontario and McMaster Universities Osteoarthritis Index (WOMAC) can range from 0 to 500 for the pain subscale, 0 to 200 for the stiffness"
"17857";"OP concomitant medications (%)"
"17858";"OP, no VFx"
"17859";"OP, VFx"
"17860";"OPAQb physical function score"
"17861";"Open"
"17862";"Open-label clopidogrel after completion of study drug"
"17863";"Open-Label Phase (Baseline=Week 0)"
"17864";"Open-label population"
"17865";"Open — no. (%)"
"17866";"Open triple (n=537)"
"17867";"Operative Procedure"
"17868";"OPG, (ng/mL)"
"17869";"Ophthalmologic events"
"17870";"OPTION"
"17871";"OR"
"17872";"OR (95 % CI)"
"17873";"OR (95% CI)"
"17874";"OR (95% CI)a"
"17875";"OR (95% Cl)"
"17876";"OR (95% Cl) = 0 88 (0.60, 1 29)"
"17877";"OR (95% Cl) = 0.80 (0 51.1.26)"
"17878";"OR (95% Cl) = 0.90 (0.71. 1.14)"
"17879";"OR (95% Cl) = 1 37(0.72. 2 61)"
"17880";"OR (ITT) (n=1532)"
"17881";"OR (unadjusted)"
"17882";"OR [95% Cl]"
"17883";"OR [95%CI]"
"17884";"OR 95% CI"
"17885";"or death"
"17886";"or ESRD"
"17887";"OR for CANA vs PBO (95% CI)||"
"17888";"OR for CANA vs PBO (95% CI)§"
"17889";"OR morbidity and mortality"
"17890";"or no microalbuminuria or macroalbuminuria"
"17891";"OR per Unit for Continuous Variables"
"17892";"or placebo treatment"
"17893";"OR primary outcome"
"17894";"or raloxifene"
"17895";"or severe"
"17896";"or taking antihypertensive medication"
"17897";"or ulcerations,® n (%)"
"17898";"OR, 1.2 (95% Cl, 0.7-1.9)"
"17899";"OR, 1.8 (95% Cl, 1.1- 3.0)"
"17900";"OR, 2.2 (95% Cl, 1.5-3.5)"
"17901";"OR, 3.8 (95% Cl, 2.7-5.5)"
"17902";"OR, 4.2 (95% Cl, 2.7—6,4)"
"17903";"OR, 4.2 (95% Cl, 2.9-6.3)"
"17904";"OR: 1.35 (1.06, 1.74); p=0.017"
"17905";"OR、 (95% CI)"
"17906";"OR=0.51(0.40–0.64)<0.001"
"17907";"OR=0.87(0.68–1.11)0.26"
"17908";"OR=1.30(0.95–1.77)0.10"
"17909";"OR=3.46(2.62–4.56)<0.001"
"17910";"ORadj (95% CI)"
"17911";"ORadj (95% Cl)"
"17912";"Oral"
"17913";"Oral (%)"
"17914";"Oral agent"
"17915";"Oral agent and/or insulin therapy"
"17916";"Oral agents"
"17917";"Oral agents use"
"17918";"Oral aminosalicylates"
"17919";"Oral anti-DM drug status, No. (%)"
"17920";"Oral anticoagulant"
"17921";"Oral anticoagulant — no./total no. (%)"
"17922";"Oral anticoagulant agent"
"17923";"Oral anticoagulant drugs"
"17924";"Oral anticoagulant drugs, n (%)"
"17925";"Oral anticoagulant N(%)"
"17926";"Oral anticoagulant, n (%)"
"17927";"Oral anticoagulants"
"17928";"Oral antidiabetes combination therapy without insulina, n (%)"
"17929";"Oral antidiabetes monotherapya, n (%)"
"17930";"Oral antidiabetic drugs"
"17931";"oral antidiabetic drugs/insulin (%/%)"
"17932";"Oral antihyperglycaemic, n (%)"
"17933";"Oral blood glucose-lowering"
"17934";"Oral blood glucose-lowering drug 23 (27.1)"
"17935";"Oral contraceptive pills — no./total no. (%)"
"17936";"Oral contraceptives"
"17937";"Oral corticosteroid"
"17938";"Oral corticosteroid dose (mg/day)"
"17939";"Oral corticosteroid use at baseline"
"17940";"Oral corticosteroid use at enrolmentt"
"17941";"Oral corticosteroid use, n (%)"
"17942";"Oral corticosteroids"
"17943";"Oral diabetic agent"
"17944";"Oral fi-blockers"
"17945";"Oral glucocorticoid dose, mg (prednisone equivalent)"
"17946";"Oral glucocorticoid use"
"17947";"Oral glucocorticoid use at baseline — no. (%):t"
"17948";"Oral hypoglycaemics only"
"17949";"Oral hypoglycemic"
"17950";"Oral hypoglycemic agent"
"17951";"Oral hypoglycemic agents"
"17952";"Oral hypoglycemic agentsj"
"17953";"Oral hypoglycemic drug"
"17954";"Oral hypoglycemic drugs only"
"17955";"Oral hypoglycemics"
"17956";"Oral hypoglycemics Hormone replacement"
"17957";"Oral medications"
"17958";"Oral or other systemic corticosteroid"
"17959";"Oral β-adrenergics, n (%)"
"17960";"Oral study drug administered — no./total no. (%)"
"17961";"Oral Treprostinil (n=151)"
"17962";"Oral Treprostinil (n=233)"
"17963";"Oralb"
"17964";"ORC (95% Cl)"
"17965";"Oretal"
"17966";"Organ system involvement, no. (%)"
"17967";"Organic"
"17968";"Oriental"
"17969";"Origin [n (%)]"
"17970";"Original dabigatran protocol"
"17971";"Oropharyngeal pain"
"17972";"ORs (95% Cis):"
"17973";"Orthopaedic"
"17974";"Orthopnea"
"17975";"Orthopnea, (%)"
"17976";"Orthopnea, frequent/continuous"
"17977";"Orthostatic hypotension"
"17978";"orthostatic test*"
"17979";"OS domain"
"17980";"Osmotic diuresis-related AEs"
"17981";"Osteitis"
"17982";"Osteoarthritis"
"17983";"Osteopontin (ng/ml)"
"17984";"Osteoporosis"
"17985";"Osteoporosis drug"
"17986";"Osteoprotegerin decreased"
"17987";"other"
"17988";"Other"
"17989";"Other'"
"17990";"Other'i'"
"17991";"Other— no. (%)"
"17992";"Other (%) Diabetes (Interaction: p=0.94)"
"17993";"Other (2.1%)t"
"17994";"Other (n — 66)"
"17995";"Other (n = 49)"
"17996";"Other (n = 904)"
"17997";"Other (n, %)"
"17998";"Other (n=13, 4)"
"17999";"Other (n=13, 4]"
"18000";"Other (n=83)"
"18001";"Other , n(%)"
"18002";"Other {n=83)"
"18003";"Other anti-hypertensive"
"18004";"Other anti-hypertensives"
"18005";"Other anti-platelet agents"
"18006";"Other antiarrhythmics^"
"18007";"Other anticoagulant"
"18008";"Other antihyperglycemic agents, not listed"
"18009";"Other antihypertensive"
"18010";"Other antihypertensive agents"
"18011";"Other antihypertensive drug"
"18012";"Other antihypertensive medications"
"18013";"Other antiplatelet"
"18014";"Other antiplatelet agent 一 no. (%)"
"18015";"Other antiplatelet agents"
"18016";"Other antiplatelet agents, n (%)"
"18017";"Other antithrombotic medication for index event — no. (%)"
"18018";"Other AScvD"
"18019";"Other ASCVD"
"18020";"Other ASCVD, No. (%)"
"18021";"other Asian"
"18022";"Other Asian"
"18023";"Other atherosclerotic"
"18024";"Other atherosclerotic CVD"
"18025";"Other atherosclerotic CVD ST depression on"
"18026";"Other Atherosclerotic CVD**"
"18027";"Other atherosclerotic CVDd,e"
"18028";"Other atherosclerotic event"
"18029";"other bDMARD§"
"18030";"Other bDMARDs (no TNFi taken)t, n (%)"
"18031";"Other biologic agent"
"18032";"Other blood-pressure drug"
"18033";"Other blood glucose-lowering agents"
"18034";"Other blood pressure-lowering drugs"
"18035";"Other BP drug"
"18036";"Other BPH-LUTS therapy"
"18037";"Other cardiac surgery, n (%)"
"18038";"Other cardiovascular risk factors"
"18039";"Other cause"
"18040";"Other cause, n (%)"
"18041";"Other CHD"
"18042";"Other climate subset"
"18043";"Other clinical characteristics"
"18044";"Other combination"
"18045";"Other countries"
"18046";"Other defined"
"18047";"Other determined etiology"
"18048";"Other diagnostic procedure*"
"18049";"Other diuretic"
"18050";"Other DMARD use"
"18051";"Other DMARDs"
"18052";"Other drug therapy, n (%)"
"18053";"Other drugs"
"18054";"Other drugs — no. (%)"
"18055";"Other end points"
"18056";"Other forms of"
"18057";"Other forms of atherosclerosis^"
"18058";"Other forms of atherosclerosis’"
"18059";"Other GLP-1 receptor agonist"
"18060";"Other glucose-lowering drugs"
"18061";"Other glucose status"
"18062";"Other hypoglycemic agent, n (%)"
"18063";"Other ICS"
"18064";"Other ICS versus no ICS"
"18065";"Other individual and exploratory end points"
"18066";"Other ischaemic heart disease (non-infarction)"
"18067";"Other lipid-lowering medication"
"18068";"Other lipid-modifying drug 一 no. (%)"
"18069";"Other lipid-modifying drug use at study entry, n (%)"
"18070";"Other lipid lowering drugs"
"18071";"Other lipid parameters"
"18072";"Other LLT at randomization"
"18073";"Other LLT use"
"18074";"Other major risk factors"
"18075";"Other medical history — no. (%)"
"18076";"Other medical history — no./total no. (%)"
"18077";"Other medical history, no. (%)"
"18078";"Other Medication Usage"
"18079";"Other medications"
"18080";"Other medications at enrollment"
"18081";"Other n (%)"
"18082";"Other NSAIDs"
"18083";"Other NSAIDS"
"18084";"Other or missing data"
"18085";"Other oral hypoglycemic drug(s)"
"18086";"Other osteoporosis medication"
"18087";"Other outcomes"
"18088";"Other Pacific Islander"
"18089";"Other plain vitamin preparations"
"18090";"Other prespecified end points"
"18091";"Other race"
"18092";"Other race, n (%)"
"18093";"Other risk factors"
"18094";"Other selected AEs"
"18095";"Other SGLT-2 inhibitor"
"18096";"Other statin"
"18097";"Other stent"
"18098";"Other steroids"
"18099";"Other sulfonylurea 一 no. (%)"
"18100";"Other supraventricular tachycardia"
"18101";"Other TEAEs"
"18102";"Other treatment assignment"
"18103";"Other UC-related Gi surgical procedure"
"18104";"Other vascular disease"
"18105";"Other vascular disease — no. (%)"
"18106";"Other vascular disease (CVD or PAD), %"
"18107";"Other vascularS"
"18108";"Other vasodilator"
"18109";"Other vasodilators§"
"18110";"Other!"
"18111";"Other(n=83)"
"18112";"Other*"
"18113";"Other* (n=153)"
"18114";"other*’"
"18115";"Other, n (%)"
"18116";"Other, No. (%)"
"18117";"Other/missing"
"18118";"Other/Missing"
"18119";"Other/mixed (n=74)"
"18120";"Other/multiple"
"18121";"Other/multiracial"
"18122";"Other::"
"18123";"Other^"
"18124";"Other® Region — no. (%)"
"18125";"Other†"
"18126";"Other1"
"18127";"Othera"
"18128";"Otherb"
"18129";"Otherc"
"18130";"Otherd"
"18131";"Otherf"
"18132";"OtherJ^:"
"18133";"Others"
"18134";"Others, classes I and IIIc"
"18135";"Others, n (%)"
"18136";"Othersc"
"18137";"Othert"
"18138";"Otherx"
"18139";"Othery Ethnicity, n (%)"
"18140";"Othery Ethnicity, n (%)*"
"18141";"Otherz"
"18142";"outcome"
"18143";"Outcome"
"18144";"Outcome - Variant"
"18145";"Outcome (N, %}"
"18146";"Outcome according to no. of risk factors for VTE"
"18147";"Outcome according to primary cancer site — no./total no. (%)"
"18148";"Outcome According to Renal Function Level (in mL/min)"
"18149";"Outcome according to stage of cancer — no./total no. (%)"
"18150";"Outcome and Metabolizer Phenotype"
"18151";"Outcome measure"
"18152";"Outcome severity"
"18153";"Outcome type"
"18154";"Outcome_subgroup"
"18155";"Outcomes"
"18156";"Outcomes by Treatment (spironolactone vs placebo)"
"18157";"Outcomes during ACCORD"
"18158";"Ovary"
"18159";"over past 5 years, n (%)"
"18160";"Overaii"
"18161";"Overaii (N=4230)"
"18162";"Overaii (N=4963)"
"18163";"Overal event rate"
"18164";"Overall"
"18165";"OVERALL"
"18166";"Overall (12,174)"
"18167";"Overall (ITT) (n=1532)"
"18168";"Overall (ITT) (n=1591)"
"18169";"Overall (ITT) (n=1604)"
"18170";"Overall (ITT) (n=1612)"
"18171";"Overall (ITT) (n=1615)"
"18172";"Overall (ITT) (n=2123)"
"18173";"Overall (ITT) (n=2151)"
"18174";"Overall (N = 1,630)"
"18175";"Overall (N = 1306)"
"18176";"Overall (n = 17,717)"
"18177";"Overall (N = 214)"
"18178";"Overall (n = 359)"
"18179";"Overall (N = 493)"
"18180";"Overall (n = 838)"
"18181";"Overall (n=1091)"
"18182";"OVERALL (n=1516)"
"18183";"OVERALL (N=4060)"
"18184";"Overall (n=442)"
"18185";"Overall (n=554 vs 279)"
"18186";"Overall (n=874)"
"18187";"Overall (n=U685)"
"18188";"Overall (per protocol) (n=1503)"
"18189";"Overall (per protocol) (n=1517)"
"18190";"Overall (per protocol) (n=1998)"
"18191";"Overall (PP) (n=1479)"
"18192";"Overall (W = 4844), 0/0"
"18193";"Overall 26352"
"18194";"Overall A phase population"
"18195";"Overall analysis"
"18196";"Overall cohort (post hoc analysis excluding metformin users)"
"18197";"Overall cohort (primary analysis)"
"18198";"Overall CTD"
"18199";"Overall DLQI score"
"18200";"Overall DLQI score7"
"18201";"Overall early-morning COPD symptom severity scorec"
"18202";"Overall Effect"
"18203";"Overall efficacy"
"18204";"Overall event rate"
"18205";"Overall FREEDOM population (N = 7808)"
"18206";"Overall HR (95% Cl)"
"18207";"Overall mortality"
"18208";"Overall N (N/lOOpy)"
"18209";"Overall N=3,214"
"18210";"Overall night-time COPD symptom severity scorec"
"18211";"Overall PAD"
"18212";"Overall PEA population"
"18213";"Overall population"
"18214";"Overall Population"
"18215";"Overall population (n - 207)"
"18216";"Overall population (n - 209)"
"18217";"Overall Population (N = 10 194): Non-CANA (n = 3640); CANA 100 mg (n = 3092); CANA 300 mg (n = 3462)"
"18218";"Overall Population (N=1902)"
"18219";"overall study period"
"18220";"Overall study population"
"18221";"Overall treatment effect"
"18222";"Overall VERO population"
"18223";"Overall, male:female"
"18224";"Overall, N = 305"
"18225";"Overall; QVAI49-SFC"
"18226";"Overall®    0.1436"
"18227";"Overall®    0.1909"
"18228";"Overall®    0.8990"
"18229";"Overallb"
"18230";"Overally"
"18231";"Overweight"
"18232";"Overweight (25 to <30 kg/m2)"
"18233";"Overweight (BMI £25 to <30)"
"18234";"Overweight (BMI=25-29.9)"
"18235";"Oxcarbazepine"
"18236";"Oxidative stress"
"18237";"Oxypurinol (n = 203)"
"18238";"p"
"18239";"P"
"18240";"P'Value"
"18241";"p- interactio n"
"18242";"p- interaction"
"18243";"P- value"
"18244";"P- value (Int)"
"18245";"p-blocker"
"18246";"p-Blocker"
"18247";"P-Blocker"
"18248";"p-blocker (%)"
"18249";"p-blocker intake at randomisation (n=5820)"
"18250";"P-blocker intake at randomisation (n=582O)"
"18251";"P-Blocker Use"
"18252";"p-Blocker Yes"
"18253";"p-blockers"
"18254";"p-Blockers"
"18255";"P-Blockers"
"18256";"p-blockers (%)"
"18257";"P-Blockers, n (%)"
"18258";"p-Blocking agents, selective"
"18259";"p-for interaetion"
"18260";"P-gp inhibitor"
"18261";"P-gp use"
"18262";"p-heterogeneity"
"18263";"P-heterogeneity"
"18264";"p-int"
"18265";"P-int"
"18266";"P-int."
"18267";"P-inte Faction"
"18268";"P-Inter"
"18269";"p-interaction"
"18270";"P-interaction"
"18271";"P-sitosterol/Lathosterol"
"18272";"P-sitosterol/Total C (|imol/mmol)"
"18273";"p-val. (10)"
"18274";"p-val. (5)"
"18275";"p-value"
"18276";"p-Value"
"18277";"p‐Value"
"18278";"P-value"
"18279";"P‐value"
"18280";"P-Value"
"18281";"P‐Value"
"18282";"p-value """
"18283";"P-value (■nt)"
"18284";"p-value (ANCOVA treatment difference)a"
"18285";"p-value (ANOVA)"
"18286";"P-value (Int)"
"18287";"P-Value (Int)"
"18288";"P-value (interaction)≠"
"18289";"P-value (Overall)"
"18290";"P-Value (Trend)"
"18291";"P-value (vs placebo)"
"18292";"P-value D 110 mg vs. warfarin"
"18293";"P-value D 150 mg vs. warfarin"
"18294";"P-value for"
"18295";"P-value for East Asian versus non-East Asian*"
"18296";"p-value for interaction"
"18297";"p-value for Interaction"
"18298";"P-value for interaction"
"18299";"P-value for Interaction"
"18300";"p-value for interaction 0.64"
"18301";"P-value for interaction*"
"18302";"p-value for interaction13 :"
"18303";"P-value for trend across categories"
"18304";"P-value for trend*"
"18305";"p-value for variance"
"18306";"P-value interaction"
"18307";"P-Value Interaction"
"18308";"p-Value low vs. high NFS^"
"18309";"P-value n/n (%)"
"18310";"P-value vs. placebo"
"18311";"P-value(lnteraction)"
"18312";"p-Value*''"
"18313";"P‐value*"
"18314";"P-value*"
"18315";"P-value}"
"18316";"p-Value‘’"
"18317";"p-value¶"
"18318";"P-value13"
"18319";"P-valuea"
"18320";"P-valueb"
"18321";"p-Valuec"
"18322";"P-valuec"
"18323";"P—value for Interaction"
"18324";"P -value"
"18325";"P (95% Cl)"
"18326";"P (inter- action)"
"18327";"P (Losartan versus Placebo)"
"18328";"P (Women vs Men)"
"18329";"p .b *int"
"18330";"p .b “int"
"18331";"P [Int]"
"18332";"p 1 Interaction"
"18333";"p 1 interaction Women vs Men"
"18334";"P between age groups"
"18335";"p blocker"
"18336";"P blocker"
"18337";"P Blocker"
"18338";"P blocker before admission"
"18339";"P blocker*"
"18340";"p blockers"
"18341";"P blockers"
"18342";"P blockers (%)"
"18343";"P blockersubgroup"
"18344";"P for i"
"18345";"P for inter -act"
"18346";"p for interaction"
"18347";"p for Interaction"
"18348";"P for interaction"
"18349";"P for Interaction"
"18350";"P for interaction between RHTN and no RHTN and treatmenta"
"18351";"P for interaction*"
"18352";"p for trend"
"18353";"p for trend-"
"18354";"P for trend"
"18355";"P for Trend"
"18356";"P inleraclion"
"18357";"P Int.f"
"18358";"P Inter"
"18359";"p interaction"
"18360";"p Interaction"
"18361";"P interaction"
"18362";"P Interaction"
"18363";"P Interaction (Rx Arm *Sex)"
"18364";"P interaction Women vs Men"
"18365";"P interaction=0.002"
"18366";"p J 3 * trend"
"18367";"P lace of randomization (Interaction: p=0.10)"
"18368";"P Trend"
"18369";"p Vaiue"
"18370";"P Vaiue"
"18371";"P Vaiue (interaction)"
"18372";"p value"
"18373";"p Value"
"18374";"P value"
"18375";"P Value"
"18376";"P VALUE"
"18377";"P value (aged >65 vs. <65 years)"
"18378";"P Value (Cangrelor Versus Clopidogrel in Men)"
"18379";"P Value (Cangrelor Versus Clopidogrel in Women)"
"18380";"P Value (int)"
"18381";"P Value (Int)"
"18382";"P Value (Inter)"
"18383";"P Value (Interaction)"
"18384";"P Value (Men Versus Women)"
"18385";"p value (nominal)"
"18386";"P value (On vs off OMT)"
"18387";"p Value (vs. previous time point)"
"18388";"P value *"
"18389";"p value 十"
"18390";"P Value 0.81"
"18391";"p Value Between Groups"
"18392";"P value by GT"
"18393";"P Value by GT"
"18394";"P value c"
"18395";"p value f"
"18396";"P Value fo Interactio"
"18397";"P Value for"
"18398";"P Value for  interaction"
"18399";"P value for adjusted HR"
"18400";"P value for DM vs. no DM"
"18401";"P Value for Heterogeneity"
"18402";"P Value for Heterogeneity （Rosiglitazone versus Glyburide）"
"18403";"P Value for Heterogeneity（Rosiglitazone versus Metformin）"
"18404";"p value for interaction"
"18405";"P value for interaction"
"18406";"P value for Interaction"
"18407";"P Value for interaction"
"18408";"P Value for Interaction"
"18409";"P Value for Interaction - dosage with Dabigatran, 110 mg"
"18410";"p value for interaction (age continuous)"
"18411";"p value for interaction (age groups)*"
"18412";"P value for interaction by region"
"18413";"P Value for Interaction, dosage with Dabigatran, 150 mg"
"18414";"P Value for Interaction^"
"18415";"p Value for interaction®"
"18416";"p Value for interaction® Vertebral fracture at FLEX baseline:"
"18417";"P Value for Interactiont"
"18418";"P Value for MRA vs No MRA"
"18419";"p value for trend"
"18420";"p Value for Trend"
"18421";"p Value for Trend Across Tertiles"
"18422";"p Value for Trend*"
"18423";"P Value Heart Failure vs No Heart Failure"
"18424";"P value interaction"
"18425";"p value versus placebo"
"18426";"P value within category"
"18427";"p value*"
"18428";"p Value*"
"18429";"P value*"
"18430";"P Value*"
"18431";"P Value*, Placebo Group P Value*, Hyponatremia Normonatremic Group, Tolvaptan vs Hyponatremic vs Placebo"
"18432";"p value*3"
"18433";"p Value∥"
"18434";"P value§ (<65 vs. >=65 years)"
"18435";"P value§ (<75 vs. >=75 years)"
"18436";"P value§®(w"
"18437";"P value2"
"18438";"p value3"
"18439";"P Value8"
"18440";"p valuea"
"18441";"P valuea"
"18442";"p valueb"
"18443";"P valueb"
"18444";"P valuec"
"18445";"P Valued"
"18446";"P Valuej'"
"18447";"P valuer"
"18448";"p values"
"18449";"P values"
"18450";"P Valuey"
"18451";"P vs placebo"
"18452";"p value"
"18453";"P Value"
"18454";"P Value for Interaction"
"18455";"P Values for Interaction"
"18456";"P Values of Interaction"
"18457";"P vs. placebo"
"18458";"P(INTER)"
"18459";"P)atients with >1 exacerbations resulting in emergency department visit"
"18460";"P, All vs All"
"18461";"P, Interaction!"
"18462";"P, Net Difference"
"18463";"P, Regional Difference"
"18464";"P, Regional Difference*"
"18465";"P, Subgroup*"
"18466";"P, Treatment-by-Region Interaction"
"18467";"p. interaction"
"18468";"p.O)"
"18469";"P/Interaction"
"18470";"P: Interaction"
"18471";"P<0.05) between the study groups in any of the baseline characteristics. ACE"
"18472";"P20 vs no treatment 4271"
"18473";"P2Y12 antagonist"
"18474";"P2Y12 antagonists"
"18475";"P2Y12 inhibitor"
"18476";"p30 min twice/week"
"18477";"P3Z3 (N = 1223)"
"18478";"P40 vs placebo"
"18479";"P40 vs usual care"
"18480";"pa"
"18481";"Pace, no. (36)"
"18482";"Pacemaker"
"18483";"Pacemaker — no. (%)"
"18484";"Pacemaker or ICD"
"18485";"Pacemaker, (%)"
"18486";"Pacemaker, n (%)"
"18487";"PACI"
"18488";"PACI (n=850)"
"18489";"Pacific"
"18490";"Pacific Islander"
"18491";"pack-years (IQR)"
"18492";"Pack-years smoked"
"18493";"Pack-years, mean (SD)"
"18494";"pack years"
"18495";"Paclitaxel"
"18496";"Paclitaxel-eluting"
"18497";"Paclitaxel-eluting stent use, n (%)"
"18498";"PAD"
"18499";"PAD (n - 1,143)"
"18500";"PAD at baseline"
"18501";"PAD details, n (%)"
"18502";"PAD lower extremities"
"18503";"PAD symptoms (%)"
"18504";"PAH-CTD"
"18505";"PAH-MCTD/CTD-other"
"18506";"PAH-SLE"
"18507";"PAH-SSc"
"18508";"PAH classification"
"18509";"PAH classification — no. (%)"
"18510";"PAH etiology"
"18511";"PAH Etiology:"
"18512";"PAH origin/cause"
"18513";"PAH therapy at baseline"
"18514";"Pain"
"18515";"Pain (0-100 mm VAS)"
"18516";"Pain (100 mm VAS)"
"18517";"Pain (VAS)"
"18518";"Pain subscale"
"18519";"Pain VAS (range 0-100), mean ± SD"
"18520";"Pain VAS, 0-100 mm"
"18521";"Pain VAS, mean change from baselinea"
"18522";"Pain VAS, mean change from baselined"
"18523";"Pain VAS, range 0-100 mm, mean (SD)"
"18524";"Pain, 0-100 mm VAS"
"18525";"Pain, mm"
"18526";"Pairwise comparison"
"18527";"Pancolitis"
"18528";"Pancreas"
"18529";"Pancreatic cancer"
"18530";"Panel A"
"18531";"Panel B"
"18532";"PaO2 at rest, mm Hg"
"18533";"PAOD"
"18534";"Paracetamol"
"18535";"Parameter"
"18536";"Parameter (mg/dl)"
"18537";"Parameter at baseline"
"18538";"Parameter mean±s.d."
"18539";"Parameter statistics"
"18540";"Parameter, % (95% CI)"
"18541";"Parameter, N (%)"
"18542";"Parameter/variable"
"18543";"Parameters"
"18544";"Parameters at baseline"
"18545";"Parental history of MI before age 60 y"
"18546";"Parental history of MIi"
"18547";"Parental history of Ml before age 60 y Yes"
"18548";"Parental history of myocardial infarction before 60 yr of age (%)"
"18549";"Parental history of myocardial infarction before age 60 y"
"18550";"Parental history of myocardial infarction before age 60 y Yes"
"18551";"Parenteral anticoagulalion before randomization"
"18552";"Parenteral anticoagulation"
"18553";"Paresthesia"
"18554";"Paroxysmal"
"18555";"Paroxysmal (n, %)"
"18556";"Paroxysmal AF"
"18557";"Paroxysmal atrial fibrillation — no. (%)"
"18558";"Paroxysmal nocturnal dyspnea"
"18559";"Paroxysmal!"
"18560";"Paroxysmal, n (%)"
"18561";"Partial evolving to secondarily generalized (IC)"
"18562";"Partial Mayo Clinic scored"
"18563";"Partial Mayo score"
"18564";"Partial Mayo score$||"
"18565";"Partial Mayo score, mean (SD)"
"18566";"Participant-reported hypertension — no. {%)"
"18567";"Participants"
"18568";"Participants at baseline, n"
"18569";"Participants n"
"18570";"Participants randomized,"
"18571";"Participants taking insulin"
"18572";"Participants with a history of CABG"
"18573";"Participants with an event per 1000 patient-years"
"18574";"Participants With Heart Failure"
"18575";"Participants With HF at Baseline"
"18576";"Participants with metabolic syndrome"
"18577";"Participants without a history of CABG"
"18578";"Participants Without Heart Failure"
"18579";"Participants Without HF at Baseline"
"18580";"Participants without metabolic syndrome"
"18581";"Participants, n"
"18582";"Participants, No. (%)"
"18583";"Participated in a previous febuxostat studyb, n (%)"
"18584";"Participation in phase A"
"18585";"Participation in Phase A"
"18586";"partner, n (% Yes)"
"18587";"PASI"
"18588";"PASI #3 at week 100,"
"18589";"PASI [c], median (min - max)"
"18590";"PASI <10*"
"18591";"PASI 100"
"18592";"PASI 75"
"18593";"PASI 90"
"18594";"PASI response by baseline MTX use, no./total no. (%)* PASI75"
"18595";"PASI response by baseline weight, no./total no. (%)* PASI75"
"18596";"PASI score"
"18597";"PASI score (0-72)"
"18598";"PASI score (0-72), mean (SD)"
"18599";"PASI score (0-72)d"
"18600";"PASI score (0-72)t, mean (SD)"
"18601";"PASI score (0–72 scale)"
"18602";"PASI score >10*"
"18603";"PASI score!**"
"18604";"PASI score, 0-72*"
"18605";"PASI score, mean (SD)"
"18606";"PASI score, mean ± SD"
"18607";"PASI score1"
"18608";"PASI*"
"18609";"PASI, mean (SD)"
"18610";"PASI, median (range)**"
"18611";"PASI^I"
"18612";"PASI100a"
"18613";"PASI75 response}"
"18614";"PASI75, no./total no. (%)4"
"18615";"PASI75a"
"18616";"PASI90"
"18617";"PASI90 response}"
"18618";"PASI90, no./total no. (%)4"
"18619";"PASI90a"
"18620";"PASIa"
"18621";"Passive smoker"
"18622";"Past"
"18623";"Past cardiovascular history, no. (%)"
"18624";"Past only"
"18625";"Past or current"
"18626";"Past or current angina pectoris"
"18627";"Past or never"
"18628";"Past or nonsmoker (n = 370)"
"18629";"Past smoker"
"18630";"Past smoker, n (%)"
"18631";"Past smoking"
"18632";"Past treatment for PAOD"
"18633";"Patella fracture"
"18634";"Patent foramen ovale"
"18635";"Paternal history, n (%)"
"18636";"Pathologic Q waves — no. (%)"
"18637";"Pathologic Q waves, n (%)"
"18638";"Pathological Q waves"
"18639";"Patient"
"18640";"Patient's assessment of pain"
"18641";"Patient's Assessment of Pain (0-100 VAS)"
"18642";"Patient's Assessment of Pain!"
"18643";"Patient's GA, 0-100 mm VAS"
"18644";"Patient's global assessment"
"18645";"Patient's global assessment (VAS)"
"18646";"Patient's global assessment of"
"18647";"Patient's Global Assessment of Disease"
"18648";"Patient's global assessment of disease activity (0-100 mm VAS), mean (SD)"
"18649";"Patient's global assessment of disease activity, mean (SD)"
"18650";"Patient's global assessment of disease status score"
"18651";"Patient's global assessment of response to therapy score"
"18652";"Patient's Global Assessment!"
"18653";"Patient's history of:"
"18654";"Patient's preference not to take"
"18655";"Patient's preference not to take VKA, only reason"
"18656";"Patient's preference not to take VKA, only reason**"
"18657";"Patient-reported hypertension — no. {%)"
"18658";"Patient-reported outcome measures"
"18659";"Patient-reported outcomes"
"18660";"patient-years) HR (unadjusted)"
"18661";"Patient assessment of arthritis pain, mm"
"18662";"Patient assessment of disease activity, mm"
"18663";"Patient assessment of pain (0-10 cm, VAS)"
"18664";"Patient assessment of pain (0-100 mm), mean (SD)"
"18665";"Patient Characteristic"
"18666";"Patient characteristics"
"18667";"Patient Characteristics"
"18668";"Patient characteristics at randomization"
"18669";"Patient classification"
"18670";"Patient demographics Age — yr"
"18671";"Patient global assessment (0-100 mm VAS)"
"18672";"Patient global assessment of disease"
"18673";"Patient global assessment of disease activity (0-10 cm, VAS)"
"18674";"Patient Global Assessment of disease activity (VAS 0-100 mm)"
"18675";"Patient global assessment of disease activity, mean (SD)"
"18676";"Patient Global Assessment of pain (VAS 0-100 mm)"
"18677";"Patient history of disease"
"18678";"Patient history of disease n (%)"
"18679";"Patient population"
"18680";"Patient presentation"
"18681";"Patient status after wake-up, % of days patient woke:"
"18682";"Patient years"
"18683";"Patients"
"18684";"Patients' characteristics"
"18685";"Patients' characteristics Age (years), mean + SD"
"18686";"Patients (ft)"
"18687";"Patients (full analysis sety), n"
"18688";"Patients (n)"
"18689";"Patients (treated set*), n"
"18690";"Patients <65 y"
"18691";"Patients <65 y*"
"18692";"Patients <8%"
"18693";"Patients >65 y"
"18694";"Patients >65 y*"
"18695";"Patients >8%"
"18696";"Patients aged >65 y, no, (SS)"
"18697";"Patients analyzed, n"
"18698";"Patients assessed"
"18699";"Patients entering PT period n=108"
"18700";"Patients entering PT period n=71"
"18701";"Patients having exacerbation"
"18702";"Patients in analysis, n"
"18703";"patients in the placebo group; NT-proBNP values were reported for 203 patients"
"18704";"Patients included in analysis"
"18705";"Patients meeting the criteria to receive 30 mg of"
"18706";"Patients n"
"18707";"Patients not receiving corticosteroids at baseline"
"18708";"Patients not receiving immunosuppressive agents at baseline"
"18709";"Patients not receiving MTX, N ="
"18710";"Patients not receiving statin"
"18711";"Patients not treated with statins (n=473)"
"18712";"Patients not treated with statins (n=485)"
"18713";"Patients on antihypertensive medications, n (%)||"
"18714";"Patients on atorvastatin, rosuvastatin, or simvastatin at"
"18715";"Patients per 1000 patient-years"
"18716";"Patients randomised, N"
"18717";"Patients randomized"
"18718";"Patients randomized, n"
"18719";"Patients randomized, no."
"18720";"Patients randomly assigned"
"18721";"Patients receiving 30 mg of edoxaban at randomization — no. (%)f"
"18722";"Patients receiving any UC medication, n (%)"
"18723";"Patients receiving corticosteroids at baseline"
"18724";"Patients Receiving ENL, No. (%)"
"18725";"Patients receiving immunosuppressive agents at baseline"
"18726";"Patients receiving Immunotherapy, no. (%)"
"18727";"Patients Receiving LCZ, No. (%)"
"18728";"Patients receiving MTX"
"18729";"Patients receiving MTX, N ="
"18730";"Patients receiving statin"
"18731";"Patients taking MTX, n (%)"
"18732";"Patients taking MTX, no. (%)"
"18733";"Patients taking oral corticosteroids at baseline, n (%)"
"18734";"Patients total no."
"18735";"Patients treated"
"18736";"Patients treated and operated, n (%)"
"18737";"Patients treated for >24 weeks (%)"
"18738";"Patients Treated with Atenoloi (n = 3484)"
"18739";"Patients treated with insulin"
"18740";"Patients Treated with Losartan (n = 3402)"
"18741";"Patients treated with statins (n=113)"
"18742";"Patients treated with statins (n=117)"
"18743";"Patients using concurrent tiotropium"
"18744";"Patients who did not use insulin pump"
"18745";"Patients who had ulcerations at"
"18746";"Patients who received 1 drug"
"18747";"Patients who received 2 or 3 drugs"
"18748";"Patients who received indeterminate results on test for antibodies to infliximabt"
"18749";"Patients who received negative results on test for antibodies to infliximabt"
"18750";"Patients who received positive results on test for antibodies to infliximabt"
"18751";"Patients who used insulin pump"
"18752";"Patients with $1 dactylitis digit at week 100 Enthesitis"
"18753";"Patients with $3% BSA at baseline, no."
"18754";"Patients with >1 exacerbation in previous 12 months"
"18755";"Patients with >1 exacerbation requiring admission to hospital in the 12 months before screening"
"18756";"Patients with >1 exacerbation requiring ER visit or admission to hospital in the 12 months before screening"
"18757";"Patients with >1 exacerbations resulting in ED visit"
"18758";"Patients with >1 exacerbations resulting in emergency department visit"
"18759";"Patients with >1 exacerbations resulting in hospital admission"
"18760";"Patients with >12% ■ 200 mL increase in FEV1 post-bronchodilator (%)"
"18761";"Patients with >3 co-AEDs"
"18762";"Patients with >3% BSA"
"18763";"Patients with >3% BSA psoriasis skin involvement, n (%)"
"18764";"Patients with 1 co-AED"
"18765";"Patients with 2 co-AEDs"
"18766";"Patients with 3 co-AEDs"
"18767";"Patients With a Prior MI or Stroke at Baseline"
"18768";"Patients with an event per 1000 patient-years"
"18769";"Patients with any clinical"
"18770";"Patients with any clinical event"
"18771";"Patients with ASCVD but no prior Ml HR (95% Cl)"
"18772";"Patients with at least one concomitant disease*"
"18773";"Patients with at least one concomitant disease||"
"18774";"Patients with baseline CRP concentration £10 mg/L"
"18775";"Patients with baseline CRP concentration <10 mg/L"
"18776";"Patients with BP $130/80 mmHg (ABPM) at baseline, nt"
"18777";"Patients with BW decrease of $5% in patients with baseline BMI of $27 kg/m2+"
"18778";"Patients with cardiac disorders, n (%)§"
"18779";"Patients with cardiac disorders, n (%)c"
"18780";"Patients with change from baseline in PsA-modified total SHS score #0"
"18781";"Patients with change from baseline in total PsA‐modified SHS ≤0"
"18782";"Patients with chronic"
"18783";"Patients with Clinically Evident Vascular Disease"
"18784";"Patients with complicated events"
"18785";"Patients with complicated events (p=0-74十)"
"18786";"Patients with dactylitis"
"18787";"Patients with dactylitis at baseline, no."
"18788";"Patients with dactylitis at week 24, n (%)"
"18789";"Patients with dactylitis, no. (%)"
"18790";"Patients with dactylitisa"
"18791";"Patients with Deep-Vein Thrombosis Only"
"18792";"Patients with diabetes"
"18793";"Patients With Diabetes Mellitus"
"18794";"Patients With Diabetes Mellitus (n=3391)"
"18795";"Patients with diabetesb"
"18796";"Patients with diabetic nephropathy"
"18797";"Patients with digits with dactylitis, n (%)"
"18798";"Patients with DM (n = 4171)"
"18799";"Patients with DM (n = 4221)"
"18800";"Patients with DM vs. patients without DM"
"18801";"Patients with draining fistulae at baseline[n = 57]"
"18802";"Patients with early CD (n = 63)"
"18803";"Patients with eGFR <60 mL/min/1.73m2 at baseline"
"18804";"Patients with eGFR >60 mL/min/1.73m2 at baseline"
"18805";"Patients with eGFR >90 ml/min/1.73m2, n"
"18806";"Patients with eGFR 2>30 to <60 ml/min/1.73m2, n"
"18807";"Patients with eGFR 2>60 to <90 ml/min/1.73m2, n"
"18808";"Patients with eligible SES-CD score"
"18809";"Patients with End Point"
"18810";"Patients with endpoin t, n (%)"
"18811";"Patients with enthesitis"
"18812";"Patients with enthesitis (LEI >0)"
"18813";"Patients with enthesitis at baseline, no."
"18814";"Patients with enthesitis at week 100 Radiographic progression§ Change from baseline to week 52 in PsA-modified total SHS score"
"18815";"Patients with enthesitis at week 24, n (%)"
"18816";"Patients with enthesitis, n (%)"
"18817";"Patients with enthesitis, no. (%)"
"18818";"Patients with EOT data, n"
"18819";"Patients with established CV disease aged >50 years."
"18820";"Patients with evaluable endoscopy"
"18821";"Patients with event (n, %)"
"18822";"Patients with event/ patients analysed"
"18823";"Patients with event/ patients analyzed"
"18824";"Patients with event/analyzed"
"18825";"Patients with fingernail involvement"
"18826";"Patients with fistulas at baseline"
"18827";"Patients with glycated hemoglobin <7.0% and no severe hypoglycemia or diabetic ketoacidosis"
"18828";"Patients with glycated hemoglobin >7.0% and >1 episode of severe hypoglycemia*"
"18829";"Patients with glycated hemoglobin >7.0% and >1 episode ofdiabetic ketoacidosis*"
"18830";"Patients with hospitalized pneumonia events, n (%)"
"18831";"Patients with improvement $0.3"
"18832";"Patients with level >500 pg/ml"
"18833";"Patients with low (<16 mg/dl) C4"
"18834";"Patients with low (<90 mg/dl) C3"
"18835";"Patients with macroalbuminuria at baseline"
"18836";"Patients with measurement"
"18837";"Patients with microalbuminuria at baseline"
"18838";"Patients with microvascular complications, n (%)"
"18839";"Patients with mild pain (WOMAC pain score, 125-300)"
"18840";"Patients with moderate-to-severe pain (WOMAC pain score, 301-400)"
"18841";"Patients with nail psoriasis (mNAPSI >0)"
"18842";"Patients with negative anti-dsDNA"
"18843";"Patients with no prior CVD (primary"
"18844";"Patients with normoalbuminuria at baseline"
"18845";"Patients with only MRF HR (95% Cl)"
"18846";"Patients with perianal fistulae, n [%]"
"18847";"Patients with pneumonia event, n (%)#"
"18848";"Patients with pneumonia events, n (%)#"
"18849";"Patients with pneumonia resulting in death, n (%)"
"18850";"Patients with possible new DM at randomization (FPG>126-400)"
"18851";"Patients with possible new DM at randomization (HbA1c >6.5-10%)"
"18852";"Patients with prevalent kidney disease at baseline"
"18853";"Patients with previous intolerance of infliximab"
"18854";"Patients with previous loss of response to and intolerance of infliximab*"
"18855";"Patients with previous loss of response to infliximab"
"18856";"Patients with prior COPD-related"
"18857";"Patients with prior DMARD use, n (%)a"
"18858";"Patients with prior Ml HR (95% Cl)"
"18859";"Patients with psoriasis (BSA ≥ 3%)"
"18860";"Patients with psoriasis (n = 52)"
"18861";"Patients with psoriasis >3% of body surface area"
"18862";"Patients with Pulmonary Embolism"
"18863";"Patients with RA, AS, or PsA (n = 280)"
"18864";"Patients with radiographic erosion, n/N (%)"
"18865";"Patients with remission"
"18866";"Patients with serum 25(OH)D ≥ 9.2 and < 20 ng/mL, n/N (%)"
"18867";"Patients with specific disease characteris-"
"18868";"Patients with specific disease characteristics"
"18869";"Patients with specific disease characteristics, n (%)"
"18870";"Patients with supplemental vitamin D dose of 2000 IU/day starting at screeningc, n (%)"
"18871";"Patients with syndesmophytes at baseline"
"18872";"Patients with uncomplicated events"
"18873";"Patients with uncomplicated events (p=O-63十)"
"18874";"Patients with weekly ISS MID response, n (%)v"
"18875";"Patients without"
"18876";"Patients Without a Prior MI or Stroke at Baseline"
"18877";"Patients without chronic"
"18878";"Patients without Clinically Evident Vascular Disease"
"18879";"Patients without diabetes"
"18880";"Patients Without Diabetes Mellitus (n=8257)"
"18881";"Patients without diabetesb"
"18882";"Patients without DM (n = 13,739)"
"18883";"Patients without DM (n = 13892)"
"18884";"Patients without draining fistulae at baseline[n = 404]"
"18885";"Patients without prevalent kidney disease at baseline"
"18886";"Patients without psoriasis (n = 2786)"
"18887";"Patients without RA, AS, or PsA (n = 18,609)"
"18888";"Patients without syndesmophytes at baseline"
"18889";"Patients, n"
"18890";"patients, n (%)"
"18891";"Patients, n (%)"
"18892";"Patients, n/N (%)a"
"18893";"Patients, no."
"18894";"Patients, No."
"18895";"Patients, No./Total No. (%)"
"18896";"Patients, n (%)"
"18897";"Patients/events n"
"18898";"Patientswith BP $130/80 mmHg (ABPM) at baseline, nt"
"18899";"Patientswith BP ,130/80 mmHg (ABPM) at baseline, n§"
"18900";"PAV, Mean (95% CI)"
"18901";"pb"
"18902";"PBO"
"18903";"PBO-adjusted LS mean change"
"18904";"PBO-Adjusted LS mean change (SE)"
"18905";"PBO-SC every other week (n = 219)"
"18906";"PBO (n- 183)"
"18907";"PBO (n-156)"
"18908";"PBO (n -192)"
"18909";"Pbo (N = 107)"
"18910";"Pbo (N = 107) vs"
"18911";"Pbo (N = 119)"
"18912";"PBO (n = 119)"
"18913";"Pbo (N = 119) vs"
"18914";"PBO (n = 137)"
"18915";"PBO (n = 164)"
"18916";"PBO (N = 170)"
"18917";"PBO (n = 178)"
"18918";"PBO (n = 18)"
"18919";"Pbo (N = 183)"
"18920";"PBO (N = 21)"
"18921";"PBO (N = 22)"
"18922";"PBO (n = 23)"
"18923";"PBO (n = 237)"
"18924";"PBO (n = 259)"
"18925";"PBO (n = 261)"
"18926";"PBO (n = 266)"
"18927";"PBO (n = 312)"
"18928";"PBO (n = 334)"
"18929";"PBO (n = 380)"
"18930";"PBO (n = 40)"
"18931";"PBO (n = 409)"
"18932";"PBO (n = 42)"
"18933";"Pbo (N = 43)"
"18934";"Pbo (N = 43) vs"
"18935";"PBO (N = 44)"
"18936";"PBO (n = 468)"
"18937";"PBO (n = 509)"
"18938";"PBO (n = 606)"
"18939";"PBO (n = 646)"
"18940";"PBO (n = 85)"
"18941";"Pbo (N = 99)"
"18942";"Pbo (N = 99) vs"
"18943";"PBO (n 5 115)"
"18944";"PBO (n 5 531)"
"18945";"PBO (n = 109)"
"18946";"PBO (n = 12)"
"18947";"PBO (n = 97)"
"18948";"PBO (n=163)"
"18949";"PBO (n=483)"
"18950";"PBO (n5 164)"
"18951";"PBO (n5119)"
"18952";"PBO (n542)"
"18953";"Pbo + statin"
"18954";"Pbo + statin    1"
"18955";"Pbo + statin n=261"
"18956";"Pbo + statin n=353"
"18957";"Pbo + statin n=395"
"18958";"PBO CZP 200 mg Q2W Week 16 (N=30)"
"18959";"PBO CZP 200 mg Q2W Week 24 (N=30)"
"18960";"PBO CZP 400 mg Q4W Week 16 (N=29)"
"18961";"PBO CZP 400 mg Q4W Week 24 (N=31)"
"18962";"Pbo n (%)"
"18963";"PBO N=216"
"18964";"PBO to CZP Week 16 Dose Combined"
"18965";"PBO to CZP Week 24 Dose Combined"
"18966";"PBO, n=37"
"18967";"PBO, n=59"
"18968";"PBO, n=69"
"18969";"Pbo, No. (%)^"
"18970";"Pbo, No. (o/o)^’"
"18971";"PBO/SIMVA - 7yr KM rale (%)"
"18972";"PBO+MTX"
"18973";"PBO+MTX n=157"
"18974";"PBO+MTX n=213"
"18975";"PBO+MTX to MTX"
"18976";"PBO+MTX^MTX"
"18977";"PCI"
"18978";"PCI—No. (%)"
"18979";"PCI — no. (%)"
"18980";"PCI — no. {%)"
"18981";"PCI (%)"
"18982";"PCI >1 month ago"
"18983";"PCI alone (n=838)"
"18984";"PCI data"
"18985";"PCI delay due to low risk"
"18986";"PCI duration"
"18987";"PCI duration in min (median, IQR)"
"18988";"PCI during index hospitalization"
"18989";"PCI for Index Event"
"18990";"PCI for index MI (%)"
"18991";"PCI history"
"18992";"PCI indication"
"18993";"PCI or CABG surgery for index event"
"18994";"PCI orCABG"
"18995";"PCI performed"
"18996";"PCI Postindex event"
"18997";"PCI revascuLarization"
"18998";"PCI, n (%)"
"18999";"PCI/thrombolysis at randomization"
"19000";"pci:"
"19001";"PCI=percutaneous coronary intervention. CABG=coronary-artery bypass graft. For HOPE >201 mg/L; for EUROPA >250 mg/L or on a lipid-lowering treatment; for PEACE, data are mean (SD). Data are mean (SD) unless otherwise indicated."
"19002";"PCIperformed for qualifying event"
"19003";"PCR after ACS"
"19004";"PCS score"
"19005";"PCS score (0–100 scale)"
"19006";"PcTindopnl- indapamide (n=5569)"
"19007";"PDE-5i"
"19008";"PDE-5i monotherapy"
"19009";"PDE5 inhibitor monotherapy"
"19010";"PDE5 inhibitors"
"19011";"PDQ-39"
"19012";"PDQOL scale"
"19013";"PE"
"19014";"PE (with or without DVT)"
"19015";"PE ± DVT"
"19016";"PE and DVT"
"19017";"PE associated with DVT at diagnosis"
"19018";"PE only"
"19019";"PE With/Without DVT"
"19020";"PEACE (n=8290)"
"19021";"Peak creatine kinase-MB, U/L"
"19022";"Peak FEV1(0-3h) response"
"19023";"Peak procedural ACT — sec"
"19024";"Peak systolic pressure gradient"
"19025";"Peak Systolic Pressure Gradient"
"19026";"Pedal edema, slight/moderate/marked"
"19027";"PEF at baseline, l_/min"
"19028";"PEF!"
"19029";"PEF, post-bronchodilator, % predicted normal"
"19030";"PEFAM (L/min)∗"
"19031";"PEFPM (L/min)∗"
"19032";"Pelvic fractures"
"19033";"pen-label empagliflozin 25 mg (baseline HbA1c >10%)"
"19034";"Penetrating"
"19035";"Penetrating disease, %"
"19036";"Penetrating No. of resections, n (%)"
"19037";"Pentraxin-3 (ng/ml)"
"19038";"People with diabetes N = 1554"
"19039";"People without diabetes N = 3680"
"19040";"Pepsinogen I/II ratio"
"19041";"Per body weight, U/kg"
"19042";"Percent  Change"
"19043";"Percent activity impairment due to asthma"
"19044";"Percent Atheroma Volume at Baseline"
"19045";"percent change"
"19046";"Percent Change from Baseline at Week 24"
"19047";"Percent change from baseline to week 12 in AUC (mean, SEM)"
"19048";"Percent impairment while working due to asthma"
"19049";"Percent improvement, baseline to week 100, median (IQR)"
"19050";"Percent of Patients"
"19051";"Percent of predicted FEV1"
"19052";"Percent of predicted normal value"
"19053";"Percent of predicted value before bronchodilation^"
"19054";"Percent of the time that INR was in the therapeutic range"
"19055";"Percent overall work impairment due to asthma"
"19056";"Percent Stenosis [Core Lab]"
"19057";"Percent Stenosis [Investigator]"
"19058";"Percent work time missed due to asthma"
"19059";"percentage"
"19060";"Percentage difference (95% Cl)"
"19061";"Percentage of BSA involved"
"19062";"Percentage of females"
"19063";"Percentage of FEVj reversibility"
"19064";"Percentage of P"
"19065";"Percentage of patients receiving dose adjustment"
"19066";"Percentage of patients using ICS or ICS/LABA on entry"
"19067";"Percentage of Patients with Event"
"19068";"Percentage of predicted pre-bronchodilator FEV^"
"19069";"Percentage of time in therapeutic INR range, mean (SD)"
"19070";"Percentage patients reaching target"
"19071";"percentage points"
"19072";"Percentage unless otherwise noted. CABG indicates coronary artery bypass graft; LVH, left ventricular hypertrophy; NSAIDs, nonsteroidal antiinflammatory drugs; PVD, peripheral vascular disease; TIA, transient ischemic attack. ‘History of hypercholesterolemia or reporting use of lipid-lowering medications at baseline. tHistory of or currently have elevated serum creatinine level <4 mg/dL. tBased on participant history or review of chart."
"19073";"Percentage with disease duration <2 years"
"19074";"Percentages"
"19075";"Percentages of patients with event"
"19076";"Percutaneous coronary intervention"
"19077";"Percutaneous coronary intervention done*"
"19078";"Percutaneous coronary intervention N(%)"
"19079";"Percutaneous coronary intervention or coronary-artery bypass grafting for index acute coronary syndrome — no. {%)"
"19080";"Percutaneous coronary intervention or coronary artery bypass graft surgery, n (%)"
"19081";"Percutaneous coronary intervention, n (%)"
"19082";"Percutaneous coronary intervention§"
"19083";"Percutaneous coronary revascularization"
"19084";"Percutaneous intervention"
"19085";"Percutaneous transluminal coronary angioplasty"
"19086";"Perfusion defectsatinclusion"
"19087";"Peri- or postmenopausal"
"19088";"Peri-op ACE-inhibitors/ARBs: No (n=655)"
"19089";"Peri-op amiodarone: No (n=1295)"
"19090";"Peri-op beta-blockers: No (n=456)"
"19091";"Peri-op statins: No (n=550)"
"19092";"Peri-operative CABG Participants:"
"19093";"Perianal GI tract"
"19094";"Perianal or anus"
"19095";"Perianal, n (%)"
"19096";"Perindopril"
"19097";"Perindopril-indapamide"
"19098";"Period I"
"19099";"Period II"
"19100";"Periostin"
"19101";"Periostin (ng/ml)"
"19102";"Periostin high"
"19103";"Periostin low"
"19104";"Peripherai arteriai disease"
"19105";"Peripheral"
"19106";"Peripheral-artery disease"
"19107";"Peripheral-artery disease — no. (%)"
"19108";"Peripheral-artery disease (%)"
"19109";"Peripheral-artery stenosis"
"19110";"Peripheral angioplasty"
"19111";"peripheral arterial disease"
"19112";"Peripheral arterial disease"
"19113";"Peripheral arterial disease — no. (%)"
"19114";"Peripheral arterial disease — no. (%)§"
"19115";"Peripheral arterial disease (n=21 096)"
"19116";"Peripheral arterial disease, n (%)"
"19117";"Peripheral arterial disease§"
"19118";"Peripheral arterial revascularization"
"19119";"Peripheral arterial stenosis"
"19120";"Peripheral artery"
"19121";"Peripheral artery disease"
"19122";"Peripheral artery disease--"
"19123";"Peripheral artery disease — no. (%)"
"19124";"Peripheral artery disease 一 no. (%)"
"19125";"Peripheral artery disease details"
"19126";"Peripheral artery disease*"
"19127";"Peripheral artery diseaseb"
"19128";"Peripheral artery diseasef"
"19129";"Peripheral artery occlusive disease"
"19130";"Peripheral artery occlusive disease (stage 0/1/2/3/4)"
"19131";"Peripheral artery revascularization without amputation"
"19132";"Peripheral edema"
"19133";"Peripheral embolism"
"19134";"Peripheral limb vascular efficacy"
"19135";"Peripheral neuropathy"
"19136";"Peripheral revascularisation"
"19137";"Peripheral revascularization"
"19138";"Peripheral Revascularization (n = 934)"
"19139";"Peripheral sensory neuropathy"
"19140";"Peripheral vascular disease"
"19141";"Peripheral vascular disease, n (%)"
"19142";"Peripheral vasodilators"
"19143";"Periprocedural anticoagulant"
"19144";"Periprocedural medications"
"19145";"Periprocedural medications — no./total no."
"19146";"Periprocedural medications — no./total no. (%)"
"19147";"Periprocedural medications, n (%)"
"19148";"Periprocedural medications, n (%) Clopidogrel, 300 mg*"
"19149";"Permanent"
"19150";"Permanent (n, %)"
"19151";"Permanent AF"
"19152";"Permanent users"
"19153";"Permanent users, n"
"19154";"Permanent, n (%)"
"19155";"Permanently stopped study drug because of adverse events"
"19156";"Persisent"
"19157";"Persistent"
"19158";"Persistent (n, %)"
"19159";"Persistent AF"
"19160";"Persistent AF, n (%)"
"19161";"Persistent anemia Bsl Hb < 120g I-1; Yr 1 < 120g I 1"
"19162";"Persistent FAOD (n [ 113)"
"19163";"Persistent FAOL (n [ 155)"
"19164";"Persistent or paroxysmal"
"19165";"Persistent or permanent immobilization"
"19166";"Persistent WRF (n = 283)"
"19167";"Persistent*"
"19168";"Persistent, n (%)"
"19169";"Persistent/permanent"
"19170";"Person-years"
"19171";"Pervious cerebrovascular event"
"19172";"PFO + ASA"
"19173";"PFO Closure"
"19174";"PFO Closure Group (N = 238)"
"19175";"PFO with large shunt and atrial septal aneurysm"
"19176";"PFO with large shunt without atrial septal aneurysm"
"19177";"PFO with mild-to-moderate shunt and atrial septal aneurysm"
"19178";"Pfor"
"19179";"pfor heterogeneity"
"19180";"pfor interaction"
"19181";"Pfor interaction"
"19182";"Pfor Interaction"
"19183";"pfor trend"
"19184";"PGA score (range)"
"19185";"PGA score, mean (SD)"
"19186";"PGA subscore"
"19187";"PGA, 0-10"
"19188";"PGI-S, n (%)y:"
"19189";"Phakic"
"19190";"Pharmaco-Invasive (n=944)"
"19191";"Pharmaco-invasive n=944"
"19192";"Pharmacological therapy for HF"
"19193";"Pharmacotherapy"
"19194";"Pharyngitis"
"19195";"Phenobarbital"
"19196";"PhGADA (mm)"
"19197";"Phi (N-161)"
"19198";"PhI (n=171)"
"19199";"Philippines"
"19200";"phosphatase, mean (SD), ng/'mLf"
"19201";"Phosphate (mmol/L)"
"19202";"Phosphodiesterase type 5 inhibitors"
"19203";"Phospholipid omega-3 levels: <4% (n=200)"
"19204";"Phosphorus, mmol 1 1"
"19205";"Phototherapy"
"19206";"Phototherapy Previous systemic treatment, n (%)"
"19207";"Physical activity (hours walking/wk)"
"19208";"Physical activity, kcal/wk"
"19209";"Physical activity, kcal/wk <1000"
"19210";"Physical activity, kcal/wk*"
"19211";"Physical Activity§"
"19212";"Physical and cognitive examination:!:"
"19213";"Physical characteristics"
"19214";"Physical component"
"19215";"Physical component score (PCS)"
"19216";"Physical exam oedema"
"19217";"Physical examination"
"19218";"Physical examinations"
"19219";"Physical function"
"19220";"Physical function (0-100, Short Form-36 subscale)"
"19221";"Physician"
"19222";"Physician's assessment of disease activity (VAS), mm"
"19223";"Physician's GA, 0-100 mmVAS"
"19224";"Physician's global assessment"
"19225";"Physician's global assessment (VAS)"
"19226";"Physician's global assessment of dis-"
"19227";"Physician's global assessment of disease activity (0-100 mm VAS), mean (SD)"
"19228";"Physician's global assessment of disease status score"
"19229";"Physician's Global Assessment!"
"19230";"Physician's global assessment. mean 6 SD"
"19231";"Physician's judgment that VKA"
"19232";"Physician's judgment that VKA inappropriate"
"19233";"Physician's judgment that VKA inappropriate]"
"19234";"Physician global assessment (0-100 mm VAS)"
"19235";"Physician global assessment of disease"
"19236";"Physician global assessment of disease activity (0-10 cm, VAS)"
"19237";"Physician Global Assessment of disease activity (VAS 0-100 mm)"
"19238";"Physician global assessment of disease activity, mean (SD)"
"19239";"Physiological measures"
"19240";"PI"
"19241";"Piacebo"
"19242";"Piacebo (N=7740) no. of participants with events (%)"
"19243";"PIFR L/min"
"19244";"PIGR (ng/ml)"
"19245";"Pin/"
"19246";"Pint"
"19247";"pinteraction"
"19248";"Pinteraction"
"19249";"pinteraction for treatment and history of heart failure"
"19250";"Pinteraction=0.003"
"19251";"PIO 15"
"19252";"PIO 30"
"19253";"PIO 45"
"19254";"Pioglitazone"
"19255";"Pioglitazone (n = 1939)"
"19256";"Pioglitazone (N = 303)"
"19257";"Pioglitazone (N =1,939)"
"19258";"Pioglitazone (n=1939)"
"19259";"Pioglitazone (n=2605)"
"19260";"Pioglitazone dose, mean (SD), mg"
"19261";"Pioglitazone Events / N (%)"
"19262";"Pioglitazone Group (n = 644)"
"19263";"Pioglitazone only"
"19264";"Pioglitazone Pts / N (%)"
"19265";"Piroxicam"
"19266";"Pitavastatin 4 mg"
"19267";"Pla"
"19268";"PLA"
"19269";"PLA « = 82"
"19270";"PLA n = 107"
"19271";"PLA n = 38"
"19272";"Plac"
"19273";"Place of randomization"
"19274";"Place!"
"19275";"placebo"
"19276";"Placebo"
"19277";"PLACEBO"
"19278";"Placebo-adjusted mean difference in % HbA1c (95% CI; [ p value])"
"19279";"Placebo-Control Study"
"19280";"Placebo‐controlled period"
"19281";"Placebo       no.of events/total no. (%)"
"19282";"Placebo    |"
"19283";"Placebo    119"
"19284";"Placebo    1o1"
"19285";"Placebo "" (n = 157)"
"19286";"Placebo %"
"19287";"Placebo ( N = 466)"
"19288";"Placebo (%)"
"19289";"Placebo (« = 4672)"
"19290";"Placebo (» = 4672)"
"19291";"Placebo (0=244)"
"19292";"Placebo (593, 50.5%)"
"19293";"Placebo (DM- vs. DM+)"
"19294";"Placebo (DM-vs. DM+)"
"19295";"Placebo (events/n(%))"
"19296";"Placebo (LSM)"
"19297";"Placebo (n-207)"
"19298";"Placebo (n - 16)"
"19299";"Placebo (N - 209)"
"19300";"Placebo (n -10.090)"
"19301";"Placebo (n — 230)"
"19302";"Placebo (n : 418)"
"19303";"Placebo (n [ 159)"
"19304";"Placebo (n [ 83)"
"19305";"Placebo (n = 1,118)"
"19306";"Placebo (n = 1,161)"
"19307";"Placebo (n = 1,776)"
"19308";"Placebo (N = 10,186)"
"19309";"Placebo (n = 100)"
"19310";"Placebo (n = 1010)"
"19311";"Placebo (n = 105)"
"19312";"Placebo (N = 1069)"
"19313";"Placebo (n = 107)"
"19314";"Placebo (n = 108)"
"19315";"Placebo (N = 108)"
"19316";"Placebo (n = 110)"
"19317";"Placebo (N = 112)"
"19318";"Placebo (n = 113)"
"19319";"Placebo (n = 113)†"
"19320";"Placebo (n = 114)"
"19321";"Placebo (n = 116)"
"19322";"Placebo (N = 122)"
"19323";"Placebo (n = 1231)"
"19324";"Placebo (N = 1244)"
"19325";"Placebo (n = 1256)"
"19326";"Placebo (n = 128)"
"19327";"Placebo (N = 13,224)"
"19328";"Placebo (N = 131)i-"
"19329";"Placebo (n = 132)"
"19330";"Placebo (N = 133)"
"19331";"Placebo (n = 134)"
"19332";"Placebo (n = 136)"
"19333";"Placebo (N = 137)"
"19334";"Placebo (n = 1379)"
"19335";"Placebo (n = 140)"
"19336";"Placebo (n = 142)"
"19337";"Placebo (N = 143)"
"19338";"Placebo (n = 1441)"
"19339";"Placebo (n = 147)"
"19340";"Placebo (N = 149)"
"19341";"Placebo (N = 15,224)"
"19342";"Placebo (n = 153)"
"19343";"Placebo (n = 154)"
"19344";"Placebo (N = 1604)"
"19345";"Placebo (n = 163)"
"19346";"Placebo (n = 164)"
"19347";"Placebo (N = 1649)"
"19348";"Placebo (n = 166)"
"19349";"Placebo (n = 167)"
"19350";"Placebo (n = 168)"
"19351";"Placebo (n = 170)"
"19352";"Placebo (N = 1723)"
"19353";"Placebo (N = 1726) 61.9±8.6"
"19354";"Placebo (n = 173)"
"19355";"Placebo (n = 174)"
"19356";"Placebo (n = 1758)"
"19357";"Placebo (N = 176)"
"19358";"Placebo (n = 177)"
"19359";"Placebo (n = 178)"
"19360";"Placebo (n = 18,330)"
"19361";"Placebo (N = 18,330)"
"19362";"Placebo (n = 180)"
"19363";"Placebo (n = 181)"
"19364";"Placebo (N = 181)"
"19365";"Placebo (n = 1817)"
"19366";"Placebo (n = 1835)"
"19367";"Placebo (N = 185)"
"19368";"Placebo (n = 186)"
"19369";"Placebo (n = 187)"
"19370";"Placebo (n = 19 939)"
"19371";"Placebo (n = 19 942)"
"19372";"Placebo (n = 19)"
"19373";"Placebo (N = 19,942)"
"19374";"Placebo (n = 190)"
"19375";"Placebo (N = 191)"
"19376";"Placebo (n = 1937)"
"19377";"Placebo (n = 196)"
"19378";"Placebo (N = 197)"
"19379";"Placebo (N = 198)"
"19380";"Placebo (n = 19939)"
"19381";"Placebo (n = 20)"
"19382";"Placebo (N = 201)"
"19383";"Placebo (n = 202)"
"19384";"Placebo (N = 202)"
"19385";"Placebo (n = 203)"
"19386";"Placebo (n = 2061)"
"19387";"Placebo (N = 208)"
"19388";"Placebo (n = 21)"
"19389";"Placebo (n = 215)"
"19390";"Placebo (n = 2167)"
"19391";"Placebo (n = 2176)"
"19392";"Placebo (N = 2215)"
"19393";"Placebo (N = 226)"
"19394";"Placebo (N = 229)"
"19395";"Placebo (n = 230)"
"19396";"Placebo (N = 2327) 71.7±9.0"
"19397";"Placebo (N = 233)"
"19398";"Placebo (N = 2333)"
"19399";"Placebo (n = 234)"
"19400";"Placebo (n = 24)"
"19401";"Placebo (n = 248)"
"19402";"Placebo (n = 25)"
"19403";"Placebo (N = 2510)"
"19404";"Placebo (n = 2526)"
"19405";"Placebo (n = 257*)"
"19406";"Placebo (n = 26)"
"19407";"Placebo (N = 2679)"
"19408";"Placebo (N = 2753)"
"19409";"Placebo (n = 28)"
"19410";"Placebo (n = 29)"
"19411";"Placebo (n = 2988)"
"19412";"Placebo (N = 299)"
"19413";"Placebo (n = 3,941)"
"19414";"Placebo (N = 3006)"
"19415";"Placebo (n = 302)"
"19416";"Placebo (N = 3034)"
"19417";"Placebo (n = 31)"
"19418";"Placebo (N = 313)"
"19419";"Placebo (N = 324)"
"19420";"Placebo (n = 3281)"
"19421";"Placebo (n = 331)"
"19422";"Placebo (n = 345)"
"19423";"Placebo (n = 3485)"
"19424";"Placebo (n = 3485)'"
"19425";"Placebo (N = 3511)"
"19426";"Placebo (N = 3687)"
"19427";"Placebo (N = 3906) n (%)"
"19428";"Placebo (n = 399)"
"19429";"Placebo (n = 4,271)"
"19430";"Placebo (N = 409)"
"19431";"Placebo (N = 419)"
"19432";"Placebo (n = 424)"
"19433";"Placebo (n = 426)"
"19434";"Placebo (N = 4347)"
"19435";"Placebo (n = 437)"
"19436";"Placebo (N = 4502)"
"19437";"Placebo (N = 4675)"
"19438";"Placebo (n = 47)"
"19439";"Placebo (n = 483)"
"19440";"Placebo (n = 484)"
"19441";"Placebo (n = 497)"
"19442";"Placebo (n = 4i3)"
"19443";"Placebo (n = 503)"
"19444";"Placebo (N = 525"
"19445";"Placebo (n = 528)"
"19446";"Placebo (n = 537)"
"19447";"Placebo (N = 582)"
"19448";"Placebo (N = 586)"
"19449";"Placebo (N = 594)"
"19450";"Placebo (n = 596)"
"19451";"Placebo (n = 6,930)"
"19452";"Placebo (n = 60)"
"19453";"Placebo (N = 60)"
"19454";"Placebo (N = 607) 67.1±8.2"
"19455";"Placebo (n = 63)"
"19456";"Placebo (n = 64)"
"19457";"Placebo (N = 640)"
"19458";"Placebo (n = 649)"
"19459";"Placebo (n = 65)"
"19460";"Placebo (N = 662)"
"19461";"Placebo (n = 677)"
"19462";"Placebo (n = 69)"
"19463";"Placebo (N = 696)"
"19464";"Placebo (n = 7)"
"19465";"Placebo (n = 7,051)"
"19466";"Placebo (n = 7,268)"
"19467";"Placebo (N = 7067)"
"19468";"Placebo (n = 72)"
"19469";"Placebo (n = 73)"
"19470";"Placebo (n = 74)"
"19471";"Placebo (n = 741)"
"19472";"Placebo (N = 742)"
"19473";"Placebo (N = 746)"
"19474";"Placebo (n = 76)"
"19475";"Placebo (n = 7740)"
"19476";"Placebo (n = 78)"
"19477";"Placebo (n = 80)"
"19478";"Placebo (n = 812)"
"19479";"Placebo (N = 812)"
"19480";"Placebo (n = 82)"
"19481";"Placebo (N = 829)"
"19482";"Placebo (N = 8578)"
"19483";"Placebo (n = 86)"
"19484";"Placebo (n = 896)"
"19485";"Placebo (n = 933)"
"19486";"Placebo (N = 9462)"
"19487";"Placebo (N = 9552)"
"19488";"Placebo (n = 97)"
"19489";"Placebo (n = 98)"
"19490";"Placebo (N =1,937)"
"19491";"Placebo (n =154)"
"19492";"Placebo (n =163)"
"19493";"Placebo (n =167)"
"19494";"Placebo (N =353)"
"19495";"Placebo (N =720)"
"19496";"Placebo (n 5 1,785)"
"19497";"Placebo (n 5 154)"
"19498";"Placebo (n 5 232)"
"19499";"Placebo (n 5 418)"
"19500";"Placebo (n 5 5786)"
"19501";"Placebo (n 5 692)"
"19502";"Placebo (n 5 78)"
"19503";"Placebo (n 5280)"
"19504";"Placebo (n Z 1033)"
"19505";"Placebo (n Z 146)"
"19506";"Placebo (n Z 1965)"
"19507";"Placebo (n Z 261)"
"19508";"Placebo (n Z 435)"
"19509";"Placebo (n Z 600)"
"19510";"Placebo (n Z 77)"
"19511";"Placebo (n Z 932)"
"19512";"Placebo (n = 1,261)"
"19513";"Placebo (n = 105)"
"19514";"Placebo (n = 155)"
"19515";"Placebo (N = 23)"
"19516";"Placebo (n = 234)"
"19517";"Placebo (n = 301)"
"19518";"Placebo (n = 49)"
"19519";"Placebo (n = 506)"
"19520";"Placebo (n = 103)"
"19521";"Placebo (n = 104)"
"19522";"Placebo (n = 125)"
"19523";"Placebo (n = 128)"
"19524";"Placebo (n = 129)"
"19525";"Placebo (n = 2,717)"
"19526";"Placebo (n = 21)"
"19527";"Placebo (n = 25)"
"19528";"Placebo (n = 26)"
"19529";"Placebo (n = 51)"
"19530";"Placebo (n = 626)"
"19531";"Placebo (N[130)"
"19532";"Placebo (n[1544)"
"19533";"Placebo (N = 117)"
"19534";"Placebo (n = 1597)"
"19535";"Placebo (n = 167)"
"19536";"Placebo (n = 1770)"
"19537";"Placebo (n = 20)"
"19538";"Placebo (n = 236)"
"19539";"Placebo (n = 270)"
"19540";"Placebo (n = 273)a"
"19541";"Placebo (n = 331)a"
"19542";"Placebo (N = 34)"
"19543";"Placebo (n = 40)"
"19544";"Placebo (n = 52)"
"19545";"Placebo (n = 525)"
"19546";"Placebo (n = 563)"
"19547";"Placebo (n = 578)"
"19548";"Placebo (n = 578)b"
"19549";"Placebo (N = 83)"
"19550";"Placebo (n= 1,174)"
"19551";"Placebo (n= 225)"
"19552";"Placebo (n= 350)"
"19553";"Placebo (n= 352)"
"19554";"Placebo (N=10 090)"
"19555";"Placebo (n=1005)"
"19556";"Placebo (n=102)"
"19557";"Placebo (n=1070)"
"19558";"Placebo (n=108)"
"19559";"Placebo (N=1080)"
"19560";"Placebo (n=112)"
"19561";"Placebo (n=116)"
"19562";"Placebo (n=118)"
"19563";"Placebo (n=122)"
"19564";"Placebo (n=124)"
"19565";"Placebo (N=1267)"
"19566";"Placebo (n=129)"
"19567";"Placebo (n=130)"
"19568";"Placebo (n=1300)"
"19569";"Placebo (n=134)"
"19570";"Placebo (n=137)"
"19571";"Placebo (n=1382)"
"19572";"Placebo (n=139)"
"19573";"Placebo (n=140)"
"19574";"Placebo (n=1428)"
"19575";"Placebo (N=146)"
"19576";"PLACEBO (N=151)"
"19577";"Placebo (n=1518)"
"19578";"Placebo (N=15224)"
"19579";"Placebo (n=1545)"
"19580";"Placebo (N=1569)"
"19581";"Placebo (n=1645)"
"19582";"Placebo (n=1654)"
"19583";"Placebo (n=168)"
"19584";"Placebo (n=1694)"
"19585";"Placebo (N=1726)"
"19586";"Placebo (N=1739)"
"19587";"Placebo (n=179)"
"19588";"Placebo (N=18 618)"
"19589";"Placebo (N=181)"
"19590";"Placebo (n=1827)"
"19591";"placebo (n=1917)"
"19592";"Placebo (n=1917)"
"19593";"Placebo (n=193)"
"19594";"Placebo (n=1937)"
"19595";"Placebo (n=197)"
"19596";"Placebo (n=20)"
"19597";"Placebo (n=206)"
"19598";"Placebo (N=2061)"
"19599";"Placebo (n=2078)"
"19600";"Placebo (n=211*)"
"19601";"Placebo (N=2118)"
"19602";"Placebo (n=2191)"
"19603";"Placebo (n=22 891)"
"19604";"Placebo (n=22 923)"
"19605";"Placebo (n=22)"
"19606";"Placebo (n=224)"
"19607";"Placebo (n=225)"
"19608";"Placebo (N=228)"
"19609";"Placebo (N=2289)"
"19610";"Placebo (n=232)"
"19611";"Placebo (n=235)"
"19612";"Placebo (n=236)"
"19613";"Placebo (N=2448)"
"19614";"Placebo (N=247)"
"19615";"Placebo (n=2477)"
"19616";"Placebo (n=248)"
"19617";"Placebo (n=249)"
"19618";"Placebo (n=258)"
"19619";"Placebo (n=26)"
"19620";"Placebo (n=260)"
"19621";"Placebo (n=2633)"
"19622";"Placebo (n=267)"
"19623";"Placebo (n=2679)"
"19624";"Placebo (n=269)"
"19625";"Placebo (n=271)"
"19626";"Placebo (n=275)"
"19627";"Placebo (n=277)"
"19628";"Placebo (n=294)"
"19629";"Placebo (n=315)"
"19630";"Placebo (n=3182)"
"19631";"Placebo (n=3417)"
"19632";"Placebo (n=348l)"
"19633";"Placebo (n=352)"
"19634";"Placebo (n=354)"
"19635";"Placebo (n=362)"
"19636";"Placebo (N=3667)"
"19637";"Placebo (n=3689)"
"19638";"Placebo (n=381)"
"19639";"Placebo (n=399)"
"19640";"Placebo (N=4,672)"
"19641";"Placebo (n=403)"
"19642";"Placebo (n=407)"
"19643";"Placebo (n=4127)"
"19644";"Placebo (n=413)"
"19645";"Placebo (n=42)"
"19646";"Placebo (n=425)"
"19647";"Placebo (n=428)"
"19648";"Placebo (n=4287)"
"19649";"Placebo (n=430)"
"19650";"Placebo (n=440)"
"19651";"Placebo (N=4661)"
"19652";"Placebo (N=4672)"
"19653";"Placebo (n=4732)"
"19654";"Placebo (n=476)"
"19655";"Placebo (n=488)"
"19656";"Placebo (N=52)"
"19657";"Placebo (n=552)"
"19658";"Placebo (n=5571)"
"19659";"Placebo (N=5786)"
"19660";"Placebo (n=583O)"
"19661";"Placebo (n=585)"
"19662";"Placebo (n=59)"
"19663";"Placebo (n=596)"
"19664";"Placebo (N=607)"
"19665";"Placebo (n=635)"
"19666";"Placebo (n=646)"
"19667";"Placebo (N=6471 )"
"19668";"Placebo (n=658)"
"19669";"Placebo (n=667)"
"19670";"Placebo (n=675)"
"19671";"Placebo (n=6l)"
"19672";"Placebo (N=703)"
"19673";"Placebo (n=749)"
"19674";"Placebo (N=752)"
"19675";"Placebo (N=758)"
"19676";"Placebo (n=76)"
"19677";"Placebo (n=760)"
"19678";"placebo (n=762)"
"19679";"Placebo (n=762)"
"19680";"Placebo (n=77)"
"19681";"Placebo (n=770)"
"19682";"Placebo (n=779)"
"19683";"Placebo (n=80)"
"19684";"Placebo (n=815)"
"19685";"Placebo (n=82)"
"19686";"Placebo (N=8212)"
"19687";"Placebo (N=847)"
"19688";"Placebo (n=929)"
"19689";"Placebo (n=95)"
"19690";"Placebo (N=96)"
"19691";"Placebo (n=961)"
"19692";"Placebo (n=98)"
"19693";"Placebo (n=l69)"
"19694";"Placebo (symptom days a week)"
"19695";"Placebo (W = 238)"
"19696";"Placebo (W = 239)"
"19697";"Placebo [N = 112|"
"19698";"Placebo [N = 122]"
"19699";"Placebo [N = 198|"
"19700";"Placebo [n Z 51]"
"19701";"Placebo [n Z 66]"
"19702";"Placebo + 20 mg/d of Simvastatin"
"19703";"Placebo + 20 mg/d of Simvastatin (n = 2232)"
"19704";"Placebo + glimepiride"
"19705";"Placebo + insulin (n = 272)"
"19706";"Placebo + Insulin (n=272)"
"19707";"Placebo + insulin glargine (AWARD-9; N = 150)"
"19708";"Placebo + MTX"
"19709";"Placebo + MTX (n=249)"
"19710";"Placebo + pioglitazone (n=97)"
"19711";"Placebo + Statin (n = 1,584)"
"19712";"Placebo 0.07"
"19713";"Placebo 0.35"
"19714";"Placebo 1030"
"19715";"Placebo 1116"
"19716";"Placebo 127"
"19717";"Placebo 128"
"19718";"Placebo 129"
"19719";"Placebo 137"
"19720";"Placebo 151"
"19721";"Placebo 152"
"19722";"Placebo 1556"
"19723";"Placebo 16,186"
"19724";"Placebo 18/66"
"19725";"Placebo 3 Year KM (%)"
"19726";"Placebo 3 yr KM%"
"19727";"Placebo 317"
"19728";"Placebo 321"
"19729";"Placebo 50/66"
"19730";"Placebo allocation"
"19731";"Placebo Allocation"
"19732";"Placebo analysed (%)"
"19733";"Placebo arm"
"19734";"Placebo Croup, n/n (%)"
"19735";"Placebo Diabetes n=18"
"19736";"Placebo dn = 16)"
"19737";"Placebo dr = 42)"
"19738";"Placebo Estimated mean"
"19739";"Placebo Event Rate (n=1814), %"
"19740";"Placebo Event Rate (n=6625), %"
"19741";"Placebo Events / N (%)"
"19742";"Placebo Events/patients ("
"19743";"Placebo Events/patients (%)"
"19744";"Placebo every 2 weeks (n=54)"
"19745";"Placebo group"
"19746";"Placebo Group"
"19747";"Placebo group  (n =459)"
"19748";"Placebo Group (n = 159)"
"19749";"Placebo Group (n = 160)"
"19750";"Placebo Group (n = 166)"
"19751";"Placebo group (N = 18 618) (180 652 person years)"
"19752";"Placebo Group (N = 210)f"
"19753";"Placebo group (n = 263)"
"19754";"Placebo Group (N = 328)’j'"
"19755";"Placebo Group (N = 381)"
"19756";"Placebo Group (N = 383)"
"19757";"Placebo group (n = 459)"
"19758";"Placebo Group (N = 7740)"
"19759";"Placebo Group (n = 810)"
"19760";"Placebo Group (n=157)"
"19761";"Placebo group (n=196)"
"19762";"Placebo Group (N=253)"
"19763";"Placebo group (n=3264)"
"19764";"Placebo Group (n=381)"
"19765";"Placebo Group (N=7740)"
"19766";"Placebo group (n=8881)"
"19767";"Placebo KM%"
"19768";"Placebo LS means (N)"
"19769";"Placebo MDI"
"19770";"Placebo mean"
"19771";"Placebo Mean (n)"
"19772";"Placebo Mean change (SD)"
"19773";"Placebo monthly (n=55)"
"19774";"Placebo Mortality Rate, Events per 1000 Person-y"
"19775";"placebo N"
"19776";"Placebo N (%)"
"19777";"Placebo n (Rate)*"
"19778";"Placebo n (rate)1"
"19779";"Placebo n = 115"
"19780";"Placebo N = 117"
"19781";"Placebo N = 118 n (%)"
"19782";"Placebo N = 123"
"19783";"Placebo n = 126"
"19784";"Placebo N = 144"
"19785";"Placebo n = 149"
"19786";"Placebo n = 154"
"19787";"Placebo N = 159"
"19788";"Placebo N = 160"
"19789";"Placebo n = 1651"
"19790";"Placebo n = 172"
"19791";"Placebo N = 180"
"19792";"Placebo N = 189"
"19793";"Placebo n = 202"
"19794";"Placebo n = 229"
"19795";"Placebo n = 278"
"19796";"Placebo n = 35"
"19797";"Placebo n = 355"
"19798";"Placebo n = 53"
"19799";"Placebo n = 73"
"19800";"Placebo n = 76"
"19801";"Placebo n =107"
"19802";"Placebo N =156"
"19803";"Placebo N(%)"
"19804";"Placebo n/N"
"19805";"Placebo n/N (%)"
"19806";"Placebo N[130"
"19807";"Placebo n=169"
"19808";"Placebo N=1771"
"19809";"Placebo N=191"
"19810";"Placebo N=193"
"19811";"Placebo N=2232"
"19812";"Placebo N=2625"
"19813";"Placebo N=3161"
"19814";"Placebo n=3184"
"19815";"Placebo n=401"
"19816";"Placebo N=4015"
"19817";"Placebo N=4941 Subjects"
"19818";"Placebo n=51"
"19819";"Placebo N=6207"
"19820";"Placebo N=638"
"19821";"Placebo n=639"
"19822";"Placebo N=651"
"19823";"Placebo N=7339"
"19824";"Placebo N=7396"
"19825";"Placebo No Diabetes n=46"
"19826";"Placebo No. (3-y KM%)"
"19827";"Placebo no. of events/no."
"19828";"Placebo No./ total (%)"
"19829";"Placebo No./Total No."
"19830";"Placebo patients with events"
"19831";"Placebo patients with events/total"
"19832";"Placebo patients/events n"
"19833";"Placebo plus Aspirin"
"19834";"Placebo plus Statin (N = 1696)"
"19835";"Placebo Pts / N (%)"
"19836";"Placebo r%"
"19837";"Placebo secukinumab 150 mg"
"19838";"Placebo secukinumab 75 mg"
"19839";"Placebo secukinumab pooled"
"19840";"Placebo Slope LSM ± SE (mm/year)"
"19841";"Placebo Tiotropium n =114 Non-tiotropium n =323"
"19842";"Placebo Tiotropium n =115 Non-tiotropium n =335"
"19843";"Placebo to ustekinumab 45 mgt"
"19844";"Placebo Tolvaptan (30 mg) (n 5 232) (n 5 243)"
"19845";"Placebo(n = 2573)"
"19846";"Placebo(n=1895)"
"19847";"Placebo(n=1895), n (%)"
"19848";"Placebo(N=842)"
"19849";"Placebo(n=881)"
"19850";"Placebo* (add on to basal insulin)"
"19851";"placebo,"
"19852";"Placebo, % (n/N)"
"19853";"Placebo, % >    (n/N)"
"19854";"Placebo, 1.14 ml (N = 317)"
"19855";"Placebo, 2.00 ml (N = 321)"
"19856";"Placebo, events/patients (%)"
"19857";"Placebo, n"
"19858";"Placebo, n (%)"
"19859";"Placebo, n (rate)"
"19860";"placebo, n = 123"
"19861";"placebo, n = 423"
"19862";"placebo, n = 802"
"19863";"placebo, n = 88"
"19864";"Placebo, N = i334"
"19865";"Placebo, n = l47"
"19866";"Placebo, N =153"
"19867";"Placebo, N(%)"
"19868";"Placebo, n*"
"19869";"Placebo, n/N (%)"
"19870";"Placebo, N = 1334"
"19871";"Placebo, N = 442"
"19872";"Placebo, n=147"
"19873";"Placebo, n=4111"
"19874";"Placebo/"
"19875";"Placebo/ Simvastatin"
"19876";"Placebo/open-label abatacept"
"19877";"Placebo/Rosu vastatin"
"19878";"Placebo/Simva"
"19879";"Placebo/Simvastatin"
"19880";"Placebo+MTX"
"19881";"Placebo+Statin"
"19882";"Placebo→Golimumab 50 mg/100 mga,b"
"19883";"Placebo§"
"19884";"Placeboa"
"19885";"PlacebofiGolimumab 50 mg/100 mgt"
"19886";"Plaeebo"
"19887";"Planned conservative therapy subgroup"
"19888";"Planned Thienopyridine at baseline"
"19889";"Planned Thienopyridine at enrollment"
"19890";"Planned treatment duration, n (%)"
"19891";"Planned treatment strategy"
"19892";"Planned valve surgery, n (%)"
"19893";"Plaque (N, %)"
"19894";"Plaque score (1-8)"
"19895";"Plasma cholesterol — mg/dl"
"19896";"Plasma creatine, mg/dL"
"19897";"Plasma DHA, mean (SD) weight, %"
"19898";"Plasma glucose — mmol per liter"
"19899";"Plasma glucose 2 hr after glucose load — mmol/liter"
"19900";"Plasma lipids (mg/dl)5 Total cholesterol Mean"
"19901";"Plasma lipoproteins, mmol/L"
"19902";"Plasma triglyceride — mg/dl"
"19903";"Platelet aggregation inhibitors excluding heparin"
"19904";"Platelet aggregation inhibitors, n (%)"
"19905";"Platelet count, X 103 mm3"
"19906";"Platelet, 109/L"
"19907";"Platelets xlOOO/mm^"
"19908";"Pleased"
"19909";"PLP-C, mean (SD), mg/dL"
"19910";"Plus–minus values are means ±SD. CABG denotes coronary-artery by-pass graft, PTCA percutaneous transluminal coronary angioplasty, and ACE angiotensin-converting enzyme. Hypertension and diabetes were de-fined by clinical history. A more complete list of base-line characteristics is given in Rubins et al.
18
†Nitrates includes all preparations except as-needed nitroglycerin. ‡Any antianginal drug includes any nitrate (as defined above), calcium-channel blocker, or beta-blocker. §The body-mass index is the weight in kilograms divided by the square of the height in meters. ¶To convert values for cholesterol to millimoles per liter, multiply by 0.02586. To convert values for triglycerides to millimoles per liter, multiply by 0.01129."
"19911";"Plus metformin"
"19912";"PM PEF (SD), L/min"
"19913";"PM, n (%)"
"19914";"PND"
"19915";"Pneumonia"
"19916";"Pneumonia events, n"
"19917";"Pneumonia in past year"
"19918";"PnorCABG"
"19919";"PnorPCI"
"19920";"POBA, n (%)"
"19921";"POCI"
"19922";"POCI (n=236)"
"19923";"Poland"
"19924";"Pollen exposure"
"19925";"Pollent < 10"
"19926";"Pollent s 10"
"19927";"Polyarticular arthritis, no rheumatoid nodules"
"19928";"Polyvascular disease (n=1930)"
"19929";"Polyvascular disease and no type 2 diabetes (n=1193)"
"19930";"Polyvascular disease and type 2 diabetes (n=737)"
"19931";"Polyvascular disease* (n=1930)"
"19932";"Polyvascular disease* and type 2 diabetes status"
"19933";"Polyvascular disease* status"
"19934";"Pool of FH I and II studies"
"19935";"Pool of LONG TERM (HeFH patients only) and HIGH FH"
"19936";"Pooled"
"19937";"Pooled analysis"
"19938";"Pooled analysis of SUSTAIN 1—5 trials"
"19939";"Pooled analysis sample"
"19940";"Pooled empagliflozin (N = 4687)"
"19941";"Pooled EZE/SIMVA"
"19942";"Pooled ITT"
"19943";"Pooled Non-CANVAS Studies (N = 5867): Non-CANA (n = 2199); CANA 100 mg (n = 1647); CANA 300 mg (n = 2021)"
"19944";"Pooled PAH-MCTD and PAH"
"19945";"Pooled placebo"
"19946";"Pooled secukinumab"
"19947";"Pooled SIMVA"
"19948";"Pooled Simvastatin Factorial Studies"
"19949";"Pooled trials* n = 5325"
"19950";"Poor"
"19951";"Poor compliance/noncompliance"
"19952";"Poor outcome at 6 months"
"19953";"Population"
"19954";"Populations:"
"19955";"Positive"
"19956";"Positive atopic status"
"19957";"Positive cTnl (n = 2843)"
"19958";"Positive CU index test"
"19959";"Positive CU index test,z n (%)"
"19960";"Positive family history of type 2 diabetes (%)"
"19961";"Positive for anti-cyclic citrullinated peptide antibody — no. (%)f"
"19962";"Positive for HLA-B27, n (%)"
"19963";"Positive for rheumatoid factor — no. (%):t"
"19964";"Positive for rheumatoid factor, anti-cyclic citrullinated peptide antibodies, or both — %ff"
"19965";"Positive HLA-B27 status, n (%)"
"19966";"Positive orthostatic test}"
"19967";"Positive troponin I or T, No. (%)"
"19968";"Positive troponin or CK-MB"
"19969";"Positive vs. negative"
"19970";"Positive vs. Negative"
"19971";"Poslmenopausal, HT"
"19972";"Poslmenopausal, no HT"
"19973";"Post-acute ischemic stroke"
"19974";"Post-albuterol% predicted FEV1 Mean (SD)e"
"19975";"Post-bronchodilation FEV1"
"19976";"Post-bronchodilation FVC"
"19977";"Post-bronchodilator"
"19978";"Post-bronchodilator FEV i Reversibility, %b"
"19979";"Post-bronchodilator FEV, % predicted"
"19980";"Post-bronchodilator FEV, (L)"
"19981";"Post-bronchodilator FEV, reversibility"
"19982";"Post-bronchodilator FEV,, % predicted"
"19983";"Post-bronchodilator FEV,/FVC"
"19984";"Post-bronchodilator FEV1 — % of predicted value"
"19985";"Post-bronchodilator FEV1 — liters"
"19986";"Post-bronchodilator FEV1 (% predicted normal)a"
"19987";"Post-bronchodilator FEV1 (% predicted*)"
"19988";"Post-bronchodilator FEV1 (L)"
"19989";"Post-bronchodilator FEV1 (l)*"
"19990";"Post-bronchodilator FEV1 (L)a"
"19991";"Post-bronchodilator FEV1 at screening"
"19992";"post-bronchodilator FEV1 mL"
"19993";"Post-bronchodilator FEV1 reversibility, %"
"19994";"Post-bronchodilator FEV1 reversibility, %a"
"19995";"Post-bronchodilator FEV1% predictedb"
"19996";"Post-bronchodilator FEV1, % predicted"
"19997";"Post-bronchodilator FEV1, % predicted of normal value"
"19998";"Post-bronchodilator FEV1, % predicted, mean (SD)"
"19999";"Post-bronchodilator FEV1, % predicted, mean (SD)c"
"20000";"Post-bronchodilator FEV1, L"
"20001";"Post-bronchodilator FEV1, L *"
"20002";"Post-bronchodilator FEV1, L, mean (SD)"
"20003";"Post-bronchodilator FEV1, L, mean (SD)c"
"20004";"Post-bronchodilator FEV1, mean (SD), L"
"20005";"Post-bronchodilator FEV1, reversibility percentage of baseline value"
"20006";"Post-bronchodilator FEV1,% predicted"
"20007";"Post-bronchodilator FEV1/FVC (%)a"
"20008";"Post-bronchodilator FEV1/FVC ratio, mean (SD)"
"20009";"Post-bronchodilator FEV1/FVC, %"
"20010";"Post-bronchodilator FEV1; % Predicted"
"20011";"Post-bronchodilator FEVi, n (%)"
"20012";"Post-bronchodilator FEVi1    % predicted"
"20013";"Post-bronchodilator FEVX (L)"
"20014";"Post-bronchodilator FVC (L)a"
"20015";"Post-bronchodilator percent of predicted FEV1, % (SD)"
"20016";"Post-bronchodilator ratio of FEV1 to FVC — %"
"20017";"post-bronchodilator Reversibility FEV1 (%) Mean (SD)"
"20018";"Post-bronchodilator screening"
"20019";"Post-bronchodilator screening FEV1 mL"
"20020";"Post-CABG"
"20021";"Post-dose"
"20022";"Post-fibrinolysis angioplasty (n = 104)"
"20023";"Post-menopausal (A)"
"20024";"Post-menopausal with hormone replacement"
"20025";"Post-menopausal without hormone replacement"
"20026";"Post-MI"
"20027";"Post-procedure"
"20028";"Post-salbutamol FeV1 (l)b, mean (sD)"
"20029";"Post-salbutamol FeV1/FVCb, mean (sD)"
"20030";"Post erior-anterior spine"
"20031";"Post FEV1"
"20032";"Post FEV1 % pred"
"20033";"Post FVC"
"20034";"Post FVC % pred"
"20035";"Post Hoc Analysis"
"20036";"Post SVC"
"20037";"Postamendment"
"20038";"Postbaseline binding antibodies"
"20039";"Postbaseline new-onset diabetes - n (%)"
"20040";"Postbronchodilator"
"20041";"Postbronchodilator 1.10 (0.38)"
"20042";"Postbronchodilator 36.2 (10.2)"
"20043";"Postbronchodilator FEV1 reversibility, %"
"20044";"Postbronchodilator FEV1, % predicted"
"20045";"Postbronchodilator FEV1, L"
"20046";"Postbronchodilator FEV1,L"
"20047";"Postbronchodilator FEV1/FVC, %"
"20048";"Postbronchodilator FEVj (% predicted)"
"20049";"Postbronchodilator lung function at screening"
"20050";"Postdose FEV/FVC at screening"
"20051";"Posterior circulation"
"20052";"Postmenopausal"
"20053";"Postmenopausal (%)"
"20054";"Postmenopausal and current HRT"
"20055";"Postmenopausal and current HT"
"20056";"Postmenopausal and no HRT"
"20057";"Postmenopausal and no HT"
"20058";"Postmenopausal hormone use"
"20059";"Postmenopausal,"
"20060";"Postmenopausal, current hormone"
"20061";"Postmenopausal, current hormone therapy use"
"20062";"Postmenopausal, current HRT"
"20063";"Postmenopausal, never or past hormone therapy use"
"20064";"Postmenopausal, no HRT"
"20065";"Postoperative glucocorticoid use"
"20066";"Postoperative glucocorticoid use POST-RANDOMISATION CHARACTERISTIC**"
"20067";"Postoperative NSAID or glucocorticoid use"
"20068";"Postoperative NSAID or glucocorticoid USE POST-RANDOMISATION CHARACTERISTIC**"
"20069";"Postoperative use of p-blocker"
"20070";"Postprandial indices"
"20071";"Potassium"
"20072";"Potassium-sparing at enrollment"
"20073";"Potassium-sparing at last follow-up"
"20074";"Potassium-sparing diuretic"
"20075";"Potassium — mg/dl"
"20076";"Potassium — mmol/liter"
"20077";"potassium (mEq/L)"
"20078";"Potassium (mEqL), mean + SD, available for 3662 patients"
"20079";"Potassium (mg/dl)"
"20080";"Potassium (mmol/L)"
"20081";"Potassium at admission, mmol/l-1"
"20082";"Potassium supplement"
"20083";"Potassium, mean (SD), mEq/L"
"20084";"Potassium, mEq/dL, mean"
"20085";"Potassium, mEq/l"
"20086";"Potassium, mmol/L"
"20087";"Potent phosphorylated glycoprotein inhibitor use"
"20088";"Potential injection site reactions"
"20089";"Potential predictor"
"20090";"PPBC score, mean (SD)"
"20091";"PPCI"
"20092";"PPCI (n=173)"
"20093";"PPCI IN-1671"
"20094";"PPG post-meal test, mmol/L"
"20095";"PPG, mg/dL"
"20096";"PPG, mmol/L"
"20097";"PPI"
"20098";"PPI but no aspirin"
"20099";"PPI or H2 receptor antagonist, n (%)"
"20100";"PPI use"
"20101";"PPI use (p=0-28t)"
"20102";"PPI use (p=0-36t)"
"20103";"PPI use (p=0-97t)"
"20104";"PPI use (p=0.27t)"
"20105";"PPI use at baseline"
"20106";"PPI use within 6 months of randomization"
"20107";"PR/Virgin Islands, n (%)"
"20108";"PRA, median (min, max), ng/mL/h"
"20109";"Pramlintide"
"20110";"Prasugrel"
"20111";"Pravastatin"
"20112";"PRAVASTATIN"
"20113";"Pravastatin (N = 4512>"
"20114";"Pravastatin (n=2081)"
"20115";"Pravastatin 40 mg"
"20116";"Pravastatin 80 mg"
"20117";"Pravastatin n = 793"
"20118";"Pravastatin n =793"
"20119";"Pravastatin Sodium"
"20120";"Pravastatin vs Usual Care"
"20121";"Pre'rtous eptscde(s} d DVT/PE"
"20122";"Pre-BD FVC <65% of predicted"
"20123";"Pre-BD FVC s65% of predicted"
"20124";"Pre-bronchodilation FEV1"
"20125";"Pre-bronchodilation FVC"
"20126";"Pre-bronchodilator"
"20127";"Pre-bronchodilator FEF25.75 (mL/s) Baseline blood eosinophil count"
"20128";"Pre-bronchodilator FEV i (L)"
"20129";"Pre-bronchodilator FEV, % predicted"
"20130";"Pre-bronchodilator FEV, (L)"
"20131";"Pre-bronchodilator FEV^ (L)"
"20132";"Pre-bronchodilator FEV1"
"20133";"Pre-bronchodilator FEV1 (% predicted normal)"
"20134";"Pre-bronchodilator FEV1 (L)"
"20135";"Pre-bronchodilator FEV1, L*"
"20136";"Pre-bronchodilator FEV1/FVC (%)"
"20137";"Pre-bronchodilator FEV1/FVC ratio*"
"20138";"Pre-bronchodilator FEVi change"
"20139";"Pre-bronchodilator FEVi/FVC"" %"
"20140";"Pre-bronchodilator FEVj"
"20141";"Pre-bronchodilator FEVr % pred"
"20142";"Pre-bronchodilator FEVr L"
"20143";"Pre-bronchodilator FVC (L)"
"20144";"Pre-bronchodilator FVC’ % pred"
"20145";"Pre-bronchodilator mean (SD) FEV1,.L"
"20146";"Pre-bronchodilator screening"
"20147";"Pre-bronchodilator screening FEV1 mL"
"20148";"Pre-dose"
"20149";"Pre-enrollment antihyperglycemic therapy"
"20150";"Pre-h"
"20151";"Pre-hospital ticagrelor (n=906)"
"20152";"Pre-menopausal with hormone replacement"
"20153";"Pre-menopausal without hormone replacement"
"20154";"Pre-operative cardiac medications*"
"20155";"Pre-procedure"
"20156";"Pre-randomization PCI"
"20157";"Pre-specified HR (95% Cl)"
"20158";"Pre-specified Trial Endpoints"
"20159";"Pre-treatedforhypertension [n (%)]"
"20160";"Pre-treatment[n (%)]c"
"20161";"Pre–Diabetes Mellitus"
"20162";"Pre–Diabetes Mellitus, n=2103"
"20163";"Pre FEV1"
"20164";"Pre FEV1 % pred"
"20165";"Pre FVC"
"20166";"Pre FVC % pred"
"20167";"Pre hospital ticagrelor"
"20168";"Pre SVC"
"20169";"Preamendment"
"20170";"Prebronchodilator"
"20171";"Prebronchodilator FEV1"
"20172";"Prebronchodilator FEV1 (%"
"20173";"Prebronchodilator FEV1 (% predicted normal)t"
"20174";"Prebronchodilator FEV1 (L)"
"20175";"Prebronchodilator FEV1 (L)t"
"20176";"Prebronchodilator FEV1, % predicted"
"20177";"Prebronchodilator FEV1, L"
"20178";"Prebronchodilator FEV1, mean (SD), L"
"20179";"Prebronchodilator FEV1,L"
"20180";"Prebronchodilator FEV1/FVC"
"20181";"Prebronchodilator FEVi — liters"
"20182";"Prebronchodilator FEVi (% predicted)"
"20183";"Prebronchodilator FEVj (% predicted)"
"20184";"Prediabetes — no. (%)1"
"20185";"Prediabetes, %"
"20186";"Prediabetes, n (%)"
"20187";"Prediabetese"
"20188";"Prediabeticb"
"20189";"Predicted normal (%)"
"20190";"predicted normal)t"
"20191";"Predictive factor"
"20192";"Prednisone"
"20193";"Prednisone-equivalent dose — mg"
"20194";"Prednisone-equivalent dose, mg,"
"20195";"Prednisone or equivalent dose (mg/day)"
"20196";"Prednisone use, %"
"20197";"Predominant cardiac diagnosis — no. (%)"
"20198";"Predominant type of heparin"
"20199";"Predose FEV-, at randomization"
"20200";"Predose FEV/FVC"
"20201";"Predose FEV^ at screening"
"20202";"Predose FEV1 (L)*"
"20203";"Predose FVC (L)"
"20204";"Predose FVC (L)*"
"20205";"Preferred term, %"
"20206";"Pregnancy"
"20207";"Prehospital Ticagrelor (N = 909)"
"20208";"Premature CAD among family members"
"20209";"Premature discontinuation"
"20210";"Premature treatment discontinuation"
"20211";"Premenopausal"
"20212";"Premenopausal, %"
"20213";"Premixed insulin only (%)"
"20214";"Premixed insulin with OADs (%)"
"20215";"Preoperative blood pressure (mm Hg) Patients fulfilling eligibility criteria"
"20216";"Preoperative heart rate (beats per minute)"
"20217";"Preoperative p-blocker use Yes"
"20218";"Preoperative serum creatinine >175 pmol/L"
"20219";"Preoperative use p-Blocker"
"20220";"Prerandomization PCI"
"20221";"Prerandomization statin therapy"
"20222";"Presence of angioedema at baseline"
"20223";"Presence of dactylitis"
"20224";"Presence of dactylitis, n (%)"
"20225";"Presence of enthesitis"
"20226";"Presence of enthesitis, n (%)"
"20227";"Presence of erosions, n (%)"
"20228";"Presence of honeycombing,1 n (%)"
"20229";"Presence of MetS"
"20230";"Presence of MetS (%)a"
"20231";"Presence of tophi"
"20232";"Presence of tophi, n (%)"
"20233";"Present"
"20234";"Present (£100 mg/dL)"
"20235";"Present (£110 mg/dL)"
"20236";"Present (>100 mg/dL)"
"20237";"Present at screening"
"20238";"Present smoker"
"20239";"Present smokerc"
"20240";"Presentation of index event"
"20241";"Presentation to tertiary care hospital — %"
"20242";"Presentation*"
"20243";"Presenting condition, n (%)"
"20244";"Presenting diagnosis"
"20245";"Presenting Diagnosis"
"20246";"Presenting history or diagnosis — no. (%)"
"20247";"Presenting signs and symptoms"
"20248";"Prespecified Analysis"
"20249";"Prespecified medical conditions, n (%)f"
"20250";"Prespecified subgroup analyses"
"20251";"Prespecified subgroups"
"20252";"pressure (mm Hg)"
"20253";"pressure,"
"20254";"Prestudy treatment (%)a"
"20255";"Prestudy treatment status"
"20256";"Pretreatment HDL-C"
"20257";"Pretreatment triglycerides"
"20258";"Pretreatment/ concomitant treatment"
"20259";"Prevalence of each metabolic syndrome criterion"
"20260";"Prevalent CVD"
"20261";"Prevalent kidney disease (eGFR< 60 mL/min/USm^ or maeroalbuminuria UACR >300 mg/g)"
"20262";"Prevalent vertebral fracture"
"20263";"Prevalent vertebral fracture status"
"20264";"Prevalent vertebral fracture, n (%)"
"20265";"prevention), n (%) Patients on LLT (other than statin), n (%)"
"20266";"Previous"
"20267";"Previous 5-ARI use (%)"
"20268";"Previous 5ARI use"
"20269";"Previous a-blocker"
"20270";"Previous a-blocker use"
"20271";"Previous acute hypersensitivity reaction to infliximab — no. of patients (%)"
"20272";"Previous AF"
"20273";"Previous AMI"
"20274";"Previous AMI, n (%)"
"20275";"Previous analgesic products n (%)"
"20276";"Previous angina pectoris"
"20277";"Previous angina, n (%)"
"20278";"Previous angioplasty, n (%)"
"20279";"Previous anti-inflammatory/antirheumatic products n (%)"
"20280";"Previous anti-TNF therapy, N [%]"
"20281";"Previous antiarrhythmic treatment — no. (%)"
"20282";"Previous antihypertensive treatment"
"20283";"Previous antihypertensive treatment — no.(%)"
"20284";"Previous antiparkinson medication, No. (%)"
"20285";"Previous aorta-femoral or lower extremity bypass surgery, PTA of iliac, or infrainguinal artery"
"20286";"Previous balloon angioplasty"
"20287";"Previous balloon angioplasty, n (%)"
"20288";"Previous bDMARD received"
"20289";"Previous bowel resection performed — no. of patients (%)"
"20290";"Previous bypass surgery, n (%)"
"20291";"Previous CABG"
"20292";"Previous CABG (% total)"
"20293";"Previous CABG (before index ACS)*"
"20294";"Previous CABG surgery"
"20295";"Previous CABG, n (%)"
"20296";"Previous CAD"
"20297";"Previous CAD, n (%)"
"20298";"Previous cancer"
"20299";"Previous cancer — no. (%)"
"20300";"Previous cancer, n (%)"
"20301";"Previous cancerc"
"20302";"Previous cardiovascular disease!"
"20303";"Previous cardiovascular event — no. (%)"
"20304";"Previous cardiovascular event (%)"
"20305";"Previous cardiovascular event at randomization"
"20306";"Previous cardiovascular events"
"20307";"Previous CD related surgery (ref)a"
"20308";"Previous cerebrovascular event"
"20309";"Previous CHF"
"20310";"Previous CHF — no. (%)"
"20311";"Previous CHF, n (%)"
"20312";"Previous chronic kidney disease"
"20313";"Previous chronic use of antiplatelet drugs"
"20314";"Previous clinical stroke or TIA"
"20315";"Previous clinical stroke or transient ischemic attack (%)"
"20316";"Previous congestive heart failure"
"20317";"Previous congestive heart failure — no. (%)"
"20318";"Previous congestive heart failure (%)"
"20319";"Previous COPD treatment, n (%)*"
"20320";"Previous coronary-artery bypass grafting"
"20321";"Previous coronary angioplasty, n (%)"
"20322";"Previous coronary artery bypass graft"
"20323";"Previous coronary artery bypass grafting"
"20324";"Previous coronary artery bypass surgery, no. (%)"
"20325";"Previous coronary artery disease, n (%)"
"20326";"Previous coronary heart disease"
"20327";"Previous coronary intervention"
"20328";"Previous coronary procedure (% of group)"
"20329";"Previous coronary revascularisation"
"20330";"Previous coronary revascularization"
"20331";"Previous coronary revascularization — no. (%)"
"20332";"Previous CV event"
"20333";"Previous CV Event"
"20334";"Previous CV events"
"20335";"Previous CVD^"
"20336";"Previous deep-vein thrombosis or pulmonary embolism"
"20337";"Previous diabetes"
"20338";"Previous Diabetes Mellitus"
"20339";"Previous diagnosis"
"20340";"Previous digoxin use"
"20341";"Previous digoxin use (%)"
"20342";"Previous disease — no. (%)f"
"20343";"Previous disease and drug use"
"20344";"Previous disease:"
"20345";"Previous DM"
"20346";"Previous DM, n(%)"
"20347";"Previous DMARDs use, n (%)"
"20348";"Previous DMARDs, mean ± SD"
"20349";"Previous episode of heart failure"
"20350";"Previous events, No. (%)"
"20351";"Previous exposure to a vitamin K antagonist — no. (%) Current or Former Never"
"20352";"Previous exposure to biologic systemic psoriasis therapyb (yes), n (%)"
"20353";"Previous exposure to non-biologic systemic psoriasis therapyb (yes), n (%)"
"20354";"Previous exposure to systemic psoriasis therapyb (yes), n (%)"
"20355";"Previous heart failure"
"20356";"Previous heart failure — no. (%)"
"20357";"Previous HF"
"20358";"Previous HF hospitalization, n (%)"
"20359";"Previous history of cardiovascular events"
"20360";"Previous hospital admission for heart failure"
"20361";"Previous hospitalization for heart failure"
"20362";"Previous hospitalization for unstable angina"
"20363";"Previous HTN, n (%)"
"20364";"Previous hypersensitivity reaction — no. (%)"
"20365";"Previous hypertension"
"20366";"Previous ICS alone"
"20367";"Previous ICS only"
"20368";"Previous ICS/LABD"
"20369";"Previous infarction"
"20370";"Previous infarction (% of group)"
"20371";"Previous infliximab therapy — no. of patients (%)**"
"20372";"Previous infliximab therapy||"
"20373";"Previous intervention (%)"
"20374";"Previous intolerance of infliximab, n (%)*"
"20375";"Previous ischemic heart disease — no. (%)"
"20376";"Previous ischemic stroke orTIA"
"20377";"Previous ischemic stroke, n (%)"
"20378";"Previous Ischemic Stroke/ TIA (n=5973; 28.3%)"
"20379";"Previous LABD alone"
"20380";"Previous LABD only"
"20381";"Previous LEV only"
"20382";"Previous limb or foot amputation"
"20383";"Previous loss of response to and intolerance of infliximab, n (%)*"
"20384";"Previous loss of response to infliximab, n (%)*"
"20385";"Previous major bleeding"
"20386";"Previous medication for respiratory disease — no. (%)"
"20387";"Previous medications, n (%)"
"20388";"Previous metformin use, %"
"20389";"Previous MI"
"20390";"Previous MI — no. (%)"
"20391";"Previous MI (%)"
"20392";"Previous MI, %"
"20393";"Previous MI, n (%)"
"20394";"Previous Ml"
"20395";"Previous Ml (before index ACS)"
"20396";"Previous Ml (Interaction: p=0.09)"
"20397";"Previous Ml or abnormal angiogram"
"20398";"Previous myocardial infarction"
"20399";"Previous myocardial infarction — no. (%)"
"20400";"Previous myocardial infarction (%)"
"20401";"Previous myocardial infarction, n (%)"
"20402";"Previous myocardial infarction, no. (%)"
"20403";"Previous myocardiaUnfarction"
"20404";"Previous number of CIU/CSU medications"
"20405";"Previous OAD (%)"
"20406";"Previous or current CS use: No"
"20407";"Previous or current IM use: No"
"20408";"Previous or current use of IM and CS: No"
"20409";"Previous or current use of IM or CS: No"
"20410";"Previous oral antidiabetic medication use, n (%)"
"20411";"Previous oral glucose-lowering agents, % of patients"
"20412";"Previous PCI"
"20413";"Previous PCI (% total)"
"20414";"Previous PCI (before index ACS)"
"20415";"Previous PCI or CABG"
"20416";"Previous PCI, n (%)"
"20417";"Previous PCI/CABG, n (%)"
"20418";"Previous PDE5-I therapy, no. (%)"
"20419";"Previous PDE5 inhibitors"
"20420";"Previous percutaneous coronary intervention"
"20421";"Previous percutaneous coronary intervention, %"
"20422";"Previous Pneumonia"
"20423";"Previous receipt of therapy against TNF-a — no. (%)"
"20424";"Previous renal disease, n(%)"
"20425";"Previous respiratory disease other than COPD — no. (%)"
"20426";"Previous revascularization"
"20427";"Previous segmental resection — no. (%)"
"20428";"Previous segments resection(s)*"
"20429";"Previous smoker"
"20430";"Previous smokers"
"20431";"Previous statin use"
"20432";"Previous stenting (% previous PCI)"
"20433";"Previous stroke"
"20434";"Previous stroke— no. (%) Concomitant treatment—no. (%)"
"20435";"Previous stroke — no. (%)"
"20436";"Previous stroke 一 no. (%)"
"20437";"Previous stroke or TIA"
"20438";"Previous stroke or TIA (%)"
"20439";"Previous stroke or TIA (n=1195)"
"20440";"Previous stroke or TIA (n=1233)"
"20441";"Previous stroke or TIA, n (%)"
"20442";"Previous stroke or Tl A"
"20443";"Previous stroke or Tl A    1-39"
"20444";"Previous stroke or transient ischemic attack — no./total"
"20445";"Previous stroke or transient ischemic attack, No./total No. (%)"
"20446";"Previous stroke orTIA"
"20447";"Previous stroke orTIA    2-19"
"20448";"Previous stroke ortransient ischaemic attack (%)"
"20449";"Previous stroke Yes (n, %) Previous myocardial infarction"
"20450";"Previous stroke*"
"20451";"Previous stroke, n (%)"
"20452";"Previous stroke/TIA"
"20453";"Previous systemic treatment, n (%)"
"20454";"Previous therapies, n (%)"
"20455";"Previous therapy"
"20456";"Previous TIA"
"20457";"Previous TIA or stroke"
"20458";"Previous TNF-antagonist use, n (%)"
"20459";"Previous TNF antagonist exposure, n (%)"
"20460";"Previous transient ischaemic attack/ischaemic stroke Previous warfarin use"
"20461";"Previous transient ischemic attack"
"20462";"Previous treatment"
"20463";"Previous treatment failure — no. (%)§**"
"20464";"Previous treatment in the healing study, n (%)"
"20465";"Previous treatment with a LABA and / or LAMA, n (%)c"
"20466";"Previous treatment with infliximab"
"20467";"Previous treatment with TNF antagonist — no. (%)§"
"20468";"Previous treatment?"
"20469";"Previous use of amiodarone"
"20470";"Previous use of antiarrhythmic drugs"
"20471";"Previous use of antiplatelet drugs"
"20472";"Previous use of biologic systemic therapy, n (%)"
"20473";"Previous use of niacin or Niaspan§"
"20474";"Previous use of nonbiologic systemic therapy, n (%)"
"20475";"Previous use of other biologic agents in addition to TNE"
"20476";"Previous use of systemic steroids for CIU/CSU"
"20477";"Previous use of systemic steroids, n (%)"
"20478";"Previous use of vitamin K antagonist for >60 days — no. (%)"
"20479";"Previous vascular disease"
"20480";"Previous venous thromboembolism — no. (%)"
"20481";"Previous venous thromboembolism —no. (%)"
"20482";"Previous VKA Use"
"20483";"Previous VKA use (stratified randomization)"
"20484";"Previous VTE"
"20485";"Previous VTE — no. (%)"
"20486";"Previous VTE n (%)"
"20487";"Previous VTE, n (%)"
"20488";"Previous warfarin use, No. (%)"
"20489";"Previousdistaldeep-veinthrombosisorsuperficial-vein thrombosis"
"20490";"Previously"
"20491";"Previously failed anti-TNF treatment, no. (%)"
"20492";"Previously on ACEI+ARB"
"20493";"Previously taken any other DMARDs, n (%)"
"20494";"Previously taken DMARDs other than methotrexate, %"
"20495";"Previously taken methotrexate, %"
"20496";"Previously taken TNFi, %"
"20497";"Previously untreated isolated systolic hypertension"
"20498";"Primary"
"20499";"Primary-prevention cohort"
"20500";"Primary +GUSTO severe bleeding"
"20501";"Primary analysis"
"20502";"Primary and secondary prevention subgroups; adjusted for age, gender, hypertension, diabetes mellitus, and smoking. HR indicates hazard ratio; 95% Cl, 95% confidence interval; TIA, transient ischemic attack."
"20503";"Primary angioplasty (n = 108)"
"20504";"Primary cardiovascular endpoint"
"20505";"Primary cause of CHF"
"20506";"Primary cause of heart failure"
"20507";"Primary composite end point"
"20508";"Primary composite end point‡"
"20509";"Primary composite end points"
"20510";"Primary composite endpoint‡"
"20511";"Primary composite outcome"
"20512";"Primary composite^"
"20513";"Primary CV endpoint"
"20514";"Primary efficacy outcome"
"20515";"Primary end-point"
"20516";"Primary end point"
"20517";"Primary End point"
"20518";"Primary End Point"
"20519";"Primary end point |"
"20520";"Primary End Point Kaplan-Meier Rate, %"
"20521";"Primary end point"""
"20522";"Primary end point*"
"20523";"Primary End Point, No. of Events/Total No. (%)"
"20524";"Primary end point: Death/MI/IDR/ST"
"20525";"Primary end points"
"20526";"Primary endpoint"
"20527";"Primary Endpoint"
"20528";"Primary endpoint death/MI/IDR/ST"
"20529";"Primary endpoint:"
"20530";"Primary endpoint^"
"20531";"Primary endpoint’"
"20532";"Primary endpoint4"
"20533";"Primary enrollment diagnoses, n (%)"
"20534";"Primary EP (CVD/MI/RI)"
"20535";"Primary hemorrhagic stroke"
"20536";"Primary indication"
"20537";"Primary ischemic stroke"
"20538";"Primary MACE endpoint"
"20539";"Primary nonresponse"
"20540";"Primary outcome"
"20541";"Primary Outcome"
"20542";"Primary Outcome (3-Point MACE)"
"20543";"Primary outcome plus revascularization or nonfatal HF"
"20544";"Primary outcome!"
"20545";"Primary outcome! (n=743)"
"20546";"Primary outcome: 20% decrease in WOMAC pain score"
"20547";"Primary outcomes"
"20548";"Primary PCI"
"20549";"Primary PCi (n = 686)"
"20550";"Primary PCI (n = 806)"
"20551";"Primary PCI (N = 806)"
"20552";"Primary PCI (N = 948)"
"20553";"Primary PCI (n=948)"
"20554";"Primary PCI n=948"
"20555";"Primary PCI no."
"20556";"Primary PCIt"
"20557";"Primary prevention subgroup"
"20558";"Primary Prevention Subgroup"
"20559";"Primary Renal Endpoint"
"20560";"Primary Renal Endpoint or Death"
"20561";"Primary safety end point: Severe/life-threatening"
"20562";"Primary safety outcome -"
"20563";"Primary study joint, n (%)"
"20564";"Primary target vessel (%)"
"20565";"Primary trial end point"
"20566";"Primary*"
"20567";"Primary/key efficacy endpoint"
"20568";"Primary+GUSTO moderate or severe bleeding"
"20569";"Prior"
"20570";"Prior a-blocker use"
"20571";"Prior ACBi or ARB use"
"20572";"Prior ADMb"
"20573";"Prior AEDs, ≥1, n (%)"
"20574";"Prior AF ablation, n (%)"
"20575";"Prior amputation"
"20576";"Prior analgesic products, n (%)"
"20577";"Prior angina"
"20578";"Prior Angina"
"20579";"Prior angina (n = 2,768)"
"20580";"Prior angina pectoris"
"20581";"Prior angina pectoris — no./total no. (%)"
"20582";"Prior angina, n/N (%)"
"20583";"Prior angiography showing stenosis ≥50%, N = 247 235a"
"20584";"Prior angiography showing stenosis ≥50%, N = 521 09a"
"20585";"Prior angiography showing stenosis >50%, N = 52109°"
"20586";"Prior angioplasty"
"20587";"Prior anti-TNF exposure"
"20588";"Prior anti-TNF failure"
"20589";"Prior anti-TNF therapy"
"20590";"Prior anti-TNF therapy — no. (%)"
"20591";"Prior anti-TNF treatment"
"20592";"Prior antihypertensive medication, n (%)"
"20593";"Prior antiinflammatory/antirheumatic products, n (%)"
"20594";"Prior aortocoronary bypass surgery"
"20595";"Prior aortocoronary bypass surgery — no. (%)"
"20596";"Prior aortocoronary bypass surgery 一no. (%)"
"20597";"Prior arrhythmias, n (%)"
"20598";"Prior ASA use"
"20599";"Prior aspirin"
"20600";"Prior aspirin use"
"20601";"Prior BB plus ACBi plus ARB use"
"20602";"Prior biologic exposure"
"20603";"Prior biologic therapeutic failures, n (%)"
"20604";"Prior biologic therapy (including anti-TNFs)"
"20605";"Prior biologic use"
"20606";"Prior bisphosphonate usage"
"20607";"Prior BP use"
"20608";"Prior brachytherapy"
"20609";"Prior bypass graft surgery"
"20610";"Prior CABG"
"20611";"Prior CABG (before index ACS)"
"20612";"Prior CABG surgery"
"20613";"Prior CABG, %"
"20614";"Prior CAD"
"20615";"Prior cancer"
"20616";"Prior Cancer"
"20617";"Prior cardiac resynchronization therapy, n (%)"
"20618";"Prior cardiac surgery, n (%)"
"20619";"Prior cardiovascular disease"
"20620";"Prior cardiovascular event"
"20621";"Prior cardiovascular event— no. (%)-j-"
"20622";"Prior cardiovascular event""'"""
"20623";"Prior cardiovascular history"
"20624";"Prior carotid intervention"
"20625";"Prior cerebrovascular disease"
"20626";"Prior CHF"
"20627";"Prior CHF, %"
"20628";"Prior clinical fracture (since age 45)"
"20629";"Prior congestive heart failure"
"20630";"Prior Congestive heart failure"
"20631";"Prior congestive heart failure Yes"
"20632";"Prior conventional synthetic DMARDs, n (%)"
"20633";"Prior COPD medication"
"20634";"Prior COPD medicationa, n (%)"
"20635";"Prior coronary artery bypass graft"
"20636";"Prior coronary artery bypass graft surgery"
"20637";"Prior coronary artery bypass grafting"
"20638";"Prior coronary artery bypass surgery"
"20639";"Prior coronary artery disease Yes"
"20640";"Prior coronary intervention or coronary artery bypass grafting"
"20641";"Prior coronary revascularization"
"20642";"Prior coronary revascularization — no. {%)"
"20643";"Prior coronary revascularization (PCI or CABG)"
"20644";"Prior coronary revascularization, n (%)"
"20645";"Prior coronary revascularization, n(%)"
"20646";"Prior coronary revascularization, n/N (%)"
"20647";"Prior coronary revascularization, no. (%)"
"20648";"Prior corticosteroid failure only"
"20649";"Prior corticosteroid treatment"
"20650";"Prior CV event"
"20651";"Prior CV Event"
"20652";"Prior CV event at randomization!"
"20653";"Prior CV history"
"20654";"Prior CV history, n (%)"
"20655";"Prior CVD"
"20656";"Prior diabetes"
"20657";"Prior Diagnosis- no. (%)"
"20658";"Prior disease"
"20659";"Prior disease-modifying drugs resulting in inadequate response — mean no./patient"
"20660";"Prior DM"
"20661";"Prior ED therapy"
"20662";"Prior electrical cardioversion for AF (n=21 104)"
"20663";"Prior failure of anti-TNF therapy — no. (%)"
"20664";"Prior gestational diabetes"
"20665";"Prior heart failure"
"20666";"Prior Heart Failure"
"20667";"Prior heart failure — no. {%)"
"20668";"Prior Heart Failure (n = 2,105)"
"20669";"Prior Heart Failure Yes"
"20670";"Prior heart failure, %"
"20671";"Prior heart failure, n (%)"
"20672";"Prior heart failure, n/N (%)"
"20673";"Prior HF (n = 1,069)"
"20674";"Prior HF hospitalization"
"20675";"Prior HF Hospitalization (n=147)"
"20676";"Prior HF n=1068"
"20677";"Prior history Ml or stroke"
"20678";"Prior history of bleeding on OAC"
"20679";"Prior history of cardiovascular disease, n (%)"
"20680";"Prior history of MI or ischaemic stroke"
"20681";"Prior history of Ml or ischemic stroke"
"20682";"Prior hospitalization for HF, %"
"20683";"Prior hospitalizations, n (%)"
"20684";"Prior HTN (n = 1,659)"
"20685";"Prior hypertension"
"20686";"Prior Hypertension Yes"
"20687";"Prior hypertensiona Yes"
"20688";"prior immunnosupressive failure but no anti-TNF failure"
"20689";"Prior immunosuppressant failure"
"20690";"Prior immunosuppressant failure"""
"20691";"Prior immunosuppressant failurec"
"20692";"Prior immunosuppressive exposure, n (%)"
"20693";"Prior implantable cardiodefibrillator, n (%)"
"20694";"Prior infarction"
"20695";"Prior insulin use (years)"
"20696";"Prior ischemic stroke"
"20697";"Prior Ischemic Stroke"
"20698";"Prior known stenosis >50%"
"20699";"Prior LEV"
"20700";"Prior LEV treatment"
"20701";"Prior LEV treatment, n (%)"
"20702";"Prior LEV use"
"20703";"Prior LGI event"
"20704";"Prior lipid-lowering agent use"
"20705";"Prior lipid-modifying therapy"
"20706";"Prior LLT"
"20707";"Prior lower GI clinical event"
"20708";"Prior medication use, n (%)"
"20709";"Prior medications"
"20710";"Prior mesalazine use*"
"20711";"Prior MI"
"20712";"Prior MI (n - 2,456)"
"20713";"Prior MI (n = 2,151)"
"20714";"Prior MI (n= 3,584)"
"20715";"Prior MI diagnosis:"
"20716";"Prior MI n=2147"
"20717";"Prior MI within 5 y, no. (%)"
"20718";"Prior MI, %"
"20719";"Prior MI, n/N (%)"
"20720";"Prior migraine"
"20721";"Prior Migraine*"
"20722";"Prior Ml"
"20723";"Prior Ml (before index ACS)"
"20724";"Prior Ml or abnormal angiogram"
"20725";"Prior Ml or stroke at baseline"
"20726";"Prior Ml/stroke"
"20727";"Prior MS treatment with IFN-beta or"
"20728";"Prior MS treatment with IFN-beta or glatiramer acetate. No. (%)"
"20729";"Prior myocardial infarction"
"20730";"Prior myocardial Infarction"
"20731";"Prior Myocardial Infarction"
"20732";"Prior myocardial infarction — no. (%)"
"20733";"Prior myocardial infarction — no. {%)"
"20734";"Prior myocardial infarction — no./total no. (%)"
"20735";"Prior myocardial infarction (%)"
"20736";"Prior myocardial infarction 一no. (%)"
"20737";"Prior myocardial infarction Yes"
"20738";"Prior myocardial infarction, %"
"20739";"Prior myocardial infarction, n (%)"
"20740";"Prior myocardial infarction, n(%)"
"20741";"Prior myocardial infarction, No./total No. (%)"
"20742";"Prior myocardial intarction"
"20743";"Prior non-CNS SE"
"20744";"Prior non-haemorrhagic stroke"
"20745";"Prior nonvertebral fracture"
"20746";"Prior nonvertebral fracture at age >55 years"
"20747";"Prior NSAID use"
"20748";"Prior NSAID, n (%)a"
"20749";"Prior OABG surgery"
"20750";"Prior OAC"
"20751";"Prior OAD:"
"20752";"Prior OM"
"20753";"Prior OMA use"
"20754";"Prior OMA use (N = 120)"
"20755";"Prior or new diabetes"
"20756";"Prior pacemaker, n (%)"
"20757";"Prior PAD"
"20758";"Prior PCI"
"20759";"Prior PCI or CABG"
"20760";"Prior PCI or CABG surgery"
"20761";"Prior PCI, %"
"20762";"Prior percutaneous coronary intervention"
"20763";"Prior percutaneous coronary intervention — no. (%)"
"20764";"Prior percutaneous coronary intervention — no./total no. (%)"
"20765";"Prior percutaneous coronary intervention, n (%)"
"20766";"Prior Peripheral arterial disease"
"20767";"Prior peripheralarterialdisease"
"20768";"Prior PTCA or CABG"
"20769";"Prior PTCA or PCI"
"20770";"Prior PTCA/PCI"
"20771";"Prior revascularization"
"20772";"Prior revascularization (%)"
"20773";"Prior revascularization (n = 1,690)"
"20774";"Prior smoker"
"20775";"Prior Statin (n=379, 372)"
"20776";"Prior statin use"
"20777";"Prior statin use (n = 144)"
"20778";"Prior STEMI"
"20779";"Prior stent"
"20780";"Prior Stent"
"20781";"Prior stroke"
"20782";"Prior Stroke"
"20783";"Prior stroke — no. (%)"
"20784";"Prior stroke (%)"
"20785";"Prior stroke (before index event)"
"20786";"Prior stroke (N = 902)"
"20787";"Prior stroke or TIA"
"20788";"Prior Stroke or TIA"
"20789";"Prior stroke or TIA, %"
"20790";"Prior stroke or transient ischemic attack"
"20791";"Prior Stroke or TZA"
"20792";"Prior stroke/MI, N (%)"
"20793";"Prior stroke/TIA"
"20794";"Prior Stroke/TIA"
"20795";"Prior sulfasalazine use*"
"20796";"Prior surgery for CD, n (%)"
"20797";"Prior surgery for CD, n [%]"
"20798";"Prior surgery: No"
"20799";"Prior therapy with omalizumab: Yes"
"20800";"Prior therapy with TNF antagonist, n (%)"
"20801";"Prior therapy, %"
"20802";"Prior Thienopyridine (-)"
"20803";"Prior Thienopyridine (+)"
"20804";"Prior TIA"
"20805";"Prior TNF antagonist failure-No"
"20806";"Prior TNF antagonist failure-Yes"
"20807";"Prior TNF antagonist failure, n [%]"
"20808";"Prior TNF antagonist failure, n(%)b"
"20809";"Prior TNF antagonist treatment-No"
"20810";"Prior TNF antagonist treatment-Yes"
"20811";"Prior TNF antagonist, n [%]‘*"
"20812";"Prior TNF inhibitor exposure"
"20813";"Prior TNF inhibitor exposure, no. (%)"
"20814";"Prior TNFI Treatment"
"20815";"Prior TNFi, n (%)"
"20816";"Prior to index event"
"20817";"Prior tobacco use, n (%)"
"20818";"Prior transient ischaemic"
"20819";"Prior transient ischemic attack"
"20820";"Prior treatment"
"20821";"Prior treatment — %"
"20822";"Prior treatment — no. (%)"
"20823";"Prior treatment History1"
"20824";"Prior UGI event"
"20825";"Prior upper GI clinical event"
"20826";"Prior urate lowering therapies, n (%)"
"20827";"Prior use of $ 2 systemic therapies"
"20828";"Prior use of biologic agents"
"20829";"Prior use of biologics, n (%)"
"20830";"Prior use of conventional DMARDs only (biologic-nai've), n (%)"
"20831";"Prior use of osteoporosis medications"
"20832";"Prior use of osteoporosis medications, n (%)"
"20833";"Prior use of synthetic DMARDs"
"20834";"Prior use of synthetic DMARDs, n (%)"
"20835";"Prior use of systemic"
"20836";"Prior VKA experience"
"20837";"Prior VKA use for >60 d, %"
"20838";"Prior years taking warfarin"
"20839";"Priorbone disease"
"20840";"Priorheartfailure,%"
"20841";"Priorother(not predefined) medical conditions"
"20842";"Priorother(predefined) medical conditions"
"20843";"Priorvascular disease,%"
"20844";"Pro-active intervention"
"20845";"Pro/Pro homozygotes"
"20846";"Proactive Intervention (n = 436a)"
"20847";"proADM (ng/ml)"
"20848";"Probability""of event %"
"20849";"Probable"
"20850";"Probable stent thrombosis"
"20851";"Probenecid"
"20852";"Procalcitonin (ng/ml)"
"20853";"Procedure"
"20854";"Procedure**"
"20855";"Procedures after discharge — no. (%)"
"20856";"Procedures for index event"
"20857";"Procedures in the hospital — no. (%)"
"20858";"Proctosigmoiditis"
"20859";"Profound thrombocytopenia (<20x109/L)"
"20860";"Progestins"
"20861";"Progression of albuminuria"
"20862";"Progression to Diabetes"
"20863";"Propafenone"
"20864";"Propionic acid derivatives"
"20865";"proportion"
"20866";"Proportion (%) of individuals • Control    Alirocumab"
"20867";"Proportion (%) of individuals A Alirocumab • Placebo"
"20868";"Proportion (95% CI) adjusted for baseline HbA1c , %"
"20869";"Proportion of angioedema-free days from week 4 to week 12x"
"20870";"Proportion of Patients in Corticosteroid-free Clinical Remission at Week 26"
"20871";"Proportion of patients who achieved ACR20 n/N (%)"
"20872";"Proportion of patients with trough FEVi >100 mL above baseline, n (%)"
"20873";"Proportion of predicted normal FEV1 value;,§"
"20874";"Proportion of responders n/N (%)"
"20875";"Proportion taking pulmonary medications (%)b"
"20876";"Proportions, n (%)"
"20877";"Proprotein Convertase Subtil/Kexin Typ9 (ng/mL) -Baseline - < Median (n=215, 203)"
"20878";"Proprotein Convertase Subtil/Kexin Typ9 (ng/mL) -Baseline - >= Median (n=201, 209)"
"20879";"PROSPER"
"20880";"Prostate biopsy"
"20881";"Prostate cancer"
"20882";"Prostate volume (cm3)"
"20883";"Prostate volume (mL)"
"20884";"Prosthetic"
"20885";"Protein in urine, ≥1+"
"20886";"Proteinuria (>2 g/24 h), %"
"20887";"Proteinuria3 (g/day)"
"20888";"Prothrombin mutation (%)"
"20889";"Proton-pump inhibitor"
"20890";"Proton-pump inhibitors"
"20891";"Proton pump inhibitor"
"20892";"Proton pump inhibitor (n, %)"
"20893";"Proton pump inhibitor use"
"20894";"Proton pump inhibitors"
"20895";"Provoked"
"20896";"Proximal"
"20897";"Proximal-MainLeft"
"20898";"Proximal gastrointestinal tract"
"20899";"Proximal GI tract"
"20900";"Proximal Gl tract, n (%)"
"20901";"Proximal to the splenic flexure"
"20902";"PsA"
"20903";"PSA"
"20904";"PsA-modified MASES score (1-15)"
"20905";"PsA‐modified MASES score (1–15 scale)"
"20906";"PsA-modified SHS of hands & feet1(0-528)"
"20907";"PsA‐modified SHS of hands and feet"
"20908";"PsA-modified SHS(0-528)"
"20909";"PsA-modified total SHS"
"20910";"PSA (ng/mL)"
"20911";"PsA duration (years)"
"20912";"PsA duration (years), mean (SD)"
"20913";"PsA duration, years"
"20914";"PSA level, ng/mL"
"20915";"PsA pain (VAS)"
"20916";"PsA reported, n (%)"
"20917";"PsA subtypes, n (%)"
"20918";"PSA, ng/ml, mean (SD)"
"20919";"PSAP-B (ng/ml)"
"20920";"PsAQOL"
"20921";"Psoriasis"
"20922";"psoriasis (n ="
"20923";"Psoriasis > 3% of BSA"
"20924";"Psoriasis affecting >3% of body-surface"
"20925";"Psoriasis body surface area >3%"
"20926";"Psoriasis BSA >3%, n (%)"
"20927";"Psoriasis characteristics"
"20928";"Psoriasis covering >3% BSA, n (%)§"
"20929";"Psoriasis duration (years), mean (SD)"
"20930";"Psoriasis duration, mean ± SD, years"
"20931";"Psoriasis duration, years"
"20932";"Psoriasis duration, yrs*"
"20933";"Psoriatic arthritis"
"20934";"Psoriatic arthritis pain]"
"20935";"Psoriatic arthritis, %"
"20936";"Psychoactivesd"
"20937";"Psychogenic"
"20938";"Psycholeptics"
"20939";"Pt"
"20940";"PT baseline (Week 52)"
"20941";"Pt. Years= 245"
"20942";"Pt. Years= 556"
"20943";"Pt. Years= 810"
"20944";"Pt. Years=1484"
"20945";"Pt. Years=1563"
"20946";"Pt. Years=2283"
"20947";"Pt. Years=3099"
"20948";"Pt. Years=3818"
"20949";"Pt. Years=3898"
"20950";"Pt. Years=4572"
"20951";"Pt. Years=4825"
"20952";"Pt. Years=5136"
"20953";"PTCA"
"20954";"PTCA only"
"20955";"PTCA or PCI"
"20956";"PTCA/CABG"
"20957";"PtGA (0-10 cm VAS)"
"20958";"PtGA of disease activity (0‒100 mm), mean (SD)†"
"20959";"PtGA, 0-10"
"20960";"PtGA⁎⁎⁎"
"20961";"PtGADA (mm)"
"20962";"ptrend Across Doses"
"20963";"Pts"
"20964";"PTX3 (ng/mL)"
"20965";"Puerperium"
"20966";"Puerto Rican"
"20967";"Pulmonary congestion (CXR)"
"20968";"pulmonary disease"
"20969";"Pulmonary disease"
"20970";"Pulmonary disease — no. (%)"
"20971";"Pulmonary embolism"
"20972";"Pulmonary embolism ± deep vein thrombosis"
"20973";"Pulmonary embolism only"
"20974";"Pulmonary embolisma, n/N (%)"
"20975";"Pulmonary embolismb, n/N (%)"
"20976";"Pulmonary function tests (post-bronchodilator), mean (SD)"
"20977";"Pulmonary function tests, % of predicted"
"20978";"Pulmonary medication during baseline!'"
"20979";"Pulmonary medications (%)"
"20980";"Pulmonary rales"
"20981";"Pulmonary rales, n (%)"
"20982";"Pulmonary vascular resistance, dyne • s • cm 5"
"20983";"Pulse — beats/min"
"20984";"Pulse (beats/min) Cholesterol (mmol/l)"
"20985";"Pulse in beats/minute, mean(SD)"
"20986";"Pulse pressure"
"20987";"Pulse Pressure (Median 50.0]"
"20988";"Pulse pressure (mm Hg)"
"20989";"Pulse pressure (mmHg)"
"20990";"Pulse rate (bpm)"
"20991";"Pulse rate (mean 24 h), bpm*"
"20992";"Pulse rate, bpm (mean 24 h), mean (SD)*"
"20993";"Pulse, beats/min"
"20994";"Pump"
"20995";"Pure motor hemiparesis"
"20996";"Pure sensory stroke"
"20997";"PUVA"
"20998";"PV, mL"
"20999";"pvalue"
"21000";"pValue"
"21001";"Pvalue"
"21002";"PValue"
"21003";"PValue for Heterogeneity"
"21004";"Pvalue∗"
"21005";"pValuefor Any MI Versus No MI"
"21006";"pvaluefor interaction 0-28"
"21007";"pvaluefor interaction 0-39"
"21008";"pValuefor Trend"
"21009";"PValuefor Trend"
"21010";"PVD"
"21011";"PVR volume, ml, mean (SD)"
"21012";"PVR, mL"
"21013";"PY*"
"21014";"PY=1630.8)"
"21015";"PY=1948)"
"21016";"PY=2187.2)"
"21017";"PY=2612.8)"
"21018";"PY=2766.7)"
"21019";"PY=2957.6)"
"21020";"Pyrexia"
"21021";"Q-wave MI"
"21022";"Q (Q 1\"
"21023";"Q wave in the infarct territory at baseline*, %"
"21024";"Q wave MI"
"21025";"Q waves in the infarct territory at baseline*, %"
"21026";"Q1-Q3"
"21027";"Q1 (n = 82)"
"21028";"Q1: <55.05 kg (n=139vs70)"
"21029";"Q2 (n = 106)"
"21030";"Q2: 55.05 to <65.15 kg (n=141 vs 66)"
"21031";"Q2W (n 5 490)"
"21032";"Q3 (n = 92)"
"21033";"Q3: 65.15 to <78.25 kg (n=135 vs 73)"
"21034";"Q4 (n = 96)"
"21035";"Q4: >78.25 kg (n=139vs70)"
"21036";"Q4W (n = 28)"
"21037";"Q4W (n = 425)"
"21038";"Q4W (n = 438)"
"21039";"Q8W (n = 30)"
"21040";"Q8W (n = 428)"
"21041";"Q8W (n = 441)"
"21042";"QD"
"21043";"QIDS-SR16"
"21044";"Qmax (ml/S)"
"21045";"Qmax (mL/s)"
"21046";"Qmax category, n (%):"
"21047";"Qmax, mL/s"
"21048";"Qmax, ml/s, mean (SD)"
"21049";"Qmaxi rn L/s"
"21050";"QMI"
"21051";"QoL"
"21052";"QoL due to urinary symptoms,"
"21053";"QRS $120 ms (95% CL) (n - 613)"
"21054";"QRS <120 ms (95% CL) (n - 2,813)"
"21055";"QRS <120 msec"
"21056";"QRS >120 ms*"
"21057";"QRS >120 ms, % (n)"
"21058";"QRS >120 ms, n (%), available for 3653 patients"
"21059";"QRS >120 msec 6-Min walk test"
"21060";"QRS duration > 120 ms, n (%)"
"21061";"QRS duration, ms"
"21062";"QRS interval >120 msec — no. (%)"
"21063";"QRS width, ms"
"21064";"QTc >450 n=1190"
"21065";"QTC<450 n=5117"
"21066";"Qualifying ACS event — no. (%)"
"21067";"Qualifying Atherosclerosis"
"21068";"Qualifying CV event, n (%)"
"21069";"Qualifying diagnosis"
"21070";"Qualifying event"
"21071";"Qualifying event — no. (%)"
"21072";"Qualifying events"
"21073";"Qualifying HbA1c (%)"
"21074";"Qualifying high-risk features — %"
"21075";"Qualifying index event as PE"
"21076";"Qualifying MI $2 yrs prior"
"21077";"Qualifying MI <2 yrs prior"
"21078";"Qualifying MI type"
"21079";"Qualifying MI: STEMI"
"21080";"Qualifying myocardial infarction"
"21081";"Qualifying Myocardial Infarction"
"21082";"Qualifying NSTEMI, n (%)"
"21083";"Qualifying peripheral arterial disease"
"21084";"Qualifying risk factor"
"21085";"Qualifying risk factor — no. (%)"
"21086";"Qualifying risk factor, n (%)"
"21087";"Qualifying risk factors — no. (%)"
"21088";"Qualifying stroke"
"21089";"Qualifying symptomatic event, n (%)a"
"21090";"Qualifying type of atherosclerosis — no. (%)"
"21091";"Qualifying type of atherosclerosis, n (%)"
"21092";"Quality of life"
"21093";"Quartiles of FGF-23 (RU/ml)"
"21094";"Question 1 (fatigue/tiredness)"
"21095";"Question 2 (neck/back/hip pain)"
"21096";"Question 3 ( pain/swelling in joints other than neck/back/hips)"
"21097";"Question 4 (discomfort from any areas tender to touch/pressure)"
"21098";"Question 5 (morning stiffness since arising)"
"21099";"Question 6 (length of morning stiffness since arising)"
"21100";"QUICKI"
"21101";"Quintile (n)"
"21102";"Quintile 1 (1.11%-3.58%) (n=497)"
"21103";"Quintile 2 (3.59%-5.26%) (n=497)"
"21104";"Quintile 3 (5.26%-7.30%) (n=496)"
"21105";"Quintile 4 (7.30%-11.14%) (n=496)"
"21106";"Quintile 5 (11.15%-63.48%) (n=497)"
"21107";"Quintile, range, mg/dL"
"21108";"QVA149 110/50 |ig od n=372"
"21109";"QVA149110/50 pg once daily (n=258)"
"21110";"Qveral"
"21111";"R"
"21112";"r-tPA"
"21113";"R 10 mg"
"21114";"R 10 mg («=52)"
"21115";"R 10 mg + FA"
"21116";"R 10 mg + FA («=52)"
"21117";"R 20 mg"
"21118";"R 20 mg (n=53)"
"21119";"R 20 mg + FA"
"21120";"R 20 mg + FA («=52)"
"21121";"R 5 mg"
"21122";"R 5 mg (n=68)"
"21123";"R 5 mg + FA"
"21124";"R 5 mg + FA («=73)"
"21125";"R ight coronar y artery"
"21126";"R ight coronary"
"21127";"R wave in aVL (mm)"
"21128";"R|R''' (95% CI)"
"21129";"R10 (n = 98)"
"21130";"R10 + EZIO (n = 122)"
"21131";"R20 (n = 121)"
"21132";"R5 + EZIO (n = 99)"
"21133";"RA"
"21134";"rA-beAM"
"21135";"RA duration (months)*"
"21136";"RA duration (years), mean (s.e.)"
"21137";"Ra ndosii zat ion"
"21138";"RA symptom duration—year"
"21139";"RA symptom duration <3 months—number (%)"
"21140";"RAAS inhibitor"
"21141";"RAAS inhibitor use"
"21142";"RAAS inhibitors"
"21143";"Race"
"21144";"RACE"
"21145";"Race- no. (%)"
"21146";"Race-Non- White"
"21147";"Race-nonwhite"
"21148";"Race - n (%)"
"21149";"Race - no. (%)"
"21150";"Race - Non-White (n=26, 24)"
"21151";"Race - White (n=397, 399)"
"21152";"Race — no. (%)"
"21153";"Race — no. (%)'("
"21154";"Race — no. (%):c"
"21155";"Race — no. (%):t"
"21156";"Race — no. (%)|"
"21157";"Race — no. (%)卞"
"21158";"Race — no. (%)f"
"21159";"Race — no. {%)'i'"
"21160";"Race — no. {%)-i-"
"21161";"Race — no./total no. (%)f"
"21162";"Race (% White)"
"21163";"Race (%)"
"21164";"Race (%) White"
"21165";"Race (%)$"
"21166";"Race (%))'"
"21167";"Race (%)*"
"21168";"Race (non-white) (%)"
"21169";"Race (p=O-85)"
"21170";"Race (white, n [%])"
"21171";"Race / ethnicity, n (%)"
"21172";"Race and SS at baseline"
"21173";"Race n (%)"
"21174";"Race N(%)"
"21175";"Race nonwhitet"
"21176";"Race or ethnic background — no. (%)f"
"21177";"Race or ethnic group"
"21178";"Race or ethnic group — no. (%):t"
"21179";"Race or ethnic group — no. (%)f"
"21180";"Race or ethnic group — no. {%)■'( White"
"21181";"Race or ethnic group — no./total no. (%)f"
"21182";"Race or ethnic group — no.f"
"21183";"Race or ethnic group (%)"
"21184";"Race or ethnic group (%)f"
"21185";"Race or ethnic group, n (%)*"
"21186";"Race or ethnic group, no. (%)"
"21187";"Race or ethnic origin"
"21188";"Race or ethnicity"
"21189";"Race or ethnicity, n (%)"
"21190";"Race White"
"21191";"Race*"
"21192";"Race, %"
"21193";"Race, % Caucasian"
"21194";"Race, % nonwhite"
"21195";"Race, % of patients"
"21196";"Race, % white"
"21197";"Race, Asian, n (%)"
"21198";"Race, Black or African-American, n (%)"
"21199";"Race, n (%)"
"21200";"Race, N (%)"
"21201";"Race, n (%) White"
"21202";"Race, n (%)*"
"21203";"Race, n (%):"
"21204";"Race, n (%)’"
"21205";"Race, n (%)+"
"21206";"Race, n (%)a"
"21207";"Race, n (%)b"
"21208";"Race, n (%)t"
"21209";"Race, n (%)y"
"21210";"Race, n (%]"
"21211";"Race, n(%)"
"21212";"Race, no. (%)"
"21213";"Race, No. (%)"
"21214";"Race, no. (%) white"
"21215";"Race, no. (%)*"
"21216";"Race, no. (%)b"
"21217";"Race, No. (%)c"
"21218";"Race, No./total (%)"
"21219";"Race, Non-White"
"21220";"Race, While"
"21221";"Race, white (%)"
"21222";"Race, white, n (% of patients)"
"21223";"Race, white, n (%)"
"21224";"Race, White, n (%)"
"21225";"Race, white, n (%)"
"21226";"Race, zz (%)"
"21227";"Race, n (%)"
"21228";"Race,*’ n (%)"
"21229";"Race,n (%)"
"21230";"Race,n(%)"
"21231";"Race/ethnicity"
"21232";"Race/Ethnicity"
"21233";"Race/ethnicity Chinese"
"21234";"Race/ethnicity n (%)"
"21235";"Race/ethnicity White"
"21236";"Race/ethnicity, %"
"21237";"Race/ethnicity, % White non-Hispanic"
"21238";"Race/ethnicity, no. (%)"
"21239";"Race/ethnicity, No. (%)"
"21240";"Race/ethnicity, no. (%)*"
"21241";"Race/ethnicity, zz (%)"
"21242";"Race:"
"21243";"Race: Non-White"
"21244";"Race: White"
"21245";"Race_White, %"
"21246";"Race§"
"21247";"Race3"
"21248";"Racea"
"21249";"Racea White"
"21250";"Racec, n (%)"
"21251";"Racey,z"
"21252";"Racial category"
"21253";"Racial category*"
"21254";"Racial group, n (%)"
"21255";"Radial"
"21256";"Radial access"
"21257";"Radial access — no./total no. (%)"
"21258";"Radial access site"
"21259";"RADIATE"
"21260";"Radiographic characteristics at baseline and randomization"
"21261";"Radiographic progression based on change from baseline > SDC"
"21262";"Radionuclide ventriculography"
"21263";"Radius fracture"
"21264";"Raee"
"21265";"RAGE (ng/ml)"
"21266";"Rales"
"21267";"Rales, (%)"
"21268";"Rales, n (%)"
"21269";"Ramus"
"21270";"Rando. in NA**"
"21271";"Randomisation scheme"
"21272";"Randomisation visit (baseline)"
"21273";"Randomised patients (n)"
"21274";"Randomised patients with >3% BSA psoriasis skin involvement at baseline"
"21275";"Randomised patients with BASDAI assessment at baseline and week 12, N"
"21276";"Randomised patients with BASDAI assessment at baseline and week 24, N"
"21277";"Randomised patients with dactylitis at baseline"
"21278";"Randomised patients with enthesitis at baselinet"
"21279";"Randomised patients with spondylitis at baseline, N"
"21280";"Randomised to canakinumab 150 mg"
"21281";"Randomised to canakinumab 300 mg"
"21282";"Randomised to canakinumab 50 mg"
"21283";"Randomised treatment"
"21284";"randomization"
"21285";"Randomization"
"21286";"Randomization-to-"
"21287";"Randomization-to- angiography"
"21288";"Randomization-to- angiography distribution time"
"21289";"Randomization group"
"21290";"Randomization Groups 1 and 2"
"21291";"Randomization Groups 1 and 3"
"21292";"Randomization Stratum"
"21293";"Randomization to"
"21294";"Randomization to angiography"
"21295";"Randomization to arrival in catheterization laboratory"
"21296";"Randomization to arterial sheath insertion"
"21297";"Randomization to end of study"
"21298";"Randomization to first balloon inflation, min"
"21299";"Randomization to placebo or telmisartan"
"21300";"randomization)"
"21301";"randomization, n (%)"
"21302";"Randomize"
"21303";"Randomized"
"21304";"Randomized <4 hr after presentation — %"
"21305";"Randomized group by subgroup interaction"
"21306";"Randomized group by subgroup Interaction"
"21307";"Randomized patients"
"21308";"Randomized to active yitamin E"
"21309";"Randomized to aspirin use"
"21310";"Randomized to canakinumab 150 mg"
"21311";"Randomized to canakinumab 300 mg"
"21312";"Randomized to canakinumab 50 mg"
"21313";"Randomized to receive aspirin Yes"
"21314";"Randomized to receive beta carotene"
"21315";"Randomized to receive vitamin E"
"21316";"Randomized to receiveaspirin"
"21317";"Randomized treatment"
"21318";"Randomized treatment, % (n)"
"21319";"Randomized treatments, n (%)"
"21320";"Randomized, Double-Blind Reversal Phase (Baseline=Week 26)"
"21321";"Randomly assigned to ACE"
"21322";"Randomly assigned to calcium channel blocker"
"21323";"Randomly assigned to diuretic"
"21324";"range"
"21325";"Range"
"21326";"Range (min, max)"
"21327";"Range (Min, Max)"
"21328";"Range ED etiology (n)"
"21329";"Range IGA modified 2011 score, n (%)"
"21330";"Range of SBP"
"21331";"Range Race, n (%)"
"21332";"Range, (min, max)"
"21333";"Range: min, max"
"21334";"Range: min,max"
"21335";"Rank based on treatment = placebo"
"21336";"Rankin grade"
"21337";"Rankin scale ≥3"
"21338";"Ranolazine"
"21339";"Ranolazine (n = 1,789)"
"21340";"Ranolazine (n = 3279)"
"21341";"Ranolazine (n = 462)    Placebo (n = 465)"
"21342";"Ranolazine (n 5 232)"
"21343";"Ranolazine (n=1401)"
"21344";"Ranolazine (n=2441)"
"21345";"Ranolazine (n=707)"
"21346";"Ranolazine n=3161"
"21347";"Ranolazine vs. Placebo KM Failure Rate"
"21348";"Ranolazine, N = i3i7"
"21349";"Ranolazine, N = 1317"
"21350";"Ranolazine, N = 472"
"21351";"Ranotazine vs. Placebo KM Failure Rate"
"21352";"Ranozaline"
"21353";"Rarely"
"21354";"Rarely/Never"
"21355";"Rarertd antocagibtcn before andorrtzafon"
"21356";"RAS-aldosterone inhibitor^"
"21357";"RAS % target dose"
"21358";"RAS agents"
"21359";"RAS antagonist, %"
"21360";"Rasagiline, 1 mg/day"
"21361";"Rasagiline, 2 mg/day"
"21362";"Rash"
"21363";"Rate"
"21364";"RATE-CONTROL GROUP (N=2027)"
"21365";"Rate (% per year)"
"21366";"rate (mL/min/1.73m2)"
"21367";"Rate difference (events/year)"
"21368";"Rate difference (lebrikizumab-placebo)"
"21369";"Rate estimate (95% CI)"
"21370";"Rate in All Participants, %/y"
"21371";"Rate of non-progression (defined as CFB in mTSS £0), n/N (%)*"
"21372";"Rate of non-progression (defined as CFB in mTSS £0.5), n/N (%)*"
"21373";"Rate of oral or systemic corticosteroid"
"21374";"Rate of SAREs"
"21375";"Rate per 100-patient-years (control vs alirocumab)*"
"21376";"Rate per 100-patient-years (control vs alirocumab)i"
"21377";"Rate per 100 Patient-Years"
"21378";"Rate per 1000 patient-years"
"21379";"Rate ratio"
"21380";"Rate ratio (95% CI)"
"21381";"Rate Ratio (95% Ci)"
"21382";"Rate ratio (95% Cl)"
"21383";"Rate Ratio (95% Cl)"
"21384";"Rate ratio (95%CI)"
"21385";"Rate ratio (lebrikizumab vs placebo, 95% Cl)"
"21386";"Rate ratio {95% Cl)"
"21387";"Rate ratio MEPO/PBO (95% CI)"
"21388";"Rate ratio vs placebo (95% CI)"
"21389";"Rate reduction (%)"
"21390";"Rate(%/year)"
"21391";"Rate*"
"21392";"Rate* (n)"
"21393";"Rate, %/y"
"21394";"Rate/100 PYO"
"21395";"Rate/1000 patient- years"
"21396";"Rate/1000 patient-years"
"21397";"Rate†"
"21398";"Rate‡"
"21399";"rates"
"21400";"Rates per 100 patient-years"
"21401";"Ratet"
"21402";"Ratet    n (%)"
"21403";"Ratet (95% Cl)"
"21404";"Ratio"
"21405";"Ratio (95% CI)*"
"21406";"Ratio FP/SAL:SAL (95% CI)"
"21407";"Ratio MEPO/PBO (95% CI)"
"21408";"Ratio of FEV1 to FVC"
"21409";"Ratio of FEV1to FVC (%)"
"21410";"Ratio of HRs (95% CI), p for sex interaction"
"21411";"Ratio of HRs (95% Cl), p for sex interaction"
"21412";"Ratio of LDL to HDL"
"21413";"Ratio of LDL to HDL cholesterol"
"21414";"Ratio of urinary albumin (mg) to creatinine (g)"
"21415";"Ratio of urinary albumin (mg) to creatinine (g) Median"
"21416";"Ratio of women to men — %"
"21417";"Ratio to baseline in eosinophil count at week 32, geometric mean (SE on loge scale) cells/ll"
"21418";"Ratio to baseline in total IgE at week 32, geometric mean (SE on loge scale) U/ml"
"21419";"RCA"
"21420";"RCA, n (%)"
"21421";"RE-COVER 1 Dabigatran"
"21422";"RE-COVER 1 Warfarin"
"21423";"RE-COVER II"
"21424";"RE-COVER/RE-COVER II"
"21425";"RE-MEDY"
"21426";"Readmission (n=421)"
"21427";"Reason for discontinuation of previous TNFa inhibitor"
"21428";"Reason for enrollment in ACTIVE A"
"21429";"Reason for enrollment in ACTIVE A — no. (%)"
"21430";"Rec. Ischemia"
"21431";"Rec. Ischemia due to ECG changes"
"21432";"Rec. Ischemia due worsening angina"
"21433";"Rec. Ischemia leading to hasp"
"21434";"Rec. Ischemia leading to hosp"
"21435";"Rec. Ischemia requiring revasc"
"21436";"Received >2 prior anti-TNF therapies, n"
"21437";"Received 1 prior anti-TNF therapy, n"
"21438";"Received 1 prior biologic therapy, n"
"21439";"Received 2 prior biologic therapies, n"
"21440";"Received 3 prior biologic therapies, n"
"21441";"Received an oral AHA within 8 weeks prior to screening"
"21442";"Received antihypertensive within last 3 days, n (%)"
"21443";"Received drug-eluting stent"
"21444";"Received first loading dose"
"21445";"Receiving antihypertensive"
"21446";"Receiving antihypertensive treatment -"
"21447";"Receiving antihypertensive treatment, n (%) Blood pressure, mm Hg, mean (sd)"
"21448";"Receiving concomitant corticosteroids"
"21449";"Receiving concomitant NSAIDs and/or COX-2 inhibitors"
"21450";"Receiving insulin therapy"
"21451";"Recent cardiovascular eventf"
"21452";"Recent cardioversion (within 5 days before randomization) —"
"21453";"Recent cardioversion (within 5 days before randomization) — no. (%)"
"21454";"Recent surgery or trauma"
"21455";"Recent treatment (<3 months MMF/GGs)"
"21456";"Recent use of allopurinol (within 30 days of"
"21457";"receptor blocker"
"21458";"receptor blockers"
"21459";"receptor blockers, n (%)"
"21460";"receptor blockers, n (%) Baseline lipid and apolipoprotein levels"
"21461";"Recervini}"
"21462";"Recervng"
"21463";"Rectal bleeding subscore"
"21464";"Rectal bleeding subscore{"
"21465";"Rectum"
"21466";"Rectum and sigmoid colon only"
"21467";"Recurrent heart failure"
"21468";"Recurrent HF"
"21469";"Recurrent HF hospitalization"
"21470";"Recurrent infections (>1 per year)"
"21471";"Recurrent ischemia"
"21472";"Recurrent Ischemia"
"21473";"Recurrent ischemia- urgent revascularization"
"21474";"Recurrent VTE (statin use vs non-use)"
"21475";"Red blood cell counting, 1012/L"
"21476";"Redon"
"21477";"Reduced EF"
"21478";"Reduced HDL cholesterol"
"21479";"Reduction in Odds %"
"21480";"Reduction in risk % (95% CI)"
"21481";"Reduction of HbA1c from baseline≥0.5%"
"21482";"Reduction of HbA1c from baseline≥0.7%"
"21483";"Reduction of HbA1c from baseline≥1.0%"
"21484";"REDUCTION
IN RISK
(95% CI) %"
"21485";"Ref."
"21486";"REF§"
"21487";"Reference"
"21488";"Referent"
"21489";"Refractory to corticosteroids, n (%)"
"21490";"Refractory to such therapy — no. (%)"
"21491";"Regadenoson"
"21492";"Regadenoson (n = 334)"
"21493";"region"
"21494";"Region"
"21495";"Region-North America"
"21496";"Region - n (%)"
"21497";"Region - no. (%)"
"21498";"Region — no. (%)"
"21499";"Region — no. {%)"
"21500";"Region    North America"
"21501";"Region (%)"
"21502";"Region (pooled)"
"21503";"Region (US)"
"21504";"Region 一no. (%)"
"21505";"Region Latin American"
"21506";"Region N(%)"
"21507";"Region of enrollment"
"21508";"Region of enrollment— no. (%)"
"21509";"Region of enrollment — no. (%)"
"21510";"Region of enrollment, n (%)+"
"21511";"Region of enrollment, No. (%)"
"21512";"Region of residence (p=0 09)"
"21513";"Region of the world"
"21514";"Region of world — no. (%)"
"21515";"Region ofenrollment — %"
"21516";"Region ofthe world"
"21517";"Region United States"
"21518";"Region*"
"21519";"Region,"
"21520";"Region, %"
"21521";"Region, Asia/Paafic"
"21522";"Region, Europe"
"21523";"Region, Europe Union"
"21524";"Region, Latin America"
"21525";"Region, n (%)"
"21526";"Region, N (%)"
"21527";"Region, n (%)a"
"21528";"Region, no. (%)"
"21529";"Region, No. (%)"
"21530";"Region, No. (%)c"
"21531";"Region, No./total (%)"
"21532";"Region, North America"
"21533";"Region, n (%)"
"21534";"Region:"
"21535";"Regional anaesthesia"
"21536";"Regions, n (%)"
"21537";"Regiont"
"21538";"Regular alcohol consumption per week, no. (%)"
"21539";"Regular aspirin use"
"21540";"Regular PPI use"
"21541";"Reinfarction"
"21542";"Related to study druga"
"21543";"Relative decrease >10%"
"21544";"Relative decrease >5%"
"21545";"Relative risk (95% CI)"
"21546";"Relative Risk (95% CI)"
"21547";"Relative Risk (95% CI) ofPrimary End Point"
"21548";"Relative risk (95% Cl)"
"21549";"Relative Risk (95% Cl)"
"21550";"Relative Risk (95% Cl) Comparing ICD Therapy and Placebo Using a Linear Interaction Term in the Model (SHFMXICD)*"
"21551";"Relative Risk (95% confidence interval)"
"21552";"Relative Risk (95% Confidence Interval)"
"21553";"Relative Risk (95%CI)"
"21554";"Relative Risk {95%CI)"
"21555";"Relative Risk Comparing ICD Therapy and Placebo"
"21556";"Relative risk reduction (95% Cl)"
"21557";"Relative Risk Reduction (95% Cl) percent"
"21558";"Relative Risk vs. Placebo (95% Cl)"
"21559";"Relative risk* (95% Cl)"
"21560";"Relative risk®' (95% Cl)"
"21561";"Relative risk® (95% Cl)"
"21562";"Relative wall thickness"
"21563";"Remaining patients"
"21564";"Remission"
"21565";"Remission at maintenance-trial entry — no. (%)"
"21566";"Remission by: baseline duration of steroid"
"21567";"Remission by: baseline steroid doses"
"21568";"remission component of variable"
"21569";"Remission in overall population"
"21570";"Remission, n (%)"
"21571";"Remodeling"
"21572";"Renal"
"21573";"Renal biopsy class"
"21574";"Renal composite*"
"21575";"Renal disease"
"21576";"Renal disease)"
"21577";"Renal dysfunction"
"21578";"Renal Dysfunction"
"21579";"Renal events"
"21580";"Renal failure"
"21581";"Renal fmclicn: creatntoe clearance"
"21582";"Renal function"
"21583";"Renal function (eGFR) according to MDRD, n (%)"
"21584";"Renal function (eGFR, ml/min/1.73 m2)"
"21585";"Renal function (eGFR, mL/min/1.73 m2, according to MDRD), n (%)"
"21586";"Renal function (ml/min)"
"21587";"Renal function <60 eGFR, mL/min/1.73 m2"
"21588";"renal Function at randomization"
"21589";"Renal function subgroups"
"21590";"Renal function*"
"21591";"Renal Function, Moderate"
"21592";"Renal Function, Normal- Mild"
"21593";"Renal Function, Severe"
"21594";"Renal Function,bn (%)"
"21595";"Renal function: creatinine clearance"
"21596";"Renal function:!: n (%)"
"21597";"Renal Functiona"
"21598";"Renal Functionb"
"21599";"Renal Functionc, n (%)"
"21600";"Renal impairment"
"21601";"Renal impairment (CrCl <50 mL/min)"
"21602";"Renal impairment*"
"21603";"Renal impairment, n (%)"
"21604";"Renal impairmentf"
"21605";"Renal impairmentt"
"21606";"Renal Insufficiency"
"21607";"Renal insufficiency— no. (%)"
"21608";"Renal Insufficiency or Failure"
"21609";"Renal insufficiency*"
"21610";"Renal insufficiency/ failure"
"21611";"Renal insufficiency/failure"
"21612";"Renal insufficiency11"
"21613";"Renal parameters"
"21614";"Renal subgroup"
"21615";"Renin-angiotensin-aldosterone system blocker"
"21616";"Renin-angiotensin inhibitors"
"21617";"Renin-angiotensin system inhibitor use"
"21618";"Renin–angiotensin system inhibitor"
"21619";"Renin inhibitor"
"21620";"Renin inhibitor (e.g. aliskerin)"
"21621";"Renin inhibitors"
"21622";"Rentrop score"
"21623";"Repaired CHD"
"21624";"Repaired congenital shunts"
"21625";"Repaired S-P Shunts"
"21626";"Reported diabetes mellitus"
"21627";"Reported high cholesterol'!"
"21628";"Reported hypertension*"
"21629";"Reported in eCRF"
"21630";"Reqion"
"21631";"Required corticosteroid and/or antibiotic (without hospitalization)"
"21632";"Required hospitalization"
"21633";"requiring assistance"
"21634";"Rerandomization to Placebo (N = 171)f"
"21635";"Rescue medication use, inh/d{"
"21636";"Rescue medication use, mean inhalations/previous 3 d"
"21637";"Rescue use: mean No. of inhalations/d"
"21638";"Resection performed — no. {%)"
"21639";"Resection performed, %"
"21640";"Residence in Asia, n (%)"
"21641";"Residual deep-vein thrombosis, No. (%)"
"21642";"Residual perfusion defect >10% on lung scan, No. (%)"
"21643";"Resistant HTN n = 403"
"21644";"Resistant HTN: placebo n = 212"
"21645";"Resistant HTN: spiro n = 191"
"21646";"Reslizumab"
"21647";"Reslizumab (n=232)"
"21648";"Reslizumab (n=245)"
"21649";"Reslizumab 0.3 mg/kg (n = 104)"
"21650";"Reslizumab 3.0 mg/kg (n = 398)"
"21651";"Reslizumab 3.0 mg/kg (n = 106)"
"21652";"Resllzumab"
"21653";"Respiratory-related^"
"21654";"Respiratory medication (%)"
"21655";"Respiratory medication taken at baseline, n (%)"
"21656";"Respiratory rate (breaths/min)"
"21657";"Respiratory rate, breaths/min"
"21658";"Responder analyses (achieving AlC <7.0%)"
"21659";"Responders of three-item end point at 24 weeks*"
"21660";"Rest-of-world (n=645)"
"21661";"Rest-of-World (n=645)"
"21662";"Rest angina but not past 48 h"
"21663";"Rest angina past 48 h"
"21664";"Rest of the world"
"21665";"Rest of the World"
"21666";"Rest of world"
"21667";"Rest of World"
"21668";"Rest of world n Z 474"
"21669";"Rest ofthe world"
"21670";"Rest ofworld"
"21671";"Rest pain"
"21672";"Restenotic vessel"
"21673";"Restriction in normal activities in the past 2 weeks"
"21674";"Result"
"21675";"Ret/Abx- Facil. PCI"
"21676";"Reteplase"
"21677";"Reteplase/Abciximab-Facilitated PCI (n = 828)"
"21678";"retinopathy"
"21679";"Retinopathy"
"21680";"Retinopathy — %"
"21681";"Retinopathy — no. (%)"
"21682";"Retinopathy (stage 0/1/2/3)"
"21683";"Revascularisation but no antiplatelets, lipid-lowering agents, or p blockers"
"21684";"Revascularisation, n (%)"
"21685";"Revascularisation+antiplatelets+ lipid-lowering agents+p blockers"
"21686";"revascularization"
"21687";"Revascularization"
"21688";"Revascularization during index hospitalization, %"
"21689";"Revascularization history"
"21690";"Revascularization in 9 days"
"21691";"Reversibility"
"21692";"Reversibility — %"
"21693";"Reversibility %"
"21694";"Reversibility (% predicted FEV1)*"
"21695";"Reversibility (%)"
"21696";"Reversibility (%), median (range)c"
"21697";"Reversibility (%)t"
"21698";"Reversibility (anticholinergic), %, mean (SD)$"
"21699";"Reversibility (b2-agonist), %, mean (SD)1"
"21700";"Reversibility [%], median (range)"
"21701";"Reversibility <12% (ITT) (n=1123)"
"21702";"Reversibility <12% (ITT) (n=1132)"
"21703";"Reversibility <12% (ITT) (n=1141)"
"21704";"Reversibility <12% (ITT) (n=1505)"
"21705";"Reversibility <12% (n=1025)"
"21706";"Reversibility >12% (ITT) (n=468)"
"21707";"Reversibility >12% (ITT) (n=472)"
"21708";"Reversibility >12% (ITT) (n=474)"
"21709";"Reversibility >12% (ITT) (n=477)"
"21710";"Reversibility >12% (ITT) (n=618)"
"21711";"Reversibility >12% (ITT) (n=627)"
"21712";"Reversibility >12% (n=507)"
"21713";"Reversibility of FEV1 (%)"
"21714";"Reversibility S12% (ITT) (n=1135)"
"21715";"Reversibility S12% (ITT) (n=1524)"
"21716";"Reversibility stratum*"
"21717";"Reversibility to"
"21718";"Reversibility to salbutamol, %"
"21719";"reversibility to salbutamolc,d, mean (sD)"
"21720";"Reversibility*"
"21721";"Reversibility, %"
"21722";"Reversibility: <5%"
"21723";"Reversibility: >12%"
"21724";"Reversibility: >5 - <12%"
"21725";"Reversibility’' %"
"21726";"reversible"
"21727";"Reversible (%)"
"21728";"Reversible to albuterolc,d, n (%)"
"21729";"Reversible to bronchodilator,b %"
"21730";"REVIVE I"
"21731";"REVIVE II"
"21732";"RF-positive, > 14 IU/ml, %"
"21733";"RF (IU/mL)"
"21734";"RF (mg/dl)"
"21735";"RF (mg/dl; per unit)"
"21736";"RF and ACPA negative, n (%)"
"21737";"RF and ACPA negative8"
"21738";"RF and ACPA positive, n (%)"
"21739";"RF negative and ACPA positive, n (%)"
"21740";"RF or ACPA positive"
"21741";"RF positive"
"21742";"RF positive—number (%)"
"21743";"RF positive (>14 IU/mL), n (%)"
"21744";"RF positive and ACPA negative, n (%)"
"21745";"RF positive, %"
"21746";"RF positive, n (%)"
"21747";"RF positive, no. (%)"
"21748";"RF, % positive"
"21749";"Rhabdomyolysis"
"21750";"Rhabdomyolysis (N=31)"
"21751";"Rhabdomyolysis or myopathy"
"21752";"Rhabdomyolysis, myopathy, or elevated creatine phosphokinase >5x upper limit of normal (N=111)"
"21753";"Rhabdomyolysis, myopathy, or myalgia with CK elevation >5x ULN"
"21754";"Rheumatic heart disease"
"21755";"Rheumatoid arthritis"
"21756";"Rheumatoid factor-positive"
"21757";"Rheumatoid factor and ACPA positive"
"21758";"Rheumatoid factor or ACPA positive, or both"
"21759";"Rheumatoid factor positive"
"21760";"Rheumatoid factor Positive"
"21761";"Rheumatoid factor positive§, n (%)"
"21762";"Rheumatoid factor!"
"21763";"Rhinitis"
"21764";"RHYTHM-CONTROL GROUP (N=2033)"
"21765";"Rib"
"21766";"right"
"21767";"Right"
"21768";"Right coronary"
"21769";"Right coronary artery"
"21770";"Right coronary artery, n (%)"
"21771";"Right ventricular dysfunction — no./total no. (%)§"
"21772";"Right ventricular dysfunction, n/n (%)J"
"21773";"Right ventriculardysfunction atinclusion"
"21774";"Risedronate (N = 680)"
"21775";"Risedronate (N=435)"
"21776";"Risedronate n/N (%)"
"21777";"risk"
"21778";"Risk"
"21779";"Risk  Ratio [95% Cl]"
"21780";"Risk At"
"21781";"Risk Categories"
"21782";"Risk Category (Points)"
"21783";"Risk Difference"
"21784";"Risk Factor"
"21785";"Risk factor (predefined) for falling at screening, n (%)"
"21786";"Risk factor for venous thromboembolism, no. (%)"
"21787";"Risk factor profile index event"
"21788";"Risk factors"
"21789";"Risk Factors"
"21790";"Risk factors — no. (%)"
"21791";"Risk factors (% of group)"
"21792";"Risk factors (%)"
"21793";"Risk factors and diabetes status (%)"
"21794";"Risk factors and immobility level, n (%)"
"21795";"Risk factors and medical history"
"21796";"Risk factors BMI (kg/m2), mean + SD"
"21797";"Risk factors for atherosclerosis"
"21798";"Risk factors for PAD"
"21799";"Risk factors for recurrent VTE — no. (%)f"
"21800";"Risk factors for stroke"
"21801";"Risk factors for stroke, No. (%)"
"21802";"Risk factors specified as inclusion criteria — no. (%)f"
"21803";"Risk factors, %"
"21804";"Risk factors, No. (%)"
"21805";"Risk group"
"21806";"Risk level at admission"
"21807";"Risk Marker and Model"
"21808";"Risk Model Endpoint"
"21809";"Risk of bleeding"
"21810";"Risk of moderate/severe exacerbations"
"21811";"Risk Reduction (%; 95% CI)"
"21812";"Risk Reduction (95% Cl)"
"21813";"Risk Reduction, %"
"21814";"Risk Score Category (Points)"
"21815";"Risk stratum"
"21816";"Risk*"
"21817";"Rituximab"
"21818";"Rituximab (2x1000 mg) + MTX"
"21819";"Rituximab (2x1000 mg) + MTX (n=250)"
"21820";"Rituximab (2x500 mg) + MTX"
"21821";"Rituximab (2x500 mg) + MTX (n=249)"
"21822";"Rituximab, n = 292"
"21823";"Rituximab, n=292"
"21824";"Riva roxa ban n/N    {%) 3671731    (2.1)"
"21825";"Rivaroxaban"
"21826";"Rivaroxaban (N = 1731)"
"21827";"Rivaroxaban (N = 602)"
"21828";"Rivaroxaban (n = 1002)"
"21829";"Rivaroxaban (n = 417)"
"21830";"Rivaroxaban (n = 585)"
"21831";"Rivaroxaban 2.5 mg BID + Aspirin 100 mg OD"
"21832";"Rivaroxaban 20 mg"
"21833";"Rivaroxaban Alone (N = 9117)"
"21834";"Rivaroxaban Alone (N = 9117) 68.2±7.9"
"21835";"Rivaroxaban alone (n=2474)"
"21836";"Rivaroxaban alone (n=8250)"
"21837";"Rivaroxaban plus"
"21838";"Rivaroxaban plus Aspirin (95% Cl)"
"21839";"Rivaroxaban plus Aspirin (N = 9152)"
"21840";"Rivaroxaban plus Aspirin (N = 9152) 68.3±7.9"
"21841";"Rivaroxaban+"
"21842";"Rivaroxaban+ Aspirin"
"21843";"Rivastigmine"
"21844";"Rivastigmine (n = 365)"
"21845";"Rofecoxib"
"21846";"Roflumilast (n = 1,178)"
"21847";"Role emotional"
"21848";"Role physical"
"21849";"Rolofylline"
"21850";"Rolofylline (n = 1,356)"
"21851";"Rolofylline (N=104)"
"21852";"Rolofylline (N=266)"
"21853";"Rolofylline (N=741)"
"21854";"Rolofylline 30 mg (N=185)"
"21855";"Rolofylline Dose"
"21856";"Rolofylline N"
"21857";"Rolofylline Rx"
"21858";"Romania"
"21859";"Rope score"
"21860";"RoPE score**"
"21861";"Rosigiitazone ± OAD"
"21862";"Rosiglitazone"
"21863";"Rosiglitazone (n = 1456)"
"21864";"Rosiglitazone (N = 1456)"
"21865";"Rosiglitazone (n=333)"
"21866";"Rosiglitazone 8 mg daik"
"21867";"rosiglitazone 8 mg daily"
"21868";"Rosiglitazone versus Glyburide"
"21869";"Rosiglitazone versus Metformin"
"21870";"Rosuva 10 mg"
"21871";"ROSUVA 10 mg N = 221"
"21872";"ROSUVA 10 mg N = 82"
"21873";"Rosuva 20 mg"
"21874";"Rosuva 40 mg"
"21875";"ROSUVA, rosuvastatin; SD, standard deviation; T2DM, type 2 diabetes mellitus."
"21876";"Rosuvastain + Fenofibric Acid 72=253"
"21877";"Rosuvastain + Fenofibric Acid n = 253"
"21878";"Rosuvastatin"
"21879";"Rosuvastatin (n = 1855)"
"21880";"Rosuvastatin (n=1711)"
"21881";"Rosuvastatin (N=2285)"
"21882";"Rosuvastatin (n=77, 34)"
"21883";"Rosuvastatin (n=777)"
"21884";"Rosuvastatin (n=81. 35)"
"21885";"Rosuvastatin +"
"21886";"Rosuvastatin + Fenofibric Acid"
"21887";"Rosuvastatin 10 mg"
"21888";"Rosuvastatin 15 mg"
"21889";"Rosuvastatin 20 mg"
"21890";"Rosuvastatin 30 mg"
"21891";"Rosuvastatin 40 mg"
"21892";"Rosuvastatin 5-10 mg (n = 262)"
"21893";"Rosuvastatin 5 mg"
"21894";"Rosuvastatin Events/patients (%)"
"21895";"Rosuvastatin n (Rate)"
"21896";"Rosuvastatin n (Rate)*"
"21897";"Rosuvastatin n (rate)1"
"21898";"Rosuvastatin n=251"
"21899";"Rosuvastatin of patients (rate)"
"21900";"Rosuvastatin n = 251"
"21901";"Rosuvastatin, events/patients (%)"
"21902";"Rosuvastatin, n (%)"
"21903";"Rosuvastatin, n (rate)"
"21904";"Rotablator use, n (%)"
"21905";"Rotigotine (n = 170)"
"21906";"Rotigotine (n = 184)"
"21907";"Rotigotine n = 174"
"21908";"ROW"
"21909";"ROW* N= 618"
"21910";"ROW* N= 624"
"21911";"RoW§"
"21912";"RR"
"21913";"RR (95% CI)"
"21914";"RR (95% CI)*"
"21915";"RR (95% CI)c"
"21916";"RR (95% Cl)"
"21917";"RR (95% Cl)    P Value"
"21918";"RR (95% Cl) [/’Value]"
"21919";"RR (95%CI)"
"21920";"RR (Cl)"
"21921";"RR 0-60 (0.36, 0,55)’"
"21922";"RR 0.47 (0.23,0.95)*"
"21923";"RR 0.56 <0.34, 0.93)*"
"21924";"RR 0.66 (0.17, 2.49)"
"21925";"RR 0.68 (0.43, 1.07)"
"21926";"RR 0.68 (0.46, 0.99)*"
"21927";"RR 0.69 (0.50.0.95)"
"21928";"RR 0.70 (0.20, 2.49}"
"21929";"RR 0.72(0.54, 0.96)*"
"21930";"RR 0.73 (0.53, 1.00)"
"21931";"RR 0.76 (0.56, 1.03)"
"21932";"RR 0.77 (0.52,1.13)"
"21933";"RR 0.77(0.47. 1.27)"
"21934";"RR 0.78 (0.65, 0.94)**"
"21935";"RR 0.81 (0.44,1.49)"
"21936";"RR 0.82 (0.53, 1.28)"
"21937";"RR 0.82(0.65. 1.05)"
"21938";"RR 0.83 (0.63, 1.10)"
"21939";"RR 0.86 (0.65,1.14)"
"21940";"RR 0.87 (0.65, 1.17)"
"21941";"RR 0.87 (0.66,1.15)"
"21942";"RR 0.87 (0.72,1.05)"
"21943";"RR 0.88 (0.46,1.66)"
"21944";"RR 0.88 (0.57. 1.36)"
"21945";"RR 0.89 (0.61,1.30)"
"21946";"RR 0.90 (0.21, 3.85)"
"21947";"RR 0.93(0.74, 1.18)"
"21948";"RR 0.94 (0.71,1.25)"
"21949";"RR 0.94(0.75, 1.19)"
"21950";"RR 0.96 (0.80, 1.16)"
"21951";"RR 0.97 (0.28, 3.40)"
"21952";"RR 0.97 (0.71,1.32)"
"21953";"RR 0.97 (0.72, 1.29)"
"21954";"RR 1.02"
"21955";"RR 1.05 (0.63, 1.75)"
"21956";"RR 1.07"
"21957";"RR 1.08 (0.82, 1.42)"
"21958";"RR 1.09"
"21959";"RR 1.10(0.66, 1.81)"
"21960";"RR 1.14(0.72. 1.82)"
"21961";"RR 1.17"
"21962";"RR 1.25"
"21963";"RR 1.34"
"21964";"RR 1.35"
"21965";"RR 1.35 (0.41,4.49)"
"21966";"RR 1.37"
"21967";"RR 1.46"
"21968";"RR 1.47"
"21969";"RR 1.48"
"21970";"RR 1.58"
"21971";"RR 1.62 (0.46, 5.73)"
"21972";"RR 1.79 (0.07,46.02)"
"21973";"RR 3.14(0.30, 32.79"
"21974";"RR 3.50(0.16, 77.92)"
"21975";"RR reduction, 0/0 (950/0 Cl)"
"21976";"RR(957aCI) [P Value]"
"21977";"RR*"
"21978";"RR^ (95% CI)"
"21979";"RR0.55 (0-35. 0.91)*"
"21980";"RR0.87 (0.56. 1.37)"
"21981";"RR0.88 (0-56, 1.37)"
"21982";"RR1.22 (0.80. 1.84)"
"21983";"RRO.83 (0.51.1.36)"
"21984";"RRO31 (0.48, 1.39)"
"21985";"RRR"
"21986";"RRR (95% Cl)"
"21987";"RS-Breathlessnessb"
"21988";"RS-Chest Symptomsd"
"21989";"RS-Cough & Sputumc"
"21990";"RS-Totala"
"21991";"rs11212617"
"21992";"rs12208357"
"21993";"rs1532085"
"21994";"rs2068888"
"21995";"rs2289669"
"21996";"rs2923084"
"21997";"rs622342"
"21998";"rs622342 & rs2289669"
"21999";"rs622342 (AA) & rs2289669"
"22000";"rs622342 (AC) & rs2289669"
"22001";"rs622342 (CC) & rs2289669"
"22002";"RSG 4 mg/day"
"22003";"RSG 8 mg/day"
"22004";"ruled out Non-fatal PE with or"
"22005";"Russia"
"22006";"Russia and Georgia"
"22007";"Russia/Georgia"
"22008";"Russia/Georgia (n=1678)"
"22009";"RV and Pulmonary Vascular"
"22010";"Rvalue"
"22011";"Rvalue for Interaction"
"22012";"RVFAC (%)"
"22013";"rvW"
"22014";"S"
"22015";"S-ASA compounds at baseline"
"22016";"S (S41"
"22017";"S 130 mmHg"
"22018";"S 5 yrs"
"22019";"s Arm"
"22020";"S fS 71"
"22021";"S fS 91"
"22022";"s Median"
"22023";"S Median"
"22024";"S wave in V3 (mm)"
"22025";"S.E."
"22026";"S/SE, MB or death"
"22027";"S100 (n = 247)"
"22028";"s113 mg/mmol"
"22029";"S20-40 vs placebo"
"22030";"s226 mg/mmol"
"22031";"s23 kg/m^"
"22032";"s28 kg/m2"
"22033";"s3 exacerbations"
"22034";"S3 gallop, n (%)"
"22035";"S40 vs placebo"
"22036";"s56.5 mg/mmol"
"22037";"s65 years (n=2474)"
"22038";"s75 years"
"22039";"S80 ml/min"
"22040";"S84(18.S)"
"22041";"s9-0-s10.5%"
"22042";"S9 months"
"22043";"SA"
"22044";"SA ACS"
"22045";"SABA"
"22046";"SABA (inhaled),c n (%)"
"22047";"SABA puffs per day at baseline"
"22048";"SABA reversibility"
"22049";"SABA use in past 3 days"
"22050";"SABA use, occasions/weekt"
"22051";"SABA§"
"22052";"saBae"
"22053";"Sack"
"22054";"Sacral and/or lumbar"
"22055";"Sacubitril/valsartan"
"22056";"Sacubitril/Valsartan (n = 1916)"
"22057";"Sacubitril/Valsartan (n = 2271)"
"22058";"Sacubitril/valsartan (n=1907)"
"22059";"Sacubitril/valsartan (n=2280)"
"22060";"SAEs"
"22061";"Safety population"
"22062";"Safety population, n (%)"
"22063";"Safety variable"
"22064";"Safety, %"
"22065";"Safety, n (%)b"
"22066";"Safety: non-CABG-related bleeding"
"22067";"SAL (n = 1232)"
"22068";"SAL (n = 1,334)"
"22069";"SAL 50 mg"
"22070";"SAL 50 pg (N = 325)"
"22071";"SAL 50 pg (N= 325)"
"22072";"salbutamol, %"
"22073";"Salmeterol"
"22074";"Salmeterol- Fluticasone Group"
"22075";"Salmeterol-Fluticasone Group (N = 1682)"
"22076";"Salmeterol (n [1542)"
"22077";"Salmeterol (N = 3669)"
"22078";"Salmeterol (n[1542)"
"22079";"Salmeterol 50 gg bid"
"22080";"Salmeterol/fluticasone 50/500 pg twice daily"
"22081";"Salmeterol/fluticasone 50/500 μg b.i.d."
"22082";"SAMA"
"22083";"SAMA,b n (%)"
"22084";"SAMA1"
"22085";"saMac"
"22086";"sample size"
"22087";"Sample size (n)"
"22088";"Sample Size, n"
"22089";"Sample size, n (%) by treatment"
"22090";"sample sizea"
"22091";"Sample statistics"
"22092";"Saphenous vein graft"
"22093";"Saudi Arabia"
"22094";"SAXA 10 mg (n 5 335)"
"22095";"SAXA 10 mg 1 metformin (n 5 323)"
"22096";"SAXA 2.5 mg"
"22097";"SAXA 2.5 mg (n = 18)"
"22098";"SAXA 2.5 mg (n = 44)"
"22099";"SAXA 2.5 mg (n = 85)"
"22100";"SAXA 5 mg 1 metformin (n 5 320)"
"22101";"SAXA+DAPA+MET n =179"
"22102";"SAXA+DAPA+MET n=179"
"22103";"SAXA+MET n =176"
"22104";"SAXA+MET n=176"
"22105";"Saxagiiptin"
"22106";"saxagliptin"
"22107";"Saxagliptin"
"22108";"Saxagliptin (%)"
"22109";"Saxagliptin (n = 1,169)"
"22110";"Saxagliptin (n = 3,990)"
"22111";"Saxagliptin (n = 4,290)"
"22112";"Saxagliptin (n = 7,111)"
"22113";"Saxagliptin (N = 8280)"
"22114";"Saxagliptin 2.5 mg"
"22115";"Saxagliptin 2.5 mg (n = 1,122)"
"22116";"Saxagliptin 2.5 mg (n = 172)"
"22117";"Saxagliptin 2.5 mg (n Z 264)"
"22118";"Saxagliptin 2.5 mg (n Z 492)"
"22119";"Saxagliptin 5 mg"
"22120";"Saxagliptin 5 mg (n = 6,986)"
"22121";"Saxagliptin 5mg"
"22122";"Saxagliptin 5mg(n Z 247)"
"22123";"Saxagliptin 5mg(n Z 509)"
"22124";"SBP"
"22125";"SBP (mean over 24 h), mmHg"
"22126";"SBP (mm Hg)"
"22127";"SBP (mm Hg), median (IQR)"
"22128";"SBP (mmgHG), mean (SD)"
"22129";"SBP (mmHg)"
"22130";"SBP (mmHg) <120"
"22131";"SBP (mmHg)*"
"22132";"SBP (mmHg), mean (SD)"
"22133";"SBP (mmHg), mean ± SD"
"22134";"SBP (office measurement), mmHg"
"22135";"SBP (SD)"
"22136";"SBP (SD), mm Hg"
"22137";"SBP <129mm Hg"
"22138";"SBP <130 mmHg"
"22139";"SBP <140 mm Hg and DBP <90 mm Hg    81/2907"
"22140";"SBP <140 mmHg"
"22141";"SBP <140 mmHg and DBP <90 mmHg"
"22142";"SBP <160 mmHg"
"22143";"SBP ≥140 mmHg"
"22144";"SBP > 138mmHg n= 466"
"22145";"SBP >140 mm Hg and/or DBP >90 mm Hg 83/1780"
"22146";"SBP >140 mmHg"
"22147";"SBP >140 mmHg and/or DBP >90 mmHg"
"22148";"SBP >140 mmHg or DBP >90 mmHg"
"22149";"SBP >160 mmHg"
"22150";"SBP at Baseline"
"22151";"SBP at Visit 2"
"22152";"SBP during the follow-up period (mmHg)"
"22153";"SBP indicates systolic blood pressure; DBP, diastolic blood pressure; AA, arachidonic acid; EPA, eicosapentaenoic acid. Values for age, BMI, total cholesterol, LDL cholesterol, HDL cholesterol, SBP, DBP, AA, EPA, and EPA/AA ratio represent the mean values represent the median (interquartile range). P values are for the differences between the no EPA and EPA groups."
"22154";"SBP(mm Hg)"
"22155";"SBP, baseline"
"22156";"SBP, difference"
"22157";"SBP, last"
"22158";"SBP, mean (sd) mm Hg"
"22159";"SBP, mean (SD), mm Hg"
"22160";"SBP, mean (SD), mmHg"
"22161";"SBP, mean = SD, mmHg"
"22162";"SBP, mean ±SD (mmHg)"
"22163";"SBP, mm Hg"
"22164";"SBP, mm Hg (mean 24 h), mean (SD)"
"22165";"SBP, mm Hg (office measurement), mean (SD)"
"22166";"SBP, mm Hg, mean + SDC"
"22167";"SBP, mm Hg, mean ± SDC"
"22168";"SBP, mm Hg"
"22169";"SBP, mm Hg"
"22170";"SBP, mm Hg (SD)"
"22171";"SBP, mmHg"
"22172";"SBP, systolic blood pressure; SD, standard deviation; DBP, diastolic blood pressure; b.p.m., beats per minute; MI, myocardial infarction; TIA, transient ischaemic attack."
"22173";"SBP,Difference vs placebo (95% Cl)"
"22174";"SBP. mean (sd) mm Hg"
"22175";"SBP/DBP $130/$85 mmHg"
"22176";"SBP/DBP (mmHg)"
"22177";"SBP/DBP Mean"
"22178";"SBP< 118mmHg n = 403"
"22179";"SBP<129mm Hg"
"22180";"SBP<129mmHg"
"22181";"SBP<median (n=13O6)"
"22182";"SBP> median (n=400)"
"22183";"SBP>130mm Hg"
"22184";"SBP>130mmHg"
"22185";"SBP>130mnn Hg"
"22186";"SC belimumab 200 mg (n = 248)"
"22187";"Scale—Cognitive Portion; LDL — low-"
"22188";"Scalp psoriasis, n (%)"
"22189";"Scarring on renal biopsy"
"22190";"SCD (%)"
"22191";"scDBP, mean (SD), mmHgf"
"22192";"Schwab & England score"
"22193";"Sco.’ita'ROjS DVT.'PE"
"22194";"score"
"22195";"score (>5) at 8 monthsb Unadjusted OR"
"22196";"Score 一no. (%)"
"22197";"Score > 15%, % of patients"
"22198";"Score >2.5"
"22199";"Score >2.75"
"22200";"Score 1-3"
"22201";"Score 3.0"
"22202";"Score 4-9"
"22203";"score at week 32, mean (SE) Difference MEPO-PBO (95% CI)"
"22204";"Score distribution:"
"22205";"Score distribution: <5"
"22206";"Score improvement, baseline to week 100, median (IQR)"
"22207";"Score of #9, no. (%)"
"22208";"Score of $10, no. (%)"
"22209";"Score of >5.1 — %"
"22210";"Score on Asthma Control Questionnaire**"
"22211";"Score on Modified Mini-Mental State Examination — median (IQR)"
"22212";"Score on Modified Rankin Scale — median (IQR)"
"22213";"Score on modified Rankin Scale — no. (%)§"
"22214";"Score on modified Rankin scale ('%/'"
"22215";"Score on NIH Stroke Scale — median (IQR)"
"22216";"Score on St. George's Respiratory Questionnaire^^"
"22217";"Score on the Minnesota Living with Heart Failure scaled"
"22218";"Score, %"
"22219";"Score, No. (%)"
"22220";"Scores for global and pain assessments§"
"22221";"Scr, gmol/L"
"22222";"Screening"
"22223";"Screening % predicted FEV1"
"22224";"Screening % reversibility FEV1"
"22225";"Screening (Visit 1)"
"22226";"Screening absolute reversibility FEV1,mL"
"22227";"Screening and baseline lung function characteristics"
"22228";"Screening BMI (kg/m2)"
"22229";"Screening FEV1 % predicted"
"22230";"Screening HbA1c (%)"
"22231";"Screening prebronchodilator FEV1,L"
"22232";"Screening visit"
"22233";"screening, L"
"22234";"screening, mean (SD) Morning PEF, mean"
"22235";"scSBP, mean (SD), mmHge"
"22236";"SD"
"22237";"SD = standard deviation; BMI = body mass index; ED = erectile"
"22238";"SD of SBP"
"22239";"SD or %"
"22240";"SD, standard"
"22241";"SDAI"
"22242";"SDAI (0-86)"
"22243";"SDAI <11 t"
"22244";"SDAI <3.3*"
"22245";"SDAI, mean (SD)"
"22246";"SDC (0.5-0.9 ng/ml)"
"22247";"SDC (1.2-2.0 ng/ml)"
"22248";"SDC (ng/ml)"
"22249";"SE"
"22250";"Seated DBP, mean (SD), mmHg"
"22251";"Seated SBP at 24 weeks, mmHg+"
"22252";"Seated SBP at 8 weeks, mmHg+**"
"22253";"Seated SBP, mean (SD), mmHg"
"22254";"seated SBP, N"
"22255";"Second-generation stent"
"22256";"Second (N=2344)"
"22257";"Second co-primary"
"22258";"Second Co-Primary Outcome"
"22259";"Second loading dose"
"22260";"Second MI"
"22261";"Second primary (estimated change in total UPDRS score from baseline to wk 72)"
"22262";"Second primary composite outcome"
"22263";"Second prior MI"
"22264";"Second serum creatinine"
"22265";"Second year!"
"22266";"Secondary' outcomes"
"22267";"Secondary-prevention cohort"
"22268";"Secondary #1"
"22269";"Secondary #2"
"22270";"Secondary #3"
"22271";"Secondary (change in total UPDRS score from baseline to final visit in phase 1)"
"22272";"Secondary cardiovascular endpoint"
"22273";"Secondary DVT.'FE"
"22274";"Secondary end points"
"22275";"Secondary end points 1"
"22276";"Secondary end points II"
"22277";"Secondary end points III"
"22278";"Secondary endpoints:"
"22279";"Secondary III*"
"22280";"Secondary IP"
"22281";"Secondary Kidney Composite Outcome"
"22282";"Secondary MACE endpoint"
"22283";"Secondary nonresponse"
"22284";"Secondary outcome"
"22285";"Secondary Outcome"
"22286";"Secondary outcomes"
"22287";"Secondary P"
"22288";"Secondary PCI"
"22289";"Secondary Prevention Subgroup"
"22290";"Secondary*"
"22291";"Section 6a"
"22292";"Section 6b"
"22293";"Section 6c"
"22294";"Section 7a"
"22295";"Section 7b"
"22296";"Section 7c"
"22297";"Secukinumab"
"22298";"Secukinumab 150 mg"
"22299";"Secukinumab 150 mg (N = 138)"
"22300";"Secukinumab 150 mg (n = 29)"
"22301";"Secukinumab 150 mg (n 5 692)"
"22302";"Secukinumab 150 mg (n=100)"
"22303";"Secukinumab 150 mg"
"22304";"Secukinumab 150 mg (N = 116)"
"22305";"Secukinumab 150 mg (N = 31)"
"22306";"Secukinumab 150 mg (N = 85)"
"22307";"Secukinumab 150 mg no load (N = 117)"
"22308";"Secukinumab 150 mg no load (N = 32)"
"22309";"Secukinumab 150 mg no load (N = 85)"
"22310";"Secukinumab 300 mg"
"22311";"Secukinumab 300 mg (N = 139)"
"22312";"Secukinumab 300 mg (n = 29)"
"22313";"Secukinumab 300 mg (n 5 691)"
"22314";"Secukinumab 300 mg (n=100)"
"22315";"Secukinumab 300 mg"
"22316";"Secukinumab 75 mg"
"22317";"Secukinumab 75 mg (n=99)"
"22318";"Secukinumab intravenous 150 mg (n=86)"
"22319";"Secukinumab intravenous 75 mg (n=82)"
"22320";"Secukinumab pooled† (N = 46)"
"22321";"Secukinumab, 150 mg (N = 202)"
"22322";"Secukinumab, 75 mg (N = 202)"
"22323";"SeDBP"
"22324";"SeDBP (mmHg) [mean _SD]d"
"22325";"SeDBP (mmHg) [mean_ SD]a"
"22326";"Sedentary"
"22327";"Seizure frequency during 8‐week baseline, median (range)"
"22328";"Seizure history, n (%)"
"22329";"Seizure types reported during baseline,b n(%)"
"22330";"Seizure types reported during baselinee"
"22331";"Select lipids and lipoproteins"
"22332";"Selected baseline medications"
"22333";"Selected clinical characteristics"
"22334";"Selected clinical characteristics — no./total no. (%)"
"22335";"Selected clinical characteristics, n (%)"
"22336";"Selected key secondary efficacy endpoints"
"22337";"Selected medications — no. (%)"
"22338";"Selective vascular history"
"22339";"SELENA-SLEDAI (range U-1U5)t"
"22340";"SELENA-SLEDAI >10, %"
"22341";"SELENA-SLEDAI activity, n (%)"
"22342";"SELENA-SLEDAI mean score (SD)"
"22343";"SELENA-SLEDAI total score"
"22344";"Selexipag"
"22345";"Selexipag (N = 122)"
"22346";"Selexipag (N = 179)"
"22347";"Selexipag (N = 55)"
"22348";"Selexipag (N = 574)"
"22349";"Selexipag patients/events n"
"22350";"Selexipag vs placebo Hazard ratio (95% Cl)"
"22351";"Self-rated health status"
"22352";"Self-reported descent, n (%)"
"22353";"Semaglutide"
"22354";"Semaglutide (N = 1648)"
"22355";"Semaglutide 0.5 mg"
"22356";"Semaglutide 1.0 mg"
"22357";"Semaglutide exposure, nmol/L"
"22358";"Semuloparin (N = 1608)"
"22359";"Sensitive"
"22360";"Sensitive Responder (N=1711)"
"22361";"sensitive responders (n=1366)"
"22362";"Sensitivity analyses"
"22363";"Sensorimotor stroke"
"22364";"Septal anomaly — no. (%)"
"22365";"Serious"
"22366";"Serious adverse events"
"22367";"Serious AE"
"22368";"Serious AEs"
"22369";"Serious decline in kidney function*"
"22370";"Serious decline in kidney function1"
"22371";"Serious GI disorder"
"22372";"Serious infections"
"22373";"Serious TEAEs"
"22374";"SERMs"
"22375";"Seronegative (RF -ve and ACPA -ve) subgroup"
"22376";"Seropositive (RF +ve and/or ACPA +ve) subgroup"
"22377";"Seropositivity"
"22378";"Seropositivity status, n"
"22379";"Sertraline"
"22380";"Serum"
"22381";"Serum 25-hydroxyvitamin D, ng/mL"
"22382";"Serum 25(OH)D concentrations, ng/mL, mean (SD)"
"22383";"Serum albumin-adjusted calcium (mg/dL)"
"22384";"Serum albumin concentration, g/l"
"22385";"Serum albumin, g 1 1"
"22386";"Serum albumin, g/dl"
"22387";"Serum albumin, g/l"
"22388";"Serum biochemistry Potassium, mmol/L"
"22389";"Serum bone-specific alkaline"
"22390";"Serum C-terminal telopeptide of"
"22391";"Serum calcium, mmol/l"
"22392";"Serum cholesterol — mmol/liter"
"22393";"Serum cholesterol (mg/L)*"
"22394";"Serum cholesterol, mean (sd) mg/dl"
"22395";"Serum cholesterol, mean (SD), mg/dL"
"22396";"Serum cholesterol, median (IQR), mg/dL"
"22397";"Serum cholesterol, mg/dL"
"22398";"Serum cholesterol, mg/dld"
"22399";"Serum creatinine"
"22400";"Serum creatinine - mean (sd, N)"
"22401";"Serum creatinine — mg/dl"
"22402";"Serum creatinine — mg/dl||"
"22403";"Serum creatinine — mg/dl§"
"22404";"Serum creatinine — pmol/liter"
"22405";"Serum creatinine (gmol/)"
"22406";"Serum creatinine (mg/dl)"
"22407";"Serum creatinine (mg/dL)"
"22408";"Serum creatinine (mmol/L)"
"22409";"Serum creatinine (pmol/L), mean (SD)"
"22410";"Serum creatinine >130 /xmol/l, n (%)||"
"22411";"Serum creatinine >130 Mmol/L, n (%)"
"22412";"Serum creatinine >130 pmol/l. n (%) |"
"22413";"serum creatinine concentration and randomization to losartan"
"22414";"Serum creatinine level"
"22415";"Serum creatinine level, mean (SD), mg/dL"
"22416";"Serum creatinine, /xmol/l||"
"22417";"Serum creatinine, ^mol/l"
"22418";"Serum creatinine, ≥2.5 mg/dL"
"22419";"Serum creatinine, ≥3.0 mg/dL"
"22420";"Serum creatinine, μmol/l"
"22421";"Serum creatinine, gmol/'L, mean (SD)"
"22422";"Serum creatinine, gmol/l |"
"22423";"Serum creatinine, Limo 1 1"
"22424";"Serum creatinine, mean (sd) mg/dl"
"22425";"Serum creatinine, mean (SD), mg/dL"
"22426";"Serum creatinine, mean (SD), pmol/L"
"22427";"Serum creatinine, mg/dl"
"22428";"Serum creatinine, mg/dL"
"22429";"Serum creatinine, mg/dL, mean (SD)"
"22430";"serum creatinine, mg/dlb"
"22431";"Serum creatinine, umol/Lf"
"22432";"Serum creatinine,弘mol儿||"
"22433";"Serum Creatinine. mg/dL"
"22434";"Serum CTX-1, ng/mL, median (IQR)"
"22435";"Serum CTX (ng/ml)"
"22436";"Serum CTX I (ng/mL)"
"22437";"Serum FG, mg/dL"
"22438";"Serum gastrinT, pg/mL"
"22439";"Serum glucose (mmol/L)"
"22440";"Serum glucose(mg/dl)"
"22441";"Serum haemoglobin A1c concentration (%), mean (SD)"
"22442";"Serum HDL cholesterol (mmol/L), mean (SD)"
"22443";"Serum K+ Level and Drug Treatment"
"22444";"Serum LDL cholesterol"
"22445";"Serum Mg <0.74 mmol/L (hypomagnesemia)"
"22446";"Serum Mg >0.74 mmol/L (normal Mg/hvpermagnesemia)"
"22447";"Serum N-propeptide of type 1 collagen,"
"22448";"Serum P1NP (^g/liter)"
"22449";"Serum pepsinogen I/IIT"
"22450";"Serum phosphate, mmol/l"
"22451";"Serum potassium — mmol/liter"
"22452";"Serum potassium (mmol/L)"
"22453";"Serum potassium 一mmol/liter"
"22454";"Serum potassium level, mean (SD), mEq/L"
"22455";"Serum potassium, >5.5 mmol/L"
"22456";"Serum potassium, >6.0 mmol/L"
"22457";"Serum potassium, mean (sd) mmol/l"
"22458";"Serum potassium, mEq/L"
"22459";"Serum potassium: <4.18mmol/L (n=729)"
"22460";"Serum sodium — mEq/liter"
"22461";"Serum sodium — mmol/liter"
"22462";"Serum sodium, mEq/l"
"22463";"Serum sodium, mEq/L"
"22464";"Serum Sodium. mEq/L"
"22465";"Serum total cholesterol (mmol/L), mean (SD)"
"22466";"Serum total cholesterol, mmol/l (SD)"
"22467";"Serum total IgE, IU/mL"
"22468";"Serum TRAP-5b (U/liter)"
"22469";"Serum triglycerides — mmol/liter"
"22470";"Serum triglycerides — pmol/liter"
"22471";"Serum triglycerides, mg/dle"
"22472";"Serum urate (mg/dL)"
"22473";"Serum Urate (mg/dL)"
"22474";"Serum urate (mg/dl), n (%)"
"22475";"Serum Urea Nitrogen, mg/dL"
"22476";"Serum uric acid (mg/dL)"
"22477";"serum uric acid, difference vs placebo (95% Cl)"
"22478";"serum uric acid, N"
"22479";"Serum values"
"22480";"Serum values^"
"22481";"Serum vitamin D (nmol/L)"
"22482";"SES-CD, mean (SD)"
"22483";"SeSBP"
"22484";"SeSBP (mmHg) [mean - SD]d"
"22485";"SeSBP (mmHg) [mean _SD]a"
"22486";"severe"
"22487";"Severe"
"22488";"Severe (<30 mL·min−1·1.73 m−2), n (%)"
"22489";"Severe (>16)"
"22490";"Severe (>20)"
"22491";"Severe (FEV, <30% predicted)"
"22492";"Severe (GOLD 3)"
"22493";"Severe (IIEF-EF <10)"
"22494";"Severe (IIEF-EF 1-10), n (%)"
"22495";"Severe (IPSS > 20)"
"22496";"Severe (IPSS > 20) Age group"
"22497";"Severe (IPSS >20)"
"22498";"Severe (IPSS >20) (n = 185)"
"22499";"Severe (ITT) (n=1257)"
"22500";"Severe (ITT) (n=1265)"
"22501";"Severe (ITT) (n=1270)"
"22502";"Severe (ITT) (n=1274)"
"22503";"Severe (ITT) (n=1676)"
"22504";"Severe (ITT) (n=1694)"
"22505";"Severe (N1 = 115)"
"22506";"Severe (N1 = 56)"
"22507";"Severe AEs"
"22508";"Severe COPD"
"22509";"Severe COPDc [N Z 140]"
"22510";"Severe CORD*: QVAI49-SFC"
"22511";"Severe disease"
"22512";"Severe ED"
"22513";"Severe episodes in previous year — no./patient"
"22514";"Severe exacerbations"
"22515";"Severe exacerbations, ITT population; n (%)"
"22516";"Severe Hyperkalemia'S"
"22517";"Severe Hyperkalemia‘s"
"22518";"Severe Hyperkalemiac"
"22519";"Severe hypoglycemia"
"22520";"Severe impairment    (eGFR <30)"
"22521";"Severe impairment (<30)"
"22522";"Severe impairment (eGFR <30 mL/min/m^)"
"22523";"Severe impairment (eGFR <30)"
"22524";"Severe impairment (eGFR <30), N (%)"
"22525";"Severe n Z 1932"
"22526";"Severe OA symptoms at baselined"
"22527";"Severe OAB subgroup"
"22528";"Severe or moderate"
"22529";"Severe or very severe"
"22530";"Severe or very severe COPD"
"22531";"Severe or very severe Smoking status"
"22532";"Severe or worse airflow limitation"
"22533";"Severe recurrent ischemia"
"22534";"Severe renal impairment"
"22535";"Severe TEAEs"
"22536";"Severe to end-stage impairment (530 mL/min)"
"22537";"Severe, GOLD 3"
"22538";"Severe, n (%)b"
"22539";"Severe/life threatening"
"22540";"Severe/life ttireatening"
"22541";"Severe/lite threatening"
"22542";"Severe/Moderate"
"22543";"Severe/very severea"
"22544";"Severely impaired"
"22545";"SEVERITY"
"22546";"Severity n (%)"
"22547";"Severity of airflow limitation"
"22548";"Severity of airflow limitation (GOLD 2011-2014), n (%)"
"22549";"Severity of airflow limitation (GOLD 2013), n (%)"
"22550";"Severity of airflow obstruction"
"22551";"Severity of COPD"
"22552";"Severity of COPD — no. (%)f"
"22553";"Severity of COPD*, n (%)"
"22554";"Severity of COPD, (GOLD 20087), %"
"22555";"Severity of COPD, airflow limitation, n (%)"
"22556";"Severity of COPD, combined assessment, n (%)"
"22557";"Severity of COPD, n (%) (GOLD 2008): Moderate"
"22558";"Severity of COPD, n (%)*"
"22559";"Severity of COPDa, Airflow Limitation, n (%)"
"22560";"Severity of COPDa, Combined Assessment of COPD, n (%)"
"22561";"Severity of heartburnb"
"22562";"Severity of hypertensionb"
"22563";"Severity of the disease (GOLD 2008), n (%)"
"22564";"Severity ofCOPD (GOLD2015),n (%)"
"22565";"Severity ofhypertension [n (%)]b"
"22566";"Severitya"
"22567";"sex"
"22568";"Sex"
"22569";"Sex— no. (%)"
"22570";"Sex—No. (%)"
"22571";"Sex — no. (%)"
"22572";"Sex — no./total no. (%)"
"22573";"Sex (%)"
"22574";"Sex (female)"
"22575";"Sex (Female)"
"22576";"Sex (Interaction: p=0.59)"
"22577";"Sex (male)"
"22578";"Sex (male)- no. (%)"
"22579";"Sex (male) Ethnic origin"
"22580";"Sex (male), %"
"22581";"Sex (male), n (%)"
"22582";"Sex (male, %)"
"22583";"Sex (male/female)"
"22584";"Sex (male/female) (n)"
"22585";"Sex (men/women)"
"22586";"Sex (no.)"
"22587";"Sex (p=050)"
"22588";"Sex (women, men)"
"22589";"Sex (women, n [%])"
"22590";"Sex M/F"
"22591";"Sex, %"
"22592";"Sex, % female"
"22593";"Sex, % male"
"22594";"Sex, female"
"22595";"Sex, Female"
"22596";"Sex, female, %"
"22597";"Sex, female, n (%)"
"22598";"Sex, female, n (%)"
"22599";"Sex, male"
"22600";"Sex, Male"
"22601";"Sex, male, n (%)"
"22602";"Sex, male, no. (%)"
"22603";"Sex, male/female, %"
"22604";"Sex, men (%)"
"22605";"Sex, men/women, %"
"22606";"Sex, n (%)"
"22607";"Sex, n (%) Male"
"22608";"Sex, n (%)*"
"22609";"Sex, n (%)b"
"22610";"Sex, No, (%)"
"22611";"Sex, no. (%)"
"22612";"Sex, No. (%)"
"22613";"Sex, no. (%) male"
"22614";"Sex:"
"22615";"Sex: female"
"22616";"Sex: male"
"22617";"Sex: Male"
"22618";"Sex: Male (n=1094)"
"22619";"Sexa Male"
"22620";"Sexually active"
"22621";"Sexually active with female"
"22622";"Sexually active1 (%)"
"22623";"Sexy"
"22624";"SF-12 MCS score"
"22625";"SF-12 PCS score"
"22626";"SF-36 (health transition score)"
"22627";"SF-36 bodily pain, mean change from baselineb"
"22628";"SF-36 bodily pain, mean change from baselinee"
"22629";"SF‐36 health survey"
"22630";"SF-36 MCS"
"22631";"SF-36 PCS"
"22632";"SF‐36 PCS, LS mean change ± SE"
"22633";"SF-36 PCS, LS mean change from baseline ± SE"
"22634";"SF-36 physical component summaryJJ"
"22635";"SF-36 score"
"22636";"SF-36 summary scores"
"22637";"SF-36v2 domain scores, mean [SD]"
"22638";"SF-36v2 MCS, mean [SD]"
"22639";"SF-36v2 PCS, mean [SD]"
"22640";"SF36-PCS"
"22641";"SFC"
"22642";"SFC (n [1546)"
"22643";"SFC (n = 1240)"
"22644";"SFC (n = 1,392)"
"22645";"SFC (n[546)"
"22646";"SFC 50 mg/500 mg"
"22647";"SFC 50/500 |ig bid n=369"
"22648";"SFC 50/500 mg Twice Daily (n = 1,005)"
"22649";"SFC 50/500 mg Twice Daily (n = 672)"
"22650";"SFC 50/500 pg twice daily (n=264)"
"22651";"SFC50/500 pg b.i.d. n = 297"
"22652";"SGLT-2 inhibitors^"
"22653";"SGRQ-C total scoreb"
"22654";"SGRQ Responder (%)"
"22655";"SGRQ score, mean (SD)"
"22656";"SGRQ Scores, mean (SD)"
"22657";"SGRQ total score"
"22658";"SGRQ Total Score"
"22659";"SGRQ total score (units)"
"22660";"SGRQ total score (units):!:"
"22661";"SGRQ total score (week"
"22662";"SGRQ total score* (units)"
"22663";"SGRQ total score**"
"22664";"SGRQ total score1"
"22665";"Shared epitope,a % positive"
"22666";"SHFM Annual Mortality"
"22667";"Short-acting"
"22668";"Short-acting anticholinergics"
"22669";"Short-acting b2-agonists"
"22670";"Short (<10 years) duration of diabetes"
"22671";"Short (<10 years) Duration of Diabetes"
"22672";"Short Form 36 (SF-36)"
"22673";"Short term (n = 321)+"
"22674";"Short term^"
"22675";"SHS (0-440; per 10 score)"
"22676";"SHS, mean ± SD"
"22677";"SHS, mean 6 SD"
"22678";"Si.gni.fi.canr ECG changes, positive biomarkers, and age <60 vrs"
"22679";"Significant worsening in KCCQ clinical"
"22680";"Significant worsening in KCCQ clinical score (≥5) at 8 mo†"
"22681";"Significant worsening in KCCQ clinical score (>5) at 8 months3"
"22682";"Sildenafil (n = 189)"
"22683";"Silodosin 8 mg (n = 381)"
"22684";"Simple partial (IA)"
"22685";"Simplified disease activity index"
"22686";"Simplified Disease Activity Index"
"22687";"Simplified Disease Activity Index score"
"22688";"Simplified Disease Activity Index score (0-86)"
"22689";"Simva"
"22690";"SIMVA"
"22691";"Simva (%)"
"22692";"SIMVA („ = 1234}"
"22693";"SIMVA (n = 1234)"
"22694";"Simva N=346 n (%)"
"22695";"Simva N=8728 n (%)"
"22696";"Simvastatin"
"22697";"Simvastatin (40/80 mg/d)"
"22698";"Simvastatin (40/80 mg/d) (n = 2265)"
"22699";"Simvastatin (n = 24)"
"22700";"Simvastatin (n=6. 9)"
"22701";"Simvastatin (n=7, 9)"
"22702";"Simvastatin 20 mg (n = 189)*"
"22703";"Simvastatin 20 mg Plus Fenofibrate 160 mg (n = 388/"
"22704";"Simvastatin 40 mg"
"22705";"Simvastatin 40 mg (n = 4,380)"
"22706";"Simvastatin 40 mg (n = 69)"
"22707";"Simvastatin 60 mg"
"22708";"Simvastatin 80 mg"
"22709";"Simvastatin Monotherapy (n = 1,031*)"
"22710";"Simvastatin, n (%)"
"22711";"Since diagnosis"
"22712";"Since onset"
"22713";"Single"
"22714";"Single-vessel disease"
"22715";"Single-vessel disease, n (%)"
"22716";"Single vessel coronary artery disease*"
"22717";"Single vessel coronary artery disease†"
"22718";"Single vessel coronary artery disease1"
"22719";"Single vessel coronary artery diseasea"
"22720";"Single vessel PCI"
"22721";"Sinus rhythm"
"22722";"Sinus rhythm at baseline"
"22723";"Sinus tracts/perforation,'^ n (%)"
"22724";"Sinusitis"
"22725";"SIRIUS"
"22726";"Sirolimus"
"22727";"Sirolimus-eluting"
"22728";"Sirolimus-eluting stent use, n (%)"
"22729";"Sirukumab 100 mg q2w"
"22730";"Sirukumab 50 mg q4w"
"22731";"SITA 100"
"22732";"SITA 100 mg (n = 378)"
"22733";"SITA 100 mg (n = 649)"
"22734";"SITA 100 mg (n = 744)"
"22735";"SITA 100+ PIO 15"
"22736";"SITA 100+ PIO 30"
"22737";"SITA 100+ PIO 45"
"22738";"SITA/PIO 100/15"
"22739";"SITA/PIO 100/30"
"22740";"SITA/PIO 100/45"
"22741";"Sitagliptin"
"22742";"Sitagliptin    218"
"22743";"Sitagliptin    265"
"22744";"Sitagliptin    62    11.0 士 2.6 2-h Postprandial Plasma Glucose (PPG) (mmol/L)"
"22745";"Sitagliptin    62    8.5 士 0.9 Fasting Plasma Glucose (FPG) (mmol/L)"
"22746";"Sitagliptin (n = 352)"
"22747";"Sitagliptin (n=111)"
"22748";"Sitagliptin (n=132)"
"22749";"Sitagliptin (n=243)"
"22750";"Sitagliptin (n=249)"
"22751";"Sitagliptin ± OAD"
"22752";"Sitagliptin 100 mg N = 122"
"22753";"Sitagliptin 100 mg N = 128"
"22754";"Sitagliptin 100 mg N = 191"
"22755";"Sitagliptin 100 mg N=157"
"22756";"Sitagliptin 100mg N = 185"
"22757";"Sitagliptin 288"
"22758";"Sitagliptin 291"
"22759";"Sitagliptin 292"
"22760";"Sitagliptin 296"
"22761";"Sitagliptin 314"
"22762";"Sitagliptin 315"
"22763";"Sitagliptin 317"
"22764";"Sitagliptin N=7332"
"22765";"Sitagliptin No./Total No."
"22766";"Site"
"22767";"Site of disease — no. (%)"
"22768";"Sites"
"22769";"Sitting blood pressure — mmHg"
"22770";"Sitting diastolic blood pressure (mm Hg)"
"22771";"Sitting pulse, bpma"
"22772";"Sitting systolic blood pressure (mm Hg)"
"22773";"Six-minute walk distance, m"
"22774";"six-study placebo-controlled set"
"22775";"Size (cm2) (mean ± standard deviation)"
"22776";"Size of left atrium normal — no. (%)£"
"22777";"SJC"
"22778";"SJC (/28 joints)"
"22779";"SJC (0-76), mean (SD)"
"22780";"SJC (28 joints)"
"22781";"SJC (28 joints), mean (SD)"
"22782";"SJC (76 joints)"
"22783";"SJC, 0-28"
"22784";"SJC, mean (SD)"
"22785";"sk .89"
"22786";"Skull, and facial bone fractures"
"22787";"sl35 mm Hg"
"22788";"SLE markers, n (%)"
"22789";"Sleep"
"22790";"Sleeping problems in the past 2 weeks (%)"
"22791";"slO days"
"22792";"Slowest third"
"22793";"Small-artery occlusion"
"22794";"Small-artery occlusion (lacune)"
"22795";"Small vessel"
"22796";"Small/medium"
"22797";"sMedian prednisone dose, n (%)"
"22798";"SMI:"
"22799";"SMMSE"
"22800";"SMMSE < 20"
"22801";"smoker"
"22802";"Smoker"
"22803";"Smoker (%)"
"22804";"Smoker (%)a"
"22805";"Smoker (current/former)"
"22806";"Smoker at baseline"
"22807";"Smoker or ex-smoker, n (%)"
"22808";"smoker, %"
"22809";"Smoker, n (%)"
"22810";"Smoker,! n (%)"
"22811";"Smokers"
"22812";"Smokers (at baseline)"
"22813";"Smokers, %"
"22814";"Smokers, n (%)"
"22815";"Smokers, no. (%)"
"22816";"Smokers, No. (%)"
"22817";"Smokers: QVA149-5FC"
"22818";"Smoking"
"22819";"Smoking'!'"
"22820";"Smoking—current"
"22821";"Smoking (%)"
"22822";"smoking (%) Laboratory parameters"
"22823";"Smoking (A)"
"22824";"Smoking (current)"
"22825";"Smoking (during the previous month)"
"22826";"Smoking (ever)"
"22827";"Smoking classification, n (%)"
"22828";"Smoking consumption pack-years"
"22829";"Smoking habit, n (%)"
"22830";"Smoking history"
"22831";"Smoking history — no. (%)"
"22832";"Smoking history (ever)"
"22833";"Smoking history (pack-years)"
"22834";"Smoking history (pack-years)∗"
"22835";"Smoking history (pack-yr)"
"22836";"Smoking history,"
"22837";"Smoking history, n (%)"
"22838";"Smoking History, n (%)"
"22839";"Smoking history, pack-years"
"22840";"Smoking history, pack-years, mean (SD)"
"22841";"Smoking history, r (%)"
"22842";"Smoking history, n (%)"
"22843";"Smoking history: current smoker"
"22844";"Smoking history: ex-smoker"
"22845";"Smoking in past yr"
"22846";"Smoking in the past year"
"22847";"Smoking index — pack-yr§"
"22848";"Smoking pack-years"
"22849";"smoking pack-yearsa"
"22850";"Smoking pack-yearsb, n (%)"
"22851";"Smoking pack year (years)^"
"22852";"Smoking pack year (years)fl"
"22853";"Smoking Past"
"22854";"Smoking status"
"22855";"Smoking Status"
"22856";"Smoking status—no. {%)"
"22857";"Smoking status — no. (%)"
"22858";"Smoking status — no. {%)"
"22859";"Smoking status (%)"
"22860";"Smoking status (ongoing) (n)"
"22861";"Smoking status (previous) (n)"
"22862";"Smoking status at screening"
"22863";"Smoking status at screening, n (%)"
"22864";"Smoking status Current"
"22865";"Smoking status Current smoker (n = 132)"
"22866";"Smoking status*"
"22867";"Smoking status, n (%)"
"22868";"Smoking status, n (%) Former"
"22869";"Smoking status, n (%)*"
"22870";"Smoking status, n [%]®"
"22871";"Smoking status, no. (%)"
"22872";"Smoking status. No. (%)"
"22873";"Smoking*"
"22874";"Smoking* (> 10 pack-years)"
"22875";"Smoking, %"
"22876";"Smoking, % current"
"22877";"Smoking, mean"
"22878";"Smoking, N (%)"
"22879";"Smoking: current smoker"
"22880";"Smoking: ex-smoker"
"22881";"Smokingb"
"22882";"Smokinq status"
"22883";"SNP"
"22884";"SO"
"22885";"SO 0%"
"22886";"SOC"
"22887";"SOCAlone (N = 1602)"
"22888";"Social function"
"22889";"Social functioning"
"22890";"Social interaction"
"22891";"Sodium"
"22892";"Sodium-glucose cotransporter 2 inhibitor"
"22893";"Sodium, mEq/l"
"22894";"SOE or SUE"
"22895";"Sokoiow-Lyon voitage, mV"
"22896";"Sokolow-Lyon (mm)*"
"22897";"Sokolow-Lyon voltage, mm"
"22898";"Sokolow-Lyon, mm"
"22899";"Sokolow–Lyon voltage (mV)"
"22900";"Solifenacin (n = 357)"
"22901";"Solifenacin (n = 84)"
"22902";"Some"
"22903";"Some college"
"22904";"Some college/tech"
"22905";"Some physical activity"
"22906";"Some walking"
"22907";"Some Walking"
"22908";"Somnolence"
"22909";"Sonti Amenca"
"22910";"Sotagliflozin"
"22911";"Sotagliflozin (N=699)"
"22912";"Sotagliflozin 200 mg (n=261)"
"22913";"Sotagliflozin 400 mg (n=263)"
"22914";"Sotalol"
"22915";"Sou ti Africa"
"22916";"Source"
"22917";"South Africa"
"22918";"South Africa/South America"
"22919";"South America"
"22920";"South America (%)"
"22921";"South America (n=776)"
"22922";"South American"
"22923";"South Asia"
"22924";"South Asian"
"22925";"South or Central America"
"22926";"South or Central American"
"22927";"South! Central America"
"22928";"South, n (%)"
"22929";"Southern Europe"
"22930";"Southern hemisphere"
"22931";"Spacer use during the study"
"22932";"Spain"
"22933";"Spain (n=366)"
"22934";"Special interest categories"
"22935";"Specific risk of bleeding^"
"22936";"Specific syndromes"
"22937";"sPGA >4"
"22938";"Spinal"
"22939";"Spinal fractures"
"22940";"Spine"
"22941";"Spine*"
"22942";"Spiralcomputedtomographyangiography"
"22943";"Spirometric values at baseline"
"22944";"Spirometry"
"22945";"Spirometry after bronchodilation§"
"22946";"Spirono (n=121)"
"22947";"Spirono (n=50)"
"22948";"Spirono (n=71)"
"22949";"Spironolactone"
"22950";"Spironolactone (N = 1722)"
"22951";"Spironolactone(N=836)"
"22952";"Spironolactone(n=886)"
"22953";"spironolactone, n (%)"
"22954";"Spironolactone, n (%)"
"22955";"Spoke"
"22956";"Spondylitis"
"22957";"Spondylitis with peripheral arthritis"
"22958";"SPRINT ACR <3-4"
"22959";"SPRINT ACR >3-4"
"22960";"Squamous cell carcinoma"
"22961";"Sr ii B 5- CJl 3"
"22962";"SRI‐4 response rate, %"
"22963";"SRI response, %"
"22964";"β-blocker"
"22965";"β‐Blocker"
"22966";"β-Blocker"
"22967";"β-Blockers"
"22968";"SS >10(n=352vs 168)"
"22969";"SS at baseline"
"22970";"β blocker"
"22971";"β blockers"
"22972";"SS years"
"22973";"SS<9(n=202vs111)"
"22974";"ssed as LS means"
"22975";"ssi-4"
"22976";"sso-9"
"22977";"SSOmgdayP.Eq."
"22978";"SSS score"
"22979";"SSZ+MTX (n = 95)"
"22980";"ST"
"22981";"ST-"
"22982";"ST-2 (ng/ml)"
"22983";"ST-depression and T-wave inversion"
"22984";"ST-depression only"
"22985";"ST-elevation MI"
"22986";"ST-elevation myocardial infarction"
"22987";"ST-segment-elevation myocardial infarction — no. (%)"
"22988";"ST-segment—elevation myocardial infarction"
"22989";"ST-segment depression"
"22990";"ST-segment depression <0.1 mV, %"
"22991";"ST-segment depression >0.1 mV"
"22992";"ST-segment depression >0.1 mV on admission, %"
"22993";"ST-Segment Depression >1 mm"
"22994";"ST-segment depression >1 mm — no. (%)"
"22995";"ST-segment depression or T-wave inversion on ECG"
"22996";"ST-segment deviation >1 mm — no./total no. (%)"
"22997";"ST-segment deviation TIMI risk score, %"
"22998";"ST-segment elevation"
"22999";"ST-segment elevation MI"
"23000";"ST-Segment Elevation MI"
"23001";"ST-segment elevation myocardial infarction"
"23002";"ST‐STR ≥70% post PCI"
"23003";"ST‐STR ≥70% pre‐ CI"
"23004";"ST-T wave"
"23005";"ST-T wave abnormality d"
"23006";"ST-T wave changes"
"23007";"ST-T Wave, n (%)"
"23008";"ST-T wave, No. (%)"
"23009";"ST-T waveft"
"23010";"ST-T wavett"
"23011";"ST (ARC definite only)"
"23012";"ST change >1 mm"
"23013";"ST depression (without ST elevation)"
"23014";"ST depression >1 mm"
"23015";"ST Depression or Elevation"
"23016";"ST elevation"
"23017";"St George's Respiratory Questionnaire total score!"
"23018";"ST segment depression"
"23019";"ST segment elevation"
"23020";"ST/T wave"
"23021";"ST+"
"23022";"Stable angina"
"23023";"Stable Angina"
"23024";"Stable angina — no. (%)"
"23025";"Stable Angina (n - 6,358)"
"23026";"Stable Angina (n = 6,358)"
"23027";"Stable angina, n (%)"
"23028";"Stable coronary artery disease"
"23029";"Stage >3 chronic kidney disease (%)"
"23030";"Stage 1"
"23031";"Stage 1 CKD eGFR > 90 mL/ (N=842)"
"23032";"Stage 1: >90 ml/min/1.73 m2"
"23033";"Stage 2"
"23034";"Stage 2 CKD eGFR 60 to 89 mL/min (N=4069)"
"23035";"Stage 2: >=60"
"23036";"Stage 2: 60 -89 ml/min/1.73 m2"
"23037";"Stage 3"
"23038";"Stage 3 CKD eGFR 30 to 59 mL/min (N = 2817)"
"23039";"Stage 3: 30-59 ml/min/1.73 m2"
"23040";"Stage 3a"
"23041";"Stage 3A CKD cohort (post hoc analysis excluding metformin users)"
"23042";"Stage 3A CKD cohort (secondary analysis)"
"23043";"Stage 3A: >=45 and <60"
"23044";"Stage 3a: 45 -59 ml/min/1.73 m2"
"23045";"Stage 3A: eGFR >=45 and <60 ml/min per 1.73 m2"
"23046";"Stage 3b"
"23047";"Stage 3B: >=30 and <45"
"23048";"Stage 3b: 30-44 ml/min/1.73 m2"
"23049";"Stage 3B: eGFR >=30 and <45 ml/min per 1.73 m2"
"23050";"Stage 4"
"23051";"Stage 4 CKD eGFR 15 to 29 mL/min (N = 73)"
"23052";"Stage 4: <30"
"23053";"Stage 4: 15 -29 ml/min/1.73 m2"
"23054";"Stage 5: <15 ml/min/1.73 m2"
"23055";"Stage I (GFR >90 ml/min per 1.73 m2) and stage V (GFR <15 ml/min per 1.73 m2) were not considered because they included only 0 and 1 patient, respectively. CHF, congestive"
"23056";"Stage II"
"23057";"Stage III"
"23058";"Stage IV"
"23059";"Stage of PDa"
"23060";"Stalin"
"23061";"Standard"
"23062";"Standard (3)"
"23063";"Standard (8)"
"23064";"Standard (N = 247)"
"23065";"Standard (n=2162)"
"23066";"Standard (n=3367)"
"23067";"Standard allocation"
"23068";"Standard BP Lowering, <140 mm Hg (n=2177)"
"23069";"Standard care"
"23070";"Standard Care"
"23071";"Standard Care (n=558)"
"23072";"Standard care (n=5874)"
"23073";"Standard Care Allocation"
"23074";"Standard Care N (%)"
"23075";"Standard Care N (%)    /100py"
"23076";"Standard Care N(%)    /100py"
"23077";"Standard Care Slope LSM ± SE (mm/year)"
"23078";"Standard Control"
"23079";"Standard Control (N=5569)  No.of patients (percent)"
"23080";"Standard therapy"
"23081";"Standard Therapy (N = 5123)"
"23082";"Standard Therapyy (N = 1718)"
"23083";"Standard Treatment (n - 801)"
"23084";"Standardized Mean Difference"
"23085";"Standardized total hip BMD (g/cm2)"
"23086";"Standing after 1 minute Change from baseline"
"23087";"Standing after 3 minutes Change from baseline"
"23088";"State"
"23089";"Statin"
"23090";"Statin — no./total no. (%)"
"23091";"Statin (%)"
"23092";"Statin (n - 252)"
"23093";"Statin (n = 252)"
"23094";"statin (n=137)"
"23095";"statin (n=84)"
"23096";"Statin (open)"
"23097";"Statin + Ezetimibe"
"23098";"Statin + ezetimibe (n=125. 65)"
"23099";"Statin + ezetimibe {n=120, 62)"
"23100";"Statin + ezetimibe, n (%)"
"23101";"Statin + fibrate or"
"23102";"Statin + Fibrate or Niacin"
"23103";"Statin alone"
"23104";"Statin and/or ezetimibe"
"23105";"Statin and/or other lipid-lowering agent therapy"
"23106";"Statin at enrollment"
"23107";"Statin at last follow-up"
"23108";"Statin during admission"
"23109";"Statin group"
"23110";"Statin intensity per ACC/AHAC"
"23111";"Statin intensity1*8"
"23112";"Statin intolerance8, n (%)"
"23113";"Statin intolerant*"
"23114";"Statin medication"
"23115";"Statin monotherapy"
"23116";"Statin non-users (N=348)"
"23117";"Statin only"
"23118";"Statin only (n=32, 19)"
"23119";"Statin only (n=35,19)"
"23120";"Statin only, n (%)"
"23121";"Statin or ezetimibe"
"23122";"Statin or Ezetimibe"
"23123";"Statin potency Medium (N=582)"
"23124";"Statin potency stratum, n (%)"
"23125";"Statin therapy"
"23126";"Statin treatment"
"23127";"Statin usage"
"23128";"Statin use"
"23129";"Statin Use"
"23130";"Statin use — no. {%)"
"23131";"Statin use (%)"
"23132";"Statin use at baseline"
"23133";"Statin Use at Baseline:"
"23134";"Statin use at study entry, n (%)"
"23135";"Statin use, n (%)"
"23136";"Statin users"
"23137";"Statin users (N=276)"
"23138";"Statin with ezetimibe"
"23139";"Statin with fibrate"
"23140";"Statin with niacin"
"23141";"Statin with other LLT"
"23142";"Statin without other LLT"
"23143";"Statin(s)"
"23144";"Statin, % (n)"
"23145";"Statin, n (%)"
"23146";"Statin+ER Niacin (n=1034)"
"23147";"Statin+ER Niacin (n=1718)"
"23148";"Statin+Placebo (n=1020)"
"23149";"Statin+Placebo (n=1696)"
"23150";"Stating"
"23151";"Statini"
"23152";"Statins"
"23153";"Statins 一 no. (%)"
"23154";"Statins used during follow-up"
"23155";"Statins, n (%)"
"23156";"Statins, No. (%)"
"23157";"Statins/ezetimibe"
"23158";"Statistic**"
"23159";"Statisticd"
"23160";"Statistics"
"23161";"status (SPMSQ <21"
"23162";"status (SPMSQ >21"
"23163";"STD N (N/lOOpy)"
"23164";"STEMI"
"23165";"STEMI (%)"
"23166";"Stenosis >50%"
"23167";"Stent"
"23168";"Stent (n = 459)"
"23169";"Stent (n=199)"
"23170";"Stent (n=209)"
"23171";"Stent (n=51)"
"23172";"Stent diameter $3 mm"
"23173";"Stent diameter < 3 mm"
"23174";"Stent group (n=81)"
"23175";"Stent implanted"
"23176";"Stent length per lesion, mm"
"23177";"Stent plus abciximab"
"23178";"Stent plus Medical Therapy"
"23179";"Stent plus placebo"
"23180";"Stent thrombosis"
"23181";"Stent Thrombosis"
"23182";"Stent Thrombosis-Related MI"
"23183";"Stent Thrombosis ARC Definite/Probable"
"23184";"Stent thrombosis or MI"
"23185";"Stent thrombosis*"
"23186";"Stent type"
"23187";"Stented lesions"
"23188";"Stented vessel"
"23189";"Stented vessels"
"23190";"Stenting plus Medical Therapy (N=459)"
"23191";"Stents per lesion, n"
"23192";"Steroid-free CR-100"
"23193";"Steroid-free remission"
"23194";"Steroid-sparing remission*"
"23195";"Steroid use at baseline"
"23196";"Steroid use at baseline (mg/day)"
"23197";"Steroid use at baseline, n (%)"
"23198";"Steroid use, %"
"23199";"Steroids (inhaled)a"
"23200";"Steroids (n=480 vs 240)"
"23201";"Steroids (other)"
"23202";"Steroids, n (%)"
"23203";"Steroids§§"
"23204";"stiffness (min)"
"23205";"Stiffness subscale"
"23206";"Still taking alendronate at study entry, n (%)"
"23207";"Stomach"
"23208";"Stool frequency subscore"
"23209";"Storage subscore"
"23210";"Strain (%)"
"23211";"Strata modelb HR, 95% CI, P value"
"23212";"Strategy"
"23213";"Stratification factor: Menopausal status, n (%)"
"23214";"Stratification factors"
"23215";"Stratification variables"
"23216";"Stratified analyses"
"23217";"Stratified by"
"23218";"Stratified Hazard Ratio (95% CI)"
"23219";"Stratified Log-Rank P Value"
"23220";"Stratified Log-Rank P Value"
"23221";"Stratum"
"23222";"Stratum 1: inadequate response or intolerance to 1-2 bDMARDs of same MoA"
"23223";"Stratum 2: inadequate response or intolerance to >3 bDMARDs of same MoA or >2 of multiple MoA"
"23224";"Stratum I"
"23225";"Stratum II"
"23226";"Stratum*"
"23227";"Stratum, n (%)"
"23228";"Streptokinase"
"23229";"Stricturing"
"23230";"stroke"
"23231";"Stroke"
"23232";"Stroke — no. (%)"
"23233";"Stroke — no./total no. (%)"
"23234";"Stroke (fatal/nonfatal)"
"23235";"Stroke (vs TIA)"
"23236";"Stroke and TIA, n (%)"
"23237";"Stroke Any"
"23238";"Stroke at entry"
"23239";"Stroke at entry (vs transient ischemic attack)"
"23240";"Stroke deaths"
"23241";"Stroke N(%)"
"23242";"stroke n=213"
"23243";"Stroke Non-fatal"
"23244";"Stroke of any etiology"
"23245";"Stroke of atherosclerotic origin"
"23246";"Stroke of undetermined cause"
"23247";"Stroke or"
"23248";"Stroke or cerebrovascular disease"
"23249";"Stroke or PVD, (%)"
"23250";"Stroke or SE (S/SE)"
"23251";"Stroke or SEE"
"23252";"Stroke or systemic"
"23253";"Stroke or systemic embolism"
"23254";"Stroke or TIA"
"23255";"Stroke or TIA — no. (%)"
"23256";"Stroke or transient ischemic attack"
"23257";"Stroke orTIA"
"23258";"Stroke orTIAb"
"23259";"Stroke risk score"
"23260";"Stroke subtype"
"23261";"Stroke subtype, n (%)"
"23262";"Stroke thought due to atherothrombotic disease"
"23263";"Stroke, fatal and nonfatal"
"23264";"Stroke, n (%)"
"23265";"Stroke, SEE, or CV death"
"23266";"Stroke, SEE, or death"
"23267";"Stroke, total"
"23268";"Stroke/Embolism"
"23269";"Stroke/M 1"
"23270";"Stroke/M l/HF hospitalization"
"23271";"Stroke/Non-"
"23272";"Stroke/SE"
"23273";"Stroke/SEE"
"23274";"Stroke/TIA"
"23275";"Stroke/transient ischemic attack"
"23276";"StrokeZSEE"
"23277";"Structural"
"23278";"Structural heart disease"
"23279";"Structural heart disease — no. (%)f"
"23280";"Structural heart disease§"
"23281";"STSD >1 mm on admission (n = 2,246)"
"23282";"Study"
"23283";"Study 1"
"23284";"Study 1222.11"
"23285";"Study 1222.12"
"23286";"Study 1222.13"
"23287";"Study 1222.14"
"23288";"Study 2"
"23289";"Study 36-item Short-Form General Health Survey (SF-36) can range from 4 to 71 for the physical component and from 2 to 74 for the mental"
"23290";"Study drug"
"23291";"Study drug loading days (actual): 0 (n=34)"
"23292";"study druga"
"23293";"Study end concentration"
"23294";"Study eye characteristics"
"23295";"Study medication — no. (%)"
"23296";"study medication, pre-dose"
"23297";"study period Fatal PE"
"23298";"Study population"
"23299";"Study Population"
"23300";"Study treatment"
"23301";"Study treatment — no./total no. (%)"
"23302";"SU"
"23303";"SU monotherapy"
"23304";"SU Monotherapy"
"23305";"SU, n (%)"
"23306";"SU/MET"
"23307";"SU/TZD"
"23308";"SUA <9.5"
"23309";"Subacute (1-30 days)"
"23310";"Subarachnoid hemorrhage"
"23311";"Subcortical WML load diameter, mm, mean (SD)"
"23312";"Subcortical WML load diameter, mm,, mean (SD)"
"23313";"Subcutaneous (N = 194)"
"23314";"Subcutaneous injections"
"23315";"Subcutaneous unfractionated heparin"
"23316";"Subdural/epidural"
"23317";"subgoup_name"
"23318";"subgroup"
"23319";"Subgroup"
"23320";"Subgroup    1"
"23321";"Subgroup analyses"
"23322";"Subgroup analysis: Change from baseline in HbA1c at Week 26 per baseline HbA1c category"
"23323";"Subgroup based on:"
"23324";"Subgroup by treatment interaction p-value"
"23325";"subgroup level"
"23326";"Subgroup level"
"23327";"subgroup levels"
"23328";"Subgroup name/level"
"23329";"Subgroup No."
"23330";"Subgroup Overall"
"23331";"Subgroup p-value3"
"23332";"Subgroup p Value!"
"23333";"Subgroup P Value本"
"23334";"Subgroup p Valuef"
"23335";"Subgroup Sex"
"23336";"Subgroup statistics"
"23337";"Subgroup Treatment"
"23338";"Subgroup w.r.t. RE-COVER"
"23339";"subgroup_level"
"23340";"Subgroups"
"23341";"SUBGROUPt"
"23342";"Subject Characteristics"
"23343";"Subject completion status, n (%)"
"23344";"Subject disposition, N (%)"
"23345";"Subject Group"
"23346";"Subjects"
"23347";"Subjects $65 years of age, n (%)"
"23348";"Subjects (N)"
"23349";"Subjects ,65 years of age, n (%)"
"23350";"Subjects n"
"23351";"Subjects randomized"
"23352";"Subjects stratified by baseline PRA"
"23353";"Subjects who did not receive LABD prior to the study"
"23354";"Subjects who did receive LABD prior to the study"
"23355";"Subjects with imputed value for end‐of‐treatment body weight"
"23356";"Subjects with prevalent vertebral fracture, n (%) Prevalent vertebral fracture"
"23357";"Subpopulation"
"23358";"Subpopulation analyses according to baseline HbA1c"
"23359";"Subpopulation analyses according to BMI"
"23360";"subscale, and 0 to 1700 for the function subscale; normalized scores can range from 0 to 300. Scores for the Health Assessment Question-"
"23361";"Subset of patients not on metformin"
"23362";"Subset of patients on metformin"
"23363";"Subsets"
"23364";"Subtrochanteric"
"23365";"Sudden cardiac death§"
"23366";"Sudden Death"
"23367";"sufficient"
"23368";"SUIT index, nmol/mmol"
"23369";"SUIT quartile 1 (b 24.5 nmol/mmol) (n = 110)"
"23370";"SUIT quartile 2 (>24.5-<34.7 nmol/mmol) (n = 109)"
"23371";"SUIT quartile 3 (>34.7-<49.6 nmol/mmol) (n = 109)"
"23372";"SUIT quartile 4 (>49.6 nmol/mmol) (n =109)"
"23373";"Sulfasalazine"
"23374";"Sulfasalazine (mean dose: 1.69 g/day)"
"23375";"Sulfasalazine treatment"
"23376";"Sulfasalazine use at randomization"
"23377";"Sulfasalazine use at randomization, n (%)"
"23378";"Sulfonylurea"
"23379";"Sulfonylurea — no. (%)"
"23380";"Sulfonylurea based"
"23381";"Sulfonylurea derivatives"
"23382";"Sulfonylurea use at baseline"
"23383";"Sulfonylureaa"
"23384";"Sulfonylureas"
"23385";"Sulfonylureasb"
"23386";"Sulphonamides, urea derivatives"
"23387";"Sulphonylurea"
"23388";"Sulphonylureas"
"23389";"Sulphonylureas only"
"23390";"SUN-101 (25)"
"23391";"Supine after 5 minutes Change from baseline"
"23392";"Supplemental oxygen"
"23393";"Supplementary oxygen"
"23394";"Supplementary Table 3. Change from baseline in urine albumin-to-creatinine ratio by HbA1c at baseline in patients with normoalbuminuria microalbuminuria and macroalbuminuria."
"23395";"Supraventricular tachyarrhythmias (incl. atrial"
"23396";"Surgery"
"23397";"Surgical repair of VSD or PDA >1-year duration"
"23398";"Surgical technique"
"23399";"Surgical technique POST-RANDOMISATION CHARACTERISTIC**"
"23400";"Suspected myocardial infarction"
"23401";"SUSTAIN"
"23402";"SUSTAIN 1"
"23403";"SUSTAIN 1: Semaglutide vs. placebo"
"23404";"SUSTAIN 2"
"23405";"SUSTAIN 2: Semaglutide vs. sitagliptin 100 mg"
"23406";"SUSTAIN 3"
"23407";"SUSTAIN 3: Semaglutide vs. exenatide ER 2.0 mg"
"23408";"SUSTAIN 4"
"23409";"SUSTAIN 4: Semaglutide vs. IGlar"
"23410";"SUSTAIN 5"
"23411";"SUSTAIN 5: Semaglutide add‐on to insulin vs. placebo"
"23412";"Sustained decrease of >40% in eGFR®"
"23413";"Sustained ESRD, death due to kidney failure, or sustained decrease of >40% in eGFR from baseline"
"23414";"Sustained ESRD, death due to kidney failure, or sustained decrease of >50% in eGFR from baseline"
"23415";"Sustained mucosal healingc"
"23416";"Sustained mucosal healingc n/n (%)"
"23417";"Swollen"
"23418";"Swollen-joint count (of 66 joints assessed) — no."
"23419";"Swollen-joint count (of 76 joints)"
"23420";"Swollen-joint count, of 66 joints examined"
"23421";"Swollen joint count"
"23422";"Swollen joint count (0-44)"
"23423";"Swollen joint count (0-66 joints)"
"23424";"Swollen joint count (0-66 possible joints)"
"23425";"Swollen joint count (0-66)"
"23426";"Swollen joint count (0–66 joints), mean (SD)"
"23427";"Swollen joint count (0—44; per swollen joint)"
"23428";"Swollen joint count (28 joints)"
"23429";"Swollen joint count (28), mean (SD)"
"23430";"Swollen joint count (66 joints), mean (SD)"
"23431";"Swollen joint count (66 joints), mean (SD)’"
"23432";"Swollen joint count (66), mean (SD)"
"23433";"Swollen joint count (76 joints)"
"23434";"Swollen joint count (n/68)"
"23435";"Swollen joint count (range 0-66 joints)"
"23436";"Swollen joint count of 66 joints"
"23437";"Swollen joint count, of 28"
"23438";"Swollen joint count, of 66"
"23439";"Swollen joints (66-joint count), mean ± SD"
"23440";"Swollen joints >1, n (%)"
"23441";"Symbol digit score"
"23442";"Symmetric T-wave inversions"
"23443";"Symmetric T wave inversions"
"23444";"Symptom-free days in the past 2 weeks (%)"
"23445";"Symptom bother"
"23446";"Symptom duration"
"23447";"Symptom duration, months"
"23448";"Symptom Onset"
"23449";"Symptom onset-to-"
"23450";"Symptom onset-to-randomization"
"23451";"Symptom onset to arrival in catheterization laboratory"
"23452";"Symptom onset to enrollment"
"23453";"Symptom onset to first medical contact: ambulance or emergency department"
"23454";"Symptom onset to hospital admission"
"23455";"Symptom onset to hospital arrival, hours"
"23456";"Symptom onset to hospital arrival, median (IQR), h"
"23457";"Symptom onset to hospitalization"
"23458";"Symptom onset to PCI, h"
"23459";"Symptom onset to randomization"
"23460";"Symptom onset to start of reperfusion treatment: tenecteplase or arterial sheath insertion!"
"23461";"Symptom score (SD)"
"23462";"Symptomatic"
"23463";"Symptomatic deep-vein thrombosis"
"23464";"Symptomatic heart fail"
"23465";"Symptomatic hypoglycaemia"
"23466";"Symptomatic hypotension"
"23467";"Symptomatic Hypotension"
"23468";"Symptomatic hypotension (SBP <90 mmHg)"
"23469";"Symptomatic hypotension with SBP <90 mm Hg"
"23470";"Symptomatic ICH"
"23471";"Symptomatic infarct swelling"
"23472";"Symptomatic localization-related"
"23473";"Symptomatic PAD"
"23474";"Symptomatic PAD of lower extremities*"
"23475";"Symptomatic PADt"
"23476";"Symptomatic PE"
"23477";"Symptomatic remissionb n/n (%)"
"23478";"Symptomaticb"
"23479";"Symptoms"
"23480";"symptoms mean (SD)"
"23481";"Symptoms of atrial fibrillation in the 3 months before randomiza-"
"23482";"Symptoms of atrial fibrillation in the 3 months before randomization — no. (%)"
"23483";"Symptoms onset to first balloon inflation, min"
"23484";"Syncope"
"23485";"Syncope — no. (%)"
"23486";"Syndecan-1 (ng/ml)"
"23487";"Syndesmophyte present, n (%)"
"23488";"Syndrome, n (%)"
"23489";"Synovitis"
"23490";"Sys: NS Dia: <0.001"
"23491";"Syst. BP (mmHg)"
"23492";"Systemic arterial hypertension, n (%)"
"23493";"Systemic corticosteroid use"
"23494";"Systemic corticosteroids — no. (%)"
"23495";"Systemic corticosteroids, n (%)"
"23496";"Systemic corticosteroids, n (%)a"
"23497";"systemic embolism"
"23498";"Systemic glucocorticoid use at randomisation"
"23499";"Systemic glucocorticoid use at randomization, n (%)"
"23500";"Systemic hypertension"
"23501";"Systemic SLE medications, n (%)"
"23502";"Systemic symptoms"
"23503";"Systoiic biood pressure, mm Hg"
"23504";"systolic"
"23505";"Systolic"
"23506";"Systolic—mean (SD) (mm Hg)"
"23507";"Systolic — mm Hg"
"23508";"Systolic (mean, SD)"
"23509";"Systolic (mm Hg)"
"23510";"Systolic (mmHg)"
"23511";"Systolic blood pressure"
"23512";"Systolic blood pressure - mmHg"
"23513";"Systolic blood pressure — mm Hg"
"23514";"Systolic blood pressure — mmHg"
"23515";"Systolic blood pressure (change from baseline)"
"23516";"Systolic Blood Pressure (median 125.0)"
"23517";"Systolic blood pressure (mm Hg)"
"23518";"Systolic blood pressure (mm Hg), mean (SD)"
"23519";"Systolic blood pressure (mmHg)"
"23520";"Systolic blood pressure (mmHg), mean±SD"
"23521";"Systolic blood pressure [mmHg] (Interaction: p=0.56)"
"23522";"Systolic blood pressure <140 mm Hg and diastolic"
"23523";"Systolic blood pressure <140 mm Hg and diastolic blood pressure <90 mm Hg"
"23524";"Systolic blood pressure >130 mm Hg — no. (%)"
"23525";"systolic blood pressure >130 mm Hg,"
"23526";"Systolic blood pressure >130 mm Hg, n (%)"
"23527";"Systolic blood pressure >140 mm Hg or diastolic"
"23528";"Systolic blood pressure >140 mm Hg or diastolic blood pressure >90 mm Hg"
"23529";"Systolic Blood Pressure mmHg, mean (sd)"
"23530";"Systolic blood pressure subgroups"
"23531";"Systolic blood pressure,"
"23532";"Systolic blood pressure, (mm Hg)"
"23533";"Systolic blood pressure, mean (SD), mm Hg"
"23534";"Systolic blood pressure, mean (SD), mm Hga"
"23535";"Systolic blood pressure, mm Hg"
"23536";"Systolic blood pressure, mm Hg (SD)"
"23537";"Systolic blood pressure, mm Hg <140"
"23538";"Systolic blood pressure, mm Hg, mean (SD)"
"23539";"Systolic blood pressure, mm Hg, mean±SD"
"23540";"Systolic blood pressure, mm Hg, median (range)"
"23541";"Systolic blood pressure, mm Hg^"
"23542";"Systolic blood pressure, mm Hq"
"23543";"Systolic blood pressure, mm Hg"
"23544";"Systolic blood pressure, mmHg"
"23545";"Systolic blood pressure, mmHg*"
"23546";"Systolic blood pressure, mmHg, mean (SD)"
"23547";"Systolic blood pressure^"
"23548";"Systolic blood pressurea, mm Hg"
"23549";"Systolic BP"
"23550";"Systolic BP (mm Hg)"
"23551";"systolic BP (mmHg)"
"23552";"Systolic BP (mmHg)"
"23553";"Systolic BP (mmHg)*"
"23554";"Systolic BP at Baseline:"
"23555";"Systolic BP, mm Hg"
"23556";"Systolic BP, mm Hg (mean) NYHA class"
"23557";"Systolic BP, mm Hg, mean (SD)"
"23558";"Systolic BP, mm Hg, mean (SD)"
"23559";"Systolic BP, mmHg"
"23560";"Systolic BP, mmHg (SD)"
"23561";"Systolic BP, mmHg, mean (SD)"
"23562";"Systolic BP, mmHg, mean ± SD"
"23563";"Systolic pressure — mm Hg"
"23564";"Systolic pressure at ankle level (mmHg), mean ± SD"
"23565";"Systolic pressure, mm Hg"
"23566";"Systolic pulmonary arterial pressure, mean (SD), mm Hg"
"23567";"Systolic, mean (SD), mm Hg h"
"23568";"Systolic, total"
"23569";"Systolic, treated at baseline"
"23570";"t"
"23571";"T-JJ (0-73)"
"23572";"T-Score at Femoral neck"
"23573";"T-score categories Lumbar spineb"
"23574";"T-wave inversion"
"23575";"T-wave inversion only"
"23576";"t (n=2,042)"
"23577";"T 0.2 mg"
"23578";"T 0.4 mg"
"23579";"T wave inversion"
"23580";"T1 (0.44-4.09 ng/mL)"
"23581";"T1D"
"23582";"T1DM"
"23583";"T2 (4.11 -6.66 ng/mL)"
"23584";"T2 lesion volume, mm'"
"23585";"T2 lesion volume, mm3"
"23586";"T2D"
"23587";"T2D duration, years"
"23588";"T2DM"
"23589";"T2DM duration (years)"
"23590";"T2DM duration, y"
"23591";"T3 (6.67- 139.83 ng/mL)"
"23592";"tA"
"23593";"TA (n = 155)"
"23594";"Table 1 Baseline characteristics of total study sample and stratified by treatment assignment and testosterone levela"
"23595";"Table 1. Characteristics of Patients Treated With Losartan and Atenolol*"
"23596";"Table 1. Characteristics of the Patients at Baseline.*"
"23597";"Table 1. Selected Baseline Characteristics of the Study Patients.*"
"23598";"table_group"
"23599";"Tachyarrhythmias, n (%)"
"23600";"TACI"
"23601";"TACI (n=129)"
"23602";"Tadalafil"
"23603";"Tadalafil 10 mg n = 120"
"23604";"Tadalafil 2.5 mg"
"23605";"Tadalafil 2.5 mg (n = 394)"
"23606";"Tadalafil 2.5 mg n = 113"
"23607";"Tadalafil 20 mg n = 116"
"23608";"Tadalafil 5 mg"
"23609";"Tadalafil 5 mg (N = 492)"
"23610";"Tadalafil 5 mg (N = 752)"
"23611";"Tadalafil 5 mg (n = 923)"
"23612";"Tadalafil 5 mg Mean change (SD)"
"23613";"Tadalafil 5 mg n = 117"
"23614";"TAH (n = 155)"
"23615";"Taiwan"
"23616";"Taking antihypertensive medication at baseline, No. (%)e"
"23617";"Taking antihypertensive treatment at"
"23618";"Taking calcium supplements at baseline, n (%)"
"23619";"Taking statins, n (%)a"
"23620";"tAmong those enrolling via BNP stratum. The study-qualifying BNP or"
"23621";"Tamsulosin"
"23622";"Tamsulosin (n = 112)"
"23623";"Tamsulosin (W= 1611), 0/0"
"23624";"Tamsulosin 0.2 mg (n = 165)"
"23625";"Tamsulosin 0.2 mg vs. placebo"
"23626";"Tamsulosin 0.4 mg (n = 162)"
"23627";"Tamsulosin 0.4 mg (n = 384)"
"23628";"Tamsulosin 0.4 mg vs. placebo"
"23629";"Tamsulosin 0.4mg vs. 0.2mg"
"23630";"Tanezumab (all doses combined)"
"23631";"Tanezumab (all doses combined) + NSAIDa"
"23632";"Tanezumab 10 mg"
"23633";"Tanezumab 10 mg + NSAID"
"23634";"Tanezumab 2.5 mg"
"23635";"Tanezumab 2.5 mg + NSAID"
"23636";"Tanezumab 5 mg"
"23637";"Tanezumab 5 mg + NSAID"
"23638";"Target-vessel revascularization"
"23639";"Target nail NAPSI score (1–8 scale)"
"23640";"Target vessel"
"23641";"TASS’"
"23642";"TBP"
"23643";"TC"
"23644";"TC (mg/dL)"
"23645";"TC (mmol/L)"
"23646";"TC level, mean (SD) mg/dL"
"23647";"TC, mean (SD)"
"23648";"TC, mean (SD), rrig/dL"
"23649";"TC, mg/dL, mean + SD"
"23650";"TC, mg/dL, mean ± SD"
"23651";"TC, mmol/L (mg/dL)"
"23652";"TC/HDL-C"
"23653";"TC/HDL-C ratio"
"23654";"TC:HDLC"
"23655";"TCHDL-C, mean (SD)"
"23656";"tComparison of proportion of patients with NYHA class lll/IV heart failure."
"23657";"TCZ-SC 162 mg every other week (n = 437)"
"23658";"TCZ 8 mg/kg n=51"
"23659";"TCZ+MTX (n)"
"23660";"TDI E' (septal) (cm/sec)"
"23661";"TDI total score (week 12"
"23662";"TEAEs"
"23663";"TEAEs (>3% in any treatment group)"
"23664";"TEAEs (>5% in any treatment group)*"
"23665";"TEAEs in a5% of individuals"
"23666";"TEAEs leading to discontinuation of study drug"
"23667";"TEAEs Of special interest"
"23668";"TEAEs reported by ≥5% patients in the overall BRV group, n (%)"
"23669";"TEAEs, cases per 100-patient years (CI)"
"23670";"Telmisartan"
"23671";"Telmisartan (N = 10,146)"
"23672";"Telmisartan (n=390)"
"23673";"Telmisartan Group (n=390)"
"23674";"Temporal data and management strategy"
"23675";"Temporary discontinuation of study drug"
"23676";"Temporary Factors"
"23677";"Temporary risk factor"
"23678";"Tender"
"23679";"Tender- or painful-joint count (of 68 joints assessed) — no."
"23680";"Tender-joint count (of 78 joints)"
"23681";"Tender-joint count, of 68 joints examined"
"23682";"Tender and swollen joints — mean no.::"
"23683";"Tender joint count"
"23684";"Tender joint count (0-44)"
"23685";"Tender joint count (0-44; per tender joint)"
"23686";"Tender joint count (0-68 joints)"
"23687";"Tender joint count (0-68 possible joints)"
"23688";"Tender joint count (0-68)"
"23689";"Tender joint count (0–68 joints), mean (SD)"
"23690";"Tender joint count (28 joints)"
"23691";"Tender joint count (28), mean (SD)"
"23692";"Tender joint count (68 joints), mean (SD)"
"23693";"Tender joint count (68 joints), mean (SD)’"
"23694";"Tender joint count (68), mean (SD)"
"23695";"Tender joint count (78 joints)"
"23696";"Tender Joint count (n/66)"
"23697";"Tender joint count (range 0-68 joints)"
"23698";"Tender joint count of 68 joints"
"23699";"Tender joint count, of 28"
"23700";"Tender joint count, of 68"
"23701";"Tender joints (68-joint count), mean ± SD"
"23702";"Tenecteplase"
"23703";"Tenecteplase and PCI (n=829)"
"23704";"Teriparatide (N = 680)"
"23705";"Teriparatide n/N (%)"
"23706";"Terlile 1"
"23707";"Terminal ileum"
"23708";"terol; HDL-C, high-density Lipoprotein cholesterol;"
"23709";"Terrible"
"23710";"Tertiary"
"23711";"Tertiary amines"
"23712";"Tertiary end points"
"23713";"Tertiary endpoints:"
"23714";"Tertile 1"
"23715";"Tertile 1 (<3.98 ng/mL) n-482"
"23716";"Tertile 1 (n = 400)"
"23717";"Tertile 1 Index PCI performed"
"23718";"Tertile 1: 4.78 (0.016)"
"23719";"Tertile 2"
"23720";"Tertile 2 (3.99-5.43 pg/mL) n=483"
"23721";"Tertile 2 (n = 387)"
"23722";"Tertile 2: 5.66 (0.19)"
"23723";"Tertile 3"
"23724";"Tertile 3 (>5.43 pg/mL) n-482"
"23725";"Tertile 3 (n = 404)"
"23726";"Tertile 3: 6.58 (0.44)"
"23727";"Tertile of Total Cholesterol at Baseline, Mean (SD), mmol/L"
"23728";"Test for interaction"
"23729";"Test for Interaction (p Value)"
"23730";"test for interaction between treatment and race"
"23731";"Test for trend"
"23732";"Testing order"
"23733";"Testosterone (nmol/L)"
"23734";"Testosterone (TT) (nmol/L)"
"23735";"Testosterone level (nmol/L)"
"23736";"tests for categoric"
"23737";"TexCAPS"
"23738";"TG"
"23739";"TG (mg/dL)"
"23740";"TG (mg/dl), median ± SD"
"23741";"TG (mmol/L)"
"23742";"TG (mmol/L)c"
"23743";"TG (mmol/L, median)"
"23744";"TG > 150. HDL <40 (mg/dL) (/? = 957)"
"23745";"TG >150 mg/dl, n (°/o)"
"23746";"TG >3.1"
"23747";"TG mg/dL, median (SD)"
"23748";"TG*"
"23749";"TG, median (interquartile range)"
"23750";"TG, median (min, max)"
"23751";"TG, median (SDy rng/cJL"
"23752";"TG, mg/dL, mean ± SD"
"23753";"TG, mmol/L (mg/dL) [median]"
"23754";"TG, mmol/L [mg/dL]"
"23755";"TG, triglycerides. *Median values (standard deviation for medians)."
"23756";"TG’"
"23757";"TG+"
"23758";"TG< 150, HDL>40 (n = 6614)"
"23759";"TG<=3.1"
"23760";"TG§"
"23761";"TGs (mg/dl)"
"23762";"TGt"
"23763";"TH (100%)"
"23764";"th C"
"23765";"the American College of Rheumatology)."
"23766";"The metabolic syndrome^"
"23767";"the Netherlands, Australia, New Zealand, and South Africa"
"23768";"The plot shows hazard ratios and 95% confidence intervals for the primary outcome, with patients stratified according to eight sub-groups prespecified in the statistical analysis plan. No heterogeneity was observed for these subgroups."
"23769";"the square of the height in meters. Patient's and physician's global assessment scores can range from 0 to 100. Scores for the Western"
"23770";"The test for heterogeneity (interaction) indicates whether the treatment effect varied significantly among the sub-groups. The Hochberg method was applied to each of the two comparisons of the treatment groups. BMI denotes body-mass index (the weight in kilograms divided by the square of the height in meters)."
"23771";"Theophylline compound"
"23772";"Theophylline use at screening"
"23773";"Theophyllines"
"23774";"Therapies"
"23775";"therapy"
"23776";"Therapy-Fatigue (FACIT-F, 0-52)"
"23777";"therapy (ASA 3,261/Placebo 3264)"
"23778";"therapy (ASA 4626/Placebo 4703)"
"23779";"therapy (ASA 530/Placebo 481)"
"23780";"therapy (ASA 6,091/Placebo 5957)"
"23781";"Therapy at discharge"
"23782";"therapy use"
"23783";"Thiazide"
"23784";"Thiazide at enrollment"
"23785";"Thiazide at last follow-up"
"23786";"Thiazide diuretic"
"23787";"Thiazide diuretic*"
"23788";"Thiazide diuretics"
"23789";"Thiazide users"
"23790";"Thiazides"
"23791";"Thiazolidinedione"
"23792";"Thiazolidinedione (includes Pioglitazone)"
"23793";"Thiazolidinedione 一 no. (%)"
"23794";"Thiazolidinedione based"
"23795";"Thiazolidinedione No"
"23796";"Thiazolidinedione use at baseline"
"23797";"Thiazolidinedione Yes"
"23798";"Thiazolidinedioneb"
"23799";"Thiazolidinediones"
"23800";"Thiazolidinediones*"
"23801";"Thiazolidinedionesc"
"23802";"Thienopyridine"
"23803";"Thienopyridine (N=2162)"
"23804";"Thienopyridine (N=3696)"
"23805";"Thienopyridine alone"
"23806";"Thienopyridine at baseline"
"23807";"Thienopyridine at discharge"
"23808";"Thienopyridine at Enrollment"
"23809";"Thienopyridine at randomization"
"23810";"Thienopyridine at Randomization"
"23811";"Thienopyridine drug at start of open-label period"
"23812";"Thienopyridine N=1805"
"23813";"Thienopyridine N=4057"
"23814";"Thienopyridine Type"
"23815";"Thienopyridine+dipyridamole"
"23816";"Third heart sound"
"23817";"Third heart sound, n (%)"
"23818";"Third primary (change in UPDRS score/wk, wk 48-72)"
"23819";"Third yeart"
"23820";"This study"
"23821";"Thoracic cage fractures"
"23822";"Threatened abrupt vessel closure"
"23823";"Three-point MACE"
"23824";"Three-vessel disease"
"23825";"Three arm"
"23826";"Three of seven risk factors"
"23827";"Three or more agents"
"23828";"Three or more drugs"
"23829";"Three or more lesions"
"23830";"Thromboaspiration"
"23831";"Thromboaspiration — no. (%)"
"23832";"Thrombocytopenia"
"23833";"thromboembolism"
"23834";"Thrombolysis"
"23835";"Thrombolytic agents"
"23836";"Thrombolytic treatment before randomization"
"23837";"Thrombophilia"
"23838";"Thrombophilia, No. (%)e"
"23839";"Thrombus-containing lesion"
"23840";"Thrombus aspiration"
"23841";"Thrombus aspiration done per lesion†"
"23842";"Thyroid disease"
"23843";"Thyroid hormone"
"23844";"TIA"
"23845";"TIA, n (%)"
"23846";"Tibia fracture"
"23847";"Ticagrelor 60 mg"
"23848";"Ticagrelor 60 mg 3 Year KM (%)"
"23849";"Ticagrelor 60 mg 3 yr KM%"
"23850";"Ticagrelor 60 mg Diabetes n=20"
"23851";"Ticagrelor 60 mg KM %"
"23852";"Ticagrelor 60 mg No Diabetes n=38"
"23853";"Ticagrelor 60 mg vs. Placebo HR (95% CI)"
"23854";"Ticagrelor 90 mg"
"23855";"Ticagrelor 90 mg 3 Year KM (%)"
"23856";"Ticagrelor 90 mg 3 yr KM%"
"23857";"Ticagrelor 90 mg Diabetes n=12"
"23858";"Ticagrelor 90 mg No diabetes n=46"
"23859";"Ticagrelor 90 mg vs. Placebo HR (95% CI)"
"23860";"Ticagrelor in‐Hosp (N = 116)"
"23861";"Ticagrelor pre‐Hosp (N = 98)"
"23862";"Ticagrelor, 60 mg (N = 7045)"
"23863";"Ticagrelor, 90 mg (N = 7050)"
"23864";"Ticlopidin"
"23865";"Ticlopidine"
"23866";"Ticlopidine (n = 870)"
"23867";"Ticlopidine after completion of study drug"
"23868";"tics — no. (%)"
"23869";"Tier 1 AEs"
"23870";"Tier 1AEs"
"23871";"TIM 1 nsk score"
"23872";"Time-to-first-infusion from hip surgery (days), n (%)"
"23873";"Time-to-first infusion"
"23874";"time (sec)*"
"23875";"Time between cessation of full-dose warfarin therapy and enrollment (mo)"
"23876";"Time between index ACS and randomization — days"
"23877";"Time between index ACS and randomization (days)"
"23878";"Time from ACS to randomization"
"23879";"Time from ACS to randomization (median, IQR)"
"23880";"Time from acute coronary syndrome to randomization (days)"
"23881";"Time from end of FIT, years (meaniSD)"
"23882";"Time from event to randomization — days"
"23883";"Time from fibrinolytic therapy to study-drug administration — no./total no. (%)"
"23884";"Time from first eval"
"23885";"Time from hospital admission to enrollment,"
"23886";"Time from hospital admission to PCI, h, median (Q1, Q3)"
"23887";"Time from hospitalization to randomization — hr"
"23888";"Time from index AcS event to randomisation (days)"
"23889";"Time from last dose of P2Y12 inhibitor, days"
"23890";"Time from LD to PCI, min; median (Q1–Q3)"
"23891";"Time from longest event to randomisation"
"23892";"Time from most recent qualifying"
"23893";"Time from onset of pain to randomization — hr"
"23894";"Time from onset of pain to randomization, median (25th—75th percentiles), n"
"23895";"Time from onset of pain to randomization, median (IQR), h"
"23896";"Time from onset of qualifying stroke to randomization"
"23897";"Time from onset of symptoms to presentation — hr"
"23898";"Time from onset of symptoms to randomization — days"
"23899";"Time from onset of symptoms to start of fibrinolytic therapy — hr"
"23900";"Time from onset to medication, h, mean±SD"
"23901";"Time from onset to randomization, h, mean±SD"
"23902";"Time from PAH diagnosis months"
"23903";"Time from Parkinson’s disease diagnosis in months, mean (SD)"
"23904";"Time from presentation to randomization — hr"
"23905";"Time from psoriatic arthritis diagnosis [a], years"
"23906";"Time from qualifying ECG to balloon inflation"
"23907";"Time from qualifying event to randomization"
"23908";"Time from qualifying MI, %"
"23909";"Time from qualifying MI, yrs"
"23910";"Time from qualifying myocardial infarction"
"23911";"Time from Qualifying Myocardial Infarction"
"23912";"Time from qualifying stroke to randomization"
"23913";"Time from RA diagnosis, years, median"
"23914";"Time from randomization to CABG — hr"
"23915";"Time from randomization to coronary angiography— hr"
"23916";"Time from randomization to PCI — hr"
"23917";"Time from randomization to PCI (non-ST-elevation MI), h"
"23918";"Time from randomization to PCI (ST-elevation MI), min"
"23919";"Time from randomization to study-drug administration — hr"
"23920";"Time from randomization to study-drug initiation — hr"
"23921";"Time from study drug administration to coronary revascularization, median (IQR), h"
"23922";"Time from sx onset to baseline ECG, min"
"23923";"Time from symptom onset of RA, years, median"
"23924";"Time from symptom onset to balloon inflation"
"23925";"Time from symptom onset to enrollment,"
"23926";"Time from symptom onset to randomization"
"23927";"Time from symptom onset to start of fibrinolytic therapy — hr"
"23928";"Time from symptoms to randomization, h"
"23929";"Time from symptoms to treatment"
"23930";"Time from, median (IQR), h"
"23931";"Time in therapeutic range"
"23932";"Time in therapeutic range before inclusion"
"23933";"Time in therapeutic range, median (IQR), %"
"23934";"Time in Trial"
"23935";"Time Intervals"
"23936";"Time intervals, h"
"23937";"Time of qualifying ECG to balloon inflation (hrs)"
"23938";"Time of randomization"
"23939";"Time of Randomization"
"23940";"Time of randomization (Interaction: p=0.04)"
"23941";"Time of symptom onset to balloon inflation (hrs)"
"23942";"Time of symptom onset to randomization (hrs)"
"23943";"Time point"
"23944";"Time sample drawn (h)"
"23945";"Time since AS diagnosis (years), mean (SD)"
"23946";"Time since AS diagnosis (years), mean ± SD"
"23947";"Time since AS diagnosis, mean (SD) years"
"23948";"Time since asthma"
"23949";"Time since asthma diagnosis (years)"
"23950";"Time since asthma diagnosis [years], median (range)"
"23951";"Time since asthma diagnosis years"
"23952";"Time since BPH diagnosis (years)"
"23953";"Time since CABG"
"23954";"Time since cessation of full-dose warfarin therapy"
"23955";"Time since COPD diagnosis (yrs)"
"23956";"Time since diagnosis — mo"
"23957";"Time since diagnosis of CIU/CSU (years)2"
"23958";"Time since diagnosis of CIU/CSUf (y)"
"23959";"Time since diagnosis of COPD, years"
"23960";"Time since diagnosis of diabetes"
"23961";"Time since diagnosis of diabetes — no. (%)"
"23962";"Time since diagnosis of diabetes (years) (median, IQR)"
"23963";"Time since diagnosis of diabetes, mean (SD)"
"23964";"Time since diagnosis of diabetes, n (%)"
"23965";"Time since diagnosis of diabetesa, n (%)"
"23966";"Time since diagnosis of heart failure"
"23967";"Time since diagnosis of LN, years"
"23968";"Time since diagnosis of osteoarthritis — yr"
"23969";"Time since diagnosis of PAH — yrf"
"23970";"Time since diagnosis of PAH years#"
"23971";"Time since diagnosis of PsA (years), mean (SD)"
"23972";"Time since diagnosis of SLE, years"
"23973";"Time since diagnosis of T2DM"
"23974";"Time since diagnosis of T2DM, y, n (%)"
"23975";"Time since diagnosis of type 2 diabetes"
"23976";"Time since diagnosis of type 2 diabetes - no. (%)"
"23977";"Time since diagnosis of type 2 diabetes mellitus"
"23978";"Time since diagnosis, years"
"23979";"Time since end of FIT, mean (SD), y"
"23980";"Time since epilepsy diagnosis (years)"
"23981";"Time since first AF diagnosis, yrs"
"23982";"Time since first COPD diagnosis (years)"
"23983";"Time since first LUTS (years)"
"23984";"Time since first psoriasis diagnosis (y), mean (SD)"
"23985";"Time since IPF diagnosisa, mean years (SD)"
"23986";"Time since last dose of"
"23987";"Time since most recent myocardial"
"23988";"Time since onset (h)"
"23989";"Time since PAH diagnosisc (years)"
"23990";"Time since PD diagnosis, mean ± SD,"
"23991";"Time since primary diagnosis,"
"23992";"Time since prior alendronate use, n (%)"
"23993";"Time since PsA diagnosis (years), mean (SD)"
"23994";"Time since PsA onset, mean years (SD)"
"23995";"Time since psoriasis diagnosis, years1"
"23996";"Time since qualifying event"
"23997";"Time since randomization"
"23998";"Time since rheumatoid arthritis diagnosis, years"
"23999";"Time since start insulin (years)"
"24000";"Time since start of FIT, mean (SD), y"
"24001";"Time since start of FIT, years (meaniSD)"
"24002";"Time to admission, min"
"24003";"Time to all-cause death up to end of the study"
"24004";"Time to angiography — hr"
"24005";"Time to balloon/needle, min*"
"24006";"Time to death due to PAH or hospitalization due to PAH up to the end of the treatment periodd"
"24007";"Time to end-of-study IVUS, median (IQR), days"
"24008";"Time to first CV hospitalization or death from any cause"
"24009";"Time to first exacerbation"
"24010";"Time to first inhaled corticosteroid (%)"
"24011";"Time to first morbidity/mortality event up to the end of the treatment periodd"
"24012";"Time to first oral or systemic corticosteroid (%)"
"24013";"Time to first SARE*(%)"
"24014";"Time to randomisation [hours] (Interaction: p=0.71)"
"24015";"Time to randomization"
"24016";"Time to randomization (h)"
"24017";"Time to randomization from symptom onset"
"24018";"Time to rx"
"24019";"Time to treatment"
"24020";"Time to treatment (min)t"
"24021";"Time to treatment initiation (min)"
"24022";"Time to treatment initiation (min;"
"24023";"Time to treatment, h"
"24024";"Time, mean (SD), min Procedure"
"24025";"TIMI-bleeding major/minor"
"24026";"TIMI-defined bleeding"
"24027";"TIMI ≥2"
"24028";"TIMI ≥3"
"24029";"TIMI ≥3 and spoke"
"24030";"TIMI ≥3 and spoke and time ≤2 h"
"24031";"TIMI ≥3 and spoke and time ≤3 h"
"24032";"TIMI ≥3 and spoke and time ≤4 h"
"24033";"TIMI ≥3 and spoke and time ≤5 h"
"24034";"TIMI ≥4"
"24035";"TIMI ≥5"
"24036";"TIMI clinically significant"
"24037";"TIMI flow grade 3 of MI culprit vessel post‐PCI"
"24038";"TIMI flow grade 3 of MI culprit vessel pre‐PCI"
"24039";"TIMI flow‡"
"24040";"TIMI major"
"24041";"TIMI Major"
"24042";"TIMI major bleeding"
"24043";"TIMI major or"
"24044";"TIMI major or minor bleeding"
"24045";"TIMI major/minor"
"24046";"TIMI Major/Minor"
"24047";"TIMI major/minor bleeding"
"24048";"TIMI minor"
"24049";"TIMI Minor"
"24050";"TIMI minor bleeding"
"24051";"TIMI non-CABG major"
"24052";"TIMI risk score"
"24053";"TIMI risk score — %"
"24054";"TIMI risk score — no. (%):t"
"24055";"TIMI risk score — no./total no. (%):c"
"24056";"TIMI risk score — no./total no. (%)f"
"24057";"Timi risk score (Interaction: p=0.49)"
"24058";"TIMI risk score >5, %"
"24059";"TIMI Risk Score >5, %"
"24060";"TIMI risk score >5, n (%)"
"24061";"TIMI Risk Score 0-2"
"24062";"TIMI Risk Score 3-7"
"24063";"TIMI risk score category—No. (%)"
"24064";"TIMI risk score!"
"24065";"TIMI risk score*"
"24066";"TIMI Risk Score*"
"24067";"TIMI risk score, %"
"24068";"TIMI risk score, n/N (%)"
"24069";"TIMI risk scoret"
"24070";"Timing of clopidogrel loading dose"
"24071";"TIO"
"24072";"TIO (N 5 258)"
"24073";"TIO (N 5 869)"
"24074";"TIO 18 |ig (n=508)"
"24075";"TIO i8 mcg (N=508)"
"24076";"tion — no. (%)"
"24077";"tion; OS = overall satisfaction; Qmax = maximal urinary flow rate."
"24078";"Tiotropium"
"24079";"Tiotropium (N = 2986)"
"24080";"Tiotropium (N = 3707)"
"24081";"Tiotropium (n=1076)"
"24082";"Tiotropium (n=1304)"
"24083";"Tiotropium (n=1384)"
"24084";"Tiotropium (n=250)"
"24085";"Tiotropium (nZ2251)"
"24086";"Tiotropium (nZ735)"
"24087";"Tiotropium + olodaterol 2.5/ 5 pg"
"24088";"Tiotropium + olodaterol 2.5/ 5 Pg"
"24089";"Tiotropium + olodaterol 5/5"
"24090";"Tiotropium + olodaterol 5/5 pg"
"24091";"Tiotropium + placeb (n[570)"
"24092";"Tiotropium + placebo (n[561)"
"24093";"Tiotropium 18 gg qd"
"24094";"Tiotropium 18 meg (n=466)"
"24095";"Tiotropium 18mg(n=267"
"24096";"Tiotropium 2.5 μg (n = 154)"
"24097";"Tiotropium 2.5 Mg"
"24098";"Tiotropium 2.5 pg"
"24099";"Tiotropium 2.5 μg (n = 121)"
"24100";"Tiotropium 2.5 μg (n = 129)"
"24101";"Tiotropium 2.5 μg (n = 22)"
"24102";"Tiotropium 2.5 μg (n = 30)"
"24103";"Tiotropium 2.5 μg (n = 71)"
"24104";"Tiotropium 2.5 μg (n = 80)"
"24105";"Tiotropium 5 m g"
"24106";"Tiotropium 5 Mg"
"24107";"Tiotropium 5 mg Respimat® (n = 1952)"
"24108";"Tiotropium 5 mg Respimat® (n Z 1058)"
"24109";"Tiotropium 5 mg Respimat® (n Z 894)"
"24110";"Tiotropium 5 mg(n = 1033)"
"24111";"Tiotropium 5 Pg"
"24112";"Tiotropium 5 μg (n = 120)"
"24113";"Tiotropium 5 μg (n = 127)"
"24114";"Tiotropium 5 μg (n = 155)"
"24115";"Tiotropium 5 μg (n = 25)"
"24116";"Tiotropium 5 μg (n = 32)"
"24117";"Tiotropium 5 μg (n = 58)"
"24118";"Tiotropium 5 μg (n = 94)"
"24119";"Tiotropium 5Mg"
"24120";"Tiotropium Group (N = 388)"
"24121";"Tiotropium Salmeterol no. of patients/total no."
"24122";"Tiotropium vs. salmeterol"
"24123";"Tiotropium/ olodaterol 2.5/5 Mg"
"24124";"Tiotropium/ olodaterol 5/5 Mg"
"24125";"Tiotropium/olodaterol 5/5 mg"
"24126";"Tiotropium/olodaterol 5/5 mg(n = 1029)"
"24127";"Tiotropium+olodaterol 2.5/5 Mg"
"24128";"Tiotropium+olodaterol 2.5/5 pg"
"24129";"Tiotropium+olodaterol 5/5 Mg"
"24130";"Tiotropium+olodaterol 5/5 pg"
"24131";"Tiotropiumc"
"24132";"TIROFIBAN (N=2398)"
"24133";"Titre (U/mL) t"
"24134";"Titre (U/mL)t"
"24135";"TJ (15-50)"
"24136";"TJ (16%)"
"24137";"TJC"
"24138";"TJC (/28 joints)"
"24139";"TJC (0-78), mean (SD)"
"24140";"TJC (28 joints)"
"24141";"TJC (28 joints), mean (SD)"
"24142";"TJC (78 joints)"
"24143";"TJC, 0-28"
"24144";"TJC, mean (SD)"
"24145";"tk"
"24146";"TlMi risk score"
"24147";"TNF-alpha (pg/mL)"
"24148";"TNF-failure patientsa"
"24149";"TNF-failurea"
"24150";"TNF-IR"
"24151";"TNF-naïve"
"24152";"TNF-naive patientsa"
"24153";"TNF-naivea"
"24154";"TNF-R1a (ng/ml)"
"24155";"TNF antagonist"
"24156";"TNF antagonist-exposed"
"24157";"TNF antagonist-failure population (n - 157)"
"24158";"TNF antagonist-failure population (n - 158)"
"24159";"TNF antagonist-naive'’"
"24160";"TNF antagonist-naive subgroup (n - 50)"
"24161";"TNF antagonist-naive subgroup (n - 51)"
"24162";"TNF antagonist-naive®"
"24163";"TNF inhibitor"
"24164";"TNF inhibitors"
"24165";"TNFi-exposed†"
"24166";"TNFi-IR"
"24167";"TNFi-naive"
"24168";"TNFi-naïve"
"24169";"TNFi-naïve, n (%)"
"24170";"TNFi (no other bDMARD taken)t, n (%)"
"24171";"TNFi and other bDMARDst, n (%)"
"24172";"TNFi exposed"
"24173";"TNFi naive"
"24174";"Tnglycendes < Median"
"24175";"Tngtycendes a Median"
"24176";"Tngtycerides < Median"
"24177";"Tngtycerides a Median"
"24178";"TnI ultrapositive ≥0.04 µg/L, n = 970 1023"
"24179";"TnI ultrapositive, ≥0.04 µg/L, N = 322 312"
"24180";"Tnl ultrapositive >0.04 pg/L, 0 = 9701023"
"24181";"TNT and IDEAL (pooled)"
"24182";"to randomization"
"24183";"TOAST classification"
"24184";"TOAST classification of qualifying stroke"
"24185";"TOAST classification of qualifying stroke (%)"
"24186";"TOAST classification of qualifying stroke, no. (%)"
"24187";"Tobacco abuse"
"24188";"Tobacco use"
"24189";"Tobacco use — no. (%)"
"24190";"Tobacco use (%)"
"24191";"Tobacco use, n (%)"
"24192";"Tobacco Use, n (%)"
"24193";"Tobacco use, yes, n (%)"
"24194";"Tobacco User"
"24195";"Tocilizumab"
"24196";"Tocilizumab (n = 225)"
"24197";"Tofacitinib"
"24198";"Tofacitinib 10 mg BID"
"24199";"Tofacitinib 10 mg BID (n = 905)"
"24200";"Tofacitinib 10 mg BID (n = 905)"
"24201";"Tofacitinib 10 mg BID (n=21)"
"24202";"Tofacitinib 10 mg BID (n=95)"
"24203";"Tofacitinib 10 mg BID [N = 197|"
"24204";"Tofacitinib 10 mg BID [N = 429|"
"24205";"Tofacitinib 10 mg BID [N = 476|"
"24206";"Tofacitinib 10 mg twice daily N=1066"
"24207";"Tofacitinib 10 mg twice daily N=1090"
"24208";"Tofacitinib 10 mg twice daily N=251"
"24209";"Tofacitinib 10 mg twice daily N=253"
"24210";"Tofacitinib 10 mg two times a day"
"24211";"Tofacitinib 15 mg BID"
"24212";"Tofacitinib 5 mg BID"
"24213";"Tofacitinib 5 mg BID (n=22)"
"24214";"Tofacitinib 5 mg BID [N = 198|"
"24215";"Tofacitinib 5 mg twice daily N=1043"
"24216";"Tofacitinib 5 mg twice daily N=1071"
"24217";"Tofacitinib 5 mg twice daily N=258"
"24218";"Tofacitinib 5 mg twice daily N=259"
"24219";"Tofacitinib 5 mg two times a day"
"24220";"Tofacitinib, 10 mg (N = 132)"
"24221";"Tofacitinib, 10 mg (N = 197)"
"24222";"Tofacitinib, 10 mg (N = 245)"
"24223";"Tofacitinib, 10 mg (N = 429)"
"24224";"Tofacitinib, 10 mg (N = 476)"
"24225";"Tofacitinib, 10 mg twice daily"
"24226";"Tofacitinib, 15 mg twice daily"
"24227";"Tofacitinib, 5 mg (N = 131)"
"24228";"Tofacitinib, 5 mg (N = 198)"
"24229";"Tofacitinib, 5 mg (N = 243)"
"24230";"Toial cholcsierol (mg/dl)"
"24231";"Tolal choleslerol"
"24232";"Tolal choleslerol-lo-HDL choleslerol ralio"
"24233";"Tolvaptan"
"24234";"Tolvaptan (n = 2072)"
"24235";"Tonic"
"24236";"Tonic–clonic"
"24237";"Took prior antihyperglycemic agent (any)"
"24238";"Tophi present, n (%)"
"24239";"Tophi Present, n (%)"
"24240";"Topical"
"24241";"Topical non-prescription"
"24242";"Topical prescription"
"24243";"Topical therapy"
"24244";"Topiramate"
"24245";"toricoxib 90 mg n= 2032) (%)"
"24246";"Torsemide"
"24247";"Totai mortaiity"
"24248";"total"
"24249";"Total"
"24250";"Total-C"
"24251";"Total-C:HDL-C"
"24252";"Total-hip BMD T-score"
"24253";"Total (N [ 386)"
"24254";"Total (n = 1,301)"
"24255";"Total (N = 10,142)--"
"24256";"Total (n = 1065)"
"24257";"Total (N = 1156)"
"24258";"Total (N = 1176)"
"24259";"Total (n = 146)"
"24260";"Total (N = 2,019)"
"24261";"Total (n = 2313)"
"24262";"Total (N = 252)"
"24263";"Total (N = 327)"
"24264";"Total (N = 3297)"
"24265";"Total (N = 376)"
"24266";"Total (N = 39 876)"
"24267";"Total (N = 39876)"
"24268";"Total (N = 4327)"
"24269";"Total (N = 4447)"
"24270";"Total (n = 462)"
"24271";"Total (n = 494)"
"24272";"Total (N = 5059)"
"24273";"Total (n = 528)"
"24274";"Total (N = 547)"
"24275";"Total (n = 561)"
"24276";"Total (N = 639)"
"24277";"Total (N = 70)"
"24278";"Total (N = 755)"
"24279";"Total (N = 895)"
"24280";"Total (n = 955)"
"24281";"Total (N =1,186)"
"24282";"Total (N =39,876)"
"24283";"Total (N 5 1889)"
"24284";"Total (N 5 424)"
"24285";"Total (n 5 467)"
"24286";"Total (n = 376)"
"24287";"Total (N = 464)"
"24288";"Total (n)"
"24289";"Total (n = 1161)"
"24290";"Total (n = 42)"
"24291";"Total (n = 459)"
"24292";"Total (N = 506)"
"24293";"Total (n = 566)"
"24294";"Total (n = 94)"
"24295";"Total (n= 2,048)"
"24296";"Total (N=1,017)"
"24297";"Total (n=1461)"
"24298";"Total (N=1863)"
"24299";"Total (N=1962)"
"24300";"Total (N=2019)"
"24301";"Total (n=2039)"
"24302";"Total (N=21 105)"
"24303";"Total (n=344)"
"24304";"Total (N=351)"
"24305";"Total (N=4158)"
"24306";"Total (n=4331)"
"24307";"Total (n=5356)"
"24308";"Total (N=782)"
"24309";"Total (n=8101)"
"24310";"Total (n=8681)"
"24311";"Total (n=878)"
"24312";"Total (V= 18,889)"
"24313";"Total >atients"
"24314";"Total 22180"
"24315";"Total AIM‐HIGH Study"
"24316";"Total antihypertensive use"
"24317";"Total asthma symptom score"
"24318";"Total Asthma Symptom Score"
"24319";"Total asthma symptom score, mean ± SD‡"
"24320";"Total asthma symptom score, mean ± SDz"
"24321";"Total asthma symptom score:"
"24322";"Total back pain score (0–100 mm scale), mean ± SD"
"24323";"Total back pain, 0–100 mm VAS, mean ± SD"
"24324";"Total back pain, mean (SD)"
"24325";"Total BASDAI score, mean (SD)"
"24326";"Total BASDAI score, mean ± SD"
"24327";"Total BASDAI, mean (SD)"
"24328";"Total baseline insulin dose"
"24329";"Total bilirubin > 2 x ULN1"
"24330";"Total bilirubin, mg/dl"
"24331";"Total bleeding"
"24332";"Total bleeds"
"24333";"Total body"
"24334";"Total body (without head)"
"24335";"Total by treatment"
"24336";"Total C"
"24337";"Total C (mg/dl) *"
"24338";"Total C (mmol/L, mean)"
"24339";"Total C/HDL-C ratio **"
"24340";"Total CARMELINA Population"
"24341";"Total Cataract"
"24342";"Total Cataract Extraction"
"24343";"Total chol, mg/DL"
"24344";"Total cHol, mg/DL"
"24345";"Total cholesterohHDL cholesterol ratio"
"24346";"Total cholesterol"
"24347";"Total Cholesterol"
"24348";"Total cholesterol-to-HDL cholesterol ratio"
"24349";"Total cholesterol - mg/dL**"
"24350";"Total cholesterol — mg/dl"
"24351";"Total cholesterol (median, IQR), mg/dL"
"24352";"total cholesterol (mg/dl)"
"24353";"Total cholesterol (mg/dl)"
"24354";"Total cholesterol (mg/dL)"
"24355";"Total Cholesterol (mg/dl)"
"24356";"Total cholesterol (mg/dL), mean + SD, available for 3658 patients"
"24357";"Total cholesterol (mmo 1/1)"
"24358";"Total cholesterol (mmol/l)"
"24359";"Total cholesterol (mmol/L)"
"24360";"Total cholesterol (mmol/L), mean (SD)"
"24361";"Total cholesterol (mmol/L):"
"24362";"Total cholesterol (SD), mg/dL"
"24363";"Total cholesterol (week 24)"
"24364";"Total cholesterol <4-87 mmol/Lt"
"24365";"Total cholesterol <4 97 mmol/Lt"
"24366";"Total cholesterol >200 mg/dl"
"24367";"Total cholesterol >4'97 mmol/Lt"
"24368";"Total cholesterol >4-87 mmol/Lt"
"24369";"Total cholesterol level, mg/dL"
"24370";"Total cholesterol*"
"24371";"Total cholesterol, %"
"24372";"Total cholesterol, mean (SD)"
"24373";"Total cholesterol, mean (SD), mg/dL"
"24374";"Total cholesterol, mg/dl"
"24375";"Total cholesterol, mg/dL"
"24376";"Total cholesterol, mg/dL""^"
"24377";"Total cholesterol, mg/dL, mean (SD)"
"24378";"Total cholesterol, mg/dL^"
"24379";"Total cholesterol, mmol/L"
"24380";"Total cholesterol, mmol/L (SD)"
"24381";"Total cholesterol, mmol/l, mean (SD)"
"24382";"Total cholesterol, mmol/L, mean (SD)"
"24383";"Total cholesterol, mmol/l本"
"24384";"Total cholesterol, mmol/le"
"24385";"Total cholesterol, mmol/lt"
"24386";"Total cholesterol/HDL-C"
"24387";"Total cholesterol:HDL-C ratio"
"24388";"Total cholesterol^"
"24389";"Total cholesterol3 <194 mg/dL"
"24390";"Total cholesterol3 >194 mg/dL"
"24391";"Total cigarette pack-years, mean (SD)"
"24392";"Total cohort"
"24393";"Total Cohort"
"24394";"Total comparators (n = 1920)"
"24395";"Total comparators, patients with events/total patients"
"24396";"Total daily dose of ICS, mean, μgc"
"24397";"Total daily insulin dose (lU/kg)"
"24398";"Total daily insulin dose (U/day)"
"24399";"Total daily insulin dose, U"
"24400";"Total daily insulin dose, units/kgt"
"24401";"Total death"
"24402";"Total deaths"
"24403";"Total Deaths, n"
"24404";"Total diuretic dose (IV + oral) on day 1, mg"
"24405";"Total Events, n"
"24406";"Total feet score"
"24407";"Total gadolinium-enhancing lesion count, No. (%)"
"24408";"Total gadolinium-enhancing lesion count. No. (%)"
"24409";"Total glucose mg/dL"
"24410";"Total Glucose mg/dL"
"24411";"Total group"
"24412";"Total Group (n=551)"
"24413";"Total hands score"
"24414";"Total HAQ, 0-3"
"24415";"Total hip"
"24416";"Total hip (n = 1,687) BMD (g/cm2) (SD)"
"24417";"Total hip BMD (g/cm2)"
"24418";"Total hip BMD T-score"
"24419";"Total hip BMI) T-score"
"24420";"Total hip or knee replacement"
"24421";"Total hipc"
"24422";"Total HO population (n = 4951)"
"24423";"Total ICS dose at entry, /xg/d"
"24424";"Total IgE — lU/ml"
"24425";"Total IgE levelx (IU/mL), median (range)"
"24426";"Total IgE, geometric"
"24427";"Total included in combined analysis"
"24428";"Total intravenous loop diuretic (mg) Median"
"24429";"Total intravenous loop diuretics, mg"
"24430";"Total Invasive Cancer"
"24431";"Total IPSS"
"24432";"Total LDL-C*"
"24433";"Total length of implanted stents, mm, mean (SD)"
"24434";"Total macular volume, mean (SD), mm3"
"24435";"Total Mayo score"
"24436";"Total Mayo score$||"
"24437";"Total mortality"
"24438";"Total Mortality"
"24439";"Total mortality All"
"24440";"Total n"
"24441";"Total N = 827"
"24442";"Total N = 958"
"24443";"Total N =534"
"24444";"Total n = 867"
"24445";"Total N= 1404 n (%)"
"24446";"Total n1"
"24447";"Total no."
"24448";"Total No."
"24449";"total no. 26449"
"24450";"Total No. of Events (% of Participants)/ Total No. of Participants"
"24451";"Total No. of Events/ Total No. of Participants"
"24452";"Total No. of Events/Participants"
"24453";"Total No. of patients"
"24454";"Total No. of Patients"
"24455";"Total Number of Events/Participants"
"24456";"Total number of patients"
"24457";"Total occlusion, n (%)"
"24458";"Total pack-years Mean (SD)"
"24459";"Total pack-yrs"
"24460";"Total patients"
"24461";"Total Patients"
"24462";"Total patients n=157"
"24463";"Total patients n=159"
"24464";"Total patients, n"
"24465";"Total periventricular WML score, mean (SD)"
"24466";"total phase 3 pooled (n=1684)"
"24467";"Total population"
"24468";"Total Population"
"24469";"Total population (n = 6112)"
"24470";"Total population n"
"24471";"Total PsA‐modified SHS"
"24472";"Total randomised (N)"
"24473";"Total randomized"
"24474";"Total randomized, n"
"24475";"Total resolution of dactylitisb"
"24476";"Total resolution of enthesitisc"
"24477";"Total resolution of nail psoriasisd"
"24478";"Total sample =1174 (%)"
"24479";"Total score"
"24480";"Total score (0–528 scale)"
"24481";"Total score <12"
"24482";"Total score >12"
"24483";"Total score on the SGRQ-C;i;"
"24484";"Total score§"
"24485";"Total scores (total score range: 32-224)"
"24486";"Total SGRQ mean total score (SD)"
"24487";"Total SGRQ score"
"24488";"Total stent length"
"24489";"Total stent length- mm"
"24490";"Total stent length (mm), Mean±SD"
"24491";"Total stent length, mm"
"24492";"Total study ITT population (n = 4844)"
"24493";"Total study population"
"24494";"Total study population (n = 27,939)"
"24495";"Total Study Population (N=894)"
"24496";"Total subjects"
"24497";"Total time of fondaparinux treatment before"
"24498";"Total UPDRS score (baseline), mean (SD)"
"24499";"Total UPDRS score (range, 0-176)卞"
"24500";"Total UPDRS score (range, 0—176)y"
"24501";"Total vdH-S score"
"24502";"Total vdH-S score (0-448) (n)"
"24503";"Total!"
"24504";"Total! By baseline diabetic status"
"24505";"Total(N=2313)"
"24506";"Total*"
"24507";"Total, adjusted weight of 0.1 for gastrointestinal bleeding"
"24508";"Total, adjusted weight of 0.25 for gastrointestinal bleeding"
"24509";"Total, adjusted weight of 0.5 for gastrointestinal bleeding"
"24510";"Total, N = 439"
"24511";"Total, N = 745"
"24512";"total, n=16 485"
"24513";"Total, N=439"
"24514";"TotaLHDL cholesterol ratio"
"24515";"TOWARD"
"24516";"TP vs No TP"
"24517";"TPASI 75"
"24518";"TPM-exposed"
"24519";"TPM-naive"
"24520";"TPM subgroup, n = 122"
"24521";"TR jet velocity (m/sec)"
"24522";"Traditional Chinese medicine for respiratory disease — no. (%)"
"24523";"Traditional NSAID"
"24524";"Traditional NSAID use"
"24525";"Trait"
"24526";"Trandolapril"
"24527";"Trandolapril (n=4153)"
"24528";"Transaminases increased"
"24529";"Transfemoral"
"24530";"transfusion"
"24531";"Transfusion"
"24532";"Transfusion ≥2 units RBCs or whole blood"
"24533";"Transfusions"
"24534";"Transient"
"24535";"Transient ischaemic attack"
"24536";"Transient Ischaemic attack—No. (%)"
"24537";"Transient ischemic attack"
"24538";"Transient ischemic attack (%) Type of lacunar syndrome (%)"
"24539";"Transient monocular blindness"
"24540";"Transient ST elevation"
"24541";"Transradial"
"24542";"Treated"
"24543";"Treated at baseline"
"24544";"Treated at baseline, mean (SD), mm Hg"
"24545";"Treated at baseline, mm Hg: SBP, mean (SD)"
"24546";"Treated for hypertension, %"
"24547";"Treated hypertension:"
"24548";"Treated lesions‡"
"24549";"Treated patients with baseline and   1 post-baseline efﬁcacy measurement; bP value for treatment group comparison (proactive intervention vs usual care) was calculated based on a 2-sample t test for continuous variables and chi-square test for categorical variables; cBP values were measured at baseline (week 0), whereas information on all of the other variables listed was collected during screening.
Abbreviations: BMI, body mass index; BP, blood pressure; CHD, coronary heart disease; CRUCIAL, Cluster Randomized Usual Care vs Caduet Investigation Assessing Long-Term-Risk; DBP, diastolic blood pressure; DM, diabetes mellitus; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; SD, standard deviation; SBP, systolic blood pressure; TC, total cholesterol; TG, triglyceride."
"24550";"Treated vessel"
"24551";"Treated vessel - Native coronary"
"24552";"Treated vessel!"
"24553";"Treated vessel(s)"
"24554";"Treated with Atenolol (n = 1104)"
"24555";"Treated with Atenolol (n = 3484)"
"24556";"Treated with CABG — no./total no. (%)"
"24557";"Treated with insulin"
"24558";"Treated with LABA, %"
"24559";"Treated with Losartan (n = 1203)"
"24560";"Treated with Losartan (n = 3402)"
"24561";"Treated with PCI — no./total no. (%)"
"24562";"treatment"
"24563";"Treatment"
"24564";"Treatment-by-subgroup interaction"
"24565";"Treatment-by-subgroup interaction, P =  0.06"
"24566";"Treatment-by-subgroup interaction, P = 0.67"
"24567";"Treatment (DE vs warfarin) by thrombophilia interaction"
"24568";"Treatment after admission"
"24569";"Treatment after randomization, in the single-dummy phase — days]"
"24570";"Treatment and parameter"
"24571";"Treatment arm"
"24572";"Treatment Arm"
"24573";"Treatment arm (zoledronate) (%)"
"24574";"Treatment at baseline"
"24575";"Treatment at randomisation"
"24576";"Treatment at randomization"
"24577";"Treatment at randomization — no. (%)"
"24578";"Treatment before admission (%)"
"24579";"Treatment before catheterization"
"24580";"Treatment before randomization — days"
"24581";"Treatment before randomization, %"
"24582";"Treatment by eGFR stage"
"24583";"Treatment by subgroup interaction"
"24584";"Treatment Characteristics"
"24585";"Treatment comparison"
"24586";"Treatment comparison (mg/day)t"
"24587";"Treatment Diff. vs TIO (95% CI)"
"24588";"Treatment difference"
"24589";"Treatment Difference"
"24590";"Treatment Difference % (95% Cl)"
"24591";"Treatment difference (95% CI)"
"24592";"Treatment difference (95% Cl)"
"24593";"Treatment Difference (95% Cl)"
"24594";"Treatment Difference, mL"
"24595";"Treatment duration before randomization — days"
"24596";"Treatment duration Mean (SD)"
"24597";"Treatment duration, days"
"24598";"Treatment during or after catheterization"
"24599";"Treatment effect (HR)"
"24600";"Treatment for latent tuberculosis^"
"24601";"Treatment glargine"
"24602";"Treatment group"
"24603";"Treatment Group"
"24604";"Treatment group, on-treatment IL-6 threshold"
"24605";"Treatment groups [n/Nb(%)]"
"24606";"Treatment groups, n (%)"
"24607";"treatment period Index DVT: event"
"24608";"Treatment randomization"
"24609";"Treatment Stratum^:"
"24610";"Treatment throughout study"
"24611";"Treatment with anti-platelet drugs"
"24612";"Treatment with antiplatelet drugs"
"24613";"Treatment with any blood-pressure-"
"24614";"Treatment with any BP lowering drugs"
"24615";"Treatment with candesartan"
"24616";"Treatment with drugeluting stent"
"24617";"Treatment with open-label perindopril"
"24618";"Treatment with statins"
"24619";"Treatment with sulphonylurea + biguanide, n (%)"
"24620";"Treatment with sulphonylurea + biguanide, n {%)"
"24621";"Treatment with sulphonylurea, n (%)"
"24622";"treatment, n (%)"
"24623";"Treatment × lipid interaction"
"24624";"Treatmentofpulmonary embolismpriorto randomization"
"24625";"Treatments at randomisation"
"24626";"Trend/het. test"
"24627";"Triacylglycerol, mmol/l, mean (SD)"
"24628";"Triacylglycerol, mmol/le"
"24629";"Trial"
"24630";"Trial 1"
"24631";"Trial 2"
"24632";"Trial 3"
"24633";"Trial completers"
"24634";"Trigl yeerides* (m mol/l)"
"24635";"Triglyceride"
"24636";"Triglyceride  a"
"24637";"Triglyceride (median: mg/dL)a [25-75 percentile]"
"24638";"Triglyceride (median; mg/dL)-1 [25-75 percentile|"
"24639";"Triglyceride (mg/dL)"
"24640";"Triglyceride (mg/dl) 3"
"24641";"Triglyceride (mg/dL)d"
"24642";"Triglyceride (mm"
"24643";"Triglyceride (mmol/L)"
"24644";"Triglyceride (mmol/L)* Blood pressure"
"24645";"Triglyceride (mmol/L)t"
"24646";"Triglyceride level"
"24647";"Triglyceride, mg/dL, mean (SD)"
"24648";"Triglyceride, mmol/L"
"24649";"Triglycerides"
"24650";"Triglycerides - mg/dL**"
"24651";"Triglycerides — mg/dl"
"24652";"Triglycerides — mg/dl^"
"24653";"Triglycerides — mg/dl||"
"24654";"Triglycerides — mmol/L"
"24655";"Triglycerides — mmol/liter"
"24656";"Triglycerides $150 mg/dL (1.69 mmol/L)"
"24657";"Triglycerides (median, IQR), mg/dL"
"24658";"triglycerides (mg/dl)"
"24659";"Triglycerides (mg/dL)"
"24660";"Triglycerides (mg/dL)**"
"24661";"Triglycerides (mg/dL), mean + SD, available for 3643 patients"
"24662";"Triglycerides (mmol/l)"
"24663";"Triglycerides (mmol/L)"
"24664";"Triglycerides (mmol/L) (median, IQR)"
"24665";"Triglycerides (mmol/L), mean (SD)"
"24666";"Triglycerides (mmol/L):"
"24667";"Triglycerides (SD), mg/dL"
"24668";"Triglycerides (week 24)a"
"24669";"Triglycerides <1-69 mmol/L"
"24670";"Triglycerides >1-69 mmol/L"
"24671";"Triglycerides >150 mg/dl"
"24672";"Triglycerides >150 mg/dL (>1.70 mmol/L)"
"24673";"Triglycerides 1st third"
"24674";"Triglycerides 2nd third"
"24675";"Triglycerides 3,d third"
"24676";"Triglycerides at Baseline"
"24677";"Triglycerides level, mg/dL"
"24678";"Triglycerides Mean"
"24679";"Triglycerides mean (mg/dl ± SD)"
"24680";"Triglycerides Tx difference vs Pbo, LS mean % change from baseline (SE)"
"24681";"Triglycerides*"
"24682";"Triglycerides* (mg/dl)"
"24683";"Triglycerides**"
"24684";"Triglycerides, median (IQR), mg/dL"
"24685";"Triglycerides, median (Q1:Q3)"
"24686";"Triglycerides, median (QI, Q3), mmol/L"
"24687";"Triglycerides, median (Ql, Q3), mmol/L"
"24688";"Triglycerides, median (range)"
"24689";"Triglycerides, mg/dl"
"24690";"Triglycerides, mg/dL"
"24691";"TriglyceriDes, mg/DL"
"24692";"Triglycerides, mg/dL, median (Q1:Q3)"
"24693";"Triglycerides, mg/dL^"
"24694";"Triglycerides, mg/L"
"24695";"Triglycerides, mmol/L"
"24696";"Triglycerides, mmol/L, mean (SD)"
"24697";"Triglycerides, mmol/L, mean±SD"
"24698";"Triglycerides, mmol/l§"
"24699";"Triglycerides, mmol/L®"
"24700";"Triglycerides, mmol/Lf"
"24701";"Triglycerides, mmolT1 (GM*)"
"24702";"Triglycerides,* mmol/L"
"24703";"Triple-vessel disease, n (%)"
"24704";"Triple therapy use at screening, n (%)"
"24705";"Trochanter"
"24706";"Troponin"
"24707";"Troponin (-)"
"24708";"Troponin (+)"
"24709";"Troponin 1 at baseline"
"24710";"Troponin 1 at baseline*"
"24711";"Troponin I (pg/ml)"
"24712";"Troponin Level"
"24713";"Troponin Negative (N=888)"
"24714";"Troponin Positive (N=1291)"
"24715";"Troponin T"
"24716";"Troponin T (pg/ml)"
"24717";"Trough FEV, response (L)i"
"24718";"Trough FEV| response (L)"
"24719";"Trough FEV1"
"24720";"Trough FEV1 response"
"24721";"Trough FEVi L"
"24722";"Trough FVC response (L)"
"24723";"Trough FVC response (L)!"
"24724";"Trough seated DBP (mmHg)a"
"24725";"Trough seated HR (bpm)a"
"24726";"Trough seated SBP (mmHg)a"
"24727";"Troy (ng/ml)"
"24728";"TT"
"24729";"TTf-fV"
"24730";"TTR (warfarin arm only)"
"24731";"TVR"
"24732";"Two-dimensional echocardiography"
"24733";"Two-sided P-value for hetero- geneity"
"24734";"Two-vessel disease"
"24735";"Two agents"
"24736";"Two arm"
"24737";"Two lesions"
"24738";"Two of the above"
"24739";"Two or more"
"24740";"Two or more antihypertensive medications"
"24741";"Two or more at baseline"
"24742";"Type"
"24743";"type 1 collagen, mean (SD), ng/mL£"
"24744";"Type 1, n (%)"
"24745";"Type 2 diabetes"
"24746";"Type 2 diabetes — no. (%)"
"24747";"Type 2 diabetes — no. (%)§"
"24748";"Type 2 diabetes — no. {%)§"
"24749";"Type 2 Diabetes (n=87, 88)"
"24750";"Type 2 diabetes 一no. (%)"
"24751";"Type 2 diabetes duration, mean (SD), years"
"24752";"Type 2 diabetes duration, years"
"24753";"Type 2 diabetes history, n (%)"
"24754";"Type 2 diabetes meiiitus"
"24755";"Type 2 diabetes mellitus"
"24756";"Type 2 diabetes mellitus'1'"
"24757";"Type 2 diabetes mellitus, n (%)"
"24758";"Type 2 diabetes mellitus’"
"24759";"Type 2 diabetes mellitusa"
"24760";"Type 2 diabetes Pbo (N = 43) vs EvoMab (N = 77)"
"24761";"Type 2 diabetes*"
"24762";"Type 2 diabetes, n (%)"
"24763";"Type 2 diabetes, n (%)d"
"24764";"Type 2 diabetes, No. (%)"
"24765";"Type 2 diabetes. n (%)"
"24766";"Type 2, n (%)"
"24767";"Type B2/C lesions, n (%)"
"24768";"Type IA"
"24769";"Type IB"
"24770";"Type IC"
"24771";"Type II diabetes"
"24772";"Type of AF"
"24773";"Type of AF, n (%)"
"24774";"Type of antihypertensive medication use among patients using antihypertensive medications, n (%)"
"24775";"Type of atrial fibrillation"
"24776";"Type of atrial fibrillation - n (%)"
"24777";"Type of atrial fibrillation — no./total no. (%)"
"24778";"Type of atrial fibrillation (%)"
"24779";"Type of atrial fibrillation (n=21 099)"
"24780";"Type of atrial fibrillation, n (%)"
"24781";"Type of atrial fibrillation, No./total No. (%)"
"24782";"Type of basal insulin, n (%)"
"24783";"Type of concomitant statin"
"24784";"Type of Concomitant Statin"
"24785";"Type of concomitant statin by daily dose"
"24786";"Type of concomitant statin by daily dose- no. (%)"
"24787";"Type of DES"
"24788";"Type of DES at index procedure"
"24789";"Type of drug-eluting stent, n (%)"
"24790";"Type of End Point"
"24791";"Type of event"
"24792";"Type of event — no. (%)"
"24793";"Type of event:"
"24794";"Type of hospital care"
"24795";"Type of Hospitalization"
"24796";"Type of index event — no. (%)"
"24797";"Type of insulin"
"24798";"Type of insulin therapy— no. (%)5"
"24799";"Type of intervention"
"24800";"Type of Lipid-Lowering Regimen"
"24801";"Type of MI (%)"
"24802";"Type of Ml, No. (%)"
"24803";"Type of myocardial infarction — no. (%)"
"24804";"Type of reference treatment strategy"
"24805";"Type of stent at index procedure"
"24806";"Type of surgery"
"24807";"Type of surgery CABG"
"24808";"Type of surgery CABG only"
"24809";"Type of TNF antagonist failure, n (%)'’"
"24810";"Type of TNF antagonist failure, n (“/o)”"
"24811";"Type of TNF failure, n (%)b"
"24812";"Type of treatment, n (%)"
"24813";"Type of vessel involved"
"24814";"Type/No. of valves repaired/replaced Mitral"
"24815";"Types of antihypertensive medications at 1 year †"
"24816";"Types of antihypertensive medications at last visit §"
"24817";"Types of fibrinolytic agent"
"24818";"TZD"
"24819";"U.S. Black Patients"
"24820";"U.S. Non-Black Patients"
"24821";"U.S. site"
"24822";"U.S. sites"
"24823";"u»c»(mg/g)"
"24824";"UA"
"24825";"UA (N =204)"
"24826";"UAC ="
"24827";"UAC >300 mg/g"
"24828";"UAC 30-300 mg/g"
"24829";"UACR"
"24830";"UACR — mg/g, median (IQR)"
"24831";"UACR (mg/g)"
"24832";"UACR (mg/g, median [IQR])"
"24833";"UACR (mgg-1)"
"24834";"uACR Not Available"
"24835";"uACR <3 mg/mmol∗"
"24836";"uACR ≥3 mg/mmol∗"
"24837";"UACR*, mg/g (q1; q3)"
"24838";"UACR, median (IQR), mg/g"
"24839";"UACR, mg/g, median (25th−75th percentile)"
"24840";"UACR, mg/g, median (IQR)"
"24841";"UACR, mg/mmol (interquartile range)b"
"24842";"UACR, mgg 1 (GM)"
"24843";"UACR, n (%)†"
"24844";"UACR, pg/mg"
"24845";"UACRa, mg/g, gMean = gCV"
"24846";"UACRa, mg/g, n (%)"
"24847";"UAE (p,g/min)"
"24848";"UAS7{"
"24849";"UAS76"
"24850";"UC"
"24851";"UC (n = 1325)"
"24852";"UC (n = 1514)"
"24853";"UC (n = 2119)"
"24854";"UC (n = 492)"
"24855";"UC (n = 755)"
"24856";"UC (n = 989)"
"24857";"UC [GEMINI 1]‘"
"24858";"UC disease duration (y)"
"24859";"UC disease durslion"
"24860";"UC duration, y, mean (range)"
"24861";"UC history"
"24862";"UCL"
"24863";"UCR"
"24864";"udy entry"
"24865";"UFH"
"24866";"UFH Only"
"24867";"UGT induction status: as randomizeda, n (%)"
"24868";"UGT induction status: per AEDa, n (%)"
"24869";"UIstekinumab"
"24870";"UKPDS 10-year risk score <20%"
"24871";"UKPDS 10-year risk score >20%"
"24872";"Ukraine"
"24873";"Ularitide (N = 1088)"
"24874";"Ularitide n/N (%)"
"24875";"Ulcer"
"24876";"Ulcer, n (%)a"
"24877";"Ulcerative colitis"
"24878";"Ulcers/gangrene"
"24879";"ULPASI 75"
"24880";"Ultra"
"24881";"Ultrasound carotid arteries"
"24882";"UMEC 62.5 |ig (n=509)"
"24883";"UMEC 62.5 mcg (N=509)"
"24884";"UMEC/VI 62.5/25"
"24885";"UMEC/VI 62.5/25 (N 5 275)"
"24886";"UMEC/VI 62.5/25 (N 5 878)"
"24887";"umied"
"24888";"Unacceptable adverse events"
"24889";"Unacceptable side effects"
"24890";"Unadjusted"
"24891";"Unadjusted 8-y Risk per 100 Population = SE (Adjusted Rate)"
"24892";"Unadjusted Hazard Ratio (95% Ci)"
"24893";"Unadjusted Hazard Ratio (95% Cl)"
"24894";"Unadjusted HR"
"24895";"Unadjusted HR (95% CI) for 1 SD increment"
"24896";"Unadjusted HR (95% CI) for 1 standard deviation increment"
"24897";"Unadjusted HR (95% CI)a"
"24898";"Unadjusted HR."
"24899";"Unadjusted IRR"
"24900";"Unadjusted model HR, 95% CI, P value"
"24901";"Unadjusted OR (95% CI) P Value"
"24902";"Unadjusted P-value for Interaction"
"24903";"Unadjusted p Value"
"24904";"Unadjusteda Beta (SE)"
"24905";"Unbound PCSK9 (nmol/L)"
"24906";"Uncerlain"
"24907";"Uncertain"
"24908";"Unclassified"
"24909";"Uncodable"
"24910";"Uncontrolled"
"24911";"Uncontrolled on basal insulin"
"24912";"Uncontrolled on OAD(s)"
"24913";"Uncontrolled: ACQ-6 >1.5"
"24914";"UNCOVER-2"
"24915";"UNCOVER-3"
"24916";"Undergoing major vascular surgery"
"24917";"Underlying disease"
"24918";"Undetermined"
"24919";"Undetermined etiology"
"24920";"Undetermined etiology, n (%)"
"24921";"Undetermined, other, or cardioembolism"
"24922";"Undeterminedc"
"24923";"Undiagnosed Diabetes (n = 142)"
"24924";"Undiagnosed Diabetes Mellitus"
"24925";"Undiagnosed Diabetes Mellitus, n=1106"
"24926";"Unfractionated"
"24927";"Unfractionated heparin"
"24928";"Unfractionated heparin — no. (%)"
"24929";"Unfractionated Heparin (N = 10,223)"
"24930";"Unfractionated heparin (n = 1961)"
"24931";"Unfractionated Heparin (n = 4985)"
"24932";"Unfractionated heparin (n = 872)"
"24933";"Unfractionated heparin before randomisation"
"24934";"Unfractionated heparin only"
"24935";"Unfractionated Heparin or Enoxaparin plus Glycoprotein IIb/IIIa Inhibitors (N = 4603)"
"24936";"Unfractionated heparin within 3 hr before randomization — no./total no. (%)"
"24937";"Unfractionated only"
"24938";"Unhappy"
"24939";"Unified Parkinson Disease"
"24940";"United States"
"24941";"United States (n = 1,388)"
"24942";"United States and Canada"
"24943";"United States or Canada"
"24944";"United States, Canada"
"24945";"United States, Canada,"
"24946";"UNITI-1"
"24947";"UNITI-1 and UNITI-2    IM-UNITI"
"24948";"UNITI-2"
"24949";"Units per week, mean (SD)"
"24950";"Univariable"
"24951";"Univariable OR (95% CI), p Value*"
"24952";"Univariate logistic modela"
"24953";"Unknown"
"24954";"Unknown — no. {%)"
"24955";"Unknown (%)"
"24956";"Unknown (none of the above)"
"24957";"Unknown or missing"
"24958";"Unknown type"
"24959";"Unknown/missing"
"24960";"Unprotected left main stented"
"24961";"Unprovoked"
"24962";"Unprovoked VTE n (%)"
"24963";"Unrelated to effectiveness"
"24964";"Unspecified"
"24965";"Unstable"
"24966";"Unstable angina"
"24967";"Unstable Angina"
"24968";"Unstable angina — no. (%)"
"24969";"Unstable angina (biomarker negative)"
"24970";"Unstable angina (n = 2,874)"
"24971";"Unstable angina >1 mo ago"
"24972";"unstable angina Age"
"24973";"Unstable angina requiring hospitalization"
"24974";"Unstable angina*"
"24975";"Unstable angina, n (%)"
"24976";"Unstable angina§"
"24977";"Unstable anginad"
"24978";"Unstable anginat"
"24979";"Unstable but no rest angina"
"24980";"Unstableangina"
"24981";"Unsuccessful procedure"
"24982";"Untreated"
"24983";"Untreated at baseline"
"24984";"Untreated at baseline, mean (SD), mm Hg"
"24985";"Untreated at baseline, mm Hg: SBP, mean (SD)"
"24986";"UPA 15mg QD"
"24987";"UPA 30 mg QD"
"24988";"Upadacitinib 15 mg (n=l64)"
"24989";"Upadacitinib 30 mg (n=l65)"
"24990";"UPCR, n (%)"
"24991";"UPDRS III (motor)"
"24992";"UPDRS score"
"24993";"UPDRS total (II + III)"
"24994";"UPDRS, Part II (ADL)"
"24995";"UPDRS, Part III (motor)"
"24996";"UPLIFT® population"
"24997";"upper"
"24998";"Upper abdominal pain"
"24999";"Upper gastrointestinal"
"25000";"Upper gastrointestinal tract"
"25001";"Upper Limb"
"25002";"Upper limb fracture"
"25003";"Upper limb fractures"
"25004";"Upper limbs"
"25005";"Upper respiratory tract infection"
"25006";"Upper respiratory tract infection 84 (5.7)"
"25007";"Upper respiratory tract inflammation"
"25008";"Upper tertile: > 0.37"
"25009";"UPS score, mean (SD)"
"25010";"ure"
"25011";"Urgency episodes/24h"
"25012";"Urgent Cor Revasc"
"25013";"Urgent coronary revascularization"
"25014";"Urgent peripheral revascularization"
"25015";"Urgent revascularisation due to unstable angina"
"25016";"Urgent revascularizati on"
"25017";"Urgent revascularization because of unstable angina"
"25018";"Urgent surgery"
"25019";"Urgent vascular hospitalization"
"25020";"Uric acid (mg/dL)"
"25021";"uric acid (mg/dl) creatinine clearance (ml/min per 1.73 m2)"
"25022";"Uric acid fertile 3 (>6.51 mg/dl)"
"25023";"Uric acid tertile 1 (<5.2 mg/dl)"
"25024";"Uric acid tertile 2 (5.2 to <6.51 mg/dl)"
"25025";"Uric acid tertile 3 (>6.51 mg/dl)"
"25026";"Urinary ACR"
"25027";"Urinary ACR (mg/mmol)"
"25028";"Urinary albumimcreatinine ratio"
"25029";"Urinary albumin-to-creatinine ratio — no. (%)§"
"25030";"Urinary albumin-to-creatinine ratio^"
"25031";"Urinary albumin-to-creatinine ratio§"
"25032";"urinary albumin/creatinine ratio, median mg/g (range)"
"25033";"Urinary albumin:creatinine ratio (mg/g)"
"25034";"Urinary albumin:creatinine ratio (pg/mg), median (IQR)"
"25035";"Urinary albumin:creatinine ratio*"
"25036";"Urinary albumin:creatinine ratio^"
"25037";"Urinary albumin:creatinine ratioa (mg/g)"
"25038";"Urinary protein-to-creatinine ratio||"
"25039";"Urinary protein:creatinine ratioa (mg/mg)"
"25040";"Urinary tract infection"
"25041";"Urine ACR (mg/g)"
"25042";"Urine ACR (mg/mmol)"
"25043";"Urine ACR < Median"
"25044";"Urine ACR >= Median"
"25045";"Urine ACR geometric mean (CV %),a,b mg/g"
"25046";"Urine albumin-to-creatinine ratio"
"25047";"Urine albumin-to-creatinine ratio - no. (%)§§"
"25048";"Urine albumin-to-ereatinine ratio"
"25049";"Urine albumin/creatinine (mg/mmol)"
"25050";"Urine albumin/creatinine ratio (mg/g)"
"25051";"Urine albumin/creatinine ratio, mg/mmol"
"25052";"Urine P/Cr"
"25053";"Urine Qmax, ml/s"
"25054";"URTI"
"25055";"Urticaria"
"25056";"US"
"25057";"US (N=4097)"
"25058";"US N= 96"
"25059";"US Resident"
"25060";"US site"
"25061";"US site of enrollment"
"25062";"US W= 92"
"25063";"USA"
"25064";"USA (n=1,293)"
"25065";"USA (n=446)"
"25066";"USA and Canada"
"25067";"USA(n=1293)"
"25068";"USA/Canada"
"25069";"use"
"25070";"Use"
"25071";"use (%)"
"25072";"Use 5-ASA compounds"
"25073";"Use at baseline"
"25074";"Use at baseline, n"
"25075";"Use of ACE inhibitor"
"25076";"Use of ACE inhibitor, ARB, or both — no. (%)"
"25077";"Use of ACE inhibitors/ARBs, n (%)"
"25078";"Use of anti-hypertensive agents, n (%) *"
"25079";"Use of antiarrhythmic agent"
"25080";"use of antihypertensive drugs"
"25081";"Use of antiplatelet agents — no./total no. (%)"
"25082";"Use of antiplatelet agents, n (%)"
"25083";"Use of antiplatelet agents^"
"25084";"Use of aspirin at time of qualifying event (%)"
"25085";"Use of beta-blocker"
"25086";"Use of beta-blockers"
"25087";"Use of blood pressure lowering medication*"
"25088";"Use of cardiac medication*"
"25089";"Use of CGM (Yes)"
"25090";"Use of CGM interaction test p-value^ ="
"25091";"Use of clopidogrel"
"25092";"Use of compression stockings, No. (%)"
"25093";"Use of concomitant lipid-lowering therapy- no. (%)"
"25094";"Use of concomitant lipid-lowering treatment"
"25095";"Use of concomitant lipid-modifying therapy"
"25096";"Use of Concomitant Lipid-Modifying Therapy"
"25097";"Use of diuretics, n (%)"
"25098";"Use of H2 bloekers, n (%)"
"25099";"Use of high-dose inhaled glucocorticoid — no. {%)"
"25100";"Use of hormone replacement therapy (A)"
"25101";"Use of ICS"
"25102";"Use of ICS at baseline, %"
"25103";"Use of inhaled glucocorticoids at baseline"
"25104";"Use of inhaled glucocorticoids at screening — no. (%)"
"25105";"Use of loop diuretics"
"25106";"Use of loop diuretics, n (%)"
"25107";"Use of Low-dose Aspirin (< 325"
"25108";"Use of low-dose aspirin (< 325 mg daily)"
"25109";"Use of low-dose aspirin (<325 mg daily)"
"25110";"Use of medication at baseline — no. (%)"
"25111";"Use of medication for PAH"
"25112";"Use of medication from randomization through 24 hr — no./total no. (%)"
"25113";"Use of medications for PAH — no. (%)"
"25114";"Use of methotrexate at randomization —"
"25115";"Use of oral glucocorticoids"
"25116";"Use of other medications — no. (%)"
"25117";"Use of parenteral antithrombotic"
"25118";"Use of parenteral antithrombotic agents — no. (%)"
"25119";"Use of PCI or thrombolysis within one day of Randomization"
"25120";"Use of proton inhibitors, n (%)"
"25121";"Use of rescue albuterol, puffs/day*"
"25122";"Use of rescue medication"
"25123";"Use of statin at any follow-up visit (%)"
"25124";"Use of statins"
"25125";"Use of supplemental oxygen, n (%)"
"25126";"Use of systemic glucocorticoid at random-"
"25127";"Use of ticagrelor"
"25128";"Use of verapamil or quinidine"
"25129";"Use oforal glucose-lowering agent— no. (%)"
"25130";"used"
"25131";"Useofmedical therapyathospitaldischarge"
"25132";"User"
"25133";"Using alendronate at baseline (%)"
"25134";"Using HRT or raloxifene at baseline (%)"
"25135";"Usteki"
"25136";"Ustekinu"
"25137";"Ustekinumab"
"25138";"Ustekinumab'’ (n = 46)"
"25139";"Ustekinumab 45 mg (n=205)"
"25140";"Ustekinumab 90 mg (n=204)"
"25141";"Ustekinumab Combined"
"25142";"Ustekinumab® (n = 155)"
"25143";"Usual care"
"25144";"Usual Care"
"25145";"Usual Care (n = 276a)"
"25146";"Usual Care (n = 38la)"
"25147";"Usual care (n=2119)"
"25148";"UTI"
"25149";"UTIs"
"25150";"UVB"
"25151";"Uveitis"
"25152";"V alsartan/HCTZ, n (%)"
"25153";"V(n=190)"
"25154";"V/HCTZ"
"25155";"V/HCTZ (n=103)"
"25156";"V/HCTZ (n=67)"
"25157";"V160 (n = 1"
"25158";"VaDAS score*"
"25159";"Val/HCTZ (n=46)"
"25160";"Val/HCTZ (n=63)"
"25161";"Val/HCTZ (n=80)"
"25162";"Valdecoxib"
"25163";"Valproate"
"25164";"Valsartan"
"25165";"Valsartan (N = 722)"
"25166";"Valsartan (n = 836)"
"25167";"Valsartan (N =4631)"
"25168";"Valsartan (n=565)"
"25169";"Valsartan n/N"
"25170";"Valsartan, n (%)"
"25171";"Valsartan, n/N (%)"
"25172";"Valsartan/HCTZ"
"25173";"Valsartan/HCTZ (n = 832)"
"25174";"Valsartan/HCTZ, n/N (%)"
"25175";"value"
"25176";"Value"
"25177";"Value for nteraction"
"25178";"Value*"
"25179";"Values are expressed as percentages unless otherwise indicated. BMI, Body mass index; CABG, coronary artery bypass ischemic attack; NSAIDS, nonsteroidal anti-inflammatory drugs, SBP, systolic BP; DBP, diastolic BP. *History of or currently taking antidiabetic or lipid-lowering medications."
"25180";"Values are mean±SD, median [quartile range], or %. ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BNP, B-type natriuretic peptide; BP, blood pressure; BUN, blood urea nitrogen; LVEF, left ventricular ejection fraction; and NT-proBNP, N-terminal pro-B-type natriuretic peptide."
"25181";"Values are presented as mean SD unless stated otherwise. Data shown are for the randomized population. *Body mass index values were missing from 5 patients in the aliskiren group and 2 patients in the hydrochlorothiazide group. †Obesity was defined as body mass index  30 kg/m2. ‡Metabolic syndrome was defined according to the Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) criteria10 as any 3 of the following: waist circumference  102 cm for men or  88 cm for women; triglycerides  150 mg/dL; high-density lipoprotein cholesterol  40 mg/dL for men or  50 mg/dL for women; msSBP  130 mm Hg or msDBP  85 mm Hg; fasting glucose  110 mg/dL. §By medical history.  Aliskiren, n 566; hydrochlorothiazide, n 558."
"25182";"Values expressed as mean   SD or number (percent). * Two patients were missing values for body mass index.
†
Other forms of atherosclerosis are peripheral arterial disease, abdom-inal aortic aneurysm, symptomatic carotid artery disease, transient isch-emic attack, and stroke.
‡
Family history of premature CHD deﬁned as CHD in male ﬁrst-degree relative aged  55 years or female ﬁrst-degree relative  45 years.
§
Blood pressure  130/85 mm Hg, on antihypertensive medication, or diagnosis of hypertension based on medical history. n   number of randomly assigned patients; NCEP ATP   National Cholesterol Education Program Adult Treatment Panel."
"25183";"values were calculated using t tests for continuous variables and chi-square"
"25184";"values were reported for 229 patients in the spironolactone group and 239"
"25185";"Valve repair/replacement only"
"25186";"Valve repair/replacement with or without CABG"
"25187";"Valve replacement/ repair with or without CABG"
"25188";"Valve surgery, n (%)"
"25189";"Valvular disease"
"25190";"Valvular disease (%)"
"25191";"Valvular disease, mitral"
"25192";"Valvular heart disease"
"25193";"Valvular heart disease — no. (%)"
"25194";"Valvular heart disease, n (%)"
"25195";"van der Heijde mTSS, mean (SD)"
"25196";"Varespladib"
"25197";"Varespladib (n = 2572)"
"25198";"variable"
"25199";"Variable"
"25200";"VARIABLE"
"25201";"Variable'!'"
"25202";"Variable Demographic characteristics"
"25203";"variable_level"
"25204";"variables"
"25205";"Variables"
"25206";"Variables*"
"25207";"variables."
"25208";"Variables3"
"25209";"VAS (0-100)"
"25210";"Vascular"
"25211";"Vascular access site†"
"25212";"Vascular accidents, n (%)"
"25213";"Vascular death"
"25214";"Vascular disease"
"25215";"Vascular disease (% of group)"
"25216";"Vascular Disease Indicator    No (n=6650)"
"25217";"Vascular disordersb"
"25218";"Vascular history, %"
"25219";"Vascular intervention"
"25220";"Vascular risk score — no. {%)^"
"25221";"Vascular risk score |"
"25222";"Vascular risk score*"
"25223";"Vascular territory #1"
"25224";"Vascular territory #2"
"25225";"Vasodilator"
"25226";"Vasodilator therapy"
"25227";"Vasoprotectives"
"25228";"VASP PRI-defined HPR (% patients)"
"25229";"vdHmTSS"
"25230";"VDZ n = \99"
"25231";"VDZ n = 394"
"25232";"VDZ n = 99"
"25233";"VDZ/PBO [n = 135]"
"25234";"VDZ/PBO [n = 18]"
"25235";"VDZ/PLA n = 36"
"25236";"VDZ/PLA n = 77"
"25237";"VDZ/VDZ [n = 269]"
"25238";"VDZ/VDZ [n = 39]"
"25239";"Vedolizumab"
"25240";"Vedolizumab Cohort 1 (n = 130)"
"25241";"Vedolizumab Cohort 1 (n = 82)"
"25242";"Vedolizumab Cohort 2 (n = 222)"
"25243";"Vedolizumab Cohort 2 (n = 258)"
"25244";"Vedolizumab n = 130"
"25245";"Vedolizumab n = 160"
"25246";"Vedolizumab n = 225"
"25247";"Vedolizumab n = 269"
"25248";"Vedolizumab n = 429"
"25249";"Vedolizumab n = 95"
"25250";"veflonzumao"
"25251";"VEGFR (ng/ml)"
"25252";"Vein bypass graft stented"
"25253";"Vein bypass stented"
"25254";"Vein graft stented"
"25255";"Venous"
"25256";"Venous graft"
"25257";"Venous insufficiency"
"25258";"Ventricular tachyarrhythmias"
"25259";"Ventricular tachycardia or fibrillation"
"25260";"vents/patients"
"25261";"Verapamil-SR (« = 11 094)"
"25262";"Verapamil-SR strategy"
"25263";"Verapamil (n, %)"
"25264";"Verapamil SR"
"25265";"Verapamil SR (No.=3169)"
"25266";"Verapamil SR n=3169"
"25267";"Verapamil SR strategy (n = 2,922)"
"25268";"VerifyNow PRU-defined HPR (% patients)"
"25269";"versus olodaterol 5 pg"
"25270";"versus tiotropium 2.5 pg"
"25271";"versus tiotropium 5 pg"
"25272";"versus tiotropium 5 pg Tiotropium + olodaterol 2-5/5 pg"
"25273";"versus tiotropium 5 pg Tiotropium + olodaterol 2.5/5 pg"
"25274";"versus tiotropium+olodaterol 2.5/5 pg"
"25275";"Vertebral fracture and/or T score -2.0"
"25276";"Vertebral fracture and/or T score S -2.5"
"25277";"Vertebral fractures at baseline"
"25278";"Vertebrobasilar infarct"
"25279";"Very elderly patients (n - 2098)"
"25280";"Very g ood/ ex cellent"
"25281";"Very good or excellent"
"25282";"Very high"
"25283";"Very high (> 3xULN) n = 197"
"25284";"Very high risk"
"25285";"very high vs. normal"
"25286";"very high vs. normalb"
"25287";"Very severe"
"25288";"Very severe (GOLD 4)"
"25289";"Very severe (ITT) (n=334)"
"25290";"Very severe (ITT) (n=339)"
"25291";"Very severe (ITT) (n=341)"
"25292";"Very severe (ITT) (n=342)"
"25293";"Very severe (ITT) (n=447)"
"25294";"Very severe (ITT) (n=457)"
"25295";"Very severe COPD"
"25296";"Very severe n Z 903"
"25297";"Very severe, GOLD 4"
"25298";"Vessel size, mean (SD), mm"
"25299";"Vessel treated, n"
"25300";"VHD"
"25301";"VHD Event Rate/Year (n)"
"25302";"VI -18% (-72%, 19%)"
"25303";"VI -35% (-185%, 3%)"
"25304";"VI –7% (95% CI –35–15%)"
"25305";"VI    12% (-10%, 30%)"
"25306";"VI 1% (95% CI –13–14%)"
"25307";"VI 16% (95% CI 5–25%)"
"25308";"VI 19% (95% CI –9–40%)"
"25309";"VI 25 µg"
"25310";"VI 25 mg (n = 818)"
"25311";"VI 26% (-29%, 58%)"
"25312";"Viidagliptin 100 mg daily + glimepiride"
"25313";"Vilanterol, n=4118"
"25314";"Vildagliptin"
"25315";"Vildagliptin (n=137)"
"25316";"Vildagliptin (n=139)"
"25317";"Vildagliptin + metformin (VLDM)"
"25318";"vildagliptin 100 mg daily"
"25319";"Vildagliptin 100 mg daily"
"25320";"Vildagliptin 50 mg bid"
"25321";"Vildagliptin 50 mg bid N = 146"
"25322";"Vildagliptin 50 mg daily + glimepiride"
"25323";"Vildagliptin 50 mg qd"
"25324";"Vildagliptin 50 mg qd N = 148"
"25325";"Visit"
"25326";"Visit 1 blood pressures:"
"25327";"Visit 2 blood pressures:"
"25328";"Visit 2 DBP, mm Hg"
"25329";"Visit 2 LDL cholesterol strata"
"25330";"Visit 2 SBP, mm Hg"
"25331";"Vital signs, mean (SD)"
"25332";"Vitality"
"25333";"Vitamin C"
"25334";"Vitamin D§"
"25335";"Vitamin E"
"25336";"Vitamin K antagonist"
"25337";"Vitamin K antagonist (e.g. warfarin/coumarol)"
"25338";"Vitamin K antagonist experienced, n (%)"
"25339";"Vitamin K antagonist experiencedk (n=21 104)"
"25340";"Vitamin K antagonist naive"
"25341";"Vitamin K antagonists"
"25342";"Vitamins"
"25343";"VKA"
"25344";"VKA (n = 215)"
"25345";"VKA (n = 287)"
"25346";"VKA (n = 502)"
"25347";"VKA at randomization"
"25348";"VKA at Randomization"
"25349";"VKA experienced"
"25350";"VKA Experienced"
"25351";"VKA naive"
"25352";"VKA Naive"
"25353";"VKA naive, n (%)"
"25354";"VKA Naxve"
"25355";"VKA therapy"
"25356";"VKA, only reason"
"25357";"VLDL"
"25358";"VLDL-C"
"25359";"VLDL cholesterol"
"25360";"VLDM n = 2501"
"25361";"VLDM n = 422"
"25362";"VLDM n = 643"
"25363";"VLDM n = 681"
"25364";"VLDM n = 755"
"25365";"Voided volume, mL"
"25366";"Voiding subscore"
"25367";"Volume change, mm^"
"25368";"Volume depletion-related AEs"
"25369";"Volumetric BMD by QCT"
"25370";"Voluntary"
"25371";"Vomiting"
"25372";"Vonoprazan 10 mg n = 278"
"25373";"Vonoprazan 20 mg n = 271"
"25374";"Vora"
"25375";"Vorapaxar"
"25376";"Vorapaxar    Placebo 3-Yr. KM% rate"
"25377";"Vorapaxar (n = 10.080)"
"25378";"Vorapaxar (N = 13,225)"
"25379";"Vorapaxar (n = 7,223)"
"25380";"Vorapaxar (N=10 080)"
"25381";"Vorapaxar (N=2435)"
"25382";"Vorapaxar (N=6473 )"
"25383";"Vorapaxar 3-y"
"25384";"Vorapaxar Event Rate (n=1809), %"
"25385";"Vorapaxar Event Rate (n=6648), %"
"25386";"Vorapaxar group (n=8898)"
"25387";"Vorapaxar N=2255"
"25388";"Vorapaxar N=6203"
"25389";"Vorapaxar No. (3-y KM%)"
"25390";"Vorapaxar Placebo"
"25391";"Vorapaxar Placebo 3-yr%"
"25392";"Vorapaxar Placebo 3-yr. KM%"
"25393";"Vorapaxar(n=1892)"
"25394";"Vorapaxar(n=1892), n (%)"
"25395";"vs. Placebo"
"25396";"vs. Warfarin"
"25397";"VTE at day 28+"
"25398";"VTE/VTE-related deathsa, n/N (%)"
"25399";"VTE/VTE-related deathsb, n/N (%)"
"25400";"W"
"25401";"W    Event (rate)"
"25402";"W eight ( k g)"
"25403";"W est Europe"
"25404";"W Europe"
"25405";"W hite"
"25406";"W. Europe"
"25407";"Wafarin"
"25408";"Wafarin Event Incidence/N"
"25409";"Waist-hip ratio"
"25410";"Waist-to-hip ratio"
"25411";"Waist-to-hip, female"
"25412";"Waist-to-hip, male"
"25413";"Waist (cm)"
"25414";"Waist circumference"
"25415";"Waist circumference — cm"
"25416";"Waist circumference — cmj"
"25417";"Waist circumference (cm)"
"25418";"Waist Circumference (cm): mean ± SD"
"25419";"Waist circumference S102 (men) or >88 cm (women)"
"25420";"Waist circumference women: > 35 in (88 cm) men: > 40 in (102 cm) TC 2c 150 mg/dL"
"25421";"Waist circumference, (cm)"
"25422";"Waist circumference, cm"
"25423";"Waist circumference, cm (SD)"
"25424";"Waist circumference, cm mean (SD)"
"25425";"Waist circumference, cm, mean (SD)"
"25426";"Waist circumference, mean (SD), cm"
"25427";"Waist circumference, mean (SD), in"
"25428";"Waist circumference."
"25429";"Waist/Hip < Median"
"25430";"Waist:hip ratio"
"25431";"Waisthip ratio"
"25432";"WaisVHip >= Median"
"25433";"Walk for exercise"
"25434";"Walk for exercise (%)"
"25435";"Walking"
"25436";"WAP4C (ng/ml)"
"25437";"War"
"25438";"WAR"
"25439";"Warf"
"25440";"Warfarin"
"25441";"Warfarin % (n/N)"
"25442";"Warfarin (%)"
"25443";"Warfarin (n - 5,594)"
"25444";"Warfarin (N = 1266)"
"25445";"Warfarin (N = 1426)"
"25446";"Warfarin (N = 1669)"
"25447";"Warfarin (n = 184)"
"25448";"Warfarin (N = 2453)"
"25449";"Warfarin (N = 4122)"
"25450";"Warfarin (N = 7036)"
"25451";"Warfarin (N=1558)"
"25452";"Warfarin (n=1685)"
"25453";"Warfarin (n=199)"
"25454";"Warfarin (n=263)"
"25455";"Warfarin (n=407)"
"25456";"Warfarin (n=6022)"
"25457";"Warfarin (n=670)"
"25458";"Warfarin (n=7023)"
"25459";"Warfarin (n=7036), n (%/y)"
"25460";"Warfarin (n=756)"
"25461";"Warfarin (S5% Cl)"
"25462";"Warfarin at enrollment"
"25463";"Warfarin at last follow-up"
"25464";"Warfarin Events/n (%/y)"
"25465";"Warfarin group"
"25466";"Warfarin Group"
"25467";"Warfarin Group (n = 244)"
"25468";"Warfarin Group (N=255)"
"25469";"Warfarin N = 3584"
"25470";"Warfarin N = 3584 n/N (%)"
"25471";"Warfarin N = 538"
"25472";"Warfarin N = 538 n/N (%)"
"25473";"Warfarin n/N; rate (%)"
"25474";"Warfarin n=2326"
"25475";"Warfarin n=3696"
"25476";"Warfarin, No. (%)"
"25477";"WC (cm)"
"25478";"We recorded no significant interactions for any subgroup analysis. NYHA= New York Heart Association. LVEF=left ventricular ejection fraction. '95% Cl was calculated by Cox proportional hazards model. tMedian value. Data for total cholesterol were available for 4537 patients (2266 rosuvastatin, 2271 placebo)."
"25479";"We recorded no significant interactions for any subgroup analysis. PUFA=polyunsaturated fatty acids. NYHA=New York Heart Association. LVEF=left ventricular ejection fraction. *95% Cl was calculated with a Cox proportional hazards model. tMedian value. Data for total cholesterol were available for 6918 patients (3467 n-3 PUFA, 3451 placebo)."
"25480";"Week"
"25481";"Week-30 changea"
"25482";"Week 0"
"25483";"Week 0 — mg/liter"
"25484";"Week 0 CZP 200 mg Q2W"
"25485";"Week 0 CZP 200 mg Q2W (N=138)"
"25486";"Week 0 CZP 400 mg Q4W"
"25487";"Week 0 CZP 400 mg Q4W (N=135)"
"25488";"Week 0 CZP Dose Combined"
"25489";"Week 0 CZP dose combined (N = 273)"
"25490";"Week 0 Mayo endoscopy subscorea"
"25491";"Week 0 Mean±SEM"
"25492";"Week 104"
"25493";"Week 108"
"25494";"Week 12"
"25495";"Week 12 - Baseline"
"25496";"Week 12 — mg/liter^"
"25497";"Week 12 FPG, mean (s.e.)"
"25498";"Week 12 HbA1c, mean (s.e.)"
"25499";"Week 12 Mean+SEM"
"25500";"Week 12 outcome"
"25501";"Week 12 Outcomes"
"25502";"Week 12 Overall population"
"25503";"Week 12 Responders, (n = 45)"
"25504";"Week 13"
"25505";"Week 14"
"25506";"Week 148"
"25507";"Week 16"
"25508";"Week 16 (before EE)"
"25509";"Week 16 (ITT Population)"
"25510";"Week 164"
"25511";"Week 18 mean 士 SD"
"25512";"Week 196"
"25513";"Week 2 CRP"
"25514";"Week 216"
"25515";"Week 24"
"25516";"Week 24 (non-EE responders)"
"25517";"Week 24 mean (SD)"
"25518";"Week 24 mean (SE)"
"25519";"Week 24 Overall population"
"25520";"Week 256"
"25521";"Week 26"
"25522";"Week 26 % of patients"
"25523";"Week 26 (geometric mean, CV)"
"25524";"week 26 (mean, SD)"
"25525";"Week 26 (mean, SD)"
"25526";"Week 26 (mmol/L)"
"25527";"Week 26 ertugliflozin 15 mg vs placebo"
"25528";"Week 26 ertugliflozin 15 mg vs. placebo"
"25529";"Week 26 ertugliflozin 5 mg vs placebo"
"25530";"Week 26 ertugliflozin 5 mg vs. placebo"
"25531";"Week 26, % (n)"""""
"25532";"Week 26, % (n)#"
"25533";"Week 26, % (n)# OR for CANA vs PBO (95% CI)||"
"25534";"Week 26, % (n)**"
"25535";"Week 26, % (n)^"
"25536";"Week 26, % (n)|| OR for CANA vs PBO (95% CI)§"
"25537";"Week 26, % (n)§"
"25538";"Week 26, % (n)1"
"25539";"Week 26, % (n)1 OR for CANA vs PBO (95% CI)||"
"25540";"Week 26, % (n)J"
"25541";"Week 28"
"25542";"Week 3"
"25543";"Week 30"
"25544";"Week 36"
"25545";"Week 4"
"25546";"Week 4 CRP"
"25547";"Week 44"
"25548";"Week 48"
"25549";"Week 48*"
"25550";"Week 48*’’"
"25551";"Week 52"
"25552";"Week 52/ET"
"25553";"Week 52a"
"25554";"Week 56"
"25555";"Week 56 % of patients"
"25556";"Week 6"
"25557";"Week 6 Responders, (n = 172)"
"25558";"Week 6 Responders, (n = 195)"
"25559";"Week 60"
"25560";"Week 78"
"25561";"Week 8"
"25562";"Week 8 CRP"
"25563";"Week 96"
"25564";"Week and"
"25565";"Week o (baseline) mean 士 SD"
"25566";"Week 26"
"25567";"Weekly"
"25568";"Weekly ISS{"
"25569";"Weekly ISS6"
"25570";"Weekly number of hives score{"
"25571";"Weekly number of hives score6"
"25572";"Weekly size of largest hives score{"
"25573";"WeekO Mean+SEM"
"25574";"Weeks"
"25575";"Weeks_measured"
"25576";"wegu"
"25577";"Weight"
"25578";"Weight— kg"
"25579";"Weight—kg (median)"
"25580";"Weight - kg"
"25581";"Weight - kg, Median (IQR)"
"25582";"Weight — kg"
"25583";"Weight — kg Cardiovascular history — no. (%)"
"25584";"Weight — no. (%)"
"25585";"Weight #60 kg"
"25586";"Weight $70.0 kg, <82.0 kg, N"
"25587";"Weight $82.0 kg, N"
"25588";"Weight (kg )"
"25589";"Weight (kg)"
"25590";"Weight (kg) (mean ± SD)"
"25591";"Weight (kg) BMI (kg/m2)"
"25592";"Weight (kg)*"
"25593";"Weight (kg), mean (s.d.)"
"25594";"Weight (kg), mean (s.e.)"
"25595";"Weight (kg), mean (SD)"
"25596";"Weight (kg), mean ± SD"
"25597";"Weight (kg), mean±SD"
"25598";"Weight (kg), Mean±SD"
"25599";"Weight (kg), median (IQR)"
"25600";"Weight (kg), median (m/n, max)"
"25601";"Weight (kg)十"
"25602";"Weight (kg)a"
"25603";"Weight (kg/m2) [median (25th to 75th percentile)]"
"25604";"Weight (kg}, median (min, max}"
"25605";"Weight (median [IQR]), kg"
"25606";"Weight (range) (kg)"
"25607";"Weight [kg]"
"25608";"Weight < 60 kg"
"25609";"Weight < 70.0 kg, N"
"25610";"Weight <60 kg"
"25611";"Weight <60 kg, n (%)"
"25612";"Weight 一kg"
"25613";"Weight > 60 kg"
"25614";"Weight > 80 kg, n(%)"
"25615";"WEIGHT 100+"
"25616";"WEIGHT 50-99"
"25617";"Weight Ab,%"
"25618";"WeIgHt Ab,%"
"25619";"Weight at baseline"
"25620";"Weight at randomization (kg)"
"25621";"Weight category"
"25622";"Weight group, no. (%)"
"25623";"Weight in kg (baseline: mean (SD) [n]; wk 48 and change: mean (SE) [n])"
"25624";"Weight in kg, mean (SD)"
"25625";"Weight in kg, median (IQR)"
"25626";"Weight of < 60 kg, n (%)"
"25627";"Weight, kg"
"25628";"Weight, kg (mean ± s.d.)"
"25629";"Weight, kg (mean 6 SD)"
"25630";"Weight, kg Blood pressure, mm Hg"
"25631";"Weight, kg Duration of PAH, n (%)"
"25632";"Weight, kg Mean (SD)"
"25633";"Weight, kg*"
"25634";"Weight, kg, mean (SD)"
"25635";"Weight, kg, mean ± SD"
"25636";"Weight, kg, median (25th, 75th)"
"25637";"Weight, kg, median (range)"
"25638";"Weight, kg: mean (SD)"
"25639";"Weight, kg1"
"25640";"Weight, lbs"
"25641";"Weight, mean (SD) (kg)"
"25642";"Weight, mean (SD) kg"
"25643";"Weight, mean (sd) lbs."
"25644";"Weight, mean (SD), kg"
"25645";"Weight, mean (SD), kgb"
"25646";"Weight, mean ± SD kg"
"25647";"Weight, mean 6 SD kg"
"25648";"Weight, median (25th—75th percentiles), kg"
"25649";"Weight, median (interquartile range), kg"
"25650";"Weight, median (IQR), kg"
"25651";"Weight, median (SD), kg"
"25652";"Weight,mean(SD),kg"
"25653";"Weight; mean ± SD (kg)"
"25654";"Weight^;"
"25655";"WEIGHT<50"
"25656";"West Europe"
"25657";"Western"
"25658";"Western Europe"
"25659";"Western Europe (%)"
"25660";"Western Europe (including South Africa)"
"25661";"Western Europe (n = 1,908)"
"25662";"Western Europe / Australia"
"25663";"Western Europe and Australia"
"25664";"Western Europe and Israel"
"25665";"Western Europe and Lebanon"
"25666";"Western Europe and other"
"25667";"Western Europe and Other"
"25668";"Western Europe HR (95% Cl)"
"25669";"Western Europe plus other"
"25670";"Western Europe, Australia, New Zealand"
"25671";"Western Europe, Australia, New Zealand, and Middle East"
"25672";"Western Europe, Australia, New Zealand, Middle Eai"
"25673";"Western Europe, Australia, New Zealand, Middle East"
"25674";"Western Europe, Israel, Australia, or South Africa"
"25675";"Western Europe/Australia"
"25676";"Western Europe/Australia/Israel"
"25677";"Western European includinq Australia, Israel, and South Africa"
"25678";"Western friroce"
"25679";"While"
"25680";"While ethnic origin"
"25681";"White"
"25682";"White-cell count — x10_9/liter"
"25683";"White (84.4%)"
"25684";"White (n — 350)"
"25685";"White (n = 1328)"
"25686";"White (N = 1328)"
"25687";"White (n = 444)"
"25688";"White (n = 5,006)"
"25689";"White (n=1538)"
"25690";"White (n=6,660)"
"25691";"White (n=6660)"
"25692";"white : black : other"
"25693";"White blood cell count, cellsx103"
"25694";"White ethnic origin"
"25695";"White ethnicity"
"25696";"White Hispanic"
"25697";"White Hispanic - n (%)"
"25698";"White MTX (n)"
"25699";"White non-Hispanic"
"25700";"White Non-Hispanic"
"25701";"White non-Hispanic - n (%)"
"25702";"White not of Hispanic origin"
"25703";"White or Caucasian, n (%)"
"25704";"White race"
"25705";"White race—number (%)"
"25706";"White race — no. (%):"
"25707";"White race — no. (%):t"
"25708";"White race — no. (%)f"
"25709";"White race — no. (%)y Left ventricular ejection fraction — %"
"25710";"White race — no. {%)'i'"
"25711";"White race — no. {%)-i-"
"25712";"White race — no. {%)$"
"25713";"White race — no. {%)t"
"25714";"White race — no./total no. (%)$"
"25715";"White race — no./total no. (%)f"
"25716";"White race (n=21 104)"
"25717";"White race, %"
"25718";"White race, n (%)"
"25719";"White TCZ+MTX (n)"
"25720";"White, %"
"25721";"White, n (%)"
"25722";"White, n (%) Medical history, n (%)"
"25723";"White, n(%)"
"25724";"White, n/N (%)"
"25725";"White, No. (%)"
"25726";"White, non-Hispanic"
"25727";"White/Caucasian"
"25728";"White/European"
"25729";"White/other"
"25730";"Whitea"
"25731";"Whiteb"
"25732";"WHO FC II symptoms at baseline"
"25733";"WHO FC II symptoms at baseline1"
"25734";"WHO FC II symptoms at baselinef"
"25735";"WHO FC III symptoms at baseline"
"25736";"WHO functional class"
"25737";"WHO functional class — no. (%):c"
"25738";"WHO functional class II/III"
"25739";"WHO/IDF IFG"
"25740";"WHO/IDF Impaired Fasting Glucose"
"25741";"Whole cohort"
"25742";"With (n = 457)"
"25743";"With ACEI/ARB"
"25744";"With alogliptin 12.5 mg"
"25745";"With alogliptin 12.5 mg (n 5 203)"
"25746";"With alogliptin 25 mg"
"25747";"With alogliptin 25 mg (n 5 198)"
"25748";"With an SFUa"
"25749";"With antiplatelets"
"25750";"With any stent"
"25751";"With Aspirin (n = 1,970)"
"25752";"With baseline CRP level of>10 mg/liter"
"25753";"With baseline vertebral fracture"
"25754";"With Beta Blocker"
"25755";"With cerebrovascular disease"
"25756";"With CKD (4060)"
"25757";"With CKD intensive (N = 1836)"
"25758";"With CKD standard (N = 1800)"
"25759";"With concomitant ICS"
"25760";"With corticosteroid treatment < 20"
"25761";"With corticosteroid treatment > 20"
"25762";"With DES"
"25763";"With diabetes"
"25764";"With DM"
"25765";"With DM (N Proactive Intervention (n = 324a)"
"25766";"With Dyspnoea"
"25767";"with events (%)"
"25768";"with higher classes indicating greater limitations on physical activity owing to"
"25769";"with highest BWa"
"25770";"with highest HbA1cc"
"25771";"with ICS, n (%)"
"25772";"with LABA, n (%) Pretreatment"
"25773";"With lipid-lowering agents"
"25774";"With long-acting j82-agonists"
"25775";"with lowest BWb"
"25776";"with lowest HbA1cd"
"25777";"With metabolic syndrome"
"25778";"With Metabolic Syndrome"
"25779";"With MetS"
"25780";"With p blockers"
"25781";"With placebo"
"25782";"With placebo (n 5 99)"
"25783";"With previous surgery"
"25784";"With Prior MI/Stroke (n=3692)"
"25785";"With psoriasis (n = 495)"
"25786";"With psoriasis (n = 52)"
"25787";"With psoriasis (zi = 495)"
"25788";"With psoriasis (zi = 52)"
"25789";"with rehospitalization, urgent coronary revascularization"
"25790";"With revascularisation"
"25791";"With stent"
"25792";"With stent^l"
"25793";"With T2DM N = 182"
"25794";"With tamsulosin"
"25795";"With tiotropium"
"25796";"With Treatment"
"25797";"Withdrawals, n/N(%)"
"25798";"Withdrew consent"
"25799";"within 24 h"
"25800";"within 48 h"
"25801";"within 72 h after"
"25802";"within 72 h after first procedure"
"25803";"Within last 30 d"
"25804";"Without (n = 14 214)"
"25805";"Without ACEI/ARB"
"25806";"Without an SFUa"
"25807";"Without antiplatelets"
"25808";"Without Aspirin (n = 7,223)"
"25809";"Without baseline vertebral fracture"
"25810";"Without Beta Blocker"
"25811";"Without cerebrovascular disease"
"25812";"Without CKD (8114)"
"25813";"Without concomitant ICS"
"25814";"Without diabetes"
"25815";"Without DM"
"25816";"Without DM (N = 8I7*)"
"25817";"without DVT DVT alone"
"25818";"Without Dyspnoea"
"25819";"Without Hx of HF"
"25820";"without hypertension at baseline to hypertension"
"25821";"Without insulin or insulin-modifying therapy"
"25822";"Without lipid-lowering agents"
"25823";"Without metabolic syndrome"
"25824";"Without Metabolic Syndrome"
"25825";"Without MetS"
"25826";"Without p blockers"
"25827";"Without previous surgery"
"25828";"Without psoriasis (n = 18,394)"
"25829";"Without psoriasis (n = 2786)"
"25830";"Without psoriasis (zi = 18,394)"
"25831";"Without psoriasis (zi = 2786)"
"25832";"Without revascularsation"
"25833";"Without stent"
"25834";"Without T2DM N = 434"
"25835";"Without tamsulosin"
"25836";"WML load at baseline MRI"
"25837";"WML load at follow-up MRI"
"25838";"WML load at follow-up MRI stratified by baseline severity of WML load"
"25839";"WOMAC function score"
"25840";"WOMAC pain score"
"25841";"WOMAC score"
"25842";"WOMAC stiffness score"
"25843";"Woman"
"25844";"women"
"25845";"Women"
"25846";"Women - no. (%)"
"25847";"Women — no. (%)"
"25848";"Women (%)"
"25849";"Women (n (%))"
"25850";"Women (n = 2291), n/N (%)"
"25851";"Women (n=1139 vs 572)"
"25852";"Women (n=2291)"
"25853";"Women (N=2476)"
"25854";"Women (N=2487) Events"
"25855";"Women (N=2925)"
"25856";"Women (N=3051)"
"25857";"Women (n=369)"
"25858";"Women (n=4416)"
"25859";"Women < 65 years"
"25860";"Women > 65 years"
"25861";"Women Ethnic origin"
"25862";"Women Men"
"25863";"Women T"""
"25864";"Women taking estrogen"
"25865";"Women, %"
"25866";"Women, <90 cm"
"25867";"Women, >90 cm"
"25868";"women, n (%)"
"25869";"Women, n (%)"
"25870";"Women, n (%) *"
"25871";"Women, no. (%)"
"25872";"Women, No. (%)"
"25873";"Women/men [%]"
"25874";"Women/men, %"
"25875";"Women: <50 mg/dL (<1.30 mmol/L)"
"25876";"Women; QVA149-SFC"
"25877";"Womens"
"25878";"Worldwide Black Patients"
"25879";"Worldwide Non-Black Patients"
"25880";"Worsened"
"25881";"Worsening angina"
"25882";"Worsening Angina"
"25883";"Worsening heart failure"
"25884";"WOSCOPS"
"25885";"Wrist"
"25886";"Wrist fracture"
"25887";"Wssng"
"25888";"WT, second, median"
"25889";"X Cr 1.094 X age"
"25890";"x/n"
"25891";"X/n*"
"25892";"X?=0-0; p=0-9"
"25893";"X?=0-l;p=0-8"
"25894";"X?=l-6;p=0-2"
"25895";"X13, n (%)"
"25896";"X2=0-2; p=0-7"
"25897";"X2=0-5;p=0-8"
"25898";"X2=0-l;p=0-8"
"25899";"x2=08;p=0-4"
"25900";"X2=6-6; p=0-01"
"25901";"X65 years"
"25902";"X65, n (%)"
"25903";"Xanthine"
"25904";"Xanthines"
"25905";"Xanthines,b n (%)"
"25906";"Xanthines11"
"25907";"Xanthinesg"
"25908";"xHo;p=o-2"
"25909";"Xi=°-°6"
"25910";"xi=0-3;p=0-6"
"25911";"Xi=0.01"
"25912";"Xi=0.02"
"25913";"Xi=0.04"
"25914";"Xi=0.10"
"25915";"Xi=0.17"
"25916";"Xi=0.20"
"25917";"Xi=0.23"
"25918";"Xi=0.24"
"25919";"Xi=0.42"
"25920";"Xi=0.47"
"25921";"Xi=1-28"
"25922";"Xi=1-89"
"25923";"Xi=106"
"25924";"Xi=2-3;p=0-l"
"25925";"Xi=2-4;p=0-l"
"25926";"Xi=2-5;p=O-l"
"25927";"Xi=2-6;p=01"
"25928";"Xi=2.06"
"25929";"Xi=2.73"
"25930";"xi=3-l;p=0-08"
"25931";"Xi=4.18"
"25932";"xi=l’3;P=0-3"
"25933";"Xi=o-3;p=o-6"
"25934";"Xi=o-4;p=o-5"
"25935";"xi=oo;p=o-9"
"25936";"Y es"
"25937";"Yaa"
"25938";"Year-1"
"25939";"Year-2"
"25940";"Year-4"
"25941";"Year 1"
"25942";"Year 2"
"25943";"Year 3"
"25944";"Year 4"
"25945";"Year From Randomization"
"25946";"Year of publication of primary results"
"25947";"year, n (%)"
"25948";"Yearl"
"25949";"years"
"25950";"years (mean ± SD)"
"25951";"years (SD)"
"25952";"years [range]"
"25953";"Years duration OA"
"25954";"years Male gender, n (%)"
"25955";"years Modified Hoehn and Yahr stage, n (%)"
"25956";"Years of education*"
"25957";"Years of education, mean (SD)"
"25958";"Years of follow-up, mean (SD) [maximum]"
"25959";"Years since diagnosis"
"25960";"Years since diagnosis of type 2 diabetes, n (%)"
"25961";"Years since diagnosis, mean"
"25962";"Years since last gout flare"
"25963";"Years since menopause"
"25964";"Years since MI (median,"
"25965";"Years since myocardial infarction"
"25966";"Years since PAH diagnosis"
"25967";"Years since PD diagnosis, mean ± SD"
"25968";"Years since symptom onset"
"25969";"Years with gout"
"25970";"Years with Gout"
"25971";"Years with gout, mean ± SD"
"25972";"Years with gouty arthritis"
"25973";"years)"
"25974";"years, mean (SD)"
"25975";"Years, mean (SD)"
"25976";"years, n (%) Smoking, n (%) Current"
"25977";"yes"
"25978";"Yes"
"25979";"Yes '"
"25980";"Yes (%)"
"25981";"Yes (%) Weight [kg] (Interaction: p=0.37)"
"25982";"Yes (any)"
"25983";"Yes (n =481)"
"25984";"Yes (n, %)"
"25985";"Yes (n=1060)"
"25986";"Yes (n=1135)"
"25987";"Yes (n=1582)"
"25988";"Yes (n=160)"
"25989";"Yes (n=167)"
"25990";"Yes (n=270)"
"25991";"Yes (N=314)"
"25992";"Yes (n=362)"
"25993";"Yes (n=756)"
"25994";"Yes (n=861)"
"25995";"Yes (n=966)"
"25996";"Yes (stopped for trial)"
"25997";"Yes Previous revascularization"
"25998";"Yes vs. No"
"25999";"Yes(N=1418)"
"26000";"Yes(N=1604)"
"26001";"Yes(n=1731)"
"26002";"Yes(N=3063)"
"26003";"Yes(N=839)"
"26004";"Yes*"
"26005";"Yes, 4 1 y"
"26006";"Yes, Insulin-treated"
"26007";"Yes, n (%)"
"26008";"Yes, Non-insulin-treated"
"26009";"Yes, o 2 cm"
"26010";"Yes, r 1 y"
"26011";"Yes, Z 2 cm"
"26012";"Younger patients (aged575 years)"
"26013";"Younger subjects (aged <55 years)"
"26014";"z\tonastaiin"
"26015";"ZE + statin"
"26016";"Zoledronic acid"
"26017";"Zoledronic acid (n = 745)"
"26018";"Zoledronic acid arm"
"26019";"Zotarolimus"
"26020";"Zotarolimus-eluting"
"26021";"Zotarolimust"
"26022";"zt=65"
"26023";"Placebo-ezetimibe 10/simvastatin 20-fenofibrate 160-ezetimibe 10/simvastatin 20/ezetimibe 160"
"26024";"L-dopa/carbidopa-L-dopa/carbidopa/entacapone"
"26025";"ARB-ARB/CCB"
"26026";"other-candesartan"
"26027";"Benazepril/hydrochlorothiazide-Benazepril/amlodipine"
"26028";"Atenolol-losartan"
"26029";"Amlodipine-amlodipine/valsartan"
"26030";"mycophenolate mofetil-cyclophosphamide"
"26031";"Atorvastatin-pravastatin"
"26032";"Placebo-Abatacept 30/10-Abatacept 10/10"
"26033";"Bivalirudin-Heparin plus GPI"
"26034";"Olmesartan/CCB-Olmesartan/diuretic"
"26035";"Comparator-linagliptin"
"26036";"Placebo-linagliptin"
"26037";"Placebo-dexlansoprazole"
"26038";"Placebo-carisbamate 800mg-carisbamate 1200mg"
"26039";"Ezetimibe/simvastatin-double dose statin-rosuvastatin"
"26040";"Stent/abciximab-stent/placebo"
"26041";"Insulin lispro mix 25/Lispro mix 50-Insulin glargine/Insulin lispro"
"26042";"IDegLira-Ideg-Lira"
"26043";"Placebo-IDegLira"
"26044";"IDegLira-Ideg"
"26045";"Budesonide-budesonide/formoterol"
"26046";"Placebo-Vonoprazan 10-Vonoprazan 20"
"26047";"Fluticasone-Fluticasone/salmeterol"
"26048";"Febuxostat-febuxostat/lesinurad 200-febuxostat/lesinurad 400"
"26049";"Telmisartan/amlodipine-telmisartan/amlodipine/hydrochlorothiazide"
"26050";"Chlorthalidone-amlodipine-lisinopril"
"26051";"Placebo-Famotidine 40- Famotidine 20"
"26052";"Air insulin-insulin glargine-air insulin/insulin glargine"
"26053";"Olmesartan 40-olmesartan 40/hydrochlorothiazide 12.5"
"26054";"SDC 0.5-0.9 ng/ml"
"26055";"SDC 1.2-2.0 ng/ml"
"26056";"HF symptomatic improvement"
"26057";"HF symptom unchanged"
"26058";"HF symptom worsened"
"26059";"CV death/HF hospitalization"
"26060";"Vertebral fracture"
"26061";"Nonvertebral fracture"
"26062";"LDL-C <2.6 mmol/l"
"26063";"LDL-c"
"26064";"Mortality, shock or congestive heart failure within 90 days"
"26065";"Main ACCORD endpoint"
"26066";"Fatal/nonfatal MI (excluding silent MI)"
"26067";"Cardiovascular death or nonfatal MI (excluding silent MI)"
"26068";"Cardiovascular death, nonfatal MI (excluding silent MI), or stroke"
"26069";"Combined efficacy and safety endpoint"
"26070";"Mean change from baseline BP at week 4"
"26071";"Median change in atheroma volume, %"
"26072";"Nonvertebral fractures"
"26073";"Clinical Vertebral Fractures"
"26074";"Complete clinical response at week 52"
"26075";"Death or MI at 6 days"
"26076";"Death or MI at 40 days"
"26077";"1-year Mortality"
"26078";"Net adverse clinical events at day 30"
"26079";"ADAS-cog"
"26080";"CDR-SOB"
"26081";"ADCS-ADL"
"26082";"NPI"
"26083";"Proportion of >=50% responder rates"
"26084";"LDL-C concentration"
"26085";"Non-HDLc concentration"
"26086";"HDLC- concentration"
"26087";"Apolipoprotein A"
"26088";"Apolipoprotein B"
"26089";"Complete ulcer healing at week 12"
"26090";"Major amputations at week 24"
"26091";"Mean percentage of nights without heartburn"
"26092";"new or worsening vertebral fracture at 24 months"
"26093";"new vertebral fracture at 24 months"
"26094";"Seizure reduction from baseline"
"26095";"HDL-c"
"26096";"Apolipoprotein A-I"
"26097";"HbA1c at week 26"
"26098";"Primary endpoint at 30 days"
"26099";"Primary endpoint at 6 months"
"26100";"DUAL I extension - end of trial HbA1c"
"26101";"DUAL IV - end of trial HbA1c"
"26102";"DUAL II - end of trial HbA1c"
"26103";"HbA1c at week 24"
"26104";"Proportion of days without heartburn at week 2, percentage"
"26105";"First severe asthma exacerbation"
"26106";"Change in FEV1 at week 16"
"26107";"Serum UA <5mg/dl by month 6"
"26108";"Control of sitting BP at week 8"
"26109";"Rate of atrial fibrillation"
"26110";"Combined 6-year CVD"
"26111";"Percentage of days without heartburn"
"26112";"HbA1c at week 52"
"26113";"BP goal at week 8"
"26114";"Previous use of digoxin"
"26115";"Cardiothoracic ratio"
"26116";"age"
"26117";"Retinal severity change"
"26118";"Serum uric acid, mg/dl"
"26119";"Concomitant statin use"
"26120";"Study protocol"
"26121";"Concomitant MAO-B inhibitor use"
"26122";"CKD at baseline"
"26123";"CVD, CKD"
"26124";"ACEi use"
"26125";"Beta blocker use"
"26126";"Nitrate use"
"26127";"Sirolimus eluting stent"
"26128";"Vessel disease"
"26129";"Kilip Class"
"26130";"Time to randomisation from symptom onset (h)"
"26131";"Time from symptoms onset to 1st balloon inflation (h)"
"26132";"Time from randomisation to 1st balloon inflation (h)"
"26133";"First medical contact"
"26134";"Stent placement"
"26135";"Previous MI and T2DM"
"26136";"Baseline peripheral artery disease"
"26137";"Fibrinolytic agent given"
"26138";"Shock risk indext"
"26139";"Aetiology"
"26140";"Baseline 6-min walk distance m"
"26141";"Baseline WHO functional class"
"26142";"Age at baseline years"
"26143";"Diabetes and untreated hypertension"
"26144";"Clinically evident vascular disease"
"26145";"Ethnicity, location"
"26146";"Alcohol intake, drinks/week"
"26147";"History of statin use"
"26148";"Low-density lipoprotein, mg/dl"
"26149";"High-density lipoprotein, mg/dl"
"26150";"Baseline BMD T score at femoral neck"
"26151";"Prior treatment status"
"26152";"Inclusion diagnosis"
"26153";"Modified Braunwald class"
"26154";"High-risk criterion"
"26155";"CADILLAC Score"
"26156";"Arterial access site"
"26157";"Vessels with stenosis >50%"
"26158";"Stent type implanted"
"26159";"Heparin pre-randomization"
"26160";"P2Y12 inhibitor loading dos"
"26161";"P2Y12 inhibitor maintenance"
"26162";"Primary management strategy"
"26163";"Clinical dementia rating score"
"26164";"Cholinesterase inhibitor use"
"26165";"Apolipoprotein E carrier"
"26166";"Prior exposure to levetiracetam"
"26167";"Prior exposure to carbamazepine"
"26168";"Prior exposure to topiramate"
"26169";"Prior exposure to lamotrigine"
"26170";"Thienopyridine use"
"26171";"Intent to use GP IIb/IIIa"
"26172";"Intent to use DTI"
"26173";"Troponin or CKMB value"
"26174";"TIMI score"
"26175";"Investigator-reported hypoglycaemia"
"26176";"Nocturnal heartburn severity"
"26177";"Concurrent medication"
"26178";"Antiepileptic drug type at baseline"
"26179";"Cardiogenic shock"
"26180";"Type of MI"
"26181";"Target vessel diameter"
"26182";"Onset of chest pain"
"26183";"Received PCI"
"26184";"ACEi or ARB pre-randomisation"
"26185";"ACEi or ARB post-randomisation"
"26186";"BB after randomisation"
"26187";"ACEi/ARB and BB after randomisation"
"26188";"Pulsed blood pressure"
"26189";"Admission CrCl"
"26190";"Admission K, mmol/l"
"26191";"Randomisation"
"26192";"NERD Grade"
"26193";"Asthma control"
"26194";"Eosinophil count (cells/microlitre)"
"26195";"Baseline uric acid"
"26196";"Disease stage"
"26197";"Disease severity"
"26198";"Hispanic or latino"
"26199";"Chronic heart failure class II-III"
"26200";"Prior MI/Stroke"
"26201";"Cardiovascular status"
"26202";"eGFR, ml/min (MDRD)"
"26203";"Diabetic retinopathy at baseline"
"26204";"Type of reflux disease"
"26205";"Number of symptom days per week"
"26206";"Cardiac surgery type"
"26207";"Baseline eGFR"
"26208";"Hiatus hernia"
"26209";"H. pylori infection"
"26210";"Hypertension severity"
"26211";"0.25-0.45"
"26212";"<0.25"
"26213";"<0.55"
"26214";">0.55"
"26215";"<50"
"26216";"50-59"
"26217";"60-69"
"26218";"70-79"
"26219";">80"
"26220";"<65 y"
"26221";">= 65y"
"26222";"<2"
"26223";"2-3"
"26224";">3 or incident vitrectomy or photocoagulation"
"26225";">9.5"
"26226";"<9.5"
"26227";"Stage 1(Cockcroft-Gault)"
"26228";"Stage 2(Cockcroft-Gault)"
"26229";"Stage 3(Cockcroft-Gault)"
"26230";"Stage 4(Cockcroft-Gault)"
"26231";"Stage 1(four-variable modification of diet in kidney disease)"
"26232";"Stage 2(four-variable modification of diet in kidney disease)"
"26233";"Stage 3(four-variable modification of diet in kidney disease)"
"26234";"Stage 4(four-variable modification of diet in kidney disease)"
"26235";"< 75"
"26236";"> 75"
"26237";"< 25"
"26238";"25 to < 30"
"26239";"> 30"
"26240";"< 60"
"26241";"> 60"
"26242";"Western EU, Australia, New Zealand"
"26243";"Eastern EU"
"26244";"< -2.5"
"26245";"> -2.5"
"26246";"Atorvastatin 10mg"
"26247";"Atorvastatin 20mg"
"26248";"803"
"26249";"804"
"26250";">27.2 kg/m2"
"26251";"<65"
"26252";">65"
"26253";"<75"
"26254";">=75"
"26255";">=2"
"26256";"Yes, Yes"
"26257";"Yes, No"
"26258";"No, Yes"
"26259";"No, No"
"26260";"<=75"
"26261";">75"
"26262";"II-III"
"26263";"0-2"
"26264";">2-4"
"26265";">4"
"26266";"<=4"
"26267";"<=2"
"26268";">2"
"26269";"PCI-hospital"
"26270";"Non-PCI hospital/ambulance"
"26271";"Non-European"
"26272";">70"
"26273";">135 mm Hg"
"26274";"<80.3 mm Hg"
"26275";">80.3 mm Hg"
"26276";"<7.3%"
"26277";">7.3%"
"26278";"<83.79 ml/min/1.73 m2"
"26279";">83.79 ml/min/1.73 m2"
"26280";"<4"
"26281";"<60"
"26282";"<6"
"26283";"6 to <13"
"26284";"13-24"
"26285";"<120"
"26286";"120-139"
"26287";"140-159"
"26288";">160"
"26289";"<70"
"26290";"70-89"
"26291";"90-109"
"26292";">110"
"26293";"IPAH/FPAH/drug and toxin"
"26294";"Repaired congenital shunt"
"26295";"<380"
"26296";">380"
"26297";"III/IV"
"26298";"60"
"26299";">60"
"26300";"Black, worldwide"
"26301";"Non-black, worldwide"
"26302";"Black, US"
"26303";"Non-black, US"
"26304";"0"
"26305";"1-7"
"26306";">8"
"26307";"<55"
"26308";">=55"
"26309";">=median"
"26310";"Past or nonsmoker"
"26311";">30"
"26312";"<30"
"26313";">-2.0"
"26314";">-2.5 to <-2.0"
"26315";"<-2.5"
"26316";"Naïve"
"26317";"Recent"
"26318";"Inadequate"
"26319";">=71"
"26320";"<76"
"26321";">=76"
"26322";"<26"
"26323";">=26"
"26324";"Current non-smoker"
"26325";"Non-Q-wave Ml"
"26326";"No rest angina"
"26327";"Rest angina"
"26328";"No antianginal drug"
"26329";"1 antianginal drug"
"26330";"32 antianginal drugs"
"26331";"Intermediate risk"
"26332";"Single vessel disease"
"26333";"At least one drug-eluting stent"
"26334";"All bare metal stents"
"26335";"Prasugrel or ticagrelor"
"26336";"Non-LAD"
"26337";"PCI Procedure"
"26338";"Non PCI Procedure"
"26339";"Non Europe"
"26340";"0.5"
"26341";"1"
"26342";"2"
"26343";"65-74"
"26344";"75-84"
"26345";">75years"
"26346";"< 60 kg"
"26347";"> 60 kg"
"26348";"<60 CrCl"
"26349";"3-4"
"26350";"5-7"
"26351";"< 65"
"26352";"> 65"
"26353";"< 15%"
"26354";"> 15%"
"26355";"<Mild"
"26356";"Mild-<Moderate"
"26357";"Moderate-<severe"
"26358";"Severe-very severe"
"26359";"<53"
"26360";">53"
"26361";"<90.8"
"26362";">90.8"
"26363";"<95mmHg"
"26364";">95mmHg"
"26365";"Enzyme inducing"
"26366";"Non-enzyme inducing"
"26367";">=9.0"
"26368";"<=65"
"26369";">2.5mm"
"26370";"<=2.5mm"
"26371";"<6h"
"26372";">=6h"
"26373";">=65"
"26374";"<45"
"26375";">=45"
"26376";"<40"
"26377";">=40"
"26378";"<=60 ml/min"
"26379";">=4"
"26380";"Pre-hospital"
"26381";"In-hospital"
"26382";"<=25"
"26383";">25"
"26384";"<=8%"
"26385";"12-17"
"26386";"18-64"
"26387";"<8%"
"26388";">8%"
"26389";"Russia/Ukraine/Belarus"
"26390";"Poor, tried previous glucocorticoid/non-LABA"
"26391";"Poor, tried previous glucocorticoid+LABA"
"26392";"Good, tried previous glucocorticoid+LABA"
"26393";"Good, tried previous glucocorticoid"
"26394";">64"
"26395";"<100"
"26396";">=100"
"26397";"<200"
"26398";">=200"
"26399";"<300"
"26400";">=300"
"26401";"<400"
"26402";">=400"
"26403";">=5mg/dl"
"26404";"Advanced"
"26405";"1.5"
"26406";"2.5"
"26407";"3"
"26408";">6"
"26409";"<=8.5%"
"26410";">8.5%"
"26411";"<=10"
"26412";">10"
"26413";"Established disease"
"26414";"Risk factors only"
"26415";"Pre-mixed insulin"
"26416";"Yes; Proliferative"
"26417";"Yes; Non-proliferative"
"26418";"Yes; Unknown"
"26419";"Unknown/Missing"
"26420";"Erosive reflux disease"
"26421";"Gastrooesophageal reflux disease"
"26422";"0-1"
"26423";">1,<=2"
"26424";"Non-CABG or combined"
"26425";">90"
"26426";"60-89"
"26427";">40"
"26428";"< 18.5"
"26429";"18.5-25.0"
"26430";">25.0"
"26431";"< 3"
"26432";"3-6"
"26433";"<7%"
"26434";"<6.5%"
"26435";"tx"
"26436";"tx2"
"26437";"tx3"
"26438";"type"
"26439";"Amlodipione-chlorthalidone"
"26440";"Lisinopril-chlorthalidone"
"26441";"famotidine 20-famotidine 40"
"26442";"Placebo-famotidine 20"
"26443";"Placebo-famotidine 40"
"26444";"air insulin-air insulin/insulin glargine"
"26445";"Air insulin-air insulin/insulin glargine"
"26446";"insulin glargine-air insulin/insulin glargine"
"26447";"Placebo-Vonoprazan 10"
"26448";"Placebo-Vonoprazan 20"
"26449";"Febuxostat-febuxostat/lesinurad 200"
"26450";"Febuxostat-febuxostat/lesinurad 400"
"26451";"P-value2"
"26452";"OR_value"
"26453";"OR2"
"26454";"OR2_value"
"26455";"P-value3"
